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1. History of blood transfusion
The first historical attempt at blood transfusion was described by the 17th century chronicler 
Stefano Infessura. Infessura relates that, in 1492, as Pope Innocent VIII sank into a coma, the 
blood of three boys was infused into the dying pontiff (through the mouth, as the concept of 
circulation and methods for intravenous access did not exist at that time) at the suggestion of 
a physician. The boys were ten years old, and had been promised a ducat each. However, not 
only did the pope die, but so did the three children. Some authors have discredited Infessura’s 
account, accusing him of anti-papalism. 
Beginning with Harvey’s experiments with circulation of the blood, more sophisticated re-
search into blood transfusion began in the 17th century, with successful experiments in transfu-
sion between animals. However, successive attempts on humans continued to have fatal results.
The first fully documented human blood transfusion was administered by Dr. Jean-Baptiste De-
nys, eminent physician to King Louis XIV of France, on June 15, 1667. He transfused the blood of 
a sheep into a 15-year-old boy, who survived the transfusion. Denys performed another transfu-
sion into a labourer, who also survived. Both instances were likely due to the small amount of 
blood that was actually transfused into these people. This allowed them to withstand the allergic 
reaction. Denys’ third patient to undergo a blood transfusion was Swedish Baron Bonde. He re-
ceived two transfusions. After the second transfusion Bonde died. In the winter of 1667, Denys 
performed several transfusions on Antoine Mauroy with calf’s blood, who on the third account 
died. Much controversy surrounded his death. Mauroy’s wife asserted Denys was responsible 
for her husband’s death; she was accused as well. Though it was later determined that Mauroy 
actually died from arsenic poisoning, Denys’ experiments with animal blood provoked a heated 
controversy in France. Finally, in 1670 the procedure was banned. In time, the British Parliament 
and even the pope followed suit. Blood transfusions fell into obscurity for the next 150 years.
Richard Lower examined the effects of changes in blood volume on circulatory function and 
developed methods for cross-circulatory study in animals, obviating clotting by closed arteriov-
enous connections. His newly devised instruments eventually led to actual transfusion of blood.
Towards the end of February 1665 he selected one dog of medium size, opened its jugular 
vein, and drew off blood, until its strength was nearly gone. Then, to make up for the great 
loss of this dog by the blood of a second, I introduced blood from the cervical artery of a fairly 
large mastiff, which had been fastened alongside the first, until this latter animal showed it 
was overfilled by the inflowing blood.” After he “sewed up the jugular veins,” the animal 
recovered “with no sign of discomfort or of displeasure.”
Lower had performed the first blood transfusion between animals. He was then requested by 
the Honorable Robert Boyle to acquaint the Royal Society with the procedure for the whole 
experiment,” which he did in December of 1665 in the Society’s Philosophical Transactions. 
On 15 June 1667 Denys, then a professor in Paris carried out the first transfusion between hu-
mans and claimed credit for the technique, but Lower’s priority cannot be challenged. 
Six months later in London, Lower performed the first human transfusion in Britain, where he 
“superintended the introduction in a patient’s arm at various times of some ounces of sheep’s blood 
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at a meeting of the Royal Society, and without any inconvenience to him.” The recipient was 
Arthur Coga, “the subject of a harmless form of insanity.” Sheep’s blood was used because of spec
ulation about the value of blood exchange between species; it had been suggested that blood from 
a gentle lamb might quiet the tempestuous spirit of an agitated person and that the shy might be 
made outgoing by blood from more sociable creatures. Lower wanted to treat Coga several times, 
but his patient refused. No more transfusions were performed. Shortly before, Lower had moved 
to London, where his growing practice soon led him to abandon research.
In 1667 - Jean-Baptiste Denis in France reported successful transfusions from sheep to humans. In 
1678 transfusion from animals to humans, having been tried in many different ways, was confirmed 
to be unsuccessful, and was subsequently outlawed by the Paris Society of Physicians because of 
reactions and associated mortality. In 1795 in Philadelphia USA, an American physician Philip Syng 
Physick, performed the first known human Blood transfusion, although he did not publish the de
tails of his findings. In 1818 James Blundell, a British obstetrician, performed the first successful 
transfusion of human blood to a patient for the treatment of post partum haemorrhage. Using the 
patient’s husband as a donor, he extracted a small amount of Blood from the husband’s arm and 
using a syringe, he successfully transfused the wife. Between 1825 and 1830 he performed ten docu
mented transfusions, five of which proved beneficial to his patients, and published these results. 
He also devised various instruments for performing Blood transfusions. 1840 in London England, 
Samuel Armstrong Lane, aided by consultant Dr. Blundell, performed the first successful whole 
Blood transfusion to treat haemophilia. In 1867 English surgeon Joseph Lister utilized antiseptics to 
control infection during Blood transfusions. In 1901 - Karl Landsteiner, an Austrian physician, and 
the most important individual in the field of Blood transfusion, documented the first three human 
Blood groups (A, B and O). A year later in 1902 a fourth main blood type, AB was found by A. De
castrello and A. Sturli.  In 1907 Hektoen suggested that the safety of transfusion might be improved 
by cross-matching blood between donors and patients to exclude incompatible mixtures. Reuben 
Ottenberg performed the first blood transfusion using blood typing and cross-matching. Ottenberg 
also observed the ‘Mendelian inheritance’ of blood groups and recognized the “universal” utility 
of group O donors. In 1908 - French surgeon Alexis Carrel devised a way to prevent blood from 
clotting. His method involved joining an artery in the donor, directly to a vein in the recipient with 
surgical sutures. He first used this technique to save the life of the son of a friend, using the father as 
donor. This procedure, not feasible for Blood transfusion, paved the way for successful organ trans
plantation, for which Carrel received the Nobel Prize in 1912. In 1908 - Carlo Moreschi documented 
the antiglobulin reaction. In 1914 long-term anticoagulants, among them sodium citrate, were devel
oped, allowing longer preservation of Blood. In 1915 at Mt. Sinai Hospital in New York City, Richard 
Lewisohn was documented to have used sodium citrate as an anticoagulant which in the future 
transformed transfusion procedure from one that had to be performed with both the donor and the 
receiver of the transfusion in the same place at the same time, to basically the Blood banking system 
in use today. Further, in the same time period, R. Weil demonstrated the feasibility of refrigerated 
storage of such anticoagulated Blood. In 1916 Francis Rous and J. R. Turner introduced a citrate-
glucose solution that permitted storage of Blood for several days after collection. Also, as in the 1915 
Lewisohn discovery allowed for Blood to be stored in containers for later transfusion, and aided in 
the transition from the vein-to-vein method to direct transfusion. This discovery also directly led to 
the establishment of the first Blood depot by the British during World War I. Oswald Robertson was 
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credited as the creator of the Blood depots.  In 1925 - Karl Landsteiner, then working in New 
York City, in collaboration with Phillip Levine, discovered three more Blood groups: M, N 
and P. View Nobel Biography. In 1926 the British Red Cross instituted the first human Blood 
transfusion service in the world.  In 1932, the first facility functioning as a Blood bank was es-
tablished in a Leningrad Russia hospital. 1937, Bernard Fantus, director of therapeutics at the 
Cook County Hospital in Chicago, Illinois (U. S.), established the first hospital Blood bank in 
the United States. In creating a hospital laboratory that could preserve and store donor Blood, 
Fantus originated the term ‘Blood bank. In 1939 and 1940 - The Rh Blood group system was 
discovered by Karl Landsteiner, Alex Wiener, Philip Levine and R. E. Stetson and was soon 
recognized as the cause of the then majority of transfusion reactions. Known as the Rhesus 
(Rh) system, once this reliable test for this grouping had been established, transfusion reac-
tions became rare. Identification of the Rh factor has stood next to ABO as another important 
breakthrough in Blood banking.
2. Antigen
An antigen is a substance which in an appropriate biological circumstance can stimulate the 
production of an antibody. Such substances will react specifically with the antibody in an 
observable manner. Such observable ways includes;agglutination(the clumping of red blood 
cells in the presence of an antibody. The antibody or other molecule binds multiple particles 
and joins them, creating a large complex) and precipitation (the coalescing of small particles 
that are suspended in a solution; these larger masses are then (usually) precipitated. Blood 
group antigens are located within the red cell membrane. Antigens are made up of antigenic 
determinants (antigen binding sites). There are more antigenic determinants on a red cell of 
an individual who is homozygote for a particular antigen compared to a heterozygote. For 
example a homozygote (DD) individual has about 25-37,000 Rh (DD) antigenic determinants 
compared to 10,000-15,000 for a heterozygote (Dd). Similarly a homozygote show a stronger 
reaction with the corresponding group specific antibody compared to a heterozygote. This is 
the reason why red cells with homozygous antigen expression is preferred as a red cell rea-
gent used for antibody detection and identification.
Characteristics of antigens. In order for a substance to be an antigen to you it must be foreign 
(not found in the host). The more foreign a substance the better it is an antigen. Antigens can 
either be autologous or homologous. Autologous antigens are your own antigens (not foreign 
to you). Homologous, or allogeneic, antigens are antigens from someone else (within the 
same species) that may be foreign to you. 
Antigens must be chemically complex. Proteins and polysaccharides are antigenic due to their 
complexity. On the other hand, lipids are antigenic only if coupled to protein or sugar. Be-
sides being chemically complex, antigens must also be large enough to stimulate antibody 
production. Their molecular weight needs to be at least 10,000. Due to the complexity of these 
molecules there are specific antigenic determinants (antigen sites) which are those portions of 
the antigen that reacts specifically with the antibody. 
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Antigen-antibody reaction occurs in 2 stages; sensitization and agglutination. The characteristics of 
an antigen and antibody reaction include; the antigen reacts with thegroup specific antibody and 
the reaction occurs in optimum proportion. Factors affecting antigen –antibody reaction includes:
Factors affecting antigen-antibody reaction
Specificity (good fit between antigen and antibody)
Resolution of discrepancy in ABO
Number of antigenic determinants (binding sites)
Optimum temperatures (IgG = 37˚C, IgM = 4˚C).
Optimum pH of the medium
Factors that play a role in antigen antibody reactions 
Techniques used in identification. ABO blood group antibodies bind red cells (containing 
the group specific antigen) suspended in saline. ABO blood group antibodies are IgM anti
bodies. They are high molecular weight antibodies that can span the distance that red cells 
keep apart (zeta potential) when suspended in saline whereas Rh antibodies are IgG antibod
ies and will require antihuman globulin (AHG) and or enzyme techniques for its detection.
Effect of enzymes. Enzymes like papain (from paw paw) and ficin (from figs) and bromelin 
(pineapple) can either enhance the reactivity of antigen-antibody reaction (Rhesus) or destroy 
(remove) antigen structures of some antigens (Duffy). Characteristics of an antigen includes; 
foreign (not found in the host) and react specifically with corresponding antibody.
Factors determining the effectiveness of an antigen
Factors determining the effectiveness or whether an antigen will stimulate an antibody response:
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keep apart (zeta potential) when suspended in saline whereas Rh antibodies are IgG antibod-
ies and will require antihuman globulin (AHG) and or enzyme techniques for its detection.
Effect of enzymes. Enzymes like papain (from paw paw) and ficin (from figs) and bromelin 
(pineapple) can either enhance the reactivity of antigen-antibody reaction (Rhesus) or destroy 
(remove) antigen structures of some antigens (Duffy). Characteristics of an antigen includes; 
foreign (not found in the host) and react specifically with corresponding antibody.
Factors determining the effectiveness of an antigen
Degree of foreignness
Genetic makeup of host
Dose and frequency of exposure
Size and complexity
Factors determining the effectiveness or whether an antigen will stimulate an antibody response:
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Red cell agglutination. Agglutination is the clumping of particles. The word agglutination 
comes from the Latin word agglutinare, meaning to glue. Red cell agglutination occurs when 
antigens on the red cell membrane of the red cells are cross-linked with their group spe-
cific antibody to form a three–dimensional lattice structure (clumps). Agglutination occur in 
2 phases; primary (antibody sensitization) and the secondary phase (agglutination). Each of 
these phases are affected by certain factors.
Primary phase (Sensitization). Sensitization is a chemical reaction (interaction) between an 
antigen and the group specific antibody. It is the coating of the antigen by the group specific 
antibody. It is a reaction in which antigen and antibody associate and dissociate until equilib-
rium is reached. Sensitization is governed by the law of mass action and it is concentration 
dependent. The higher the concentration of the antigen and antibody the more the AG-AB 
complexes formed and the stronger the agglutination. These complexes are held together by 
ionic, hydrogen, hydrophobic bonds as well as covalent van der Waal’s forces. Sensitization 
is affected by factors such as;
1. Temperature. The type of antigen-antibody bonding determines the opti-
mum reactive temperation. Some antigens particularly carbonhydrate an-
tigens (A, B, P1 H, Lea, Leb and I) form hydrogen bonds which dissipitate 
the heat generated during Ag-Ab reaction. These antigens reacts optimally 
at a cold (exothermic) temperation of 4-20°C. Non exothermic protein anti-
gens (Rh, Duffy, Kell, Kidd and Lutheran) non-hydrogen bonding antigens 
react optimally at a warmer temperature of 37°C. Most IgM antibodies 
(ABO) reacts optimally at cold temperature while IgG antibody (Rh) react 
optimally at 37°C.
2. Ionic strength of the medium. Red cells when suspended in saline becomes 
negatively charged and repel each other. Antigens and antibody molecules 
are themselves charged molecules. Reduction of the charge (reduced Na+ 
and Cl - ions per unit volume) of the medium in which the red cells are 
suspended reduces the electrostatic barrier that exist between red cells sus-
pended in saline (Zeta potential) facilitates faster antigen-antibody reac-
tion. The surface of red cells carry a negative charge due to the ionization 
of the carboxyl group of NeuNac (N-acetyl neuraminic acid), also called 
NANA or sialic acid. In saline, red cells will attract positively charged Na+, 
and an ionic cloud will form around each cell. Thus the cells will be re-
pelled and stay a certain distance apart. Zeta potential is a measure of this 
repulsion and is measured in microvolts at the boundary of sheer or slip-
ping plane. Zeta potential is measured at the “slipping plane” and results 
from the difference in electrostatic potential at the surface of the RBCS and 
the boundary of shear (slipping plane). When zeta potential decreases, the 
RBCS can come closer together, allowing them to be agglutinated by the 
small IgG molecule. For IgG molecules to span the distance between red 
cells in saline, the ZP must be reduced so the cells can come closer. Reduc-
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tion of the ionic strength reduces the interfering effect of the electrostatic 
barrier and facilitates better attraction between the antigen and antibody. 
Lower ionic strength saline (LISS) (0.003M saline plus glycine) produces an 
isotonic environment due to the reduced Na+ and Cl - ions concentration. 
LISS facilitate better agglutination and thus shorter incubation times com
pared to normal saline. LISS is not a potentiating medium (does not reduce 
the ionic cloud that exist between red cells suspended in saline and thus 
does not reduce the distance between red cells like Bovine Serum Albu
min. It merely facilitates the non-specific interaction between red cells and 
antibody. This is why the the ionic strength and the optimum antigen and 
antibody ratio are most important factors in agglutination reaction.
Figure 1: Demonstration of the effect of zeta potential on agglutination reaction
3. . Since the immu
noglobulins and the red cell membranes both have an electrical charge, there 
is an optimum pH. pH differences cause differences in chemical structures 
of antigens/antibodies, affecting the “fit”. 
4. Shape and structure of antigen and antibody (fit). Specificity between an
tigens and antibodies depends on the spatial and chemical “fit” between 
antigen and antibody. The better the fit between the antigenic determinants 
(antigen site) and the antibody combining sites, the better the agglutination. 
Effect of pH
Demonstration of the effect of pH of medium of cell suspension on agglutination reaction
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comes from the Latin word agglutinare, meaning to glue. Red cell agglutination occurs when 
antigens on the red cell membrane of the red cells are cross-linked with their group spe
cific antibody to form a three–dimensional lattice structure (clumps). Agglutination occur in 
2 phases; primary (antibody sensitization) and the secondary phase (agglutination). Each of 
these phases are affected by certain factors.
Primary phase (Sensitization). Sensitization is a chemical reaction (interaction) between an 
antigen and the group specific antibody. It is the coating of the antigen by the group specific 
antibody. It is a reaction in which antigen and antibody associate and dissociate until equilib
rium is reached. Sensitization is governed by the law of mass action and it is concentration 
dependent. The higher the concentration of the antigen and antibody the more the AG-AB 
complexes formed and the stronger the agglutination. These complexes are held together by 
ionic, hydrogen, hydrophobic bonds as well as covalent van der Waal’s forces. Sensitization 
is affected by factors such as;
1. . The type of antigen-antibody bonding determines the opti
mum reactive temperation. Some antigens particularly carbonhydrate an
tigens (A, B, P1 H, Lea, Leb and I) form hydrogen bonds which dissipitate 
the heat generated during Ag-Ab reaction. These antigens reacts optimally 
at a cold (exothermic) temperation of 4-20°C. Non exothermic protein anti
gens (Rh, Duffy, Kell, Kidd and Lutheran) non-hydrogen bonding antigens 
react optimally at a warmer temperature of 37°C. Most IgM antibodies 
(ABO) reacts optimally at cold temperature while IgG antibody (Rh) react 
optimally at 37°C.
2. . Red cells when suspended in saline becomes 
negatively charged and repel each other. Antigens and antibody molecules 
are themselves charged molecules. Reduction of the charge (reduced Na+ 
and Cl - ions per unit volume) of the medium in which the red cells are 
suspended reduces the electrostatic barrier that exist between red cells sus
pended in saline (Zeta potential) facilitates faster antigen-antibody reac
tion. The surface of red cells carry a negative charge due to the ionization 
of the carboxyl group of NeuNac (N-acetyl neuraminic acid), also called 
NANA or sialic acid. In saline, red cells will attract positively charged Na+, 
and an ionic cloud will form around each cell. Thus the cells will be re
pelled and stay a certain distance apart. Zeta potential is a measure of this 
repulsion and is measured in microvolts at the boundary of sheer or slip
ping plane. Zeta potential is measured at the “slipping plane” and results 
from the difference in electrostatic potential at the surface of the RBCS and 
the boundary of shear (slipping plane). When zeta potential decreases, the 
RBCS can come closer together, allowing them to be agglutinated by the 
small IgG molecule. For IgG molecules to span the distance between red 
cells in saline, the ZP must be reduced so the cells can come closer. Reduc
7Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
tion of the ionic strength reduces the interfering effect of the electrostatic 
barrier and facilitates better attraction between the antigen and antibody. 
Lower ionic strength saline (LISS) (0.003M saline plus glycine) produces an 
isotonic environment due to the reduced Na+ and Cl - ions concentration. 
LISS facilitate better agglutination and thus shorter incubation times com-
pared to normal saline. LISS is not a potentiating medium (does not reduce 
the ionic cloud that exist between red cells suspended in saline and thus 
does not reduce the distance between red cells like Bovine Serum Albu-
min. It merely facilitates the non-specific interaction between red cells and 
antibody. This is why the the ionic strength and the optimum antigen and 
































































Figure 1: Demonstration of the effect of zeta potential on agglutination reaction
3. pH of the medium in which the red cells are suspended. Since the immu-
noglobulins and the red cell membranes both have an electrical charge, there 
is an optimum pH. pH differences cause differences in chemical structures 
of antigens/antibodies, affecting the “fit”. 
4. Shape and structure of antigen and antibody (fit). Specificity between an-
tigens and antibodies depends on the spatial and chemical “fit” between 
antigen and antibody. The better the fit between the antigenic determinants 
(antigen site) and the antibody combining sites, the better the agglutination. 
Effect of pH
pH 7.5 pH 7.0
Demonstration of the effect of pH of medium of cell suspension on agglutination reaction
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Antibody combining site
Antigen determinant
Good fit Poor fit
Demonstration of the effect of shape and structure on agglutination
1. The antigen-antibody ratio. The greater the antibody amount for a given 
antigen the more antibodies will be bound to the corresponding antigen 
and the greater the agglutination reaction. The more the antibody bound 
to a red cell (sensitization) and more the agglutination. Antigen and an-
tibody reaction occur in optimum proportion. If the antibody concentra-
tion is high (excess) and the antigen concentration is low, the antigen sites 
(antigenic determinants) becomes saturated with more antibodies com-
peting for the few antigen sites present resulting in few agglutination 
(Prozone effect). The optimum ratio is 80 parts antibody to 1 part antigen. 
There are specific terms for variations in this ratio. In order to get opti-
mum antigen-antiboy concentration in Blood Banking we make washed 
3% saline suspension of red cells to mix with our reagents.
Demonstration of the effect of antigen-antibody ratio on agglutination reaction
2. Prozone effect. Excess antibodies saturates all the antigen sites leaving no 
room for the formation of cross-linkages between sensitized cells. Thus 
even though there are antibodies in the plasma that are specific against 
the corresponsing antigens on the red cells suspended in saline a false 
negative reaction with no agglutination observed may be evident. Zone 
of equivalence: Antibodies and antigens present in optimum proportion 
and significant agglutination is formed. Zone of antigen excess: Too many 
antigens are present to bind with fewer antibodies. Thus the agglutina-
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tion formed is often super-imposed by the large masses of unagglutinat
ed antigens. This can cause a false negative reaction.
The second phase of the agglutination process involves the cell to cell cross linking by anti
bodies. The level of agglutination observed is affected by the rate at which red cells sensitized 
with antibody collide with each other. Red cell collision (attraction) is dependent on the fol
lowing aggregating forces:
1. . Red cells are attracted together by gravity. This attraction can be 
facilitated by centrifugation. Centrifugation of the cells attempts to bring 
the red blood cells closer together, but even then the smaller IgG antibod
ies usually can not reach between two cells. The larger antibodies, IgM, can 
reach between cells that are further apart and cause agglutination. The 
second phase of agglutination involving an IgG antibody can only be en
hanced either by altering the suspending environment by using an aggre
gating or potentiating mwdium (20% BSA) or by altering the red cell mem
brane of the red cells using enzyme treatment (papain, ficin or bromelin) 
or by using an additional cross linking reagent (anti- human globulin) to 
facilitate agglutination.
2. The concept Zeta potential is important to understand why 
the cells will maintain a certain distance from each other. Zeta potential re
fers to the repulsion between the red blood cells. It is due to an electric charge 
surrounding cells suspended in saline. It is caused by sialic acid groups on 
the red blood cell membrane which gives the cells a negative charge. The 
positive ions in saline are attracted to the negatively charged red blood cells. 
The net positive charge surrounding the cells in saline keeps them far apart 
due to repulsion from electric charges. Smaller antibodies (IgG) cannot cause 
agglutination when zeta potential exists. To overcome the effect of the zeta 
potential, there is the need to neutralize these charges. One of the commonest 
technique is to add a potentiating medium (Bovine Serum Albumin 22%) to 
the mixture. The hydroxyl group (OH-) neutralizes the net postitive charge 
and and draw the red cells closer to each other reducing the gap between 
the red cells. This facilitate the ability of low molecular weight IgG antibody 
to bridge the gap between red cells and cause agglutination. The effect of 
these aggregating forces are ofter resisted by the zeta potential (occurs when 
negatively charged red cells suspended in saline repel each other creating an 
ionic cloud between themselves). The minimum distance between red cells 
suspended in saline is > 14nm. Thus the closest the cells can approach each 
other is the edge of their individual ionic clouds (slipping plane). IgG anti
bodies are low molecular weight antibodies (150,000) and thus are unable 
to span the slipping plane that exist beween cells suspended in saline. IgM 
antiboies on the other hand are a high molecular weight (900,000) molecule 
Good fit Poor fit
Demonstration of the effect of shape and structure on agglutination
1.  The greater the antibody amount for a given 
antigen the more antibodies will be bound to the corresponding antigen 
and the greater the agglutination reaction. The more the antibody bound 
to a red cell (sensitization) and more the agglutination. Antigen and an
tibody reaction occur in optimum proportion. If the antibody concentra
tion is high (excess) and the antigen concentration is low, the antigen sites 
(antigenic determinants) becomes saturated with more antibodies com
peting for the few antigen sites present resulting in few agglutination 
(Prozone effect). The optimum ratio is 80 parts antibody to 1 part antigen. 
There are specific terms for variations in this ratio. In order to get opti
mum antigen-antiboy concentration in Blood Banking we make washed 
3% saline suspension of red cells to mix with our reagents.
Demonstration of the effect of antigen-antibody ratio on agglutination reaction
2. Prozone effect. Excess antibodies saturates all the antigen sites leaving no 
room for the formation of cross-linkages between sensitized cells. Thus 
even though there are antibodies in the plasma that are specific against 
the corresponsing antigens on the red cells suspended in saline a false 
negative reaction with no agglutination observed may be evident. Zone 
of equivalence: Antibodies and antigens present in optimum proportion 
and significant agglutination is formed. Zone of antigen excess: Too many 
antigens are present to bind with fewer antibodies. Thus the agglutina
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tion formed is often super-imposed by the large masses of unagglutinat-
ed antigens. This can cause a false negative reaction.
Secondary stage of agglutination reaction
The second phase of the agglutination process involves the cell to cell cross linking by anti-
bodies. The level of agglutination observed is affected by the rate at which red cells sensitized 
with antibody collide with each other. Red cell collision (attraction) is dependent on the fol-
lowing aggregating forces:
1. Gravity. Red cells are attracted together by gravity. This attraction can be 
facilitated by centrifugation. Centrifugation of the cells attempts to bring 
the red blood cells closer together, but even then the smaller IgG antibod-
ies usually can not reach between two cells. The larger antibodies, IgM, can 
reach between cells that are further apart and cause agglutination. The 
second phase of agglutination involving an IgG antibody can only be en-
hanced either by altering the suspending environment by using an aggre-
gating or potentiating mwdium (20% BSA) or by altering the red cell mem-
brane of the red cells using enzyme treatment (papain, ficin or bromelin) 
or by using an additional cross linking reagent (anti- human globulin) to 
facilitate agglutination.
2. Surface tension. The concept Zeta potential is important to understand why 
the cells will maintain a certain distance from each other. Zeta potential re-
fers to the repulsion between the red blood cells. It is due to an electric charge 
surrounding cells suspended in saline. It is caused by sialic acid groups on 
the red blood cell membrane which gives the cells a negative charge. The 
positive ions in saline are attracted to the negatively charged red blood cells. 
The net positive charge surrounding the cells in saline keeps them far apart 
due to repulsion from electric charges. Smaller antibodies (IgG) cannot cause 
agglutination when zeta potential exists. To overcome the effect of the zeta 
potential, there is the need to neutralize these charges. One of the commonest 
technique is to add a potentiating medium (Bovine Serum Albumin 22%) to 
the mixture. The hydroxyl group (OH-) neutralizes the net postitive charge 
and and draw the red cells closer to each other reducing the gap between 
the red cells. This facilitate the ability of low molecular weight IgG antibody 
to bridge the gap between red cells and cause agglutination. The effect of 
these aggregating forces are ofter resisted by the zeta potential (occurs when 
negatively charged red cells suspended in saline repel each other creating an 
ionic cloud between themselves). The minimum distance between red cells 
suspended in saline is > 14nm. Thus the closest the cells can approach each 
other is the edge of their individual ionic clouds (slipping plane). IgG anti-
bodies are low molecular weight antibodies (150,000) and thus are unable 
to span the slipping plane that exist beween cells suspended in saline. IgM 
antiboies on the other hand are a high molecular weight (900,000) molecule 
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that is large enogh to bridge this slipping plane and cause agglutination. IgM 
can agglutinate cells suspended in saline while IgG antibodies cannot. IgG 
antibody will however require an alteration to the environment by a poten-
tiating medium to be able to agglutinate cells containing the group specigen 
antigens suspended in saline.
3. Antigen-antibody ratio: Antigen- antibody reaction occurs in optimum 
proportion. The optimum ratio is 80 parts of antibody to 1 part of an-
tigen. If the antigen –antibody ratio is optimum, agglutination occurs 
(zone of equivalence) but if the antibody ration is higher than the antigen 
a false negative reaction (prozone effect) results. But if the antigen ra-
tion exceeds the antibody ration the agglutinated red cells are masked by 
masses of the unagglutinated antigens (Post-zone effect).
Examples of such potentiating medium are:
1. Bovine serum albumin: Bovine albumin (20- 22%) or polybrene (hex-
adimethrine bromide) can potentially reduce the dielectric constant 
(charge density) of the red cell suspension medium thereby reducing the 
net repulsive force between cells suspended in saline. This potentially re-
duced the distance apart between red cells allowing low molecular weight 
IgG antibody to span the gap and cause a reversible aggregation. This ag-
gregation cross linkages between antibody sensitized red cells to produce 
agglutination. Polyethylene glycol (PEG) can potential enhance the uptake 
of antibody onto the red cells and can be used in conjunction with the AHG 
technique.
2. Enzyme (Papain, ficin and bromelin). The negative charge on the red cells 
is carried on the glycoprotein molecule of the red cell membrane. Proteolytic 
enzymes at the correct concentration can potentially remove some of these 
protein molecules and thus reduce the negative charge on the red cells and 
thus reduces the gap allowing IgG antibody to be able to span the gap and 
produce agglutination. However removal of these glycoprotein molecules 
by enzyme treatment can potential expose some antigenic specificities by 
removing charge proteins physically close to the antigen (reduction of steric 
hindrance) and facilitate their reaction with antibody containg the corre-
sponding group specific antibodies. Enzyme treatment facilitate the reaction 
by Rh and Kell antigens. Enzyme treat however destroy certain proteins 
present with the glycoproteins. Such antigens are therefore not detectable by 
enzyme technique (Fya, Fyb, Xga, S, s, M and N).
3. Anti humanglobulin (AHG) reagent. Anti-human globulin reagent are an-
tibodies produced against human globulin (IgG) and will detect the pres-
ence of human globulin coating on red cells (sensitized red cells) by forming 
cross linksbetween the IgG antibody coating on sensitized red cells. The Fab 
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portion of the anti-human globulin cross link with the Fc portion of the IgG 
molecule and help overcome the challenge caused by the zeta potential al
lowing the reaction links between the antigens on the red cells and antibod
ies in the plasma to be visualized in the form of agglutination. Antiglobulin 
test is one of the most important serological tests done in a routine blood 
transfusion laboratory. It utilizes the anti-human globulin (AHG) reagent to 
bring about agglutination of red cells coated with immunoglobulin or com
plement component, which do not show any agglutination in saline. Red 
cells which are coated with incomplete (IgG) antibodies show agglutination 
on addition of anti-human globulin (AHG or Coombs; reagent). The coating 
can occur either in vivo or in vitro following incubation with serum contain
ing the antibody. The majority of incomplete antibodies are IgG which attach 
to the red cell membrane by he Fab portion. The two arm of IgG molecule 
are unable to bridge the gap between red cells which are separated from 
each other because of the negative charge on their surface. While this results 
in sensitization of the cells, agglutination is not seen as the RBCs do not form 
lattice. Addition of AHG reagent results in the Fab portion of the AHG mol
ecule combining with the Fc portion of two adjacent IgG molecules, thereby 
bridging the gap between the red cells and causing agglutination.
 Demonstration of role of AHG reagent in causing agglutination of IgG sensitizes RBCS
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that is large enogh to bridge this slipping plane and cause agglutination. IgM 
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(charge density) of the red cell suspension medium thereby reducing the 
net repulsive force between cells suspended in saline. This potentially re
duced the distance apart between red cells allowing low molecular weight 
IgG antibody to span the gap and cause a reversible aggregation. This ag
gregation cross linkages between antibody sensitized red cells to produce 
agglutination. Polyethylene glycol (PEG) can potential enhance the uptake 
of antibody onto the red cells and can be used in conjunction with the AHG 
technique.
2. Enzyme (Papain, ficin and bromelin). The negative charge on the red cells 
is carried on the glycoprotein molecule of the red cell membrane. Proteolytic 
enzymes at the correct concentration can potentially remove some of these 
protein molecules and thus reduce the negative charge on the red cells and 
thus reduces the gap allowing IgG antibody to be able to span the gap and 
produce agglutination. However removal of these glycoprotein molecules 
by enzyme treatment can potential expose some antigenic specificities by 
removing charge proteins physically close to the antigen (reduction of steric 
hindrance) and facilitate their reaction with antibody containg the corre
sponding group specific antibodies. Enzyme treatment facilitate the reaction 
by Rh and Kell antigens. Enzyme treat however destroy certain proteins 
present with the glycoproteins. Such antigens are therefore not detectable by 
enzyme technique (Fya, Fyb, Xga, S, s, M and N).
3. Anti humanglobulin (AHG) reagent. Anti-human globulin reagent are an
tibodies produced against human globulin (IgG) and will detect the pres
ence of human globulin coating on red cells (sensitized red cells) by forming 
cross linksbetween the IgG antibody coating on sensitized red cells. The Fab 
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portion of the anti-human globulin cross link with the Fc portion of the IgG 
molecule and help overcome the challenge caused by the zeta potential al-
lowing the reaction links between the antigens on the red cells and antibod-
ies in the plasma to be visualized in the form of agglutination. Antiglobulin 
test is one of the most important serological tests done in a routine blood 
transfusion laboratory. It utilizes the anti-human globulin (AHG) reagent to 
bring about agglutination of red cells coated with immunoglobulin or com-
plement component, which do not show any agglutination in saline. Red 
cells which are coated with incomplete (IgG) antibodies show agglutination 
on addition of anti-human globulin (AHG or Coombs; reagent). The coating 
can occur either in vivo or in vitro following incubation with serum contain-
ing the antibody. The majority of incomplete antibodies are IgG which attach 
to the red cell membrane by he Fab portion. The two arm of IgG molecule 
are unable to bridge the gap between red cells which are separated from 
each other because of the negative charge on their surface. While this results 
in sensitization of the cells, agglutination is not seen as the RBCs do not form 
lattice. Addition of AHG reagent results in the Fab portion of the AHG mol-
ecule combining with the Fc portion of two adjacent IgG molecules, thereby 
bridging the gap between the red cells and causing agglutination.
RBC RBC
IgG Coating RBC
Anti Human IgG 
 Demonstration of role of AHG reagent in causing agglutination of IgG sensitizes RBCS
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Figure 5: Effect of surface tension on agglutination reaction
Demonstration of the first stage of agglutination (Sensitization). 
Demonstration of the second stage of the agglutination process (Clumping)
Red Cell Membrane. The red cell membrane is made up of lipids (40%), proteins (49%) and car-
bohydrate (7%). The membrane of the red blood cell plays many roles that aid in regulating their 
surface deformability, flexibility, adhesion to other cells and immune recognition. The red blood 
cell membrane is composed of 3 layers: the glycocalyx on the exterior, which is rich in carbohy-
drates; the lipid bilayer which contains many transmembrane proteins, besides its phoslipid main 
constituents; and the membrane skeleton, a structural network of proteins located on the inner 
surface of the lipid bilayer. The erythrocyte cell membrane comprises a typical lipid bilayer, simi-
lar to what can be found in virtually all human cells. Simply put, this lipid bilayer is composed of 
cholesterol and phospholipids in equal proportions by weight. The lipid composition is important 
as it defines many physical properties such as membrane permeability and fluidity. 
Lipids. Phospholipids are the major lipid component of the red cells and constitute 75% of the 
lipid component. The lipid bilayer is made up of a hydrophilic water soluble head and two 
hydrophobic water insoluble tail groups. This bilayer confers the property of impemeability 
to ions and other metabolites as well as the deformability.
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. The interaction of proteins and the lipid bilayer allow for selective transport across the 
membrane bi-layer as well as the maintenance of the skeletal function. Red cell protein appears 
either as free component or anchored to the ankrin and spectrin protein underneath the phospholi
pid bi-layer. Proteins of the membrane skeleton are responsible for the deformability, flexibility and 
durability of the red blood cell, enabling it to squeeze through tiny capillaries. There are currently 
more than 50 known membrane proteins. Approximately 25 of these membrane proteins carry the 
various blood group antigens, such as the A, B and Rh antigens. These membrane proteins can 
perform a wide diversity of functions, such as transporting ions and molecules across the red cell 
membrane, adhesion and interaction with other cells. Disorders of the proteins in these membranes 
are associated with many disorders, such as hereditary spherocytosis, hereditary elliptocytosis, he
reditary stomatocytosis, and paroxysmal nocturnal hemoglobinuria. The red blood cell membrane 
proteins organized according to their function. Red Blood Cell membrane major proteins performs 
3 major functions; selective transport across the membrane barrier, cell adhesion and structural role. 
. The following blood group antigens (ABO, Lewis) are essentially carbohy
drates. Majority of the carbonhydrate components of the red cell membrane occur either as 
glycoproteins (Rh, Kidd, Lutheran, Kell, Duddy) or glycolipids (P antigen). Glycolipid con
stitutes 5% of the total lipid component of the red cell membrane. The glycoproteins sialo
glycoproteins) constitute a significant portion of the red cell membrane Sialic acid (N-acetyl-
neuramic acid) component. Sialic acid is a major charged molecule of the red cell membrane 
that confers the red cell with a net negative charge. Examples of sialoglycoproteins include 
glycophorin A (MN antigens) and B (Ss antigens).
Complement regulation
Rhesus, Kidd, Diego, Colton and Kx
Cell adhesion molecules Lutheran, LW, XG and Indian
Membrane bound enzymes Kell and Cartwright
Structural assembly MNSs and Gerbich
Chemokine receptor Duffy
Blood group antigen and associated red cell membrane functions
. The red cell membrane plays an active role in selective 
transport. Band 3 is an anion transporter that defines the Diego blood group. It is also an 
important structural component of the erythrocyte cell membrane (makes up to 25% of the 
cell membrane surface and each red cell contains approximately one million copies). Aqua
porin 1 is a water transport protein and defines the Colton blood group. Glut1 is a glucose 
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Figure 5: Effect of surface tension on agglutination reaction
Demonstration of the first stage of agglutination (Sensitization). 
Demonstration of the second stage of the agglutination process (Clumping)
 The red cell membrane is made up of lipids (40%), proteins (49%) and car
bohydrate (7%). The membrane of the red blood cell plays many roles that aid in regulating their 
surface deformability, flexibility, adhesion to other cells and immune recognition. The red blood 
cell membrane is composed of 3 layers: the glycocalyx on the exterior, which is rich in carbohy
drates; the lipid bilayer which contains many transmembrane proteins, besides its phoslipid main 
constituents; and the membrane skeleton, a structural network of proteins located on the inner 
surface of the lipid bilayer. The erythrocyte cell membrane comprises a typical lipid bilayer, simi
lar to what can be found in virtually all human cells. Simply put, this lipid bilayer is composed of 
cholesterol and phospholipids in equal proportions by weight. The lipid composition is important 
as it defines many physical properties such as membrane permeability and fluidity. 
. Phospholipids are the major lipid component of the red cells and constitute 75% of the 
lipid component. The lipid bilayer is made up of a hydrophilic water soluble head and two 
hydrophobic water insoluble tail groups. This bilayer confers the property of impemeability 
to ions and other metabolites as well as the deformability.
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Proteins. The interaction of proteins and the lipid bilayer allow for selective transport across the 
membrane bi-layer as well as the maintenance of the skeletal function. Red cell protein appears 
either as free component or anchored to the ankrin and spectrin protein underneath the phospholi-
pid bi-layer. Proteins of the membrane skeleton are responsible for the deformability, flexibility and 
durability of the red blood cell, enabling it to squeeze through tiny capillaries. There are currently 
more than 50 known membrane proteins. Approximately 25 of these membrane proteins carry the 
various blood group antigens, such as the A, B and Rh antigens. These membrane proteins can 
perform a wide diversity of functions, such as transporting ions and molecules across the red cell 
membrane, adhesion and interaction with other cells. Disorders of the proteins in these membranes 
are associated with many disorders, such as hereditary spherocytosis, hereditary elliptocytosis, he-
reditary stomatocytosis, and paroxysmal nocturnal hemoglobinuria. The red blood cell membrane 
proteins organized according to their function. Red Blood Cell membrane major proteins performs 
3 major functions; selective transport across the membrane barrier, cell adhesion and structural role. 
Carbonhydrate. The following blood group antigens (ABO, Lewis) are essentially carbohy-
drates. Majority of the carbonhydrate components of the red cell membrane occur either as 
glycoproteins (Rh, Kidd, Lutheran, Kell, Duddy) or glycolipids (P antigen). Glycolipid con-
stitutes 5% of the total lipid component of the red cell membrane. The glycoproteins sialo-
glycoproteins) constitute a significant portion of the red cell membrane Sialic acid (N-acetyl-
neuramic acid) component. Sialic acid is a major charged molecule of the red cell membrane 
that confers the red cell with a net negative charge. Examples of sialoglycoproteins include 
glycophorin A (MN antigens) and B (Ss antigens).
Red cell membrane function Associated blood group antigens
Complement regulation Cromer and Knops
Membrane transport Rhesus, Kidd, Diego, Colton and Kx
Cell adhesion molecules Lutheran, LW, XG and Indian
Membrane bound enzymes Kell and Cartwright
Structural assembly MNSs and Gerbich
Chemokine receptor Duffy
Blood group antigen and associated red cell membrane functions
Functions of the red cell membrane. The red cell membrane plays an active role in selective 
transport. Band 3 is an anion transporter that defines the Diego blood group. It is also an 
important structural component of the erythrocyte cell membrane (makes up to 25% of the 
cell membrane surface and each red cell contains approximately one million copies). Aqua-
porin 1 is a water transport protein and defines the Colton blood group. Glut1 is a glucose 
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and L-dehydroascorbic acid transporter. Kidd antigen protein is responsible for urea trans-
porter. RhAG is a major gas transporter, probably of carbon dioxide (defines Rh blood group 
and the associated unusual blood group phenotype Rh null phenotype. The Kx and Diego 
blood group antigens are also associated with membrane transport The red cell membrane 
also plays an active role in cell adhesion. Examples of blood group antigen associated with 
cell adhesion include the; Lutheran, LW, XG and the Indian blood group antigen proteins. 
Examples of blood group antigen associated with membrane bound enzymes include the; 
Cartwright and Kell blood group antigen proteins. The red cell membrane plays a structural 
role. The following membrane proteins establish linkages with skeletal proteins and may play 
an important role in regulating cohesion between the lipid bilayer andmembrane skeleton, 
likely enabling the red cell to maintain its favorable membrane surface area by preventing the 
membrane from collapsing; ankyrin-based macromolecular complex - proteins linking the 
bilayer to the membrane skeleton through the interaction of their cytoplasmic domains with 
Ankyrin. The MNSs and Gerbich are associated with structural assembly. The Duffy blood 
group antigen play an active role as a chemokine receptor while the Cromer and Knops blood 
group antigen have been found associated with complement regulation.
Antibody
 An antibody is a proteins occurring in body fluids produced by lymphocytes as a result of 
stimulation by an antigen and which can interact specifically with that particular antigen. An-
tibodies are immune system-related proteins called immunoglobulin. Each antibody consists 
of four polypeptides– two heavy chains and two light chains joined to form a “Y” shaped mol-
ecule and linked by disulphide bonds. There are two pairs of chains in the molecule: heavy 
and light. There are two classes (isotypes) of the light chain called kappa and lambda. Heavy 
chains have five different isotypes which divide the Igs into five different classes (IgG1-4, 
IgA1-2, IgD, IgM, and IgE). The amino acid sequence in the tips of the “Y” varies greatly 
among different antibodies. This variable region, composed of 110-130 amino acids, give the 
antibody its specificity for binding antigen. The variable region includes the ends of the light 
and heavy chains. Treating the antibody with a protease can cleave this region, producing 
Fab or fragment antigen binding that includes the variable ends of an antibody. Antibodies 
are immunoglobulin. The clases of immunoglobulins include; IgG which provides long-term 
immunity or protection, IgM which is the first antibody produced in response to an antigenic 
stimulus, IgA which are found in secretions and help protects against infections in urinary, 
gastro intestinal and respiratory tracts, IgE which are involved in allergic reactions and IgD 
which occur as surface receptor of B lymphocytes. The most clinically significant antibodies 
in transfusion medicine are IgM and IgG and to an extent IgA. IgG frequently cause in vivo 
haemolysis compared to Igm which does not cause invivo haemolysis except for ABO blood 
group antibodies. The clinical significance of a red cell antibody depends on the following:
• Ability of the red cell antibody to cause haemolysis in vivo
• Ability of the red cell antibody to cause a transfusion reaction
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• Ability of the red cell antibody to cause haemolytic disease of the 
foetus and newborn (HDFN).
1. Heavy chains - made of alpha, gamma, delta, mu, or epsilon chains 
2. Light chains - made of kappa or lambda chains 
3. Disulfide bonds - hold chains together 
4. Hinge region - allows antibody to flex to reach more antigen sites 
5. Fab fragments - contains variable portion of antibody: antigen-binding 
sites 
. Antibodies are immunoglobulin used by the immune system to iden
tify and neutralize foreign substances (antigen) such as bacteria and viruses. The antibody 
recognizes a unique part of the foreign target, termed an antigen. Each antibody contains a 
paratope that is specific for one particular epitope on an antigen, allowing these two struc
tures to bind together with precision. Using this binding mechanism, an antibody can tag a 
microbe or an infected cell for attack by other parts of the immune system, or can neutralize 
its target directly (for example, by blocking a part of a microbe that is essential for its invasion 
and survival). Antibodies are produced via the humoral immune response mechanism. Anti
gens are processed by the antigen presenting cells (APC) which are macrophages. The proc
essed antigen is presented by the APC together with a glycoprotein coded for by the Major 
Histocompaibility Complex (MHC) to a CD4+ (helper) T-lymphocyte. These in turn intearacts 
with other cells including interlukin-1 which stimulates the CD4+ cells to secrete cytokines 
and interferon which help to stimulate proliferation of more T lymphocytes resulting in the 
activation of B lymphocytes. The activated B cells differentiate into either antibody-producing 
cells called plasma cells that secrete soluble antibody or memory cells that survive in the 
body for years afterward in order to allow the immune system to remember an antigen and 
respond faster upon future exposures. The plasma cells synthesizes and secretes antibody 
molecule that is specific for the antigen structure that stimulated it’s production. A variable 
number of B lymphocytes may be involved in each immune response. A number of plasma 
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stimulus, IgA which are found in secretions and help protects against infections in urinary, 
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• Ability of the red cell antibody to cause haemolytic disease of the 
foetus and newborn (HDFN).
Structure of an Antibody
Parts of an antibody:
1. Heavy chains - made of alpha, gamma, delta, mu, or epsilon chains 
2. Light chains - made of kappa or lambda chains 
3. Disulfide bonds - hold chains together 
4. Hinge region - allows antibody to flex to reach more antigen sites 
5. Fab fragments - contains variable portion of antibody: antigen-binding 
sites 
Antibody production. Antibodies are immunoglobulin used by the immune system to iden-
tify and neutralize foreign substances (antigen) such as bacteria and viruses. The antibody 
recognizes a unique part of the foreign target, termed an antigen. Each antibody contains a 
paratope that is specific for one particular epitope on an antigen, allowing these two struc-
tures to bind together with precision. Using this binding mechanism, an antibody can tag a 
microbe or an infected cell for attack by other parts of the immune system, or can neutralize 
its target directly (for example, by blocking a part of a microbe that is essential for its invasion 
and survival). Antibodies are produced via the humoral immune response mechanism. Anti-
gens are processed by the antigen presenting cells (APC) which are macrophages. The proc-
essed antigen is presented by the APC together with a glycoprotein coded for by the Major 
Histocompaibility Complex (MHC) to a CD4+ (helper) T-lymphocyte. These in turn intearacts 
with other cells including interlukin-1 which stimulates the CD4+ cells to secrete cytokines 
and interferon which help to stimulate proliferation of more T lymphocytes resulting in the 
activation of B lymphocytes. The activated B cells differentiate into either antibody-producing 
cells called plasma cells that secrete soluble antibody or memory cells that survive in the 
body for years afterward in order to allow the immune system to remember an antigen and 
respond faster upon future exposures. The plasma cells synthesizes and secretes antibody 
molecule that is specific for the antigen structure that stimulated it’s production. A variable 
number of B lymphocytes may be involved in each immune response. A number of plasma 
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cells may be stimulated to secrete monospecific antibody which is aimed at a single antigenic 
specificity. The immune response is dependent on a number of factors such as; the amount 
of antigen introduced, the immune competence of the individual and the immunogenicity 
of the substance. The production of antibody involving circulating monocytes, T and B lym-
phocytes and tissue bound macrophages can result in either a primary or secondary immune 
response. The antibody molecule is made up of heavy and light chains held together by a 
non-covalent disulphide bond. There are five types of chains; gamma (G), MU (M), alpha (A), 
delta (D) and epsilon (E) which determines the 5 classes of immunoglobulin (IgG, IgM, IgA, 
IgD and IgE respectively). IgG is made up of 4 classes (IgG 1 to 4). The subtypes IgG 1 and 3 
are most immune compared to 2 and 4. There are 2 types of light chains; kappa (K) and Lamd 
(L). Most blood grou antibodies are predominantly Igm, IgG and IgA and never IgD and E.
Summary of a primary immune response
Immunisation by foreign substance (Antigen)
Contact betwen antigen and antigen presenting cells (APC)
Ingestion of antigen and MHC class 2 protein by APC
Interaction between APC and CD4 lymphocites (recognising antigen)
APC secrets IL-1 and CD4 secretes cytokine promote T cell proliferation
Interaction between CD4 and Bcell growth factors
B cell divides to produce identical daughter cells
Daughter cells develop into plasma and memory
Plasma cells secretes antibodies
Primary and secondary immune responses. Following an encounter with a foreign antigenic 
substances (several weeks and months), the body produces small amount of IgM antibod-
ies. This constitutes a primary immune response. Once the IgM antibody has been produced 
some of the B cells (memory B cells) will survive in the body and remember that same antigen 
in subsequent future exposure leading to the production of antibody of the IgG class. This 
type of immune response produced by primed (memory) B lymphocytes (anamnestic or sec-
ondary immune response) following a second exposure to a second dose of the antigen pro-
duces a larger amount of IgG with less delay as in primary immune response. The antibody 
produced following a secondary immune response has a better affinity for the corresponding 
specifc antigen (Avidity).
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. Response to red cell 
antigen exposure: An individual can become exposed to the red cell of another person either 
throgh blood transfusion or pregnancy. Either of these exposure can result in antibody pro
duction if the red cell antigen introdued is foreign or the exposed individual lacks the intro
duced antigen. Such exposure stimulates the recipient immune system to produce immune 
alloantibodies. About 2-9% of patients produces immune antibodies. Transfusion of a red 
cell containing antigen which the receipinet lacks can stimulate the recipient to produce im
mune antibody against that antigen (for example transfusing Kell positive red cells to a Kell 
negative receipient). Feto maternal haemorrhage during pregnancy or delivery can introduce 
foetal red cells containing red cells antigen which the mother lacks into the maternal circula
tion and stimulate the mum to produce immune antibody against the foetal red cell antigen 
(example is feto maternal haemorrhage of Rhesus positive foetal red cells into a mum that is 
Rhesus negative).
Chemical structures (carbonhydrate) similar to red cell 
antigen are common in nature (food and surface of bacterial). Exposures of the body to these 
chemical structures can result in the production of antibodies. The anti-A, anti-B and anti 
A,B present in group B,A and O individuals respectively are thought to arise as a result to 
exposure to ABO like chemical substances which occur in nature. This happens at an early 
age because sugars that are identical to or very similar to the ABO blood group antigens are 
found throughout nature. This is based on the observation that animals kept in a sterile room 
from birth were shown to lack these antibodies. 
. The classes of immunoglobulins can de divided into subclasses 
based on small differences in the amino acid sequences in the constant region of the heavy 
chains. All immunoglobulins within a subclass will have very similar heavy chain constant 
region amino acid sequences. IgG subclasses includes; IgG1 - Gamma 1 heavy chains, IgG2 
- Gamma 2 heavy chains, IgG3 - Gamma 3 heavy chains and IgG4 - Gamma 4 heavy chains. 
The IgA subclasses includes; IgA1 - alpha 1 heavy chain and IgA2 - Alpha 2 heavy chains.
. IgM normally exists as a pentamer but it can also exist as a monomer. 
In the pentameric form all heavy chains are identical and all light chains are identical. IgM has 
an extra domain on the mu chain (CH4) and it has another protein covalently bound via a S-S 
bond called the J chain. This chain functions in polymerization of the molecule into a pentam
er. IgM is the third most common serum Ig. IgM is the first Ig to be made by the fetus and the 
first Ig to be made by a virgin B cells when it is stimulated by antigen. As a consequence of its 
pentameric structure, IgM is a good complement fixing Ig. Thus, IgM antibodies are very ef
ficient in leading to the lysis of microorganisms. As a consequence of its pentameric structure, 
IgM is a good complement fixing Ig. Thus, IgM antibodies are very efficient in leading to the 
lysis of microorganisms. As a consequence of its structure, IgM is also a good agglutinating 
Ig. Thus, IgM antibodies are very good in clumping microorganisms for eventual elimination 
from the body. IgM binds to some cells via Fc receptors.
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Circumstances surrounding the production of red cells antibodies. Response to red cell 
antigen exposure: An individual can become exposed to the red cell of another person either 
throgh blood transfusion or pregnancy. Either of these exposure can result in antibody pro-
duction if the red cell antigen introdued is foreign or the exposed individual lacks the intro-
duced antigen. Such exposure stimulates the recipient immune system to produce immune 
alloantibodies. About 2-9% of patients produces immune antibodies. Transfusion of a red 
cell containing antigen which the receipinet lacks can stimulate the recipient to produce im-
mune antibody against that antigen (for example transfusing Kell positive red cells to a Kell 
negative receipient). Feto maternal haemorrhage during pregnancy or delivery can introduce 
foetal red cells containing red cells antigen which the mother lacks into the maternal circula-
tion and stimulate the mum to produce immune antibody against the foetal red cell antigen 
(example is feto maternal haemorrhage of Rhesus positive foetal red cells into a mum that is 
Rhesus negative).
Exposure to environmental antigen: Chemical structures (carbonhydrate) similar to red cell 
antigen are common in nature (food and surface of bacterial). Exposures of the body to these 
chemical structures can result in the production of antibodies. The anti-A, anti-B and anti 
A,B present in group B,A and O individuals respectively are thought to arise as a result to 
exposure to ABO like chemical substances which occur in nature. This happens at an early 
age because sugars that are identical to or very similar to the ABO blood group antigens are 
found throughout nature. This is based on the observation that animals kept in a sterile room 
from birth were shown to lack these antibodies. 
Immunoglobulin subclasses. The classes of immunoglobulins can de divided into subclasses 
based on small differences in the amino acid sequences in the constant region of the heavy 
chains. All immunoglobulins within a subclass will have very similar heavy chain constant 
region amino acid sequences. IgG subclasses includes; IgG1 - Gamma 1 heavy chains, IgG2 
- Gamma 2 heavy chains, IgG3 - Gamma 3 heavy chains and IgG4 - Gamma 4 heavy chains. 
The IgA subclasses includes; IgA1 - alpha 1 heavy chain and IgA2 - Alpha 2 heavy chains.
IgM immunoglobulin. IgM normally exists as a pentamer but it can also exist as a monomer. 
In the pentameric form all heavy chains are identical and all light chains are identical. IgM has 
an extra domain on the mu chain (CH4) and it has another protein covalently bound via a S-S 
bond called the J chain. This chain functions in polymerization of the molecule into a pentam-
er. IgM is the third most common serum Ig. IgM is the first Ig to be made by the fetus and the 
first Ig to be made by a virgin B cells when it is stimulated by antigen. As a consequence of its 
pentameric structure, IgM is a good complement fixing Ig. Thus, IgM antibodies are very ef-
ficient in leading to the lysis of microorganisms. As a consequence of its pentameric structure, 
IgM is a good complement fixing Ig. Thus, IgM antibodies are very efficient in leading to the 
lysis of microorganisms. As a consequence of its structure, IgM is also a good agglutinating 
Ig. Thus, IgM antibodies are very good in clumping microorganisms for eventual elimination 
from the body. IgM binds to some cells via Fc receptors.
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IgG immunoglobulin. All IgG’s are monomers (7S immunoglobulin). The subclasses differ 
in the number of disulfide bonds and length of the hinge region. IgG is the most versatile 
immunoglobulin because it is capable of carrying out all of the functions of immunoglobulin 
molecules. IgG is the major Ig in serum - 75% of serum Ig is IgG. IgG is the major Ig in extra 
vascular spaces. Placental transfer - IgG is the only class of Ig that crosses the placenta. Trans-
fer is mediated by a receptor on placental cells for the Fc region of IgG. Not all subclasses 
cross equally well; IgG2 does not cross well. Fixes complement - Not all subclasses fix equally 
well; IgG4 does not fix complement. Binding to cells - macrophages, monocytes, and some 
lymphocytes have Fc receptors for the Fc region of IgG. Not all subclasses bind equally well. 
IgG2 and IgG4 do not bind to Fc receptors. A consequence of binding to the Fc receptors on 
PMNs, monocytes and macrophages is that the cell can now internalize the antigen better. 
The antibody has prepared the antigen for eating by the phagocytic cells. The term opsonin is 
used to describe substances that enhance phagocytosis. IgG is a good opsonin. Binding of IgG 
to Fc receptors on other types of cells results in the activation of other functions.
IgA immunoglobulin. Serum IgA is a monomer but IgA found in secretions is a dimer. When 
IgA is found in secretions is also has another protein associated with it called the secretory 
piece or T piece; IgA is sometimes referred to as 11S immunoglobulin. Unlike the remainder 
of the IgA which is made in the plasma cell, the secretory piece is made in epithelial cells 
and is added to the IgA as it passes into the secretions. The secretory piece helps IgA to be 
transported across mucosa and also protects it from degradation in the secretions. IgA is the 
2nd most common serum Ig. IgA is the major class of Ig in secretions - tears, saliva, colostrum, 
mucus. Since it is found in secretions secretory IgA is important in local (mucosal) immunity. 
Normally IgA does not fix complement, unless aggregated. IgA can bind to some cells - poly-
morphonuclear leukocytes and some lymphocytes.
IgD immunoglobulin. IgD exists only as a monomer. IgD is found in low levels in serum; 
its role in serum uncertain. IgD is primarily found on B cell surfaces where it functions as a 
receptor for antigen. IgD on the surface of B cells has extra amino acids at C-terminal end for 
anchoring to the membrane. It also associates with the Ig-alpha and Ig-beta chains. IgD does 
not bind complement.
IgE immunoglobulin. IgE exists as a monomer and has an extra domain in the constant re-
gion. IgE is the least common serum Ig since it binds very tightly to Fc receptors on basophils 
and mast cells even before interacting with antigen. Involved in allergic reactions - As a con-
sequence of its binding to basophils an mast cells, IgE is involved in allergic reactions. Bind-
ing of the allergen to the IgE on the cells results in the release of various pharmacological 
mediators that result in allergic symptoms. IgE also plays a role in parasitic helminth diseases. 
Since serum IgE levels rise in parasitic diseases, measuring IgE levels is helpful in diagnosing 
parasitic infections. Eosinophils have Fc receptors for IgE and binding of eosinophils to IgE-
coated helminths results in killing of the parasite. IgE does not fix complement.
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An antibody (immunoglobulin) is a large Y-shaped protein used by the immune system to 
identify and neutralize foreign objects such as bacteria and viruses. The immunoglobulin 
molecule can be brokem down into its functional parts by the action of a proteolytic enzymes 
papain into 2 Fab fragments and one Fc fragment. The Fab fragment is made up of an intact 
light chain and the amino –terminal end of the heavy chain linked by a disulphide bondThe 
Fab portion is predominantly carbonhydrate and contains specific antigen binding ability 
(contain antigen binding site). The Fc (Fragment Crystalline) portion is made up of carboxy 
terminal portions of 2 heavy chains linked by disulphide bond. It is commonly associated 
with some IgG molecule and play a role in complement and macrophage binding.
1. Fab region
2. Fc region
3. Heavy chain (blue) with one variable (VH) domain followed by a constant domain (CH1), a hinge 
region, and two more constant (CH2 and  CH3) domains.
4. Light chain (green) with one variable (VL) and one constant (CL) domain
5. Antigen binding site (paratope)
6. Hinge regions.
Immunoglobulins are composed of four polypeptide chains: two “light” chains (lambda or 
kappa), and two “heavy” chains (alpha, delta, gamma, epsilon or mu). The type of heavy 
chain determines the immunoglobulin isotype (IgA, IgD, IgG, IgE, and IgM respectively). 
Light chains are composed of 220 amino acid residues while heavy chains are composed of 
440-550 amino acids. Each chain has “constant” and “variable” regions. 
. Variable regions are contained within the amino (NH2) terminal end of the 
polypeptide chain (amino acids 1-110). When comparing one antibody to another, these ami
no acid sequences are quite distinct. This region determines the specificity of an antibody and 
is composed of variable amino acids sequences. 
. Constant regions, comprising amino acids 111-220 (or 440-550), are rather 
uniform, in comparison from one antibody to another, within the same isotype. This section 
determines the biological function such as complement activation, placenta transfer and the 
ability to bind to macropgages.
. The hinge region is located within the constant section of the heavy chain and 
provides the heavy chain a degree of flexibility enabling it to change its shape. The hinge re
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and mast cells even before interacting with antigen. Involved in allergic reactions - As a con
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ing of the allergen to the IgE on the cells results in the release of various pharmacological 
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coated helminths results in killing of the parasite. IgE does not fix complement.
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Functional parts of an immunoglobulin molecule.
An antibody (immunoglobulin) is a large Y-shaped protein used by the immune system to 
identify and neutralize foreign objects such as bacteria and viruses. The immunoglobulin 
molecule can be brokem down into its functional parts by the action of a proteolytic enzymes 
papain into 2 Fab fragments and one Fc fragment. The Fab fragment is made up of an intact 
light chain and the amino –terminal end of the heavy chain linked by a disulphide bondThe 
Fab portion is predominantly carbonhydrate and contains specific antigen binding ability 
(contain antigen binding site). The Fc (Fragment Crystalline) portion is made up of carboxy 
terminal portions of 2 heavy chains linked by disulphide bond. It is commonly associated 
with some IgG molecule and play a role in complement and macrophage binding.
1. Fab region
2. Fc region
3. Heavy chain (blue) with one variable (VH) domain followed by a constant domain (CH1), a hinge 
region, and two more constant (CH2 and  CH3) domains.
4. Light chain (green) with one variable (VL) and one constant (CL) domain
5. Antigen binding site (paratope)
6. Hinge regions.
Immunoglobulins are composed of four polypeptide chains: two “light” chains (lambda or 
kappa), and two “heavy” chains (alpha, delta, gamma, epsilon or mu). The type of heavy 
chain determines the immunoglobulin isotype (IgA, IgD, IgG, IgE, and IgM respectively). 
Light chains are composed of 220 amino acid residues while heavy chains are composed of 
440-550 amino acids. Each chain has “constant” and “variable” regions. 
Variable region. Variable regions are contained within the amino (NH2) terminal end of the 
polypeptide chain (amino acids 1-110). When comparing one antibody to another, these ami-
no acid sequences are quite distinct. This region determines the specificity of an antibody and 
is composed of variable amino acids sequences. 
Constant region. Constant regions, comprising amino acids 111-220 (or 440-550), are rather 
uniform, in comparison from one antibody to another, within the same isotype. This section 
determines the biological function such as complement activation, placenta transfer and the 
ability to bind to macropgages.
Hinge region. The hinge region is located within the constant section of the heavy chain and 
provides the heavy chain a degree of flexibility enabling it to change its shape. The hinge re-
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gion allows the IgG immunoglobulin to maintain its T shape in serum or plasma and enable 
the antigen binding sites to be maximally distant from each other. The IgG molecule becomes 
a characteristically Y shaped on binding with an antigen allowing for greater accessibility of 
the constant region and facillites complement activation.
Structure of IgG and IgM immunoglobulin
Property IgG IgM
Capacity to cross the placenta Yes No
Capable of complement activation Yes Yes
Normal temperature of reaction 4-20°C 37°C
Number of subclasses 4 None
Approximate molecular weight 150,000 900,000
Number of antigen-binding sites 2 10
Size of antibody
Comprises of single im-
munoglobulin subunit 
(monomer)
Comprised of 5 immunoglob-
ulin subunits (pentamer)
Table: Comparison between the properties of IgM and IgG immunoglobulin.
3. Blood Group Systems and ABO groups
Blood Group terminologies
There are terminologies used to represent different blood group antigens. Correct usage of 
these terminologies is critical to ensure that the correct information is recorded and transmit-
ted. These terminologies include:
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• Allerlic genes are represented as superscript. Examples as; Duffy A 
(Fy ), B (Fyb), Kidd blood group as (JK  and JKb), Lewis blood group 
antigen as (Le  and Leb).
• Positive and negative signs are often used to represent the presence 
or absence of red cell antigens. For examples; Fy (a+b ), K+. However 
in the ABO blood group system a positive and negative sign after the 
ABO blood group indicates the presence of not just the ABO group 
but the Rh (D) antigen. For example A+ indicates presence of antigen 
A and D.
• Short hand notations and subscript symbols and letter as well as 
subscript numbers are often used as nomenclature for the Rh blood 
group system. Examples are (rʹ, rʹ) or Ro, R1, R2 Rz).
• Antibodies are written as their antigen notations with the prefix anti-. 
Examples are; anti-D, anti –K, anti-Fy  and anti –S).
• If a patient is grouped using single antibody specificity say anti-S 
and found positive. It is erroneous to assume that the patients is 
negative for the antithetical antigen s-. This assumption will only be 
correct if the patient red cells was also tested against an antibody 
with anti-s specificity.
• If a patient is positive for an alloantibody say anti-Le , it is wrong to 
assume that the patient is negative for antigen Le  unless the patient 
red cells have been tested against anti- Le sera). Grouping a patient 
to establish negativity for a red cell antigen can sometimes be used to 
confirm the specificity of an alloantibody.
• ISBT numbers are now being used to produce uniformity in the ter
minology used to identify red cell antigens (eye readable and adapt
able for computer use). Each red cell antigen is given a 6 unique digit 
number (first 3 representing the blood group system and the 2  three 
the antigen itself). The table below shows the nomenclature includ
ing the ISBT number for the 9 most clinical significant blood group 
systems.
001 A, A1, A2, B, AB,A1B, A2B and O
002 M+, M-, N+, N-, S+,S-,s+ & s-
003 P1 & P P1 and P2
Rhesus (Rh) 004 C+, C-, c+, c-, D+, D-, E+ and e-
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• Allerlic genes are represented as superscript. Examples as; Duffy A 
(Fya), B (Fyb), Kidd blood group as (JKa and JKb), Lewis blood group 
antigen as (Lea and Leb).
• Positive and negative signs are often used to represent the presence 
or absence of red cell antigens. For examples; Fy (a+b  _), K+. However 
in the ABO blood group system a positive and negative sign after the 
ABO blood group indicates the presence of not just the ABO group 
but the Rh (D) antigen. For example A+ indicates presence of antigen 
A and D.
• Short hand notations and subscript symbols and letter as well as 
subscript numbers are often used as nomenclature for the Rh blood 
group system. Examples are (rʹ, rʹ) or Ro, R1, R2 Rz).
• Antibodies are written as their antigen notations with the prefix anti-. 
Examples are; anti-D, anti –K, anti-Fya and anti –S).
• If a patient is grouped using single antibody specificity say anti-S 
and found positive. It is erroneous to assume that the patients is 
negative for the antithetical antigen s-. This assumption will only be 
correct if the patient red cells was also tested against an antibody 
with anti-s specificity.
• If a patient is positive for an alloantibody say anti-Lea, it is wrong to 
assume that the patient is negative for antigen Lea unless the patient 
red cells have been tested against anti- Lea sera). Grouping a patient 
to establish negativity for a red cell antigen can sometimes be used to 
confirm the specificity of an alloantibody.
• ISBT numbers are now being used to produce uniformity in the ter-
minology used to identify red cell antigens (eye readable and adapt-
able for computer use). Each red cell antigen is given a 6 unique digit 
number (first 3 representing the blood group system and the 2nd three 
the antigen itself). The table below shows the nomenclature includ-






Common antigens Phenotypic variations
ABO 001 A and B A, A1, A2, B, AB,A1B, A2B and O
MNS 002 M, N, S and s M+, M-, N+, N-, S+,S-,s+ & s-
P 003 P1 & P P1 and P2
Rhesus (Rh) 004 C, c, D, E and e C+, C-, c+, c-, D+, D-, E+ and e-
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Lutheran 005 Lua and Lub Lua+, Lua-, Lub+ and Lub-
Kell 006 K, k, Kpa, Kpb, Jsa and Jsb K+, K-, k+, and k-.
Lewis 007 Lea and Leb Lea-, Lea+, Leb+ and Leb-
Duffy 008 Fya, Fyb Fya+ Fya-, Fyb+ and Fyb-
Kidd 009 Jka and Jkb Jka+, Jka-, Jkb+, Jkb-
Table: Nomenclature for the most clinical significant blood group systems
The ABO Blood group system
The ABO blood group system first described by the Austrian scientist Karl Landsteiner in 1901 is the 
most clinically significant blood group system in human blood transfusion. Four major groups were 
characterized (A, B, AB and O). This characterization was based on the occurrence of two antigens (A 
and B) occurring singly as A or B, doubling as AB or the absence of both as O. The associated anti-A 
and anti-B antibodies are usually IgM antibodies, which are not present in the newborn at birth but, 
appear after the first 6 months of life by sensitization to environmental substances such as food, bac-
teria (Gram negative E. Coli), and viruses (Influenza). Anti-A and anti-B antibodies are not able to 
pass through the placenta barrier to the fetal blood circulation and seldom cause hemolytic disease 
of the foetus and newborn (HDFN). However, some group O-type mother can produce IgG-type 
ABO antibodies. which have the potential to cross the placenta barrier and cause a less severe HDFN. 
Majority of the hemolytic blood transfusion reactions observed in practice are caused by the clerical 
and technical errors associated the ABO blood group system (complement-mediated lysis) of the 
RBCs. Landsteiner discovered this system out of curiosity after observing that the serum/plasma 
of certain health individuals agglutinated the red cells of others. This led to the postulation of the 
theory that: individuals who have the A and B antigens on their red cells lack the corresponding an-
tibodies in their plasma. Historically, while Landsteiner described A, B, and O antigens, Alfred von 
Decastello and Adriano Sturli discovered the fourth type (AB), in 1902. Ludwik Hirszfeld and von 
Dungern discovered the heritability of ABO blood groups in 1910–11. Felix Bernstein demonstrating 
the correct blood group inheritance pattern of multiple alleles at one locus in 1924 while Watkins 
and Morgan, in England, discovered that the ABO epitopes were conferred by specific sugars; N-
acetylgalactosamine for the A-type and galactose for the B-type. The ABO blood group system is the 
most clinical significant system for the following reasons.
• The regular occurrence of ABO blood group antibodies in the plasma 
or serum of healthy persons who lack the corresponding antigens on 
their red cells.
• The ability of ABO antibodies to cause intravascular haemolysis in 
the circulation of recipient transfused with red cells antigen to which 
they have the corresponding antibody.
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• The high frequency of the determinant A and B antigen in both Black 
and Caucasian population. 
A antigen Anti-B
B antigen Anti-A
A and B antigens
Anti-A and anti-B
ABO phenotypes and possible genotypes
ABO blood group antibodies are universally present in the serum /plasma of healthy adults. As 
a result of this fact, these antibodies were thought to be naturally occurring. However from the 
definition of an antibody, it is clear that an antibody only occurs as a result of stimulation by 
an antigen. In reality, ABO antibodies in the serum are not formed naturally. Their production 
is stimulated when the immune system encounters ABO blood group like antigens in foods or 
in micro-organisms. This happens at an early age because sugars that are identical to, or very 
similar to, the ABO blood group antigens are found throughout nature. The ABO locus has 
three main alleleic forms: A, B, and O. The A allele encodes a glycosyltransferase that produces 
the A antigen (N-acetylgalactosamine is its immunodominant sugar), and the B allele encodes a 
glycosyltransferase that creates the B antigen (D-galactose is its immunodominant sugar). ABO 
blood group antibodies react optimally at 16-22°C. They bind complements. ABO blood group 
antibodies can be immune (IgG) if stimulated by pregnancy and incompatible blood transfu
sion. To buttress this the agument that ABO antibodies are naturally occurring;
• Animal studies have shown that animal kept in a sterile room from 
birth do not produce antibodies. This is an indication that antibody 
production results from exposure to environmental stimulus.
• Children at birth have no ABO antibodies. Neonates under the age 
of 6 months have little or no ABO group antibody. Any ABO blood 
group antibody detected at birth is likely to be maternaternal anti
body that have been passively transferred via the placenta. ABO anti
body levels reaches the adult level about the age of 5years, remaining 
relatively stable during adult life and then usually decline at old age.
Clinical significance of the ABO blood group system
Transfusion of ABO incompatible unit (such as transfusing a B patient with 
group A red cell, a group A patient with a group B red cells or transfusing a group O patient 
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Table: Nomenclature for the most clinical significant blood group systems
The ABO blood group system first described by the Austrian scientist Karl Landsteiner in 1901 is the 
most clinically significant blood group system in human blood transfusion. Four major groups were 
characterized (A, B, AB and O). This characterization was based on the occurrence of two antigens (A 
and B) occurring singly as A or B, doubling as AB or the absence of both as O. The associated anti-A 
and anti-B antibodies are usually IgM antibodies, which are not present in the newborn at birth but, 
appear after the first 6 months of life by sensitization to environmental substances such as food, bac
teria (Gram negative E. Coli), and viruses (Influenza). Anti-A and anti-B antibodies are not able to 
pass through the placenta barrier to the fetal blood circulation and seldom cause hemolytic disease 
of the foetus and newborn (HDFN). However, some group O-type mother can produce IgG-type 
ABO antibodies. which have the potential to cross the placenta barrier and cause a less severe HDFN. 
Majority of the hemolytic blood transfusion reactions observed in practice are caused by the clerical 
and technical errors associated the ABO blood group system (complement-mediated lysis) of the 
RBCs. Landsteiner discovered this system out of curiosity after observing that the serum/plasma 
of certain health individuals agglutinated the red cells of others. This led to the postulation of the 
theory that: individuals who have the A and B antigens on their red cells lack the corresponding an
tibodies in their plasma. Historically, while Landsteiner described A, B, and O antigens, Alfred von 
Decastello and Adriano Sturli discovered the fourth type (AB), in 1902. Ludwik Hirszfeld and von 
Dungern discovered the heritability of ABO blood groups in 1910–11. Felix Bernstein demonstrating 
the correct blood group inheritance pattern of multiple alleles at one locus in 1924 while Watkins 
and Morgan, in England, discovered that the ABO epitopes were conferred by specific sugars; N-
acetylgalactosamine for the A-type and galactose for the B-type. The ABO blood group system is the 
most clinical significant system for the following reasons.
• The regular occurrence of ABO blood group antibodies in the plasma 
or serum of healthy persons who lack the corresponding antigens on 
their red cells.
• The ability of ABO antibodies to cause intravascular haemolysis in 
the circulation of recipient transfused with red cells antigen to which 
they have the corresponding antibody.
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• The high frequency of the determinant A and B antigen in both Black 




ABO blood group antigen  
present on red cells




A A A antigen Anti-B AA or AO
B B B antigen Anti-A BB or BO
AB AB A and B antigens None AB
O O None Anti-A and anti-B OO
ABO phenotypes and possible genotypes
Are ABO blood group antibodies really naturally occurring?
ABO blood group antibodies are universally present in the serum /plasma of healthy adults. As 
a result of this fact, these antibodies were thought to be naturally occurring. However from the 
definition of an antibody, it is clear that an antibody only occurs as a result of stimulation by 
an antigen. In reality, ABO antibodies in the serum are not formed naturally. Their production 
is stimulated when the immune system encounters ABO blood group like antigens in foods or 
in micro-organisms. This happens at an early age because sugars that are identical to, or very 
similar to, the ABO blood group antigens are found throughout nature. The ABO locus has 
three main alleleic forms: A, B, and O. The A allele encodes a glycosyltransferase that produces 
the A antigen (N-acetylgalactosamine is its immunodominant sugar), and the B allele encodes a 
glycosyltransferase that creates the B antigen (D-galactose is its immunodominant sugar). ABO 
blood group antibodies react optimally at 16-22°C. They bind complements. ABO blood group 
antibodies can be immune (IgG) if stimulated by pregnancy and incompatible blood transfu-
sion. To buttress this the agument that ABO antibodies are naturally occurring;
• Animal studies have shown that animal kept in a sterile room from 
birth do not produce antibodies. This is an indication that antibody 
production results from exposure to environmental stimulus.
• Children at birth have no ABO antibodies. Neonates under the age 
of 6 months have little or no ABO group antibody. Any ABO blood 
group antibody detected at birth is likely to be maternaternal anti-
body that have been passively transferred via the placenta. ABO anti-
body levels reaches the adult level about the age of 5years, remaining 
relatively stable during adult life and then usually decline at old age.
Clinical significance of the ABO blood group system
Transfusion. Transfusion of ABO incompatible unit (such as transfusing a B patient with 
group A red cell, a group A patient with a group B red cells or transfusing a group O patient 
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with a group A, B or AB red cells) to a patient has result in the activation of complements lead-
ing to life threatening acute intravascular haemolysis
Organ and bone marrow. The ABO blood group system is the most clinically significant or-
gan transplantation medicine. ABO antigens are expressed on most blood cells, organs, and 
tissues and in most body fluids in a variety of tissue cells within the body. Some transplanted 
organs (kidney or liver) must be ABO compatible to prevent rejection.
Recipients Blood Group Donor’s Blood Group
O O
A A or O
B B or O
AB A, B, AB or O
Table: Organ Transplant and ABO blood group requirement
Pregnancy. ABO blood group antibodies are a common cause of Haemolytic Disease of the 
Foetus and Newborn (HDFN). This is a common occurrence when there is ABO blood group 
incompatibility between mother and developing foetus. This often occurs when mother is O 
(and has IgG anti-A,B) and baby is group A or B). The IgG anti-A,B in the maternal circulation 
is able to cross the placenta barrier and cause the coating and eventual destruction of the foetal 
red cell. The effect of ABO HDFN is often mild. Such baby may have a positive DAT at birth.
Universal donors and recipients phenomenom. Individuals who are blood group AB are 
called universal recipient: This is based on the notion that because they lack ABO blood group 
antibodies in their plasma, it should be safe for them to receive blood from blood donors who 
are group A, B and O. Similarly individuals who are group O lack ABO blood group antigens 
on their red cell and as such should be able to donate blood for use by other individuals of 
other ABO groups (A, B and AB). However there is one caveat to this universal donor/recipi-
ent phenomenon. This is the fact that the universal donor phenomenon only applies to packed 
RBCs, and not to whole blood products. This is because blood group O individuals have anti-A 
and anti-B antibodies in the serum. Some blood group O individuals have a high titre of this 
anti-A and B haemolysin that are capable of producing a hemolytic transfusion reaction when 
their whole blood is given to A, B and AB patients. Also blood group A, B and O whole blood 
containing high titre A and B haemolysin when given to group AB individuals (based on group 
AB being universal recipient) can cause complement activation resulting in hemolytic transfu-
sion reaction. As a rule, all group O blood that are intended for use against ABO blood group 
barrier by A, B and AB individuals must be tested for high titre anti-A and B haemolysis. Only 
those that are negative should be used for group A, B and AB recipients. Those that are positive 
for anti A and B haemolysins should be reserved strictly for recipients who are group O. Blood 
group O individuals are said to be universal donors. Blood group O red cells can be given not 
only to group O individuals, but also to individuals who are group A, B and AB. However use 
of group O blood against the ABO blood group barrier to A, B and AB individuals should be 
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with caution as some group O individual s are positive for high titres anti A and B haemolysins 
which are capable of causing the haemolysis of A and D cells of the recipients 
1st Choice
- - -
Transfusion policy for Fresh frozen Plasma (FFP)
Red blood cell compatibility. The aim of red cell transfusion is for the management of anaemia. 
For red cell transfusion to achieve this aim, the transfused red cell must be able to survive the 
red cell life span of 120 days the recipients system to allow for enough time for the recipients 
haematopoietic system to start its own red cell production. Among other consideration, for a 
blood transfusion to be successful, units selected for crossmatch and transfused to recipients 
must be AB0 blood groups compatible with the donor unit. If they are not, the red blood cells 
from the donated unit will clump or agglutinate. The agglutinated red cells can clog blood 
vessels and stop the circulation of the blood to various parts of the body. The agglutinated red 
blood cells also can have their membrane damaged and its contents leak out in the body. 
Plasma compatibility. Plasma –related products (fresh frozen plasma, cryoprecipitate and 
platelets) for transfusion should be selected with caution and should take into consideration 
the ABO blood groups of donors and recipients. In addition to donating to the same blood 
group; plasma from type AB can be given to AB, A, B and O. Plasma from types A, B and 
AB can be given to O. Recipients can receive plasma of the same blood group. The donor-
recipient compatibility for blood plasma is the converse of that of RBCs. Plasma extracted 
from type AB blood can be transfused to individuals of any blood group. Individuals of blood 
group O can receive plasma from any blood group and type O plasma can be used only by 
type O recipients. Under normal circumstances, plasma from a group A donor should not 
be transfused to a B patient. Also plasma from a B donor should not be transfused to an A 
patient. However blood group A and B individuals can be transfused with B and A plasma 
respectively provided they have been test for high titre anti-A and anti-B haemolysis and 
found to be negative. Also all plasma intended for transfusion should be free from antibody 
D and other atypical antibodies.
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ABO blood group antibodies are a common cause of Haemolytic Disease of the 
Foetus and Newborn (HDFN). This is a common occurrence when there is ABO blood group 
incompatibility between mother and developing foetus. This often occurs when mother is O 
(and has IgG anti-A,B) and baby is group A or B). The IgG anti-A,B in the maternal circulation 
is able to cross the placenta barrier and cause the coating and eventual destruction of the foetal 
red cell. The effect of ABO HDFN is often mild. Such baby may have a positive DAT at birth.
Individuals who are blood group AB are 
called universal recipient: This is based on the notion that because they lack ABO blood group 
antibodies in their plasma, it should be safe for them to receive blood from blood donors who 
are group A, B and O. Similarly individuals who are group O lack ABO blood group antigens 
on their red cell and as such should be able to donate blood for use by other individuals of 
other ABO groups (A, B and AB). However there is one caveat to this universal donor/recipi
ent phenomenon. This is the fact that the universal donor phenomenon only applies to packed 
RBCs, and not to whole blood products. This is because blood group O individuals have anti-A 
and anti-B antibodies in the serum. Some blood group O individuals have a high titre of this 
anti-A and B haemolysin that are capable of producing a hemolytic transfusion reaction when 
their whole blood is given to A, B and AB patients. Also blood group A, B and O whole blood 
containing high titre A and B haemolysin when given to group AB individuals (based on group 
AB being universal recipient) can cause complement activation resulting in hemolytic transfu
sion reaction. As a rule, all group O blood that are intended for use against ABO blood group 
barrier by A, B and AB individuals must be tested for high titre anti-A and B haemolysis. Only 
those that are negative should be used for group A, B and AB recipients. Those that are positive 
for anti A and B haemolysins should be reserved strictly for recipients who are group O. Blood 
group O individuals are said to be universal donors. Blood group O red cells can be given not 
only to group O individuals, but also to individuals who are group A, B and AB. However use 
of group O blood against the ABO blood group barrier to A, B and AB individuals should be 
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with caution as some group O individual s are positive for high titres anti A and B haemolysins 
which are capable of causing the haemolysis of A and D cells of the recipients 
RBC Compatibility chart
Recipient ABO blood group  Group O Group A Group B Group AB
1st Choice O * A B AB
2nd Choice A AB A ** A **
3rd Choice B B ** AB B **
4th Choice AB - - -
Transfusion policy for Fresh frozen Plasma (FFP)
Key 
* = Group O FFP must only be transfused to group O patients
** = All group A and B FFP intended for use against ABO blood group barrier (Group A FFP given to a 
group B patient or group B FFP given to an A patient) must be tested and found negative for high titre 
anti-A and B haemolysin. 
Red blood cell compatibility. The aim of red cell transfusion is for the management of anaemia. 
For red cell transfusion to achieve this aim, the transfused red cell must be able to survive the 
red cell life span of 120 days the recipients system to allow for enough time for the recipients 
haematopoietic system to start its own red cell production. Among other consideration, for a 
blood transfusion to be successful, units selected for crossmatch and transfused to recipients 
must be AB0 blood groups compatible with the donor unit. If they are not, the red blood cells 
from the donated unit will clump or agglutinate. The agglutinated red cells can clog blood 
vessels and stop the circulation of the blood to various parts of the body. The agglutinated red 
blood cells also can have their membrane damaged and its contents leak out in the body. 
Plasma compatibility. Plasma –related products (fresh frozen plasma, cryoprecipitate and 
platelets) for transfusion should be selected with caution and should take into consideration 
the ABO blood groups of donors and recipients. In addition to donating to the same blood 
group; plasma from type AB can be given to AB, A, B and O. Plasma from types A, B and 
AB can be given to O. Recipients can receive plasma of the same blood group. The donor-
recipient compatibility for blood plasma is the converse of that of RBCs. Plasma extracted 
from type AB blood can be transfused to individuals of any blood group. Individuals of blood 
group O can receive plasma from any blood group and type O plasma can be used only by 
type O recipients. Under normal circumstances, plasma from a group A donor should not 
be transfused to a B patient. Also plasma from a B donor should not be transfused to an A 
patient. However blood group A and B individuals can be transfused with B and A plasma 
respectively provided they have been test for high titre anti-A and anti-B haemolysis and 
found to be negative. Also all plasma intended for transfusion should be free from antibody 
D and other atypical antibodies.
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Recipient ABO blood group  Group O Group A Group B Group AB
1st Choice O * A B AB
2nd Choice A AB A ** A **
3rd Choice B B ** AB B **
4th Choice AB - - -
Transfusion policy for Fresh frozen Plasma (FFP)
Key 
* = Group O FFP must only be transfused to group O patients
** = All group A and B FFP intended for use against ABO blood group barrier (Group  A FFP given to a 
group B patient  or a group B FFP given to a group A patient) must be tested and found negative for 
high titre anti-A and B haemolysin. 
Recipient ABO blood group O A B AB
1st Choice O A B AB
2nd Choice A * B * A * A * or B*
3rd Choice B * O * O * O *
Transfusion policy for Platelet concentrate
Key 
* = All group A, B and O platelet concentrate intended for use against ABO blood group barrier (Group A 
platelet given to a group B O and AB patients and group B platelet concentrate given to a group A, O and 
AB patient as well as group O platelet concentrate given to an A, B and AB patients must be tested and 
found negative for high titre anti-A and B haemolysin.
** = Due to the possibility that platelet concentrate may be contaminated with red cell, it is advisable to 
transfuse all Rhesus negative women of child bearing age with Rhesus negative platelet to prevent the 
risk of Rh sensitization and production of immune anti-D. Also platelet concentrate intended for trans-
fusion to pregnant and immunocompromised (including HIV positive patient) must be CMV negative. 
Blood grouping. The blood group of an individual can be determined in two ways. You can 
determine the ABO blood group antigens present on the red cells of the individuals by using 
potent monoclonal anti-A, Anti -B and anti-AB (cell, forward or front group). The principle is 
based on the principle that anti-A and B will agglutinate red cells containing the group specific 
A and B antigens. Alternatively you can determine the ABO blood group antibody present in 
the serum or plasma by add the patient serum or plasma to the red cells of known ABO antigen 
status (A1 and B). This is known as reverse/serum or back group). The principle is based on 
identifying the antibody present in the plasma based on their agglutination of the A1 and B cells. 
Plasma that agglutinates A1 contains anti-A while those that agglutinate B cells contain anti-B. 
ABO blood group antibodies are universally present in the serum /plasma of healthy adults. It is 
not possible to determine the back group of neonate until they are 6 months of age. This is due 
to the fact that ABO antibodies are not fully developed at this age (6 months). These 2 methods 
must be used together to routinely determine the ABO group of a patient because of the clini-
cal significance of the ABO blood group system in transfusion and to avoid error in grouping 
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as well as possibly identify rare and unusual ABO groups. The result obtained should reflect 
the results shown in the 2 tables below. If the back group is not in agreement with the forward 
group or the result obtained does not agree with the group recorded on the laboratory informa
tion management system (LIMS) / the patient notes or if there are unusual reactions, it must be 
investigated. It should first be repeated. If results remain inconclusive, a repeat sample must 
be requested before attempting to selects unit for transfusion. The ABO blood group antigens 
remain of prime importance in transfusion medicine—they are the most immunogenic of all the 
blood group antigens. The most common cause of death from a blood transfusion is a clerical 
error in which an incompatible type of ABO blood is transfused.
W
X




 Serum grouping results (Backward grouping)
N= Negative reaction
Common causes of ABO blood group 
anomalies include; technical errors, weak reacting antigen and antibody, effect of alloantibod
ies and autoantibodies, age related issues, previous transfusion or bone marrow transplant 
and other factors.
If red cell and serum sample is taken from the wrong patient. The forward and 
back group may be different from that on the LMIS or patient case note. If serum or antisera reagent 
was mistakenly not added the desired result will not be evident. If patient sample is haemolysed 
or plasma sample is denatured due to poor storage. Use of antisera reagent that has lost it potency 
due to suboptimal storage conditions can cause false result. Inadequate incubation time or incorrect 
1st Choice
- - -
Transfusion policy for Fresh frozen Plasma (FFP)
** = All group A and B FFP intended for use against ABO blood group barrier (Group  A FFP given to a 
group B patient  or a group B FFP given to a group A patient) must be tested and found negative for 
high titre anti-A and B haemolysin. 
1st Choice
Transfusion policy for Platelet concentrate
** = Due to the possibility that platelet concentrate may be contaminated with red cell, it is advisable to 
transfuse all Rhesus negative women of child bearing age with Rhesus negative platelet to prevent the 
risk of Rh sensitization and production of immune anti-D. Also platelet concentrate intended for trans-
fusion to pregnant and immunocompromised (including HIV positive patient) must be CMV negative. 
The blood group of an individual can be determined in two ways. You can 
determine the ABO blood group antigens present on the red cells of the individuals by using 
potent monoclonal anti-A, Anti -B and anti-AB (cell, forward or front group). The principle is 
based on the principle that anti-A and B will agglutinate red cells containing the group specific 
A and B antigens. Alternatively you can determine the ABO blood group antibody present in 
the serum or plasma by add the patient serum or plasma to the red cells of known ABO antigen 
status (A1 and B). This is known as reverse/serum or back group). The principle is based on 
identifying the antibody present in the plasma based on their agglutination of the A1 and B cells. 
Plasma that agglutinates A1 contains anti-A while those that agglutinate B cells contain anti-B. 
ABO blood group antibodies are universally present in the serum /plasma of healthy adults. It is 
not possible to determine the back group of neonate until they are 6 months of age. This is due 
to the fact that ABO antibodies are not fully developed at this age (6 months). These 2 methods 
must be used together to routinely determine the ABO group of a patient because of the clini
cal significance of the ABO blood group system in transfusion and to avoid error in grouping 
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as well as possibly identify rare and unusual ABO groups. The result obtained should reflect 
the results shown in the 2 tables below. If the back group is not in agreement with the forward 
group or the result obtained does not agree with the group recorded on the laboratory informa-
tion management system (LIMS) / the patient notes or if there are unusual reactions, it must be 
investigated. It should first be repeated. If results remain inconclusive, a repeat sample must 
be requested before attempting to selects unit for transfusion. The ABO blood group antigens 
remain of prime importance in transfusion medicine—they are the most immunogenic of all the 
blood group antigens. The most common cause of death from a blood transfusion is a clerical 
error in which an incompatible type of ABO blood is transfused.
Red cell Sample Anti-A Anti-B Anti AB ABO Group
W N N N O
X P P P AB
Y P N P A
Z N P P B








E P N Anti A + B O
F P N Nil AB
G P N Anti-A B
H P N Anti-B A




Common causes of ABO blood group anomalies. Common causes of ABO blood group 
anomalies include; technical errors, weak reacting antigen and antibody, effect of alloantibod-
ies and autoantibodies, age related issues, previous transfusion or bone marrow transplant 
and other factors.
Technical errors. If red cell and serum sample is taken from the wrong patient. The forward and 
back group may be different from that on the LMIS or patient case note. If serum or antisera reagent 
was mistakenly not added the desired result will not be evident. If patient sample is haemolysed 
or plasma sample is denatured due to poor storage. Use of antisera reagent that has lost it potency 
due to suboptimal storage conditions can cause false result. Inadequate incubation time or incorrect 
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incubation temperature. Use of time expired products (irrespective of whether reagent is still potent 
or not, ABO blood grouping reagents must not be used after the manufacturers stated expiry date). 
Antigen and antibody reaction occur in optimal proportion. In an agglutination test, a person’s se-
rum (which contains antibodies) is added to a test tube which contains antigen (red cells). Occasion-
ally, it is observed that when the concentration of antibody is high, there is no agglutination and then, 
as the sample is diluted, agglutination occurs. The lack of agglutination at high concentrations of 
antibodies is called the prozone effect. Lack of agglutination in the prozone is due to antibody excess 
resulting in very small complexes that do not clump to form visible agglutination.
Weak reacting antigen and antibody. Red cell that has fewer antigenic determinants is likely 
to react less strongly with the corresponding antibody compared to one with more antigenic 
determinants. Also the titre of ABO blood group antibody tends to diminish in old age and as 
such will result in a weaker than expected reactions in the serum/back group.
Effect of an alloantibody and autoantibody. Presence of an alloantibody or autoantibody can 
produce non-specific reactions during forward and back groups. For patients who have an al-
loantibody with a positive DAT, the autoantibody coating the red cells may need to be eluted 
first to allow the ABO group to be effectively determined.
Age-related issues. It is not possible to determine the back group of neonate until they are 6 
months of age. This is due to the fact that ABO antibodies are not fully developed at this age (6 
months). ABO antibody levels reaches the adult level about the age of 5 years, remaining relatively 
stable during adult life and then usually decline at old age and may affect serum/back group.
Previous transfusion or bone marrow transplant. Previous transfusion or marrow transplant 
with ABO compatible rather than specific red cells or marrow can cause some considerable 
challenges in ABO group determination. Such information must always be included in the 
patient case note and on the LIMS.
Other Factors. Other factors that can cause anomaly during blood group determination in-
clude; disease conditions (cancers and agammaglobulinaemia), Chimerism phenomenom, ge-
netic abnormalities, presence of rare or low incidence ABO groups and sub-groups and staff 
carrying out test not adequately trained and certified competent to do test.
Acquired (Pseudo) B phenomenom. Difficulty is sometimes experienced in determining the ABO 
group in some patients. It is commonly seen in group A individual who react as AB. These patients 
are often grouped as AB with a weakly reacting B component, while their serum contained anti-B 
agglutinins. The saliva also characteristically does not contained B substance. It is now known to 
be caused by the enzymatic (enzyme produced by Escherichia coli) breakdown (deacetylation) 
of group A antigen (N acetyl-D-galactosamine) to galactosamine which is similar in structure to 
group B antigen immunodominant sugar (D-galactose). This enzymatic change is often brought 
about by some bacteria in-vivo in patients with gastrointestinal septicaemia. It can also occur if the 
red cells reagent is infected with bacteria (in-vitro). This phenomenon can result in a patient’s red 
cell being polyagglutibable (being agglutinated by all human sera including serum form a blood 
group B individual. This occurrence has also been observed in patients with bowel carcinoma.
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Use more specific reagents
Check sample integrity and reagents (expiration) haemolysis)
Check for possible effect of diagnosis and race
Approach to resolution of discrepancy in ABO grouping 
The A blood type contains about twenty subgroups, of which 
A1 and A2 are the most common (over 99%). These sub groups exist as a result of genetic vari
ations which often results in weaker and variable reactions of the A antigen with the group 
specific A antibody. A1 makes up about 80% of all A-type blood, with A2 making up the rest. 
These two subgroups were first described by von Dungern and Herszfeld. Individuals who 
are group A2 has fewer antigenic determinants (antigen sites) compared to A1 individuals 
(250,000 versus 1,000,000 per cell respectively). The antibody A found in group B contains in
separable anti- A and A1 antibodies. While the anti-A reacts with both A1 and A2 red cells, the 
anti-A1 reacts only against A1 cells. The A1 gene is dominant over A2 gene. Both A1 and A2 
are codominant with B. Individuals who are phenotypically A1 will have the genotype A1A1, 
A1O or A1A2. Some 1-8% of A2 individuals and 22-35% of group A2B individuals produce a 
naturally occurring clinically insignificant cold reacting anti-A1.
1 1 1 1 1
1 1
 Possible phenotypes and genotypes based on subgroups of A
incubation temperature. Use of time expired products (irrespective of whether reagent is still potent 
or not, ABO blood grouping reagents must not be used after the manufacturers stated expiry date). 
Antigen and antibody reaction occur in optimal proportion. In an agglutination test, a person’s se
rum (which contains antibodies) is added to a test tube which contains antigen (red cells). Occasion
ally, it is observed that when the concentration of antibody is high, there is no agglutination and then, 
as the sample is diluted, agglutination occurs. The lack of agglutination at high concentrations of 
antibodies is called the prozone effect. Lack of agglutination in the prozone is due to antibody excess 
resulting in very small complexes that do not clump to form visible agglutination.
Red cell that has fewer antigenic determinants is likely 
to react less strongly with the corresponding antibody compared to one with more antigenic 
determinants. Also the titre of ABO blood group antibody tends to diminish in old age and as 
such will result in a weaker than expected reactions in the serum/back group.
Effect of an alloantibody and autoantibody. Presence of an alloantibody or autoantibody can 
produce non-specific reactions during forward and back groups. For patients who have an al
loantibody with a positive DAT, the autoantibody coating the red cells may need to be eluted 
first to allow the ABO group to be effectively determined.
 It is not possible to determine the back group of neonate until they are 6 
months of age. This is due to the fact that ABO antibodies are not fully developed at this age (6 
months). ABO antibody levels reaches the adult level about the age of 5 years, remaining relatively 
stable during adult life and then usually decline at old age and may affect serum/back group.
 Previous transfusion or marrow transplant 
with ABO compatible rather than specific red cells or marrow can cause some considerable 
challenges in ABO group determination. Such information must always be included in the 
patient case note and on the LIMS.
 Other factors that can cause anomaly during blood group determination in
clude; disease conditions (cancers and agammaglobulinaemia), Chimerism phenomenom, ge
netic abnormalities, presence of rare or low incidence ABO groups and sub-groups and staff 
carrying out test not adequately trained and certified competent to do test.
Acquired (Pseudo) B phenomenom. Difficulty is sometimes experienced in determining the ABO 
group in some patients. It is commonly seen in group A individual who react as AB. These patients 
are often grouped as AB with a weakly reacting B component, while their serum contained anti-B 
agglutinins. The saliva also characteristically does not contained B substance. It is now known to 
be caused by the enzymatic (enzyme produced by Escherichia coli) breakdown (deacetylation) 
of group A antigen (N acetyl-D-galactosamine) to galactosamine which is similar in structure to 
group B antigen immunodominant sugar (D-galactose). This enzymatic change is often brought 
about by some bacteria in-vivo in patients with gastrointestinal septicaemia. It can also occur if the 
red cells reagent is infected with bacteria (in-vitro). This phenomenon can result in a patient’s red 
cell being polyagglutibable (being agglutinated by all human sera including serum form a blood 
group B individual. This occurrence has also been observed in patients with bowel carcinoma.
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Resolution of discrepancy in ABO grouping
Check samples (name, hospital number & DOB)
Repeat test with fresh sample
Use more specific reagents
Possible referral to reference laboratory
Repeat test on primary sample with contols
Check sample integrity and reagents (expiration) haemolysis)
Check for possible effect of diagnosis and race
Approach to resolution of discrepancy in ABO grouping 
Subgroups of Group A and B. The A blood type contains about twenty subgroups, of which 
A1 and A2 are the most common (over 99%). These sub groups exist as a result of genetic vari-
ations which often results in weaker and variable reactions of the A antigen with the group 
specific A antibody. A1 makes up about 80% of all A-type blood, with A2 making up the rest. 
These two subgroups were first described by von Dungern and Herszfeld. Individuals who 
are group A2 has fewer antigenic determinants (antigen sites) compared to A1 individuals 
(250,000 versus 1,000,000 per cell respectively). The antibody A found in group B contains in-
separable anti- A and A1 antibodies. While the anti-A reacts with both A1 and A2 red cells, the 
anti-A1 reacts only against A1 cells. The A1 gene is dominant over A2 gene. Both A1 and A2 
are codominant with B. Individuals who are phenotypically A1 will have the genotype A1A1, 
A1O or A1A2. Some 1-8% of A2 individuals and 22-35% of group A2B individuals produce a 
naturally occurring clinically insignificant cold reacting anti-A1.
ABO Groups Phenotype Possible genotype
A A1 A1A1, A1A2, A1O
B B BB and BO
AB A1B and A2B A1B and A2B
O O OO
 Possible phenotypes and genotypes based on subgroups of A
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A1 33 19 26 27 56 0
A
2
10 8 3 Rare 0 0
A1B 3 3 9 5 0 0
A
2
B 1 1 1 Rare 0 0
Racial variations in the distribution of the subgroups of A









. Occur in 1 out of 1000 of group A individuals. Produces a mixed field reaction 
with polyclonal anti-A and anti-AB. Occur as a result of fewer A antigenic determinants on 
A3 red cells. Monoclonal anti sera often produces a strong and complete reaction with A3 red 
cells. A3 individuals have anti-B in their sera and may occasionally produce anti-A1. All reacted 





. 1 in 40,000 to 77,000 groups A individuals are A4 or AX. A4 or AX individuals 
have very few A antigenic determinants (5,000) on their red cells. Cells are only agglutinated by 
monoclonal anti-A and some anti A, B sera as well as some polyclonal anti-A, B sera but not by 
polyclonal anti-A. Group A4 or AX individuals often have anti-B and occasionally anti-A1 in their 
sera. Show a strong agglutination with anti-H lectin. 
Subgroups of B. Subgroups of B are rare but occur predominantly among Africans, Chinese 
and Indian population where the frequency of B antigen is high. Occur as a result of fewer B 
antigenic determinants on the red cells of these individuals resulting in a weak and variable 
reaction with anti-B. Examples of weak group B include B3, BX, Bm and Bel.. Red blood cells in 
the Bel subgroup show no agglutination with anti-B or anti-A, B antisera. B antigen is only de-
tected by adsorption with polyclonal group A sera. Bel can be differentiated from Bm by saliva 
testing, which only detects only the H antigen.
ABO blood group discripancies. Any deviation fromthe expected pattern of antigen on red 
cells and the opposite antibodies in plasma or serum constitute a discrepancy and must be 
investigated before any attempt is made to select units for crossmatching. All ABO blood 
grouping discrepancies must be investigated and resolved. In receipients the discrepancies 
must be resolved before any blood component is transfused. If not resolved before blood is 
needed, transfuse group O blood. If there is a discrepancy in the Rh type also, group O Nega-
tive must be tenasfused until discrepancy is resolved. In donor the discrepancies must be re-
solved before any blood is labeled with a blood type. The general rules involved in resolution 
of blood group discripancies include:
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Always re-test first
Check results of the screening cells.   
Check for clerical/technical errors    
Clerical errors (Transcription errors). Clerical errors are the most common types of error that 
cause discripancies in blood group result. To avoid such errors the following must be taken 
into consideration. Record the results as you read each tube. Always check which tube you are 
reading and record the results immediately. Make sure you are recording the results on the right 
worksheet. One way to prevent this error is to minimize the times you are working with more 
than one patient or donor at a time. Recording results in the wrong spot on worksheet could 
occur when you put some of the serum results in the cell typing area or vice versa. Be sure you 
have techniques that will prevent you from performing this error (Appriopriate labelling). 
There are a number of technical errors that can occur in blood grouping. They 
include; Sample mix-up such as wrong serum tube, failure to add serum or reagent can lead to 
technical errors where no reaction is occurring where one is expected (remember for both ABO 
and Rh always add your reagent antisera and serum before adding cells), addition of wrong 
reagent such as screening cells, which are O, instead of A1 and B cells, can lead to significant 
technical errors, use of suboptimal red cell suspension (few cells in suspension), use of con
taminated reagents could result in either false negative or false positive results depending on 
whether the reagent added neutralized or added to the reactivity of the original reagent. Over 
centrifugation can lead to you reading the reaction as positive while there is still a button on 





1 1 1 0 0
Racial variations in the distribution of the subgroups of A
, A ).
 Occur in 1 out of 1000 of group A individuals. Produces a mixed field reaction 
with polyclonal anti-A and anti-AB. Occur as a result of fewer A antigenic determinants on 
A3 red cells. Monoclonal anti sera often produces a strong and complete reaction with A3 red 
cells. A3 individuals have anti-B in their sera and may occasionally produce anti-A1. All reacted 
strongly with anti-H lectin.
1 in 40,000 to 77,000 groups A individuals are A4 or AX. A4 or AX individuals 
have very few A antigenic determinants (5,000) on their red cells. Cells are only agglutinated by 
monoclonal anti-A and some anti A, B sera as well as some polyclonal anti-A, B sera but not by 
polyclonal anti-A. Group A4 or AX individuals often have anti-B and occasionally anti-A1 in their 
sera. Show a strong agglutination with anti-H lectin. 
 Subgroups of B are rare but occur predominantly among Africans, Chinese 
and Indian population where the frequency of B antigen is high. Occur as a result of fewer B 
antigenic determinants on the red cells of these individuals resulting in a weak and variable 
reaction with anti-B. Examples of weak group B include B3, BX, Bm el.. Red blood cells in 
the Bel subgroup show no agglutination with anti-B or anti-A, B antisera. B antigen is only de
tected by adsorption with polyclonal group A sera. Bel can be differentiated from Bm by saliva 
testing, which only detects only the H antigen.
Any deviation fromthe expected pattern of antigen on red 
cells and the opposite antibodies in plasma or serum constitute a discrepancy and be 
investigated before any attempt is made to select units for crossmatching. All ABO blood 
grouping discrepancies  be investigated and resolved. In receipients the discrepancies 
must be resolved before any blood component is transfused. If not resolved before blood is 
needed, transfuse group O blood. If there is a discrepancy in the Rh type also, group O Nega
tive must be tenasfused until discrepancy is resolved. In donor the discrepancies must be re
solved before any blood is labeled with a blood type. The general rules involved in resolution 
of blood group discripancies include:
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General rules in resolution grouping discripancies
Always re-test first
Check the patient’s age
Check the transfusion history
Check the diagnosis
Check transplant history (Bone marrow and organ)
Check results of the screening cells.   
Look out for weakest reaction that can cause doubt
Check for clerical/technical errors    
Types of discripancies 
Clerical errors (Transcription errors). Clerical errors are the most common types of error that 
cause discripancies in blood group result. To avoid such errors the following must be taken 
into consideration. Record the results as you read each tube. Always check which tube you are 
reading and record the results immediately. Make sure you are recording the results on the right 
worksheet. One way to prevent this error is to minimize the times you are working with more 
than one patient or donor at a time. Recording results in the wrong spot on worksheet could 
occur when you put some of the serum results in the cell typing area or vice versa. Be sure you 
have techniques that will prevent you from performing this error (Appriopriate labelling). 
Technical errors. There are a number of technical errors that can occur in blood grouping. They 
include; Sample mix-up such as wrong serum tube, failure to add serum or reagent can lead to 
technical errors where no reaction is occurring where one is expected (remember for both ABO 
and Rh always add your reagent antisera and serum before adding cells), addition of wrong 
reagent such as screening cells, which are O, instead of A1 and B cells, can lead to significant 
technical errors, use of suboptimal red cell suspension (few cells in suspension), use of con-
taminated reagents could result in either false negative or false positive results depending on 
whether the reagent added neutralized or added to the reactivity of the original reagent. Over 
centrifugation can lead to you reading the reaction as positive while there is still a button on 
the bottom of the tube or your shaking to dislodge the button broke up the agglutination reac-
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tion, warming the test could result in a false negative reaction since ABO antibodies are IgM 
that react better in the cold, failure to control the reagent before use, inappriopriate storage of 
antisera and red cell reagents, too many cells in your cell suspension can lead to decreased or 
negative reactions since there are too many cells for the number of antibodies present in the 
reagents. Remember we want to be in the zone of equivalence for our reactions, failure to detect 
weak results can occur if you are not watching the reactions while you are shaking them out or if 
you shake too hard, failure to detect hemolysis can be a definite problem. Remember a positive 
reaction can be hemolysis as well as agglutination since the antigen-antibody reaction can bind 
complement. When complement is bound it can lead to hemolysis that is also an indication of a 
positive reaction and dirty glassware can cause the cells to artificially clumping of cells. 
Foward group (Cell group)
Back Group (Serum 
group) Possible reason for discripancy 
Anti-A Anti-B Anti –A, B A1 Cell B Cell
4 0 4 0 0
Age-related weak or no back group/
failure to add serum
4 4 4 0 4
Pseudo B phenomenom 
 (? Septicaemia of colon by gram 
negative organism)
4 4 4 4 4
Strong positive DAT/infected red cell 
reagents
0 4 4 0 0
Age-related weak or no back group/
failure to add serum
Table: Examples of common discripancies in ABO blood grouping
Problems associated with red cell testing. There are a number of problems that can occur 
with the red cell testing including, mixed-field agglutination, weak or missing antigens, un-
expected antigen and polyagglutinable cells. 
Cell of forward grouping Serum or backward grouping
Anti-A Anti-B A1 cells B cells
Mixed-field agglutination
MF 0 0 4+ 
Polyagglutinable cells
0 0 0 4+
Weak or missing antigen
0 0 0 4+
Unexpected antigen 
4+ 2+ 0 4+
Table: Common causes of Discripancies in red cell grouping
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Problems can occur in serum grouping. It is important to in
vestigate the problem to determine if it is actually a true discrepancy between the ABO cell type 
and the ABO serum test. Problems with serum testing are more common than problems with 
cell typing. This is either manifest as an extra antibody present or an expected antibody missing. 
The steps to follow to resolve a discrepancy in serum grouping include the following:
1. Check birth date since newborns and the elderly are more likely to demon
strate this discrepancy. Newborn antibodies are not present until at least 6 
months. As individuals ages they may also lose their ability to maintain their 
antibody levels. Therefore, the very elderly have decreased antibody levels. 
2. Check diagnosis since patient conditions such as; immune deficien
cies, chemotherapy, radiatiotherapy and bone marrow transplantation 
may affect serum grouping. 
Add two more drops of serum just in case you forgot to add them the first time and centrifuge. 
If negative then incubate in cold (4-18 C) 15-30 minutes. Include autocontrol to rule out inter
ference from natural anti-I when incubating at (4-18 C).
Anti-A Anti-B A1 Cell
0 
0 0
 Descripancies in serum grouping
Anti-A Anti-B Anti-A,B A1 Cells
0 0 0
0 0 0
0 0 0 0 0
An extreme example of no reaction in the reverse typings.
1. 0 0 0
Group O at 4°
Anti-A and Anti-B enhanced
0 0
Group O at 4°
Auto-Anti-I enhanced
tion, warming the test could result in a false negative reaction since ABO antibodies are IgM 
that react better in the cold, failure to control the reagent before use, inappriopriate storage of 
antisera and red cell reagents, too many cells in your cell suspension can lead to decreased or 
negative reactions since there are too many cells for the number of antibodies present in the 
reagents. Remember we want to be in the zone of equivalence for our reactions, failure to detect 
weak results can occur if you are not watching the reactions while you are shaking them out or if 
you shake too hard, failure to detect hemolysis can be a definite problem. Remember a positive 
reaction can be hemolysis as well as agglutination since the antigen-antibody reaction can bind 
complement. When complement is bound it can lead to hemolysis that is also an indication of a 
positive reaction and dirty glassware can cause the cells to artificially clumping of cells. 
0 0 0
Age-related weak or no back group/
failure to add serum
0
Pseudo B phenomenom
 (? Septicaemia of colon by gram 
negative organism)
Strong positive DAT/infected red cell 
reagents
0 0 0
Age-related weak or no back group/
failure to add serum
Table: Examples of common discripancies in ABO blood grouping
There are a number of problems that can occur 
with the red cell testing including, mixed-field agglutination, weak or missing antigens, un









Table: Common causes of Discripancies in red cell grouping
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Problems with serum grouping. Problems can occur in serum grouping. It is important to in-
vestigate the problem to determine if it is actually a true discrepancy between the ABO cell type 
and the ABO serum test. Problems with serum testing are more common than problems with 
cell typing. This is either manifest as an extra antibody present or an expected antibody missing. 
The steps to follow to resolve a discrepancy in serum grouping include the following:
1. Check birth date since newborns and the elderly are more likely to demon-
strate this discrepancy. Newborn antibodies are not present until at least 6 
months. As individuals ages they may also lose their ability to maintain their 
antibody levels. Therefore, the very elderly have decreased antibody levels. 
2. Check diagnosis since patient conditions such as; immune deficien-
cies, chemotherapy, radiatiotherapy and bone marrow transplantation 
may affect serum grouping. 
Add two more drops of serum just in case you forgot to add them the first time and centrifuge. 
If negative then incubate in cold (4-18oC) 15-30 minutes. Include autocontrol to rule out inter-
ference from natural anti-I when incubating at (4-18oC).
Cell grouping Serum grouping
Anti-A Anti-B A1 Cell B Cell
Extra Antibody
4+ 0 2+ 4+ 
Missing Antibody
4+ 0 4+ 0
 Descripancies in serum grouping
Forward or cell grouping Back or serum grouping
Anti-A Anti-B Anti-A,B A1 Cells B Cells
4 0 4 0 0
0 4 4 0 0
0 0 0 0 0








Anti-A Anti-B A1 Cell B Cell 
1. 0 0 2+ 2+ 0
Group O at 4°C. 
Anti-A and Anti-B enhanced
2. 0 0 2+ 2+ 2+
Group O at 4°C. 
Auto-Anti-I enhanced
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3. 4+ 0 0 2+ 0
Group A at 4°C. Anti-B en-
hanced
4. 4+ 0 0 2+ 0
Anti-I enhanced along with 
anti-A and incubated at 18°C
Examples of interference from natural anti-I
Key
At 4°C Anti-A and Anti-B enhanced since they are saline, cold-acting antibodies as seen in this example 
for an O individual.
Compare this with a 4°C Auto-Anti-I enhanced would have a positive autocontrol.
Group A or Group B can serve as its own negative control. 4°C Anti-B enhanced 
If anti-I enhanced along with anti-B, can re-set up and incubate at 18°C. As seen in this example of 
18°C: Anti-B enhanced, anti-I nonreactive 
Presence of unexpected Anti-A 
The presence of Anti-A1 should be suspected when the antibody is reactive against the A cells 
but not the screening cells at immediate spin as seen in the example below.
Cell Grouping Serum Grouping
Anti-A Anti-B A1 Cell B Cell 
4+ 0 2+ 4+
Antibody screen
Screening cells Immediate Spin AHG
Screening Cell I 0 0
Screening Cell II 0 0
Autocontrol 0 0
Naturally anti-A1 occurs in subgroups of A or is passively-transfused from Group O platelets and other 
blood products.
How to Resolve the Issue of Unexpected Anti-A: 
1. Check recent transfusion history for group O products, (especially plate-
lets) that would explain the presence of this antibody.
2.  Test patient cells with lectin-A1. Subgroups will be negative with this 
reagent but A1cells will be positive. 
• Lectin + A1 cell = 4+ 
• Lectin + A subgroups cells = 0 
3. Test patient serum with three A1 cells and three A2 cells and if it is an 
anti-A1. Anti-A1 will react only with the A1 cells but not with the A2 cells. 
The following reactions will occur: 
• Anti-A1: serum + A1 cells = + 
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• Serum + A2 cells = 0 
4. In the case of passive Anti-A from Group O platelets the reactions would 
be the following: 
• Serum + A1 cells = Positive 
• Serum + A2 cells = Positive 
You may have 
a positive reaction with the reagent A1 or B cell that is due to a room-temperature antibody 
reacting with an antigen other than A or B on the cells. For example, if the patient had an anti-
N that was showing up at room temperature according to the antibody identification process, 
you would then type for N on the reagent cells used for the reverse typing. If anti-N is causing 
your problem, then the cells should have N antigen present. 
Anti-A Anti-B A1 Cell
0
Immediate spin antibody screening
Screening Cell I
Screening Cell II 0
Autocontrol 0
Table: Unexpected A antibody in patients with a positive antibody screen 
How to Resolve the Issue of Unexpected Anti-A that is probably another antibody due to the 
results of the Antibody Screening:
1. Identify the antibody by performing an identification panel at room tem
perature. 
2. Pre-warm away (use caution) the effect of this antibody by doing the re
verse typing with prewarmed serum and reagent cells. 
3. Type reagent A1 or B cell for the corresponding antigen once the antibody 
is identified. 
Rouleaux can 
give unexpected agglutination in all serum tests. Rouleaux may also give false positive cell 
0 0 0
Group A at 4°C. Anti-B en-
0 0 0
Anti-I enhanced along with 
anti-A and incubated at 18°
Examples of interference from natural anti-I
At 4°C Anti-A and Anti-B enhanced since they are saline, cold-acting antibodies as seen in this example 
for an O individual.
Compare this with a 4°C Auto-Anti-I enhanced would have a positive autocontrol.
Group A or Group B can serve as its own negative control. 4°C Anti-B enhanced 
If anti-I enhanced along with anti-B, can re-set up and incubate at 18°C. As seen in this example of 
18°C: Anti-B enhanced, anti-I nonreactive 
The presence of Anti-A1 should be suspected when the antibody is reactive against the A cells 
but not the screening cells at immediate spin as seen in the example below.
0
Screening cells AHG
Screening Cell I 0 0
Screening Cell II 0 0
Autocontrol 0 0
Naturally anti-A1 occurs in subgroups of A or is passively-transfused from Group O platelets and other 
blood products.
1. Check recent transfusion history for group O products, (especially plate
lets) that would explain the presence of this antibody.
2.  Test patient cells with lectin-A1. Subgroups will be negative with this 
reagent but A1cells will be positive. 
• Lectin + A1 cell = 4+ 
• Lectin + A subgroups cells = 0 
3. Test patient serum with three A1 cells and three A2 cells and if it is an 
anti-A1. Anti-A1 will react only with the A1 cells but not with the A2 cells. 
The following reactions will occur: 
• Anti-A1: serum + A1 cells = + 
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• Serum + A2 cells = 0 
4. In the case of passive Anti-A from Group O platelets the reactions would 
be the following: 
• Serum + A1 cells = Positive 
• Serum + A2 cells = Positive 
Unexpected A and B antibody in patients with a positive antibody screen. You may have 
a positive reaction with the reagent A1 or B cell that is due to a room-temperature antibody 
reacting with an antigen other than A or B on the cells. For example, if the patient had an anti-
N that was showing up at room temperature according to the antibody identification process, 
you would then type for N on the reagent cells used for the reverse typing. If anti-N is causing 
your problem, then the cells should have N antigen present. 
Red cell grouping Serum grouping
Anti-A Anti-B A1 Cell B Cell 
4+ 0 2+ 4+
Immediate spin antibody screening
Screening Cell I 2+
Screening Cell II 0
Autocontrol 0
Table: Unexpected A antibody in patients with a positive antibody screen 
How to Resolve the Issue of Unexpected Anti-A that is probably another antibody due to the 
results of the Antibody Screening:
1. Identify the antibody by performing an identification panel at room tem-
perature. 
2. Pre-warm away (use caution) the effect of this antibody by doing the re-
verse typing with prewarmed serum and reagent cells. 
3. Type reagent A1 or B cell for the corresponding antigen once the antibody 
is identified. 
Rouleaux formation giving unexpected agglutination in serum grouping. Rouleaux can 
give unexpected agglutination in all serum tests. Rouleaux may also give false positive cell 
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typing if strong enough and cells are insufficiently washed. This phenomenon is due to altera-
tion in serum protein concentration such as: 
Diseases associated with Rouleaux 
Multiple myeloma 
Macroglobulinemia 
Liver disease (decreased albumin)
Patients on volume expanders ( crystalloids dextran)
Also seen in patients who have had volume expanders such as crystalloids (dextran) 
Characteristics of rouleaux. Rouleaux are stacks of red blood cells (RBCs) which form be-
cause of the unique discoid shape of the cells in vertebrate body. The flat surface of the discoid 
RBCs give them a large surface area to make contact and stick to each other; thus, forming 
a rouleau. They occur when the plasma protein concentration is high, and because of them 
the ESR (erythrocyte sedimentation rate) is also increased. This is a non-specific indicator of 
the presence of certain diseases. Conditions which cause rouleaux formation include infec-
tions, Multiple myeloma, inflammatory and connective tissue disorders, and cancers. It also 
occurs in diabetes mellitus and is one of the causative factors for microvascular occlusion in 
diabetic retinopathy. The presence of acute phase proteins, particularly fibrinogen, interacts 
with sialic acid on the surface of RBC and allows the formation of rouleau. Anaemia, by alter-
ing the ratio of RBC to plasma, increases rouleaux formation and accelerates sedimentation. 
Rouleaux formation is retarded by albumin proteins. To resolve rouleaux-related problems, 
you do saline replacement technique: Re-centrifuge the test tube. Draw off serum without 
disturbing cell button. Add two drops of saline. Resuspend. Rouleax disperses in saline why 
true agglutination remains intact.
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Typical mammalian erythrocytes: (a) Normal red cells (b) Red cells forming rouleaux.
Mixed-field agglutination. In transfusion medicine, mixed-field (MF) reaction refers to reac
tions during cell grouping where 2 distict populations of red cells are present. Agglutinated 
cells are admixed with unagglutinated cells. The presence of two or more cell population is 
known as chimerism. MF agglutination is an important cause of ABO typing and genotype 
discripancies. Most times the cause of MF should be investigated prior to giving a blood 
transfusion. Mixed-field agglutination is seen as large or small agglutinates with many unag
glutinated cells. Usually mixed-field agglutination means a mixed cells population (aggluti
nated and non-agglutinated cell population). There are 2 types of chimerism:
By far the most common cause of mixed-field agglutination is false chimerism 
artificially induced through transfusion of identical donor red cells or through a stem cell trans
plant. For example, a type B individual who has received massive transfusion of group O donor 
red cells may show mixed field agglutination with anti-B sera whereby his own group B red 
cells are agglutinated, while the group O donor red cells in his circulation are unagglutinated.
A true chimerism is a rare sporadic phenomenon whereby an individual has 
a dual cell population derived from more than one zygote. This may result from intrauterine 
exchange of erythrocyte precursors between twins (twin chimerism) or two fertilized eggs 
fuse into one individual. Twin chimerism results from mixing of blood between two twin 
fetuses through placental blood vessel anastomoses, leading to engraftment of hematopoietic 
stem cells from one twin within the marrow of the other. Each twin ends up with two distinct 
cell populations of varying proportions. The causes of mixed-field agglutination can be: 
1. Mixed cell populations resulting from massive transfusion of another 
blood group such as an A individual receiving “O” red blood cell donor 
units due to inadequate supply of group A donor unit. Such O blood used 
against ABO blood group barrier must be tested for high titre (HT) beta 
haemolysis and found negative
2. Bone marrow transplant patients may have both some of their original 
type of cells and the type of the bone marrow transplant. 
typing if strong enough and cells are insufficiently washed. This phenomenon is due to altera
tion in serum protein concentration such as: 
Also seen in patients who have had volume expanders such as crystalloids (dextran) 
Rouleaux are stacks of red blood cells (RBCs) which form be
cause of the unique discoid shape of the cells in vertebrate body. The flat surface of the discoid 
RBCs give them a large surface area to make contact and stick to each other; thus, forming 
a rouleau. They occur when the plasma protein concentration is high, and because of them 
the ESR (erythrocyte sedimentation rate) is also increased. This is a non-specific indicator of 
the presence of certain diseases. Conditions which cause rouleaux formation include infec
tions, Multiple myeloma, inflammatory and connective tissue disorders, and cancers. It also 
occurs in diabetes mellitus and is one of the causative factors for microvascular occlusion in 
diabetic retinopathy. The presence of acute phase proteins, particularly fibrinogen, interacts 
with sialic acid on the surface of RBC and allows the formation of rouleau. Anaemia, by alter
ing the ratio of RBC to plasma, increases rouleaux formation and accelerates sedimentation. 
Rouleaux formation is retarded by albumin proteins. To resolve rouleaux-related problems, 
you do saline replacement technique: Re-centrifuge the test tube. Draw off serum without 
disturbing cell button. Add two drops of saline. Resuspend. Rouleax disperses in saline why 
true agglutination remains intact.
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Typical mammalian erythrocytes: (a) Normal red cells (b) Red cells forming rouleaux.
Mixed-field agglutination. In transfusion medicine, mixed-field (MF) reaction refers to reac-
tions during cell grouping where 2 distict populations of red cells are present. Agglutinated 
cells are admixed with unagglutinated cells. The presence of two or more cell population is 
known as chimerism. MF agglutination is an important cause of ABO typing and genotype 
discripancies. Most times the cause of MF should be investigated prior to giving a blood 
transfusion. Mixed-field agglutination is seen as large or small agglutinates with many unag-
glutinated cells. Usually mixed-field agglutination means a mixed cells population (aggluti-
nated and non-agglutinated cell population). There are 2 types of chimerism:
False chimerism: By far the most common cause of mixed-field agglutination is false chimerism 
artificially induced through transfusion of identical donor red cells or through a stem cell trans-
plant. For example, a type B individual who has received massive transfusion of group O donor 
red cells may show mixed field agglutination with anti-B sera whereby his own group B red 
cells are agglutinated, while the group O donor red cells in his circulation are unagglutinated.
True chimerism: A true chimerism is a rare sporadic phenomenon whereby an individual has 
a dual cell population derived from more than one zygote. This may result from intrauterine 
exchange of erythrocyte precursors between twins (twin chimerism) or two fertilized eggs 
fuse into one individual. Twin chimerism results from mixing of blood between two twin 
fetuses through placental blood vessel anastomoses, leading to engraftment of hematopoietic 
stem cells from one twin within the marrow of the other. Each twin ends up with two distinct 
cell populations of varying proportions. The causes of mixed-field agglutination can be: 
1. Mixed cell populations resulting from massive transfusion of another 
blood group such as an A individual receiving “O” red blood cell donor 
units due to inadequate supply of group A donor unit. Such O blood used 
against ABO blood group barrier must be tested for high titre (HT) beta 
haemolysis and found negative. 
2. Bone marrow transplant patients may have both some of their original 
type of cells and the type of the bone marrow transplant. 
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3. Weak subgroups of A3 traditionally give a mixed field reaction. 
4. Chimerism due to intrauterine exchange of erythrocyte precursors be-
tween twins or 2 fertilized eggs fuse into one individual. 
5. Exchange transfusion in HDFN when a group A or B baby whose mother 
is O is giving an O exchange transfusion.
6. Cause of mixed field agglutination must be investigated before attempting 
to transfuse a patient. It is also worthwhile to check the patient’s transfu-
sion records and clinical history. 
Weak or missing antigen. Weak or missing antigen may be due to the following; very weak 
subgroup of A or B, loss of transferase in acute leukemia, massive transfusion of group O and 
bone marrow transplant.
Anti-A Anti-B A1 Cell B Ccell 
0 0 0 4+
Table: Example of a weak or missing antigen
How would you resolve a weak or missing antigen?
1. Obtain recent transfusion history and any clinical history of bone marrow 
transplant. 
2. Read forward grouping microscopically. 
3. Use anti-A,B and incubate at 4-22oC at least 15 minutes. 
4. Use monoclonal antisera that is known to react with antigens like Ax and Bx 
5. Perform specialized tests if the above steps do not resolve the problem.
6. Specialized tests would include absorption/elution techniques and saliva studies.
Acquired B antigen. Acquired B antigens are seen in problems with the colon or infections with 
Gram-negative rods. Bacterial enzymes modify the A antigen to a B antigen and the patient for-
ward types as an AB but reverses as an A. 
Example of acquired B antigen reaction
Anti-A Anti-B A1 Cell B Cell 
4+ 2+ 0 4+
Resolution of a possible acquired B antigen
1. Set-up an autocontrol. The patient’s own anti-B will not agglutinate their 
own AB cells. 
2. Check clinical history for evidence of colon problems or Gram-negative rods. 
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3. Check monoclonal anti-B product inserts since some will not react with 
B acquired antisera 
4. Acidify some reagents anti-B to pH 6 and re-test. Modified (acquired) B 
antigens will not react in the acidified antiserum but normal B antigens 
will still react 
Most monoclonal anti-A and anti-B will show problems with 
polyagglutinable cells if it is a problem with the cell membrane that leads to the agglutination. 
The most likely causes of due to the following; Wharton’s Jelly found in cord blood and strong 
positive direct antiglobulin test due to a cold agglutinin. In the case of the strong positive DAT, 
it would appear to be an AB in the forward type and an O on reverse.
Anti-A Anti-B Anti-A+B 1
Polyagglutinable RBCS with forward group appearing as group AB and serum group as O
 Wharton’s jelly (substantia gelatinea funiculi umbilicalis) is a gelatinous sub
stance within the umbilical cord, largely made up of mucopolysaccharides (hyaluronic acid 
and chondroitin sulfate). It also contains some fibroblasts and macrophages. It is derived 
from extra-embryonic mesoderm. Wharton’s jelly can cause some challenges particularly 
when determing the blood groups of neonates because of it’s potential to make red cells of 
newborn polyagglutinable. Wharton’s jelly can coats newborn cord cells and the child’s type 
may appear AB. Reverse grouping would have been able to resolve such anomaly. However 
we do not do a reverse on newborn blood since they have not made any anti-A or anit-B yet. 
If the baby types as an AB re-check by washing cells several times and re-testing since you 
need to make sure you have removed the Wharton’s Jelly and the baby is truly an AB. Better 
yet always wash cord blood 3-4 times in saline before determining the bloog group of the baby. 
. For example, early European races 
are characterized by a very low type B frequency, and a relatively high type A frequency while 
the Asian races are characterized by a high frequency of types A and B. The frequency with 
which Blood types are observed is determined by the frequency with which the three alleles 
of the ABO gene are found in different parts of the world. Variation in this allele frequency of 
the ABO gene reflects the social tendency of populations to marry and reproduce within their 
national, regional, or ethnic group. As people throughout the world intermingle to a greater 
degree, the distribution of the different Blood types will continue to become more uniform. 
Blood Type O - Type O Blood, which is known as the standard form of Blood types is widely 
distributed over the whole world uniformly, where populations have mixed.
3. Weak subgroups of A3 traditionally give a mixed field reaction. 
4. Chimerism due to intrauterine exchange of erythrocyte precursors be
tween twins or 2 fertilized eggs fuse into one individual. 
5. Exchange transfusion in HDFN when a group A or B baby whose mother 
is O is giving an O exchange transfusion.
6. Cause of mixed field agglutination  be investigated before attempting 
to transfuse a patient. It is also worthwhile to check the patient’s transfu
sion records and clinical history. 
Weak or missing antigen may be due to the following; very weak 
subgroup of A or B, loss of transferase in acute leukemia, massive transfusion of group O and 
bone marrow transplant.
0 0 0
Table: Example of a weak or missing antigen
1. Obtain recent transfusion history and any clinical history of bone marrow 
transplant. 
2. Read forward grouping microscopically. 
3. Use anti-A,B and incubate at 4-22 C at least 15 minutes. 
4. Use monoclonal antisera that is known to react with antigens like Ax x
5. Perform specialized tests if the above steps do not resolve the problem.
6. Specialized tests would include absorption/elution techniques and saliva studies.
Acquired B antigens are seen in problems with the colon or infections with 
Gram-negative rods. Bacterial enzymes modify the A antigen to a B antigen and the patient for
ward types as an AB but reverses as an A. 
Anti-A Anti-B A1 Cell
0
1. Set-up an autocontrol. The patient’s own anti-B will not agglutinate their 
own AB cells. 
2. Check clinical history for evidence of colon problems or Gram-negative rods. 
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3. Check monoclonal anti-B product inserts since some will not react with 
B acquired antisera 
4. Acidify some reagents anti-B to pH 6 and re-test. Modified (acquired) B 
antigens will not react in the acidified antiserum but normal B antigens 
will still react 
Polyagglutinable red cells. Most monoclonal anti-A and anti-B will show problems with 
polyagglutinable cells if it is a problem with the cell membrane that leads to the agglutination. 
The most likely causes of due to the following; Wharton’s Jelly found in cord blood and strong 
positive direct antiglobulin test due to a cold agglutinin. In the case of the strong positive DAT, 
it would appear to be an AB in the forward type and an O on reverse.
Forward (Cell group) Back (Serum group)
Anti-A Anti-B Anti-A+B A1 Cell B Cell
2+ 2+ 2+ 4+ 4+
Polyagglutinable RBCS with forward group appearing as group AB and serum group as O
Wharton’s Jelly. Wharton’s jelly (substantia gelatinea funiculi umbilicalis) is a gelatinous sub-
stance within the umbilical cord, largely made up of mucopolysaccharides (hyaluronic acid 
and chondroitin sulfate). It also contains some fibroblasts and macrophages. It is derived 
from extra-embryonic mesoderm. Wharton’s jelly can cause some challenges particularly 
when determing the blood groups of neonates because of it’s potential to make red cells of 
newborn polyagglutinable. Wharton’s jelly can coats newborn cord cells and the child’s type 
may appear AB. Reverse grouping would have been able to resolve such anomaly. However 
we do not do a reverse on newborn blood since they have not made any anti-A or anit-B yet. 
If the baby types as an AB re-check by washing cells several times and re-testing since you 
need to make sure you have removed the Wharton’s Jelly and the baby is truly an AB. Better 
yet always wash cord blood 3-4 times in saline before determining the bloog group of the baby. 
Ethnic variation in distribution of ABO blood groups. For example, early European races 
are characterized by a very low type B frequency, and a relatively high type A frequency while 
the Asian races are characterized by a high frequency of types A and B. The frequency with 
which Blood types are observed is determined by the frequency with which the three alleles 
of the ABO gene are found in different parts of the world. Variation in this allele frequency of 
the ABO gene reflects the social tendency of populations to marry and reproduce within their 
national, regional, or ethnic group. As people throughout the world intermingle to a greater 
degree, the distribution of the different Blood types will continue to become more uniform. 
Blood Type O - Type O Blood, which is known as the standard form of Blood types is widely 
distributed over the whole world uniformly, where populations have mixed.
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 Ethnic variation in ABO blood group distribution
Ethnic Groups Group O (%) Group A (%) Group B (%) Group AB (%)
Nigerians 58.2 21 17 2
South Africans 45 40 11 4
Kenyan 60 19 20 1
Arabs 34 31 29 6
United Kingdom 47 42 8 3
French 43 47 7 3
Germans 41 43 11 5
Indians 37 22 33 7
US (Blacks) 49 27 20 4
US (Whites) 45 40 11 4
Disease pre-disposition. Compared to non-O group (A, AB, and B) individuals, O group in-
dividuals have a 14% reduced risk of squamous cell carcinoma and 4% reduced risk of basal 
cell carcinoma. It is also associated with a reduced risk of pancreatic cancer. The B antigen 
links with increased risk of ovarian cancer. Gastric cancer has reported to be more common in 
blood group A and least in group O. 
The ABO antigen production and the peculiar role of the H substance. The genes for the 
ABO system are on chromosome 9. The A, B and H gene codes for a different enzyme (glycosyl 
transferase) which acts on different sugars on the polypeptide or lipid (precursor substance) 
to produce a unique antigen. The A and B antigens are defined by specific sugars attached 
to a chain of oligosaccharide which protrude from the red cell membrane. The H substance 
is produced by the action of the H gene (HH or Hh). The H antigen is an essential precursor 
to the ABO blood group antigens. The H locus is located on chromosome 19. It encodes the 
enzyme fucosyl transferase which transfers the sugar L-fucose to the terminal sugar of the 
membrane galactose. This is known as the H antigen. The H antigen is the structure found in 
group O and is also the precursor required for the addition of the A and B antigens. Two genes 
regulate the production of the H antigen on red cells (FUT1) and other tissues (FUT2). The A 
allele encodes a glycosyltransferase that bonds α-N-acetylgalactosamine to D-galactose end 
of H antigen, producing the A antigen. The B allele encodes a glycosyltransferase that joins 
α-D-glucosamine bonded to D-galactose end of H antigen, creating the B antigen. Group O 
is amorphic and thus contain the highest amount of H substance. Groups A, B and AB have 
less H substance since a significant portion has been converted to A and or B antigens. The 
A1 is more effective in the conversion of H substance compared to A2. Thus A2 individuals 
have more H substance compared to A1. AB individuals have little or no H substance as a 
considerable amount of it has been converted to A and B antigens. A1 and A1B are capable of 
sometimes producing anti-H because of the insignificant amount of H substance on their red 
cell membrane. Such antibodies are usually cold reacting naturally acquired non-clinically 
significant and may sometimes be detected by a sensitive IAT antibody screen at 37°C.
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Table: Gene products and carbohydrate expression on the H, A and B gene
ABO and H antigens are not only present in the red cell membrane but also 
in most other cells of the body where they exist as glycolipds. Approximately 80% of the popula
tion secrete A, B and H substances of the same specificity as that found on the red cells in their 
serum/plasma (as glycoproteins) and in certain other body fluids such as saliva. These A, B and 
H are produced and secreted by the mucous gland (secretion). These individuals (secretors) have 
the secretor (Se) gene. These individuals who have the genotypes (SeSe or Sese) are known as se
cretors. These people secrete water-soluble blood group substances in their saliva and other body 
fluids. Group A individuals secretes A substance and a small amount of H, group B secretes B (and 
H) substance, group O secretes H substance only, and group AB secretes A, B, and a small amount 
of H. These substances can act as interference during red cell grouping. It is extremely important 
to wash red cell in saline before grouping to prevent these water soluble serum and plasma an
tigens from inhibiting the test and produce false negative reaction. There are laboratory test to 
determine if a person is a secretor. This test is based on the principle of 
he presence of agglutination means a negative test, and no agglutination is interpreted as a posi
tive result. The test is divided into phases; antibody neutralization and agglutination inhibition.
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Compared to non-O group (A, AB, and B) individuals, O group in
dividuals have a 14% reduced risk of squamous cell carcinoma and 4% reduced risk of basal 
cell carcinoma. It is also associated with a reduced risk of pancreatic cancer. The B antigen 
links with increased risk of ovarian cancer. Gastric cancer has reported to be more common in 
blood group A and least in group O. 
 The genes for the 
ABO system are on chromosome 9. The A, B and H gene codes for a different enzyme (glycosyl 
transferase) which acts on different sugars on the polypeptide or lipid (precursor substance) 
to produce a unique antigen. The A and B antigens are defined by specific sugars attached 
to a chain of oligosaccharide which protrude from the red cell membrane. The H substance 
is produced by the action of the H gene (HH or Hh). The H antigen is an essential precursor 
to the ABO blood group antigens. The H locus is located on chromosome 19. It encodes the 
enzyme fucosyl transferase which transfers the sugar L-fucose to the terminal sugar of the 
membrane galactose. This is known as the H antigen. The H antigen is the structure found in 
group O and is also the precursor required for the addition of the A and B antigens. Two genes 
regulate the production of the H antigen on red cells (FUT1) and other tissues (FUT2). The A 
allele encodes a glycosyltransferase that bonds α-N-acetylgalactosamine to D-galactose end 
of H antigen, producing the A antigen. The B allele encodes a glycosyltransferase that joins 
α-D-glucosamine bonded to D-galactose end of H antigen, creating the B antigen. Group O 
is amorphic and thus contain the highest amount of H substance. Groups A, B and AB have 
less H substance since a significant portion has been converted to A and or B antigens. The 
A1 is more effective in the conversion of H substance compared to A2. Thus A2 individuals 
have more H substance compared to A1. AB individuals have little or no H substance as a 
considerable amount of it has been converted to A and B antigens. A1 and A1B are capable of 
sometimes producing anti-H because of the insignificant amount of H substance on their red 
cell membrane. Such antibodies are usually cold reacting naturally acquired non-clinically 
significant and may sometimes be detected by a sensitive IAT antibody screen at 37°C.
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Table: Gene products and carbohydrate expression on the H, A and B gene
ABH Secretor status. ABO and H antigens are not only present in the red cell membrane but also 
in most other cells of the body where they exist as glycolipds. Approximately 80% of the popula-
tion secrete A, B and H substances of the same specificity as that found on the red cells in their 
serum/plasma (as glycoproteins) and in certain other body fluids such as saliva. These A, B and 
H are produced and secreted by the mucous gland (secretion). These individuals (secretors) have 
the secretor (Se) gene. These individuals who have the genotypes (SeSe or Sese) are known as se-
cretors. These people secrete water-soluble blood group substances in their saliva and other body 
fluids. Group A individuals secretes A substance and a small amount of H, group B secretes B (and 
H) substance, group O secretes H substance only, and group AB secretes A, B, and a small amount 
of H. These substances can act as interference during red cell grouping. It is extremely important 
to wash red cell in saline before grouping to prevent these water soluble serum and plasma an-
tigens from inhibiting the test and produce false negative reaction. There are laboratory test to 
determine if a person is a secretor. This test is based on the principle of Agglutination Inhibition. 
The presence of agglutination means a negative test, and no agglutination is interpreted as a posi-
tive result. The test is divided into phases; antibody neutralization and agglutination inhibition.
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Antibody Neutralization. Saliva is mixed with commercial antiserum (Anti-A, Anti-B or An-
ti-H) and allowed to incubate briefly. If the patient is a secretor, the soluble blood group anti-
gens in the saliva will react with and neutralize the antibodies in the commercial antiserum. 
It is necessary, however, to dilute the commercial antiserum so that its antibody titer more 
closely matches the antigen level in the saliva. 
Agglutination Inhibition. When commercial RBC of the appropriate blood group are then 
added to the test mixture, there should be no free antibody to agglutinate them if the patient 
is a secretor, because the antibodies have already reacted with the blood group antigens in 
the saliva (neutralization). The will be no reaction (no agglutination) which indicates that the 
patient is positive for secretor status. However if the patient is a non-secretor, there will be 
no blood group antigens in the saliva; the antibodies in the antiserum will not be neutralized 
and will be free to react when the test cells are added. Therefore, agglutination is a negative 
test for secretor status. 
Reagents, equipment used for determining the secretors status of patient
1. Clean tube to collect saliva 
2. 16 x 100 mm Pyrex test tube 
3. Disposable pipettes 
4. Boiling water bath 
5. 12 x 75 mm tubes 
6. Reagent Anti-A, Anti-B or Anti-H, diluted to give about 2+ reactions. 
7. Reagent A1 cells, B cells or O cells (Screening cells) 
8. Centrifuge 
9. Lighted agglutination viewer 
Procedure
1. Collect 2 to 3 ml saliva in a clean tube. Use paraffin wax or clean rubber bands 
to stimulate secretions (do not use chewing gum to prevent contamination). 
2. Place in a boiling water bath for 10 minutes. This process inactivates en-
zymes that might otherwise destroy blood group substances. 
3. Allow to cool briefly and then transfer to a 12 x 75 mm tube. 
4. Centrifuge for at least 5 minutes. 
5. Label three 12 x 75 mm test tubes (A test, B test and H test) 
6. Label three more tubes (A Control, B Control and H Control )
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7. The aim of these controls (step 6 and 7) is to as dilution controls to ensure 
that the anti-sera are not diluted beyond its capacity to agglutinate red 
cells containing the corresponding group specific antigens. 
8. Add one drop of the appropriate dilute antiserum to each tube (one drop 
dilute anti-A to the A cell and A control, one drop dilute anti-B to the B 
cell and B control and one drop anti-H to the H cell and H control )
9. To each test tube containing anti-A, B and H, add one drop of clear saliva. 
10. To each control tube, add one drop of saline. 
11. Mix and incubate at room temperature 10 minutes. 
12. Add one drop of the appropriate reagent red cells to each tube (A1 cells 
for the A test and control, B cells for the B test and control and Screening 
cell I or II for the H test and control). 
13. Mix and incubate at room temperature 10 minutes. 
14. Centrifuge test and control tubes in the centrifuge lightly for 2-3 minutes.
15. Using the lighted agglutination viewer, read, grade and record the reactions. 
16. The control tube should have agglutination for the test to be valid. 
. Agglutination in all of the patient test tubes indicates a negative result 
for secretor status. If any one of the patient test tubes is not agglutinated, this indicates a posi
tive test for secretor status, and the tube showing the non-agglutination should indicate the 
ABO secretor status of the patient. 
Bombay Phenotype (Oh). Individuals with the rare Bombay phenotype (hh) do not express 
antigen H on their red blood cells. As H antigen serves as precursor for producing A and B 
antigens, the absence of H antigen means the individuals do not have A or B antigens as well 
(similar to O blood group). However, unlike blood group O individuals, the H antigen is absent 
on their red cells while the corresponding specific anti-H isoantibodies to antigen H as well as 
to both A and B antigens are present in their serum/plasma. This antibody is so called naturally 
acquired and acts as both an agglutinin and a haemolysis and produces a strong reaction at 
20°C and 37°C. This antibody is clinically significant since only compatible unit from a Bombay 
phenotype donor (Oh) can be transfused. If these patients receive blood from a group donor, the 
anti-H antibodies in the recipient’s serum/plasma will bind to H antigen on RBC of donor blood 
and destroy the RBCs by complement-mediated lysis. Therefore Bombay phenotype individu
als can only receive blood only from Bombay phenotype (hh) donors. The Bombay phenotype 
although more predominant in people of Bombay (0.007%) is not restricted only to the Indian 
subcontinent. Anti-H (lectin) reagents can be prepared from the seeds of a common gorse bush 
(Ulex europaeus). Ulex europaeus gorse is a common gorse and an evergreen shrub in the fam
ily Fabaceae, native to western Europe from the northerly point of the United Kingdom south 
to Portugal, and from the westerly point of the Republic of Ireland east to Galicia in Poland and 
Ukraine. Lectin extracted from seeds of this species binds to and is remarkably specific for and 
Antibody Neutralization. Saliva is mixed with commercial antiserum (Anti-A, Anti-B or An
ti-H) and allowed to incubate briefly. If the patient is a secretor, the soluble blood group anti
gens in the saliva will react with and neutralize the antibodies in the commercial antiserum. 
It is necessary, however, to dilute the commercial antiserum so that its antibody titer more 
closely matches the antigen level in the saliva. 
When commercial RBC of the appropriate blood group are then 
added to the test mixture, there should be no free antibody to agglutinate them if the patient 
is a secretor, because the antibodies have already reacted with the blood group antigens in 
the saliva (neutralization). The will be no reaction (no agglutination) which indicates that the 
patient is positive for secretor status. However if the patient is a non-secretor, there will be 
no blood group antigens in the saliva; the antibodies in the antiserum will not be neutralized 
and will be free to react when the test cells are added. Therefore, agglutination is a negative 
test for secretor status. 
Reagents, equipment used for determining the secretors status of patient
1. Clean tube to collect saliva 
2. 16 x 100 mm Pyrex test tube 
3. Disposable pipettes 
4. Boiling water bath 
5. 12 x 75 mm tubes 
6. Reagent Anti-A, Anti-B or Anti-H, diluted to give about 2+ reactions. 
7. Reagent A1 cells, B cells or O cells (Screening cells) 
8. Centrifuge 
9. Lighted agglutination viewer 
1. Collect 2 to 3 ml saliva in a clean tube. Use paraffin wax or clean rubber bands 
to stimulate secretions (do not use chewing gum to prevent contamination). 
2. Place in a boiling water bath for 10 minutes. This process inactivates en
zymes that might otherwise destroy blood group substances. 
3. Allow to cool briefly and then transfer to a 12 x 75 mm tube. 
4. Centrifuge for at least 5 minutes. 
5. Label three 12 x 75 mm test tubes (A test, B test and H test) 
6. Label three more tubes (A Control, B Control and H Control )
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7. The aim of these controls (step 6 and 7) is to as dilution controls to ensure 
that the anti-sera are not diluted beyond its capacity to agglutinate red 
cells containing the corresponding group specific antigens. 
8. Add one drop of the appropriate dilute antiserum to each tube (one drop 
dilute anti-A to the A cell and A control, one drop dilute anti-B to the B 
cell and B control and one drop anti-H to the H cell and H control )
9. To each test tube containing anti-A, B and H, add one drop of clear saliva. 
10. To each control tube, add one drop of saline. 
11. Mix and incubate at room temperature 10 minutes. 
12. Add one drop of the appropriate reagent red cells to each tube (A1 cells 
for the A test and control, B cells for the B test and control and Screening 
cell I or II for the H test and control). 
13. Mix and incubate at room temperature 10 minutes. 
14. Centrifuge test and control tubes in the centrifuge lightly for 2-3 minutes.
15. Using the lighted agglutination viewer, read, grade and record the reactions. 
16. The control tube should have agglutination for the test to be valid. 
Result interpretation. Agglutination in all of the patient test tubes indicates a negative result 
for secretor status. If any one of the patient test tubes is not agglutinated, this indicates a posi-
tive test for secretor status, and the tube showing the non-agglutination should indicate the 
ABO secretor status of the patient. 
Bombay Phenotype (Oh). Individuals with the rare Bombay phenotype (hh) do not express 
antigen H on their red blood cells. As H antigen serves as precursor for producing A and B 
antigens, the absence of H antigen means the individuals do not have A or B antigens as well 
(similar to O blood group). However, unlike blood group O individuals, the H antigen is absent 
on their red cells while the corresponding specific anti-H isoantibodies to antigen H as well as 
to both A and B antigens are present in their serum/plasma. This antibody is so called naturally 
acquired and acts as both an agglutinin and a haemolysis and produces a strong reaction at 
20°C and 37°C. This antibody is clinically significant since only compatible unit from a Bombay 
phenotype donor (Oh) can be transfused. If these patients receive blood from a group donor, the 
anti-H antibodies in the recipient’s serum/plasma will bind to H antigen on RBC of donor blood 
and destroy the RBCs by complement-mediated lysis. Therefore Bombay phenotype individu-
als can only receive blood only from Bombay phenotype (hh) donors. The Bombay phenotype 
although more predominant in people of Bombay (0.007%) is not restricted only to the Indian 
subcontinent. Anti-H (lectin) reagents can be prepared from the seeds of a common gorse bush 
(Ulex europaeus). Ulex europaeus gorse is a common gorse and an evergreen shrub in the fam-
ily Fabaceae, native to western Europe from the northerly point of the United Kingdom south 
to Portugal, and from the westerly point of the Republic of Ireland east to Galicia in Poland and 
Ukraine. Lectin extracted from seeds of this species binds to and is remarkably specific for and 
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is the standard method for identification of H-substance (absent in the hh antigen system) on 
human red blood cells. The vast majority of humans express H-substance, which is the basis for 
the ABO blood group system, but a few rare individuals (“Bombay phenotype”) do not--and a 
chemical isolated from Ulex europaeus is used to identify these individuals.
Group
Grouping sera (Back group)
Auto
Red cell (Forward 
group)
Anti-A Anti-B Anti- A,B Anti-A1 Anti-H A1 A2 B O
O N N N N P N P P P N
Bombay phe-
notype (Oh)
N N N N N N P P P P
Blood grouping results from a group O and Bombay phenotype individual
Key: 
P= Positive reaction 
N= Negative reaction 
ABO haemolytic disease of the newborn (ABO HDN). In ABO haemolytic disease of the new-
born maternal IgG antibodies with specificity for the ABO blood group system pass through 
the placenta to the fetal circulation where they can cause haemolysis of foetal red blood cells 
which can lead to foetal anaemia and HDN. In contrast to Rh disease, about half of the cases of 
ABO HDN occur in a firstborn baby and ABO HDN does not become more severe after further 
pregnancies. The ABO blood group system is the best known surface antigen system, expressed 
on a wide variety of human cells. For Caucasian populations about one fifth of all pregnancies 
have ABO incompatibility between the fetus and the mother, but only a tiny minority develop 
symptomatic ABO HDN. The latter only occurs in mothers of blood group O because they can 
produce enough IgG antibodies to cause hemolysis. Although very uncommon, cases of ABO 
HDN have been reported in infants born to mothers with blood groups A and B.
Causes of ABO HDN
Environmental exposure: Anti-A and anti-B antibodies are usually IgM and do not pass 
through the placenta, but some mothers “naturally” have IgG anti-A or IgG anti-B antibodies, 
which can pass through the placenta. Exposure to A-antigens and B-antigens, which are both 
widespread in nature, usually leads to the production of IgM anti-A and IgM anti-B antibod-
ies but occasionally IgG antibodies are produced.
Foetal-maternal transfusion: Some mothers may be sensitized by foetal-maternal transfusion 
of ABO incompatible red blood and produce immune IgG antibodies against the antigen they 
do not have and their baby does. For example, when a mother of genotype OO (blood group 
O) carries a fetus of genotype AO (blood group A) she may produce IgG anti-A antibodies. 
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The father will either have blood group A, with genotype AA or AO, or more rarely, have 
blood group AB, with genotype AB.
 It would be very very rare for ABO sensitization to be caused by therapeu
tic blood transfusion as a great deal of effort and checking is done to ensure that blood is ABO 
compatible between the recipient and the donor.
 In about a third of all ABO incompatible pregnancies maternal IgG 
anti-A or IgG anti-B antibodies pass through the placenta to the foetal circulation leading to a 
weakly positive direct Coombs test for the neonate’s blood. However, ABO HDN is generally 
mild and short-lived and only occasionally severe because:
1. IgG anti-A (or IgG anti-B) antibodies that enter the foetal circulation from 
the mother find A (or B) antigens on many different foetal cell types, leav
ing fewer antibodies available for binding onto foetal red blood cells.
2. Foetal RBC surface A and B antigens are not fully developed during ges
tation and so there are a smaller number of antigenic sites on foetal RBCs.
 Routine antenatal antibody screening blood tests (indirect Coombs test) do not 
screen for ABO HDN. IgG anti-A or IgG anti-B antibodies are found in the pregnant woman’s 
blood, they are not reported with the test results, because they do not correlate well with ABO 
HDN. Diagnosis is usually made by investigation of a newborn baby who has developed 
jaundice during the first day of life.
Neonatal jaundice caused by ABO HDN is usually successfully treated with pho
totherapy, unless the ABO HDN is uncommonly severe. Treatment of moderate or severe 
HDN caused by ABO antibodies is similar to that for Rh disease.
The ABO blood group antigens are encoded by one genetic 
locus, the ABO locus which is located on chromosome 9 and has three alternative (allelic) genes- A, 
B, and O. Each individual has a pair of chromosome 9 (one inherited from each parent). A child 
receives one of the three genes from each parent, giving rise to six possible genotypes and four pos
sible blood phenotypes. The O gene is an amorph (produces no antigenic products) and it is reces
sive to the A and B genes which are both co-dominant. Each individual inherit two ABO genes (one 
from both parents). It is the combination of these 2 genes that determine an individual ABO groups. 
The A phenotype is produced by the genotype AA or AO, the B phenotype by BB or BO  while the 
AB and O phenotypes are produced respectively by the AB and OO genotype. The ABO blood 
group antigen do not exhibit a dosage effect (the reaction produced by a A or B person who has the 
genotype AA or BB has the same strength as a person who has genotype AO or BO. The genotypes 
AA/AO and BB/BO are only distinguishable by family studies and molecular genetics techniques 
(DNA analysis).
is the standard method for identification of H-substance (absent in the hh antigen system) on 
human red blood cells. The vast majority of humans express H-substance, which is the basis for 
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chemical isolated from Ulex europaeus is used to identify these individuals.
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Key: 
N= Negative reaction 
ABO haemolytic disease of the newborn (ABO HDN). In ABO haemolytic disease of the new
born maternal IgG antibodies with specificity for the ABO blood group system pass through 
the placenta to the fetal circulation where they can cause haemolysis of foetal red blood cells 
which can lead to foetal anaemia and HDN. In contrast to Rh disease, about half of the cases of 
ABO HDN occur in a firstborn baby and ABO HDN does not become more severe after further 
pregnancies. The ABO blood group system is the best known surface antigen system, expressed 
on a wide variety of human cells. For Caucasian populations about one fifth of all pregnancies 
have ABO incompatibility between the fetus and the mother, but only a tiny minority develop 
symptomatic ABO HDN. The latter only occurs in mothers of blood group O because they can 
produce enough IgG antibodies to cause hemolysis. Although very uncommon, cases of ABO 
HDN have been reported in infants born to mothers with blood groups A and B.
Anti-A and anti-B antibodies are usually IgM and do not pass 
through the placenta, but some mothers “naturally” have IgG anti-A or IgG anti-B antibodies, 
which can pass through the placenta. Exposure to A-antigens and B-antigens, which are both 
widespread in nature, usually leads to the production of IgM anti-A and IgM anti-B antibod
ies but occasionally IgG antibodies are produced.
Some mothers may be sensitized by foetal-maternal transfusion 
of ABO incompatible red blood and produce immune IgG antibodies against the antigen they 
do not have and their baby does. For example, when a mother of genotype OO (blood group 
O) carries a fetus of genotype AO (blood group A) she may produce IgG anti-A antibodies. 
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The father will either have blood group A, with genotype AA or AO, or more rarely, have 
blood group AB, with genotype AB.
Blood transfusion: It would be very very rare for ABO sensitization to be caused by therapeu-
tic blood transfusion as a great deal of effort and checking is done to ensure that blood is ABO 
compatible between the recipient and the donor.
Other moderating factors: In about a third of all ABO incompatible pregnancies maternal IgG 
anti-A or IgG anti-B antibodies pass through the placenta to the foetal circulation leading to a 
weakly positive direct Coombs test for the neonate’s blood. However, ABO HDN is generally 
mild and short-lived and only occasionally severe because:
1. IgG anti-A (or IgG anti-B) antibodies that enter the foetal circulation from 
the mother find A (or B) antigens on many different foetal cell types, leav-
ing fewer antibodies available for binding onto foetal red blood cells.
2. Foetal RBC surface A and B antigens are not fully developed during ges-
tation and so there are a smaller number of antigenic sites on foetal RBCs.
Diagnosis: Routine antenatal antibody screening blood tests (indirect Coombs test) do not 
screen for ABO HDN. IgG anti-A or IgG anti-B antibodies are found in the pregnant woman’s 
blood, they are not reported with the test results, because they do not correlate well with ABO 
HDN. Diagnosis is usually made by investigation of a newborn baby who has developed 
jaundice during the first day of life.
Treatment: Neonatal jaundice caused by ABO HDN is usually successfully treated with pho-
totherapy, unless the ABO HDN is uncommonly severe. Treatment of moderate or severe 
HDN caused by ABO antibodies is similar to that for Rh disease.
Inheritance of ABO Blood Groups. The ABO blood group antigens are encoded by one genetic 
locus, the ABO locus which is located on chromosome 9 and has three alternative (allelic) genes- A, 
B, and O. Each individual has a pair of chromosome 9 (one inherited from each parent). A child 
receives one of the three genes from each parent, giving rise to six possible genotypes and four pos-
sible blood phenotypes. The O gene is an amorph (produces no antigenic products) and it is reces-
sive to the A and B genes which are both co-dominant. Each individual inherit two ABO genes (one 
from both parents). It is the combination of these 2 genes that determine an individual ABO groups. 
The A phenotype is produced by the genotype AA or AO, the B phenotype by BB or BO  while the 
AB and O phenotypes are produced respectively by the AB and OO genotype. The ABO blood 
group antigen do not exhibit a dosage effect (the reaction produced by a A or B person who has the 
genotype AA or BB has the same strength as a person who has genotype AO or BO. The genotypes 
AA/AO and BB/BO are only distinguishable by family studies and molecular genetics techniques 
(DNA analysis).
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Blood group Red cell antigen (phenotype) Genes present (Genotype)
A A AA or AO
B B BB or BO
AB A and B AB
O None OO
Table: Possible phenotypes and genotypes of ABO blood group system
Genetics in transfusion medicine. Inheritance of ABO blood groups is based on Mendelian 
principles of inheritance. The basic principles is based on the following:
1. Each parent contributes 1/2 of the genetic information. 
2. The genetic information is contained on chromosomes composed of DNA 
3. Humans have 23 pairs of chromosomes (22 matched (autosomal) chro-
mosomes and 1pair of sex chromosomes (females have 2 X chromosomes 
and males an X and a Y chromosome). 
Genetic aspects of blood groups. Genes are the units of inheritance within the chromosomes. 
At each location, or loci, on the chromosomes there are possibilities of different forms of the 
genes, these different forms are called alleles. (For example the ABO Blood Group System, there 
are A1, A2, B, and O as common alleles. or allelic genes). When the inherited alleles are the same 
the person is homozygous such as OO, when the individual inherits 2 different alleles such as 
AO, they are heterozygous for both the A and O genes. On occasion we will see examples of 
dosage where some antibodies will react more strongly with homozygous cells than with het-
erozygous cells. For example, an anti-E that reacts as a 3+ with EE cells and only 1+ with Ee cells. 
A Punnett Square is used to determine the inheritance possibilities for a particular mating. For 
example if the mother’s genotype (genes) are AO and the father’s genotype (genes) are BO, you 
would have the following Punnet square possibilities. In this example there three heterozygous 
possibilities AB, AO, and BO and one homozygous possibility OO.
Blood group system Common Genes Located on Chromosome
ABO A, B, O 9
MNSsU M, N, S,s,U 4
P P1 22
Rh D, C, E, c, e 1
Kell K, k, Kpa, Jsa,Kpb, Jsb 7
Lewis Le, le 19
Duffy Fya, Fyb, Fy3 1
Kidd Jka, Jkb 18
Xg Xga X
Examples of Chromosome locations for common Blood Groups
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Punnett Square showing the inheritance of ABO blood groups
In the above Punnett Square, the AB genotype will have both A and B antigens, therefore the 
phenotype are AB since both are expressed. AO and BO genotypes will demonstrate only the 
A and the B antigens respectively and therefore the phenotypes are A and B respectively. The 
individual that is OO will have the O phenotype. A and B genes are dominant, or co-dominant, 
and the O gene is recessive. The dominant genes will be expressed if present. Recessive genes 
will only be expressed if they are homozygous. Most Blood Group genes are co-dominant and 
therefore will be expressed if present.
. Two kinds of cell division exist (mitosis and meiosis). Mitosis is cell 
division that leads to two identical cells that has the same number of paired chromosomes. (In 
humans there are 23 pairs or 46 chromosomes). Meiosis is the cell division that occurs when 
gametes (sperm and eggs) are formed and will not have pairs of chromosomes. (In humans 
there will be 23 chromosomes in the sperm that will match up with the 23 chromosomes in 
the egg when fertilization occurs to form the gametocyte.). The sex of the child is determined 
by the X and Y chromosomes. Males provide either X or Y chromosome and females provide 
only provide X chromosomes. Genes that are found only on the X chromosome are said to be 
sex-linked. Genes found on the other 22 pairs of chromosomes are autosomal. 
 Certain characteristics that make blood genet
ics useful for the field of human genetics includes the following; simple and unquestionable pattern 
of inheritance, possibility to test or determine the phenotypes readily, the fact that more than 1 allele 
occurring fairly frequently and the fact that environmental factors does not affect the expression of 
the genes. Some discoveries that were found in blood genetics include; multiple alleles seen in ABO 
system and linkage between the secretor genes with the Lutheran genes on the same chromosome 
 Linkage between the secretor genes with the Lutheran genes on the same chromo
some was already noted. We now know that the D gene is closely linked to the Cc and Ee 
genes. The most frequently inherited Rh positive set of genes is CDe and the most frequent 
Rh negative gene is cde or ce since d is an amorph. The MNSs genes are also linked, MS, NS, 
Ms, Ns leading to a difference between the expected frequency and the observed frequency.
 Silent mutations are DNA mutations that do not result in a change to the amino 
acid sequence of a protein. They may occur in a non-coding region (outside of a gene or with
in an intron), or they may occur within an exon in a manner that does not alter the final amino 
acid sequence. As indicated already there are some amorph blood group genes that exist and 
lead to none expression of a blood antigen. The following are some examples of silent genes.
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Punnett Square showing the inheritance of ABO blood groups
In the above Punnett Square, the AB genotype will have both A and B antigens, therefore the 
phenotype are AB since both are expressed. AO and BO genotypes will demonstrate only the 
A and the B antigens respectively and therefore the phenotypes are A and B respectively. The 
individual that is OO will have the O phenotype. A and B genes are dominant, or co-dominant, 
and the O gene is recessive. The dominant genes will be expressed if present. Recessive genes 
will only be expressed if they are homozygous. Most Blood Group genes are co-dominant and 
therefore will be expressed if present.
Mitosis and Meiosis. Two kinds of cell division exist (mitosis and meiosis). Mitosis is cell 
division that leads to two identical cells that has the same number of paired chromosomes. (In 
humans there are 23 pairs or 46 chromosomes). Meiosis is the cell division that occurs when 
gametes (sperm and eggs) are formed and will not have pairs of chromosomes. (In humans 
there will be 23 chromosomes in the sperm that will match up with the 23 chromosomes in 
the egg when fertilization occurs to form the gametocyte.). The sex of the child is determined 
by the X and Y chromosomes. Males provide either X or Y chromosome and females provide 
only provide X chromosomes. Genes that are found only on the X chromosome are said to be 
sex-linked. Genes found on the other 22 pairs of chromosomes are autosomal. 
Other Concepts Relating to Blood Group Genetics. Certain characteristics that make blood genet-
ics useful for the field of human genetics includes the following; simple and unquestionable pattern 
of inheritance, possibility to test or determine the phenotypes readily, the fact that more than 1 allele 
occurring fairly frequently and the fact that environmental factors does not affect the expression of 
the genes. Some discoveries that were found in blood genetics include; multiple alleles seen in ABO 
system and linkage between the secretor genes with the Lutheran genes on the same chromosome 
Linkage: Linkage between the secretor genes with the Lutheran genes on the same chromo-
some was already noted. We now know that the D gene is closely linked to the Cc and Ee 
genes. The most frequently inherited Rh positive set of genes is CDe and the most frequent 
Rh negative gene is cde or ce since d is an amorph. The MNSs genes are also linked, MS, NS, 
Ms, Ns leading to a difference between the expected frequency and the observed frequency.
Silent genes: Silent mutations are DNA mutations that do not result in a change to the amino 
acid sequence of a protein. They may occur in a non-coding region (outside of a gene or with-
in an intron), or they may occur within an exon in a manner that does not alter the final amino 
acid sequence. As indicated already there are some amorph blood group genes that exist and 
lead to none expression of a blood antigen. The following are some examples of silent genes.
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Examples of silent gene phenomenom
Blood Group Nomenclature
1. Genes encoding the expression of blood group antigens are written in ital-
ics (or underlined if italics are not available). If the antigen name includes a 
subscript (A1), the encoding gene is expressed with a superscript (A1) 
2. Antigen names are designated by a superscript or a number (eg, Fya, Fy: 
1) are written in normal (Roman) script. Superscript letters are lowercase. 
3. When antigen phenotypes are expressed using single letter designation, 
results are usually written as + or -, set on the same line as the letter(s) of 
the antigen: K+ k-. 
4. To express phenotypes of antigens designated with a superscript letter, 
that letter is placed in parentheses on the same line as the symbol defin-
ing the antigen: Fy (a+). 
5. For antigens designated by numbers, the symbol defining the system is 
notated in capital letters followed by a colon, followed by the number 
representing the antigen tested. Plus signs do no appear when test results 
are positive (K: 1), but a minus sign is placed before negative test results: 
K: 1, K:-1. If tests for several antigens in one blood group have been done, 
the phenotypes is designated by the letter(s) of the locus or blood group 
system followed by a colon, followed by antigen numbers separated by 
commas: K: -1, 2, -3, 4. Only antigens tested are listed.
Term Description Correct Terminology Incorrect Terminology
Phenotype Fy(a+) Fya+, Fy(a+), Fya(+), Fya+, Fya(+), Duffya+
Phenotype Fy(a+b-) Fya+b-, Fy(a+b-), Fya(+)b(-), Fya(+)b(-)
Antibody Anti-Fya Anti Fya, Anti-Duffy
Antigen K Kell (name of system)
Antibody anti-k Anti-Cellano
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K:1, K:-1 k1+, K:1+, K(1), K:(1), K1-, K:1-, K1-negative
A Rh+, B Rh-
A+ (means positive for A antigen)
B- (means negative for B antigen)
M+N- M(+), MM (unproven genotypes)
Rh:-1, -2, -3, 4,5 Rh: -1, -2, -3, +4, +5, Rh: 1-,2-,3-, 4+,5+
Table: Examples of Correct and Incorrect Terminology 
Public Genes are found in most of the population. In the Kell 
Blood Group System, the Kpb is found in close to 100% of the population. Genes that are very 
rare are referred to private genes. Kp  is very rarely found (2.3% in whites and almost never 
in African Americans) and therefore close to being a private gene. 
 Parental testing is the test carried out to determine whether two individuals 
have a biological parent-child relationship. A paternity test establishes genetic proof as to whether 
a man (putative) is the biological father of an individual, and a maternity test establishes whether 
a woman is the biological mother of an individual. Though genetic testing is the most reliable 
standard, older methods also exist and includes; red cell testing for the following blood group 
systems (ABO, MNSs, Rh, Duffy, Kidd, Kell), analysis of various other proteins and enzymes, or 
using human leukocyte antigen antigens (HLA antigens). The current techniques for paternal 
testing are using polymerase chain reaction (PCR) and restriction fragment length polymorphism.
Although blood types can offer clues about 
paternity (and were used for paternity tests until the late 20th century), it is not consistent enough 
for definitive paternity test results. Human blood types stem from dominant/recessive genes simi
lar to Mendel’s rule. Dominant blood types include A and B while type O is recessive. Alleles for 
type A and type B blood are co-dominant which means that, when both are present, the resulting 
blood type is AB. Type O is am amorph meaning that it’s expression is suppressed if inherited 
along with dorminant A and B alleles. The table below illustrates possible blood types that can be 
expressed in a child from the mating of parents with blood types A, B, AB, and O (If the mother’s 
and father’s blood types are known). The inheritance of ABO blood groups is based on Mendel’s 
rule. The application of Mendel’s rule in paternity dispute is based on 2 laws:
1. For ABO blood group type to occur in a child, it 
. This law indicates that
• Two blood group O parents cannot give birth to an A, B or 
AB child.
• Two blood group AB parents cannot give birth to an O child.
• A blood group A and O parent cannot give birth to a B child.







Examples of silent gene phenomenom
1. Genes encoding the expression of blood group antigens are written in ital
ics (or underlined if italics are not available). If the antigen name includes a 
subscript (A1), the encoding gene is expressed with a superscript (A1) 
2. Antigen names are designated by a superscript or a number (eg, Fy , Fy: 
1) are written in normal (Roman) script. Superscript letters are lowercase. 
3. When antigen phenotypes are expressed using single letter designation, 
results are usually written as + or -, set on the same line as the letter(s) of 
the antigen: K+ k-. 
4. To express phenotypes of antigens designated with a superscript letter, 
that letter is placed in parentheses on the same line as the symbol defin
ing the antigen: Fy (a+). 
5. For antigens designated by numbers, the symbol defining the system is 
notated in capital letters followed by a colon, followed by the number 
representing the antigen tested. Plus signs do no appear when test results 
are positive (K: 1), but a minus sign is placed before negative test results: 
K: 1, K:-1. If tests for several antigens in one blood group have been done, 
the phenotypes is designated by the letter(s) of the locus or blood group 
system followed by a colon, followed by antigen numbers separated by 
commas: K: -1, 2, -3, 4. Only antigens tested are listed.
Fya+, Fy(a+), Fya(+), Fya+, Fya(+), Duffya+
Fy(a+b-) Fya+b-, Fy(a+b-), Fya(+)b(-), Fya(+)b(-)
Anti-Fya Anti Fya, Anti-Duffy
Antigen Kell (name of system)
anti-k Anti-Cellano
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Term Description Correct Terminology Incorrect Terminology
Phenotype K:1, K:-1 k1+, K:1+, K(1), K:(1), K1-, K:1-, K1-negative
Phenotypes A Rh+, B Rh-
A+ (means positive for A antigen) 
B- (means negative for B antigen)
Phenotype M+N- M(+), MM (unproven genotypes)
Phenotype Rh:-1, -2, -3, 4,5 Rh: -1, -2, -3, +4, +5, Rh: 1-,2-,3-, 4+,5+
Table: Examples of Correct and Incorrect Terminology 
Public versus Private Genes: Public Genes are found in most of the population. In the Kell 
Blood Group System, the Kpb is found in close to 100% of the population. Genes that are very 
rare are referred to private genes. Kpa is very rarely found (2.3% in whites and almost never 
in African Americans) and therefore close to being a private gene. 
Paternity Testing: Parental testing is the test carried out to determine whether two individuals 
have a biological parent-child relationship. A paternity test establishes genetic proof as to whether 
a man (putative) is the biological father of an individual, and a maternity test establishes whether 
a woman is the biological mother of an individual. Though genetic testing is the most reliable 
standard, older methods also exist and includes; red cell testing for the following blood group 
systems (ABO, MNSs, Rh, Duffy, Kidd, Kell), analysis of various other proteins and enzymes, or 
using human leukocyte antigen antigens (HLA antigens). The current techniques for paternal 
testing are using polymerase chain reaction (PCR) and restriction fragment length polymorphism.
Role of ABO blood groups in paternity dispute. Although blood types can offer clues about 
paternity (and were used for paternity tests until the late 20th century), it is not consistent enough 
for definitive paternity test results. Human blood types stem from dominant/recessive genes simi-
lar to Mendel’s rule. Dominant blood types include A and B while type O is recessive. Alleles for 
type A and type B blood are co-dominant which means that, when both are present, the resulting 
blood type is AB. Type O is am amorph meaning that it’s expression is suppressed if inherited 
along with dorminant A and B alleles. The table below illustrates possible blood types that can be 
expressed in a child from the mating of parents with blood types A, B, AB, and O (If the mother’s 
and father’s blood types are known). The inheritance of ABO blood groups is based on Mendel’s 
rule. The application of Mendel’s rule in paternity dispute is based on 2 laws:
1. For ABO blood group type to occur in a child, it must have been inher-
ited from one or both parents. This law indicates that
• Two blood group O parents cannot give birth to an A, B or 
AB child.
• Two blood group AB parents cannot give birth to an O child.
• A blood group A and O parent cannot give birth to a B child.
• A blood group B and O parents cannot give birth to a group 
A child.
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2. A blood group AB parent cannot give birth to a group O child.
• An O child will have the genotype OO. This indicates that the 
child must have inherited an O from both parents.
• In a mating between a blood group AB and group O parents, 
the AB parent must always contribute either A or B for every 
mating and the O parent will alway contribute O. When A 
and O is inherited from both parent, the child will be group A.
• When B and O are inherited from both parents, the child will 
be blood group B.
• A and B are co-dominant over O. When O and A or O and B is 
inherited from both parents by a child the A and B are domi-







A B AB O
A A or O A,B or O A, B or AB A or O
B B or O B or O A, B or AB B or O
AB A, B or AB A, B or AB A, B or AB A, B
O A or O B or O A or B O







A B AB O
A A, B, AB or O B or AB B or AB A, B, or O
B A or AB A, B, AB or O A or AB A, B, or O
AB A, B, AB or O A, B, AB or O A, B, or AB A, B, AB or O
O A or AB B or AB Not possible A,B or O 
Biological fathers’s possible phenotype if the mother’s and child’s ABO blood types are known. 
4. Anticoagulation and preservation in transfusion
An anticoagulant is a substance that prevents coagulation; that is, it stops blood from clotting. 
Some chemical compounds are used in blood transfusion bags to prevent blood from clotting. 
Various anticoagulant-preservative solutions have been formulated for better red cell preserva-
tion. Correct proportion of this anticoagulant to blood is crucial for effective anticoagulation. 
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Routine blood storage is limited to 21 days at 1°- 6°C when treated with 
acid citrate -dextrose (ACD), citrate phosphate-dextrose (CPD) or citrate-phosphate-double 
dextrose (CP2D) and 35 days when treated with citrate-phosphate-dextrose-adenine (CPDA1) 
(5 weeks for whole blood and 6 weeks for RBC), and involves refrigeration but usually not 
freezing. There has been increasing controversy about whether the age of blood is a factor in 
transfusion efficacy, specifically on whether older blood directly or indirectly increases risks 
of complications. Studies have not been consistent on answering this question, with some 
showing that older blood is indeed less effective but with others showing no such difference; 
nevertheless as storage time remains the only available way to estimate quality status or loss 
is a first-in-first-out inventory management approach is standard presently.
Long-term storage is relatively uncommon, compared to short-term stor
age. Cryopreservation of red blood cells is done to store rare units for up to 10 years. The cells 
are incubated in a glycerol solution which acts as a cryoprotectant (“antifreeze”) within the 
cells. The units are then placed in special sterile containers in a freezer at very cold tempera
tures. The exact temperature depends on the glycerol concentration.
1. Acid Citrate Dextrose (ACD) 
2. Citrate phosphate Dextrose solution (CPD) 
3. Citrate phosphate dextrose adenine. (CPDA-1) 
Frozen red cell
1. High glycerol solution 
2. Low glycerol solution 
The commonly used citrate based anticoagulant - preserva
tive solutions is: Acid Citrate Dextrose (ACD): The most widely used ACD solution has the 
following components;Trisodium citrate 22. Og, citric acid (monohydrate) 8.0 g, Dextrose 
(monohydrate) 24.6 g and distilled water to make upto one litre. Citrate Phosphate Dextrose 
Adenine (CPDA): For each 450 ml, whole blood, 67.5 ml of ACD solution is required. 
Citrate is a calcium chelator. It prevents coagulation of blood as well as re
tards glycolysis. Dextrose improves red cell viability, provides energy for ATP synthesis and de
creases rate of hydrolysis of phosphorus. Citric acid prevents glucose caramalization during auto
claving and provides optimal pH with citrate for red cells. ACD Solution preserves ATP level, helps 
maintain red cells shape, prevents haemolysis and maintains pH. Shelf life of whole blood or red 
cells collected in ACD and stored at 4°C ± 2°C is 21 days. Citrate phosphate dextrose (CPD) decrease 
acidosis and improves ATP synthesis. Shelf-life of whole blood stored in CPD at 4°C ± 2°C is 28 days. 
Citrate Phosphate Dextrose Adenine (CPDA) helps to maintain high ATP levels. Blood collected in 
CPDA is safe, well tolerated and has a shelf-life of 35 days when stored at at 4°C ± 2°C.
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2. A blood group AB parent  give birth to a group O child.
• An O child will have the genotype OO. This indicates that the 
child must have inherited an O from both parents.
• In a mating between a blood group AB and group O parents, 
the AB parent must always contribute either A or B for every 
mating and the O parent will alway contribute O. When A 
and O is inherited from both parent, the child will be group A.
• When B and O are inherited from both parents, the child will 
be blood group B.
• A and B are co-dominant over O. When O and A or O and B is 
inherited from both parents by a child the A and B are domi









Biological fathers’s possible phenotype if the mother’s and child’s ABO blood types are known. 
An anticoagulant is a substance that prevents coagulation; that is, it stops blood from clotting. 
Some chemical compounds are used in blood transfusion bags to prevent blood from clotting. 
Various anticoagulant-preservative solutions have been formulated for better red cell preserva
tion. Correct proportion of this anticoagulant to blood is crucial for effective anticoagulation. 
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Short-term Storage. Routine blood storage is limited to 21 days at 1°- 6°C when treated with 
acid citrate -dextrose (ACD), citrate phosphate-dextrose (CPD) or citrate-phosphate-double 
dextrose (CP2D) and 35 days when treated with citrate-phosphate-dextrose-adenine (CPDA1) 
(5 weeks for whole blood and 6 weeks for RBC), and involves refrigeration but usually not 
freezing. There has been increasing controversy about whether the age of blood is a factor in 
transfusion efficacy, specifically on whether older blood directly or indirectly increases risks 
of complications. Studies have not been consistent on answering this question, with some 
showing that older blood is indeed less effective but with others showing no such difference; 
nevertheless as storage time remains the only available way to estimate quality status or loss 
is a first-in-first-out inventory management approach is standard presently.
Long-term Storage. Long-term storage is relatively uncommon, compared to short-term stor-
age. Cryopreservation of red blood cells is done to store rare units for up to 10 years. The cells 
are incubated in a glycerol solution which acts as a cryoprotectant (“antifreeze”) within the 
cells. The units are then placed in special sterile containers in a freezer at very cold tempera-
tures. The exact temperature depends on the glycerol concentration.
Examples of commonly used anticoagulants in transfusions include:  
Whole blood
1. Acid Citrate Dextrose (ACD) 
2. Citrate phosphate Dextrose solution (CPD) 
3. Citrate phosphate dextrose adenine. (CPDA-1) 
Frozen red cell
1. High glycerol solution 
2. Low glycerol solution 
Citrate Based Anticoagulants. The commonly used citrate based anticoagulant - preserva-
tive solutions is: Acid Citrate Dextrose (ACD): The most widely used ACD solution has the 
following components;Trisodium citrate 22. Og, citric acid (monohydrate) 8.0 g, Dextrose 
(monohydrate) 24.6 g and distilled water to make upto one litre. Citrate Phosphate Dextrose 
Adenine (CPDA): For each 450 ml, whole blood, 67.5 ml of ACD solution is required. 
Mechanism of action. Citrate is a calcium chelator. It prevents coagulation of blood as well as re-
tards glycolysis. Dextrose improves red cell viability, provides energy for ATP synthesis and de-
creases rate of hydrolysis of phosphorus. Citric acid prevents glucose caramalization during auto-
claving and provides optimal pH with citrate for red cells. ACD Solution preserves ATP level, helps 
maintain red cells shape, prevents haemolysis and maintains pH. Shelf life of whole blood or red 
cells collected in ACD and stored at 4°C ± 2°C is 21 days. Citrate phosphate dextrose (CPD) decrease 
acidosis and improves ATP synthesis. Shelf-life of whole blood stored in CPD at 4°C ± 2°C is 28 days. 
Citrate Phosphate Dextrose Adenine (CPDA) helps to maintain high ATP levels. Blood collected in 
CPDA is safe, well tolerated and has a shelf-life of 35 days when stored at at 4°C ± 2°C.
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Optimal Additive Solution (OAS) for Preservation of Red Cells. Different types of additive 
systems are now in use to allow for the optimum preservation of red cells. These solutions 
contain saline, adenine and glucose and are added to the red cells after separating them from 
plasma. Blood is collected into a multiple bag system including one plastic bag containing 100 
ml of optimal additive solution. After collection the whole blood is centrifuged and maximum 
amount of plasma along with the buffy coat is expressed into a transfer bag for further process-
ing. Red cells are now suspended by running down the optimal additive solution (100 ml) to the 
main bag containing red cells. Currently available additive solutions are:
• CPD-SAG. CPD-SAG (Citrate phosphate dextrose - saline, adenine, glu-
cose). In this besides CPD as the primary anticoagulant, a satellite bag 
contains the additive solution - 100 ml physiological saline with adenine 
and glucose. CPD-SAG causes undesirable amountof haemolysis.
• CPD-SAGMAN. (Citrate phosphate dextrose -saline, adenine, glucose, 
mannitol). In this the additive solution also has mannitol to prevent lysis 
of red cels. The 24 hr post transfusion survival is better with the additive. 
• CPD-ADSOL. (Citrate phosphate dextrose Adenine- saline, glucose, manni-
tol. This additive solution is similar to CPD-SAGMAN but has greater quanti-
ties of glucose, adenine and mannitol. It has better red cell preservation and 24 
hr post-transfusion survival. The shelf life with this solution can be increased 
to 42-49 days. Advantages of optimal additive solutions include: 
Advantages of red cells additive solutions
Provides red cells with nutrients that optimizes function
Enhances viscosity of blood and ease of transfusion
Optimize yield of plasma for fractionation
Removal of unwanted buffy coat
Optimum storage of red cells from 28 days (CPDA) to 35 days
Avoidance of unnecessary plasma transfusion
Red cell lesions
The various changes that occur within both the RBC and storage media during ex vivo preserva-
tion have been collectively termed the RBC “storage lesion” These alterations can be extensive 
and are primarily classified into three broad categories: biochemical, biomechanical, and im-
munologic. Storage of red blood cells in preservative medium is associated with metabolic, bio-
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chemical and molecular changes to erythrocytes collectively referred to as the “storage lesion.” 
In addition to corpuscular injury, bio-reactive substances including cytokines and lipids accu
mulate in the medium during storage. Storage related changes can have potential clinical im
plications for red blood cell transfusion. The term “storage lesion” has been traditionally used 
to describe the progressive degradation of red cell structure and function that occurs during 
conventional red cell storage. These changes include a reduction in red blood cell deformability, 
altered red blood cell adhesiveness and aggregability. Bioactive compounds with pro-inflam
matory effects also accumulate in the storage medium. These changes reduce post transfusion 
viability of red blood cells. The clinical effects beyond post transfusion viability are uncertain, 
but a growing body of evidence suggests that the storage lesion may reduce tissue oxygen 
availability, have pro-inflammatory and immunomodulatory effects, and influence morbidity 
and mortality One of the most notable changes during RBC storage is the rapid fall in 2,3-DPG. 
2, 3-DPG is an allosteric modifier of hemoglobin which plays a critical role in the release of oxy
gen at the end-organ. Levels of 2, 3-DPG has been shown to fall quickly during the storage of 
RBC, becoming undetectable within 2 weeks. This observation has raised concern that despite 
improved oxygen delivery with transfusion, stored RBCs may not release sufficient oxygen to 
the tissues. While biologically plausible, there appears to be little clinical consequence from this 
dramatic fall in the DPG as multiple authors have failed to find a meaningful effect from the 
transfusion of RBCs deplete in DPG. In part, this lack of affect may result from the quick recov
ery of 2, 3-DPG following transfusion. Normalization of 2, 3-DPG levels begins within hours of 
transfusion and is completely restored within 48 to 72 hours.
The second well-described biochemical change of potential significance is a time-
dependent reduction in intracellular RBC ATP. Due to its central role in cellular metabolism, ad
equate levels of ATP are essential for innumerable cellular processes. Examples include the main
tenance of Na+-K+ ATPase activity, RBC membrane stability, glucose transport, oxidative stress 
defense mechanisms, membrane phospholipids distribution, and regional vasodilation under hy
poxic conditions. Raat and colleagues have shown marked reductions in ATP levels during RBC 
storage. The fall in ATP levels appear most pronounced in blood stored for greater than weeks. 
While ATP depletion can result in the characteristic deformation changes seen with prolonged 
RBC storage. These morphologic changes are readably reversed with normalization of ATP levels. 
Importantly, these levels normalize quickly after RBC transfusion. Additionally, more gradual re
ductions in intracellular ATP results in erythrocyte shape changes, increased osmotic fragility, and 
decreased deformability levels do not appear to correlate well with these morphologic changes. 
Red cells 2, 3 Di -phosphoglycerate level decreases. One of the most notable changes during RBC 
storage is the rapid fall in 2, 3-DPG. 2,3DPG is an allosteric modifier of haemoglobin which plays 
a critical role in the release of oxygen at the end-organ. Levels of 2, 3-DPG has been shown to fall 
quickly during the storage of RBC, becoming undetectable within few weeks. While structural 
changes are observed on the red cell surface as storage time increases, biochemical changes also oc
cur intracellularly, with decreases in enzymes and stored energy concentrations that affect red blood 
cell function. The metabolite and enzymatic regulator of hemoglobin, 2, 3-diphsophoglycerate (2, 3 
DPG), has been shown to decrease to near non-detectible levels within two weeks of storage. The 
decreased concentration in 2, 3-DPG leads to significant increases in hemoglobin’s affinity for oxy
Optimal Additive Solution (OAS) for Preservation of Red Cells. Different types of additive 
systems are now in use to allow for the optimum preservation of red cells. These solutions 
contain saline, adenine and glucose and are added to the red cells after separating them from 
plasma. Blood is collected into a multiple bag system including one plastic bag containing 100 
ml of optimal additive solution. After collection the whole blood is centrifuged and maximum 
amount of plasma along with the buffy coat is expressed into a transfer bag for further process
ing. Red cells are now suspended by running down the optimal additive solution (100 ml) to the 
main bag containing red cells. Currently available additive solutions are:
• CPD-SAG. CPD-SAG (Citrate phosphate dextrose - saline, adenine, glu
cose). In this besides CPD as the primary anticoagulant, a satellite bag 
contains the additive solution - 100 ml physiological saline with adenine 
and glucose. CPD-SAG causes undesirable amountof haemolysis.
• CPD-SAGMAN. (Citrate phosphate dextrose -saline, adenine, glucose, 
mannitol). In this the additive solution also has mannitol to prevent lysis 
of red cels. The 24 hr post transfusion survival is better with the additive. 
• CPD-ADSOL. (Citrate phosphate dextrose Adenine- saline, glucose, manni
tol. This additive solution is similar to CPD-SAGMAN but has greater quanti
ties of glucose, adenine and mannitol. It has better red cell preservation and 24 
hr post-transfusion survival. The shelf life with this solution can be increased 
to 42-49 days. Advantages of optimal additive solutions include: 
Removal of unwanted buffy coat
The various changes that occur within both the RBC and storage media during ex vivo preserva
tion have been collectively termed the RBC “storage lesion” These alterations can be extensive 
and are primarily classified into three broad categories: biochemical, biomechanical, and im
munologic. Storage of red blood cells in preservative medium is associated with metabolic, bio
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chemical and molecular changes to erythrocytes collectively referred to as the “storage lesion.” 
In addition to corpuscular injury, bio-reactive substances including cytokines and lipids accu-
mulate in the medium during storage. Storage related changes can have potential clinical im-
plications for red blood cell transfusion. The term “storage lesion” has been traditionally used 
to describe the progressive degradation of red cell structure and function that occurs during 
conventional red cell storage. These changes include a reduction in red blood cell deformability, 
altered red blood cell adhesiveness and aggregability. Bioactive compounds with pro-inflam-
matory effects also accumulate in the storage medium. These changes reduce post transfusion 
viability of red blood cells. The clinical effects beyond post transfusion viability are uncertain, 
but a growing body of evidence suggests that the storage lesion may reduce tissue oxygen 
availability, have pro-inflammatory and immunomodulatory effects, and influence morbidity 
and mortality One of the most notable changes during RBC storage is the rapid fall in 2,3-DPG. 
2, 3-DPG is an allosteric modifier of hemoglobin which plays a critical role in the release of oxy-
gen at the end-organ. Levels of 2, 3-DPG has been shown to fall quickly during the storage of 
RBC, becoming undetectable within 2 weeks. This observation has raised concern that despite 
improved oxygen delivery with transfusion, stored RBCs may not release sufficient oxygen to 
the tissues. While biologically plausible, there appears to be little clinical consequence from this 
dramatic fall in the DPG as multiple authors have failed to find a meaningful effect from the 
transfusion of RBCs deplete in DPG. In part, this lack of affect may result from the quick recov-
ery of 2, 3-DPG following transfusion. Normalization of 2, 3-DPG levels begins within hours of 
transfusion and is completely restored within 48 to 72 hours.
ATP reduction. The second well-described biochemical change of potential significance is a time-
dependent reduction in intracellular RBC ATP. Due to its central role in cellular metabolism, ad-
equate levels of ATP are essential for innumerable cellular processes. Examples include the main-
tenance of Na+-K+ ATPase activity, RBC membrane stability, glucose transport, oxidative stress 
defense mechanisms, membrane phospholipids distribution, and regional vasodilation under hy-
poxic conditions. Raat and colleagues have shown marked reductions in ATP levels during RBC 
storage. The fall in ATP levels appear most pronounced in blood stored for greater than weeks. 
While ATP depletion can result in the characteristic deformation changes seen with prolonged 
RBC storage. These morphologic changes are readably reversed with normalization of ATP levels. 
Importantly, these levels normalize quickly after RBC transfusion. Additionally, more gradual re-
ductions in intracellular ATP results in erythrocyte shape changes, increased osmotic fragility, and 
decreased deformability levels do not appear to correlate well with these morphologic changes. 
Red cells 2, 3 Di -phosphoglycerate level decreases. One of the most notable changes during RBC 
storage is the rapid fall in 2, 3-DPG. 2,3DPG is an allosteric modifier of haemoglobin which plays 
a critical role in the release of oxygen at the end-organ. Levels of 2, 3-DPG has been shown to fall 
quickly during the storage of RBC, becoming undetectable within few weeks. While structural 
changes are observed on the red cell surface as storage time increases, biochemical changes also oc-
cur intracellularly, with decreases in enzymes and stored energy concentrations that affect red blood 
cell function. The metabolite and enzymatic regulator of hemoglobin, 2, 3-diphsophoglycerate (2, 3 
DPG), has been shown to decrease to near non-detectible levels within two weeks of storage. The 
decreased concentration in 2, 3-DPG leads to significant increases in hemoglobin’s affinity for oxy-
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gen, which ultimately decreases oxygen delivery to the peripheral tissues upon re-infusion, because 
oxygen will not unbind from hemoglobin. The red cell devoid of 2, 3-DPG can recover its normal 
levels within 72 hours after infusion, and no irreversible effect in the function of the red cell has been 
observed. Given the delay to complete recovery of ideal enzymatic function and oxygen unloading 
in the peripheral tissue, the desired augmentation of oxygen delivery following transfusion is not 
immediate, but rather potentially delayed until 2,3-DPG levels are normalized.
Changes that occur when blood is stored
Plasma potassium level increases
Level of 2, 3-DPG decreasaes
Plasma haemoglobin level increases
ATP levels decreases
Plasma lactate level increases
Platelets becomes less effective
Coagulation factors level decreases
Days of storage
CPDA whole 
blood at day 
zero
CPDA whole 






centrate at 35 
days
% viable cell 24 hours post transfu-
sion
100 79 100 71
pH at 37°C 7.2 6.98 7.55 6.71
ATP level (% of initial value) 100 56 (± 16) 100 45 (± 12) 
2,3-DPG (% of initial value) 100 <10 100 <10
Plasma potassium level (mEq/L) 3.9 27.3 5.1 78.5
Plasma sodium level (mEq/L) 168 155 169 111
Plasma haemoglobin (mg/dl) 1.7 46.1 7.8 658
Biochemical changes of blood stored in CPDA 
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A blood donation occurs when a person voluntarily has blood drawn and used for transfu
sions or made into medications by a process called fractionation. In the developed world, 
most blood donors are unpaid volunteers who give blood for a community supply. In poorer 
countries, established supplies are limited and donors usually give blood when family or 
friends need a transfusion or for commercial reasons. Many donors donate as an act of charity, 
but some are paid and in some cases there are incentives other than money such as paid time 
off from work. 
1. Age: A donor is an adult male or female between the ages of 17-65 years
2. Frequency of donation: The interval between donations of a unit of whole 
blood is 16 weeks. The minimum interval is 12 weeks. Normally not more than 
3 donations should be collected from a donor during any 12 months period.
3. Volume of donation: A donation of 450mls ± 10% collected into a blood 
bag containing plus 63 mL of anticoagulant is required to ensure that the 
final red cell component meets specification.
4. Weight: The minimum weight for donation is 50kg (7 stone 12lb). Donors 
less than 50kg are more likely to suffer adverse reactions (dizzyness and 
fainting) after a standard donation.
5. Haemoglobin level: The haemoglobin level should be determined each 
time a potential donor presents. The acceptable lower limit for venous 
blood are 135g/L for male and 12.5g/L for female donors.
6. All donation are tested for ABO and Rh D group. All units should be test
ed for Rh types (C, c, E, e) and for presence of alloantibodies to avoid the 
transfusion of potent IgG reactive atypical antibodies in donor plasma. 
Each donor unit that are group O, A and B should also be tested for the 
presence for high titre A and B haemolysin and labelled as high titre (HT) 
positive or negative. Only those that HT negative should be transfused 
against ABO blood group barrier.
Potential donors are evaluated for anything that might make their blood unsafe to use. The 
screening includes testing for diseases that can be transmitted by a blood transfusion, includ
ing HIV and viral hepatitis. The donor is also asked about medical history and given a short 
physical examination to make sure that the donation is not hazardous to his or her health. The 
amount of blood drawn and the methods vary. The collection can be done manually or with 
automated equipment that only takes specific portions of the blood. Most of the components 
of blood used for transfusions have a short shelf life, and maintaining a constant supply 
gen, which ultimately decreases oxygen delivery to the peripheral tissues upon re-infusion, because 
oxygen will not unbind from hemoglobin. The red cell devoid of 2, 3-DPG can recover its normal 
levels within 72 hours after infusion, and no irreversible effect in the function of the red cell has been 
observed. Given the delay to complete recovery of ideal enzymatic function and oxygen unloading 
in the peripheral tissue, the desired augmentation of oxygen delivery following transfusion is not 
immediate, but rather potentially delayed until 2,3-DPG levels are normalized.
Platelets becomes less effective
% viable cell 24 hours post transfu-
100 100 71
° 6.71
ATP level (% of initial value) 100 56 (± 16) 100 45 (± 12) 
2,3-DPG (% of initial value) 100 <10 100 <10
Plasma potassium level (mEq/L) 5.1
Plasma sodium level (mEq/L) 168 155 169 111
Plasma haemoglobin (mg/dl) 1.7 46.1
Biochemical changes of blood stored in CPDA 
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5. Blood donation testing
A blood donation occurs when a person voluntarily has blood drawn and used for transfu-
sions or made into medications by a process called fractionation. In the developed world, 
most blood donors are unpaid volunteers who give blood for a community supply. In poorer 
countries, established supplies are limited and donors usually give blood when family or 
friends need a transfusion or for commercial reasons. Many donors donate as an act of charity, 
but some are paid and in some cases there are incentives other than money such as paid time 
off from work. 
Characteristics of a blood donor
1. Age: A donor is an adult male or female between the ages of 17-65 years
2. Frequency of donation: The interval between donations of a unit of whole 
blood is 16 weeks. The minimum interval is 12 weeks. Normally not more than 
3 donations should be collected from a donor during any 12 months period.
3. Volume of donation: A donation of 450mls ± 10% collected into a blood 
bag containing plus 63 mL of anticoagulant is required to ensure that the 
final red cell component meets specification.
4. Weight: The minimum weight for donation is 50kg (7 stone 12lb). Donors 
less than 50kg are more likely to suffer adverse reactions (dizzyness and 
fainting) after a standard donation.
5. Haemoglobin level: The haemoglobin level should be determined each 
time a potential donor presents. The acceptable lower limit for venous 
blood are 135g/L for male and 12.5g/L for female donors.
6. All donation are tested for ABO and Rh D group. All units should be test-
ed for Rh types (C, c, E, e) and for presence of alloantibodies to avoid the 
transfusion of potent IgG reactive atypical antibodies in donor plasma. 
Each donor unit that are group O, A and B should also be tested for the 
presence for high titre A and B haemolysin and labelled as high titre (HT) 
positive or negative. Only those that HT negative should be transfused 
against ABO blood group barrier.
Potential donors are evaluated for anything that might make their blood unsafe to use. The 
screening includes testing for diseases that can be transmitted by a blood transfusion, includ-
ing HIV and viral hepatitis. The donor is also asked about medical history and given a short 
physical examination to make sure that the donation is not hazardous to his or her health. The 
amount of blood drawn and the methods vary. The collection can be done manually or with 
automated equipment that only takes specific portions of the blood. Most of the components 
of blood used for transfusions have a short shelf life, and maintaining a constant supply 
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Screening. Donors are typically required to give consent for the process. If a potential do-
nor does not meet these criteria, they are deferred. This term is used because many donors 
who are ineligible may be allowed to donate later. Blood banks in the United States may be 
required to label the blood if it is from a therapeutic donor, so some do not accept donations 
from donors with any blood disease. The donor’s race or ethnic background is sometimes 
important since certain blood types, especially rare ones, are more common in certain ethnic 
groups. Historically, donors were segregated or excluded on race, religion, or ethnicity, but 
this is no longer a standard practice. 
Recipient safety. Donors are screened for health risks that might make the donation unsafe 
for the recipient. Some of these restrictions are controversial, such as restricting donations 
from men who have sex with men for HIV risk. Autologous donors are not always screened 
for recipient safety problems since the donor is the only person who will receive the blood. 
Donors are also asked about medications such as dutasteride since they can be dangerous to 
a pregnant woman receiving the blood. Donors are examined for signs and symptoms of dis-
eases that can be transmitted in a blood transfusion, such as HIV, malaria, and viral hepatitis. 
Screening may extend to questions about risk factors for various diseases, such as travel to 
countries at risk for malaria or variant Creutzfeldt - Jakob disease (vCJD). These questions 
vary from country to country. For example, while blood centers in Québec, Poland, and many 
other places defer donors who lived in the United Kingdom for risk of vCJD, donors in the 
United Kingdom are only restricted for vCJD risk if they have had a blood transfusion in the 
United Kingdom. 
Donor safety. The donor is also examined and asked specific questions about their medical 
history to make sure that donating blood is not hazardous to their health. The donor’s hemat-
ocrit or hemoglobin level is tested to make sure that the loss of blood will not make them ane-
mic, and this check is the most common reason that a donor is ineligible. Pulse, blood pres-
sure, and body temperature are also evaluated. Elderly donors are sometimes also deferred 
on age alone because of health concerns. The safety of donating blood during pregnancy has 
not been studied thoroughly and pregnant women are usually deferred. 
Obtaining the blood
There are two main methods of obtaining blood from a donor. 
1. The most frequent is simply to take the blood from a vein as whole blood. 
This blood is typically separated into parts, usually red blood cells and 
plasma, since most recipients need only a specific component for trans-
fusions. A typical donation is 450 milliliters (or approximately one US 
pint) of whole blood, though 500 milliliter donations are also common. 
Historically, blood donors in India would donate only 250 or 350 millilit-
ers and donors in the People’s Republic of China would donate only 200 
milliliters, though larger 300 and 400 milliliter donations have become 
more common. 
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2. The other method is to draw blood from the donor, separate it using a 
centrifuge or a filter, store the desired part, and return the rest to the do
nor. This process is called apheresis, and it is often done with a machine 
specifically designed for this purpose. This process is especially common 
for plasma and platelets.
 The blood is drawn from a large arm vein close to the skin, 
usually the median cubital vein on the inside of the elbow. The skin over the blood vessel is cleaned 
with an antiseptic such as iodine or chlorhexidine to prevent skin bacteria from contaminating the 
collected blood and also to prevent infections where the needle pierced the donor’s skin. A large 
needle (16 to 17 gauge) is used to minimize shearing forces that may physically damage red blood 
cells as they flow through the needle. A tourniquet is sometimes wrapped around the upper arm to 
increase the pressure of the blood in the arm veins and speed up the process. The donor may also be 
prompted to hold an object and squeeze it repeatedly to increase the blood flow through the vein. A 
mechanical tray agitates the bag to mix the blood with anticoagulants and prevent clotting.
. The most common method is collecting the blood from the donor’s vein into a 
container. The amount of blood drawn varies from 200 milliliters to 550 milliliters depending 
on the country, but 450-500 milliliters is typical. The blood is usually stored in a flexible plastic 
bag that also contains sodium citrate, phosphate, dextrose, and sometimes adenine. This com
bination keeps the blood from clotting and preserves it during storage. Other chemicals are 
sometimes added during processing. The plasma from whole blood can be used to make plas
ma for transfusions or it can also be processed into other medications using a process called 
fractionation. This was a development of the dried plasma used to treat the wounded during 
World War II and variants on the process are still used to make a variety of other medications. 
Apheresis, Plasmapheresis, and Plateletpheresis. Apheresis is a blood donation method 
where the blood is passed through an apparatus that separates out one particular constituent 
and returns the remainder to the donor. Usually the component returned is the red blood cells, 
the portion of the blood that takes the longest to replace. Using this method an individual can 
donate plasma or platelets much more frequently than they can safely donate whole blood. 
These can be combined, with a donor giving both plasma and platelets in the same donation. 
Platelets can also be separated from whole blood, but they must be pooled from multiple 
donations. From three to ten units of whole blood are required for a therapeutic dose. Platelet
pheresis provides at least one full dose from each donation. Plasmapheresis is frequently 
used to collect source plasma that is used for manufacturing into medications much like the 
plasma from whole blood. Plasma collected at the same time as plateletpheresis is sometimes 
called concurrent plasma. Apheresis is also used to collect more red blood cells than usual in 
a single donation and to collect white blood cells for trnsafusion. 
 Donors are usually kept at the donation site for 10–15 
minutes after donating since most adverse reactions take place during or immediately after 
the donation. Blood centers typically provide light refreshments or a lunch allowance to help 
the donor recover. The needle site is covered with a bandage and the donor is directed to 
. Donors are typically required to give consent for the process. If a potential do
nor does not meet these criteria, they are deferred. This term is used because many donors 
who are ineligible may be allowed to donate later. Blood banks in the United States may be 
required to label the blood if it is from a therapeutic donor, so some do not accept donations 
from donors with any blood disease. The donor’s race or ethnic background is sometimes 
important since certain blood types, especially rare ones, are more common in certain ethnic 
groups. Historically, donors were segregated or excluded on race, religion, or ethnicity, but 
this is no longer a standard practice. 
 Donors are screened for health risks that might make the donation unsafe 
for the recipient. Some of these restrictions are controversial, such as restricting donations 
from men who have sex with men for HIV risk. Autologous donors are not always screened 
for recipient safety problems since the donor is the only person who will receive the blood. 
Donors are also asked about medications such as dutasteride since they can be dangerous to 
a pregnant woman receiving the blood. Donors are examined for signs and symptoms of dis
eases that can be transmitted in a blood transfusion, such as HIV, malaria, and viral hepatitis. 
Screening may extend to questions about risk factors for various diseases, such as travel to 
countries at risk for malaria or variant Creutzfeldt - Jakob disease (vCJD). These questions 
vary from country to country. For example, while blood centers in Québec, Poland, and many 
other places defer donors who lived in the United Kingdom for risk of vCJD, donors in the 
United Kingdom are only restricted for vCJD risk if they have had a blood transfusion in the 
United Kingdom. 
The donor is also examined and asked specific questions about their medical 
history to make sure that donating blood is not hazardous to their health. The donor’s hemat
ocrit or hemoglobin level is tested to make sure that the loss of blood will not make them ane
mic, and this check is the most common reason that a donor is ineligible. Pulse, blood pres
sure, and body temperature are also evaluated. Elderly donors are sometimes also deferred 
on age alone because of health concerns. The safety of donating blood during pregnancy has 
not been studied thoroughly and pregnant women are usually deferred. 
There are two main methods of obtaining blood from a donor. 
1. The most frequent is simply to take the blood from a vein as whole blood. 
This blood is typically separated into parts, usually red blood cells and 
plasma, since most recipients need only a specific component for trans
fusions. A typical donation is 450 milliliters (or approximately one US 
pint) of whole blood, though 500 milliliter donations are also common. 
Historically, blood donors in India would donate only 250 or 350 millilit
ers and donors in the People’s Republic of China would donate only 200 
milliliters, though larger 300 and 400 milliliter donations have become 
more common. 
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2. The other method is to draw blood from the donor, separate it using a 
centrifuge or a filter, store the desired part, and return the rest to the do-
nor. This process is called apheresis, and it is often done with a machine 
specifically designed for this purpose. This process is especially common 
for plasma and platelets.
Site preparation and drawing blood. The blood is drawn from a large arm vein close to the skin, 
usually the median cubital vein on the inside of the elbow. The skin over the blood vessel is cleaned 
with an antiseptic such as iodine or chlorhexidine to prevent skin bacteria from contaminating the 
collected blood and also to prevent infections where the needle pierced the donor’s skin. A large 
needle (16 to 17 gauge) is used to minimize shearing forces that may physically damage red blood 
cells as they flow through the needle. A tourniquet is sometimes wrapped around the upper arm to 
increase the pressure of the blood in the arm veins and speed up the process. The donor may also be 
prompted to hold an object and squeeze it repeatedly to increase the blood flow through the vein. A 
mechanical tray agitates the bag to mix the blood with anticoagulants and prevent clotting.
Whole blood. The most common method is collecting the blood from the donor’s vein into a 
container. The amount of blood drawn varies from 200 milliliters to 550 milliliters depending 
on the country, but 450-500 milliliters is typical. The blood is usually stored in a flexible plastic 
bag that also contains sodium citrate, phosphate, dextrose, and sometimes adenine. This com-
bination keeps the blood from clotting and preserves it during storage. Other chemicals are 
sometimes added during processing. The plasma from whole blood can be used to make plas-
ma for transfusions or it can also be processed into other medications using a process called 
fractionation. This was a development of the dried plasma used to treat the wounded during 
World War II and variants on the process are still used to make a variety of other medications. 
Apheresis, Plasmapheresis, and Plateletpheresis. Apheresis is a blood donation method 
where the blood is passed through an apparatus that separates out one particular constituent 
and returns the remainder to the donor. Usually the component returned is the red blood cells, 
the portion of the blood that takes the longest to replace. Using this method an individual can 
donate plasma or platelets much more frequently than they can safely donate whole blood. 
These can be combined, with a donor giving both plasma and platelets in the same donation. 
Platelets can also be separated from whole blood, but they must be pooled from multiple 
donations. From three to ten units of whole blood are required for a therapeutic dose. Platelet-
pheresis provides at least one full dose from each donation. Plasmapheresis is frequently 
used to collect source plasma that is used for manufacturing into medications much like the 
plasma from whole blood. Plasma collected at the same time as plateletpheresis is sometimes 
called concurrent plasma. Apheresis is also used to collect more red blood cells than usual in 
a single donation and to collect white blood cells for trnsafusion. 
Recovery and time between donations. Donors are usually kept at the donation site for 10–15 
minutes after donating since most adverse reactions take place during or immediately after 
the donation. Blood centers typically provide light refreshments or a lunch allowance to help 
the donor recover. The needle site is covered with a bandage and the donor is directed to 
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keep the bandage on for several hours. Donated plasma is replaced after 2–3 days. Red blood 
cells are replaced by bone marrow into the circulatory system at a slower rate, on average 
36 days in healthy adult males. In one study, the range was 20 to 59 days for recovery. These 
replacement rates are the basis of how frequently a donor can give blood. Plasmapheresis and 
plateletpheresis donors can give much more frequently because they do not lose significant 
amounts of red cells. The exact rate of how often a donor can donate differs from country to 
country. For example, plasmapheresis donors in the United States are allowed to donate large 
volumes twice a week and could nominally give 83 liters (about 22 gallons) in a year, whereas 
the same donor in Japan may only donate every other week and could only donate about 16 
liters (about 4 gallons) in a year. Red blood cells are the limiting step for whole blood dona-
tions, and the frequency of donation varies widely depending on the type of donor and local 
policies. For example, adult men in Hong Kong can donate once every three months, women 
every four months, and youth aged sixteen or seventeen only every six months. In Canada 
and the United States it is 56 days for any type of donor. 
Complications. Donors are screened for health problems that would put them at risk for seri-
ous complications from donating. First-time donors, teenagers, and women are at a higher 
risk of a reaction. One study showed that 2% of donors had an adverse reaction to donation. 
Most of these reactions are minor. A study of 194,000 donations found only one donor with 
long-term complications. In most developed countries, a blood bank is required to report any 
adverse effect/ death that might possibly be linked to a blood donation. Examples of compli-
cations associated with blood donatiion include:
1. Bruising of the arm from the needle insertion is the most common con-
cern as well as bruising three days after donation.
2. Hypovolemic reactions can occur because of a rapid change in blood pressure. 
3. Fainting is generally the worst problem encountered. The process has 
similar risks to other forms of phlebotomy.
4. Donors sometimes have adverse reactions to the sodium citrate used in 
apheresis collection procedures to keep the blood from clotting. Since the 
anticoagulant is returned to the donor along with blood components that 
are not being collected, it can bind the calcium in the donor’s blood and 
cause hypocalcemia. These reactions tend to cause tingling in the lips, but 
may cause convulsions, seizure, hypertension, or more serious problems. 
Donors are sometimes given calcium supplements during the donation 
to prevent these side effects. In apheresis procedures, the red blood cells 
are often returned. If this is done manually and the donor receives the 
blood from a different person, a transfusion reaction can take place. Man-
ual apheresis is extremely rare in the developed world because of this risk 
and automated procedures are as safe as whole blood donations.
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5. A number of less common complications of blood donation are known to 
occur. These include; arterial puncture, delayed bleeding, nerve irritation, 
nerve injury, tendon injury, thrombophlebitis, and allergic reactions. 
Storage, supply and demand. The collected blood is usually stored as separate components, and some 
of these have short shelf lives. There are no storage solutions to keep platelets for extended periods of 
time, though some are being studied as of 2008. The longest shelf life used for platelets is seven days. 
Red blood cells, the most frequently used component, have a shelf life of 35–42 days at refrigerated 
temperatures. This can be extended by freezing the blood with a mixture of glycerol but this process is 
expensive, rarely done, and requires an extremely cold freezer for storage. Plasma can be stored frozen 
for an extended period of time and is typically given an expiration date of one year and maintaining 
a supply is less of a problem. The limited storage time means that it is difficult to have a stockpile of 
blood to prepare for a disaster. The subject was discussed at length after the September 11th attacks in 
the United States, and the consensus was that collecting during a disaster was impractical and that ef
forts should be focused on maintaining an adequate supply at all times. Blood centers in the U.S. often 
have difficulty maintaining even a three day supply for routine transfusion demands. 
Labelling of blood products
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keep the bandage on for several hours. Donated plasma is replaced after 2–3 days. Red blood 
cells are replaced by bone marrow into the circulatory system at a slower rate, on average 
36 days in healthy adult males. In one study, the range was 20 to 59 days for recovery. These 
replacement rates are the basis of how frequently a donor can give blood. Plasmapheresis and 
plateletpheresis donors can give much more frequently because they do not lose significant 
amounts of red cells. The exact rate of how often a donor can donate differs from country to 
country. For example, plasmapheresis donors in the United States are allowed to donate large 
volumes twice a week and could nominally give 83 liters (about 22 gallons) in a year, whereas 
the same donor in Japan may only donate every other week and could only donate about 16 
liters (about 4 gallons) in a year. Red blood cells are the limiting step for whole blood dona
tions, and the frequency of donation varies widely depending on the type of donor and local 
policies. For example, adult men in Hong Kong can donate once every three months, women 
every four months, and youth aged sixteen or seventeen only every six months. In Canada 
and the United States it is 56 days for any type of donor. 
 Donors are screened for health problems that would put them at risk for seri
ous complications from donating. First-time donors, teenagers, and women are at a higher 
risk of a reaction. One study showed that 2% of donors had an adverse reaction to donation. 
Most of these reactions are minor. A study of 194,000 donations found only one donor with 
long-term complications. In most developed countries, a blood bank is required to report any 
adverse effect/ death that might possibly be linked to a blood donation. Examples of compli
cations associated with blood donatiion include:
1. Bruising of the arm from the needle insertion is the most common con
cern as well as bruising three days after donation.
2. Hypovolemic reactions can occur because of a rapid change in blood pressure. 
3. Fainting is generally the worst problem encountered. The process has 
similar risks to other forms of phlebotomy.
4. Donors sometimes have adverse reactions to the sodium citrate used in 
apheresis collection procedures to keep the blood from clotting. Since the 
anticoagulant is returned to the donor along with blood components that 
are not being collected, it can bind the calcium in the donor’s blood and 
cause hypocalcemia. These reactions tend to cause tingling in the lips, but 
may cause convulsions, seizure, hypertension, or more serious problems. 
Donors are sometimes given calcium supplements during the donation 
to prevent these side effects. In apheresis procedures, the red blood cells 
are often returned. If this is done manually and the donor receives the 
blood from a different person, a transfusion reaction can take place. Man
ual apheresis is extremely rare in the developed world because of this risk 
and automated procedures are as safe as whole blood donations.
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5. A number of less common complications of blood donation are known to 
occur. These include; arterial puncture, delayed bleeding, nerve irritation, 
nerve injury, tendon injury, thrombophlebitis, and allergic reactions. 
Storage, supply and demand. The collected blood is usually stored as separate components, and some 
of these have short shelf lives. There are no storage solutions to keep platelets for extended periods of 
time, though some are being studied as of 2008. The longest shelf life used for platelets is seven days. 
Red blood cells, the most frequently used component, have a shelf life of 35–42 days at refrigerated 
temperatures. This can be extended by freezing the blood with a mixture of glycerol but this process is 
expensive, rarely done, and requires an extremely cold freezer for storage. Plasma can be stored frozen 
for an extended period of time and is typically given an expiration date of one year and maintaining 
a supply is less of a problem. The limited storage time means that it is difficult to have a stockpile of 
blood to prepare for a disaster. The subject was discussed at length after the September 11th attacks in 
the United States, and the consensus was that collecting during a disaster was impractical and that ef-
forts should be focused on maintaining an adequate supply at all times. Blood centers in the U.S. often 
have difficulty maintaining even a three day supply for routine transfusion demands. 
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6. Apheresis principle and practice
Apheresis is a process in which the blood of a donor or patient is passed through an apparatus 
that separates out one particular constituent and returns the remainder to the circulation. It 
is thus an extracorporeal therapy. The process of apheresis involves removal of whole blood 
from a patient or donor. Within an instrument that is essentially designed as a centrifuge, the 
components of whole blood are separated. One of the separated portions is then withdrawn 
and the remaining components are retransfused into the patient or donor.
Method. Depending on the substance that is being removed, different processes are em-
ployed in apheresis. If separation by density is required, centrifugation is the most common 
method. Other methods involve absorption onto beads coated with an absorbent material and 
filtration. The process involve the introduction of whole blood into a chamber that is spin-
ning, and the blood separates into components (P = plasma; PRP = platelet rich plasma; WBC 
= leukocytes; RBC = red blood cells) by gravity along the wall of the chamber. The component 
to be removed can be selected by moving the level of the aspiration device at the right. In this 
example, plasma is being removed. The centrifugation method can be divided into two basic 
categories; continuous flow centrifugation (CFC) and intermittent flow centrifugation
Continuous flow centrifugation (CFC). Continuous flow centrifugation (CFC) historically 
required two venepunctures as the “continuous” means the blood is collected, spun, and re-
turned simultaneously. Newer systems can use a single venipuncture. The main advantage of 
this system is the low extracorporeal volume (calculated by volume of the apheresis chamber, 
the donor’s haematocrit, and total blood volume of the donor) used in the procedure, which 
may be advantageous in the elderly and for children.
Intermittent flow centrifugation. Intermittent flow centrifugation works in cycles, taking blood, 
spinning/processing it and then giving back the necessary parts to the donor in a bolus. The 
main advantage is a single venipuncture site. To stop the blood from coagulating, anticoagulant 
is automatically mixed with the blood as it is pumped from the body into the apheresis machine.
Centrifugation Variables. The centrifugation process itself has four variables that can be con-
trolled to selectively remove desired components. The first is spin speed and bowl diameter, 
the second is “sit time” in centrifuge, the third is solutes added, and the fourth is not as easily 
controllable: plasma volume and cellular content of the donor. The end product in most cases 
is the classic sedimented blood sample with the RBC’s at the bottom, the “buffy coat” of plate-
lets and WBC’s (lymphocytes/granulocytes (PMN’s, basophils, eosinophils/monocytes) in the 
middle and the plasma on top.
Types of apheresis
Disinfect, insert the cannula, pull out the cannula, dress the wound. The blue pressure cuff is 
controlled by the platelet apheresis machine in newer models. There are numerous types of 
apheresis. Blood taken from a healthy donor can be separated into its component parts dur-
ing blood donation, where the needed component is collected and the “unused” components 
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are returned to the donor. Fluid replacement is usually not needed in this type of collections. 
There are large categories of component collections:
1. Plasmapheresis. Plasmapheresis is useful in collecting FFP (fresh frozen 
plasma) of a particular ABO group. Commercial uses aside from FFP for 
this procedure include immune globulin products, plasma derivatives, 
and collection of rare WBC and RBC antibodies.
2. Erythrocytapheresis. Erythrocytapheresis is the separation of erythro
cytes from whole blood. It is most commonly accomplished using the 
method of centrifugal sedimentation. This process is used for red blood 
cell diseases such as sickle cell crises or severe malaria. The automated 
red blood cell collection procedure for donating erythrocytes is referred 
to as ‘Double Reds’ or ‘Double Red Cell Apheresis.
3. Plateletpheresis (thrombapheresis, thrombocytapheresis). Plateletpher
esis, like it sounds, is the collection of platelets by apheresis; while return
ing the RBC’s, WBC’s, and component plasma. The yield is normally the 
equivalent of between six and ten random platelet concentrates. Quality 
control demands the platelets from apheresis be equal to or greater than 
3.0 × 1011 in number and have a pH of equal to or greater than 6.2 in 90% 
of the products tested and must be used within five days.
4. Leukapheresis (white blood cells). Leukopheresis is the removal of 
PMN’s, basophils, eosinophils for transfusion into patients whose PMN’s 
are ineffective or traditional therapy has failed. There is limited data to 
suggest the benefit of granulocyte infusion. The complications of this pro
cedure are the difficulty in collection and short shelf life (24 hours at 20 to 
24°C). Since the “buffy coat” layer sits directly atop the RBC layer, HES, a 
sedimenting agent, is employed to improve yield while minimizing RBC 
collection. Quality control demands the resultant concentrate be 1.0 × 1010
granulocytes in 75% of the units tested and that the product be irradiated 
to avoid graft-versus-host disease (inactivate lymphocytes). Irradiation 
does not affect PMN function. Since there is usually a small amount of 
RBC’s collected, ABO compatibility should be employed when feasible.
5. Stem cell harvesting. Cells are harvested to use in bone marrow transplant.
With the widespread implementation of component therapy and the need to maximise the une 
of a donated unit to meet the clinical need of a number of patients, the demand of specific blood 
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this system is the low extracorporeal volume (calculated by volume of the apheresis chamber, 
the donor’s haematocrit, and total blood volume of the donor) used in the procedure, which 
may be advantageous in the elderly and for children.
Intermittent flow centrifugation. Intermittent flow centrifugation works in cycles, taking blood, 
spinning/processing it and then giving back the necessary parts to the donor in a bolus. The 
main advantage is a single venipuncture site. To stop the blood from coagulating, anticoagulant 
is automatically mixed with the blood as it is pumped from the body into the apheresis machine.
The centrifugation process itself has four variables that can be con
trolled to selectively remove desired components. The first is spin speed and bowl diameter, 
the second is “sit time” in centrifuge, the third is solutes added, and the fourth is not as easily 
controllable: plasma volume and cellular content of the donor. The end product in most cases 
is the classic sedimented blood sample with the RBC’s at the bottom, the “buffy coat” of plate
lets and WBC’s (lymphocytes/granulocytes (PMN’s, basophils, eosinophils/monocytes) in the 
middle and the plasma on top.
Disinfect, insert the cannula, pull out the cannula, dress the wound. The blue pressure cuff is 
controlled by the platelet apheresis machine in newer models. There are numerous types of 
apheresis. Blood taken from a healthy donor can be separated into its component parts dur
ing blood donation, where the needed component is collected and the “unused” components 
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are returned to the donor. Fluid replacement is usually not needed in this type of collections. 
There are large categories of component collections:
1. Plasmapheresis. Plasmapheresis is useful in collecting FFP (fresh frozen 
plasma) of a particular ABO group. Commercial uses aside from FFP for 
this procedure include immune globulin products, plasma derivatives, 
and collection of rare WBC and RBC antibodies.
2. Erythrocytapheresis. Erythrocytapheresis is the separation of erythro-
cytes from whole blood. It is most commonly accomplished using the 
method of centrifugal sedimentation. This process is used for red blood 
cell diseases such as sickle cell crises or severe malaria. The automated 
red blood cell collection procedure for donating erythrocytes is referred 
to as ‘Double Reds’ or ‘Double Red Cell Apheresis.
3. Plateletpheresis (thrombapheresis, thrombocytapheresis). Plateletpher-
esis, like it sounds, is the collection of platelets by apheresis; while return-
ing the RBC’s, WBC’s, and component plasma. The yield is normally the 
equivalent of between six and ten random platelet concentrates. Quality 
control demands the platelets from apheresis be equal to or greater than 
3.0 × 1011 in number and have a pH of equal to or greater than 6.2 in 90% 
of the products tested and must be used within five days.
4. Leukapheresis (white blood cells). Leukopheresis is the removal of 
PMN’s, basophils, eosinophils for transfusion into patients whose PMN’s 
are ineffective or traditional therapy has failed. There is limited data to 
suggest the benefit of granulocyte infusion. The complications of this pro-
cedure are the difficulty in collection and short shelf life (24 hours at 20 to 
24°C). Since the “buffy coat” layer sits directly atop the RBC layer, HES, a 
sedimenting agent, is employed to improve yield while minimizing RBC 
collection. Quality control demands the resultant concentrate be 1.0 × 1010 
granulocytes in 75% of the units tested and that the product be irradiated 
to avoid graft-versus-host disease (inactivate lymphocytes). Irradiation 
does not affect PMN function. Since there is usually a small amount of 
RBC’s collected, ABO compatibility should be employed when feasible.
5. Stem cell harvesting. Cells are harvested to use in bone marrow transplant.
7. Blood component preparation
Preparation of blood component
With the widespread implementation of component therapy and the need to maximise the une 
of a donated unit to meet the clinical need of a number of patients, the demand of specific blood 
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component has arisen. The aim of component therapy is to meet the specific deficiency in sev-
eral patient using a unit of whole blood that hitherto would have wasted if given as a whole to a 
single patient. The production of blood component has been facilitated by the following:
1. Availability of large volume centrifugation techniques
2. The availability of sterile multi-blood packs 
3. Availability of strile tube connecting devices.
Blood component are produced to ensure that a concentrated form of a clinically efficient 
product is available to patient and to ensure that patient is exposed to a relative small volume 
rather than the large volume of whole blood. It also facilitate the optimal storage (storage 
temperature and shelf life) of the different components of whole blood. Donated blood is 
usually subjected to processing after it is collected, to make it suitable for use in specific pa-
tient populations. Collected blood is then separated into blood components by centrifugation: 
red bllod cells, plasma, platelets, albumin protein, clotting factor concentrates, cryoprecipi-
tate, fibrinogen concentrate, and immunoglobulins. Red cells, plasma and platelets can also 
be donated individually via a more complex process called apheresis. Blood separation is 
accomplished by centrifugation at high force (3-4000g). This result in the sedimentation of 
suspended solid particles (blood cells) from a liquid by gravity. The rate of sedimentation 
is a function of liquid viscosity, particle density, particle size, concentration of the solution 
(fraction of dissolved solids), and the force of gravity. This strategy maximizes the benefit 
derived from each individual unit while minimizing the risk to each recipient. The separation 
is achived using automated presses. The disadvange however is that there is the potential to 
infect several patients who are transfused with components produced from a unit of whole 
blood particularly if the unit is contaminated with a TTI’S. This risk is more pronounced with 
fractionated plasma products produced from a pool of several donors.
Collection pack. The blood component collection pack has a leucodepletion filter attached 
such that as the blood is collected into the primary pack all the leucocytes are selective filtered 
leaving the whole blood in the primary pack free of leucocytes. There are 2 types of pack 
configurations available; Whole Blood Filter (WBF) and the Bottom and Top (BAT) pack. Leu-
koreduction is a process in which the majority of white blood cells are removed from blood 
components. Reducing donor leukocytes helps;
1. Prevent non-haemolytic transfusion reaction
2. Prevent alloimmunization to HLA antigen
3. Prevent the transmission of leukocyte-borne viruses such as cytomega-
lovirus (CMV).
Whole Blood Filter (WBF). In this type of pack, the filter is close to the primary collection 
pack. It allow the whole blood to be filtered free of lleucocyte before it is separated into the 
various component. The advantage of this method is that the component produced from the 
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whole blood from the primary pack does not need further leucodepletion. This method is 
commonly used to prepare red cell concentrate and plasma products. Red cell concentrate is 
produced by removing most of the plasma from the primary tube and an additive solution, 
formulated to support erythrocyte metabolism, is added to the remaining red cells. Exam
ple of additive solution designed to optimise red cell preservation include saline solution 
containing added adenine, glucose and mannitol (also called SAGM, SAGMAN, Adsol or 
optimal additive solution). The disadvantage of this pack type is that a significant number of 
platelet are filtered along with the leucocytes. Most modern leucodepletion filter selectively 
filters leucocytes withput removing platelet. An example of this type of filter is the Imuflex®- 
WB-SP. It is a quadruple blood bag system (CPD/S.A.G.M.) with an integrated leukocyte 
removal whole blood filter saving platelets, designed to produce three leukocyte-depleted 
blood components: red cells, plasma and platelets.
Figure: An example of a leucocyte depletion filter blood pack
Botton and Top (BAT) pack. This method is used for platelet preparation. In this type of pack 
there is tubing coming out from the top and bottom. Separation of component is done before 
leucodepletion to allow for platelet to be extracted. The disadvantage of this pack is that each 
component needs to be leucodepleted separately. This method can be used to prepare red 
cells, plasma and platelets. 
If red blood cell and plasma components are required, 
then the donation is collected into a multiple bag system with an integral whole blood filter 
for leukoreduction. First, whole blood is filtered to to reduce the number of leukocytes. Next, 
the filtered whole blood unit is centrifuged using carefully controlled centrifugation speeds 
and temperatures to separate the red cells from the plasma. Approximately 190-260 mL of 
donor plasma is expressed into the first satellite bag (the maximum amount of plasma is re
moved). The plasma can be used to prepare Fresh Frozen Plasma (FFP), Frozen Plasma (FP) 
component has arisen. The aim of component therapy is to meet the specific deficiency in sev
eral patient using a unit of whole blood that hitherto would have wasted if given as a whole to a 
single patient. The production of blood component has been facilitated by the following:
1. Availability of large volume centrifugation techniques
2. The availability of sterile multi-blood packs 
3. Availability of strile tube connecting devices.
Blood component are produced to ensure that a concentrated form of a clinically efficient 
product is available to patient and to ensure that patient is exposed to a relative small volume 
rather than the large volume of whole blood. It also facilitate the optimal storage (storage 
temperature and shelf life) of the different components of whole blood. Donated blood is 
usually subjected to processing after it is collected, to make it suitable for use in specific pa
tient populations. Collected blood is then separated into blood components by centrifugation: 
red bllod cells, plasma, platelets, albumin protein, clotting factor concentrates, cryoprecipi
tate, fibrinogen concentrate, and immunoglobulins. Red cells, plasma and platelets can also 
be donated individually via a more complex process called apheresis. Blood separation is 
accomplished by centrifugation at high force (3-4000g). This result in the sedimentation of 
suspended solid particles (blood cells) from a liquid by gravity. The rate of sedimentation 
is a function of liquid viscosity, particle density, particle size, concentration of the solution 
(fraction of dissolved solids), and the force of gravity. This strategy maximizes the benefit 
derived from each individual unit while minimizing the risk to each recipient. The separation 
is achived using automated presses. The disadvange however is that there is the potential to 
infect several patients who are transfused with components produced from a unit of whole 
blood particularly if the unit is contaminated with a TTI’S. This risk is more pronounced with 
fractionated plasma products produced from a pool of several donors.
The blood component collection pack has a leucodepletion filter attached 
such that as the blood is collected into the primary pack all the leucocytes are selective filtered 
leaving the whole blood in the primary pack free of leucocytes. There are 2 types of pack 
configurations available; Whole Blood Filter (WBF) and the Bottom and Top (BAT) pack. Leu
koreduction is a process in which the majority of white blood cells are removed from blood 
components. Reducing donor leukocytes helps;
1. Prevent non-haemolytic transfusion reaction
2. Prevent alloimmunization to HLA antigen
3. Prevent the transmission of leukocyte-borne viruses such as cytomega
lovirus (CMV).
Whole Blood Filter (WBF). In this type of pack, the filter is close to the primary collection 
pack. It allow the whole blood to be filtered free of lleucocyte before it is separated into the 
various component. The advantage of this method is that the component produced from the 
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whole blood from the primary pack does not need further leucodepletion. This method is 
commonly used to prepare red cell concentrate and plasma products. Red cell concentrate is 
produced by removing most of the plasma from the primary tube and an additive solution, 
formulated to support erythrocyte metabolism, is added to the remaining red cells. Exam-
ple of additive solution designed to optimise red cell preservation include saline solution 
containing added adenine, glucose and mannitol (also called SAGM, SAGMAN, Adsol or 
optimal additive solution). The disadvantage of this pack type is that a significant number of 
platelet are filtered along with the leucocytes. Most modern leucodepletion filter selectively 
filters leucocytes withput removing platelet. An example of this type of filter is the Imuflex®- 
WB-SP. It is a quadruple blood bag system (CPD/S.A.G.M.) with an integrated leukocyte 
removal whole blood filter saving platelets, designed to produce three leukocyte-depleted 
blood components: red cells, plasma and platelets.
Figure: An example of a leucocyte depletion filter blood pack
Botton and Top (BAT) pack. This method is used for platelet preparation. In this type of pack 
there is tubing coming out from the top and bottom. Separation of component is done before 
leucodepletion to allow for platelet to be extracted. The disadvantage of this pack is that each 
component needs to be leucodepleted separately. This method can be used to prepare red 
cells, plasma and platelets. 
Preparation of Red cell concentrate. If red blood cell and plasma components are required, 
then the donation is collected into a multiple bag system with an integral whole blood filter 
for leukoreduction. First, whole blood is filtered to to reduce the number of leukocytes. Next, 
the filtered whole blood unit is centrifuged using carefully controlled centrifugation speeds 
and temperatures to separate the red cells from the plasma. Approximately 190-260 mL of 
donor plasma is expressed into the first satellite bag (the maximum amount of plasma is re-
moved). The plasma can be used to prepare Fresh Frozen Plasma (FFP), Frozen Plasma (FP) 
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or cryoprecipitate and cryosupernatant plasma. Then AS-3 (Nutricel®) solution is added to 
the red cells to produce AS-3 red cells, LR (Leukocyte reduced by filtration). The AS-3 RBC 
LR unit is sealed and stored at 1-6oC for 42 days. Cells are commonly re-suspended in SAG-M 
which has a shelf life of 35 days. The advantages of producing SAG-M red cells incude:
1. Adenine maintains red cell metabolism and promote survival during storage
2. Manitol help reduce the degree of storage –related haemolysis
3. SAG-M enhances the flow rate of blood close to that of whole blood.
Red cells intended for prolonged storage can be stored frozen in glycerol at -80°C. This meth-
od is useful for rare blood groups such as Vel negative, Fy(a-b-) and others as well as for pa-
tient with alloantibody to a high incidence antigen. The role of glycerol is as a cryoprotectant. 
It enters the cells and bind water molecule in the cell and prevent water loss. The glycerol 
is removed by washing when thawed prior to use. Thawed and washed red cells should be 
transfused immediately or stored at 4°C ± 2°C and transfused with 5 days.
Preparation of Fresh Frozen Plasma. Fresh Frozen Plasma is plasma that is frozen within 8 
hours of collection. It may be prepared from a whole blood donation (by separating the red 
cells and plasma collected) or from an apheresis collection. Frozen Plasma is plasma that 
is frozen within 24 hours of collection. Leucodepleted whole blood donation is centrifuged 
(3-4000g) to separate red cells from plasma. Approximately 190-260 mL of donor plasma is 
expressed (automated press or plasma ectractor) into the first satellite bag. The RBC unit is 
sealed and stored at 1 – 6°C for its shelf-life. The plasma can be stored as FP or FFP that can be 
further processed to cryoprecipitate and cryosupernatant plasma using the attached satellite 
container. Plasma is stored frozen by the manufacturer at temperatures less than minus 20°C 
for up to 12 months. FFP can be stored at -18°C or colder for up to 12 months and thawed FFP 
is stored at 1-6°C for up to 24 hours.
Preparation of Cryoprecipitate. Cryoprecipitated Antihemophilic Factor (AHF, also known 
as Cryoprecipitate or Cryo) is made from one unit (225 - 250 mls) of Fresh Frozen Plasma. 
Cryoprecipitate is the insoluble portion of plasma that precipitates when a unit of Fresh Fro-
zen Plasma is thawed between 1 - 6° C. The excess plasma is removed from the precipitate, 
creating Cryoprecipitate Poor Plasma (Cryo-Poor Plasma.). To make Cryoprecipitate, a full 
unit (225 - 250 mls) of Fresh Frozen Plasma with at least one integrally attached satellite bag 
is needed. When harvesting the Fresh Frozen Plasma from the unit of Whole Blood, allow the 
plasma to flow into one satellite bag. Seal off the two bags, but leave the line between the two 
bags open. Freeze the unit of plasma as specified in the procedure for Fresh Frozen Plasma. 
The plasma must be frozen solid before the subsequent steps to make cryoprecipitate are 
carried out. Separation of cryoprecipitate and cryoprecipitate-Poor Plasma. Allow the unit of 
Fresh Frozen Plasma to thaw at 1 - 6° C. This process takes approximately 8 hours. Harvest 
the cryoprecipitate using one of the two following methods. When the plasma becomes slushy, 
place the thawed plasma in a plasma extractor. Express the liquid plasma in to the integrally 
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attached satellite bag. The satellite bag containing liquid plasma should contain 90% of the 
original volume of the Fresh Frozen Plasma or allow the Fresh Frozen Plasma to completely 
thaw. Centrifuge the FFP using a heavy spin. The cryoprecipitate will precipitate and adhere 
to the sides of the bag. Express 90% of the supernatant in to the attached satellite bag. Using 
either method, the Cryoprecipitate Poor Plasma is expressed into the satellite bag and the 
cryoprecipitate remains in the bag that originally held the Fresh Frozen Plasma. Expiration 
is one year from the date of phlebotomy (not from the date of preparation.) Freeze the Cryo
precipitate and the Cryo Poor Plasma within 1 hour of preparation. Both products should be 
stored at -18° C or lower.
Platelet Rich Plasma is made from one unit of Fresh 
Whole Blood. To prepare Platelet Rich Plasma, a unit of Fresh Whole Blood with at least one 
integrally attached satellite bag is needed. The unit of Fresh Whole Blood should be main
tained at 22 - 25° C and processed immediately in order to harvest viable platelets. Centrifu
gation at room temperature (20-24° C) is required to prevent the platelets from aggregating. 
A “light spin” is used to keep the platelets suspended in plasma. Approximately 190-260 mL 
of donor plasma is expressed through a filter into the first satellite bag to produce platelet-
rich plasma (PRP). The RBC unit and additive pack are separated from the PRP and sent for 
preparation of AS-3 RBC LR. Following filtration, the RBC unit is sealed and stored at 1-6° C 
for 42 days. The PRP is centrifuged at room temperature using a “hard spin” to concentrate 
the platelets. All but approximately 50 mL of plasma is expressed into the second satellite bag. 
The supernatant (platelet poor) plasma is stored at temperatures of less than -20° C as Fresh 
Frozen Plasma, LR for up to 12 months. The plasma may also be shipped as recovered plasma 
for further manufacture.
Leucocytes (Granulocytes). Leucocyte (granulocyte) blood products are required for the 
treatment of patient with haematological malignancies (leukaemia) as well as patients with 
chronic bacteria infection and life threatening septicaemia. A dose of about 2 x 109 cells is 
indicated.A fresh unit of whole blood contain about 1.5 x 109 cells. Leucocyte can also be 
collected using apheresis technique. Buffy coat collected durig the preparation of platelet 
concentrate can also be used if granulocytes are not available.
or cryoprecipitate and cryosupernatant plasma. Then AS-3 (Nutricel®) solution is added to 
the red cells to produce AS-3 red cells, LR (Leukocyte reduced by filtration). The AS-3 RBC 
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2. Manitol help reduce the degree of storage –related haemolysis
3. SAG-M enhances the flow rate of blood close to that of whole blood.
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tient with alloantibody to a high incidence antigen. The role of glycerol is as a cryoprotectant. 
It enters the cells and bind water molecule in the cell and prevent water loss. The glycerol 
is removed by washing when thawed prior to use. Thawed and washed red cells should be 
transfused immediately or stored at 4°C ± 2°C and transfused with 5 days.
Preparation of Fresh Frozen Plasma. Fresh Frozen Plasma is plasma that is frozen within 8 
hours of collection. It may be prepared from a whole blood donation (by separating the red 
cells and plasma collected) or from an apheresis collection. Frozen Plasma is plasma that 
is frozen within 24 hours of collection. Leucodepleted whole blood donation is centrifuged 
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sealed and stored at 1 – 6°C for its shelf-life. The plasma can be stored as FP or FFP that can be 
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is stored at 1-6°C for up to 24 hours.
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as Cryoprecipitate or Cryo) is made from one unit (225 - 250 mls) of Fresh Frozen Plasma. 
Cryoprecipitate is the insoluble portion of plasma that precipitates when a unit of Fresh Fro
zen Plasma is thawed between 1 - 6° C. The excess plasma is removed from the precipitate, 
creating Cryoprecipitate Poor Plasma (Cryo-Poor Plasma.). To make Cryoprecipitate, a full 
unit (225 - 250 mls) of Fresh Frozen Plasma with at least one integrally attached satellite bag 
is needed. When harvesting the Fresh Frozen Plasma from the unit of Whole Blood, allow the 
plasma to flow into one satellite bag. Seal off the two bags, but leave the line between the two 
bags open. Freeze the unit of plasma as specified in the procedure for Fresh Frozen Plasma. 
The plasma must be frozen solid before the subsequent steps to make cryoprecipitate are 
carried out. Separation of cryoprecipitate and cryoprecipitate-Poor Plasma. Allow the unit of 
Fresh Frozen Plasma to thaw at 1 - 6° C. This process takes approximately 8 hours. Harvest 
the cryoprecipitate using one of the two following methods. When the plasma becomes slushy, 
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attached satellite bag. The satellite bag containing liquid plasma should contain 90% of the 
original volume of the Fresh Frozen Plasma or allow the Fresh Frozen Plasma to completely 
thaw. Centrifuge the FFP using a heavy spin. The cryoprecipitate will precipitate and adhere 
to the sides of the bag. Express 90% of the supernatant in to the attached satellite bag. Using 
either method, the Cryoprecipitate Poor Plasma is expressed into the satellite bag and the 
cryoprecipitate remains in the bag that originally held the Fresh Frozen Plasma. Expiration 
is one year from the date of phlebotomy (not from the date of preparation.) Freeze the Cryo-
precipitate and the Cryo Poor Plasma within 1 hour of preparation. Both products should be 
stored at -18° C or lower.
Preparation of Platelet Rich Plasma. Platelet Rich Plasma is made from one unit of Fresh 
Whole Blood. To prepare Platelet Rich Plasma, a unit of Fresh Whole Blood with at least one 
integrally attached satellite bag is needed. The unit of Fresh Whole Blood should be main-
tained at 22 - 25° C and processed immediately in order to harvest viable platelets. Centrifu-
gation at room temperature (20-24° C) is required to prevent the platelets from aggregating. 
A “light spin” is used to keep the platelets suspended in plasma. Approximately 190-260 mL 
of donor plasma is expressed through a filter into the first satellite bag to produce platelet-
rich plasma (PRP). The RBC unit and additive pack are separated from the PRP and sent for 
preparation of AS-3 RBC LR. Following filtration, the RBC unit is sealed and stored at 1-6° C 
for 42 days. The PRP is centrifuged at room temperature using a “hard spin” to concentrate 
the platelets. All but approximately 50 mL of plasma is expressed into the second satellite bag. 
The supernatant (platelet poor) plasma is stored at temperatures of less than -20° C as Fresh 









Leucocytes (Granulocytes). Leucocyte (granulocyte) blood products are required for the 
treatment of patient with haematological malignancies (leukaemia) as well as patients with 
chronic bacteria infection and life threatening septicaemia. A dose of about 2 x 109 cells is 
indicated.A fresh unit of whole blood contain about 1.5 x 109 cells. Leucocyte can also be 
collected using apheresis technique. Buffy coat collected durig the preparation of platelet 
concentrate can also be used if granulocytes are not available.






Volume= 450mls, Hb= >40g/unit 4°C ± 2°C/ 35 days for in CPDA
Red cell concen-
trate
Volume = 280mls, Hb= >40g/unit




Variable volume.Hb > 40g/unit.Residual protein 
< 0.5g/unit
4°C ± 2°C/24 hours
Thawed washed 
red cells
Variable volume.Hb ≥ 36g/unit 4°C ± 2°C/5 days
Platelet  
concentrate
Variable volume (160ml).Platelet ≥ 240 x 109/L In platelet agitator/22°C ± 2°C
Fresh frozen 
plasma
CPDA plasma volume > 150ml. Separated and 
frozen with 8 hoursof collection. FV111c con-
centration >0.7IU/ml.
2 years at ≤ -30°C
Cryoprecipitate 
(pooled)
Each unit produced from 5 single unit of CPDA.
Volume 150-250ml. Fibrinogen >700mg/unit 
and FV111c concentration < 350iu/unit
2 years at ≤ -30°C
Granulocytes 
(apheresis)
Variable citrated plasma volume. Granulocyte 
per unit >15 x 109/L
Properties of blood components
Donor Safety. Single use kits - Apheresis is done using single-use kits, so there is no risk of 
infection from blood-contaminated tubing or centrifuge. Immune system effects - “the im-
mediate decreases in blood lymphocyte counts and serum immunoglobulin concentrations 
are of slight to moderate degree and are without known adverse effects. Plasticizer exposure. 
Apheresis uses plastics and tubing, which come into contact with the blood. The plastics are 
made of PVC in addition to additives such as a plasticizer, often DEHP. DEHP leaches from 
the plastic into the blood, and people have begun to study the possible effects of this leached 
DEHP on donors as well as transfusion recipients.
Use in therapy. The various apheresis techniques may be used whenever the removed constit-
uent is causing severe symptoms of disease. Generally, apheresis has to be performed fairly 
often, and is an invasive process. It is therefore only employed if other means to control a par-
ticular disease have failed, or the symptoms are of such a nature that waiting for medication 
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to become effective would cause suffering or risk of complications. Apheresis techniques are 
used as a form of therapy in certain disease conditions.
within the plasma are contained antibodies and antigen-antibody complex
es that may contribute to the deleterious effects of autoimmune diseases. Removal of the 
plasma (and replacement with saline solution) will help to reduce circulating antibodies and 
immune complexes. In rare circumstances, excess blood proteins are present that may cause 








In essential thrombasthenia, polycythemia vera and rarely in myeloprolif
erative disorders, the platelet count can be very high (thrombocytosis). Removal of platelets 
can help to avoid complications of thrombosis and bleeding.
 in some cases of leukemia with very high white blood cell counts, removal of 
the excess leukocytes may help to prevent complications of thrombosis.
 the small number of circulating bone marrow stem cells can be har
vested to use in transplantation procedures.
Globally, approximately 80 million units of blood are donated each year. Of this total, 2 million units 
are donated in sub-Saharan Africa, where the need for blood transfusions is great because of ma
ternal morbidity, malnutrition, and a heavy burden of infectious diseases such as malaria. Alarmed 
by the chronic shortage of safe blood and blood products particularly in low- and medium-income 
countries, mindful that preventing the transmission of HIV and other blood borne pathogens 
through unsafe blood and blood-product transfusions requires the collection of blood only from 
donors at the lowest risk of carrying such infectious agents and recognizing that voluntary, non-
remunerated blood donation is the cornerstone of a safe and adequate national blood supply that 
meets the transfusion requirements of all patients has lead to the World Health Assembly resolu
tions WHA28.72 3 and WHA58.13 4 urging member states to develop national blood transfusion 
Whole blood 
(leucodepleted)
Volume= 450mls, Hb= >40g/unit 4°C ± 2°C/ 35 days for in CPDA
-
Volume = 280mls, Hb= >40g/unit
4°C ± 2°C /35 days for in CPDA 
and SAG-M 
Saline washed Variable volume.Hb > 40g/unit.Residual protein 
< 0.5g/unit
4°C ± 2°C/24 hours
Thawed washed 
Variable volume.Hb ≥ 36g/unit 4°C ± 2°C/5 days
Variable volume (160ml).Platelet ≥ 240 x 10 /L In platelet agitator/22°C ± 2°C
Fresh frozen 
CPDA plasma volume > 150ml. Separated and 
frozen with 8 hoursof collection. FV111c con-
centration >0.7IU/ml.
2 years at ≤ -30°C
Each unit produced from 5 single unit of CPDA.
Volume 150-250ml. Fibrinogen >700mg/unit 
and FV111c concentration < 350iu/unit
2 years at ≤ -30°C
Granulocytes Variable citrated plasma volume. Granulocyte 
per unit >15 x 10 /L
Properties of blood components
 Single use kits - Apheresis is done using single-use kits, so there is no risk of 
infection from blood-contaminated tubing or centrifuge. Immune system effects - “the im
mediate decreases in blood lymphocyte counts and serum immunoglobulin concentrations 
are of slight to moderate degree and are without known adverse effects. Plasticizer exposure. 
Apheresis uses plastics and tubing, which come into contact with the blood. The plastics are 
made of PVC in addition to additives such as a plasticizer, often DEHP. DEHP leaches from 
the plastic into the blood, and people have begun to study the possible effects of this leached 
DEHP on donors as well as transfusion recipients.
The various apheresis techniques may be used whenever the removed constit
uent is causing severe symptoms of disease. Generally, apheresis has to be performed fairly 
often, and is an invasive process. It is therefore only employed if other means to control a par
ticular disease have failed, or the symptoms are of such a nature that waiting for medica
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to become effective would cause suffering or risk of complications. Apheresis techniques are 
used as a form of therapy in certain disease conditions.
Plasmapheresis: within the plasma are contained antibodies and antigen-antibody complex-
es that may contribute to the deleterious effects of autoimmune diseases. Removal of the 
plasma (and replacement with saline solution) will help to reduce circulating antibodies and 
immune complexes. In rare circumstances, excess blood proteins are present that may cause 








Plateletpheresis: In essential thrombasthenia, polycythemia vera and rarely in myeloprolif-
erative disorders, the platelet count can be very high (thrombocytosis). Removal of platelets 
can help to avoid complications of thrombosis and bleeding.
Leukapheresis: in some cases of leukemia with very high white blood cell counts, removal of 
the excess leukocytes may help to prevent complications of thrombosis.
Stem Cell Harvesting: the small number of circulating bone marrow stem cells can be har-
vested to use in transplantation procedures.
8. Challenges of Blood transfusion in Africa 
Globally, approximately 80 million units of blood are donated each year. Of this total, 2 million units 
are donated in sub-Saharan Africa, where the need for blood transfusions is great because of ma-
ternal morbidity, malnutrition, and a heavy burden of infectious diseases such as malaria. Alarmed 
by the chronic shortage of safe blood and blood products particularly in low- and medium-income 
countries, mindful that preventing the transmission of HIV and other blood borne pathogens 
through unsafe blood and blood-product transfusions requires the collection of blood only from 
donors at the lowest risk of carrying such infectious agents and recognizing that voluntary, non-
remunerated blood donation is the cornerstone of a safe and adequate national blood supply that 
meets the transfusion requirements of all patients has lead to the World Health Assembly resolu-
tions WHA28.72 3 and WHA58.13 4 urging member states to develop national blood transfusion 
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services based on voluntary non- remunerated blood donation. The collection of blood only from 
voluntary, non-remunerated blood donors is an important measure for ensuring:
• The safety
• Quality
• Availability and accessibility of blood transfusion.
Innovative ways to recruit and retain voluntary donors in sub Saharan Africa include; celebration 
of the gift of blood donation, recognition of voluntary blood donors, increasing public awareness 
of voluntary non-remunerated blood donation, educating the public on the importance of regu-
lar voluntary non-remunerated blood donation, educating the public on the benefits of voluntary 
non- remunerated blood donation to recipients, promoting healthy living – nutrition, exercise and 
lifestyle and provision of non-cash motivation to encourage people to donate blood. Blood safety 
remains an issue of major concern in transfusion practice in most countries in sub Saharan Africa 
because;national blood transfusion services and policies are often lacking, appropriate infrastructure 
including trained personnel and financial resources are often inadequate to support the running of 
a voluntary non-remunerated donor transfusion service and predominance of family replacement 
and commercially remunerated blood donors, rather than regular benevolent, non-remunerated do-
nors who give blood as a result of altruism. Despite recommendations that all blood donors should 
be voluntary and non-remunerated, replacement donors are common throughout sub-Saharan Af-
rica (SSA). The primary steps of setting up a national blood transfusion programme should include; 
the enactment of a national policy for the blood transfusion service with time-bound programme, 
setting up of a centrally coordinated, structured and organized blood transfusion service for a coun-
try/state under a defined authority, development of a transfusion service based on an organized 
voluntary blood donor programme and the enactment of a national policy on the screening of blood 
for transfusion-transmissible infections (TTI’S) appropriate to the region, setting up an appropriate 
and evidence based use of available blood and blood products, employment and retention of quali-
fied personnel to head and manage the blood transfusion service.
In many countries in sub Saharan Africa majority and sometimes none of these steps are in 
place. There is lack of political will and open-mindedness to innovative ways to improve 
supply and safety of blood from voluntary donors. The resultant effect of this is failure in 
the stewardship of blood and blood products with a resultant effect of a high incidence of 
transmission transmissible infection. Blood transfusions remain a substantial source of HIV 
and other TTI’S in sub-Saharan Africa especially among women with pregnancy-related com-
plication and children with malaria and malnutrition –associated anaemia. The use of a cul-
turally and socially adapted environment to make the gift of blood a pleasurable and festive 
experience can generate a new pool of blood donors and spontaneously repeating donations. 
Education is an essential part of a donor recruitment strategy. There are 3 basic goals for a 
donor education motivation and recruitment campaign; 
1. To promote changes in the public’s knowledge, attitudes and beliefs so 
that they understand why blood donation is a vital. 
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2. Life saving service to the community, to promote changes in people’s behav
iour so that they become willing to donate blood on a regular, voluntary basis
3. To advocate for non-remunerated blood donation to ensure that poten
tial donors understand the importance of safe blood so that they do not 
donate blood if they are in poor health or at risk for transfusion transmis
sible infections. 
There are several cultural and awareness –related challenges associated with blood
and their distributions in sub Saharan Africa. Some controversy exists about there being in
sufficient voluntary donations. Countries in SSA need to find ways of maintaining sufficient 
blood supply from voluntary non-remunerated donors and improving blood safety from the 
available replacement donors. In brief, the reasons why replacement donors remain the main 
source of blood in SSA include;
1. It costs less to procure and fits well with the African culture of extended 
family support. 
2. The mentality of altruism through the voluntary donation of blood is not 
as accepted in SSA like it is in most developed countries. 
3. Only an insignificant number of eligible donors actually donate blood 
voluntarily in most sub Saharan African countries. 
4. There is no optimistic feeling of altruism in most African settings. Several 
issues influence donor motivation and perceptions in SSA. 
There are several prejudices and misconceptions which affect principle altruism in SSA; cul
tural differences and lack of information, fear of knowing one’s HIV serologic status, fear of 
being infected with diseases, erroneous belief that donating blood can decrease one’s libido, 
cause weight loss, cause high blood pressure or even lead to death. More effort is required 
in the drive for education, motivation and recruitment of regular donor. In most studies in 
Africa there is male gender dominance in blood donation programmes. The reason for this 
male gender predisposition to blood donation is based on;the erroneous belief that men are 
healthier than women, the general belief that women make monthly blood donations to na
ture through their menstrual cycle and other factors such as pregnancy and breastfeeding 
further restrict many women from donating blood in SSA. Interestingly this pattern seems to 
differ significantly from what obtains in some developed countries of Europe. In 2003 female 
blood donors represented 40% in Austria, 49·7% in France, 50% in Norway and 55% in Great-
Britain blood donor population. 
Blood donations are divided into groups based on who will receive the collected blood. An al
logeneic (also called homologous) donation is when a donor gives blood for storage at a blood 
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supply and safety of blood from voluntary donors. The resultant effect of this is failure in 
the stewardship of blood and blood products with a resultant effect of a high incidence of 
transmission transmissible infection. Blood transfusions remain a substantial source of HIV 
and other TTI’S in sub-Saharan Africa especially among women with pregnancy-related com
plication and children with malaria and malnutrition –associated anaemia. The use of a cul
turally and socially adapted environment to make the gift of blood a pleasurable and festive 
experience can generate a new pool of blood donors and spontaneously repeating donations. 
Education is an essential part of a donor recruitment strategy. There are 3 basic goals for a 
donor education motivation and recruitment campaign; 
1. To promote changes in the public’s knowledge, attitudes and beliefs so 
that they understand why blood donation is a vital. 
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2. Life saving service to the community, to promote changes in people’s behav-
iour so that they become willing to donate blood on a regular, voluntary basis
3. To advocate for non-remunerated blood donation to ensure that poten-
tial donors understand the importance of safe blood so that they do not 
donate blood if they are in poor health or at risk for transfusion transmis-
sible infections. 
There are several cultural and awareness –related challenges associated with blood donors 
and their distributions in sub Saharan Africa. Some controversy exists about there being in-
sufficient voluntary donations. Countries in SSA need to find ways of maintaining sufficient 
blood supply from voluntary non-remunerated donors and improving blood safety from the 
available replacement donors. In brief, the reasons why replacement donors remain the main 
source of blood in SSA include;
1. It costs less to procure and fits well with the African culture of extended 
family support. 
2. The mentality of altruism through the voluntary donation of blood is not 
as accepted in SSA like it is in most developed countries. 
3. Only an insignificant number of eligible donors actually donate blood 
voluntarily in most sub Saharan African countries. 
4. There is no optimistic feeling of altruism in most African settings. Several 
issues influence donor motivation and perceptions in SSA. 
There are several prejudices and misconceptions which affect principle altruism in SSA; cul-
tural differences and lack of information, fear of knowing one’s HIV serologic status, fear of 
being infected with diseases, erroneous belief that donating blood can decrease one’s libido, 
cause weight loss, cause high blood pressure or even lead to death. More effort is required 
in the drive for education, motivation and recruitment of regular donor. In most studies in 
Africa there is male gender dominance in blood donation programmes. The reason for this 
male gender predisposition to blood donation is based on;the erroneous belief that men are 
healthier than women, the general belief that women make monthly blood donations to na-
ture through their menstrual cycle and other factors such as pregnancy and breastfeeding 
further restrict many women from donating blood in SSA. Interestingly this pattern seems to 
differ significantly from what obtains in some developed countries of Europe. In 2003 female 
blood donors represented 40% in Austria, 49·7% in France, 50% in Norway and 55% in Great-
Britain blood donor population. 
9. Blood donation and donor types
Blood donations are divided into groups based on who will receive the collected blood. An al-
logeneic (also called homologous) donation is when a donor gives blood for storage at a blood 
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bank for transfusion to an unknown recipient. A directed donation is when a person, often a 
family member, donates blood for transfusion to a specific individual. Directed donations are 
relatively rare when an established supply exists. A replacement donor donation is a hybrid 
of the two and is common in developing countries such as Nigeria. In this case, a friend or 
family member of the recipient donates blood to replace the stored blood used in a transfu-
sion, ensuring a consistent supply. When a person has blood stored that will be transfused 
back to the donor at a later date, usually after surgery, that is called an autologous donation. 
Blood that is used to make medications can be made from allogeneic donations or from dona-
tions exclusively used for manufacturing. The actual process varies according to the laws of 
the country, and recommendations to donors vary according to the collecting organization. 
The World Health Organization gives recommendations for blood donation policies, but in 
developing countries many of these are not followed. For example, the recommended testing 
requires laboratory facilities, trained staff, and specialized reagents, all of which may not be 
available or too expensive in developing countries. An event where donors come to give allo-
geneic blood is sometimes called a blood drive or a blood donor session. These can occur at a 
blood bank but they are often set up at a location in the community such as a shopping center, 
workplace, school, or house of worship. 
Voluntary Donors
Safe blood donors are the cornerstone of a safe and adequate supply of blood and blood prod-
ucts. The safest blood donors are voluntary, non-remunerated blood donors from low-risk 
populations. Donors who give blood voluntarily and for altruistic reasons have the lowest 
prevalence of HIV, hepatitis viruses and other blood-borne infections, as compared to people 
who donate for family members or in lieu of payment. Despite this, family/replacement and 
paid donors, which are associated with a significantly higher prevalence of transfusion-trans-
missible infections (TTIs) including HIV, hepatitis B, hepatitis C, syphilis and Chagas disease, 
still provide more than 50% of the blood collected in developing countries. WHO advocates 
and recommends to its Member States to develop national blood transfusion services based 
on voluntary non-remunerated regular blood donation in accordance with World Health As-
sembly resolution 28.72, which was adopted in 1975. The key to recruiting and retaining safe 
blood donors is:
• Good epidemiological data on the prevalence (and incidence, where 
possible) of infectious markers in the general population to identify 
low-risk donor populations.
•  Effective donor education, motivation and recruitment strategy to 
recruit new voluntary non-remunerated blood donors from these 
populations. 
• A pleasant experience during blood donation, good donor care and 
effective communication between blood centre staff and blood do-
nors are all important factors for the retention of safe blood donors. 
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WHO has developed a set of simple guidelines designed to assist those responsible for blood 
donor recruitment in resource poor settings to develop and implement a programme to im
prove communication with blood donors. These guidelines provide approaches for setting 
up a communication programme – organizing, collecting information, and developing plans; 
as well as providing ideas that individual centres might consider for recruiting, educating 
and retaining safe donors. Elements and activities in promoting voluntary non-remunerated 
blood donation include;
1. National blood donor programme for the education, recruitment and re
tention of low-risk blood donors, including community-based voluntary 
blood donor organizations and youth programmes;
2. Appointment of an officer responsible for the national blood donor 
programme to include donor education, motivation, recruitment and 
retention;
3. Training of donor recruitment and donor care staff in donor education, 
motivation, recruitment, selection and retention; 
4. Development of partnerships with nongovernmental organizations, such 
as national Red Cross and Red Crescent societies, voluntary blood donor 
organizations, national service organizations and the media 
5. Identification of donor populations at low risk for transfusion-transmissi
ble infections and development of strategies to promote positive attitudes 
towards voluntary blood donation; 
6. Development of donor education and recruitment materials; 
7. Educational and media campaigns in workplaces, communities and edu
cational institutions;
8. Establishment and maintenance of a database/register of donor records; 
9. Guidelines and protocols for donor selection and deferral, donor confi
dentiality and donor care; 
10. Guidelines on the management of donor sessions and blood collection;
11. Monitoring of TTIs in donor population;
12. Training of staff in pre- and post-donation counseling;
13. Donor notification and referral for counseling;
14. Monitoring and evaluation of the blood donor programme
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Family replacement donors. Developing countries face considerable obstacles to ensuring a 
safe blood supply and safe blood transfusions. There is a tendency for developing countries 
not to have enough available blood so they depend on family blood donors. Family replace-
ment donor is one who gives blood when it is required by a member of the donor’s family or 
community. The disadvantages of this method of blood donation include; patients or their 
relatives are under intense strain when their relatives are on admission in hospital. Being 
expected to provide replacement donors puts additional responsibility and stress on them, 
there is undue pressure on members of the family to give blood, even when they know that 
donating blood may affect their own health or that they may be potentially at risk of trans-
mission of transfusion-transmissible. It is difficult for a country’s transfusion needs to be met 
solely relying on family replacement donations. The World Health Assembly recommended 
that reliance on replacement donations should be phased out due to their association with 
an increased risk of transfusion-transmitted infections. There is the challenge of transfusion 
need of recipient not being met because blood given may not necessarily be replaced in type 
or quantity. This leaves relatives who cannot find suitable donors with no other option than 
to seek commercial remunerated high risk blood donors. Blood donated by certain relatives 
particularly spouses of women of child bearing ages can put their wives/partners potentially 
at risk of producing antibodies to clinically significant antigen that the husband and the de-
veloping foetus may have but which the wife lacks. 
Commercial-remunerated donors. Blood safety remains an issue of major concern in trans-
fusion practice in most countries in sub Saharan Africa. This is further aggravated by the 
predominance of commercially remunerated blood donors, rather than regular benevolent, 
non-remunerated donors who give blood as a result of altruism. Previous reports in most 
countries in sub-Saharan Africa have indicated a high prevalence of transfusion transmissible 
infections among commercially remunerated blood donors. Blood and blood products from 
commercial remunerated donors are unsafe for various reasons;
1. They often come from the poorest sectors of the economy, may be poor 
in health.
2. Are more likely to give blood more often than recommended for finan-
cial gains.
3. Are also at a higher risk of being undernourished and having a transfu-
sion-transmissible infection from high risk behaviours like maintenance 
of multiple sex partners, intravenous drug abuse and unprotected sex-
ual intercourse.
Autologous Transfusion 
Three main techniques for autologous transfusion are; Predeposit Autologous Donation 
(PAD), Acute Normovolaemic Haemodilution (ANH), and Perioperative Cell Salvage (PCS). 
Autologous blood transfusion is; extremely safe, crossmatching is not required, iso-immuni-
sation to foreign protein is excluded, fear of transfusion transmissible disease can be ignored. 
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Some of the complications associated with allogenic blood are immunological, and are thought 
to be responsible for; increase in tumour recurrence after surgical resection, increased post-
operative infection rates, increased progression of HIV infection and multiorgan failure. These 
sequelae can be reduced by the use of syngeneic or autologous blood. Experiences in many sub 
Saharan African countries has shown that autologous transfusion can help prevent the use of 
allogenic blood. 
The global medical community has increasingly moved from allogenic blood towards autolo
gous infusion in which patients receive their own blood. The reasons for this movement include: 
1. Providing safe blood for transfusion remains a challenge despite ad
vances in preventing transmission of hepatitis B, hepatitis C, AIDS/HIV, 
West Nile virus(WNV), and transfusion-transmitted bacterial infection. 
Human errors such as misidentifying patients and drawing blood sam
ples from the wrong person present much more of a risk than transmis
sible diseases.
2. Additional risks include transfusion related acute lung injury (TRALI), 
a potentially life-threatening condition with symptoms such as dyspnea, 
fever, and hypotension occurring within hours of transfusion.
3. Transfusion-associated immunomodulation, which may suppress the im
mune response and cause adverse effects such a small increase in the risk 
of post operative infection.
4. Other risks such as variant Creutzfeldt-Jakob disease (vCJD), an invari
ably fatal disease.
5. Allogenic blood shortages coupled with the challenges of an aging popu
lation and fear of being able to meet the future blood transfusion need 
relying solely on allogenic blood.
6. Another impetus for autologous transfusion is the position of Jehovah’s 
Witnesses on blood transfusions. For religious reasons, Jehovah’s Wit
nesses will not accept any allogeneic transfusions from a volunteer’s 
blood donation, but may accept the use of autologous blood salvaged 
during surgery to restore their blood volume and homeostasis during the 
course of an operation.
Perioperative RBC salvage or Intraoperative bloods salvage 
(IBS) entails the collection and reinfusion of blood lost during or after surgery. Shed blood 
is aspirated from the operative field into a specially designed centrifuge. Citrate or heparin 
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Some of the complications associated with allogenic blood are immunological, and are thought 
to be responsible for; increase in tumour recurrence after surgical resection, increased post-
operative infection rates, increased progression of HIV infection and multiorgan failure. These 
sequelae can be reduced by the use of syngeneic or autologous blood. Experiences in many sub 
Saharan African countries has shown that autologous transfusion can help prevent the use of 
allogenic blood. 
10. Advantages of autologous blood over allogeneic blood
The global medical community has increasingly moved from allogenic blood towards autolo-
gous infusion in which patients receive their own blood. The reasons for this movement include: 
1. Providing safe blood for transfusion remains a challenge despite ad-
vances in preventing transmission of hepatitis B, hepatitis C, AIDS/HIV, 
West Nile virus(WNV), and transfusion-transmitted bacterial infection. 
Human errors such as misidentifying patients and drawing blood sam-
ples from the wrong person present much more of a risk than transmis-
sible diseases.
2. Additional risks include transfusion related acute lung injury (TRALI), 
a potentially life-threatening condition with symptoms such as dyspnea, 
fever, and hypotension occurring within hours of transfusion.
3. Transfusion-associated immunomodulation, which may suppress the im-
mune response and cause adverse effects such a small increase in the risk 
of post operative infection.
4. Other risks such as variant Creutzfeldt-Jakob disease (vCJD), an invari-
ably fatal disease.
5. Allogenic blood shortages coupled with the challenges of an aging popu-
lation and fear of being able to meet the future blood transfusion need 
relying solely on allogenic blood.
6. Another impetus for autologous transfusion is the position of Jehovah’s 
Witnesses on blood transfusions. For religious reasons, Jehovah’s Wit-
nesses will not accept any allogeneic transfusions from a volunteer’s 
blood donation, but may accept the use of autologous blood salvaged 
during surgery to restore their blood volume and homeostasis during the 
course of an operation.
Perioperative RBC salvage. Perioperative RBC salvage or Intraoperative bloods salvage 
(IBS) entails the collection and reinfusion of blood lost during or after surgery. Shed blood 
is aspirated from the operative field into a specially designed centrifuge. Citrate or heparin 
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anticoagulant is added, and the contents are filtered to remove clots and debris. Devices 
used can vary from simple, inexpensive, sterile bottles filled with anticoagulant to expensive, 
sophisticated, high-speed cell washing devices. ABT seems a feasible, effective and secure 
method that could be implemented in sub Saharan African countries. It may be a solution 
to the problems of shortage of blood products and transfusion safety. However training and 
motivation are necessary for its successful implementation. Intraoperative blood salvage (IBS) 
is used extensively after blunt abdominal trauma, but when blood is contaminated by enteric 
contents its use has been considered contraindicated. Blood component sequestration refers 
to a specific technique in which blood is collected intraoperatively, but then subjected to vari-
ous procedures, including apheresis, centrifugation and blood component separation. From 
a defined volume of whole blood, platelet concentrate, plasma and packed red blood cells are 
separated and then used as needed during the surgical procedure. The main difference be-
tween ANH or “whole blood sequestration” and blood component sequestration is cost. The 
latter requires sophisticated apheresis or autotranfusion equipment.
Indication
1. Cardiothoracic and vascular surgery, in which blood usage has tradition-
ally been high. Several processes have been developed to assist in salvag-
ing the patient’s own whole blood in the perioperative setting.
2. Coronary artery bypass grafts (CABG).
3. Valve replacement.
4. Surgical repair of the great vessels. 
Several medical devices have been developed to assist in salvaging the patient’s own blood in 
the perioperative setting. These are used frequently; cell processors and salvage devices that 
wash and save red blood cells (cell washers or RBC-savers), direct transfusion of salvaged red 
cells and ultrafiltration of whole blood. Regardless of manufacturer, there are many types of 
cell processors. Cell processors are red cell washing devices that collect anticoagulated shed 
or recovered blood, wash and separate the red blood cells (RBCs) by centrifugation, and rein-
fuse the RBCs. RBC washing devices can help remove byproducts in salvaged blood such as; 
activated cytokines, anaphylatoxins and other waste substances that may have been collected 
in the reservoir suctioned from the surgical field. The various RBC-savers also yield RBC 
concentrates with different characteristics and quality. Direct transfusion is a blood salvag-
ing method associated with cardiopulmonary bypass (CPB) circuits or other extracorporeal 
circuits (ECC) that are used in surgery such as coronary artery bypass grafts (CABG), valve 
replacement, or surgical repair of the great vessels. Following bypass surgery the ECC circuit 
contains a significant volume of diluted whole blood that can be harvested in transfer bags 
and re-infused into patients. Residual CPB blood is fairly dilute ([Hb] = 6–9 g/dL; 60–90 g/L) 
compared to normal values (12–18 g/dL; 120–180 g/L) and can also contain potentially harm-
ful contaminants such as activated cytokines, anaphylatoxins, and other waste substances 
that have been linked to organ edema and organ dysfunction and need a diuretic to reverse. 
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Hemofiltration or ultrafiltration devices constitute the third major type of blood salvage ap
pearing in operating rooms. In general, ultrafiltration devices filter the patient’s anticoagulat
ed whole blood. The filter process removes unwanted excess non-cellular plasma water, low 
molecular weight solutes, platelet inhibitors and some particulate matter through hemocon
centration, including activated cytokines, anaphylatoxins, and other waste substances mak
ing concentrated whole blood available for reinfusion. Hemofilter devices return the patient’s 
whole blood with all the blood elements and fractions including platelets, clotting factors, and 
plasma proteins with a substantial Hb level. An example of whole blood ultrafiltration de
vice in clinical use is the Hemobag. These devices do not totally remove potentially harmful 
contaminants that can be washed away by most RBC-savers. The key is that coagulation and 
homeostasis are immediately improved with the return of concentrated autologous whole 
blood.
Preoerative Autologous Donation (PAD). The risks of infection transmitted by transfusion of 
allogeneic blood components and association of allogeneic blood with increase in tumour re
currence after surgical resection, increased postoperative infection rates and multiorgan fail
ure has resulted in growing patient demand for alternatives to allogeneic blood transfusion 
and an increase in the advocacy for;increased use of intraoperative autologous transfusion 
and continuing developments in surgical techniques resulting in reduced blood requirements. 
Preoperative autologous donation (PAD) is the most popular and widely used of the autolo
gous options, which also include preoperative hemodilution and blood salvage. Interest in 
all forms of autologous transfusion, particularly PAD, mushroomed in response to the AIDS 
epidemic, beginning as early as 1983. By 1993, when participation in PAD peaked, approxi
mately 6 percent of all blood collected in the United States was collected for autologous use. 
PAD entails repeated preoperative phlebotomy, 4 - 5 weeks before surgery, during which time 
4 or 5 units of in-date blood can be collected with ease. This technique has several advantages; 
reduces exposure to allogeneic blood, it avoids many of the risks of transfusion, especially 
immunisation to red cell/platelets/ HLA antigens and the transmission of infection, the most 
obvious benefit of PAD for the donor/patient is freedom from concern about infectivity of the 
blood, assuming that the donor is not bacteremic at the time of donation and/or there are no 
clerical errors resulting in the inadvertent transfusion of the wrong unit of blood, the patient 
is also protected against hemolytic, febrile or allergic transfusion reactions; alloimmunization 
to erythrocyte, leukocyte, platelet or protein antigens; and graft-versus-host disease (GVHD). 
An additional benefit is that erythropoiesis may be stimulated by repeated phlebotomies, 
thereby enabling the patient to regenerate hemoglobin at an accelerated rate after surgery. 
PAD major drawbacks are that autologous blood is considerably more expensive than alloge
neic blood. The use of pre-operative autologous blood donation (PAD) is not recommended 
unless the clinical circumstances are exceptional. Exceptional circumstances may include:
1. Rare blood groups where allogeneic difficult to obtain
2. Children with scoliosis 
anticoagulant is added, and the contents are filtered to remove clots and debris. Devices 
used can vary from simple, inexpensive, sterile bottles filled with anticoagulant to expensive, 
sophisticated, high-speed cell washing devices. ABT seems a feasible, effective and secure 
method that could be implemented in sub Saharan African countries. It may be a solution 
to the problems of shortage of blood products and transfusion safety. However training and 
motivation are necessary for its successful implementation. Intraoperative blood salvage (IBS) 
is used extensively after blunt abdominal trauma, but when blood is contaminated by enteric 
contents its use has been considered contraindicated. Blood component sequestration refers 
to a specific technique in which blood is collected intraoperatively, but then subjected to vari
ous procedures, including apheresis, centrifugation and blood component separation. From 
a defined volume of whole blood, platelet concentrate, plasma and packed red blood cells are 
separated and then used as needed during the surgical procedure. The main difference be
tween ANH or “whole blood sequestration” and blood component sequestration is cost. The 
latter requires sophisticated apheresis or autotranfusion equipment.
1. Cardiothoracic and vascular surgery, in which blood usage has tradition
ally been high. Several processes have been developed to assist in salvag
ing the patient’s own whole blood in the perioperative setting.
2. Coronary artery bypass grafts (CABG).
3. Valve replacement.
4. Surgical repair of the great vessels. 
Several medical devices have been developed to assist in salvaging the patient’s own blood in 
the perioperative setting. These are used frequently; cell processors and salvage devices that 
wash and save red blood cells (cell washers or RBC-savers), direct transfusion of salvaged red 
cells and ultrafiltration of whole blood. Regardless of manufacturer, there are many types of 
cell processors. Cell processors are red cell washing devices that collect anticoagulated shed 
or recovered blood, wash and separate the red blood cells (RBCs) by centrifugation, and rein
fuse the RBCs. RBC washing devices can help remove byproducts in salvaged blood such as; 
activated cytokines, anaphylatoxins and other waste substances that may have been collected 
in the reservoir suctioned from the surgical field. The various RBC-savers also yield RBC 
concentrates with different characteristics and quality. Direct transfusion is a blood salvag
ing method associated with cardiopulmonary bypass (CPB) circuits or other extracorporeal 
circuits (ECC) that are used in surgery such as coronary artery bypass grafts (CABG), valve 
replacement, or surgical repair of the great vessels. Following bypass surgery the ECC circuit 
contains a significant volume of diluted whole blood that can be harvested in transfer bags 
and re-infused into patients. Residual CPB blood is fairly dilute ([Hb] = 6–9 g/dL; 60–90 g/L) 
compared to normal values (12–18 g/dL; 120–180 g/L) and can also contain potentially harm
ful contaminants such as activated cytokines, anaphylatoxins, and other waste substances 
that have been linked to organ edema and organ dysfunction and need a diuretic to reverse. 
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Hemofiltration or ultrafiltration devices constitute the third major type of blood salvage ap-
pearing in operating rooms. In general, ultrafiltration devices filter the patient’s anticoagulat-
ed whole blood. The filter process removes unwanted excess non-cellular plasma water, low 
molecular weight solutes, platelet inhibitors and some particulate matter through hemocon-
centration, including activated cytokines, anaphylatoxins, and other waste substances mak-
ing concentrated whole blood available for reinfusion. Hemofilter devices return the patient’s 
whole blood with all the blood elements and fractions including platelets, clotting factors, and 
plasma proteins with a substantial Hb level. An example of whole blood ultrafiltration de-
vice in clinical use is the Hemobag. These devices do not totally remove potentially harmful 
contaminants that can be washed away by most RBC-savers. The key is that coagulation and 
homeostasis are immediately improved with the return of concentrated autologous whole 
blood.
Preoerative Autologous Donation (PAD). The risks of infection transmitted by transfusion of 
allogeneic blood components and association of allogeneic blood with increase in tumour re-
currence after surgical resection, increased postoperative infection rates and multiorgan fail-
ure has resulted in growing patient demand for alternatives to allogeneic blood transfusion 
and an increase in the advocacy for;increased use of intraoperative autologous transfusion 
and continuing developments in surgical techniques resulting in reduced blood requirements. 
Preoperative autologous donation (PAD) is the most popular and widely used of the autolo-
gous options, which also include preoperative hemodilution and blood salvage. Interest in 
all forms of autologous transfusion, particularly PAD, mushroomed in response to the AIDS 
epidemic, beginning as early as 1983. By 1993, when participation in PAD peaked, approxi-
mately 6 percent of all blood collected in the United States was collected for autologous use. 
PAD entails repeated preoperative phlebotomy, 4 - 5 weeks before surgery, during which time 
4 or 5 units of in-date blood can be collected with ease. This technique has several advantages; 
reduces exposure to allogeneic blood, it avoids many of the risks of transfusion, especially 
immunisation to red cell/platelets/ HLA antigens and the transmission of infection, the most 
obvious benefit of PAD for the donor/patient is freedom from concern about infectivity of the 
blood, assuming that the donor is not bacteremic at the time of donation and/or there are no 
clerical errors resulting in the inadvertent transfusion of the wrong unit of blood, the patient 
is also protected against hemolytic, febrile or allergic transfusion reactions; alloimmunization 
to erythrocyte, leukocyte, platelet or protein antigens; and graft-versus-host disease (GVHD). 
An additional benefit is that erythropoiesis may be stimulated by repeated phlebotomies, 
thereby enabling the patient to regenerate hemoglobin at an accelerated rate after surgery. 
PAD major drawbacks are that autologous blood is considerably more expensive than alloge-
neic blood. The use of pre-operative autologous blood donation (PAD) is not recommended 
unless the clinical circumstances are exceptional. Exceptional circumstances may include:
1. Rare blood groups where allogeneic difficult to obtain
2. Children with scoliosis 
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3. Patients at serious psychiatric risk if blood transfusion is thought to be 
likely to cover their elective surgery 
4. Patients considered for the procedure must be candidates for elective sur-
gery, where blood transfusion is expected to be needed.
5. The admission and operation days must be guaranteed.
6. Sufficient time to enable optimal collection of the blood must be allowed 
prior to surgery but should not exceed the licensed time for storing the 
collected blood component.
7. Sufficient time should be given from the date and time of the ultimate 
PAD collection prior to surgery for the patient to make a full circulatory 
and volaemic recovery. 
8. Patient should be judged by a competent clinician to be able to tolerate 
the repeated loss of the predetermined volume of blood at each collection.
9. Patient should be provided with adequate information concerning the 
eligibility criteria for PAD and the reasons behind such criteria by the 
physicians providing the PAD service
10. Should be considered for supplementation with erythropoietin 
11. Should present with the following haemoglobin (Hb) before embarking 
on PAD
• Men, 110 to 145 grams per liter (g/L)
• Women, 130 to 145 g/L
12. For each individual case, there should be a clear reason for preferring 
PAD to allogeneic blood as PAD is not indicated for most patients not 
fulfilling the above criteria.
13. PAD is not recommended for children younger than 10 years, mainly be-
cause of technical difficulties (large bore needle in veins of limited size) 
and it can be difficult to gain sufficient co-operation.
14. Candidates who meet the criteria for PAD but who are positive for rel-
evant markers of transfusion-transmissible infection present safety issues 
for staff collecting and processing the donations and also potential for 
administrative and other errors. 
15. Although iron therapy prior to PAD has little effect on subsequent trans-
fusion needs in individuals who are iron replete, there are advocates of 
iron therapy during PAD on a priori grounds. 
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Acute normovolaemic haemodilution (ANH). Acute normovolaemic haemodilution (also 
called acute normovolaemic haemodilution, acute isovolemic hemodilution, acute normo
volemic anemia, intraoperative autolgous donation, hemospasia and controlled exsanguina
tion) is a form of autologous donation performed preoperatively in the operating theatre or 
anaesthetic area. It is usually restricted to patients in whom substantial blood loss (> 1 litre 
or 20% of blood volume) is predicted. Whole blood (1.0 - 1.5 l) is removed, and simultane
ously intravascular volume is replaced with crystalloid or colloid, or both, to maintain blood 
volume. The anticoagulated blood is then reinfused during or shortly after surgical blood 
loss has stopped in reverse order of collection. ANH is associated with reduced surgical he
morrhage and reduced allogeneic blood transfusion. Acute, since it is conducted relatively 
rapidly; normovolemia, since the volume of the patient’s blood is maintained normal by the 
hemodilution, which occurs as a result of the asanguinous fluid infusion. ANH enjoys con
siderable popularity in Europe, but has waned recently in the United States and Canada. It is 
probably one of the most misunderstood perioperative blood conservation techniques. When 
utilized correctly, ANH is an extremely helpful modality. However, when used incorrectly, it 
has limited efficacy. 
The technique essentially employs two steps. Firstly whole blood 
is collected from a patient via gravity into blood bags containing anticoagulant on the day of 
surgery before anticipated surgical blood loss. Secondly as blood is collected, asanguinous 
fluid must be infused to maintain normovolemia or euvolemia. This is accomplished with 
either crystalloid (normal saline, lactated Ringer’s solution ) or colloid (albumin, hetastarch). 
The development of hemodilution has a variety of implications for both the patient and the 
practitioner. Hemodilution is associated with; reduced blood viscosity, reduced afterload and 
increased cardiac output, the hemoglobin (Hb) concentration of the patient’s blood is reduced 
secondary to hemodilution, any blood lost via the surgical field in the form of hemorrhage, 
contains relatively less Hb, other advantages of ANH include provision of a fresh supply 
of coagulation factors and platelets. Once reinfused, these procoagulant components are 
thought to augment a patient’s inherent coagulation function and surgical hemorrhage might 
be reduced perioperatively.
Not every patient is eligible for ANH. Not every surgical procedure re
quires ANH. Patients undergoing surgical procedures associated with minimal blood loss 
clearly will not benefit from ANH. In selecting patients for ANH, one should take into consid
eration the following; Patient’s overall condition, presence or absence of anemia, presence of 
comorbid conditions and the type of surgery and the surgeon’s skills. 
Contrary to current thinking, any surgical procedure in which there 
is a potential for significant surgical blood loss is suited to ANH. This include; cardiac sur
gery - on of off-pump procedures, minimally invasive techniques, general surgery - major 
bowel or cancer resections, neurosurgery - major back procedures, orthopedic surgery - major 
back, joint replacement procedures, thoracic surgery - lobectomy, pneumonectomy, urologic 
3. Patients at serious psychiatric risk if blood transfusion is thought to be 
likely to cover their elective surgery 
4. Patients considered for the procedure must be candidates for elective sur
gery, where blood transfusion is expected to be needed.
5. The admission and operation days must be guaranteed.
6. Sufficient time to enable optimal collection of the blood must be allowed 
prior to surgery but should not exceed the licensed time for storing the 
collected blood component.
7. Sufficient time should be given from the date and time of the ultimate 
PAD collection prior to surgery for the patient to make a full circulatory 
and volaemic recovery. 
8. Patient should be judged by a competent clinician to be able to tolerate 
the repeated loss of the predetermined volume of blood at each collection.
9. Patient should be provided with adequate information concerning the 
eligibility criteria for PAD and the reasons behind such criteria by the 
physicians providing the PAD service
10. Should be considered for supplementation with erythropoietin 
11. Should present with the following haemoglobin (Hb) before embarking 
on PAD
• Men, 110 to 145 grams per liter (g/L)
• Women, 130 to 145 g/L
12. For each individual case, there should be a clear reason for preferring 
PAD to allogeneic blood as PAD is not indicated for most patients not 
fulfilling the above criteria.
13. PAD is not recommended for children younger than 10 years, mainly be
cause of technical difficulties (large bore needle in veins of limited size) 
and it can be difficult to gain sufficient co-operation.
14. Candidates who meet the criteria for PAD but who are positive for rel
evant markers of transfusion-transmissible infection present safety issues 
for staff collecting and processing the donations and also potential for 
administrative and other errors. 
15. Although iron therapy prior to PAD has little effect on subsequent trans
fusion needs in individuals who are iron replete, there are advocates of 
iron therapy during PAD on a priori grounds.
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Acute normovolaemic haemodilution (ANH). Acute normovolaemic haemodilution (also 
called acute normovolaemic haemodilution, acute isovolemic hemodilution, acute normo-
volemic anemia, intraoperative autolgous donation, hemospasia and controlled exsanguina-
tion) is a form of autologous donation performed preoperatively in the operating theatre or 
anaesthetic area. It is usually restricted to patients in whom substantial blood loss (> 1 litre 
or 20% of blood volume) is predicted. Whole blood (1.0 - 1.5 l) is removed, and simultane-
ously intravascular volume is replaced with crystalloid or colloid, or both, to maintain blood 
volume. The anticoagulated blood is then reinfused during or shortly after surgical blood 
loss has stopped in reverse order of collection. ANH is associated with reduced surgical he-
morrhage and reduced allogeneic blood transfusion. Acute, since it is conducted relatively 
rapidly; normovolemia, since the volume of the patient’s blood is maintained normal by the 
hemodilution, which occurs as a result of the asanguinous fluid infusion. ANH enjoys con-
siderable popularity in Europe, but has waned recently in the United States and Canada. It is 
probably one of the most misunderstood perioperative blood conservation techniques. When 
utilized correctly, ANH is an extremely helpful modality. However, when used incorrectly, it 
has limited efficacy. 
Basic Principles of ANH. The technique essentially employs two steps. Firstly whole blood 
is collected from a patient via gravity into blood bags containing anticoagulant on the day of 
surgery before anticipated surgical blood loss. Secondly as blood is collected, asanguinous 
fluid must be infused to maintain normovolemia or euvolemia. This is accomplished with 
either crystalloid (normal saline, lactated Ringer’s solution ) or colloid (albumin, hetastarch). 
The development of hemodilution has a variety of implications for both the patient and the 
practitioner. Hemodilution is associated with; reduced blood viscosity, reduced afterload and 
increased cardiac output, the hemoglobin (Hb) concentration of the patient’s blood is reduced 
secondary to hemodilution, any blood lost via the surgical field in the form of hemorrhage, 
contains relatively less Hb, other advantages of ANH include provision of a fresh supply 
of coagulation factors and platelets. Once reinfused, these procoagulant components are 
thought to augment a patient’s inherent coagulation function and surgical hemorrhage might 
be reduced perioperatively.
Patient Selection. Not every patient is eligible for ANH. Not every surgical procedure re-
quires ANH. Patients undergoing surgical procedures associated with minimal blood loss 
clearly will not benefit from ANH. In selecting patients for ANH, one should take into consid-
eration the following; Patient’s overall condition, presence or absence of anemia, presence of 
comorbid conditions and the type of surgery and the surgeon’s skills. 
Indications for ANH. Contrary to current thinking, any surgical procedure in which there 
is a potential for significant surgical blood loss is suited to ANH. This include; cardiac sur-
gery - on of off-pump procedures, minimally invasive techniques, general surgery - major 
bowel or cancer resections, neurosurgery - major back procedures, orthopedic surgery - major 
back, joint replacement procedures, thoracic surgery - lobectomy, pneumonectomy, urologic 
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surgery - prostatectomy, cystectomy, nephrectomy and vascular surgery including major re-
constructive vascular surgery. 
Contraindications. There are a few absolute contraindications to ANH, in which ANH can-
not be used under any circumstances. These include; presence of severe sepsis, respiratory 
failure, myocardial pumps failure, hemorrhagic shock secondary to trauma and severe ane-
mia. Less severe degrees of anemia become a relative contraindication to ANH. Patients with 
mild forms of anemia might be eligible for ANH; however, the volume of blood that may be 
collected will be less, since baseline Hb or hematocrit is reduced. Other relative contraindi-
cations include; severe respiratory disease, end-stage renal disease, coronary artery disease 
with or without a history of myocardial infarction (MI), congestive heart failure and history 
of a cerebrovascular accident (stroke). 
Procedure 
1. In order to perform ANH, blood collection bags that contain anticoagulant 
(CPDA) are needed. 
2. Most practitioners perform ANH after the induction of anesthesia, prior 
to the commencement of surgery. Performing ANH prior to the induction 
of anesthesia, with the patient awake, is performed in some centers. Ad-
vantages include having an abundance of time and the ability to assess the 
hemodynamic consequences in the absence of any anesthetic effects.
3. An adequate site for blood collection must be planned for. Peripheral ve-
nous lines are popular, but are associated with problems; venous valves, 
tubing resistance, sludging, need for an intravenous catheter of at least 18 
gauge size, arterial lines may be used - here, arterial pressure serves as a 
pressure head that pumps the blood into the collection bag. The disadvan-
tage of arterial lines is that the ability to monitor arterial blood pressure is 
lost. Central lines remain the most reliable and effective means of blood 
collection. They may be placed anywhere, although internal jugular and 
subclavian lines are the most popular. 
4. Calculation of the volume of blood to be collected. The following informa-
tion should be collated to facillitate the calculation of volume to be drawn; 
the patient’s weight (kg) is needed in order to calculate the estimated blood 
volume (EBV). This reflects the total circulating blood volume. The total 
circulating blood volume is approximately 70 mLs/ kg for females and 75 
mLs/ kg in males. Therefore, a 90 kg male patient might be expected to 
have an EBV of 90 X 75 mLs = 6750 mLs. The baseline, initial or starting 
Hb concentration or hematocrit and the target Hb for hematocrit for ANH. 
This is typically a value that reflects a level of Hb or hematocrit that is safe 
and tolerated by the patient without adverse effects. The Volume of Blood 
that may be sequestered is calculated using the formula: ANH = Baseline 
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Hb or hematocrit - target Hb or hematocrit/ Average Hb or hematocrit X 
EBV. For example, take a male patient weighing 90 kg with a starting Hb 
of 14 g/dl. We elect that an Hb of 10 g/dl is a safe, end-point for ANH. The 
volume of blood that may be sequestered = 14-10/12 X 6750 = 2,250 mLs.
5. Standard blood collection bags contain CPD anticoagulant typically have 
tubing and a needle attached. The needle may be detached and various 
connectors welded or interposed in the tubing, so that they may connect 
to a port in the intravenous line. 
6. Commencement of whole blood sequestration. The stopcock or port is opened 
and blood should be seen flowing into the blood collection bag tubing from 
the patient. The blood collection bag is placed on the ground or on an agitator.
7. Asanguinous fluid is administered concurrently with the blood collection 
process; asanginous fluid must be administered, in order to manintain normo
volemia. ANH assumes that for each mL of blood collected, one mL of fluid 
is administered. Crystalloid is particularly unique, in that following infusion, 
a sizeable proportion of that volume moves out of the circulation into the 
perivascular spaces. 
8. Storage of whole blood. Once a whole blood bag is full, it must be discon
nected, the tubing sealed, the bag labeled and kept in a safe location at room 
temperature (20 degrees C) for up to 6 hours. After 6 hours, this blood product 
should be refrigerated at 4°C ± 2°C.
9. Reinfusion of whole blood. Timing of whole blood reinfusion is an im
portant aspect in the blood management and conservation approach. 
Blood should be reinfused as surgical conditions dictate. During rapid 
uncontrolled surgical hemorrhage whole blood might be needed to re
store blood volume. If surgical hemorrhage is slow and protracted, whole 
blood would be needed to restore Hb levels to normal and correct a surgi
cal anemia. When whole blood is collected with ANH, each subsequent 
unit becomes progressively more dilute. When blood is reinfused, it is 
recommended that the last collected unit be infused first. 
The following basic hemodynamic parameters should be monitored during the 
conduct of ANH; heart rate, systemic blood pressure, pulse oximetry, capnography (is the 
monitoring of the concentration or partial pressure of carbon dioxide (CO2) in the respiratory 
gases. Its main development has been as a monitoring tool for use during anaesthesia and in
tensive care). Capnography provides information about CO2 production, pulmonary (lung) 
perfusion, alveolar ventilation, respiratory patterns, and elimination of CO2 from the anaes
thesia breathing circuit and ventilator, central venous pressure, pulmonary arterial pressure, 
cardiac output, and transesophageal echocardiography (TEE). 
surgery - prostatectomy, cystectomy, nephrectomy and vascular surgery including major re
constructive vascular surgery. 
There are a few absolute contraindications to ANH, in which ANH can
not be used under any circumstances. These include; presence of severe sepsis, respiratory 
failure, myocardial pumps failure, hemorrhagic shock secondary to trauma and severe ane
mia. Less severe degrees of anemia become a relative contraindication to ANH. Patients with 
mild forms of anemia might be eligible for ANH; however, the volume of blood that may be 
collected will be less, since baseline Hb or hematocrit is reduced. Other relative contraindi
cations include; severe respiratory disease, end-stage renal disease, coronary artery disease 
with or without a history of myocardial infarction (MI), congestive heart failure and history 
of a cerebrovascular accident (stroke). 
1. In order to perform ANH, blood collection bags that contain anticoagulant 
(CPDA) are needed. 
2. Most practitioners perform ANH after the induction of anesthesia, prior 
to the commencement of surgery. Performing ANH prior to the induction 
of anesthesia, with the patient awake, is performed in some centers. Ad
vantages include having an abundance of time and the ability to assess the 
hemodynamic consequences in the absence of any anesthetic effects.
3. An adequate site for blood collection must be planned for. Peripheral ve
nous lines are popular, but are associated with problems; venous valves, 
tubing resistance, sludging, need for an intravenous catheter of at least 18 
gauge size, arterial lines may be used - here, arterial pressure serves as a 
pressure head that pumps the blood into the collection bag. The disadvan
tage of arterial lines is that the ability to monitor arterial blood pressure is 
lost. Central lines remain the most reliable and effective means of blood 
collection. They may be placed anywhere, although internal jugular and 
subclavian lines are the most popular. 
4. Calculation of the volume of blood to be collected. The following informa
tion should be collated to facillitate the calculation of volume to be drawn; 
the patient’s weight (kg) is needed in order to calculate the estimated blood 
volume (EBV). This reflects the total circulating blood volume. The total 
circulating blood volume is approximately 70 mLs/ kg for females and 75 
mLs/ kg in males. Therefore, a 90 kg male patient might be expected to 
have an EBV of 90 X 75 mLs = 6750 mLs. The baseline, initial or starting 
Hb concentration or hematocrit and the target Hb for hematocrit for ANH. 
This is typically a value that reflects a level of Hb or hematocrit that is safe 
and tolerated by the patient without adverse effects. The Volume of Blood 
that may be sequestered is calculated using the formula: ANH = Baseline 
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Hb or hematocrit - target Hb or hematocrit/ Average Hb or hematocrit X 
EBV. For example, take a male patient weighing 90 kg with a starting Hb 
of 14 g/dl. We elect that an Hb of 10 g/dl is a safe, end-point for ANH. The 
volume of blood that may be sequestered = 14-10/12 X 6750 = 2,250 mLs.
5. Standard blood collection bags contain CPD anticoagulant typically have 
tubing and a needle attached. The needle may be detached and various 
connectors welded or interposed in the tubing, so that they may connect 
to a port in the intravenous line. 
6. Commencement of whole blood sequestration. The stopcock or port is opened 
and blood should be seen flowing into the blood collection bag tubing from 
the patient. The blood collection bag is placed on the ground or on an agitator.
7. Asanguinous fluid is administered concurrently with the blood collection 
process; asanginous fluid must be administered, in order to manintain normo-
volemia. ANH assumes that for each mL of blood collected, one mL of fluid 
is administered. Crystalloid is particularly unique, in that following infusion, 
a sizeable proportion of that volume moves out of the circulation into the 
perivascular spaces. 
8. Storage of whole blood. Once a whole blood bag is full, it must be discon-
nected, the tubing sealed, the bag labeled and kept in a safe location at room 
temperature (20 degrees C) for up to 6 hours. After 6 hours, this blood product 
should be refrigerated at 4°C ± 2°C.
9. Reinfusion of whole blood. Timing of whole blood reinfusion is an im-
portant aspect in the blood management and conservation approach. 
Blood should be reinfused as surgical conditions dictate. During rapid 
uncontrolled surgical hemorrhage whole blood might be needed to re-
store blood volume. If surgical hemorrhage is slow and protracted, whole 
blood would be needed to restore Hb levels to normal and correct a surgi-
cal anemia. When whole blood is collected with ANH, each subsequent 
unit becomes progressively more dilute. When blood is reinfused, it is 
recommended that the last collected unit be infused first. 
Monitoring. The following basic hemodynamic parameters should be monitored during the 
conduct of ANH; heart rate, systemic blood pressure, pulse oximetry, capnography (is the 
monitoring of the concentration or partial pressure of carbon dioxide (CO2) in the respiratory 
gases. Its main development has been as a monitoring tool for use during anaesthesia and in-
tensive care). Capnography provides information about CO2 production, pulmonary (lung) 
perfusion, alveolar ventilation, respiratory patterns, and elimination of CO2 from the anaes-
thesia breathing circuit and ventilator, central venous pressure, pulmonary arterial pressure, 
cardiac output, and transesophageal echocardiography (TEE). 
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)80
Efficacy of ANH: ANH efficacy may be defined in terms of an outcome variable or surrogate 
marker. Some examples include; the volume of autologous RBCs that was saved or “spared”, 
the reduction in the allogeneic blood transfusion rate, the maximal allowable or actual vol-
ume of perioperative surgical blood loss andpotential or realized economic savings. 
Challenges associated with ANH
1. Safety of the iatrogenic production of anemia: ANH produces an anae-
mic syndrome which often leads to the conclusion that it may be poten-
tially unsafe in certain patient/disease categories, since tissue hypoxia or 
ischemia may result. The recommended target Hb for ANH ranges from 
7 g/dl for the healthy patient to 10 g/dl for patients with associated car-
diac, respiratory or neurologic disease.
2. Bleeding Diasthesis: ANH is also thought to contribute to a bleeding dia-
thesis during surgery. Since coagulation factors are sequestered from the 
patient, subsequent surgical hemorrhage may be compounded by a dilu-
tional thrombocytopenia or hypofibrinogenemia.
11. Transfusion transmissible infectious diseases
Blood donor testing
The donor’s blood type must be determined if the blood will be used for transfusions. The 
collecting agency usually determines the ABO (A, B, AB, or O) and Rh D blood type (positive 
or negative) of the donor and will screen for presence of antibodies to prevent the passive 
introduction of donor alloantibody to patient. Such passively transferred alloantibody can 
react with patient red cells and other transfused donor unit if they contains antigen to which 
the alloantibody is specific. All group O donors should ideally be tested for the presence of 
high titre anti-A and B haemolysin. About 5-10% of all group O donor units have high titre 
anti-A and B. Transfusion of group O donor units containing high titre anti-A and B to non O 
patients (A and B) potentially cause life threatening haemolytic transfusion reaction. Ideally 
patient should receive blood of their own ABO blood group. However in most developing 
countries where blood is scarce, group O units (universal donors) can be transfused to non O 
patients (A,B and AB). The universal rule is that all O blood containing high titre anti A and 
B haemolysin should be reserved for group O patients and only units negative for high titre 
anti A and B should be given to non O patients. Testing for high titre anti A and B test is car-
ried out as follows:
Testing for high titre anti A and B haemolysin
1. Centrifuge 5mls of donors whole blood sample and separate the plasma
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2. Prepare 1:56 dilution of the donor plasma with saline
3. Prepare a 5% suspension of A2B red cells in saline
4. Add 2 drops of donor 1:56 diluted plasma to 1 drop of 5% A2B red cells 
suspension
5. Centrifuge lightly and observe for agglutination
6. Agglutination indicates presence of high titre anti A and B
The ABO and RH groups are determined using monoclonal anti A, B and D. The anti-A used 
must be capable of detecting the weaker groups of antigen A (Ax). Ax is a rare form of antigen 
A that show a weak expression of the A antigen. In hospitals where only forward ABO groups 
are done and where the Anti-A used for forward grouping is not capable of detecting Ax, 
these patients may be erronously grouped as O. If such donor units are transfused to group O 
patients with potent IgG anti-A, there is the risk of increased red cell destruction. The anti-D 
used for Rh D grouping must be capable of also detecting the weaker form of the D antigen 
as well as partial (variant) D types (DIV, DV and DVI). For example if partial D type (DVI) is 
wrongly grouped as Rh negative and transfused to Rh negative women of child bearing age, 
they potentially can produce immune anti-D which can potentially cause HDFN in subse
quent D positive pregnancies. Some selected units may also be tested for CMV antibody as 
well as Rh and Kell phenotype to enable the selection of appriopriate units for patients that 
require CMV negative units (HIV, fetus requiring Intra Uterine Transfusion and immunosup
pressed patients), haemoglobin S negative units (sickle cell negative red cells for sickle cell 
patients neonates and patients with certain other haematological conditions) as well as those 
patients that have developed alloantibodies as a result of previous transfusion and pregnancy 
and requires specific antigen negative red cells; Rh (C, c, E, e), M, S, s, Duffy (Fy  and Fyb), 
Kidd (Jk  and Jkb) and Kell negative units. Some units may also need to be irradiated. All 
blood for neonatal use and for haematology patient on purine analogues will need irradiated 
blood products to prevent the possibility of graft versus host disease (GvHD). In most devel
oped countries there is universal leucodepletion of all donor units by using leucodepletion 
filter. Leucodepletion can help protect donated blood from CMV infection.
More testing, including a crossmatch, is usually done before a transfusion. Group O is often 
cited as the “universal donor” but this only refers to red cell transfusions. For plasma transfu
sions the system is reversed and AB is the universal donor type. WHO recommends that, at 
minimum, all donated blood to be used for transfusion should be screened for HIV, hepatitis 
B, hepatitis C and syphilis? Complete and accurate data on the screening of donated blood 
are not available from many developing countries because; blood services are not coordinated, 
many countries do not have reliable testing systems because of staff shortages; lack of basic 
laboratory services, poor quality test kits or their irregular supply. Most blood is tested for 
diseases, including some STDs. The tests used are high-sensitivity screening tests and no 
actual diagnosis is made. The blood is usually discarded if these tests are positive, but there 
are some exceptions, such as autologous donations. The donor is generally notified of the 
80
Efficacy of ANH: ANH efficacy may be defined in terms of an outcome variable or surrogate 
marker. Some examples include; the volume of autologous RBCs that was saved or “spared”, 
the reduction in the allogeneic blood transfusion rate, the maximal allowable or actual vol
ume of perioperative surgical blood loss andpotential or realized economic savings. 
1. Safety of the iatrogenic production of anemia: ANH produces an anae
mic syndrome which often leads to the conclusion that it may be poten
tially unsafe in certain patient/disease categories, since tissue hypoxia or 
ischemia may result. The recommended target Hb for ANH ranges from 
7 g/dl for the healthy patient to 10 g/dl for patients with associated car
diac, respiratory or neurologic disease.
2. Bleeding Diasthesis: ANH is also thought to contribute to a bleeding dia
thesis during surgery. Since coagulation factors are sequestered from the 
patient, subsequent surgical hemorrhage may be compounded by a dilu
tional thrombocytopenia or hypofibrinogenemia.
The donor’s blood type must be determined if the blood will be used for transfusions. The 
collecting agency usually determines the ABO (A, B, AB, or O) and Rh D blood type (positive 
or negative) of the donor and will screen for presence of antibodies to prevent the passive 
introduction of donor alloantibody to patient. Such passively transferred alloantibody can 
react with patient red cells and other transfused donor unit if they contains antigen to which 
the alloantibody is specific. All group O donors should ideally be tested for the presence of 
high titre anti-A and B haemolysin. About 5-10% of all group O donor units have high titre 
anti-A and B. Transfusion of group O donor units containing high titre anti-A and B to non O 
patients (A and B) potentially cause life threatening haemolytic transfusion reaction. Ideally 
patient should receive blood of their own ABO blood group. However in most developing 
countries where blood is scarce, group O units (universal donors) can be transfused to non O 
patients (A,B and AB). The universal rule is that all O blood containing high titre anti A and 
B haemolysin should be reserved for group O patients and only units negative for high titre 
anti A and B should be given to non O patients. Testing for high titre anti A and B test is car
ried out as follows:
1. Centrifuge 5mls of donors whole blood sample and separate the plasma
81Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
2. Prepare 1:56 dilution of the donor plasma with saline
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The ABO and RH groups are determined using monoclonal anti A, B and D. The anti-A used 
must be capable of detecting the weaker groups of antigen A (Ax). Ax is a rare form of antigen 
A that show a weak expression of the A antigen. In hospitals where only forward ABO groups 
are done and where the Anti-A used for forward grouping is not capable of detecting Ax, 
these patients may be erronously grouped as O. If such donor units are transfused to group O 
patients with potent IgG anti-A, there is the risk of increased red cell destruction. The anti-D 
used for Rh D grouping must be capable of also detecting the weaker form of the D antigen 
as well as partial (variant) D types (DIV, DV and DVI). For example if partial D type (DVI) is 
wrongly grouped as Rh negative and transfused to Rh negative women of child bearing age, 
they potentially can produce immune anti-D which can potentially cause HDFN in subse-
quent D positive pregnancies. Some selected units may also be tested for CMV antibody as 
well as Rh and Kell phenotype to enable the selection of appriopriate units for patients that 
require CMV negative units (HIV, fetus requiring Intra Uterine Transfusion and immunosup-
pressed patients), haemoglobin S negative units (sickle cell negative red cells for sickle cell 
patients neonates and patients with certain other haematological conditions) as well as those 
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blood products to prevent the possibility of graft versus host disease (GvHD). In most devel-
oped countries there is universal leucodepletion of all donor units by using leucodepletion 
filter. Leucodepletion can help protect donated blood from CMV infection.
More testing, including a crossmatch, is usually done before a transfusion. Group O is often 
cited as the “universal donor” but this only refers to red cell transfusions. For plasma transfu-
sions the system is reversed and AB is the universal donor type. WHO recommends that, at 
minimum, all donated blood to be used for transfusion should be screened for HIV, hepatitis 
B, hepatitis C and syphilis? Complete and accurate data on the screening of donated blood 
are not available from many developing countries because; blood services are not coordinated, 
many countries do not have reliable testing systems because of staff shortages; lack of basic 
laboratory services, poor quality test kits or their irregular supply. Most blood is tested for 
diseases, including some STDs. The tests used are high-sensitivity screening tests and no 
actual diagnosis is made. The blood is usually discarded if these tests are positive, but there 
are some exceptions, such as autologous donations. The donor is generally notified of the 
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test result. Donated blood is tested by many methods, but the core tests recommended by 
the World Health Organization are these four; Hepatitis B Surface Antigen (HbsAg), Anti-
body to Hepatitis C Virus (HCV), Antibody to HIV, usually subtypes 1 and 2 and Serologic 
test for Syphilis. A variety of other tests for transfusion transmitted infections are often used 
based on local requirements. Additional testing is expensive, and in some cases the tests are 
not implemented because of the cost. These additional tests include other infectious diseases 
such as West Nile Virus. Sometimes multiple tests are used for a single disease to cover the 
limitations of each test. For example, the HIV antibody test will not detect a recently infected 
donor, so some blood banks use a p24 antigen or HIV nucleic acid test in addition to the basic 
antibody test to detect infected donors during that period. Cytomegalovirus is a special case 
in donor testing in that many donors will test positive for it. The virus is not a hazard to a 
healthy recipient, but it can harm infants and other recipients with weak immune systems. 
The potential risk of TTI’s can be reduced by the following measures:
1. A strict donor selection process
2. Improved donor testing methods using Nucleic Acid Testing (NAT-PCR)
3. Reducing inappriopriate transfusion by using the indication coding 
system
4. Increased use of alternatives to allogeneic blood (autologous transfusion, 
oral and intravenous iron as well as erythropoietin treatment).
5. Using infective agent reduction and viral inactivation techniques such 
as leucodepletion and methylene blue treatment and solvent-detergent 
treatment of plasma products.
Syphilis. Through the years, a great controversy had arisen over the need for syphilis test-
ing of blood donors. Although the American Association of Blood Banks (AABB) initially 
dropped its recommendation that donors be tested for syphilis in 1978, the Food and Drug 
administration (FDA) of the United States keeps on this requirement. This decision was rein-
forced by the HIV epidemic. It is now recommended in most countries that surrogate testing 
including syphilis should be done to prevent those at risk from donating blood. However 
cost of transfusion- transmissible infection testing is a major challenge to the provision of 
safe blood and blood products in sub Saharan Africa. Treponemics, non treponemics, im-
munochromatographics or nucleic acid testing is affordable and can significantly contribute 
to blood transfusion safety as in most resource poor countries. Most contries uses the TPHA 
test for syphilis. 
Malaria. Malaria is endemic in many tropical and subtropical regions of the world. Over 
300 million people worldwide are infected, with 1 million fatalities annually. The causative 
agent of malaria is Plasmodium, which has 4 species, namely the following; Plasmodium 
falciparum, P. Malariae, P. Ovale and P. Vivax. Malaria is spread mainly through mosquito 
bites, but cases have been reported about transfusion-transmitted malaria. The risk of spread 
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depends on the prevalence of the disease. In highly endemic areas prevalence of malaria is 
high among donors. In areas with low malara prevalence, donors who are recent travelers or 
who are immigrants from endemic areas are potential sources for transmission of the infec
tion. The FDA recommends that donors with a history of malaria be deferred for 3 years after 
becoming asymptomatic. Provided that donors are asymptomatic, travelers to endemic areas 
are deferred for 1 year in most developed countries. Malaria is a real public health problem 
in Africa. In spite of this fact, there is no consensus for measures to prevent post-transfusion 
malaria in endemic areas. Malaria remains a rare but serious complication of transfusion be
cause of the asymptomatic persistence of parasites in some donors. In non-endemic countries, 
the predominant strategy of deferral or cellular component discard from “high risk” donors 
is effective in minimizing the incidence but wasteful. In endemic countries where recipients 
are commonly immune, transfusion strategies focus on chemoprophylaxis for the donor and 
recipient or ensure that blood collected in highly endemic regions is not transfused to patients 
from areas of low endemicity. Cheap and inexpensive giemsa-stained blood films examina
tion can be a readily available minimal alternative to other more expensive malaria screening 
methods particularly in low income countries in sub Saharan Africa. The risk of introducing 
an unsafe-potentially dangerous transfusion-transmitted malaria is often lethal particularly 
Plasmodium falciparum infection. The administration of antimalarials to transfusion recipi
ents may help to prevent transmission. Nonetheless, no matter what strategy is adopted, it is 
likely that cases of transfusion-transmitted malaria may still occur, so malaria must always be 
considered in any patient with a febrile illness post-transfusion.
Screening donated blood for hepatitis C virus (HCV) is important for HCV preven
tion and is routinely practiced in most countries. The risk of HCV transmission through the 
transfusion of unscreened blood has led to be the systematic screening of blood donors in 
many settings in sub Saharan Africa. HCV is recognized as the primary cause worldwide of 
transfusion-associated non-A-non-B viral hepatitis and is endemic in West Africa. HCV an
tibody is detected 70 days after infection. NAT testing can detect HCV viral RNA in infected 
donors as low as 10 days following infection. Its use can significantly reduce the risk of the 
window phase. HCV is a spherical, enveloped, single-stranded RNA virus belonging to the 
Flaviviridae family. The World Health Organization (WHO) estimates 170 million individuals 
worldwide are infected with HCV. HCV is predominantly transmitted by means of percuta
neous exposure to infected blood. In developed countries, most new HCV infections are re
lated to intravenous drug abuse and are found because of intensive screening. The screening 
of blood donors for the HCV antibody has decreased the risk of transfusion-associated HCV 
infection significantly. The use of polymerase chain reaction (PCR) in some countries has 
further reduced the risk of acquiring HCV from blood transfusions to 1 in 230,000 donations. 
Blood transfusion was a major risk for acute HCV infection in the past. The screening of blood 
donors by donor history and elevated serum alanine aminotransferase (ALT) caused a strik
ing reduction of non-A, non-B posttransfusion hepatitis. Detection of HCV infection by MP-
NAT is the standard of care in most developed countries for the detection of the viral RNA. 
The HCV MP-NAT has reduced the window period for the detection of infection by 80-90% 
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are deferred for 1 year in most developed countries. Malaria is a real public health problem 
in Africa. In spite of this fact, there is no consensus for measures to prevent post-transfusion 
malaria in endemic areas. Malaria remains a rare but serious complication of transfusion be-
cause of the asymptomatic persistence of parasites in some donors. In non-endemic countries, 
the predominant strategy of deferral or cellular component discard from “high risk” donors 
is effective in minimizing the incidence but wasteful. In endemic countries where recipients 
are commonly immune, transfusion strategies focus on chemoprophylaxis for the donor and 
recipient or ensure that blood collected in highly endemic regions is not transfused to patients 
from areas of low endemicity. Cheap and inexpensive giemsa-stained blood films examina-
tion can be a readily available minimal alternative to other more expensive malaria screening 
methods particularly in low income countries in sub Saharan Africa. The risk of introducing 
an unsafe-potentially dangerous transfusion-transmitted malaria is often lethal particularly 
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ents may help to prevent transmission. Nonetheless, no matter what strategy is adopted, it is 
likely that cases of transfusion-transmitted malaria may still occur, so malaria must always be 
considered in any patient with a febrile illness post-transfusion.
HCV. Screening donated blood for hepatitis C virus (HCV) is important for HCV preven-
tion and is routinely practiced in most countries. The risk of HCV transmission through the 
transfusion of unscreened blood has led to be the systematic screening of blood donors in 
many settings in sub Saharan Africa. HCV is recognized as the primary cause worldwide of 
transfusion-associated non-A-non-B viral hepatitis and is endemic in West Africa. HCV an-
tibody is detected 70 days after infection. NAT testing can detect HCV viral RNA in infected 
donors as low as 10 days following infection. Its use can significantly reduce the risk of the 
window phase. HCV is a spherical, enveloped, single-stranded RNA virus belonging to the 
Flaviviridae family. The World Health Organization (WHO) estimates 170 million individuals 
worldwide are infected with HCV. HCV is predominantly transmitted by means of percuta-
neous exposure to infected blood. In developed countries, most new HCV infections are re-
lated to intravenous drug abuse and are found because of intensive screening. The screening 
of blood donors for the HCV antibody has decreased the risk of transfusion-associated HCV 
infection significantly. The use of polymerase chain reaction (PCR) in some countries has 
further reduced the risk of acquiring HCV from blood transfusions to 1 in 230,000 donations. 
Blood transfusion was a major risk for acute HCV infection in the past. The screening of blood 
donors by donor history and elevated serum alanine aminotransferase (ALT) caused a strik-
ing reduction of non-A, non-B posttransfusion hepatitis. Detection of HCV infection by MP-
NAT is the standard of care in most developed countries for the detection of the viral RNA. 
The HCV MP-NAT has reduced the window period for the detection of infection by 80-90% 
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when compared with HCV testing by detection of antibodies. Hepatitis C–positive donors are 
permanently deferred from blood donations.
HIV. HIV is a member of the Lentivirus family of retroviruses. It is the causative agent of acquired 
immunodeficiency syndrome (AIDS). Blood transfusion continues to be an important route of 
transmission of HIV particularly in developing countries among young children and pregnant 
women following transfusion for malaria associated anaemia and pregnancy-related complica-
tions. HIV antibody is detectable 40 days after infection. HIV RNA is detectable in blood after 
15-20 days after infection. HIV antigen is detectable by 20 days post infection. Most countries now 
use dual HIV antibody/antigen test to further prevent the likelihood of transfusing HIV infected 
unit during the window phase of infection. The window phase is the period between infection 
until the first detectable marker is observed. However during this period, antibody screen is nega-
tive but the blood is potentially infective. Most HIV antibody test are ELISA (enzyme linked im-
munosorbent assay). NAT testing has been introduced in most countries for the direct detection 
of the HIV virus by specific nucleic acid amplification. This method can detect infection in blood 
donors significantly earlier in the window phase of infection than conventional serological assays. 
Examples of NAT test includes the TMA or Transcription Mediated Amplification (sample prepa-
ration, amplification and detection phases) and the PCR test (Polymerase Chain Reaction). The 
PCR test involves 4 major steps (Extraction, reverse transcription, amplification and detection). 
HIV-positive individuals are permanently deferred from blood donations.
HBV. HBV is a Hepadna virus that is capable of withstanding extreme temperatures and 
humidity. Hepatitis B is a worldwide healthcare problem, especially in developing areas. An 
estimated one third of the global population has been infected with HBV. Approximately 300 
million people are lifelong carriers, and only 2% spontaneously seroconvert annually. HBV 
is transmitted hematogenously and sexually. The outcome of this infection ranges from com-
plicated viral-host interactions that result in either an acute symptomatic disease, an asymp-
tomatic disease, or a chronic carrier state. Later consequences are cirrhosis and the develop-
ment of hepatocellular carcinoma (HCC). Hepatitis B surface antigen (HBsAg) detection is a 
routine in many parts of the world. However, some chronic carriers have such a low viral load 
that screening by HBsAg may not be able to detect the infection in the donor. To overcome 
this obstacle, many blood banks in several countries also attempt to detect antibody against 
the hepatitis B core antigen (anti-HBcAg or anti-HBc). The core antibody develops early in the 
course of the infection and remains positive even in patients with low-level viremia. NAT has 
tremendous potential in this area of transfusion medicine. Hepatitis B–positive donors are 
permanently deferred from giving blood. The HBV is highly contagious and transmission of 
HBV occurs via percutaneous or permucosal routes, and infective blood or body fluids intro-
duced at birth, through sexual contact or by contaminated needles. Transfusion-transmitted 
HBV infection is increasingly becoming a major mode of transmission of HBV in high-preva-
lence areas in sub-Saharan Africa. 
Cytomegalovirus. Cytomegalovirus (CMV) belongs to the herpes group of viruses. The organ-
ism’s transmission is prevented by transfusing leukocyte-depleted blood products, which is 
consistent with the fact that CMV is a leukocyte-associated pathogen. The organism is a major 
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concern when it comes to transfusing immunocompromised hosts. For this reason, all immu
nocompromised patients are given CMV-seronegative or leukocyte-depleted blood products. 
Transfusions of blood products are associated with several complications, which can be 
broadly categorized as immunologic transfusion reactions, or non-immunologic complica
tions. Immunologic reactions include acute hemolytic reactions, delayed hemolytic reac
tions, febrile non-hemolytic reactions, allergic reactions, and post transfusion purpura (PTP). 
Non-immunologic complications include infections; transfusion associated cardiac overload 
(TACO), transfusion-related acute lung injury (TRALI), and hypothermia and transfusion 
transmissible infections (TTI’S). The risks of complications usually increase with increasing 
frequency and volume of transfusion.
 Acute haemolytic reactions occur with transfusion of red blood 
cells, and occur in about 0.016 percent of transfusions, with about 0.003 percent being fa
tal. This is usually due to ABO incompatibility between donor and recipients (for example a 
group A and B red cells given in error to an O recipient) resulting in the destruction of donor 
red cells by the group specific antibodies in the recipient. Usually this type of reaction oc
curs as a result of clerical error resulting from a sample mismatch at venepuncture or patient 
misidentification during the bed side check. The anti A and /or anti B in the recipient plasma 
often react with A or B antigens on the donors red cells resulting in intravascular haemolysis. 
Signs and symptoms usually occur after 5-10 mls of donor red cells have been transfused. 
Patients may feel agitated, flushed, feel pain in the venepuncture site, show pain in the abdo
men. Other symptoms include; fever, hypotension chills, chest pain, back pain, bleeding from 
wound and venepuncture site, increased heart rate and shortness of breath, haemglobinuria, 
disseminated intravascular coagulation and acute renal failure. It is often important to note 
that another patient may be potentially at risk due to a reciprocal error. When suspected, 
transfusion should be stopped immediately, and blood sent for tests to evaluate for presence 
of hemolysis. Laboratory investigation should include; a fall in haemoglobin, rise in lactate 
dehydrogenase, positive direct antihuman globulin test (DAT) and a serological incompatibil
ity should be observed between the post transfusion sample from the patient and the donor 
sample. Treatment is usually supportive and is aimed at preventing kidney injury resulting 
from the deposition of haemoglobin pigment on the kidney resulting in nephropathy.
Delayed haemolytic transfusion reaction occurs more fre
quently (about 0.025 percent of transfusions) and is due to the same mechanism as in acute 
haemolytic reactions. Patients in most cases may have been previously immunised by a red 
cell antigen or by a previous pregnancy and the antibody may have fallen to an undetect
able level. If the antigen is encountered again in a subsequently transfusion, the subsequent 
encounter can become a booster dose and the antibody level is boosted by this secondary 
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this obstacle, many blood banks in several countries also attempt to detect antibody against 
the hepatitis B core antigen (anti-HBcAg or anti-HBc). The core antibody develops early in the 
course of the infection and remains positive even in patients with low-level viremia. NAT has 
tremendous potential in this area of transfusion medicine. Hepatitis B–positive donors are 
permanently deferred from giving blood. The HBV is highly contagious and transmission of 
HBV occurs via percutaneous or permucosal routes, and infective blood or body fluids intro
duced at birth, through sexual contact or by contaminated needles. Transfusion-transmitted 
HBV infection is increasingly becoming a major mode of transmission of HBV in high-preva
lence areas in sub-Saharan Africa. 
 Cytomegalovirus (CMV) belongs to the herpes group of viruses. The organ
ism’s transmission is prevented by transfusing leukocyte-depleted blood products, which is 
consistent with the fact that CMV is a leukocyte-associated pathogen. The organism is a major 
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concern when it comes to transfusing immunocompromised hosts. For this reason, all immu-
nocompromised patients are given CMV-seronegative or leukocyte-depleted blood products. 
12. Complications of blood transfusion
Transfusions of blood products are associated with several complications, which can be 
broadly categorized as immunologic transfusion reactions, or non-immunologic complica-
tions. Immunologic reactions include acute hemolytic reactions, delayed hemolytic reac-
tions, febrile non-hemolytic reactions, allergic reactions, and post transfusion purpura (PTP). 
Non-immunologic complications include infections; transfusion associated cardiac overload 
(TACO), transfusion-related acute lung injury (TRALI), and hypothermia and transfusion 
transmissible infections (TTI’S). The risks of complications usually increase with increasing 
frequency and volume of transfusion.
Immunologic reactions
Acute haemolytic reactions. Acute haemolytic reactions occur with transfusion of red blood 
cells, and occur in about 0.016 percent of transfusions, with about 0.003 percent being fa-
tal. This is usually due to ABO incompatibility between donor and recipients (for example a 
group A and B red cells given in error to an O recipient) resulting in the destruction of donor 
red cells by the group specific antibodies in the recipient. Usually this type of reaction oc-
curs as a result of clerical error resulting from a sample mismatch at venepuncture or patient 
misidentification during the bed side check. The anti A and /or anti B in the recipient plasma 
often react with A or B antigens on the donors red cells resulting in intravascular haemolysis. 
Signs and symptoms usually occur after 5-10 mls of donor red cells have been transfused. 
Patients may feel agitated, flushed, feel pain in the venepuncture site, show pain in the abdo-
men. Other symptoms include; fever, hypotension chills, chest pain, back pain, bleeding from 
wound and venepuncture site, increased heart rate and shortness of breath, haemglobinuria, 
disseminated intravascular coagulation and acute renal failure. It is often important to note 
that another patient may be potentially at risk due to a reciprocal error. When suspected, 
transfusion should be stopped immediately, and blood sent for tests to evaluate for presence 
of hemolysis. Laboratory investigation should include; a fall in haemoglobin, rise in lactate 
dehydrogenase, positive direct antihuman globulin test (DAT) and a serological incompatibil-
ity should be observed between the post transfusion sample from the patient and the donor 
sample. Treatment is usually supportive and is aimed at preventing kidney injury resulting 
from the deposition of haemoglobin pigment on the kidney resulting in nephropathy.
Delayed haemolytic reactions. Delayed haemolytic transfusion reaction occurs more fre-
quently (about 0.025 percent of transfusions) and is due to the same mechanism as in acute 
haemolytic reactions. Patients in most cases may have been previously immunised by a red 
cell antigen or by a previous pregnancy and the antibody may have fallen to an undetect-
able level. If the antigen is encountered again in a subsequently transfusion, the subsequent 
encounter can become a booster dose and the antibody level is boosted by this secondary 
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immune response causing extravascular haemolysis. A delayed haemolytic reaction occurs 
when a patient develops an antibody directed against an antigen on transfused red cells. The 
antibody may cause shortened red cell survival, with clinical features of fever, jaundice and 
lower than expected haemoglobin following transfusion. Most delayed haemolytic reactions 
produce few symptoms and may go unrecognised. Delayed haemolytic reaction can be mini-
mized by performing an antibody screen as part of pre-transfusion testing for all prospective 
transfusion recipients. When an antibody is detected, it must be identified and appropriate 
antigen negative blood provided. Sometimes antibodies fall below detectable limits and may 
not be detected by pretransfusion testing. There may also be a rise in the LDH level, positive 
post transfusion DAT, spherocytes in the peripheral blood film, incompatible IAT post trans-
fusion crossmatch and antibody screen and fever and mild to severe renal failure. Treatment 
is generally not needed, but due to the presence of recipient antibodies, future compatibility 
may be affected.
Non-haemolytic febrile transfusion reactions (NHFTR). Non-haemolytic febrile transfusion 
reactions are due to anti-leucocyte antibodies in a previously transfused or pregnant patient 
reacting with the leucocytes in donor unit. It can also arise from the release of cytokines in 
stored platelets causing an inflammatory response in the patient. Occur in 1-2% of recipients. 
Symptoms include fever, shivering and general discomfort associated with less that 1°C rise 
in baseline temperature or <38 °C is generally observed. Patient must be monitored for esca-
lating symptoms. A fever of > 1°C above the baseline or > 38 °C particularly when there is no 
apparent pre-existing infective cause is a trigger to stop the transfusion. Transfusion of leu-
codepleted unit minimizes the incidence of NHFTR which occur in 1% of all transfusion and 
in up to 45% of multi transfused patients who receive non-leucodepleted units. Management 
includes slowing the transfusion and giving 1g paracetamol. Perform more frequent observa-
tions and monitor patient for additional /escalating symptoms. If symptoms do not resolve 
after 30 minutes with these measures, stop the transfusion. A febrile reaction in a neutropenic 
patient should have a blood culture and intravenous meropenim started.
Allergic reactions. Urticaria reaction occurs as results of immediate (class1) hypersensitivity 
reaction resulting from IgE antibodies in patients reacting with transfused plasma protein 
in the donor. Urticaria reaction occurs commonly with FFP and platelet transfusion. Symp-
toms include urticaria, pruritis, and wheal and flare reaction and rashes usually occur within 
minutes of the start of the transfusion and may sometimes be delayed. Swelling of lips or 
mouth or severe hypotension indicates a more serious reaction and may proceed to anaphy-
lactic shock. A few patients that are IgA deficient develop antibodies to IgA. Some of these 
patients (0.13%) experience severe anaphylaxis if exposed to IgA-containing blood in donor 
unit. Signs and symptoms include hypotension, dyspnoea, stridor, wheezing, angioedema, 
pruritis and urticaria. Laboratory investigation should include the determination of IgA and 
anti IgA level. Mast cell tryptase may be useful in differentiating between allergic and ana-
phylactic reactions. Blood gases and chest X-ray may be required if patient becomes hypoxic. 
Transfusion associated graft versus host disease (TGVHD). Engraftment of donor lym-
phocytes into an immunocompromised patient can result in TGVHD. The donor leukocyte 
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(graft) often proliferates in the host patient causing a rejection of a variety of the host tissues. 
It often occurs when non-irradiated red cell or platelet units are transfused to certain im
munocompromised patients such as those treated with purine analogues such as; recipients 
of blood from biologically related (directed) or HLA matched donors’, Intrauterine and all 
subsequent transfusion and exchange transfusion recipients, patients with congenital cellu
lar immunodeficiency, patients receiving granulocyte transfusions, patients with Hodgkin’s 
Disease, peripheral blood stem cell (PBSC) and bone marrow transplant recipients, patients 
with aplastic anaemia receiving immunosuppressive therapy and patients treated with pu
rine analogue drugs such as fludarabine. TAGVD can be minimised by transfusing such pa
tients with gamma irradiated red cells, whole blood, granulocytes and platelet. Irradiation 
inactivates donor leucocytes and thus helps minimize the incidence of TGVHD. Signs and 
symptoms include; fever, skin rash, diarrhoea, hepatorenal failure and pancytopenia (fall in 
haemoglobin, white cells and platelet count occurring 4-30 days after transfusion). Labora
tory investigation will show pancytopenia on a full blood count, impaired renal and liver 
function test and skin biopsy and PCR may demonstrate the presence of donor DNA.
Post transfusion purpura (PTP). Post transfusion purpura is rare immune-mediated throm
bocytopenias often occurring in parous women. Severe thrombocytopenia and bleeding 
usually develop 5-9 days post transfusion. This complication often occurs after transfusion 
containing platelets that express a surface protein HPA-1a. Recipients who lack this protein 
develop sensitization to this protein from prior transfusions, and develop thrombocytopenia 
about 7–9 days after subsequent transfusions. Platelet counts are often very low. Alloanti
bodies against Human Platelet Antigen HPA1a are detectable in the patient’s plasma. Plate
let transfusion should be avoided. However if there is life threatening hemorrhage, HPA1A 
negative platelet is often preferred to platelet from a random donor. Treatment is with intra
venous immunoglobulin, and recipients should only receive future transfusions with washed 
cells or HPA-1a negative cells. PTP may also occur as a result of sequestration of micro ag
gregates of fibrin, leucocytes and platelets in the spleen. These aggregates are often formed as 
the length of storage of donated blood increases. This risk is often minimised by use of filters 
during transfusion.
Transfusion-associated acute lung injury (TRALI). Transfusion-associated acute lung injury 
(TRALI) is an increasingly recognized adverse event associated with blood transfusion. TRA
LI is typically associated with plasma components rather than packed red blood cells (RBCs), 
though there is some residual plasma in RBC units. TRALI is a syndrome of acute respira
tory distress, often associated with fever, non-cardiogenic pulmonary edema, and hypotension, 
which may occur 0.05% of recipients. It is usually due to the presence of anti-leucocyte antibod
ies in the plasma of donor unit which react with recipient leucocytes causing a severe inflam
matory reaction in the patient lungs. Symptoms can range from mild to life-threatening rapid 
onset dyspnoea and non-productive cough. Chest x-ray often shows bilateral infiltrates (white-
out appearance). There is often a normal central venous pressure and raised pulmonary wedge 
pressure. Patients are often not hypervolaemic and do not have a cardiac or infective cause. The 
occurrence of acute respiratory disease syndrome occurring within a few hours of transfusion 
should trigger a suspicion of TRALI. Mortality rate from this condition is less than 10%. TRALI 
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(graft) often proliferates in the host patient causing a rejection of a variety of the host tissues. 
It often occurs when non-irradiated red cell or platelet units are transfused to certain im-
munocompromised patients such as those treated with purine analogues such as; recipients 
of blood from biologically related (directed) or HLA matched donors’, Intrauterine and all 
subsequent transfusion and exchange transfusion recipients, patients with congenital cellu-
lar immunodeficiency, patients receiving granulocyte transfusions, patients with Hodgkin’s 
Disease, peripheral blood stem cell (PBSC) and bone marrow transplant recipients, patients 
with aplastic anaemia receiving immunosuppressive therapy and patients treated with pu-
rine analogue drugs such as fludarabine. TAGVD can be minimised by transfusing such pa-
tients with gamma irradiated red cells, whole blood, granulocytes and platelet. Irradiation 
inactivates donor leucocytes and thus helps minimize the incidence of TGVHD. Signs and 
symptoms include; fever, skin rash, diarrhoea, hepatorenal failure and pancytopenia (fall in 
haemoglobin, white cells and platelet count occurring 4-30 days after transfusion). Labora-
tory investigation will show pancytopenia on a full blood count, impaired renal and liver 
function test and skin biopsy and PCR may demonstrate the presence of donor DNA.
Post transfusion purpura (PTP). Post transfusion purpura is rare immune-mediated throm-
bocytopenias often occurring in parous women. Severe thrombocytopenia and bleeding 
usually develop 5-9 days post transfusion. This complication often occurs after transfusion 
containing platelets that express a surface protein HPA-1a. Recipients who lack this protein 
develop sensitization to this protein from prior transfusions, and develop thrombocytopenia 
about 7–9 days after subsequent transfusions. Platelet counts are often very low. Alloanti-
bodies against Human Platelet Antigen HPA1a are detectable in the patient’s plasma. Plate-
let transfusion should be avoided. However if there is life threatening hemorrhage, HPA1A 
negative platelet is often preferred to platelet from a random donor. Treatment is with intra-
venous immunoglobulin, and recipients should only receive future transfusions with washed 
cells or HPA-1a negative cells. PTP may also occur as a result of sequestration of micro ag-
gregates of fibrin, leucocytes and platelets in the spleen. These aggregates are often formed as 
the length of storage of donated blood increases. This risk is often minimised by use of filters 
during transfusion.
Transfusion-associated acute lung injury (TRALI). Transfusion-associated acute lung injury 
(TRALI) is an increasingly recognized adverse event associated with blood transfusion. TRA-
LI is typically associated with plasma components rather than packed red blood cells (RBCs), 
though there is some residual plasma in RBC units. TRALI is a syndrome of acute respira-
tory distress, often associated with fever, non-cardiogenic pulmonary edema, and hypotension, 
which may occur 0.05% of recipients. It is usually due to the presence of anti-leucocyte antibod-
ies in the plasma of donor unit which react with recipient leucocytes causing a severe inflam-
matory reaction in the patient lungs. Symptoms can range from mild to life-threatening rapid 
onset dyspnoea and non-productive cough. Chest x-ray often shows bilateral infiltrates (white-
out appearance). There is often a normal central venous pressure and raised pulmonary wedge 
pressure. Patients are often not hypervolaemic and do not have a cardiac or infective cause. The 
occurrence of acute respiratory disease syndrome occurring within a few hours of transfusion 
should trigger a suspicion of TRALI. Mortality rate from this condition is less than 10%. TRALI 
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has been consistently associated with anti-HLA antibodies. Patients will often require HLA/
HNA antibody screen, HLA typing, blood gases and chest X-ray and a lymphocytotoxic/granu-
locyte crossmatch. The implicated donor unit should be screened for HLA/HNA antibodies. 
Because these types of antibodies are commonly formed during pregnancy, several transfusion 
organizations have decided to use only plasma from men for transfusion. 
Non-immunologic complications
Transfusion-associated cardiac overload (TACO). TACO is a common complication simply due 
to the excessive and rapid infusion of blood products. This is especially the case in elderly recipi-
ents with heart failure and recipients with underlying cardiac or kidney disease. Plasma transfu-
sion is especially prone to causing volume overload due to its hypertonicity. Signs and symptoms 
include dyspnoea, tachypnoea, tachycardia, pulmonary oedema, anxiety, cyanosis, sweating, car-
diac irregularities, hypotension or hypertension and raised jugular venous pressure.
Iron Overload. The human body has no active mechanism for the excretion of iron. Iron 
homeostasis thus relies on the amount that is absorbed from the small intestine. During nor-
mal physiology, the amount of iron absorbed (1-2 mg/d) is lost by sloughing of intestinal 
mucosa and skin, as well as small amounts in the urine and bile. The day-to-day iron require-
ments, as iron is needed by virtually all body cells and especially erythrocytes, are met by re-
cycling between various compartments. In some patients, noticeably those with thalassemia 
major, sickle cell disease, myelodysplastic syndrome, aplastic anemia, hemolytic anemia, and 
refractory sideroblastic anemia, who may become transfusion-dependent and receive excess 
iron with each transfusion (that the body has no means to excrete), iron gradually accumu-
lates in various tissues, causing morbidity and mortality. The accumulation of iron from the 
transfused units can cause tissue damage in the liver, heart and endocrine system. This risk 
can be minimized by the use of chelating agents such as desferrioxamine, deferiprone or de-
ferasirox which help to eliminate the unwanted iron.
Hypothermia. Hypothermia can occur with transfusions with large volume of cold blood 
products. Core body temperature can go down as low as 32 °C and can produce physiologic 
disturbances and cardiac arrest. This can be prevented by warming the blood to ambient tem-
perature prior to transfusions. Rapid infusion of large volumes of stored blood contributes to 
hypothermia in infants particularly during exchange or massive transfusion. Appropriately 
maintained blood warmers should be used during massive or exchange transfusion. 
Citrate toxicity. Citrate is an anticoagulant. It is a component of citrate phosphate dextrose 
adenine (CPDA) used in the preservation of stored blood intended for transfusion. It is usu-
ally rapidly metabolised by the liver. Rapid administration of large quantities of stored blood 
may cause hypocalcaemia and hypomagnesaemia when citrate binds calcium and magnesi-
um. This can result in myocardial depression or coagulopathy. Patients most at risk are those 
with liver dysfunction or neonates with immature liver function having rapid large volume 
transfusion. Slowing or temporarily stopping the transfusion allows citrate to be metabolised. 
Replacement therapy may be required for symptomatic hypocalcaemia or hypomagnesaemia. 
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Hypocalcemia can also occur with massive blood transfusions due to the complex of citrate 
with serum calcium.
 Blood products can rarely be contaminated with bacteria with 
possible subsequent life threatening infection, also known as transfusion transmitted bacte
rial infection. Bacteria may be introduced into the pack at the time of blood collection from 
sources such as donor skin, donor bacteraemia or equipment used during blood collection or 
processing. Bacteria may multiply during storage. Gram positive and Gram negative organ
isms have been implicated. Bacterial contamination of blood can be detected in some cases by 
inspecting the blood products prior to transfusion. Some but not all bacterially contaminated 
products can be recognised (clots, clumps, or abnormal colour). Maintaining appropriate cold 
chain management of red cells in a monitored blood bank refrigerator is important. Transfu
sions should ideally not proceed beyond the recommended infusion time (4 hours). Platelets 
are more frequently implicated than red cells. The reason platelets are more often contami
nated than other blood products is that it is often stored at room temperature. Platelet stored 
for greater than 5 days are more prone to contamination. Signs and symptoms may include 
hyper-pyrexia, rigors, nausea, hypotension, circulatory collapse, vomiting, diarrhoea and ab
dominal pain. Management involves an immediately stop of the transfusion and notification 
of the hospital blood bank. After initial supportive care, blood cultures should be taken and 
broad-spectrum antimicrobials commenced. Diagnosis of transfusion transmitted bacteria is 
made when there is a positive blood culture in the recipient and the identification of same 
contaminant in the donor blood. Patients may need to be managed with intravenous antibiot
ics. The estimated residual risk of contamination of blood products with bacterial agents is 1 
in 5,000 for platelets and 1 in 30,000 for red blood cells. It has been proposed that the higher 
incidence of bacterial transmission via platelets is due to the difference in the storage tem
peratures. Also important is the duration of storage, which has a direct correlation with the 
likelihood of bacterial contamination. An important concept in the evaluation of data regard
ing transfusion-transmitted bacterial infections (TTBIs) is the definition of a case. A widely 
accepted criterion is based upon separation of the cases into possible, probable, and definite 
contamination, and they are defined as follows.
1. Possible contamination: The blood culture from a recipient grows a bacte
rial pathogen, with documentation of no other apparent source, but there 
is failure to isolate the same bacteria from the donor blood product, either 
because the culture is negative or it could not be done. 
2. Probable contamination: The blood culture from the recipient is negative 
or could not be done, but there is definite bacterial growth in the donor 
blood product. 
3. Definite contamination: The blood culture from the recipient and the do
nor blood product grow the same bacteria
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Hypocalcemia can also occur with massive blood transfusions due to the complex of citrate 
with serum calcium.
Infectious complications
Bacterial Contamination. Blood products can rarely be contaminated with bacteria with 
possible subsequent life threatening infection, also known as transfusion transmitted bacte-
rial infection. Bacteria may be introduced into the pack at the time of blood collection from 
sources such as donor skin, donor bacteraemia or equipment used during blood collection or 
processing. Bacteria may multiply during storage. Gram positive and Gram negative organ-
isms have been implicated. Bacterial contamination of blood can be detected in some cases by 
inspecting the blood products prior to transfusion. Some but not all bacterially contaminated 
products can be recognised (clots, clumps, or abnormal colour). Maintaining appropriate cold 
chain management of red cells in a monitored blood bank refrigerator is important. Transfu-
sions should ideally not proceed beyond the recommended infusion time (4 hours). Platelets 
are more frequently implicated than red cells. The reason platelets are more often contami-
nated than other blood products is that it is often stored at room temperature. Platelet stored 
for greater than 5 days are more prone to contamination. Signs and symptoms may include 
hyper-pyrexia, rigors, nausea, hypotension, circulatory collapse, vomiting, diarrhoea and ab-
dominal pain. Management involves an immediately stop of the transfusion and notification 
of the hospital blood bank. After initial supportive care, blood cultures should be taken and 
broad-spectrum antimicrobials commenced. Diagnosis of transfusion transmitted bacteria is 
made when there is a positive blood culture in the recipient and the identification of same 
contaminant in the donor blood. Patients may need to be managed with intravenous antibiot-
ics. The estimated residual risk of contamination of blood products with bacterial agents is 1 
in 5,000 for platelets and 1 in 30,000 for red blood cells. It has been proposed that the higher 
incidence of bacterial transmission via platelets is due to the difference in the storage tem-
peratures. Also important is the duration of storage, which has a direct correlation with the 
likelihood of bacterial contamination. An important concept in the evaluation of data regard-
ing transfusion-transmitted bacterial infections (TTBIs) is the definition of a case. A widely 
accepted criterion is based upon separation of the cases into possible, probable, and definite 
contamination, and they are defined as follows.
1. Possible contamination: The blood culture from a recipient grows a bacte-
rial pathogen, with documentation of no other apparent source, but there 
is failure to isolate the same bacteria from the donor blood product, either 
because the culture is negative or it could not be done. 
2. Probable contamination: The blood culture from the recipient is negative 
or could not be done, but there is definite bacterial growth in the donor 
blood product. 
3. Definite contamination: The blood culture from the recipient and the do-
nor blood product grow the same bacteria
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)90
Viral infections. Transfusion transmissible viral infections include; human immunodeficien-
cy virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), 
hepatitis A virus (HAV), Epstein –Barr virus (EBV), human T-lymphotrophic virus (HTLV) 
and parvovirus B19. It is mandatory in most countries to test all blood donors HIV, HBV and 
HCV. However donors in the window phase of these infections (a period of time a person is 
infectious but has not had time to develop detectable antibodies) may test negative and may 
potentially cause infection in the recipient. Careful and strict donor selection process and 
pathogen reduction methods such as leucodepletion of red cells and platelets (reduce risk of 
CMV which is carried within the leucocyte) and solvent/detergent treatment of plasma frac-
tions can potentially reduce the risk of transmission. HAV and parvovirus infection can be 
reduced by pooling plasma. A significant number of donors in the pool may have antibodies 
to these viruses. The development of a nucleic acid test for the HIV-1 RNA has dramatically 
lowered the rate of donor blood seropositivity to about 1 in 3 million units in countries where 
this technology is available. The transmission of hepatitis C via transfusion currently stands 
at about a rate of 1 in 2 million units. Such low rates have mostly been attributed to the ability 
to screen for both antibody as well as nucleic acid testing for viral RNA in donor blood.
Protozoan infection. Protozoal infections are endemic in mainly tropical low income coun-
tries, affecting millions of people. Malaria, trypanosomiasis (Trypanosoma cruzi/Chagas 
disease) and protozoal tick borne diseases (Babesia), toxoplasmosis and filariasis can be 
efficiently transmitted by transfusion of cellular blood components. In non-endemic are-
as like Europe malaria, Chagas disease and Babesia are imported diseases resulting from 
travelling to endemic areas. Prevention of transfusion-associated protozoal infections in 
most development and non-endemic countries depends mainly on selection of donors us-
ing questionnaires. In most of these countries donors at risk for malaria are often deferred 
for a period of time.
Trypanosoma cruzi. T cruzi is the causative agent of Chagas disease, which is generally spread 
by the bite of the reduviid bug. The illness has an acute and a chronic form. The acute form 
principally affects children in endemic areas that include Central and South America and parts 
of Mexico and manifests as fever, lymphadenopathy, and hepatosplenomegaly. In severe cases, 
myocarditis and encephalitis may occur. The disease may take a more indolent course, and after 
a latency of decades, it can present with serious end-organ damage, causing chagasic cardiomy-
opathy and megaesophagus. Individuals from endemic areas may become chronic carriers of 
the T cruzi parasite and are responsible for transmission of T cruzi through blood transfusion. 
Such cases are well known in high-prevalence areas. Seroprevalence in the US ranges from 0.12 
to 0.20%, but only 7 cases have been reported to be transmitted by blood. Serologic testing and 
deferral of positive donors is a policy in endemic countries, and an enzyme-linked immuno-
sorbent assay (ELISA)–based screening test has been instituted in the US as well. 
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 is an intraerythrocytic protozoan parasite that produces a malarialike illness and is 
the principal cause of human babesiosis. The majority of the cases have been reported from 
the Northeast. The common mode of transmission is via an Ixodes tick bite, but B microti can 
also be acquired via transfusion of infected blood. The clinical spectrum of B microti infec
tion ranges from asymptomatic individuals to severe disease with massive parasitemias that 
cause haemolytic anaemia thrombocytopenia, shock, and death. The risk of severe infection 
is particularly high in patients who have HIV infection, have had a splenectomy, or are im
munosuppressed. Leukoreduction does not reduce the transmission risk because B microti is 
intraerythrocytic.
 L donovani belongs to a group of intracellular parasites. The com
mon mode of transmission is a bite by sandflies of the genus Phlebotomus. Cases have been 
reported in highly endemic areas regarding transmission by transfusion of blood products. 
For this reason, people returning from war zones in Iraq are being deferred from donations 
for 1 year in some developed countries.
. A mosquito-borne flavivirus infection causing encephalitis. Recent seasonal 
epidemics have occurred in North America. West Nile virus can be transmitted by blood do
nated during the viraemic phase. During the epidemic season, donors may not give blood in 
the UK for 28 days after returning from an affected area unless a test for viral RNA is negative. 
Through the years, a great controversy had arisen over the 
need for syphilis testing of blood donors. Although the American Association of Blood Banks 
(AABB) initially dropped its recommendation that donors be tested for syphilis in 1978, the 
Food and Drug administration (FDA) of the United States keeps on this requirement. This de
cision was reinforced by the HIV epidemic. It is now recommended in most countries that sur
rogate testing including syphilis should be done to prevent those at risk from donating blood.
Creutzfeldt - Jakob disease (CJD). Creutzfeldt - Jakob disease (CJD) is a form of the human 
transmissible spongiform encephalopathies (TSEs) and is characterized by mental deteriora
tion, cerebellar dysfunctions, involuntary movements, and psychiatric alterations. CJD is a 
rare disease and occurs at a rate of approximately 1 per million populations annually. The risk 
of transmission of CJD through blood transfusion has not been established, but it cannot be 
completely ruled out. The disease has a long incubation period, and studies and surveillance 
programs have not lasted long enough or included sufficient numbers of cases to conclude 
that CJD is transmitted through blood transfusion. Many people are concerned that it may be 
possible to transmit CJD through blood and related blood products such as plasma. Some ani
mal studies suggest that contaminated blood and related products may transmit the disease, 
although this has never been shown in humans.
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Transfusion transmissible viral infections include; human immunodeficien
cy virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), 
hepatitis A virus (HAV), Epstein –Barr virus (EBV), human T-lymphotrophic virus (HTLV) 
and parvovirus B19. It is mandatory in most countries to test all blood donors HIV, HBV and 
HCV. However donors in the window phase of these infections (a period of time a person is 
infectious but has not had time to develop detectable antibodies) may test negative and may 
potentially cause infection in the recipient. Careful and strict donor selection process and 
pathogen reduction methods such as leucodepletion of red cells and platelets (reduce risk of 
CMV which is carried within the leucocyte) and solvent/detergent treatment of plasma frac
tions can potentially reduce the risk of transmission. HAV and parvovirus infection can be 
reduced by pooling plasma. A significant number of donors in the pool may have antibodies 
o these viruses. The development of a nucleic acid test for the HIV-1 RNA has dramatically 
lowered the rate of donor blood seropositivity to about 1 in 3 million units in countries where 
this technology is available. The transmission of hepatitis C via transfusion currently stands 
at about a rate of 1 in 2 million units. Such low rates have mostly been attributed to the ability 
to screen for both antibody as well as nucleic acid testing for viral RNA in donor blood.
Protozoan infection. Protozoal infections are endemic in mainly tropical low income coun
tries, affecting millions of people. Malaria, trypanosomiasis (Trypanosoma cruzi/Chagas 
disease) and protozoal tick borne diseases (Babesia), toxoplasmosis and filariasis can be 
efficiently transmitted by transfusion of cellular blood components. In non-endemic are
as like Europe malaria, Chagas disease and Babesia are imported diseases resulting from 
travelling to endemic areas. Prevention of transfusion-associated protozoal infections in 
most development and non-endemic countries depends mainly on selection of donors us
ing questionnaires. In most of these countries donors at risk for malaria are often deferred 
for a period of time.
Trypanosoma cruzi. T cruzi is the causative agent of Chagas disease, which is generally spread 
by the bite of the reduviid bug. The illness has an acute and a chronic form. The acute form 
principally affects children in endemic areas that include Central and South America and parts 
of Mexico and manifests as fever, lymphadenopathy, and hepatosplenomegaly. In severe cases, 
myocarditis and encephalitis may occur. The disease may take a more indolent course, and after 
a latency of decades, it can present with serious end-organ damage, causing chagasic cardiomy
opathy and megaesophagus. Individuals from endemic areas may become chronic carriers of 
the T cruzi parasite and are responsible for transmission of T cruzi through blood transfusion. 
Such cases are well known in high-prevalence areas. Seroprevalence in the US ranges from 0.12 
to 0.20%, but only 7 cases have been reported to be transmitted by blood. Serologic testing and 
deferral of positive donors is a policy in endemic countries, and an enzyme-linked immuno
sorbent assay (ELISA)–based screening test has been instituted in the US as well. 
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Babesia microti
B microti is an intraerythrocytic protozoan parasite that produces a malarialike illness and is 
the principal cause of human babesiosis. The majority of the cases have been reported from 
the Northeast. The common mode of transmission is via an Ixodes tick bite, but B microti can 
also be acquired via transfusion of infected blood. The clinical spectrum of B microti infec-
tion ranges from asymptomatic individuals to severe disease with massive parasitemias that 
cause haemolytic anaemia thrombocytopenia, shock, and death. The risk of severe infection 
is particularly high in patients who have HIV infection, have had a splenectomy, or are im-
munosuppressed. Leukoreduction does not reduce the transmission risk because B microti is 
intraerythrocytic.
Leishmania donovani. L donovani belongs to a group of intracellular parasites. The com-
mon mode of transmission is a bite by sandflies of the genus Phlebotomus. Cases have been 
reported in highly endemic areas regarding transmission by transfusion of blood products. 
For this reason, people returning from war zones in Iraq are being deferred from donations 
for 1 year in some developed countries.
West Nile virus. A mosquito-borne flavivirus infection causing encephalitis. Recent seasonal 
epidemics have occurred in North America. West Nile virus can be transmitted by blood do-
nated during the viraemic phase. During the epidemic season, donors may not give blood in 
the UK for 28 days after returning from an affected area unless a test for viral RNA is negative. 
Treponemal infections (syphilis. Through the years, a great controversy had arisen over the 
need for syphilis testing of blood donors. Although the American Association of Blood Banks 
(AABB) initially dropped its recommendation that donors be tested for syphilis in 1978, the 
Food and Drug administration (FDA) of the United States keeps on this requirement. This de-
cision was reinforced by the HIV epidemic. It is now recommended in most countries that sur-
rogate testing including syphilis should be done to prevent those at risk from donating blood.
Creutzfeldt - Jakob disease (CJD). Creutzfeldt - Jakob disease (CJD) is a form of the human 
transmissible spongiform encephalopathies (TSEs) and is characterized by mental deteriora-
tion, cerebellar dysfunctions, involuntary movements, and psychiatric alterations. CJD is a 
rare disease and occurs at a rate of approximately 1 per million populations annually. The risk 
of transmission of CJD through blood transfusion has not been established, but it cannot be 
completely ruled out. The disease has a long incubation period, and studies and surveillance 
programs have not lasted long enough or included sufficient numbers of cases to conclude 
that CJD is transmitted through blood transfusion. Many people are concerned that it may be 
possible to transmit CJD through blood and related blood products such as plasma. Some ani-
mal studies suggest that contaminated blood and related products may transmit the disease, 
although this has never been shown in humans.
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13. Investigation of Blood transfusion reactions
Blood transfusion is the process of receiving blood products into one’s circulation intrave-
nously. Transfusions are indicated in a variety of medical conditions to replace lost com-
ponents of the blood. Early transfusions used whole blood, but modern evidenced based 
medical practice commonly uses only components of the blood, such as red blood cells, 
white blood cells, platelet, fresh frozen plasma and cryoprecipitate. Transfusion reactions 
are unintended responses in a patient which are associated with the transfusion of blood or 
blood component. These reaction may be fatal, life-threatening, incapacitating and result 
in prolong hospitalization and morbidity. Patients receiving transfusion of blood products 
must be monitored closely for clinical signs of transfusion reactions. The patient’s tempera-
ture, pulse, blood pressure and respiratory rate must be determined prior to starting the 
transfusion and regularly during and after the transfusion (to detect signs of delayed trans-
fusion reaction). It is recommended to retain all used transfusion bags for 24 hours before 
discard. This is to ensure that the donor red cells are available if a transfusion a reaction 
needs to be investigated.
Pre-transfusion testing. The pre-transfusion testing is made up of the following procedure 
aimed at ensuring that blood provided for transfusion is compatible and will accomplish the 
desired aim of improving patient haemoglobin, improving anaemia and improving the oxy-
gen delivery to tissues. The pre-transfusion testing should include the following procedures:
1. Checking the previous transfusion records of patients (manually or com-
puter) for previous grouping and antibody screening result.
2. Check and ensure that the details of patient on request form and hand 
labelled sample match and contain the minimum data set.
3. Determination of patient ABO and Rhesus blood group using appropri-
ate reagents that have been quality controlled.
4. Performance of antibody screen of patient or mother in case of neonatal 
transfusion. Identification of alloantibodies in patient with a positive an-
tibody screen.
5. Selection of appriopriate unit for crossmatching. Unit should be negative 
for antigen for which patient alloantibody is specific.
6. Crossmatching of patient serum and plasma against the donors red cells 
(Electronic issue, One tube spin or full IAT crossmatch depending on in-
dication).
7. Prepare a worksheet and record all crossmatching testing results. Label 
units with compatibility labels. Record the batch numbers of reagents used. 
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Check that reagents are in date before use. Ensure that equipment have 
had daily maintenance done before use. Sign and date all worksheet.
8. Has the record and testing result been crosschecked. 
Blood grouping must include both a forward (red cell) group and back (se
rum grouping) using IgM monoclonal anti A, B and AB (cell or forward group) and A1, B cells 
(for serum or back group). A negative control of patient own red cells versus serum or plasma 
or patient plasma against O cell must be included. 
The rhesus D blood group of a patient can be performed using two differ
ent batches of IgM monoclonal anti-D reagents. Reagents must be appriopriately controlled 
against D positive (positive control) and D negative red cells (negative control). Observed 
ABO and Rh D group of patient must be compared with previous group in patient records 
before appriopriate units are selected. All discripancies must be investigated before units are 
selected for crossmatch.
The aim of antibody screening is to detect the presence of alloantibody 
to enable the selection of units that are negative for the antigen to which the alloantibody is 
specific. The aim is to detect the presence of clinically significant antibodies in the patient 
plasma, select antigen negative units and prevent immediate or delayed transfusion reaction 
as well as ensuring that the transfused red cells survives optimally in the patient circulation. 
Antibody screening invoves testing a patient’s serum/plasma by IAT against 2 or 3 antibody 
screening cells. If antibody screening result is positive, the specificity of the antibody is car
ried out using a panel of cells (AHG and enzyme) with known antigen status.
Before a recipient receives a transfusion, compatibility testing between donor and recipient 
blood must be done. The first step before a transfusion is given is to type and screen the recipi
ent’s blood. Typing of recipient’s blood determines the ABO and Rh status. The sample is then 
screened for any alloantibodies that may react with donor blood. It takes about 45 minutes to 
complete (depending on the method used). The blood bank labotatory scientist also checks 
for special requirements of the patient (e.g. need for washed, irradiated or CMV negative 
blood) and the history of the patient to see if they have a previously identified antibody. A 
positive screen warrants an antibody panel/investigation to determine if it is clinically signifi
cant. An antibody panel consists of commercially prepared group O red cell suspensions from 
donors that have been phenotyped for commonly encountered and clinically significant al
loantibodies. Donor cells may have homozygous (e.g. K+k-), heterozygous (K+ k+) expression 
or no expression of various antigens (K-k+). The phenotypes of all the donor cells being tested 
are shown in a chart. The patient’s serum is tested against the various donor cells using an 
enhancement method, e.g. Gel or LISS. Based on the reactions of the patient’s serum against 
the donor cells, a pattern will emerge to confirm the presence of one or more antibodies. Not 
Blood transfusion is the process of receiving blood products into one’s circulation intrave
nously. Transfusions are indicated in a variety of medical conditions to replace lost com
ponents of the blood. Early transfusions used whole blood, but modern evidenced based 
medical practice commonly uses only components of the blood, such as red blood cells, 
white blood cells, platelet, fresh frozen plasma and cryoprecipitate. Transfusion reactions 
are unintended responses in a patient which are associated with the transfusion of blood or 
blood component. These reaction may be fatal, life-threatening, incapacitating and result 
in prolong hospitalization and morbidity. Patients receiving transfusion of blood products 
must be monitored closely for clinical signs of transfusion reactions. The patient’s tempera
ture, pulse, blood pressure and respiratory rate must be determined prior to starting the 
transfusion and regularly during and after the transfusion (to detect signs of delayed trans
fusion reaction). It is recommended to retain all used transfusion bags for 24 hours before 
discard. This is to ensure that the donor red cells are available if a transfusion a reaction 
needs to be investigated.
The pre-transfusion testing is made up of the following procedure 
aimed at ensuring that blood provided for transfusion is compatible and will accomplish the 
desired aim of improving patient haemoglobin, improving anaemia and improving the oxy
gen delivery to tissues. The pre-transfusion testing should include the following procedures
1. Checking the previous transfusion records of patients (manually or com
puter) for previous grouping and antibody screening result.
2. Check and ensure that the details of patient on request form and hand 
labelled sample match and contain the minimum data set.
3. Determination of patient ABO and Rhesus blood group using appropri
ate reagents that have been quality controlled.
4. Performance of antibody screen of patient or mother in case of neonatal 
transfusion. Identification of alloantibodies in patient with a positive an
tibody screen.
5. Selection of appriopriate unit for crossmatching. Unit should be negative 
for antigen for which patient alloantibody is specific.
6. Crossmatching of patient serum and plasma against the donors red cells 
(Electronic issue, One tube spin or full IAT crossmatch depending on in
dication).
7. Prepare a worksheet and record all crossmatching testing results. Label 
units with compatibility labels. Record the batch numbers of reagents used. 
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Check that reagents are in date before use. Ensure that equipment have 
had daily maintenance done before use. Sign and date all worksheet.
8. Has the record and testing result been crosschecked. 
ABO grouping. Blood grouping must include both a forward (red cell) group and back (se-
rum grouping) using IgM monoclonal anti A, B and AB (cell or forward group) and A1, B cells 
(for serum or back group). A negative control of patient own red cells versus serum or plasma 
or patient plasma against O cell must be included. 
Rh D grouping. The rhesus D blood group of a patient can be performed using two differ-
ent batches of IgM monoclonal anti-D reagents. Reagents must be appriopriately controlled 
against D positive (positive control) and D negative red cells (negative control). Observed 
ABO and Rh D group of patient must be compared with previous group in patient records 
before appriopriate units are selected. All discripancies must be investigated before units are 
selected for crossmatch.
Antibody screening. The aim of antibody screening is to detect the presence of alloantibody 
to enable the selection of units that are negative for the antigen to which the alloantibody is 
specific. The aim is to detect the presence of clinically significant antibodies in the patient 
plasma, select antigen negative units and prevent immediate or delayed transfusion reaction 
as well as ensuring that the transfused red cells survives optimally in the patient circulation. 
Antibody screening invoves testing a patient’s serum/plasma by IAT against 2 or 3 antibody 
screening cells. If antibody screening result is positive, the specificity of the antibody is car-
ried out using a panel of cells (AHG and enzyme) with known antigen status.
14. Compatibility testing
Before a recipient receives a transfusion, compatibility testing between donor and recipient 
blood must be done. The first step before a transfusion is given is to type and screen the recipi-
ent’s blood. Typing of recipient’s blood determines the ABO and Rh status. The sample is then 
screened for any alloantibodies that may react with donor blood. It takes about 45 minutes to 
complete (depending on the method used). The blood bank labotatory scientist also checks 
for special requirements of the patient (e.g. need for washed, irradiated or CMV negative 
blood) and the history of the patient to see if they have a previously identified antibody. A 
positive screen warrants an antibody panel/investigation to determine if it is clinically signifi-
cant. An antibody panel consists of commercially prepared group O red cell suspensions from 
donors that have been phenotyped for commonly encountered and clinically significant al-
loantibodies. Donor cells may have homozygous (e.g. K+k-), heterozygous (K+ k+) expression 
or no expression of various antigens (K-k+). The phenotypes of all the donor cells being tested 
are shown in a chart. The patient’s serum is tested against the various donor cells using an 
enhancement method, e.g. Gel or LISS. Based on the reactions of the patient’s serum against 
the donor cells, a pattern will emerge to confirm the presence of one or more antibodies. Not 
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all antibodies are clinically significant (i.e. cause transfusion reactions, HDN, etc.). Once the 
patient has developed a clinically significant antibody it is vital that the patient receive an-
tigen negative phenotyped red blood cells to prevent future transfusion reactions. A direct 
antiglobulin test (Coombs test) is also performed as part of the antibody investigation. If there 
is no antibody present, an immediate spin crossmatch or computer assisted crossmatch is 
performed where the recipient serum and donor serum are incubated at room tempearture. 
In the immediate spin method, two drops of patient serum are tested against a drop of 3-5% 
suspension of donor cells in a test tube and spun in a serofuge. Agglutination or hemolysis 
in the test tube is a positive reaction and the unit should not be transfused. If an antibody 
is suspected, potential donor units must first be screened for the corresponding antigen by 
phenotyping them. Antigen negative units are then tested against the patient plasma using 
an antiglobulin/indirect crossmatch technique at 37 degrees Celsius to enhance reactivity and 
make the test easier to read. In urgent cases where crossmatching cannot be completed, and 
the risk of dropping hemoglobin outweighs the risk transfusing uncrossmatched blood, O-
negative blood (C,D,E negative, Kell negative, high titre negative, HBS and CMV negative 
unit) is used, followed by crossmatch as soon as possible. O-negative is also used for children 
and women of childbearing age. It is preferable for the laboratory to obtain a pre-transfusion 
sample in these cases so a type and screen can be performed to determine the actual blood 
group of the patient and to check for alloantibodies. Cross-matching blood, in transfusion 
medicine, refers to the complex testing that is performed prior to a blood transfusion, to 
determine if the donor’s blood is compatible with the blood of an intended recipient, or to 
identify matches for organ transplants. Cross-matching is usually performed only after other, 
less complex tests have not excluded compatibility. Blood compatibility has many aspects, 
and is determined not only by the blood types (O, A, B, AB), but also by blood factors, (Rh, 
Kell, etc.). Cross-matching is done by a certified laboratory scientist, in a laboratory. It can be 
done electronically, with a computer database, or serologically. Simpler tests may be used to 
determine blood type (only), or to screen for antibodies (only). (Indirect Coombs test). Cross-
matching involves testing the patient serum or plasma against donors red cells. The aim of 
the crossmatch is to ensure that there are no antibodies in patient plasma or serum that are 
directed against antigens on the donors red cells. There are 2 types of crossmatch (immediate 
spin and IAT crossmatch. Immediate spin is indicated in patients with no previous history of 
alloantibodies and in whom the pre-transfusion antibody screen is negative. The immediate 
spin is aimed at detecting ABO blood group incompatibility between donor and recipient. An 
IAT crrossmatch must be carried out in all patients with a previous history of alloantibodies 
or patients with a positive antibody screen. IAT crossmatch is carried out at 37°C. Tube or IAT 
card must be inspected for agglutination or haemolysis before washing the cells and adding 
AHG reagent. If there is agglutination or haemolysis the unit is not compatible and should not 
be transfused. The IAT crossmatch detect presence of immune antibodies in patient plasma 
that are specific to antigens on donor’s red cells.
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1. Major Cross-match: Recipient serum is tested against donor packed cells 
to determine if the recipient has alloantibodies against any antigens on 
the donor’s cells. This is a compulsory requirement prior to release of a 
unit of packed cells.
2. Minor Cross-match: Recipient red cells are tested against donor serum 
to detect donor antibodies directed against a patient’s antigens. This is 
no longer required. It is assumed that the small amount of donor serum 
and antibodies left in a unit of packed cells will be diluted in a recipient’s 
plasma volume.
Crossmatch can also be divided into three groups depending on procedure, One tube spin 
(Saline at room temperature), Full antiglobulin (IAT) crossmatch and Albumin Techniques
One tube spin (Immediate spin). The one tube spin is a crossmatch between donor red cells 
and recipient’s plasma. Donor’s red cells is added to recipient’s serum or plasma and centri
fuged at room temperature after which the tube is observed for agglutination or haemolysis. 
The presence of agglutination or haemolysis indicates an incompatitible crossmatch and in
dicates the presence of IGM or cold antibody  It is indicated in patients with a negative anti
body screen and no previous history of clinically significant alloantibody including suspected 
prophylactic anti-D.
1. Determine ABO and Rhesus group of recipient
2. Determine the antibody screen on patient serum or plasma.
3. Arrange the units in order of outdate, and enter the unit numbers in the 
appropriate place on the worksheet, oldest units first. 
4. Label a 12 x 75 mm tube for each donor unit. 
5. Prepare a 3% suspension of each donor unit. 
6. Re-check the ABO and Rh type of each donor unit by performing an ABO 
test (forward grouping only). 
7. Confirm the ABO and Rh type of each donor unit by performing an ABO 
test (forward grouping only).
8. Record donor and recipient’s blood typing results in the appropriate spot 
on the worksheet. 
all antibodies are clinically significant (i.e. cause transfusion reactions, HDN, etc.). Once the 
patient has developed a clinically significant antibody it is vital that the patient receive an
tigen negative phenotyped red blood cells to prevent future transfusion reactions. A direct 
antiglobulin test (Coombs test) is also performed as part of the antibody investigation. If there 
is no antibody present, an immediate spin crossmatch or computer assisted crossmatch is 
performed where the recipient serum and donor serum are incubated at room tempearture. 
In the immediate spin method, two drops of patient serum are tested against a drop of 3-5% 
suspension of donor cells in a test tube and spun in a serofuge. Agglutination or hemolysis 
in the test tube is a positive reaction and the unit should not be transfused. If an antibody 
is suspected, potential donor units must first be screened for the corresponding antigen by 
phenotyping them. Antigen negative units are then tested against the patient plasma using 
an antiglobulin/indirect crossmatch technique at 37 degrees Celsius to enhance reactivity and 
make the test easier to read. In urgent cases where crossmatching cannot be completed, and 
the risk of dropping hemoglobin outweighs the risk transfusing uncrossmatched blood, O-
negative blood (C,D,E negative, Kell negative, high titre negative, HBS and CMV negative 
unit) is used, followed by crossmatch as soon as possible. O-negative is also used for children 
and women of childbearing age. It is preferable for the laboratory to obtain a pre-transfusion 
sample in these cases so a type and screen can be performed to determine the actual blood 
group of the patient and to check for alloantibodies. Cross-matching blood, in transfusion 
medicine, refers to the complex testing that is performed prior to a blood transfusion, to 
determine if the donor’s blood is compatible with the blood of an intended recipient, or to 
identify matches for organ transplants. Cross-matching is usually performed only after other, 
less complex tests have not excluded compatibility. Blood compatibility has many aspects, 
and is determined not only by the blood types (O, A, B, AB), but also by blood factors, (Rh, 
Kell, etc.). Cross-matching is done by a certified laboratory scientist, in a laboratory. It can be 
done electronically, with a computer database, or serologically. Simpler tests may be used to 
determine blood type (only), or to screen for antibodies (only). (Indirect Coombs test). Cross
matching involves testing the patient serum or plasma against donors red cells. The aim of 
the crossmatch is to ensure that there are no antibodies in patient plasma or serum that are 
directed against antigens on the donors red cells. There are 2 types of crossmatch (immediate 
spin and IAT crossmatch. Immediate spin is indicated in patients with no previous history of 
alloantibodies and in whom the pre-transfusion antibody screen is negative. The immediate 
spin is aimed at detecting ABO blood group incompatibility between donor and recipient. An 
IAT crrossmatch must be carried out in all patients with a previous history of alloantibodies 
or patients with a positive antibody screen. IAT crossmatch is carried out at 37°C. Tube or IAT 
card must be inspected for agglutination or haemolysis before washing the cells and adding 
AHG reagent. If there is agglutination or haemolysis the unit is not compatible and should not 
be transfused. The IAT crossmatch detect presence of immune antibodies in patient plasma 
that are specific to antigens on donor’s red cells.
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Types of
1. Major Cross-match: Recipient serum is tested against donor packed cells 
to determine if the recipient has alloantibodies against any antigens on 
the donor’s cells. This is a compulsory requirement prior to release of a 
unit of packed cells.
2. Minor Cross-match: Recipient red cells are tested against donor serum 
to detect donor antibodies directed against a patient’s antigens. This is 
no longer required. It is assumed that the small amount of donor serum 
and antibodies left in a unit of packed cells will be diluted in a recipient’s 
plasma volume.
Crossmatch can also be divided into three groups depending on procedure, One tube spin 
(Saline at room temperature), Full antiglobulin (IAT) crossmatch and Albumin Techniques
One tube spin (Immediate spin). The one tube spin is a crossmatch between donor red cells 
and recipient’s plasma. Donor’s red cells is added to recipient’s serum or plasma and centri-
fuged at room temperature after which the tube is observed for agglutination or haemolysis. 
The presence of agglutination or haemolysis indicates an incompatitible crossmatch and in-
dicates the presence of IGM or cold antibody  It is indicated in patients with a negative anti-
body screen and no previous history of clinically significant alloantibody including suspected 
prophylactic anti-D.
Procedure for one tube spin
1. Determine ABO and Rhesus group of recipient
2. Determine the antibody screen on patient serum or plasma.
3. Arrange the units in order of outdate, and enter the unit numbers in the 
appropriate place on the worksheet, oldest units first. 
4. Label a 12 x 75 mm tube for each donor unit. 
5. Prepare a 3% suspension of each donor unit. 
6. Re-check the ABO and Rh type of each donor unit by performing an ABO 
test (forward grouping only). 
7. Confirm the ABO and Rh type of each donor unit by performing an ABO 
test (forward grouping only).
8. Record donor and recipient’s blood typing results in the appropriate spot 
on the worksheet. 
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9. Label a tube for each donor unit, using the last 3 digits of the unit number 
and the patient’s initials. 
10. Place two drops of patient serum into each tube. 
11. Place one drop of washed 3% donor cells into the appropriate tube and 
allow to stand for 2-5 minutes at room temperature.
12. Shake to mix, and centrifuge for 30-60 seconds or for the length of time 
for the saline calibration of the centrifuge. 
13. Gently re-suspend and examine macroscopically for agglutination and 
haemolysis. Record results under the Immediate Spin (IS) column of the 
worksheet. 
14. Presence of agglutination or haemolysis indicates an incompatible cross-
match. If no agglutination or haemolysis, unit is compatible and a com-
patibility label is printed.
Antiglobulin (IAT Crossmatch). If the patient has an antibody or a record of a previous al-
loantibody, the crossmatch must be carried through the antiglobulin phase, and the donor 
units typed for the corresponding antigen. Frequently a patient may have developed an an-
tibody in the past, which is recorded in his file, but the titer may have dropped and it is no 
longer detectable in the antibody screen. If this is the case, it is not necessary to set up any 
panel cells. Merely carry the crossmatch through the LISS and AHG phase but ensure that 
the donor units are negative for the corresponding antigen to which the antibody is specific. 
If no typing serum is available in the transfusion laboratory, and the antibody is clinically 
significant, notify your Blood Transfusion Center that you need antigen-negative blood for 
the patient. Antiglobulin phase of the crossmatch adds to patient safety, even when the an-
tibody screening test is negative for the following reasons; antibodies might be missed if the 
corresponding antigens are not present on the screening cells, antibodies might be missed if 
the screening cells have only a single dose or weak expression of the corresponding antigen, 
antibodies might be missed if the biomedical scientist performing the test used a slightly less 
sensitive technique when performing the antibody screen, or if the antibody was missed due 
to a technical error or an error in reading the test. Detection of immune IgG alloantibodies 
that have sensitized donors red cell is detectable by using the antiglobulin test (using the 
AHG reagents. An indirect antiglobulin test (IAT) is indicated and it involves the incubation 
of patient’s serum and donors red cells, incubation at 37°C, and washing 3 times in saline and 
adding AHG reagent. Polyspecific antiglobulin reagent will agglutinate red cells sensitized 
with antibodies and or are coated with complements.
Compatibility testing using the IAT Method
1. Label a small clean glass tube with the donor number
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2. Pipette 3 drops of the patient’s serum into the tube and add 1 volume of 
washed 3% donor red cell suspension and mix.
3. Centrifuge lightly at 150g for one minute.
4. Gently tilt the tube back and forth and observe for agglutination or 
haemolysis. Agglutination or haemolysis indicated incompatibility at the 
saline at room temperature (one tube spin phase of the crossmatch). Re
check donors blood group as well as ensure that the correct patient sam
ple has been tested. This phase will normally detect ABO blood group 
incompatibility.
5. If there is no agglutination, mix the content of the tube and incubate at 
37°C for 20-30 minutes.
6. Centrifuge at slow speed and observe for agglutination or haemolysis. 
This phase constitute the saline at 37°C phase of the crossmatch. Aggluti
nation or haemolysis indicated incompatibility at the saline at 37°C.
7. Wash the cells three times in saline. At the end of the third wash decant 
completely the supernatant.
8. Resuspend the cells at the bottom of the tube and add 2 drops of AHG 
reagent and mix.
9. Centrifuge slowly at 150g for 1 minute and observe for agglutination or 
haemolysis. Agglutination reaction indicates incompatibility in the IAT 
phase of the crossmatch and usually indicates the presence of immune 
IgG antibody in the serum that is reactive against antigens of the donor 
red cells which may cause a transfusion reaction if donor red cell is trans
fused. Such incompatible unit must not be transfused.
10. If there is no agglutination, it means that the unit is compatible. However 
to check that the AHG reagent has worked, add a drop of AHG control 
(IgG sensitized red cells.
11. The control cell is prepared by adding equal volume of washed group o 
positive red cells to IgG anti-D. Incubate at 37°C for 30 minutes. Wash 3-4 
times in saline and resuspend the deposit in saline to make a 5% suspen
sion. When added to patient serum, donor red cells and AHG mixture 
should show a visible agglutination. 
An albumin technique can also 
be used when it is not possible to obtain AHG reagent. The following reagents are often re
quired to carry out this crossmatch technique; Patients serum, washed 3% suspension of donor 
red cells in saline and 20% bovine serum albumin (BSA) reagent. ABO blood group incompat
ibility and IgG Alloantibodies can be detected by the albumin technique (Anti-D,, other Rhesus 
9. Label a tube for each donor unit, using the last 3 digits of the unit number 
and the patient’s initials. 
10. Place two drops of patient serum into each tube. 
11. Place one drop of washed 3% donor cells into the appropriate tube and 
allow to stand for 2-5 minutes at room temperature.
12. Shake to mix, and centrifuge for 30-60 seconds or for the length of time 
for the saline calibration of the centrifuge. 
13. Gently re-suspend and examine macroscopically for agglutination and 
haemolysis. Record results under the Immediate Spin (IS) column of the 
worksheet. 
14. Presence of agglutination or haemolysis indicates an incompatible cross
match. If no agglutination or haemolysis, unit is compatible and a com
patibility label is printed.
Antiglobulin (IAT Crossmatch). If the patient has an antibody or a record of a previous al
loantibody, the crossmatch must be carried through the antiglobulin phase, and the donor 
units typed for the corresponding antigen. Frequently a patient may have developed an an
tibody in the past, which is recorded in his file, but the titer may have dropped and it is no 
longer detectable in the antibody screen. If this is the case, it is not necessary to set up any 
panel cells. Merely carry the crossmatch through the LISS and AHG phase but ensure that 
the donor units are negative for the corresponding antigen to which the antibody is specific. 
If no typing serum is available in the transfusion laboratory, and the antibody is clinically 
significant, notify your Blood Transfusion Center that you need antigen-negative blood for 
the patient. Antiglobulin phase of the crossmatch adds to patient safety, even when the an
tibody screening test is negative for the following reasons; antibodies might be missed if the 
corresponding antigens are not present on the screening cells, antibodies might be missed if 
the screening cells have only a single dose or weak expression of the corresponding antigen, 
antibodies might be missed if the biomedical scientist performing the test used a slightly less 
sensitive technique when performing the antibody screen, or if the antibody was missed due 
to a technical error or an error in reading the test. Detection of immune IgG alloantibodies 
that have sensitized donors red cell is detectable by using the antiglobulin test (using the 
AHG reagents. An indirect antiglobulin test (IAT) is indicated and it involves the incubation 
of patient’s serum and donors red cells, incubation at 37°C, and washing 3 times in saline and 
adding AHG reagent. Polyspecific antiglobulin reagent will agglutinate red cells sensitized 
with antibodies and or are coated with complements.
1. Label a small clean glass tube with the donor number
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2. Pipette 3 drops of the patient’s serum into the tube and add 1 volume of 
washed 3% donor red cell suspension and mix.
3. Centrifuge lightly at 150g for one minute.
4. Gently tilt the tube back and forth and observe for agglutination or 
haemolysis. Agglutination or haemolysis indicated incompatibility at the 
saline at room temperature (one tube spin phase of the crossmatch). Re-
check donors blood group as well as ensure that the correct patient sam-
ple has been tested. This phase will normally detect ABO blood group 
incompatibility.
5. If there is no agglutination, mix the content of the tube and incubate at 
37°C for 20-30 minutes.
6. Centrifuge at slow speed and observe for agglutination or haemolysis. 
This phase constitute the saline at 37°C phase of the crossmatch. Aggluti-
nation or haemolysis indicated incompatibility at the saline at 37°C.
7. Wash the cells three times in saline. At the end of the third wash decant 
completely the supernatant.
8. Resuspend the cells at the bottom of the tube and add 2 drops of AHG 
reagent and mix.
9. Centrifuge slowly at 150g for 1 minute and observe for agglutination or 
haemolysis. Agglutination reaction indicates incompatibility in the IAT 
phase of the crossmatch and usually indicates the presence of immune 
IgG antibody in the serum that is reactive against antigens of the donor 
red cells which may cause a transfusion reaction if donor red cell is trans-
fused. Such incompatible unit must not be transfused.
10. If there is no agglutination, it means that the unit is compatible. However 
to check that the AHG reagent has worked, add a drop of AHG control 
(IgG sensitized red cells.
11. The control cell is prepared by adding equal volume of washed group o 
positive red cells to IgG anti-D. Incubate at 37°C for 30 minutes. Wash 3-4 
times in saline and resuspend the deposit in saline to make a 5% suspen-
sion. When added to patient serum, donor red cells and AHG mixture 
should show a visible agglutination. 
Compatibility testing using a saline and albumin technique. An albumin technique can also 
be used when it is not possible to obtain AHG reagent. The following reagents are often re-
quired to carry out this crossmatch technique; Patients serum, washed 3% suspension of donor 
red cells in saline and 20% bovine serum albumin (BSA) reagent. ABO blood group incompat-
ibility and IgG Alloantibodies can be detected by the albumin technique (Anti-D,, other Rhesus 
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antibodies, occasional anti –Lewis, MNSs, Lutheran and P). Albumin technique is not as sensi-
tive as the AHG technique and will miss weak reacting Kell, Kidd and Duffy antibodies.
Procedure
1. Label two tubes with the donor number. Pipette 1 drop of patient’s serum 
into each tube. Add I drop of 3% red cell suspension of donor red cells 
into each tube.
2. Incubate one tube at 37°C for 45 minutes.
3. Centrifuge the second tube lightly at 150g for 10-15 seconds. Mix gently 
back and forth and observe for agglutination or haemolysis. This con-
stitute saline at room temperature phase of the crossmatch (One tube 
spin). Agglutination or haemolysis indicated incompatibility at the saline 
at room temperature (one tube spin phase of the crossmatch). Recheck 
donors blood group as well as ensure that the correct patient sample has 
been tested.
4. At the end of 45 minutes incubation add 1 drop of BSA to the second tube 
(allowing the reagent to run down the side of the tube).
5. Do not mix but incubate further for 10-15 minutes at 37°C and observe 
for agglutination. If there is no agglutination observe microscopically. 
Agglutination indicates an incompatible crossmatch and is an indication 
of the presence of immune IgG antibody in the patient’s serum reactive 
against the group specific antigens on the donor’s red cells.
Electronic issue (computer crossmatch). Electronic cross-matching is essentially a computer-
assisted analysis of the data entered from testing done on the donor unit and blood samples 
drawn from intended recipient. This includes ABO/Rh typing of the unit and of the recipient, 
and an antibody screen of the recipient. Electronic cross-matching can only be used if a pa-
tient has a negative antibody screen, which means that they do not have any active red blood 
cell atypical antibodies, or they are below the detectable level of current testing methods. If 
all of the data entered is compatible, the computer will print a compatibility label stating that 
the unit is safe to transfuse. Electronic issue is based of the principle that if a patient ABO 
andRh D group is known and patient antibody screen is negative, it should be possible for 
patient to receive ABO and Rh D compatible unit issued by a computer programme without 
a serological crossmatch being carried out. The patient in such cases must have a confirmed 
ABO and Rh D group (group have been determined on 2 different occasion). For this method 
to be effective there must be in place a validated automated system for confirmed ABO and 
D grouping and antibody screening including positive sample identification and electronic 
data transfer of result (no risk of transcription error in manual imput of result). The computer 
software must be validated to prevent the issue of ABO incompatible unit. A number of safe-
guards have been advocated to further improve the safety of the electron procedure. 
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1. There must be two or more ABO & Rh test results on file for the recipient.
2. The ABO group of the donor units must be retested by the hospital Blood 
Bank. 
3. A bar code scanner must be used to enter blood unit numbers and the 
computer must be used to print the blood bag labels.
Sometimes in emergency situations, blood may be required urgently 
uch that there is no enough time for a full crossmatch to be performed. Once the ABO, Rh D 
group and antibody screen has been completed, there may be no need to carry out a one tube spin 
or IAT crossmactch if the time required to carry out the crossmatch can negatively affect patient 
care. In such cases patients can be issued ABO and Rh D compatible uncrossmatched units. The 
crossmatch can however be carried out in retrospect. In the case of an emergency a physician, 
physician assistant, or nurse practitioner can request “uncross-matched blood”, or donor units 
of blood that have not been cross-matched. It is thought that this lifesaving measure is of more 
benefit than any risk of an antibody-mediated transfusion reaction. In addition, the risk of a seri
ous transfusion reaction can be minimized if the donor unit is both ABO-compatible and Rhesus 
(Rh)-compatible. Type O and Rh negative blood can be given if the recipient’s blood group is not 
known, as may happen in an emergency. In an emergency, blood grouping can be done easily and 
quickly in 2 or 3 minutes in the laboratory on glass slides with appropriate reagents, by trained 
technical staff. This method depends on the presence or absence of agglutination, which can usu
ally be visualized directly, although occasionally a light microscope may be needed. Every blood 
bank must have some units of readily available group O negative red cell that can be used in 
emergency situation when there is not enough time to wait for a compatible unit. However such 
units must be Kell negative, negative for high titre A and B haemolysin, CMV negative. 
For most surgical patients scheduled for a procedure, it is no longer neces
sary to have units crossmacted prior to the procedure. What is being done is athe determina
tion of the patient ABO, Rh group and antibody screen (type and screen). In such patients, if 
blood is need intraoperatively or post operatively, blood can be readily available either by car
rying out an immediate spin crossmatch or by electronic issue of ABO and RhD compatible 
unit based on the assurance that since unit issued is ABO and Rh compatible with patient who 
is himself negative for alloantibody the chances of incompatibility is extremely rare. However 
if the antibody screen is positive, the specificity must be determined by doing a panel. If the 
antibody is clinically significant, all effort must be made to get get appriopriate antigen nega
tive unit crossmatched by both immediate spin and IAT for the patient.
Hospitals are expected to have their own lo
cal policies for the selection and issue of blood or blood components. Hospital should have 
indication coding tool to ensure that transfusion is appriopriate. All staff involved in the 
transfusion process from the transfusion laboratory scientist to the prescribing clinician must 
be trained and competency tested on these policies or guidelines. The policy must also have 
a guide on the use of certain specialised product for specific patients (neonates and infants). 
antibodies, occasional anti –Lewis, MNSs, Lutheran and P). Albumin technique is not as sensi
tive as the AHG technique and will miss weak reacting Kell, Kidd and Duffy antibodies.
1. Label two tubes with the donor number. Pipette 1 drop of patient’s serum 
into each tube. Add I drop of 3% red cell suspension of donor red cells 
into each tube.
2. Incubate one tube at 37°C for 45 minutes.
3. Centrifuge the second tube lightly at 150g for 10-15 seconds. Mix gently 
back and forth and observe for agglutination or haemolysis. This con
stitute saline at room temperature phase of the crossmatch (One tube 
spin). Agglutination or haemolysis indicated incompatibility at the saline 
at room temperature (one tube spin phase of the crossmatch). Recheck 
donors blood group as well as ensure that the correct patient sample has 
been tested.
4. At the end of 45 minutes incubation add 1 drop of BSA to the second tube 
(allowing the reagent to run down the side of the tube).
5. Do not mix but incubate further for 10-15 minutes at 37°C and observe 
for agglutination. If there is no agglutination observe microscopically. 
Agglutination indicates an incompatible crossmatch and is an indication 
of the presence of immune IgG antibody in the patient’s serum reactive 
against the group specific antigens on the donor’s red cells.
Electronic issue (computer crossmatch). Electronic cross-matching is essentially a computer-
assisted analysis of the data entered from testing done on the donor unit and blood samples 
drawn from intended recipient. This includes ABO/Rh typing of the unit and of the recipient, 
and an antibody screen of the recipient. Electronic cross-matching can only be used if a pa
tient has a negative antibody screen, which means that they do not have any active red blood 
cell atypical antibodies, or they are below the detectable level of current testing methods. If 
all of the data entered is compatible, the computer will print a compatibility label stating that 
the unit is safe to transfuse. Electronic issue is based of the principle that if a patient ABO 
andRh D group is known and patient antibody screen is negative, it should be possible for 
patient to receive ABO and Rh D compatible unit issued by a computer programme without 
a serological crossmatch being carried out. The patient in such cases must have a confirmed 
ABO and Rh D group (group have been determined on 2 different occasion). For this method 
to be effective there must be in place a validated automated system for confirmed ABO and 
D grouping and antibody screening including positive sample identification and electronic 
data transfer of result (no risk of transcription error in manual imput of result). The computer 
software must be validated to prevent the issue of ABO incompatible unit. A number of safe
guards have been advocated to further improve the safety of the electron procedure. 
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1. There must be two or more ABO & Rh test results on file for the recipient.
2. The ABO group of the donor units must be retested by the hospital Blood 
Bank. 
3. A bar code scanner must be used to enter blood unit numbers and the 
computer must be used to print the blood bag labels.
Emergency crossmatching. Sometimes in emergency situations, blood may be required urgently 
such that there is no enough time for a full crossmatch to be performed. Once the ABO, Rh D 
group and antibody screen has been completed, there may be no need to carry out a one tube spin 
or IAT crossmactch if the time required to carry out the crossmatch can negatively affect patient 
care. In such cases patients can be issued ABO and Rh D compatible uncrossmatched units. The 
crossmatch can however be carried out in retrospect. In the case of an emergency a physician, 
physician assistant, or nurse practitioner can request “uncross-matched blood”, or donor units 
of blood that have not been cross-matched. It is thought that this lifesaving measure is of more 
benefit than any risk of an antibody-mediated transfusion reaction. In addition, the risk of a seri-
ous transfusion reaction can be minimized if the donor unit is both ABO-compatible and Rhesus 
(Rh)-compatible. Type O and Rh negative blood can be given if the recipient’s blood group is not 
known, as may happen in an emergency. In an emergency, blood grouping can be done easily and 
quickly in 2 or 3 minutes in the laboratory on glass slides with appropriate reagents, by trained 
technical staff. This method depends on the presence or absence of agglutination, which can usu-
ally be visualized directly, although occasionally a light microscope may be needed. Every blood 
bank must have some units of readily available group O negative red cell that can be used in 
emergency situation when there is not enough time to wait for a compatible unit. However such 
units must be Kell negative, negative for high titre A and B haemolysin, CMV negative. 
Type and screen. For most surgical patients scheduled for a procedure, it is no longer neces-
sary to have units crossmacted prior to the procedure. What is being done is athe determina-
tion of the patient ABO, Rh group and antibody screen (type and screen). In such patients, if 
blood is need intraoperatively or post operatively, blood can be readily available either by car-
rying out an immediate spin crossmatch or by electronic issue of ABO and RhD compatible 
unit based on the assurance that since unit issued is ABO and Rh compatible with patient who 
is himself negative for alloantibody the chances of incompatibility is extremely rare. However 
if the antibody screen is positive, the specificity must be determined by doing a panel. If the 
antibody is clinically significant, all effort must be made to get get appriopriate antigen nega-
tive unit crossmatched by both immediate spin and IAT for the patient.
Selection of blood component for transfusion. Hospitals are expected to have their own lo-
cal policies for the selection and issue of blood or blood components. Hospital should have 
indication coding tool to ensure that transfusion is appriopriate. All staff involved in the 
transfusion process from the transfusion laboratory scientist to the prescribing clinician must 
be trained and competency tested on these policies or guidelines. The policy must also have 
a guide on the use of certain specialised product for specific patients (neonates and infants). 
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Such policies must contain information on patients in which specialized products such as 
CMV negative blood products, irradiated, Kell negative, High titre, HLA matched platelet 
are indicated as well as criteria to transfuse red cells (Giving O donor red cells to A, B and AB 
patients or giving A and B donor red cells to an AB patient) and plasma against ABO blood 
group barrier.
Selection of red cells for patient with clinically significant alloantibody. Clinically signifi-
cant antibodies are antibodies that are capable of causing a haemolytic transfusion reaction 
(HTR) and haemolytic disease of the foetus and newborn (HDFN). Not all antibodies can 
cause red cell destruction invivo. However most warm reacting antibodies (react optimally 
at 37°C) are mostly clinically significant. Most cold reacting alloantibodies are not clinically 
significant. The general rule is that all patient with a clinically significant alloantibody (anti-D, 
C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, M and S) must receive red cell negative for the antigen to 
which the alloantibody is specific. Such red cells must be crossmatched by both immediate 
spin and IAT and must only be transfused if it is compatible by IAT. If antibody is not clini-
cally significant, it is not necessary to select antigen negative units (anti-Kpa, Lea, Leb P, Cw, 
Lua and others). However for patients with anti Cw, C negative unit should be selected. In 
such cases ABO and Rh D compatible Kell negative unit should be crossmatched by immedi-
ate spin and IAT and must only be transfused if it is compatible by IAT. Kell negative unit is 
most times selected to prevent the patient from developing anti-K particularly those that are 
Kell negative (most clinically significant and commonly detected after Rh-antibodies).
Dealing with cold reacting antibodies in selection of blood for transfusion. Cold reacting 
antibodies are not known to cause the destruction of red cell containing the group specific an-
tigen invivo even in hypothermic patients. Even when cold reacting antibodies (anti-Lea, Leb, 
Lua, P1, N and A1 and others) are reactive by IAT at warm temperature (37°C), ABO and Rh D 
compatible unit can be crossmatched using donor red cells and patient plasma pre-warmed at 
37°C prior to mixing donor cells and patient plasma. This should normally obviate the prob-











Group A and Rh D matched/ IAT crossmatch at 
37°C
Rhesus
Anti-D, C, c, E, 
e, Cw
Yes and Rarely for 
anti - Cw
Antigen negative unit/IAT crossmatch at 37°C (C 
negative unit in case of anti- Cw)
Kell Anti-K, k Yes Antigen negative unit/IAT crossmatch at 37°C
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Anti- Jka and 
Jkb
Antigen negative unit/IAT crossmatch at 37°C
Anti-M, S,s,U
Yes (rarely for anti-
M reactive at 37°C
Antigen negative unit/IAT crossmatch at 37°C
Duffy Anti-Fya, Fyb Antigen negative unit/IAT crossmatch at 37°C
Table: Clinically significant alloantibody and unit recommendation for transfusion
A compatibility label or slip must be completed for all red cells cross
match. The label or slip must contain the following relevant information; recipient’s name, 
recipient’s hospital number, ABO and Rh group of recipient, ABO and Rh group of donor, 
identity number of unit, nature of product, date and time of issue, compatibility status of unit 
and expiry (use by) date.
Difficulties in crossmatching. The following can pose a significant challenge during cross
matching; rouleaux, cold reacting autoagglutinins and bacterial contamination of donor cells.
Patients with protein abnormality such as multiple myeloma, patients that have 
received dextran or other crystalloids or sample that have been contaminated with Wharton’s 
jelly can cause red cells to stalk together like a pile of coins giving an appearance of agglutina
tion (pseudo or false agglutination). Rouleaux can be distinguished from a true agglutination 
by either by adding a drop of saline to the cell or by examining the red cells microscopically. 
Rouleaux usually disperse within 1-2 minutes following the addition of saline.
Some patient serum contains autoagglutinins (antibodies that show agglu
tination with patients own red cells and other red cells (autoagglutination). Autoagglutinins 
are commonly seen in the serum of patients with lymphoma, leukemia, virus pneumonia, 
systemic lupus erythaematosus, auto immune diseases and occasional in severe Plasmodium 
falciparum malaria. This pseudo agglutination is often caused by cold reacting agglutinins. 
When cold agglutinins are present, the auto control is often positive. The effect of autoaggluti
nation due to cold agglutinin can be obviated by washing the patient red cells in warm saline 
and the auto control read after incubation at 37°C for 10 minutes. The auto control is usually 
negative after incubating at 37°C. 
Patients experiencing alloantibody formation are asymptomatic. The alloantibody is discov
ered at the time of pre-transfusion testing. It is compulsory to carry out ABO, Rh group and 
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Such policies must contain information on patients in which specialized products such as 
CMV negative blood products, irradiated, Kell negative, High titre, HLA matched platelet 
are indicated as well as criteria to transfuse red cells (Giving O donor red cells to A, B and AB 
patients or giving A and B donor red cells to an AB patient) and plasma against ABO blood 
group barrier.
Selection of red cells for patient with clinically significant alloantibody. Clinically signifi
cant antibodies are antibodies that are capable of causing a haemolytic transfusion reaction 
(HTR) and haemolytic disease of the foetus and newborn (HDFN). Not all antibodies can 
cause red cell destruction invivo. However most warm reacting antibodies (react optimally 
at 37°C) are mostly clinically significant. Most cold reacting alloantibodies are not clinically 
significant. The general rule is that all patient with a clinically significant alloantibody (anti-D, 
C, E, c, e, K, k, Fya, Fyb, Jka, Jkb, M and S) must receive red cell negative for the antigen to 
which the alloantibody is specific. Such red cells must be crossmatched by both immediate 
spin and IAT and  be transfused if it is compatible by IAT. If antibody is not clini
cally significant, it is not necessary to select antigen negative units (anti-Kpa, Le , Leb P, Cw, 
Lu  and others). , C negative unit should be selected. In 
such cases ABO and Rh D compatible Kell negative unit should be crossmatched by immedi
ate spin and IAT and  be transfused if it is compatible by IAT. Kell negative unit is 
most times selected to prevent the patient from developing anti-K particularly those that are 
Kell negative (most clinically significant and commonly detected after Rh-antibodies).
Cold reacting 
antibodies are not known to cause the destruction of red cell containing the group specific an
tigen invivo even in hypothermic patients. Even when cold reacting antibodies (anti-Le , Leb, 
Lu , P1, N and A1 and others) are reactive by IAT at warm temperature (37°C), ABO and Rh D 
compatible unit can be crossmatched using donor red cells and patient plasma pre-warmed at 
37°C prior to mixing donor cells and patient plasma. This should normally obviate the prob
lem caused by cold reacting antibodies during crossmatching.
Clinical signifi
Anti-A1
Group A and Rh D matched/ IAT crossmatch at 
37°C
Rhesus
Anti-D, C, c, E, 
e, Cw
Yes and Rarely for 
anti - Cw
Antigen negative unit/IAT crossmatch at 37°C (C 
negative unit in case of anti- Cw)
Anti-K, k Antigen negative unit/IAT crossmatch at 37°C
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Kidd
Anti- Jka and 
Jkb
Yes Antigen negative unit/IAT crossmatch at 37°C
MNS Anti-M, S,s,U
Yes (rarely for anti-
M reactive at 37°C
Antigen negative unit/IAT crossmatch at 37°C
Duffy Anti-Fya, Fyb Yes Antigen negative unit/IAT crossmatch at 37°C
Table: Clinically significant alloantibody and unit recommendation for transfusion
Compatibility Label. A compatibility label or slip must be completed for all red cells cross-
match. The label or slip must contain the following relevant information; recipient’s name, 
recipient’s hospital number, ABO and Rh group of recipient, ABO and Rh group of donor, 
identity number of unit, nature of product, date and time of issue, compatibility status of unit 
and expiry (use by) date.
Difficulties in crossmatching. The following can pose a significant challenge during cross-
matching; rouleaux, cold reacting autoagglutinins and bacterial contamination of donor cells.
Rouleaux. Patients with protein abnormality such as multiple myeloma, patients that have 
received dextran or other crystalloids or sample that have been contaminated with Wharton’s 
jelly can cause red cells to stalk together like a pile of coins giving an appearance of agglutina-
tion (pseudo or false agglutination). Rouleaux can be distinguished from a true agglutination 
by either by adding a drop of saline to the cell or by examining the red cells microscopically. 
Rouleaux usually disperse within 1-2 minutes following the addition of saline.
Autoagglutinins. Some patient serum contains autoagglutinins (antibodies that show agglu-
tination with patients own red cells and other red cells (autoagglutination). Autoagglutinins 
are commonly seen in the serum of patients with lymphoma, leukemia, virus pneumonia, 
systemic lupus erythaematosus, auto immune diseases and occasional in severe Plasmodium 
falciparum malaria. This pseudo agglutination is often caused by cold reacting agglutinins. 
When cold agglutinins are present, the auto control is often positive. The effect of autoaggluti-
nation due to cold agglutinin can be obviated by washing the patient red cells in warm saline 
and the auto control read after incubation at 37°C for 10 minutes. The auto control is usually 
negative after incubating at 37°C. 
15. Red Blood Cells alloimmunisation
Patients experiencing alloantibody formation are asymptomatic. The alloantibody is discov-
ered at the time of pre-transfusion testing. It is compulsory to carry out ABO, Rh group and 
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indirect antihuman Globulin (IAT) alloantibody screening. All patients found positive should 
have their plasma tested against a panel of cell of known antigen status to identify the alloan-
tibody present. Antibody identification was carried out on serum employing commercial two-
cell panel (APAN and EPAN). However when test with the two-cell panel using standardized 
blood bank methods, a third cell panel (B Panel) may be used to facilitate the identification. 
Alloimmunization significantly concerns the Rhesus, Kell, Duffy and Kidd system which are 
clinically significant. They can cause, not invariably haemolytic transfusion reactions and 
limit the ability of safer transfusion while, others are clinically insignificant. Factors for im-
munization are complex and involve at least three main contributing elements.
1. RBC antigenic difference between the blood donor and the recipient.
2. The recipient’s immune status
3. The immunomodulatory effect of the allogenic blood transfusions on the 
recipient’s immune system.
There is relatively high risk of alloimmunization in transfusion-dependent. Red cell alloim-
munization should not be overlooked in transfusion-dependent and multi-transfused pa-
tients. Alloimmunization must always be considered in certain patients; those who repeatedly 
suffer from haemolytic transfusion reaction and those who are not able to maintain haemo-
globin at a desired level despite having regular transfusions. Regular screening for red cell 
alloantibodies testing would add towards the better management of these patients. Antibody 
identification is used as a follow-up test to a positive indirect antiglobulin test (IAT). The IAT 
is typically performed on all patients that require red cell transfusion and during each preg-
nancy to determine whether the patient and mother have developed any red blood cell (RBC) 
antibodies as part of a “Group and Screen” or “Group and Crossmatch request.” The antibody 
identification test is used to determine the RBC antigen(s) that the antibody or antibodies are 
specific and to determine their clinically significant ( Ability to cause a transfusion reaction 
and ability to cause hemolytic disease of the foetus newborn (HDFN). Some RBC antibodies 
are known to cause moderate to severe reactions while other less significant ones may cause 
a positive IAT but few or no symptoms or complications in the blood transfusion recipient 
or pregnant woman. If one or more clinically significant RBC antibodies are identified, then 
donor blood that lacks the corresponding RBC antigens must be used for transfusion. When 
someone has a disease condition that requires recurrent transfusions, they are exposed to 
many foreign RBC antigens and are more at risk of developing multiple RBC antibodies over 
time, making the process of finding compatible blood increasingly challenging. Appropriate 
antigen negative blood will be supplied. Alloimmunisation to the D and K (Kell) antigens is 
prevented by the provision of Rh (D) negative and Kell negative blood for Rh (D) negative, 
Kell negative patients. This is particularly important for females with child-bearing potential 
as these antibodies can cause severe haemolytic disease of the newborn during pregnancy. 
Patients with sickle cell disease or major haemoglobinopathy syndromes (thalassaemia) and 
haematological oncology patients who are chronically transfused are at greatest risk of allo-
antibody formation. Prior to commencing transfusion, patients with these condition should 
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have extended red cell phenotyping performed to enable the selection of blood matched for 
the patient’s Rhesus and Kell antigens is supplied for transfusion.
The development of red blood cell (RBC) isoimmunisation with alloantibodies and autoan
tibodies complicate transfusion therapy particularly in multiply transfused patients. Alloim
munization to red cell antigens is still a current problem in many settings in Saharan Africa 
for several reasons; alloantibody testing for antenatal women and patients who require red 
cell transfusion is often lacking, alloantibody testing of transfusion recipients to ensure that 
they receive red cells negative to alloantibody they may have developed is often lacking, there 
is absence of universal access to prophylactic immunoglobulin D for the prevention of Rh 
isoimmunisation in Rh negative women and the absence of cost effective means of estimating 
Feto Maternal Haemorrhage (FMH) in Rhesus negative mothers delivered of Rhesus positive 
babies and following sensitizing event during pregnancy. It is obvious that the additional test
ing of blood donors for clinically significant red cell antigens as well as alloantibody screening 
of all recipients for which red cell transfusion is indicated should be implemented as a routine 
to prevent as far as possible the incidence of alloimmunization. It would also be cost-effective, 
bearing in mind the fact that there are laborious and expensive laboratory testing necessary 
to provide compatible blood for alloimmunized patients. 
Challenges of red cell alloimmunization. Red blood cell (RBC) alloimmunization results 
from genetic disparity of RBC antigens between donor and recipients. Alloimmunization are 
significant especially when it involves a clinically significant alloantibody that causes haemo
lytic transfusion reactions and haemolytic disease of the newborn. It is very important that 
they be correctly, and some of them routinely, typed in blood donors as well as in patients. The 
development of red blood cell (RBC) isoimmunization with alloantibodies and autoantibod
ies complicate transfusion therapy particularly in multiply transfused patients. Alloimmu
nization to red cell antigens is still a current problem in many settings in SSA. Alloantibody 
testing of transfusion recipients to ensure that they receive red cells negative to alloantibody 
they may have developed is often lacking; there is absence of universal access to prophylactic 
immunoglobulin D for the prevention of Rh isoimmunization in Rh negative women coupled 
with the absence of cost effective means of estimating Feto Maternal Haemorrhage (FMH) in 
many settings in sub Saharan Africa. These factors all complicate transfusion practice in this 
region. It is obvious that the additional testing of blood donors for clinically significant red 
cell antigens as well as alloantibody screening of all recipients for which red cell transfusion 
is indicated should be implemented as a routine to prevent as far as possible the incidence 
of alloimmunization. It would also be cost-effective, bearing in mind the fact that there are 
laborious and expensive laboratory testing necessary to provide compatible blood for alloim
munized patients. Extended blood typing should be implemented for some categories of pol
ytransfused patients as well. This strategy is another step forward to improving the safety of 
blood transfusion in Africa. 
Providing blood and blood products for patients with clinically significant alloantibod
Red blood cell (RBC) alloimmunization results from genetic disparity of RBC antigens 
between donor and recipients. Alloimmunization are significant especially when it involves 
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they may have developed is often lacking; there is absence of universal access to prophylactic 
immunoglobulin D for the prevention of Rh isoimmunization in Rh negative women coupled 
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cell antigens as well as alloantibody screening of all recipients for which red cell transfusion 
is indicated should be implemented as a routine to prevent as far as possible the incidence 
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laborious and expensive laboratory testing necessary to provide compatible blood for alloim-
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a clinically significant alloantibody that causes haemolytic transfusion reactions and haemo-
lytic disease of the newborn. It is very important that they be correctly, and some of them 
routinely, typed in blood donors as well as in patients. The development of red blood cell 
(RBC) isoimmunization with alloantibody and autoantibodies complicate transfusion therapy 
particularly in multiply transfused patients. Alloimmunization to red cell antigens is still a 
current problem in many settings in Saharan Africa. Alloantibody testing of transfusion re-
cipients to ensure that they receive red cells negative to alloantibody they may have devel-
oped is often lacking; there is absence of universal access to prophylactic immunoglobulin D 
for the prevention of Rh isoimmunisation in Rh negative women coupled with the absence of 
cost effective means of estimating Feto Maternal Haemorrhage (FMH) in many settings in sub 
Saharan Africa. These factors all complicate transfusion practice in this region. It is obvious 
that the additional testing of blood donors for clinically significant red cell antigens as well as 
alloantibody screening of all recipients for which red cell transfusion is indicated should be 
implemented as a routine to prevent as far as possible the incidence of alloimmunization. It 
would also be cost-effective, bearing in mind the fact that there are laborious and expensive 
laboratory testing necessary to provide compatible blood for alloimmunized patients. Ex-
tended blood typing should be implemented for some categories of polytransfused patients 
as well. This strategy is another step forward to improving the safety of blood transfusion in 
Africa. Antibodies to red blood cells (RBCs) can be produced by the body’s immune system 
in response to being exposed to “foreign” RBC antigens, structures found on the surfaces of 
RBCs. Apart from antibodies of the ABO blood group system that universally common, those 
of other blood group system are immune and results in response to stimulation by a foreign 
antigen introduced via a blood transfusion and as a result of a foreign foetal red cell enter-
ing the maternal circulation during pregnancy or during delivery. Antibody stimulation is 
dependent on a number of factors;
1. The immunogenicity of the antigen
2. The dosage of the antigen to which the body is exposed
3. The frequency of exposure
4. The immune competence of the individuals immune system
Most antibodies that react in-vitro at 37°C by AHG technique are generally clinically signifi-
cant and can cause HDFN and transfusion reaction. It is important to investigate the alloabti-
body status of patient prior transfusion and during pregnancy. The clinical significance of 
alloantibodies depends on a number of factors;
1. The blood group specificity
2. Medium and temperature of optimum reactivity
3. Ability to activate complement
4. The immunoglobulin class of the antibody
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5. The titre of the antibody
Following exposure of an individual to an antigenic stimulus (primary immune 
response), antibody is usually detectable within 3 months (IgM). When the individual sub
sequently encounters the antigen (secondary response or booster dose), there is a more fre
quent antibody production and a switch of the immunoglobulin class of the antibody to IgG. 
Transfusion of red cells containing antigens which the recipient lacks can trigger an immune 
response leading to the development of antibody against the foreign antigen. Subsequent 
encounter with this foreign antigen can result in a transfusion reaction resulting from the 
antibody produced destroying the red cells containing the offending antigen. Such reaction 
may range from severe intravascular haemolysis in the patients circulation to extravascular 
sequestration of the antibody coated red cell by the reticuloendothelial system (macrophages 
in liver and spleen). It is vital that all individuals for which a red cell transfusion is intended 
have an antibody screen before transfusion. A positive antibody screen indicates a risk of a 
transfusion reaction irrespective of the compatibility status. The specificity of the antibody 
must be identified and specifically selected antigen negative blood is transfused.
During pregnancy and especially during delivery, foetal red cells may enter 
into maternal circulation. If these foetal cells contain antigens inherited from the father 
and which the mother lacks, these foreign fortal red cells can stimulate the mother to 
produce antibodies (immune). This test identifies the specificity of red blood cell antibod
ies in the blood that were produced in response to a previous exposure to someone else’s 
RBCs either through blood transfusion or prior pregnancy. It is often done as a follow up 
to a positive screening result by an indirect antiglobulin test (IAT) or when an antibody 
is detected attached to a patient’s RBCs by a positive direct antiglobulin test (DAT). The 
type of RBC antibodies that you may produce depends on the specific combination of 
surface antigens on your RBCs that you inherited from your parents. Normally your body 
will only produce antibodies directed against antigens not found on your own cells. The 
major RBC antigens are A, B and the Rh factor (D antigen). They determine a person’s 
basic blood type (for more on this, see Blood Type and Blood Banking). The Rh factor (D 
antigen) is a potent stimulus for antibody production. It is estimated that if an Rh negative 
person is exposed to only one or two drops of Rh positive blood, their immune system can 
be triggered to begin producing anti-D antibodies. For these reasons, blood that is to be 
transfused must be compatible with the patient. When a person with a RBC antibody is 
again exposed to RBCs bearing the “foreign” antigen, whether by another transfusion or 
pregnancy, the RBC antibodies may attach to the specific antigens on the foreign RBCs and 
target the RBCs for destruction. Depending on the antigen and antibody involved and the 
quantity of RBCs affected, this can cause a reaction ranging from mild to severe and po
tentially life-threatening. It may happen immediately, such as during a blood transfusion, 
or take longer, from one to several days following a transfusion. When antibodies attach 
to antigens, the red blood cells can be destroyed, termed hemolysis. This can occur within 
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5. The titre of the antibody
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sequestration of the antibody coated red cell by the reticuloendothelial system (macrophages 
in liver and spleen). It is vital that all individuals for which a red cell transfusion is intended 
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must be identified and specifically selected antigen negative blood is transfused.
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into maternal circulation. If these foetal cells contain antigens inherited from the father 
and which the mother lacks, these foreign fortal red cells can stimulate the mother to 
produce antibodies (immune). This test identifies the specificity of red blood cell antibod-
ies in the blood that were produced in response to a previous exposure to someone else’s 
RBCs either through blood transfusion or prior pregnancy. It is often done as a follow up 
to a positive screening result by an indirect antiglobulin test (IAT) or when an antibody 
is detected attached to a patient’s RBCs by a positive direct antiglobulin test (DAT). The 
type of RBC antibodies that you may produce depends on the specific combination of 
surface antigens on your RBCs that you inherited from your parents. Normally your body 
will only produce antibodies directed against antigens not found on your own cells. The 
major RBC antigens are A, B and the Rh factor (D antigen). They determine a person’s 
basic blood type (for more on this, see Blood Type and Blood Banking). The Rh factor (D 
antigen) is a potent stimulus for antibody production. It is estimated that if an Rh negative 
person is exposed to only one or two drops of Rh positive blood, their immune system can 
be triggered to begin producing anti-D antibodies. For these reasons, blood that is to be 
transfused must be compatible with the patient. When a person with a RBC antibody is 
again exposed to RBCs bearing the “foreign” antigen, whether by another transfusion or 
pregnancy, the RBC antibodies may attach to the specific antigens on the foreign RBCs and 
target the RBCs for destruction. Depending on the antigen and antibody involved and the 
quantity of RBCs affected, this can cause a reaction ranging from mild to severe and po-
tentially life-threatening. It may happen immediately, such as during a blood transfusion, 
or take longer, from one to several days following a transfusion. When antibodies attach 
to antigens, the red blood cells can be destroyed, termed hemolysis. This can occur within 
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the blood vessels or in the liver or spleen and cause symptoms and signs such as fever, 
chills, nausea, flank pain, low blood pressure, bloody urine, and jaundice. Antibody iden-
tification tests that detect antibodies directed against the minor RBC blood group antigens 
are not routinely done but are performed when the presence of an antibody is detected 
through a positive IAT or DAT. Antibody identification is used as a follow-up test to a posi-
tive indirect antiglobulin test (IAT). The IAT is typically performed during each pregnancy 
to determine whether the mother has developed any red blood cell (RBC) antibodies and 
before RBC transfusions as part of a “type and screen” or “type and crossmatch.” The 
antibody identification test is used to determine the RBC antigen(s) that the antibody or 
antibodies are directed against to determine if they are likely to be clinically significant, 
i.e., if they are likely to cause a transfusion reaction or hemolytic disease of the newborn 
(HDN). Some RBC antibodies are known to cause moderate to severe reactions while other 
less significant ones may cause a positive IAT but few to no symptoms or complications in 
the blood transfusion recipient or baby. If one or more clinically significant RBC antibodies 
are identified, then donor blood that lacks the corresponding RBC antigens must be used 
for transfusion. When someone has a condition that requires recurrent transfusions, they 
are exposed to many foreign RBC antigens and may develop multiple RBC antibodies over 
time, making the process of finding compatible blood increasingly challenging. An IAT 
and antibody identification test may be used as part of an investigation if a person has a 
transfusion reaction. Sometimes an RBC antibody may be present in such a small quantity 
that it does not cause a positive IAT during pre-transfusion blood compatibility testing. 
But after the blood is given to the recipient, it can trigger renewed, rapid antibody produc-
tion and cause a delayed hemolytic transfusion reaction several days later. If RBC antibod-
ies have been identified in a pregnant woman, then the baby’s condition will be monitored. 
Whether or not the antibodies will affect the baby’s condition depends upon the antibody 
present, the RBC antigens that the fetus has, and when the mother’s antibodies come into 
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Yellow = Indicates those antigens which are destroyed or depressed by enzyme treatment
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When is antibody identification test ordered? When a RBC antibody is identified, it means 
that an antibody that specifically targets an RBC antigen or antigen group is present in the 
blood. If the antibody is considered clinically significant, then it will need to be taken into 
account with each transfusion and/or pregnancy. If it is not considered clinically significant, 
then it is not likely to cause a transfusion reaction in the patient or hemolytic disease of the 
newborn. The antibody identification test may be ordered whenever an IAT or a DAT is posi
tive and may be repeated, when a person has a transfusion reaction and when a mother has a 
baby with HDN and DAT is positive.
An example of Panel used for antibody identification
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When is antibody identification test ordered? When a RBC antibody is identified, it means 
that an antibody that specifically targets an RBC antigen or antigen group is present in the 
blood. If the antibody is considered clinically significant, then it will need to be taken into 
account with each transfusion and/or pregnancy. If it is not considered clinically significant, 
then it is not likely to cause a transfusion reaction in the patient or hemolytic disease of the 
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1 + + 0 0 + 0 0 + 0 + 0 + 0 0 2 3 3 0 0 0 2 3
2 + + 0 0 + + + 0 + 0 + 2 3 0 0 0 0 0 0 2 3
3 + 0 + + 0 0 0 0 0 + 0 0 0 0 2 3 0 0 0 0 0 0
4 + 0 0 + + 0 0 0 + 0 0 2 3 0 0 0 0 0 0 0 0
5 0 + 0 + + 0 + + + + 0 2 3 0 0 3 0 2 3 0 0
6 0 0 + + + + + + + + 0 + 2 3 2 3 3 0 0 0 2 3
7 0 0 0 + + + 0 + + + 0 0 2 3 2 3 3 0 0 0 0 0
8 0 0 0 + + 0 + 0 + + + 0 2 3 2 3 0 0 2 3 0 0
9 0 0 0 + + 0 0 0 + 0 0 + 2 3 0 0 0 0 0 0 2 3
10 0 0 0 + + 0 0 + 0 + 0 + 0 0 2 3 3 0 0 0 2 3
11 + + 0 0 0 0 0 + + + 0 + 2 3 2 3 3 0 0 0 2 3
Interpretation : Sample 6 = Anti- Jka  7 = Anti-Jkb 8 = Anti- Fyb 9 = Anti-Lea 10 = Anti-Leb 
Table: Antibody Panel result
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Characteristics of panel cells used for antibody identification
1. An antibody panel usually includes at least 11 panel cells.
2. Group O red cells are often used for the preparation of panel cells since 
group O  red cells lack ABO blood group antigens.
3. Each of the panel cells has been antigen typed shown on antigram as ei
ther (+) to indicate the presence of the antigen and (-) to indicate absence.
4. Cells homozygous for the corresponding antibodies are often used to en
hance agglutination reaction. 
5. Antibodies vary in their optimum temperature of reactivity (saline at 
room temperature and at 37°C and AHG at 37°C). Most antibodies detect
able in AHG at 37°C (warm reacting IgG) are clinically sgnificant).
6. The activity of certain antigens are destroyed or depressed by enzyme (fi
cin, papain and bromeline) treatment (Duffy, MNS and Xga) while others 
are enhanced (Rhesus, Kidd, Lewis, I and P antigens).
7. Some antigens exhibits a dosage effect. Their reaction with the corre
sponding antibody is stronger if the patient is homozygous for the cor
responding antigen.
8. The key in antibody identification is that an antibody will only react with 
cells that have the corresponding antigen; antibodies will not react with 
cells that do not have the antigen
There are a few basic steps to follow when interpreting panels for alloantibody identification. 
They include:
1. “Ruling out” means crossing out antigens that did not react (Cross out 
antigens that show no reaction in any phase. Do  cross out hetero
zygous antigens that show dosage.
2. Circle the antigens that are not crossed out. Circle the entire antigen that 
you could not eliminate during the crossing out process.
3. Consider antibody’s usual reactivity pattern such as temperature and me
dium of optimum reactivity. The Lewis antibody (anti-Le ) for example
normally a cold-reacting antibody (IgM), so it makes sense that we see 
the reaction in the saline phase of testing; The E antigen will usually react 
at warmer temperatures (37°C).
4. Look for a matching pattern to enable you conclusively identify the anti
body. Single antibodies usually shows a pattern that matches one of the. 
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Characteristics of panel cells used for antibody identification
1. An antibody panel usually includes at least 11 panel cells.
2. Group O red cells are often used for the preparation of panel cells since 
group O  red cells lack ABO blood group antigens.
3. Each of the panel cells has been antigen typed shown on antigram as ei-
ther (+) to indicate the presence of the antigen and (-) to indicate absence.
4. Cells homozygous for the corresponding antibodies are often used to en-
hance agglutination reaction. 
5. Antibodies vary in their optimum temperature of reactivity (saline at 
room temperature and at 37°C and AHG at 37°C). Most antibodies detect-
able in AHG at 37°C (warm reacting IgG) are clinically sgnificant).
6. The activity of certain antigens are destroyed or depressed by enzyme (fi-
cin, papain and bromeline) treatment (Duffy, MNS and Xga) while others 
are enhanced (Rhesus, Kidd, Lewis, I and P antigens).
7. Some antigens exhibits a dosage effect. Their reaction with the corre-
sponding antibody is stronger if the patient is homozygous for the cor-
responding antigen.
8. The key in antibody identification is that an antibody will only react with 
cells that have the corresponding antigen; antibodies will not react with 
cells that do not have the antigen
There are a few basic steps to follow when interpreting panels for alloantibody identification. 
They include:
1. “Ruling out” means crossing out antigens that did not react (Cross out 
antigens that show no reaction in any phase. Do NOT cross out hetero-
zygous antigens that show dosage.
2. Circle the antigens that are not crossed out. Circle the entire antigen that 
you could not eliminate during the crossing out process.
3. Consider antibody’s usual reactivity pattern such as temperature and me-
dium of optimum reactivity. The Lewis antibody (anti-Lea) for example is 
normally a cold-reacting antibody (IgM), so it makes sense that we see 
the reaction in the saline phase of testing; The E antigen will usually react 
at warmer temperatures (37°C).
4. Look for a matching pattern to enable you conclusively identify the anti-
body. Single antibodies usually shows a pattern that matches one of the. 
Multiple antibodies are more difficult to match because they often show 
mixed reaction strengths.
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5. Again, it’s important to look at the auto control result. A negative auto 
control is an indication that the antibody detected is an alloantibody rath-
er than an autoantibody. A positive control indicates the presence of an 
autoantibody.
6. The strength of the reaction also plays a key role in the determination of 
the presence of a single or multiple antibodies. Consistent strength usu-
ally indicates the presence of one antibody. Different reaction strengths 
may indicate the presence of multiple antibodies or dosage. Strength of 
reaction may also be due to “dosage” effect. If panel cells are homozygous, 
a strong reaction may be seen while If panel cells are heterozygous, reac-
tion may be weak or even non-reactive
7. Panel cells that are heterozygous should not be crossed out because anti-
body may be too weak to react.
To identify an antibody, the rule of three must be met to confirm the presence of the antibody. 
Patient serum must; show a positive reaction with at least 3 cells with the antigen on the panel 
cell and show a negative reaction with 3 cells without the antigen on the panel cell. If there are 
not enough cells in the panel to fulfill the rule, then additional cells from another panel could be 
used. Example is the B panel cells. Most labs also carry different lot numbers of panel cells. In 
addition to the rule of three, antigen typing the patient red cells can also play a role in the con-
firmation of the identity of an antibody. You must however only perform this if the patient has 
NOT been recently transfused (donor cells could react). The principle of antigen testing is based 
on the fact that a patient can only produce antibody against a red cell antigen that he lacks. If 
reagent antisera (of the suspected antibody) are added to the patient RBCs, a negative reaction 
should result. Antigen testing of patients with an alloantibody (phenotyping) is based on the 
principle that an individual will only produce antibody to a blood group antigen that he himself 
lacks. Identification of multiple antibodies may be quite challenging. Several procedures can be 
performed to identify multiple antibodies. These include:
Use of selected Cells. Selected cells are chosen from other panel or screening cells to confirm or 
eliminate the antibody. The cells are “selected” from other panels because of their characteris-
tics. The number of selected cells needed depends on how may antibodies are identified. Every 
cell should be positive for each of the antibodies and negative for the remaining antibodies. For 
example if you ran a panel and identified 3 different antibodies: anti-S, anti-Jka, and anti-P1. Se-
lected cells 1 positive for S and negative for Jka and P1 while cell 2 should be positive for Jka but 
negative for S and P1 and cell3 should be positive for P1 and negative for S and Jka. 
Neutralization. Some antibodies may be neutralized by certain commercial substances and 
can play a role in alloantibody confirmation. Certain commercial “substances” bind to the 
antibodies in the patient serum (neutralize), causing them to show no reaction when tested 
with red cells containing the corresponding antigen. Manufacturer’s instruction should be 
followed and a dilutional control should always be used. The control should contain saline 
and serum (with no neutralizing substance) and should give a positive reaction. A control 
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shows that a loss of reactivity in the test (serum treated with the neutralizing substance) is 
due to the neutralization and not to the dilution of the antibody strength when the substance 
is added. Many of these neutralizing substances neutralize COLD antibodies. Cold antibodies 
can sometimes  more clinically significant antibodies (IgG). This is an important reason 
to use neutralization techniques.
Examples of common neutralizing substances are:
1. P1 substance (sometimes derived from hydatid cyst fluid)
2. Le  and Leb substance (soluble antigen found in plasma and saliva)
3. I substance can be found in breast milk
4.  substance derived from human or guinea pig urine
5. Chemical treatment
Proteolytic enzymes. Proteolytic enzymes can also be used to enhance or destroy certain 
blood group antigens. Enzymes remove the  from the RBC membrane, thus “de
stroying” it and allowing other antigens to be “enhanced”. Some antigens are destroyed by 
enzyme treatment while the activities of others are enhanced. Examples of antigens that are 
positive, negative or show variable reactions with enzyme treatment is shown in the table 
below. In addition, enzyme procedures may be either one-step or Two-step. If there is no 
agglutination after treatment, then it is assumed the enzymes destroyed the antigen. In the 
One-stage test, enzyme is added directly to the serum/cell mixture while in the Two-stage test, 
panel cells are pre-treated with enzyme, incubated and washed and patient serum is added 
to panel cells and tested.
Enzyme utility in antibodies identification
Rhesus, A, B, H
Cartwright (Yt)
Sex linked Xga, Hagen (JMH), 
Gerbich (Ge2 and Ge4)
 Kidd, Dombrock (Do), Land-
steiner-Weiner (LW)
Duffy (Fya, Fyb)
Lewis, Scianna (Sc), Colton (Co), 
Kx, Ok 
Indian (In), Chido (Ch), Rodgers 
(Rg), John Milton 
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autoantibody.
 of the reaction also plays a key role in the determination of 
the presence of a single or multiple antibodies. Consistent strength usu
ally indicates the presence of one antibody. Different reaction strengths 
may indicate the presence of multiple antibodies or dosage. Strength of 
reaction may also be due to “dosage” effect. If panel cells are homozygous, 
a strong reaction may be seen while If panel cells are heterozygous, reac
tion may be weak or even non-reactive
7. Panel cells that are heterozygous should not be crossed out because anti
body may be too weak to react.
To identify an antibody, the rule of three must be met to confirm the presence of the antibody. 
Patient serum how a positive reaction with at least 3 cells with the antigen on the panel 
cell and show a negative reaction with 3 cells without the antigen on the panel cell. If there are 
not enough cells in the panel to fulfill the rule, then additional cells from another panel could be 
used. Example is the B panel cells. Most labs also carry different lot numbers of panel cells. In 
addition to the rule of three,  the patient red cells can also play a role in the 
firmation of the identity of an antibody. You must however only perform this if the patient has 
NOT been recently transfused (donor cells could react). The principle of antigen testing is based 
on the fact that a patient can only produce antibody against a red cell antigen that he lacks. If 
reagent antisera (of the suspected antibody) are added to the patient RBCs, a  reaction 
should result. Antigen testing of patients with an alloantibody (phenotyping) is based on the 
principle that an individual will only produce antibody to a blood group antigen that he himself 
lacks. Identification of multiple antibodies may be quite challenging. Several procedures can be 
performed to identify multiple antibodies. These include:
Selected cells are chosen from other panel or screening cells to confirm or 
eliminate the antibody. The cells are “selected” from other panels because of their characteris
tics. The number of selected cells needed depends on how may antibodies are identified. Every 
cell should be positive for each of the antibodies and negative for the remaining antibodies. For 
example if you ran a panel and identified 3 different antibodies: anti-S, anti-Jk , and anti-P1. Se
lected cells 1 positive for S and negative for Jka and P1 while cell 2 should be positive for Jka but 
negative for S and P1 and cell3 should be positive for P1 and negative for S and Jka. 
Neutralization. Some antibodies may be neutralized by certain commercial substances and 
can play a role in alloantibody confirmation. Certain commercial “substances” bind to the 
antibodies in the patient serum (neutralize), causing them to show no reaction when tested 
with red cells containing the corresponding antigen. Manufacturer’s instruction should be 
followed and a dilutional control should always be used. The control should contain saline 
and serum (with no neutralizing substance) and should give a positive reaction. A control 
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shows that a loss of reactivity in the test (serum treated with the neutralizing substance) is 
due to the neutralization and not to the dilution of the antibody strength when the substance 
is added. Many of these neutralizing substances neutralize COLD antibodies. Cold antibodies 
can sometimes mask more clinically significant antibodies (IgG). This is an important reason 
to use neutralization techniques.
Examples of common neutralizing substances are:
1. P1 substance (sometimes derived from hydatid cyst fluid)
2. Lea and Leb substance (soluble antigen found in plasma and saliva)
3. I substance can be found in breast milk
4. Sda substance derived from human or guinea pig urine
5. Chemical treatment
Proteolytic enzymes. Proteolytic enzymes can also be used to enhance or destroy certain 
blood group antigens. Enzymes remove the sialic acid from the RBC membrane, thus “de-
stroying” it and allowing other antigens to be “enhanced”. Some antigens are destroyed by 
enzyme treatment while the activities of others are enhanced. Examples of antigens that are 
positive, negative or show variable reactions with enzyme treatment is shown in the table 
below. In addition, enzyme procedures may be either one-step or Two-step. If there is no 
agglutination after treatment, then it is assumed the enzymes destroyed the antigen. In the 
One-stage test, enzyme is added directly to the serum/cell mixture while in the Two-stage test, 
panel cells are pre-treated with enzyme, incubated and washed and patient serum is added 
to panel cells and tested.
Enzyme utility in antibodies identification
Antigens destroyed enzyme 
treatment
Antigens enhanced by Ficin/
Papain treatment
Antigen with variable reac-
tion with enzyme treatment
M, N,S,s Rhesus, A, B, H
Cartwright (Yt)
Sex linked Xga, Hagen (JMH), 
Gerbich (Ge2 and Ge4)
 Kidd, Dombrock (Do), Land-
steiner-Weiner (LW)
Duffy (Fya, Fyb)
Lewis, Scianna (Sc), Colton (Co), 
Kx, Ok 
Indian (In), Chido (Ch), Rodgers 
(Rg), John Milton 
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Sulfhydryl reagents. Ability of sulfhydryl reagents to cleave the disulfide bonds of IgM mol-
ecules can help in the differentiation between IgM and IgG antibodies. It is good to use these 
agents when you have a mixture of both IgG and IgM antibodies (warm/cold). Examples of 
Sulfhydryl reagents include; Dithiothreitol (DTT) is a thiol and will denature Kell antigens 
and 2-mercaptoethanol (2-ME)
ZZAP. Sometimes, patients with autoantiobodies require red cell transfusion. The most important 
technical issue faced by the transfusion laboratory is determining if the patient’s serum contains 
alloantibodies in addition to the autoantibody. Between 15 and 40% of patients with autoimmune 
haemolytic anaemia have alloantibodies. The most common alloantibodies detected in the sera 
of patients with AIHA in descending order are: anti-E, K, C, Fya, Jka, and c. The most frequently 
used method for detecting alloantibodies in the presence of a broadly reactive autoantibody is the 
warm auto adsorption procedure. Autoantibody is removed by treating the autologous red cells 
with ZZAP, which is a combinination of dithiothreitol and papain. Autoantibody is then adsorbed 
from plasma with these treated autologous red cells. Several adsorptions may be necessary to 
remove all of the autoantibody. If no antibody is detected, the adsorbed plasma can be used for 
crossmatching donor units. If alloantibody is present, it must be identified and antigen negative 
units selected for crossmatching. A combination of proteolytic enzymes papain and DTT help de-
natures Kell, M, N, S, Duffy and other less frequent blood group antigens but does not denature 
the Kx antigen. ZZAP is good for adsorption techniques. It “frees” autoantibody off patient’s cell, 
so that the clinically significant antibody which it is masking can be identified. It may also help in 
the possible identification and study of the autoantibody.
Autoantibodies
The recipient’s immune system may also react to someone else’s white blood cells, platelets, and 
may sometimes form autoantibodies that target their own red blood cells. Rarely, antibodies in 
the plasma of the blood donor may target the RBCs of the transfusion recipient. Some RBC an-
tibodies may not target a specific RBC antigen but may react with a broad range of different red 
blood cell antigen types, including the patient’s own. These types of antibodies can occur in as-
sociation with autoimmune disorders, lymphomas and chronic lymphocytic leukaemia, certain 
viral or mycoplasma infections, and some medications. Autoantibodies can be cold or warm 
reacting. Auto-antibodies can sometimes “mask” clinically significant allo-antibodies, so it’s im-
portant to differentiate between auto- and allo-antibodies. React at room temperature with most 
(if not all) of the panel cells and give a positive auto control. The DAT is usually positive with 
anti-C3 AHG (detects complement). A positive DAT may be indicative of the following:
1. Could be due to Mycoplasma pneumoniae, infectious mononucleosis, or 
cold haemagglutinin disease (CHAD).
2. A positive auto control or DAT may indicate that an auto-antibody is present
3. Sometimes the auto control may be positive, but the antibody screening 
may be negative, meaning something is coating the RBC. DAT in such 
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cases are usually positive indication that the patients red cells are coated 
with possibly an autoantibody.
4. The direct antiglobulin test (DAT) is a tests for the determination of in 
vivo coating of RBCs with antibody (in the body)
5. AHG serum is added to wash patient red cells to determine the presence 
of antibody coating on the surface of the patient red cells.
Although not always performed in routine pre-transfusion testing, a positive DAT can offer 
valuable information; If the patient has been transfused, the patient may have an alloantibody 
coating the transfused cells and if the patient has NOT been transfused, the patient may have 
an autoantibody coating their own cells. Mini-cold panels can be used to help identify cold 
auto antibodies. Since anti-I is one of the commonest autoantibody, cord blood cells which 
contain no I antigen are usually included in the mini cold panel. Cold auto antibodies can be 
a nuisance at times. There are a few ways to avoid the effect of their reactions:
1. Use anti-IgG AHG instead of polyspecific reagent. Most cold antibodies 
react with polyspecific AHG and anti-C AHG because they fix complement.
2. Skipping the Saline at room temperature phase avoids the attachment of 
cold auto antibodies to the red cells.
3. Use 22% Bovine Serum Albumin (BSA) which is a potentiating medium 
and facilitates the detection of clinically significant warm reacting IgG an
tibodies instead of LISS.
4. If the antibodies remain, then  can be performed. 
Red cells, serum, and saline are incubated at 37° before being combined.
5. Auto adsorption is another technique in which the autoantibody is re
moved from the patient’s serum using their own red cells. The serum can 
be used to identify any underlying alloantibodies.
6. More common than cold autoantibodies, positive DAT can also be due to 
IgG antibodies coating the red cell. In such cases the majority of panel or 
screening cells will be positive. The Rh system (e antigen) seems to be the 
main target amongst others.
7. IgG antibodies coating the red cell cause warm autoimmune hemolytic 
anemia (WAIHA). These warm autoantibody can either be: Idiopathic oc
curring either as a result of known disorder; Systemic Lupus Erythemato
sis (SLE), Rheumatoid Arthritis (RA), Leukemia, pregnancy, infectious dis
eases and lymphoma) or as a result of long term use of certain medications.
Several techniques are used when warm autoantibodies are suspected. They include;
Elution techniques “free” antibodies from the sensitized red cells so that 
the antibodies can be identified. The  is a term used for the removed antibodies. Testing 
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agents when you have a mixture of both IgG and IgM antibodies (warm/cold). Examples of 
Sulfhydryl reagents include; Dithiothreitol (DTT) is a thiol and will denature Kell antigens 
and 2-mercaptoethanol (2-ME)
Sometimes, patients with autoantiobodies require red cell transfusion. The most important 
technical issue faced by the transfusion laboratory is determining if the patient’s serum contains 
alloantibodies in addition to the autoantibody. Between 15 and 40% of patients with autoimmune 
haemolytic anaemia have alloantibodies. The most common alloantibodies detected in the sera 
of patients with AIHA in descending order are: anti-E, K, C, Fy , Jk , and c. The most frequently 
used method for detecting alloantibodies in the presence of a broadly reactive autoantibody is the 
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units selected for crossmatching. A combination of proteolytic enzymes papain and DTT help de
natures Kell, M, N, S, Duffy and other less frequent blood group antigens but does not denature 
the Kx antigen. ZZAP is good for adsorption techniques. It “frees” autoantibody off patient’s cell, 
so that the clinically significant antibody which it is masking can be identified. It may also help in 
the possible identification and study of the autoantibody.
The recipient’s immune system may also react to someone else’s white blood cells, platelets, and 
may sometimes form autoantibodies that target their own red blood cells. Rarely, antibodies in 
the plasma of the blood donor may target the RBCs of the transfusion recipient. Some RBC an
tibodies may not target a specific RBC antigen but may react with a broad range of different red 
blood cell antigen types, including the patient’s own. These types of antibodies can occur in as
sociation with autoimmune disorders, lymphomas and chronic lymphocytic leukaemia, certain 
viral or mycoplasma infections, and some medications. Autoantibodies can be cold or warm 
reacting. Auto-antibodies can sometimes “mask” clinically significant allo-antibodies, so it’s im
portant to differentiate between auto- and allo-antibodies. React at room temperature with most 
(if not all) of the panel cells and give a positive auto control. The DAT is usually positive with 
anti-C3 AHG (detects complement). A positive DAT may be indicative of the following:
1. Could be due to Mycoplasma pneumoniae, infectious mononucleosis, or 
cold haemagglutinin disease (CHAD).
2. A positive auto control or DAT may indicate that an auto-antibody is present
3. Sometimes the auto control may be positive, but the antibody screening 
may be negative, meaning something is coating the RBC. DAT in such 
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cases are usually positive indication that the patients red cells are coated 
with possibly an autoantibody.
4. The direct antiglobulin test (DAT) is a tests for the determination of in 
vivo coating of RBCs with antibody (in the body)
5. AHG serum is added to wash patient red cells to determine the presence 
of antibody coating on the surface of the patient red cells.
Although not always performed in routine pre-transfusion testing, a positive DAT can offer 
valuable information; If the patient has been transfused, the patient may have an alloantibody 
coating the transfused cells and if the patient has NOT been transfused, the patient may have 
an autoantibody coating their own cells. Mini-cold panels can be used to help identify cold 
auto antibodies. Since anti-I is one of the commonest autoantibody, cord blood cells which 
contain no I antigen are usually included in the mini cold panel. Cold auto antibodies can be 
a nuisance at times. There are a few ways to avoid the effect of their reactions:
1. Use anti-IgG AHG instead of polyspecific reagent. Most cold antibodies 
react with polyspecific AHG and anti-C AHG because they fix complement.
2. Skipping the Saline at room temperature phase avoids the attachment of 
cold auto antibodies to the red cells.
3. Use 22% Bovine Serum Albumin (BSA) which is a potentiating medium 
and facilitates the detection of clinically significant warm reacting IgG an-
tibodies instead of LISS.
4. If the antibodies remain, then pre-warmed techniques can be performed. 
Red cells, serum, and saline are incubated at 37° before being combined.
5. Auto adsorption is another technique in which the autoantibody is re-
moved from the patient’s serum using their own red cells. The serum can 
be used to identify any underlying alloantibodies.
6. More common than cold autoantibodies, positive DAT can also be due to 
IgG antibodies coating the red cell. In such cases the majority of panel or 
screening cells will be positive. The Rh system (e antigen) seems to be the 
main target amongst others.
7. IgG antibodies coating the red cell cause warm autoimmune hemolytic 
anemia (WAIHA). These warm autoantibody can either be: Idiopathic oc-
curring either as a result of known disorder; Systemic Lupus Erythemato-
sis (SLE), Rheumatoid Arthritis (RA), Leukemia, pregnancy, infectious dis-
eases and lymphoma) or as a result of long term use of certain medications.
Several techniques are used when warm autoantibodies are suspected. They include;
Elution techniques. Elution techniques “free” antibodies from the sensitized red cells so that 
the antibodies can be identified. The eluate is a term used for the removed antibodies. Testing 
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the eluate is useful in investigations of positive DATs. The red cells can also be used after elu-
tion for RBC phenotyping if needed. When tested with panel cells, the eluate usually remains 
reactive with all cells if a warm autoantibody is present. Warm autoantibody may be present 
in the following condition; HDN, transfusion reactions and autoimmune disease. The most 
common elution techniques 
1. Acid elutions (glycine acid). This method lowers pH, causing antibody to 
dissociate
2. Organic solvents (ether, chloroform). This help to dissolve the lipid bi-layer 
of RBC
3. Heat (conformational change)
4. Freeze-Thaw technique ( this lyses cells and releases the antibody coating on 
the red cells)
5. Adsorption procedures can be used to investigate underlying alloantibodies 
6. ZZAP or chloroquine diphosphate can be used to dissociate IgG antibodies 
from the RBC. After the patient RBCs are incubated, the adsorbed serum is 








Rh (C, E, c, e) MNS (U, Vw, Mur) Lutheran (Lua, Lub)
Chido/Rodgers (Cha, 
Rga)
Kell (K, k, Ku) Vel Lewis (Lea, Leb) JMH
Duffy (Fya, Fyb, Fy3) Ge MNS (M, N) Bg
Kidd (Jka, Jkb, Jk3) Hy A1 Csa
Diego (Dia, Dib, Wra) Yta P1 Xga
MNS (S, s)      
Table: RBC antibodies and their clinical significance.
There are two types of adsorption techniques:
Autoadsorption. Carried out in those patients who have not had a recent transfusion. Autoan-
tibodies are removed using patient RBCs, so alloantibodies can be identified and patient red 
cell can be phenotyped.
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Allogenic (Differential) adsorption. This method is used in patients who have recently been 
transfused. It uses other cells (allogenic) with the patient’s serum. The figure below shows the 2 
different types of autoadsorption principles. Many of elution tests can damage the antigens on 
the RBC.  (CDP) and glycine acid EDTA reagents can dissociate IgG 
from the RBC without damaging the antigens. This technique is very useful if the RBC needs 
to be antigen typed. Quinilone derivative often used as an antimalarial can also be used. It may 
however not remove autoantibody completely from DAT positive cells. Partial removal may be 
enough to antigen type the cells or to be used for autoadsorption of warm autoantibodies. 
The human red blood cell (RBC) membrane is complex and contains a variety of blood group 
antigens, the most clinically significant being the ABO system and the Rh system. The Rh sys
tem consists of two related proteins, RhD and RhCE, which express the D and CE antigens, 
respectively. People who have the D antigen on their RBCs are said to be RhD-positive, whereas 
those who do not are said to be RhD-negative. If the mother is RhD-negative and the fetus 
RhD-positive, the mother may react to fetal blood cells in her circulation by developing anti-D 
antibodies, a process known as RhD sensitization. Sensitization is unlikely to affect the cur
rent foetus but may result in haemolytic disease of the foetus and newborn (HDFN) during a 
second RhD-positive pregnancy. In its mildest form the infant has sensitized RBCs, which are 
detectable only in laboratory tests; however, HDFN may result in jaundice, anaemia, develop
mental problems, or intrauterine death.1 The frequency of RhD-negative phenotype in previous 
studies in Nigeria 4.44%, 3.9% in Kenya, 4.06% in Guinea and 2.4% in Cameroon. These find
ings are much lower than the ≥14% prevalence of Rh-negative phenotype observed in stud
ies among Caucasians. In most Sub-Saharan African countries, there are challenges associated 
with Rh pregnancies. A previous report indicated the effectiveness of anti-D prophylaxis in the 
prevention of HDFN despite poor access. The utilization rate of anti-Rh antiserum in South 
African population groups for the years 1983–1985 was investigated. The crude utilization rate 
of anti-Rh antiserum was 41%–44% for all population groups combined. The rate for Blacks, 
Whites, Indians, and Coloreds was 14%–20%, 89%–94%, 59%–64%, and 45%–51%, respectively. 
The potential risk of rhesus alloimmunization and the ensuing risk of fetal death with increas
ing parity were investigated in two groups of parturients: primiparous and grand multiparous 
Mozambican parturients. The difference did not reach statistical significance. Anti-D immu
noglobulin remains the most important alloantibody causing HDN, regardless of the availabil
ity of anti-D immunoglobulin for prophylaxis in resource-limited settings and suggests that all 
patients at booking should have an antibody screen. Care management with anti-D prophylaxis 
in patients presenting with severe alloimmunization is difficult to access in Sub-Saharan Africa. 
Beyond the challenge of access to anti-D prophylaxis, there is lack of alloimmunization pre
vention during illegal abortions and poor documentation of adequate information in patients’ 
medical notes. These factors are highly responsible for the difficult management of Rh-negative 
patients. To prevent HDFN in most developed countries, RhD-negative women are given anti-
D immununoglobulin (IgG) after delivery and often also between 28 and 34 weeks of gestation. 
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MNS (U, Vw, Mur) Lutheran (Lua, Lub)
Chido/Rodgers (Cha, 
Rga)
Kell (K, k, Ku) Lewis (Lea, Leb) JMH
Duffy (Fya, Fyb, Fy3) Ge Bg
Kidd (Jka, Jkb, Jk3) A1
Diego (Dia, Dib, Wra) P1 Xga
     
Table: RBC antibodies and their clinical significance.
There are two types of adsorption techniques:
Carried out in those patients who have not had a recent transfusion. Autoan
tibodies are removed using patient RBCs, so alloantibodies can be identified and patient red 
cell can be phenotyped.
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Allogenic (Differential) adsorption. This method is used in patients who have recently been 
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16. HDFN and management of Rh negative pregnancies
The human red blood cell (RBC) membrane is complex and contains a variety of blood group 
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prevention of HDFN despite poor access. The utilization rate of anti-Rh antiserum in South 
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Whites, Indians, and Coloreds was 14%–20%, 89%–94%, 59%–64%, and 45%–51%, respectively. 
The potential risk of rhesus alloimmunization and the ensuing risk of fetal death with increas-
ing parity were investigated in two groups of parturients: primiparous and grand multiparous 
Mozambican parturients. The difference did not reach statistical significance. Anti-D immu-
noglobulin remains the most important alloantibody causing HDN, regardless of the availabil-
ity of anti-D immunoglobulin for prophylaxis in resource-limited settings and suggests that all 
patients at booking should have an antibody screen. Care management with anti-D prophylaxis 
in patients presenting with severe alloimmunization is difficult to access in Sub-Saharan Africa. 
Beyond the challenge of access to anti-D prophylaxis, there is lack of alloimmunization pre-
vention during illegal abortions and poor documentation of adequate information in patients’ 
medical notes. These factors are highly responsible for the difficult management of Rh-negative 
patients. To prevent HDFN in most developed countries, RhD-negative women are given anti-
D immununoglobulin (IgG) after delivery and often also between 28 and 34 weeks of gestation. 
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At delivery, Rh D phenotype of the newborn is determined even if RhD fetal genotype is known. 
Maternal blood is drawn for quantification of fetomaternal transfusion within 72 hours of deliv-
ery of an Rh-positive baby and the optimum amount of anti-D immunoglobulin administered. 
Anti-D prophylaxis has significantly reduced the incidence of erythroblastosis fetalis caused by 
sensitization to the D-antigen and perinatal deaths from alloimmunization have fallen 100-fold 
in the developed world. 
The anti-D immununoglobulin is prepared from the plasma of immunized human donors 
and therefore exists in limited supply. Monoclonal anti-D antibodies have been developed 
to replace polyclonal anti-D and in vivo assays for these have been predominantly based on 
their ability to clear erythrocytes from the maternal circulation. Although the implementation 
of a program of routine antenatal anti-D prophylaxis (RAADP) has led to a significant decline 
in the residual numbers of women becoming sensitized in most developed countries, a sig-
nificant number of women are not fortunate enough to have access in Sub-Saharan Africa and 
thus continue to be affected. This is an ethical issue of utmost public health importance. The 
aim of this study is thus to highlight the challenges associated with the effective management 
and prevention of Rh alloimmunization among Rh-negative women in Sub-Saharan Africa.
Anti-D immunoglobulin. Anti-D immunoglobulin is produced by the pooling and fractiona-
tion of plasma from large numbers of donors who themselves are RhD-negative and have 
been exposed to RhD-positive RBCs to stimulate the production of RhD antibodies. The fu-
ture of anti-D immunoglobulin might involve monoclonal or recombinant products, thus 
eliminating the risks associated with human blood products. Costs would probably increase 
if recombinant products were used. Anti-D, a polyclonal IgG product is routinely and effec-
tively used to prevent HDFN. The mechanism of anti-D has not been fully elucidated. How-
ever, a correlation has frequently been observed between anti-D-mediated RBC clearance and 
prevention of the antibody response, suggesting that anti-D may be able to destroy RBCs 
without triggering the adaptive immune response. Anti-D opsonized RBCs may also elicit 
inhibitory FcgammaRIIB signaling in B cells and prevent B cell activation. The ability of anti-
gen-specific IgG to inhibit antibody responses has also been observed in a variety of animal 
models immunized with a vast array of different antigens, such as sheep RBCs. This effect has 
been referred to as antibody-mediated immune suppression.
Antenatal antibody screening. It is recommended that all women in most developed countries 
should have a blood group and antibody screening at first antenatal visit. It has been reported 
that 1.5%–2% of pregnant women show atypical blood group sensitization. Opinion is divided 
as to the clinical importance of a repeat anti-D antibody screen at 28 weeks’ gestation. Those in 
support of 28 weeks’ testing argue that there is the potential advantage to identify about 0.18% 
or fewer women particularly Rh-negative who become alloimmunized after their first antenatal 
screen possibly as a result of potential sensitizing event occurring after the first antenatal visit. 
The American Society of Clinical Pathology recommends that testing for unexpected antibody 
be carried out before antenatal anti-D is given to Rh-negative pregnant women and that repeat 
Rh testing be omitted if two documented test results confirming the Rh-negative status of the 
woman are on her record. Prior to 1970, HDFN due to anti-D was a significant cause of morbidi-
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ty and mortality. By 1990, a reduction in mortality from 1.2 per 1000 births to 0.02 per 1000 births 
had been achieved in response to the introduction of immunoprophylaxis with anti-D immu
noglobulin. At that time the sensitization rate dropped to about 1.2%. A further reduction to 
between 0.17% and 0.28% was achieved by introducing universal prophylaxis during the third 
trimester of pregnancy. These findings contributed to the National Institute for Clinical Excel
lence (NICE) in the UK for example recommend that all D-negative pregnant women who do 
not have immune anti-D should be offered anti-D immunoglobulin routinely during the third 
trimester of pregnancy. Some developed countries have also endorsed studies into the feasibil
ity of mass fetal blood group by analysis of fetal DNA in maternal plasma. The benefits of this 
testing would be twofold. Firstly, there would be a substantial reduction in the use of anti-RhD 
immunoglobulin, an expensive blood product in short supply. Secondly, women with an RhD-
negative fetus would be spared unnecessary exposure to this pooled human blood product with 
its associated discomfort and perceived risk from viral or prion contamination. Paternal testing 
of a baby’s father may be offered to all Rh-negative pregnant women to eliminate unnecessary 
blood product administration. It is recommended that partners of Rh-negative pregnant wom
en should be routinely tested. It is being suggested that the most important application of blood 
group genotyping by molecular genetics is the prediction of fetal RhD phenotype in pregnant 
women who are Rh-negative and in pregnant women with immune anti-D, in order to assess 
the risk of HDFN. This diagnostic test performed on cell-free fetal DNA in the maternal plasma 
is now available in some laboratories. High-throughput RhD genotyping of fetuses in all RhD-
negative women is feasible only in developed countries and would substantially reduce unnec
essary administration of anti-RhD immunoglobulin to RhD-negative pregnant women with an 
RhD-negative fetus.
Routine Anenatal Anti-D Prophylaxis (RAADP). Organized preventive screening programs 
for antenatal care were first introduced in Western Europe in the twentieth century with the 
hope that routine antenatal care would contribute to a reduction in maternal and infant mor
tality rates. Figures on maternal mortality in the developed world show that the risk of death 
as a result of pregnancy and child birth is approximately 1 in 7000 compared with 1 in 23 for 
women living in parts of Africa where antenatal care is poor or sometimes nonexistent. It is 
part of modern antenatal care to give all RhD-negative pregnant women an anti-RhD immu
noglobulin IgG injection at about 28 weeks’ gestation with or without a booster at 34 weeks’ 
gestation. This reduces the effect of the vast majority of sensitizing events which mostly occur 
after 28 weeks’ gestation. Anti-RhD immunoglobulin is also given to non-sensitized Rh-neg
ative women immediately within 72 hours after potentially sensitizing events that occur dur
ing pregnancy. All these advances in antenatal management of Rh-negative pregnant women 
in developed countries are beyond the reach of a vast majority of women in Sub-Saharan 
Africa. In most Sub-Saharan African countries, the recommendation is that:
1. Women should have an ABO and Rh blood group test done at the time of 
antenatal booking. 
2. Women found to be Rh-negative and who are married to Rh-positive 
men and run the risk of carrying an Rh-positive fetus and who can afford 
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The American Society of Clinical Pathology recommends that testing for unexpected antibody 
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Rh testing be omitted if two documented test results confirming the Rh-negative status of the 
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ty and mortality. By 1990, a reduction in mortality from 1.2 per 1000 births to 0.02 per 1000 births 
had been achieved in response to the introduction of immunoprophylaxis with anti-D immu-
noglobulin. At that time the sensitization rate dropped to about 1.2%. A further reduction to 
between 0.17% and 0.28% was achieved by introducing universal prophylaxis during the third 
trimester of pregnancy. These findings contributed to the National Institute for Clinical Excel-
lence (NICE) in the UK for example recommend that all D-negative pregnant women who do 
not have immune anti-D should be offered anti-D immunoglobulin routinely during the third 
trimester of pregnancy. Some developed countries have also endorsed studies into the feasibil-
ity of mass fetal blood group by analysis of fetal DNA in maternal plasma. The benefits of this 
testing would be twofold. Firstly, there would be a substantial reduction in the use of anti-RhD 
immunoglobulin, an expensive blood product in short supply. Secondly, women with an RhD-
negative fetus would be spared unnecessary exposure to this pooled human blood product with 
its associated discomfort and perceived risk from viral or prion contamination. Paternal testing 
of a baby’s father may be offered to all Rh-negative pregnant women to eliminate unnecessary 
blood product administration. It is recommended that partners of Rh-negative pregnant wom-
en should be routinely tested. It is being suggested that the most important application of blood 
group genotyping by molecular genetics is the prediction of fetal RhD phenotype in pregnant 
women who are Rh-negative and in pregnant women with immune anti-D, in order to assess 
the risk of HDFN. This diagnostic test performed on cell-free fetal DNA in the maternal plasma 
is now available in some laboratories. High-throughput RhD genotyping of fetuses in all RhD-
negative women is feasible only in developed countries and would substantially reduce unnec-
essary administration of anti-RhD immunoglobulin to RhD-negative pregnant women with an 
RhD-negative fetus.
Routine Anenatal Anti-D Prophylaxis (RAADP). Organized preventive screening programs 
for antenatal care were first introduced in Western Europe in the twentieth century with the 
hope that routine antenatal care would contribute to a reduction in maternal and infant mor-
tality rates. Figures on maternal mortality in the developed world show that the risk of death 
as a result of pregnancy and child birth is approximately 1 in 7000 compared with 1 in 23 for 
women living in parts of Africa where antenatal care is poor or sometimes nonexistent. It is 
part of modern antenatal care to give all RhD-negative pregnant women an anti-RhD immu-
noglobulin IgG injection at about 28 weeks’ gestation with or without a booster at 34 weeks’ 
gestation. This reduces the effect of the vast majority of sensitizing events which mostly occur 
after 28 weeks’ gestation. Anti-RhD immunoglobulin is also given to non-sensitized Rh-neg-
ative women immediately within 72 hours after potentially sensitizing events that occur dur-
ing pregnancy. All these advances in antenatal management of Rh-negative pregnant women 
in developed countries are beyond the reach of a vast majority of women in Sub-Saharan 
Africa. In most Sub-Saharan African countries, the recommendation is that:
1. Women should have an ABO and Rh blood group test done at the time of 
antenatal booking. 
2. Women found to be Rh-negative and who are married to Rh-positive 
men and run the risk of carrying an Rh-positive fetus and who can afford 
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treatment are offered prophylactic D immunoglobulin of 500 -1500 IU at 
28 weeks’ gestation. 
3. Tests to determine the presence of clinically significant alloantibodies in 
antenatal care patients should be carried out.
4. At delivery the blood group of the baby should be determined and if the 
baby is found to be Rh-positive, 500 -1500 IU of D immunoglobulin is 
administered. 
5. Facilities for determination of FMH should be available in developing 
countries. 
6. There should be provision of prophylactic D immunoglobulin following 
potential sensitizing events during pregnancy. 
In most developing countries including Nigeria, these requirements are not met. The result 
effect of this failure in management is that anti-D remains the most important alloantibody 
causing HDFN in Sub-Saharan Africa despite the availability of anti-D immunoglobulin for 
prophylaxis. Only in an insignificant number of centers do Rh D-negative women have an 
antibody screen at booking and repeat antibody screens during the rest of their pregnancy. 
Rh-negative women should be given an injection of human anti-D immunoglobulin after the 
termination of pregnancy procedure to prevent blood incompatibility complications in future 
pregnancies. There are many challenges to meeting this requirement in most countries in sub 
Saharan Africa:
1. Unsafe abortion, defined by the World Health Organization as a proce-
dure for terminating an unwanted pregnancy either by persons lacking 
the necessary skills or in an environment lacking the minimal medical 
standards, or both, is prevalent and continues to put Rh-negative women 
who cannot afford anti-D immunoglobulin at risk of Rh isoimmunization.
2. A broad array of personnel performs unsafe termination of pregnancy in 
Africa. Aside from the woman herself, others include physicians working 
at clandestine sites or in hospital operating theaters after normal working 
hours. 
3. Others with medical experience include midwives, traditional birth at-
tendants, pharmacists and nurses needs training on anti-D prophylaxis 
in Rh negative pregnancy.
4. Most worrisome are ‘untrained quacks’ whose motives may be financial 
and their skills negligible. 
Women who are Rh-negative should be given an injection of human anti-D immunoglobulin after 
the termination of pregnancy procedure unless the father of the fetus is also Rh-negative. This 
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prevents blood incompatibility complications in future pregnancies. The costs associated with 
providing routine antenatal anti-D prophylaxis are the cost of the anti-D immunoglobulin IgG 
and the cost of treatment administration. The price of anti-D Immunoglobulin differs according 
to its manufacturers: Bio Products Laboratory (BPL; Elstree, UK) offers anti-D IgG at a unit prize 
of £27 (US$41) for 500 IU vial while Baxter Healthcare (Deerfield, IL) anti-D IgG is offered at a 
unit prize of £23.90 (US$36) for a 1250 IU vial. Offering antenatal anti-D prophylaxis will cost an 
Rh-negative woman £47.80 (US$72) to £54 (US$82) per pregnancy depending on whether she is 
administered the BPL or Baxter product at 28 and 34 weeks. Cost-effectiveness analysis indicates 
that offering routine antenatal anti-D prophylaxis to RhD-negative women is economical and 
results in a marked impact upon the death rate associated with hemolytic disease of the newborn.
1. Drug manufacturers need to be more humane by reducing the cost of 
providing anti-D prophylaxis particularly in low-income countries in Sub-
Saharan Africa. Cost constraints have remained a limiting factor prevent
ing people from access to best possible treatment and care in Sub-Saharan 
African countries like their counterparts in most developed countries. 
2. There is also the urgent need for African leaders to take up the bold chal
lenge to provide universal access to anti-D prophylaxis for Rh-negative 
women. Per capita income in most settings is Sub-Saharan Africa is low 
and continues to affect affordability to prophylactic anti-D treatment. 
3. In the absence of anti-D prophylaxis to prevent incidence of HDFN, op
tions such as exchange blood transfusion and intrauterine transfusion 
(IUT) can significantly reduce mortality and prevent stillbirths. However, 
safety of blood and blood products remains a great concern. One of the 
biggest challenges to blood safety particularly in Sub-Saharan Africa is 
accessing safe and adequate quantities of blood and blood products. Gov
ernment and societies in Africa need to address several enduring chal
lenges; universal access to anti- D, provision of appropriate infrastructure, 
trained personnel, and financial resources to support the effective man
agement of Rh negative pregnancies and provision of ultrasonographi
cally guided IUT. This has improved the ability to treat severely anemic 
fetuses earlier in gestation and has increased the chances of survival of 
more severely affected foetuses. Around 10%–12% of fetuses affected by 
HDN will require IUT and a relatively high proportion of IUT survivors 
may suffer neurodevelopmental problems such as cerebral palsy, deaf
ness, and motor and speech delay that will require specialist input and, 
in some cases, special education while others will suffer some degree of 
developmental delay requiring physiotherapy or speech therapy.
Current guidelines in most countries recommend 
that a minimum of 500 IU anti-D IgG be offered to all non-sensitized RhD-negative women 
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Women who are Rh-negative should be given an injection of human anti-D immunoglobulin after 
the termination of pregnancy procedure unless the father of the fetus is also Rh-negative. This 
121Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
prevents blood incompatibility complications in future pregnancies. The costs associated with 
providing routine antenatal anti-D prophylaxis are the cost of the anti-D immunoglobulin IgG 
and the cost of treatment administration. The price of anti-D Immunoglobulin differs according 
to its manufacturers: Bio Products Laboratory (BPL; Elstree, UK) offers anti-D IgG at a unit prize 
of £27 (US$41) for 500 IU vial while Baxter Healthcare (Deerfield, IL) anti-D IgG is offered at a 
unit prize of £23.90 (US$36) for a 1250 IU vial. Offering antenatal anti-D prophylaxis will cost an 
Rh-negative woman £47.80 (US$72) to £54 (US$82) per pregnancy depending on whether she is 
administered the BPL or Baxter product at 28 and 34 weeks. Cost-effectiveness analysis indicates 
that offering routine antenatal anti-D prophylaxis to RhD-negative women is economical and 
results in a marked impact upon the death rate associated with hemolytic disease of the newborn.
Way forward to universal access to anti-D prophylaxis in developing countries
1. Drug manufacturers need to be more humane by reducing the cost of 
providing anti-D prophylaxis particularly in low-income countries in Sub-
Saharan Africa. Cost constraints have remained a limiting factor prevent-
ing people from access to best possible treatment and care in Sub-Saharan 
African countries like their counterparts in most developed countries. 
2. There is also the urgent need for African leaders to take up the bold chal-
lenge to provide universal access to anti-D prophylaxis for Rh-negative 
women. Per capita income in most settings is Sub-Saharan Africa is low 
and continues to affect affordability to prophylactic anti-D treatment. 
3. In the absence of anti-D prophylaxis to prevent incidence of HDFN, op-
tions such as exchange blood transfusion and intrauterine transfusion 
(IUT) can significantly reduce mortality and prevent stillbirths. However, 
safety of blood and blood products remains a great concern. One of the 
biggest challenges to blood safety particularly in Sub-Saharan Africa is 
accessing safe and adequate quantities of blood and blood products. Gov-
ernment and societies in Africa need to address several enduring chal-
lenges; universal access to anti- D, provision of appropriate infrastructure, 
trained personnel, and financial resources to support the effective man-
agement of Rh negative pregnancies and provision of ultrasonographi-
cally guided IUT. This has improved the ability to treat severely anemic 
fetuses earlier in gestation and has increased the chances of survival of 
more severely affected foetuses. Around 10%–12% of fetuses affected by 
HDN will require IUT and a relatively high proportion of IUT survivors 
may suffer neurodevelopmental problems such as cerebral palsy, deaf-
ness, and motor and speech delay that will require specialist input and, 
in some cases, special education while others will suffer some degree of 
developmental delay requiring physiotherapy or speech therapy.
Antepartum and postpartum prophylaxis. Current guidelines in most countries recommend 
that a minimum of 500 IU anti-D IgG be offered to all non-sensitized RhD-negative women 
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at 28 and 34 weeks gestation in order to prevent the risk of RhD sensitization in pregnancy. It 
is recommended that a minimum anti-D immunoglobulin of 500 -1500 IU be administered:
1. After miscarriage or threatened abortion or induced abortion
2. Ectopic pregnancy




7. Blunt trauma to the abdomen
8. Placenta previa with bleeding, external cephalic version and any other 
potentially sensitizing events at less than 20 weeks gestation in non-sen-
sitized D-negative women.
However in the event of any sensitizing event after 20 weeks’ gestation, a minimum of 500 
IU of anti D is administered and blood must tested for FMH and if the estimated fetal bleed 
is greater than 4 mL, additional anti-D is administered (125 IU per 1 mL bleed). Before ter-
mination of pregnancy, blood type and antibody screen is done and if lady or mother is a 
confirmed RhD-negative a minimum of 500 IU of anti D is given. Anti- D should ideally 
be administered with 72 hours of a potentially sensitising event. However if anti-D immu-
noglobulin is not given within 72 hours of delivery or other potentially sensitizing event; 
anti-D immunoglobulin should be given as soon as the need is recognized, for up to 28 days 
after delivery or other potentially sensitizing events. Anti-D immunoglobulin of a minimum 
of 500IU should be given routinely to all Rh-negative non-sensitized women at 28 weeks’ ges-
tation when fetal blood type is unknown or known to be Rh-positive. All pregnant women 
(D-negative or D-positive) should be typed and screened for alloantibodies with an indirect 
antiglobulin test at the first prenatal visit and again at 28 weeks. When paternity is certain, Rh 
testing of the baby’s father may be offered to all Rh-negative pregnant women to eliminate 
unnecessary blood product administration. Non-sensitized D-negative women are given a 
minimum anti-D of a minimum of 500 IU after:
1. Miscarriage or threatened abortion 
2. Induced abortion during the first 12 weeks of gestation
3. Ectopic pregnancy at less than 12 weeks’ gestation
4. Molar pregnancy 
5. Following chorionic villous sampling at less than 12 weeks. 
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At therapeutic termination of pregnancy, blood type and antibody screen is done unless re
sults of blood type and antibody screen during the pregnancy are available, in which case an
tibody screening need not be repeated. Anti-D of 500IU should be given to all non-sensitized 
D-negative women, following conditions; amniocentesis, placental abruption, blunt trauma 
to the abdomen, cordocentesis, placenta previa with bleeding, external cephalic version and 
placenta previa with bleeding. There is a substantial risk of FMH over 30 mL with above 
events, especially with blunt trauma to the abdomen. If FMH is in excess of the amount cov
ered by the dose given additional anti-D should be given for every additional fetal RBC by 
ensuring that patients receive 125IU for every 1ml FMH. Failures of anti-D immunoglobulin 
prophylaxis can occur when there is increased FMH and/or insufficient anti-D immunoglobu
lin administration was observed. The causes of prophylaxis failure in developing countries 
include; facilities for the determination of FMH to allow for optimum dosing of anti-D im
munoglobulin are often lacking in most settings in Africa. Countries in Sub-Saharan Africa 
could learn from good practices in developed countries to help reduce the incidence of Rh 
isoimmunisation and hemolytic disease of the newborn. The proposal to use human Anti-D 
immunoglobulin prophylactically in pregnancy should not detract from the most expedient 
approach to further the reduction of Rh disease; ensure that every eligible woman is given 
Anti-D immunoglobulin after delivery, abortion, and other potentially sensitizing events like 
their counterparts in the developed world, ensure that Rh-negative women at risk are offered 
family planning with the potential to limit the number of pregnancies in these women who 
are already immunized. This is likely to be an effective way to reduce the current incidence 
of hemolytic disease in Sub-Saharan Africa. Present evidence shows that blanket antepartum 
Anti-D immunoglobulin prophylactic treatment may be very costly but beneficial to a signifi
cant number of women who may not be fortunate enough to have access as a result of unaf
fordability. There is need for sensitive and practical laboratory testing for FMH to be clinically 
available to provide new data on FMH. It is suggested that the KB testing should become the 
minimal cost-effective alternative to flow cytometric testing of FMH in low-income countries 
in Sub-Saharan Africa because of the cost implication of procuring flow cytometric equip
ment and lack of trained personnel. There is the urgent need for pregnant women truly at 
risk for Rh isoimmunization to be identified by analysis of their blood during first antenatal 
visit and that this should become the rational basis for antepartum Anti-D immunoglobulin 
treatment. There are compelling advantages in cost, risks, and benefits for an approach of se
lective antepartum Anti-D immunoglobulin therapy as opposed to routine prophylaxis for all 
Rh-negative gravid women. The knowledge of anti-D prophylaxis among obstetricians can be 
improved. A continual system of education to raise awareness of evidence-based practices as 
well as clinical audit can be implemented to address this. Rh-negative women in Sub-Saharan 
Africa will benefit immensely from programs such as the RAADP, but costs remains a major 
hindrance.
Potentially sensitising events in Rh (D) negative pregnancy after 20 weeks gestation
1. Amniocentesis and cordocentesis
2. Antepartum haemorrhage and per vaginal bleed
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at 28 and 34 weeks gestation in order to prevent the risk of RhD sensitization in pregnancy. It 
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3. External cephalic version
4. Fall and other abdominal trauma
5. Intrauterine death (IUD and still birth)
6. Intrauterine therapeutic interventions like amniocentesis, intrauterine 
transfusion and surgery
7. Miscarriage
8. Therapeutic termination of pregnancy (TOP) 
Managing intermittent bleeds in Rh (D) negative pregnancy
1. If recurrent bleed occur after 20 weeks gestation, anti D will be required 
in 6 weekly intervals.
2. FMH should be performed every 2 weeks.
3. If FMH is detected, additional anti-D should be administered irrespective 
of whether passive anti-D is present or not.
4. Follow up sample should be repeated after 72 of initial intervention to 
confirm clearance of fetal red cells from maternal circulation.
5. If repeat is positive, flow cytometric test for FMH may be required to 
confirm that the circulating fetal cells is D positive cells.
Testing for Feto Maternal Haemorrhage (FMH). Rh immunization in pregnancy most com-
monly results from the fact that at delivery a variable amount of fetal blood enters the mater-
nal circulation when the placenta separates from the uterine wall. The KB test (acid elution) is 
a blood test used to quantify FMH. It measures the amount of fetal haemoglobin transferred 
from a fetus to a mother’s bloodstream. It is based on the differential properties of haemo-
globin F containing foetal red cell to withstand elution by an acid stain. It is usually per-
formed on Rh-negative mothers to identify women with a large fetomaternal haemorrhage 
(>4 mL of packed fetal RBCs) who may need additional anti-D immunoglobulin to ensure 
complete clearance of all fetal RBCs from maternal circulation and thus prevent them from 
being sensitized to produce immune antibodies against D- antigen on the surface of the fetal 
RBCs. A standard dose of 125 IU is the required dose of Anti-D immunoglobulin required to 
inhibit 1 mL bleed of fetal RBCs and thus prevent the formation of Rh- antibodies in the moth-
er and prevent Rh- disease in future Rh-positive children. The KB test is the standard method 
of detecting FMH. It takes advantage of the differential resistance of fetal haemoglobin to 
acid elution. A standard blood smear is prepared from the mother’s blood, and exposed to an 
acid bath. This removes adult haemoglobin, but not fetal haemoglobin, from the RBCs. Subse-
quent staining with eosin makes fetal cells (containing fetal haemoglobin) appear rose-pink in 
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color, while adult RBCs are only seen as ‘ghosts’. A large number of cells (>5000) are counted 
under the microscope and a ratio of fetal to maternal cells generated. In those with positive 
tests, follow-up testing as a postpartum check should be done to rule out the possibility of a 
false positive. This could be caused by:
1. A process in the mother which causes persistent elevation of fetal haemo
globin
2. Sickle cell trait 
3. Hereditary persistence of fetal haemoglobin (HPFH).
Comparison with other more expensive or technologically advanced methods such as flow 
cytometry has shown that the KB test, like the more advanced methods, is sensitive for the 
detection of FMH. Testing at the time of birth and postpartum is indicated if baby is Rh-pos
itive. A cord sample is collected from all babies born of Rh-negative mothers. Where the cord 
sample is Rh positive, a KB or flow cytometric determination of FMH is carried out and anti-D 
immunoglobulin optimal to clear the volume of FMH is administered preferably within 72 
hours of delivery.
 Since fetal and maternal blood cells have the same life expectancy in the 
maternal bloodstream, it is possible to obtain informative results from a KB stain for a fair 
period of time after a stillbirth. However, if the mother and fetus are ABO incompatible, it is 
more crucial to quickly perform the KB stain following a stillbirth, as the fetal RBCs will be 
eliminated from the maternal bloodstream very quickly, causing the KB stain to underesti
mate the degree of FMH, if any. The KB technique, based on acid elution of maternal RBCs, 
is the mostly widely used technique in the developed world for estimating the volume of 
FMH and for determining the need for additional doses of anti-D immunoglobulin to prevent 
maternal alloimmunization. Finally, anything that causes persistence of fetal haemoglobin in 
maternal blood cells will make interpretation much trickier. Certain hemoglobinopathies, the 
most common of which is sickle cell trait and HPFH do this. The KB test has been used world
wide since the 1950s to quantify the FMH and to ensure that an appropriate dose of anti-D 
immunoglobulin is administered both antenatally and postnatally to RhD-negative women 
to prevent Rh alloimmunization. Although apparently a simple test to perform, recent reports 
have suggested that unless meticulous attention is paid to both technique and interpretation, 
the accuracy of the test cannot be guaranteed and that it should be replaced with a flow cy
tometric test which would give more relevant and accurate results. Flow cytometers are not, 
however, available to all laboratories performing estimations of FMH. The comparability of 
results was assessed using a standardized KB technique with flow cytometry suggest that if 
careful attention is paid to performing a standardized KB test, then it is of value in estimating 
the size of FMH, and that flow cytometry may be of additional value for cases in which the 
Kleihauer result is equivocal or indicates that a large FMH has occurred which requires the 
administration of additional anti-D immunoglobulin. Patient samples identified by KB testing 
as having FMH >4 mL were sent for flow cytometric analysis. The report indicated that flow 
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color, while adult RBCs are only seen as ‘ghosts’. A large number of cells (>5000) are counted 
under the microscope and a ratio of fetal to maternal cells generated. In those with positive 
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false positive. This could be caused by:
1. A process in the mother which causes persistent elevation of fetal haemo-
globin
2. Sickle cell trait 
3. Hereditary persistence of fetal haemoglobin (HPFH).
Comparison with other more expensive or technologically advanced methods such as flow 
cytometry has shown that the KB test, like the more advanced methods, is sensitive for the 
detection of FMH. Testing at the time of birth and postpartum is indicated if baby is Rh-pos-
itive. A cord sample is collected from all babies born of Rh-negative mothers. Where the cord 
sample is Rh positive, a KB or flow cytometric determination of FMH is carried out and anti-D 
immunoglobulin optimal to clear the volume of FMH is administered preferably within 72 
hours of delivery.
Procedure for KB. Since fetal and maternal blood cells have the same life expectancy in the 
maternal bloodstream, it is possible to obtain informative results from a KB stain for a fair 
period of time after a stillbirth. However, if the mother and fetus are ABO incompatible, it is 
more crucial to quickly perform the KB stain following a stillbirth, as the fetal RBCs will be 
eliminated from the maternal bloodstream very quickly, causing the KB stain to underesti-
mate the degree of FMH, if any. The KB technique, based on acid elution of maternal RBCs, 
is the mostly widely used technique in the developed world for estimating the volume of 
FMH and for determining the need for additional doses of anti-D immunoglobulin to prevent 
maternal alloimmunization. Finally, anything that causes persistence of fetal haemoglobin in 
maternal blood cells will make interpretation much trickier. Certain hemoglobinopathies, the 
most common of which is sickle cell trait and HPFH do this. The KB test has been used world-
wide since the 1950s to quantify the FMH and to ensure that an appropriate dose of anti-D 
immunoglobulin is administered both antenatally and postnatally to RhD-negative women 
to prevent Rh alloimmunization. Although apparently a simple test to perform, recent reports 
have suggested that unless meticulous attention is paid to both technique and interpretation, 
the accuracy of the test cannot be guaranteed and that it should be replaced with a flow cy-
tometric test which would give more relevant and accurate results. Flow cytometers are not, 
however, available to all laboratories performing estimations of FMH. The comparability of 
results was assessed using a standardized KB technique with flow cytometry suggest that if 
careful attention is paid to performing a standardized KB test, then it is of value in estimating 
the size of FMH, and that flow cytometry may be of additional value for cases in which the 
Kleihauer result is equivocal or indicates that a large FMH has occurred which requires the 
administration of additional anti-D immunoglobulin. Patient samples identified by KB testing 
as having FMH >4 mL were sent for flow cytometric analysis. The report indicated that flow 
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cytometry is helpful for the accurate quantification and management of patients with large 
FMH, and in cases where the presence of maternal haemoglobin F-containing cells renders 
the KB technique inaccurate, worthwhile reductions in the use of anti-D immunoglobulin can 
be achieved.
Principle. Foetal haemoglobin containing red cells are resistant to both alkali denaturation 
and acid elution. Dry blood films fixed in 80% ethanol and immersed in acid buffer solution, 
red cells containing adult haemoglobin A are eluted leaving red cell ghost while red cells con-
taining foetal haemoglobin F are resistant and the haemoglobin can be stained. In preparing 
the slides, the sample must be properly mixed and samples must be taken within 72 hours 
of the sensitising event. Film should not be too thick. Thin film is made by diluting mater-
nal sample 1:2 with phosphate buffered saline. Positive and negative samples should be run 
along with the test sample.
How to prepare positive and negative control samples. To prepare positive control sample 
add 9 drops of any female patient EDTA anticoagulated sample into 2 tubes. To the first tube 
add 1 drop of a foetal sample of the same ABO group. Mix very well and add a1 drop from 
the first tube into the second tube. Add 5 drops of phosphate buffered saline. To prepare a 
negative control sample, add 15 drop of well mixed adult male EDTA anticoagulated sample 
into a tube and add 5 drops of phosphate buffered saline
Shephards stain preparation. Shephards stain is made up of 3 components; Solution 1, solu-
tion 2 and 80% ethanol. To prepare 40 mls of working solution of Shepards stain for staining 
Kleihauer;
1. Measure 2 parts (20mls) of solution one into a staining jar
2. Add 1 part (10mls) of solution 2
3. Add 1 part (10mls) of 80% ethanol
4. Mix the components
Staining
1. Fix thin film in 80% alcohol for 5 minutes and allow to air dry
2. Place slide in shepherd stain for 20 seconds
3. Rinse in running tap water and allow to dry and stain with eosin for 3 
minutes. Rinse thoroughly in running water
4. Air dry and examine at least 25 fields under the microscope at low 
power(x10 objective). Examine the positive and negative controls slides.
5. If any foetal cells are seen in the test film, the foetal cell count must be 
counted to determine the size of the bleed.
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1. Replace one of the objective of the microscope with a graticule (Miller 
square)
2. Focus the microscope making sure the graticule is on the top left hand 
corner.
3. Select the x 40 lens and count at least 50 fields of the area of the film 
where the red cells are just touching each other.
4. For each field count all the foetal cells in the large and small square.
5. Count all the maternal cells in the small square. Count fields with at least 
25-30 maternal cells.
6. To calculate the total number of maternal cells, add the total number of 
maternal cells together and multiply by 9. Also add the total number of 
foetal cells from the 50 fields.
7. The calculation of FMH is done using mollison’s rule. 
8. For example if the number of foetal red cells is 9 and the maternal cells is 
2000, the FMH = 9/2000 x 2400 =10.8 mls bleed.
Figure: Diagram of Miller square (graticule)
Anti-D administered is calculated by giving 125 IU per ml of FMH. 
For a 10.8 ml bleed you will have to administer 10.8 x 125 IU = 1350 IU of anti-D. For films where 
there is no foetal cells you assume that bleed is < 4mls and administer a minimum of 500 IU. Sam
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Foetal cell counting
1. Replace one of the objective of the microscope with a graticule (Miller 
square)
2. Focus the microscope making sure the graticule is on the top left hand 
corner.
3. Select the x 40 lens and count at least 50 fields of the area of the film 
where the red cells are just touching each other.
4. For each field count all the foetal cells in the large and small square.
5. Count all the maternal cells in the small square. Count fields with at least 
25-30 maternal cells.
6. To calculate the total number of maternal cells, add the total number of 
maternal cells together and multiply by 9. Also add the total number of 
foetal cells from the 50 fields.
7. The calculation of FMH is done using mollison’s rule. 
Mollison Rule= x 240
Number of foetal cells
Number of maternal cells
0
8. For example if the number of foetal red cells is 9 and the maternal cells is 
2000, the FMH = 9/2000 x 2400 =10.8 mls bleed.
Figure: Diagram of Miller square (graticule)
Calculation of dose of anti-D. Anti-D administered is calculated by giving 125 IU per ml of FMH. 
For a 10.8 ml bleed you will have to administer 10.8 x 125 IU = 1350 IU of anti-D. For films where 
there is no foetal cells you assume that bleed is < 4mls and administer a minimum of 500 IU. Sam-
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ples with raised FMH may need to be referred to the reference laboratory for flow cytometric esti-
mation of bleed. If flow cytometric result is higher, you will need to administer more anti-D using 
the 125 IU per 1 ml bleed rule. A repeat sample is re-tested 72 hours post anti-D administration to 
see if there are any residual foetal red cells. If any, count and administer more anti-D.
Figure: Show positive FMH with the eluted maternal cells and the elution resistant intensely stained 
foetal cells.
Testing for FMH is not indicated in the following cases
1. Rh (D) negative women who have immune anti-D
2. Women delivered of a Rhesus negative baby
3. If sensitizing event occur less than 20 weeks gestation (you give 500-1500 
iµ only)
Management of maternal alloimmunization
1. Maternal antibody titre should be monitored until a critical titre of 1:32 
which indicates a high risk for hydrops foetalis
2. At this critical titre fetus requires intense monitoring for signs of anaemia
3. In Kell alloimmunization, hydrops occur at lower titres of as low as 1:8 
4. Generally a 4-fold increase in the titre of an HDN –associated alloanti-
body is significant.
5. At such critical title amniocentesis can be performed as early as 15 weeks 
gestation.
6. It may be necessary to do a foetal genotype on maternal plasma at 16 
weeks gestation if mum has anti-D and partner is Rh (D) positive. If anti-
D level is 4-15 iu (moderate risk) and if > 15iu (high risk for HDN)
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7. If maternal antibody is anti K, confirm partner Kell phenotype. If positive 
do foetal genotype at 20 weeks gestation and monitor antibody level and 
monitor baby for signs of anaemia. A titre of 1:32 or greater is indicative 
of HDN risk.
8. If mum is anti-c positive and partner is heterozygous for c and maternal 
anti-c is >7.5 iu, there is a high risk of HDN.
9. If amniocentesis indicates high risk and there are signs of anaemia, in
trauterine transfusion may become necessary.
Management of a sensitized neonate (HDN)
1. Direct anti-human Globulin (DAT) test is positive
2. Neonate may be anaemic (HB<14)
3. Minimal haemolyis with associated neonatal bilirubin level of <4mg/dL may 
be observed in 50% of such neonate
4. Phototherapy may be indicated and neonate should be monitored for signs 
of anaemia (3-6 months)
5. In cases of moderate haemolytic disease of the newborn (25%) there is mod
erate anaemia and elevated neonatal bilirubin levels. Baby may not be jaun
diced at birth but hyperbiluribinaemia may occur 24 hours post delivery. 
Peripheral blood picture may indicates numerours nucleated red cells, im
mature neutrophils (band forms) and decreased platelet count 
6. There may be hepatosplenomegaly and increased risk of developing bi
lirubin encephalopathy without urgent exchange blood transfusion with O 
Rh (D) negative fresh red cells or a unit compatible with mum and baby.
7. In severe haemolytic disease child may either be still birth (Blue baby) or 
hydropic at birth.
Despite the fact that the prevalence of Rh-negative phenotype is significantly lower among 
Africans than in Caucasians, alloimmunization to RhD remains a major factor in perinatal 
morbidity and continues to compromise women’s obstetric care in Nigeria and the African 
continent due to the following reasons:
1. Unaffordability of anti-D immunoglobulin. A preliminary study of 67 RhD-
negative women over a 2-year period in Nigeria has shown that isoimmuniza
tion due to Rh incompatibility is poorly studied among Nigerian women, with 
many questions unanswered.
2. Absence of a management protocol for this condition, which will include both 
the clinicians and the laboratory biomedical scientist.
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2. At this critical titre fetus requires intense monitoring for signs of anaemia
3. In Kell alloimmunization, hydrops occur at lower titres of as low as 1:8 
4. Generally a 4-fold increase in the titre of an HDN –associated alloanti
body is significant.
5. At such critical title amniocentesis can be performed as early as 15 weeks 
gestation.
6. It may be necessary to do a foetal genotype on maternal plasma at 16 
weeks gestation if mum has anti-D and partner is Rh (D) positive. If anti-
D level is 4-15 iu (moderate risk) and if > 15iu (high risk for HDN)
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7. If maternal antibody is anti K, confirm partner Kell phenotype. If positive 
do foetal genotype at 20 weeks gestation and monitor antibody level and 
monitor baby for signs of anaemia. A titre of 1:32 or greater is indicative 
of HDN risk.
8. If mum is anti-c positive and partner is heterozygous for c and maternal 
anti-c is >7.5 iu, there is a high risk of HDN.
9. If amniocentesis indicates high risk and there are signs of anaemia, in-
trauterine transfusion may become necessary.
Management of a sensitized neonate (HDN)
1. Direct anti-human Globulin (DAT) test is positive
2. Neonate may be anaemic (HB<14)
3. Minimal haemolyis with associated neonatal bilirubin level of <4mg/dL may 
be observed in 50% of such neonate
4. Phototherapy may be indicated and neonate should be monitored for signs 
of anaemia (3-6 months)
5. In cases of moderate haemolytic disease of the newborn (25%) there is mod-
erate anaemia and elevated neonatal bilirubin levels. Baby may not be jaun-
diced at birth but hyperbiluribinaemia may occur 24 hours post delivery. 
Peripheral blood picture may indicates numerours nucleated red cells, im-
mature neutrophils (band forms) and decreased platelet count 
6. There may be hepatosplenomegaly and increased risk of developing bi-
lirubin encephalopathy without urgent exchange blood transfusion with O 
Rh (D) negative fresh red cells or a unit compatible with mum and baby.
7. In severe haemolytic disease child may either be still birth (Blue baby) or 
hydropic at birth.
Challenges of Rh isoimmunisation in Africa
Despite the fact that the prevalence of Rh-negative phenotype is significantly lower among 
Africans than in Caucasians, alloimmunization to RhD remains a major factor in perinatal 
morbidity and continues to compromise women’s obstetric care in Nigeria and the African 
continent due to the following reasons:
1. Unaffordability of anti-D immunoglobulin. A preliminary study of 67 RhD-
negative women over a 2-year period in Nigeria has shown that isoimmuniza-
tion due to Rh incompatibility is poorly studied among Nigerian women, with 
many questions unanswered.
2. Absence of a management protocol for this condition, which will include both 
the clinicians and the laboratory biomedical scientist.
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)130
3. Lack of alloimmunization prevention during illegal abortions and the lack of 
information about patients’ medical files are highly responsible for the difficult 
management of Rh-negative patients.
4. Cost of procuring anti-D immunoglobulin; absence of a universal access pro-
gram for all Rh-negative women.
5. Failure to recognize potential sensitizing events in pregnancy as such and to 
treat them appropriately.
6. Failure and absence of facilities to assess the extent of FMH; poor and some-
times absence of alloimmunization prevention during illegal termination of 
pregnancy in Rh-negative women
7. Dearth of information about previous pregnancies and termination in patients’ 
medical files due to poor data management
8. Failure to comply with postpartum prophylaxis guidelines to offer further 
anti-D immunoglobulin to all Rh-negative women delivered of Rh-positive 
babies with 72 hours of delivery depending on the extent of FMH; failure to 
offer Rh-negative pregnant women anti-D immunoglobulin following any 
potentially sensitizing event during pregnancy; and failure of obstetrician 
to offer these Rh-negative women the maximum standard of antenatal and 
postnatal care.
9. Suboptimal antenatal management of Rh-negative pregnant women due to 
several health system challenges: socioeconomic realities, lack of adequate 
qualified staff, inadequate referral services, shortage of supplies, and shortages 
of midwives, counselors, laboratory, and obstetrics and gynecology personnel. 
10. Lack of innovative low-cost devices and diagnostic methods such as the use 
of the KB test for determination of FMH could improve the quality of care 
offered these women. Improving the uptake of quality antenatal, intrapar-
tum, and postpartum care as well as innovative community-based strategies, 
combined with health systems strengthening and the development of an 
evidenced-based protocol for the management of Rh isoimmunization, are 
critical for evidence-based interventions required to deliver interventions to 
improve screening and treatment for risk factors and reduce the risks of Rh 
isoimmunization.
17. Transfusion alternatives and exemplary stewardship in the manage-
ment of blood and blood product
As a resource, allogenic blood has never been more in demand than it is today. Escalating 
elective surgery, shortages arising from a fall in supply, lack of a national blood transfusion 
service, policies, appropriate infrastructure, trained personnel and financial resources to sup-
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port the running of a voluntary non-remunerated donor transfusion service, old and emerg
ing threat of transfusion –transmissible infections (TTIs) have all conspired to ensure that 
allogenic blood remains very much a vital but limited asset to healthcare delivery particularly 
in sub Saharan Africa. Concerns about adverse effects of allogenic blood transfusion have 
prompted the review of transfusion practices and justify the need to search for transfusion 
alternatives to decrease or avoid the use of allogenic blood. Some of the complications as
sociated with allogenic blood are immunological, and are thought to be responsible for the 
increase in tumour recurrence after surgical resection, increased postoperative infection rates, 
increased progression of HIV infection and multi-organ failure.
The availability and use of haemopoietic growth factors on a large 
scale for in vivo and in vitro management of anaemia has opened a new era in transfusion 
medicine. Erythropoietin (EPO) was the first haemopoietic growth factor identified. Many 
anaemic patients being managed with erythropoietin alone or with some combined strategy 
of erythropoietin plus red cell replacement has shown that the red cell transfusion require
ment is substantially reduced. Anaemia is frequently diagnosed in patients with cancer. A 
systematic literature review (1996–2003) to produce evidence-based guidelines on the use of 
erythropoietin in anaemic patients with cancer shows that red blood cell (RBC) transfusion 
requirements are significantly reduced with erythropoietic protein therapy in patients with 
chemotherapy-induced anaemia or when used to prevent cancer anaemia. Level I and III 
evidence indicates that patients with chemotherapy-induced anaemia or anaemia of chronic 
disease initially classified as non-responders to standard doses proceed to respond to treat
ment following a dose increase. Similarly report on treatment with epoetin alfa as a single 
weekly dose significantly increased Hb levels in patients with cancer who were undergoing 
radiotherapy. The response was greater in patients treated with radiotherapy alone than in 
those receiving combined therapy. The duration of EPO treatment was shorter in the group 
treated with radiotherapy alone than in the combined treatment group. Experience with pre-
operative single weekly dose of 150 ug/kg of EPO, in Ghanaian patients has shown that it is 
effective in raising the pre-operative haemoglobin. Previous report to assess the effectiveness 
and safety of early initiation of EPO (initiated before eight days after birth) in reducing red 
blood cell transfusions in preterm and/or low birth weight infants indicates that early ad
ministration of EPO reduces the use one or more red blood cell transfusions, the volume of 
red blood cells transfused, and the number of donors and transfusions the infant is exposed. 
Cost and availability of EPO is a major challenge in SSA. Previous report has indicated that 
poor use of EPO is more likely in countries that had lower annual per capita health care ex
penditures, lower proportions of privately funded health care, and a national health service. 
Financial considerations and a haemoglobin level <10 g/dL appear to influence erythropoietin 
use in the United States, whereas financial considerations alone determine erythropoietin use 
abroad particularly in SSA.
A previous report has estimated that most pre-school chil
dren and pregnant women in developing countries and at least 30-40% in developed coun
tries are iron deficient. The high prevalence in Africa is due to multiple and complex factors 
related to several underlying mechanisms which include:
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3. Lack of alloimmunization prevention during illegal abortions and the lack of 
information about patients’ medical files are highly responsible for the difficult 
management of Rh-negative patients.
4. Cost of procuring anti-D immunoglobulin; absence of a universal access pro
gram for all Rh-negative women.
5. Failure to recognize potential sensitizing events in pregnancy as such and to 
treat them appropriately.
6. Failure and absence of facilities to assess the extent of FMH; poor and some
times absence of alloimmunization prevention during illegal termination of 
pregnancy in Rh-negative women
7. Dearth of information about previous pregnancies and termination in patients’ 
medical files due to poor data management
8. Failure to comply with postpartum prophylaxis guidelines to offer further 
anti-D immunoglobulin to all Rh-negative women delivered of Rh-positive 
babies with 72 hours of delivery depending on the extent of FMH; failure to 
offer Rh-negative pregnant women anti-D immunoglobulin following any 
potentially sensitizing event during pregnancy; and failure of obstetrician 
to offer these Rh-negative women the maximum standard of antenatal and 
postnatal care.
9. Suboptimal antenatal management of Rh-negative pregnant women due to 
several health system challenges: socioeconomic realities, lack of adequate 
qualified staff, inadequate referral services, shortage of supplies, and shortages 
of midwives, counselors, laboratory, and obstetrics and gynecology personnel. 
10. Lack of innovative low-cost devices and diagnostic methods such as the use 
of the KB test for determination of FMH could improve the quality of care 
offered these women. Improving the uptake of quality antenatal, intrapar
tum, and postpartum care as well as innovative community-based strategies, 
combined with health systems strengthening and the development of an 
evidenced-based protocol for the management of Rh isoimmunization, are 
critical for evidence-based interventions required to deliver interventions to 
improve screening and treatment for risk factors and reduce the risks of Rh 
isoimmunization.
As a resource, allogenic blood has never been more in demand than it is today. Escalating 
elective surgery, shortages arising from a fall in supply, lack of a national blood transfusion 
service, policies, appropriate infrastructure, trained personnel and financial resources to sup
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port the running of a voluntary non-remunerated donor transfusion service, old and emerg-
ing threat of transfusion –transmissible infections (TTIs) have all conspired to ensure that 
allogenic blood remains very much a vital but limited asset to healthcare delivery particularly 
in sub Saharan Africa. Concerns about adverse effects of allogenic blood transfusion have 
prompted the review of transfusion practices and justify the need to search for transfusion 
alternatives to decrease or avoid the use of allogenic blood. Some of the complications as-
sociated with allogenic blood are immunological, and are thought to be responsible for the 
increase in tumour recurrence after surgical resection, increased postoperative infection rates, 
increased progression of HIV infection and multi-organ failure.
Use of Erythropoietin. The availability and use of haemopoietic growth factors on a large 
scale for in vivo and in vitro management of anaemia has opened a new era in transfusion 
medicine. Erythropoietin (EPO) was the first haemopoietic growth factor identified. Many 
anaemic patients being managed with erythropoietin alone or with some combined strategy 
of erythropoietin plus red cell replacement has shown that the red cell transfusion require-
ment is substantially reduced. Anaemia is frequently diagnosed in patients with cancer. A 
systematic literature review (1996–2003) to produce evidence-based guidelines on the use of 
erythropoietin in anaemic patients with cancer shows that red blood cell (RBC) transfusion 
requirements are significantly reduced with erythropoietic protein therapy in patients with 
chemotherapy-induced anaemia or when used to prevent cancer anaemia. Level I and III 
evidence indicates that patients with chemotherapy-induced anaemia or anaemia of chronic 
disease initially classified as non-responders to standard doses proceed to respond to treat-
ment following a dose increase. Similarly report on treatment with epoetin alfa as a single 
weekly dose significantly increased Hb levels in patients with cancer who were undergoing 
radiotherapy. The response was greater in patients treated with radiotherapy alone than in 
those receiving combined therapy. The duration of EPO treatment was shorter in the group 
treated with radiotherapy alone than in the combined treatment group. Experience with pre-
operative single weekly dose of 150 ug/kg of EPO, in Ghanaian patients has shown that it is 
effective in raising the pre-operative haemoglobin. Previous report to assess the effectiveness 
and safety of early initiation of EPO (initiated before eight days after birth) in reducing red 
blood cell transfusions in preterm and/or low birth weight infants indicates that early ad-
ministration of EPO reduces the use one or more red blood cell transfusions, the volume of 
red blood cells transfused, and the number of donors and transfusions the infant is exposed. 
Cost and availability of EPO is a major challenge in SSA. Previous report has indicated that 
poor use of EPO is more likely in countries that had lower annual per capita health care ex-
penditures, lower proportions of privately funded health care, and a national health service. 
Financial considerations and a haemoglobin level <10 g/dL appear to influence erythropoietin 
use in the United States, whereas financial considerations alone determine erythropoietin use 
abroad particularly in SSA.
Use of oral and intravenous iron. A previous report has estimated that most pre-school chil-
dren and pregnant women in developing countries and at least 30-40% in developed coun-
tries are iron deficient. The high prevalence in Africa is due to multiple and complex factors 
related to several underlying mechanisms which include:
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1. Inadequate diet.
2. Poor iron absorption in the alimentary canal.
3. Increased iron requirements owing to low birth weight, growth, preg-
nancy or lactation.
4. Chronic blood loss resulting from parasitic infection including hookworm. 
Intravenous iron treatment is a readily available option in treating women with postnatal 
anaemia. Several studies have evaluated the therapeutic effectiveness, safety, and cost of in-
travenous iron and oral iron therapy over red cell transfusion and have found iron therapy 
more cost effective particularly because; 
1. Crossmatching is not required
2. Absence of risk of iso-immunisation to foreign protein
3. Fear of transfusion transmissible disease can be ignored. 
The incidence of repeated red blood cell (RBC) transfusion in anaemic gynaecologic cancer 
patients receiving platinum-based chemotherapy iron has shown that Intravenous iron is 
an alternative treatment for anaemic gynaecologic cancer patients receiving platinum-based 
chemotherapy and reduces the incidence of RBC transfusion without serious adverse events. 
Although the cost of intravenous iron sucrose therapy may seem high compared to oral, a 
lack of adherence to therapy and side effects including gastrointestinal irritation during oral 
iron therapy were not experienced during intravenous therapy. However, advocacy exist that 
concurrent blood transfusion and iron supplementation should be avoided.
 Antifibrinolytics. Concerns regarding the safety of transfused blood have led to the develop-
ment of a range of interventions to minimise blood loss during major surgery. Although use 
of antifibrinolytics may not seem cost effective in most African settings, studies have shown 
that antifibrinolytic (aprotinin, tranexamic acid, epsilon-aminocaproic acid) reduce blood 
loss in orthopedic surgery, scoliosis and coronary bypass surgery. Aprotinin and tranexamic 
acid reduced significantly the proportion of patients requiring allogeneic erythrocyte transfu-
sion according to a transfusion protocol. Recently, questions have been raised regarding the 
comparative performance of the drugs and the safety of the most popular agent, aprotinin. 
Report indicates that anti-fibrinolytic drugs provide worthwhile reductions in blood loss and 
the need for allogeneic red cell transfusion. Post partum haemorrhage is a leading cause of 
maternal death particularly in SSA. It also contributes to maternal morbidity as women may 
require a hysterectomy to control bleeding, or may require a blood transfusion, which can 
transmit viral infections. Anti-fibrinolytic agents have been proposed as a treatment for post 
partum haemorrhage. The administration of tranexamic acid was associated with a reduction 
in blood loss of 92 millilitres (95%CI 76 to 109). A review of the use of aprotinin as prophylaxis 
to prevent bleeding indicates that it reduces the need for red cell transfusion, and the need for 
re-operation due to bleeding, without serious adverse effects. 
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Prothrombin complex concentrate (PCC) is presented as a powder and solvent 
for solution for injection containing human prothrombin complex. It nominally contains; hu
man factor 11, V11, IX X, Protein S and C. It is indicated for the treatment of bleeding and 
perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex 
coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in 
case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. 
There are an increasing number of anecdotal reports and trials of recombinant activated fac
tor VII (rFVIIa) for bleeding during surgery. Major blood loss can often be life-threatening 
and is most commonly encountered in the settings of surgery and trauma. Patients receiving 
anticoagulant therapy are also at increased risk of bleeding. There is a potential role for PCC 
in controlling bleeding in patients undergoing cardiac surgery and other surgical procedures 
and reduce, and sometimes abolish, the need for allogenic blood in surgical and non surgi
cal patients. Although some of these may remain unavailable to patients particularly in SSA
because of financial constraints on the health care system. Nonetheless, physicians in Africa 
must always keep in mind that the first and foremost strategy to avoid transfusion of allo
genic blood is their thorough understanding of the pathophysiologic mechanisms involved
anaemia and coagulopathy, and their thoughtful adherence to evidence based good practices 
in the developed world can potentially reduce the likelihood of allogenic blood transfusion 
in many patients groups. 
Most clinical prac
tice guidelines recommend restrictive red cell transfusion practices, with the goal of minimis
ing exposure to allogeneic blood. The current evidence supports the use of restrictive transfu
sion triggers in patients who are free of serious cardiac disease and suggests that critically ill 
patients tolerate anaemia well and that blood transfusions may increase the risk of adverse 
outcomes. However, data from randomized controlled trials suggest that overall morbidity 
(including cardiac) and mortality, hemodynamic, pulmonary and oxygen transport variables 
are not different between restrictive (transfusion threshold between 70 and 80 g/l) and lib
eral transfusion strategies and that a restrictive transfusion strategy is not associated with 
increased adverse outcomes. In fact, a restrictive strategy may be associated with decreased 
adverse outcomes in younger and less sick critical care patients. The majority of existing 
guidelines conclude that transfusion is rarely indicated when the haemoglobin concentra
tion is greater than 100 g/l and is almost always indicated when it falls below a threshold of 
60 g/l in healthy, stable patients or more in older, sicker patients. A retrospective audit over 
a 1-year period in two Dutch hospitals has shown that a proportion of red blood cell (RBC) 
transfusions seem unnecessary and advocated that evaluation of the indications for and the 
appropriateness of RBC transfusions in the postpartum patient is vital. 
Use of artificial Oxygen carriers. The expected cost-explosion in transfusion medicine result
ing from an increasing imbalance between donors and recipients, treatment of transfusion-
associated complications has increased the socio-economic significance of the development of 
safe and effective synthetic oxygen carriers as an alternative to the transfusion of allogeneic 
red blood cells. However, a recent review of artificial oxygen carriers (AOC) indicates that 
despite decades of preclinical and clinical research on AOC, the results were disappointing. In 
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1. Inadequate diet.
2. Poor iron absorption in the alimentary canal.
3. Increased iron requirements owing to low birth weight, growth, preg
nancy or lactation.
4. Chronic blood loss resulting from parasitic infection including hookworm. 
Intravenous iron treatment is a readily available option in treating women with postnatal 
anaemia. Several studies have evaluated the therapeutic effectiveness, safety, and cost of in
travenous iron and oral iron therapy over red cell transfusion and have found iron therapy 
more cost effective particularly because; 
1. Crossmatching is not required
2. Absence of risk of iso-immunisation to foreign protein
3. Fear of transfusion transmissible disease can be ignored. 
The incidence of repeated red blood cell (RBC) transfusion in anaemic gynaecologic cancer 
patients receiving platinum-based chemotherapy iron has shown that Intravenous iron is 
an alternative treatment for anaemic gynaecologic cancer patients receiving platinum-based 
chemotherapy and reduces the incidence of RBC transfusion without serious adverse events. 
Although the cost of intravenous iron sucrose therapy may seem high compared to oral, a 
lack of adherence to therapy and side effects including gastrointestinal irritation during oral 
iron therapy were not experienced during intravenous therapy. However, advocacy exist that 
concurrent blood transfusion and iron supplementation should be avoided.
 Antifibrinolytics. Concerns regarding the safety of transfused blood have led to the develop
ment of a range of interventions to minimise blood loss during major surgery. Although use 
of antifibrinolytics may not seem cost effective in most African settings, studies have shown 
that antifibrinolytic (aprotinin, tranexamic acid, epsilon-aminocaproic acid) reduce blood 
loss in orthopedic surgery, scoliosis and coronary bypass surgery. Aprotinin and tranexamic 
acid reduced significantly the proportion of patients requiring allogeneic erythrocyte transfu
sion according to a transfusion protocol. Recently, questions have been raised regarding the 
comparative performance of the drugs and the safety of the most popular agent, aprotinin. 
Report indicates that anti-fibrinolytic drugs provide worthwhile reductions in blood loss and 
the need for allogeneic red cell transfusion. Post partum haemorrhage is a leading cause of 
maternal death particularly in SSA. It also contributes to maternal morbidity as women may 
require a hysterectomy to control bleeding, or may require a blood transfusion, which can 
transmit viral infections. Anti-fibrinolytic agents have been proposed as a treatment for post 
partum haemorrhage. The administration of tranexamic acid was associated with a reduction 
in blood loss of 92 millilitres (95%CI 76 to 109). A review of the use of aprotinin as prophylaxis 
to prevent bleeding indicates that it reduces the need for red cell transfusion, and the need for 
re-operation due to bleeding, without serious adverse effects.
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Factor V11a. Prothrombin complex concentrate (PCC) is presented as a powder and solvent 
for solution for injection containing human prothrombin complex. It nominally contains; hu-
man factor 11, V11, IX X, Protein S and C. It is indicated for the treatment of bleeding and 
perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex 
coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in 
case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. 
There are an increasing number of anecdotal reports and trials of recombinant activated fac-
tor VII (rFVIIa) for bleeding during surgery. Major blood loss can often be life-threatening 
and is most commonly encountered in the settings of surgery and trauma. Patients receiving 
anticoagulant therapy are also at increased risk of bleeding. There is a potential role for PCC 
in controlling bleeding in patients undergoing cardiac surgery and other surgical procedures 
and reduce, and sometimes abolish, the need for allogenic blood in surgical and non surgi-
cal patients. Although some of these may remain unavailable to patients particularly in SSA 
because of financial constraints on the health care system. Nonetheless, physicians in Africa 
must always keep in mind that the first and foremost strategy to avoid transfusion of allo-
genic blood is their thorough understanding of the pathophysiologic mechanisms involved in 
anaemia and coagulopathy, and their thoughtful adherence to evidence based good practices 
in the developed world can potentially reduce the likelihood of allogenic blood transfusion 
in many patients groups. 
Use of restrictive red cell transfusion practices and transfusion Triggers. Most clinical prac-
tice guidelines recommend restrictive red cell transfusion practices, with the goal of minimis-
ing exposure to allogeneic blood. The current evidence supports the use of restrictive transfu-
sion triggers in patients who are free of serious cardiac disease and suggests that critically ill 
patients tolerate anaemia well and that blood transfusions may increase the risk of adverse 
outcomes. However, data from randomized controlled trials suggest that overall morbidity 
(including cardiac) and mortality, hemodynamic, pulmonary and oxygen transport variables 
are not different between restrictive (transfusion threshold between 70 and 80 g/l) and lib-
eral transfusion strategies and that a restrictive transfusion strategy is not associated with 
increased adverse outcomes. In fact, a restrictive strategy may be associated with decreased 
adverse outcomes in younger and less sick critical care patients. The majority of existing 
guidelines conclude that transfusion is rarely indicated when the haemoglobin concentra-
tion is greater than 100 g/l and is almost always indicated when it falls below a threshold of 
60 g/l in healthy, stable patients or more in older, sicker patients. A retrospective audit over 
a 1-year period in two Dutch hospitals has shown that a proportion of red blood cell (RBC) 
transfusions seem unnecessary and advocated that evaluation of the indications for and the 
appropriateness of RBC transfusions in the postpartum patient is vital. 
Use of artificial Oxygen carriers. The expected cost-explosion in transfusion medicine result-
ing from an increasing imbalance between donors and recipients, treatment of transfusion-
associated complications has increased the socio-economic significance of the development of 
safe and effective synthetic oxygen carriers as an alternative to the transfusion of allogeneic 
red blood cells. However, a recent review of artificial oxygen carriers (AOC) indicates that 
despite decades of preclinical and clinical research on AOC, the results were disappointing. In 
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Russia, a perflourocarbons (PFC) called Perftoran is available locally and the only approved 
hemoglobin-based oxygen carrier (HBOC) called Hemopure in South Africa is not being used 
much. Other products, just prior to filing for FDA approval, did not achieve convincing study 
results and research and production was stopped. Adverse reactions such as hypotension 
and pulmonary complication have significantly affected their widespread use despite its po-
tential role in the reduction of preoperative allogeneic blood transfusion. In the light of these 
challenges, it seems that the global clinical establishment of artificial oxygen carriers is not 
to be expected in the near future. Fluid resuscitation after massive hemorrhage in major sur-
gery and trauma may result in extensive hemodilution and coagulopathy. After extensive 
hemodilution, fibrin clots are more prone to fibrinolysis because major antifibrinolytic pro-
teins are decreased. Cryoprecipitate are considered the mainstay hemostatic therapies in such 
situation. Purified factor concentrates (fibrinogen) of plasma origin and from recombinant 
synthesis are increasingly used in the management of bleeding associated with dilutional co-
agulopathy to rapidly restore targeted factors. Purified fibrinogen concentrate has been used 
extensively in the management of major obstetric haemorrhage. 
Avoidance of wastage of blood components. Blood is becoming an increasingly scarce and 
valuable resource. Shortages occur periodically because of a fall in supply. There is the need 
to avoid unnecessary wastage. A successful and sustainable future demands exemplary stew-
ardship from all players in the careful management of both blood supply and demand issues. 
Wastage of this precious gift is an unacceptable failure in the stewardship of our products. It 
is not something to be discarded casually because it was left out of a fridge for too long. In-
formation from the national blood stocks management project reported wastage of 2.25% in 
40 NHS hospitals in the UK. In the United States, an estimated 9.7% of available allogeneic red 
cell units were wasted. Red blood cell (RBC) product wastage in hospitals is reported to range 
from 0.1% to 6.7%. Data indicated that approximately 87% of wasted RBC units were either 
individual unit that were out of blood bank for more than 30 minutes. Factors identified as 
contributors to RBC wastage most amenable to improvement are; lack of awareness and train-
ing of staff ordering and handling RBC products, poor management of temperature-validated 
containers and inconsistent interpretation of RBC temperature indicators.
Monitoring requests for blood components using transfusion indication criteria, monitoring 
categories of health care workers responsible for blood wastage, not accepting short-dated 
units from blood distribution centres, and if short-dated units were accepted, being allowed 
to return those units to the blood distribution centre can help optimize the use of blood prod-
ucts. Data has shown that three factors can significantly affect RBC outdating; Distance from 
the blood supplier, mean monthly transfusion activity and month of the year. There may 
be the need to transport near-outdate RBC units to a high-usage hospital site, which would 
reduce overall discard rates, thereby increasing overall stock levels available in the blood sys-
tem and that such redistribution systems can be an effective way to reduce RBC unit discard 
rates. Even simple transportation systems have many factors affecting the RBC unit tempera-
ture. Novel temperature stabilizing materials may make future transportation of RBC units 
more reliable. Outdating rate varieS among different blood groups (group 0 less than A = B 
less than AB). Blood product production planning can bring about a significant reduction in 
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outdating and substantial economic savings for a regional blood supplier. Home transfusion 
practices are becoming very popular in most developed countries particularly for transfusion 
dependent patients. There is however increasing concern about effective cold chain monitor
ing of blood products intended for home transfusion. Home care nurses face many challenges 
in transporting and storing medications and blood products in their vehicles and in patients’ 
homes. Unlike climate-controlled institutions, products subject to the cold of winter and the 
heat of summer can easily be damaged, which can be harmful to the patient. Additionally, 
several regulations and protocols demand that products be cared for in a certain manner, 
stored in the proper container, and labelled appropriately to reduce the incidence of blood 
product wastage. Despite considerable advances in the safety of blood components, transfu
sion associated bacterial infection (TABI) remains an unresolved problem. Bacterial contami
nation of blood product also plays a significant role in blood product wastage.
Whole blood is a living tissue that circulates through the heart, arteries, veins, and capillaries 
carrying nourishment, electrolytes, hormones, vitamins, antibodies, heat, and oxygen to the 
body’s tissues. It contains red blood cells, white blood cells, and platelets suspended in fluid 
called plasma. If blood treated with anticoagulant which prevent it from clotting is centrifuged 
the denser red blood cells, settle to the bottom leaving the plasma on top; and the white blood 
cells and platelets will remain suspended in the buffy coat between the plasma and the red 
blood cells. The platelet-rich plasma is then removed and placed into a sterile bag, and it can 
be used to prepare platelets, fresh frozen plasma or cryoprecipitate. Platelets can be produced 
by a further centrifugation of the platelet-rich plasma. This process allows the platelets to 
settle at the bottom of the blood bag. Plasma and platelets are then separated and made avail
able for transfusion. The supernatant plasma can be pooled with plasma from other donors 
fractionated, to provide purified plasma proteins such as albumin, immunoglobulin (IVIG), 
and clotting factors. As a resource, allogenic blood has never been more in demand than it is 
today. Factors responsible for an increasing demand for blood and blood products include:
1. Escalating elective surgeries
2. An ageing population
3. Malaria associated anaemia in children and pregnant women
4. Poor management of intraoperative and intra and post partum bleeding
Periodic shortages arising from a fall in supply, old and emerging threat of transfusion –
transmissible infections and spiralling costs due to various safety interventions introduced 
in developed countries, the risk of transfusion transmitted infections has become exceedingly 
small in these countries. However, emerging pathogens still represent a serious challenge, 
as demonstrated by West Nile virus in the US and more recently by Chikungunya virus in 
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Russia, a perflourocarbons (PFC) called Perftoran is available locally and the only approved 
hemoglobin-based oxygen carrier (HBOC) called Hemopure in South Africa is not being used 
much. Other products, just prior to filing for FDA approval, did not achieve convincing study 
results and research and production was stopped. Adverse reactions such as hypotension 
and pulmonary complication have significantly affected their widespread use despite its po
tential role in the reduction of preoperative allogeneic blood transfusion. In the light of these 
challenges, it seems that the global clinical establishment of artificial oxygen carriers is not 
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outdating and substantial economic savings for a regional blood supplier. Home transfusion 
practices are becoming very popular in most developed countries particularly for transfusion 
dependent patients. There is however increasing concern about effective cold chain monitor-
ing of blood products intended for home transfusion. Home care nurses face many challenges 
in transporting and storing medications and blood products in their vehicles and in patients’ 
homes. Unlike climate-controlled institutions, products subject to the cold of winter and the 
heat of summer can easily be damaged, which can be harmful to the patient. Additionally, 
several regulations and protocols demand that products be cared for in a certain manner, 
stored in the proper container, and labelled appropriately to reduce the incidence of blood 
product wastage. Despite considerable advances in the safety of blood components, transfu-
sion associated bacterial infection (TABI) remains an unresolved problem. Bacterial contami-
nation of blood product also plays a significant role in blood product wastage.
18. Blood components therapy 
Whole blood is a living tissue that circulates through the heart, arteries, veins, and capillaries 
carrying nourishment, electrolytes, hormones, vitamins, antibodies, heat, and oxygen to the 
body’s tissues. It contains red blood cells, white blood cells, and platelets suspended in fluid 
called plasma. If blood treated with anticoagulant which prevent it from clotting is centrifuged 
the denser red blood cells, settle to the bottom leaving the plasma on top; and the white blood 
cells and platelets will remain suspended in the buffy coat between the plasma and the red 
blood cells. The platelet-rich plasma is then removed and placed into a sterile bag, and it can 
be used to prepare platelets, fresh frozen plasma or cryoprecipitate. Platelets can be produced 
by a further centrifugation of the platelet-rich plasma. This process allows the platelets to 
settle at the bottom of the blood bag. Plasma and platelets are then separated and made avail-
able for transfusion. The supernatant plasma can be pooled with plasma from other donors 
fractionated, to provide purified plasma proteins such as albumin, immunoglobulin (IVIG), 
and clotting factors. As a resource, allogenic blood has never been more in demand than it is 
today. Factors responsible for an increasing demand for blood and blood products include:
1. Escalating elective surgeries
2. An ageing population
3. Malaria associated anaemia in children and pregnant women
4. Poor management of intraoperative and intra and post partum bleeding
Periodic shortages arising from a fall in supply, old and emerging threat of transfusion –
transmissible infections and spiralling costs due to various safety interventions introduced 
in developed countries, the risk of transfusion transmitted infections has become exceedingly 
small in these countries. However, emerging pathogens still represent a serious challenge, 
as demonstrated by West Nile virus in the US and more recently by Chikungunya virus in 
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the Indian Ocean. In addition bacterial contamination, particularly in platelets, and proto-
zoa transmitted by blood components still represent sizeable risks in developed countries. 
In developing countries the risk of all transfusion transmitted infections is still high due to 
insufficient funding and poor organization of the health service. Safety introductions have 
all conspired to ensure that allogenic blood remains very much a vital but limited asset in 
healthcare delivery warranting the optimum utilization of whole blood separated into vari-
ous components to meet the specific clinical need of multiple patients. Medical treatments 
are becoming more complex and sophisticated, with patient receiving the specific component 
indicated for the management of their condition. This constitutes a justification for the im-
plementation of component therapy particularly in developing countries to ensure optimum 
utilization of donated whole blood.
Whole blood transfusion. Widespread use of whole blood has continued particularly in re-
source poor developing countries despite a general move to blood component therapy in 
the developed world in recent years particularly because leukocytes present in allogeneic 
cellular blood components, intended for transfusion, are associated with adverse effects; de-
velopment of febrile transfusion reactions, graft-versus-host disease, alloimmunization to 
leukocyte antigens, and the immunomodulatory effects that might influence the prognosis 
of patients with a malignancy coupled with findings that leukocytes may be the vector of 
infectious agents such as CMV, HTLV-I/II, and EBV as well as other viruses. A previous study 
involving Haematologists in charge of blood banks in England and North Wales to ascertain 
how much and for which indications whole blood was being requested. More than 90% of 
hospitals that responded had not requested whole blood during the last 12 months. The evi-
dence for the use of whole blood in preference to component therapy in the massive transfu-
sion setting was reviewed, and no compelling evidence was found for its routine use for this 
indication. However, US military physicians have used FWB in every combat operation since 
the practice was introduced in World War I and continues to do so during current military 
operations. Indications for the use of whole blood include;
1. Neonatal exchange transfusion or paediatric surgery
2. Infrequent use in adult practice was for major bleeding particularly when 
whole blood was available, and in cardiac surgery, when post-operative 
bleeding was unresponsive to standard replacement therapy. 
Red blood cells transfusion. Red cells are perhaps the most recognizable component of 
whole blood. Red blood cells contain haemoglobin, a complex iron-containing protein that 
carries oxygen throughout the body. Patients who benefit most from transfusions of red blood 
cells include those with chronic anaemia resulting from disorders such as malignancy, acute 
blood loss resulting from trauma, surgery, obstetrics haemorrhages, chemotherapy –induced 
anaemia. The red blood cell (PRBC) transfusion has been shown to impact survival in trauma 
patients with massive hemorrhage. Red blood cells contains an insignificant amount of plas-
ma and thus is indicated for the treatment of anaemia in patients with congestive heart failure 
and elderly patients with cardiovascular risk who might not tolerate the increased volume 
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in whole blood. Massive obstetric haemorrhage is a major cause of maternal death and mor
bidity; abruptio placentae, placenta praevia and postpartum haemorrhage being the main 
causes. Postpartum hemorrhage (PPH) is an obstetric emergency that can occur following 
vaginal or cesarean delivery. Traditional blood components, including packed red blood cells 
should be used in patients with significant bleeding. Upper gastrointestinal haemorrhage 
affects 50 to 150 per 100,000 adults per year and has a high mortality. Red blood cell transfu
sions are frequently given. Improvements in cell preservative solutions over the last decade 
have increased the shelf life of red blood cells from 21 to 42 days. Red blood cells (RBC) can be 
frozen in glycerol solutions and stored for many years. Thawed RBC must have the glycerol 
removed, but the recovered cells have normal survival in humans. Freezing has been used to 
store RBC of rare phenotypes for more than 40 years.
 White blood cells play a role in protecting the body from invasion by 
foreign substances. Several types of white blood cells exist; granulocytes and macrophages 
protect against infection and destroying invading bacteria and viruses while lymphocytes 
play a key role in host defence mechanism. Granulocytes can be collected by aphaeresis or 
by centrifugation of whole blood. Leukocytes have ability to distinguish between self cells 
(body own cells) and foreign (allogenic) cells on the basis of human leukocyte antigen (HLA) 
proteins that are present on the cell membrane and are effectively unique to a person. During 
allogenic whole blood transfusion a person receives large number of allogenic donor leuko
cytes and these are recognized as foreign cells by the recipient immune system which leads to 
several adverse reactions. To avoid such leukocyte-mediated adverse reactions leukodepleted 
blood transfusion is required. The effectiveness of white blood cell transfusion has been an 
issue of intense debate among scientists. The presence of leukocytes in cellular blood com
ponents is thought to be associated with a number of significant adverse effects in recipients. 
Leukocyte reduction reduces the:
1. Frequency of human leukocyte antigen alloimmunization
2. Cytomegalovirus virus and human T-cell leukemia virus infections 
3.  in the occurrence of febrile non-hemolytic transfusion reactions
4. Reduction in the risk transfusion –transmissible variant Creutzfeldt-Ja
kob disease (vCJD).
5.  Leukoreduction by filtration may reduce the incidence of post-operative 
infections and adverse outcomes in patients undergoing elective major aor
tic surgery as well as in patients undergoing abdominal Aortic surgery
 Plasma is the liquid portion of the blood and a protein-salt solution in which red and 
white blood cells and platelets are suspended. Plasma, which is 90 percent water, constitutes 
about 55 percent of blood volume. Plasma serves a variety of functions, from maintaining a 
satisfactory blood pressure and volume to supplying critical proteins for blood clotting and 
immunity. Fresh frozen plasma is plasma frozen within hours after donation in order to pre
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serve clotting factors, stored for one to seven years, and thawed before it is transfused. It is 
most often used to treat certain bleeding disorders, when a clotting factor or multiple factors 
are deficient and no factor-specific concentrate is available. It also can be used for plasma 
replacement via a process called plasma exchange. Definite indications for the use of FFP in-
clude replacement of single factor deficiencies, acute disseminated intravascular coagulation, 
thrombotic and thrombocytopenic purpura and inherited deficiencies of inhibitors of coagu-
lation. There is no justification for the use of FFP in cases of hypovolaemia, plasma exchange 
procedures, nutritional support, protein-losing states and treatment of immunodeficiency 
states. FFP must be used with 24 hours of thawing. The earlier it is used after thawing, the bet-
ter. A higher FFP: PRBC ratio is an independent predictor of survival in massively transfused 
patients and that aggressive early use of FFP may improve outcome in massively transfused 
trauma patients. Education on indications of FFP transfusion and improved identification 
of bleeding may reduce transfusion rates. FFP can partially correct abnormal coagulation. 
Although the overall risks of FFP are low, they are the least safe blood components, due to 
the following factors; Immunologic reactions such as allergy/anaphylaxis, Transfusion-relat-
ed acute lung injury (TRALI) and Haemolysis due to high titre anti-A or anti-B haemolysin 
which may be present in the plasma of donors.
Information on use of FFP
1. FFP is not indicated in disseminated intravascular coagulation without 
bleeding, is only recommended as a plasma exchange medium for throm-
botic thrombocytopenic purpura (for which cryosupernatant is a possible 
alternative).
2. FFP should never be used to reverse warfarin anticoagulation in the ab-
sence of severe bleeding, and has only a very limited place in prophylaxis 
prior to liver biopsy. Octaplex (prothrombin complex concentrate) is in-
dicated for the reversal of warfarin effect. 
3. When used for surgical or traumatic bleeding, FFP and cryoprecipitate 
doses should be guided by coagulation studies, which may include near-
patient testing.
4. FFP is not indicated to reverse vitamin K deficiency for neonates or pa-
tients in intensive care units. 
5. In the UK, methylene blue treated FFP from countries with a low bovine 
spongiform encephalopathy incidence is recommended by the Depart-
ments of Health for children born after 1 January 1996 or children less 
than 16 years on the date of transfusion. 
Cryoprecipitate. Cryoprecipitate is the portion of plasma that is rich in certain clotting factors, 
including Factor VIII, fibrinogen, von Willebrand factor, and Factor XIII. Cryoprecipitate is 
removed from plasma by freezing and then slowly thawing the plasma. It is used to prevent 
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or control bleeding in individuals with hemophilia and von Willebrand’s disease, which are 
common, inherited major coagulation abnormalities. Afibrinogenaemia is a rare bleeding dis
order with an estimated prevalence of 1:1,000,000. It is an autosomal recessive disease result
ing from mutations in any of the 3 genes that encode the 3 polypeptide chains of fibrinogen 
and are located on the long arm of chromosomes 4. Replacement therapy is the mainstay of 
treatment of bleeding episodes in these patients and plasma-derived fibrinogen concentrate 
is the agent of choice. Cryoprecipitate and fresh frozen plasma are alternative treatments that 
should be used only when fibrinogen concentrate is not available. Until the mid-80s, cryopre
cipitate has been the mainstay of treatment of patients with von Willebrand disease who were 
unresponsive to desmopressin. The advent of virally-inactivated factor VIII (FVIII) concen
trates containing von Willebrand factor (VWF), originally devoted to hemophiliacs, provided 
a better therapeutic approach to von Willebrand disease. The International Society for Throm
bosis and Haemostasis (ISTH) Disseminated Intravascular Coagulation (DIC) scoring system 
provides objective measurement of DIC. Where DIC is present the scoring system correlates 
with key clinical observations and outcomes. In DIC there is a global deficiency of coagulation 
factors. Severe hypofibrinogenaemia (<1 g/l) that persists despite FFP replacement may be 
treated with fibrinogen concentrate or cryoprecipitate. Predetermined transfusion guidelines, 
pretransfusion approval, and transfusion audits are useful tools in the education of those or
dering blood components, potentially resulting in the reduction of inappropriate use of blood 
components. Cryoprecipitate should be used within 4 hours after thawing.
Platelets (or thrombocytes) are very small cellular components of blood that help 
the clotting process by sticking to the lining of blood vessels. The platelet is vital to life, be
cause it helps prevent massive blood loss resulting from trauma. Transfused platelets are 
either pooled random-donor platelet concentrates or single-donor aphaeresis platelets. When 
stored for 5 days, all of these products are equally efficacious. A 10,000/microL prophylactic 
platelet transfusion trigger has been documented to be both hemostatically efficacious and 
cost effective in reducing platelets transfusion. Units of platelets are prepared by using a 
centrifuge to separate the platelet-rich plasma from the donated unit of whole blood. The 
platelet-rich plasma is then centrifuged again to concentrate the platelets further. Platelets 
also may be obtained from a donor by a process known as apheresis, or plateletpheresis. 
Apheresis instrument, which, using centrifugation, separates the blood into its components, 
retains the platelets, and returns the remainder of the blood to the donor. The resulting com
ponent contains about six times as many platelets as a unit of platelets obtained from whole 
blood. The advantages of aphresis platelet over pooled platelets include; the reduction in 
donor exposures and reduction in the risk of transfusion-transmitted infections and the inci
dence of platelets alloimmunization. Platelets are used to treat a condition called thrombocy
topenia, in which there is a shortage of platelets, and in patients with abnormal platelet func
tion. It is stored at room temperature for up to five days. Leukoreduction and ABO matching 
of platelet transfusions also have been associated in preliminary observational studies with 
reduced morbidity and mortality in surgical patients and reduced infections in patients with 
leukemia. There are clear indications for providing leukoreduced platelet products; reduc
tion of platelet alloimmunization rates, prevention of cytomegalovirus (CMV) transmission 
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by transfusion and reduction in febrile transfusion reactions. In addition, there are studies 
that suggest that white cells that contaminate platelet and red-cell transfusions may contrib-
ute to possible immunomodulatory effects of transfusion, such as an increased incidence of 
postoperative infections and metastasis formation in cancer patients. Gamma irradiation of 
platelet is indicated to prevent transfusion-related graft-versus-host disease (GVHD), which 
is uniformly fatal. Proven situations where -irradiation should be performed are for patients 
receiving allogeneic stem cell transplants, for patients receiving blood products from related 
donors, and for patients who are severely immunocompromised, usually because of their dis-
ease or its treatment for example patients with Hodgkin disease or other lymphomas. Three 
aspects of prophylactic platelet transfusions can be controlled by the physician; whether to 
provide prophylactic platelet transfusions to patients with chronic thrombocytopenia, what 
platelet count should initiate a platelet transfusion (appropriate platelet transfusion trigger) 
and what dose of platelets should be used. Previously, a platelet count of 20,000/µL was con-
sidered to be an indication for a prophylactic platelet transfusion. Generally accepted WHO 
bleeding grades are:
1. Grade 0: No bleeding or bleeding-related risk.
2. Grade 1: Presence of petechiae, ecchymosis, occult blood in body secre-
tions, and mild vaginal spotting.
3. Grade 2: Evidence of gross hemorrhage not requiring red cell transfu-
sions over routine transfusion needs (epistaxis, hematuria and hemate-
mesis).
4. Grade 3: Haemorrhage requiring transfusion of 1 or more units of red 
cells/day.
5.  Grade 4: Life-threatening hemorrhage, defined as massive bleeding caus-
ing hemodynamic compromise or bleeding into a vital organ (intracra-
nial, pericardial, or pulmonary hemorrhage.
In spite of prophylactic platelet transfusions given at transfusion triggers of 10,000 to 20,000 
platelets/µL, several clinical trials have demonstrated that bleeding still occurs. The risk of 
bleeding varies substantially among studies; depending on the study, WHO grade 1 bleed-
ing was observed in 46% of patients, WHO grade 2 in 12% or 58% of patients, and WHO 
grades 3 and 4 in 5%, 11%, 20%, or 36% of patients. Refractoriness to platelet transfusions 
can be separated into immune- and non-immunemediated mechanisms. Because isolated 
poor responses to an individual platelet transfusion are not uncommon, a determination of 
platelet refractoriness requires two serial platelet transfusions with poor responses. A and B 
red cell antigens are expressed on platelets and ABO-incompatible platelets have reduced 
post-transfusion platelet recoveries but normal survivals. ABO compatible means the donor 
has no A or B antigens incompatible with the recipient’s A or B antibodies. Therefore, provid-
ing ABO-compatible platelets is important both to achieve the best post-transfusion platelet 
increments but also to reduce the incidence of alloimmune platelet refractoriness. Several 
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prospective randomized platelet transfusion trials have clearly documented the effectiveness 
of transfusing leukoreduced platelet and red cells compared with standard blood products 
(control) in preventing the development of HLA antibodies. There are basically three strate
gies for managing allo-immunized platelet refractory patients:
1. Select HLA-compatible donors from an HLA-typed registry of apheresis 
2. Identify HLA-antibody specificities.
3. Select antigen-compatible apheresis donors; and perform platelet cross-
match tests to select compatible platelets.
Childhood idiopathic thrombocytopenic purpura (ITP). Childhood idiopathic thrombocy
topenic purpura (ITP) is a common disorder. However, single-institution, long-term, natural 
history data are limited. ITP is a common paediatric disease presenting at any age with low 
morbidity and mortality. Most cases can be managed by paediatricians without Haematology 
referral. Several equally successful therapeutic options exist. Chronic cases present at an older 
age with higher platelet counts. Up to 50% of cases of chronic ITP will resolve with ongoing fol
low-up. The overall prognosis in childhood ITP is excellent. Thrombopoietin receptor agonists 
are currently under clinical investigation for the treatment of ITP and may represent an alterna
tive treatment option in the future. Treatment of immune thrombocytopenic purpura (ITP), the 
most common bleeding disorder of childhood, is a controversial subject for most practitioners. 
To address the controversies, the American Society of Hematology (ASH) and the British Soci
ety for Hematology (BSH) have developed ITP practice guidelines. These guidelines, based on 
expert opinion. The ASH guidelines favour therapy based on a low platelet count, and the more 
current BSH guidelines recommend a more conservative ‘wait and watch’ approach. In addition 
to treating children with severe bleeding symptoms, there is a tendency (not evidence based) 
to treat early in order to prevent a life-threatening bleeding episode, including intracerebral 
haemorrhage. Treatment for immune thrombocytopenic purpura includes:
1. Corticosteroids are a highly effective therapy, inexpensive, and can usually 
increase the platelet count within hours to days. However, chronic or pro
longed use is associated with toxicity. 
2. Intravenous Rh immunoglobulin (IV RhIG), Inravenous Immunoglobu
lin (IVIG), are preferred by many paediatricians prefer to treat with IVIG 
and IV RhIG, reserving corticosteroid treatment for serious bleeding or 
refractory disease. However, in the UK, for the most part, corticosteroids 
are used as first-line therapy in children with ITP. 
3. Splenectomy is rarely indicated in children except for those with life-threat
ening bleeding and chronic, severe ITP with impairment of quality of life.
Plasma derivatives are concentrates of specific plasma proteins that are 
prepared from pools of plasma. Plasma derivatives are obtained through a process, known 
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post-transfusion platelet recoveries but normal survivals. ABO compatible means the donor 
has no A or B antigens incompatible with the recipient’s A or B antibodies. Therefore, provid
ing ABO-compatible platelets is important both to achieve the best post-transfusion platelet 
increments but also to reduce the incidence of alloimmune platelet refractoriness. Several 
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prospective randomized platelet transfusion trials have clearly documented the effectiveness 
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and IV RhIG, reserving corticosteroid treatment for serious bleeding or 
refractory disease. However, in the UK, for the most part, corticosteroids 
are used as first-line therapy in children with ITP. 
3. Splenectomy is rarely indicated in children except for those with life-threat-
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as fractionation. They are heat-treated and/or solvent detergent-treated to kill certain viruses, 
including HIV and hepatitis B and C. Plasma derivatives include:
Factor VIII Concentrate
Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. It is pro-
duced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor 
in factor X activation and this action is markedly enhanced by small amounts of thrombin. 
Haemophilia is a rare genetic bleeding disorder that almost always occurs in males. A per-
son has haemophilia when he or she inherits problems with certain blood clotting making 
them unable to work properly. Blood-clotting factors are needed to help stop bleeding af-
ter a cut or injury and to prevent spontaneous bleeding. The haemophilia gene can contain 
many different errors, leading to different degrees of abnormality in the amount of clotting 
factor produced. There are two major types of haemophilia; Haemophilia A is caused by a 
deficiency of active clotting factor VIII. Approximately 1 out of every 5,000 male babies is 
born with haemophilia and Haemophilia B (Christmas disease) is caused by a lack of active 
clotting factor IX. It is less common, occurring in 1 out of every 30,000 male babies. von Wil-
lebrand’s disease (VWD) is an inherited bleeding disorder characterized by deficient levels of 
or dysfunctional von Willebrand factor (VWF). Plasma-derived concentrates containing von 
Willebrand factor and factor VIII (VWF/FVIII concentrates) are the mainstay of treatment of 
patients with inherited von Willebrand’s disease (VWD) who are unresponsive or have a con-
traindication to desmopressin (DDAVP) therapy. A previous study evaluated the efficacy and 
safety of BIOSTATE(R), a high purity plasma-derived double-virus inactivated FVIII/VWF 
concentrate, when used in non-surgical bleeds, surgical procedures and prophylactic therapy 
in VWD patients for whom desmopressin treatment was deemed ineffective, inadequate or 
contraindicated. Report indicates that BIOSTATE was shown to be efficacious and well toler-
ated when treating patients with VWD. Similarly previous reports recommended that acute 
and prophylactic treatment of bleeding in von Willebrand disease (VWD) patients with von 
Willebrand factor (VWF)/factor VIII (FVIII) concentrates.
Factor IX Concentrate. Factor IX is one of the proteins of the coagulation system. Deficiency 
of this protein causes haemophilia B. Haemophilia B is an inherited bleeding disorder associ-
ated with a deficiency of coagulation factor IX. The hallmark of the severe phenotype is recur-
rent and spontaneous bleeding into joints, which can lead to joint deformity and arthritis at 
an early age. Recombinant factor IX is now increasingly regarded as the treatment of choice 
because it does not transmit human pathogens. All patients in the UK now receive this prod-
uct exclusively. Conventional treatment now consists of the administration of recombinant 
factor IX concentrate on a prophylactic basis to prevent bleeds and, hence, minimise disability 
in the long -term. A prospective clinical study of recombinant factor IX (BeneFIX (R); rFIX), 
designed to allow investigator prescribed prophylaxis according to customary practices, was 
conducted in children <6 years old with severe haemophilia B. Routine prophylaxis with 1 or 
2 rFIX infusions per week over an average of greater than 6 months of therapy resulted in near 
complete prevention of spontaneous breakthrough haemorrhages (<1 per year), with most 
143Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
children (77%) having none, including seven patients (32%) who had no bleeding episodes 
at all. Haemorrhages in joints were less common than those outside joints (27% vs. 73%) of 
haemorrhages. Factor IX Grifols (R) is a new high-purity plasma derived FIX concentrate 
with two specific pathogen elimination steps. Efficacy and safety study of a plasma-derived 
factor IX concentrate Mononine has shown that infusion therapy is safe and effective in the 
treatment of haemophilia B patients undergoing surgery, exposed to trauma, or experiencing 
severe spontaneous haemorrhage.
Octaplex is presented as a powder and solvent for solution for injection 
containing human prothrombin complex. It nominally contains; human factor 11, V11, IX X, 
Protein S and C. It is indicated for the treatment of bleeding and perioperative prophylaxis 
of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as 
deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin 
K antagonists, when rapid correction of the deficiency is required. There are an increasing 
number of anecdotal reports and trials of recombinant activated factor VII (rFVIIa) for bleed
ing during surgery. Factor V11a use for the management of bleeding following complex car
diac surgery has shown that use of rFVIIa in cardiac surgery may be effective, but definitive 
clinical trials are needed to clarify its role in clinical practice and safety. Following immediate 
measures to control bleeding, the broad principles for managing massive blood loss have 
been summarized as follows: restore volume (administer colloids or crystalloids), perform 
laboratory investigations (full blood count, blood group and cross-match, coagulation screen
ing and biochemistry), administer blood component therapy (red blood cells, platelets, fresh 
frozen plasma [FFP] or cryoprecipitate), and administer appropriate pharmacological agents 
(for instance, antifibrinolytic drugs or recombinant activated factor VII. Major blood loss can 
often be life-threatening and is most commonly encountered in the settings of surgery and 
trauma. Patients receiving anticoagulant therapy are also at increased risk of bleeding. There 
is a potential role for PCC in controlling bleeding in patients undergoing cardiac surgery 
and other surgical procedures. Major bleeding among patients receiving oral anticoagulant 
therapy (OAT) is common, affecting some 6.5% of patients per year.
Anti-Inhibitor Coagulation Complex (AICC). Strategies for the management of periopera
tive bleeding in patients with haemophilia and inhibitors have evolved rapidly as a result 
of the development of the bypassing agents; Factor Eight Inhibitor Bypassing Activity, Anti-
inhibitor Coagulant Complex (FEIBA) and activated recombinant factor VII (rFVIIa). There 
are currently no established guidelines for perioperative use of bypassing agents, and few 
controlled clinical studies have been carried out. The experiences in a recent case review 
demonstrate that both major and minor surgical procedures can be safely performed in 
patients with haemophilia and high-titre inhibitors under the cover of bypassing agents, 
with a high expectation of success. Safety and efficacy study of combined rFVIIa and FEIBA 
therapy in patients with haemophilia A and inhibitors during bleeding episodes indicates 
that concomitant infusion of low-dose rFVIIa and low-dose FEIBA, seems to be safe, effica
cious and economical in patients refractory to rFVIIa and probably other haemophilia A 
patients with an inhibitor.
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lebrand’s disease (VWD) is an inherited bleeding disorder characterized by deficient levels of 
or dysfunctional von Willebrand factor (VWF). Plasma-derived concentrates containing von 
Willebrand factor and factor VIII (VWF/FVIII concentrates) are the mainstay of treatment of 
patients with inherited von Willebrand’s disease (VWD) who are unresponsive or have a con
traindication to desmopressin (DDAVP) therapy. A previous study evaluated the efficacy and 
safety of BIOSTATE(R), a high purity plasma-derived double-virus inactivated FVIII/VWF 
concentrate, when used in non-surgical bleeds, surgical procedures and prophylactic therapy 
in VWD patients for whom desmopressin treatment was deemed ineffective, inadequate or 
contraindicated. Report indicates that BIOSTATE was shown to be efficacious and well toler
ated when treating patients with VWD. Similarly previous reports recommended that acute 
and prophylactic treatment of bleeding in von Willebrand disease (VWD) patients with von 
Willebrand factor (VWF)/factor VIII (FVIII) concentrates.
Factor IX is one of the proteins of the coagulation system. Deficiency 
of this protein causes haemophilia B. Haemophilia B is an inherited bleeding disorder associ
ated with a deficiency of coagulation factor IX. The hallmark of the severe phenotype is recur
rent and spontaneous bleeding into joints, which can lead to joint deformity and arthritis at 
an early age. Recombinant factor IX is now increasingly regarded as the treatment of choice 
because it does not transmit human pathogens. All patients in the UK now receive this prod
uct exclusively. Conventional treatment now consists of the administration of recombinant 
factor IX concentrate on a prophylactic basis to prevent bleeds and, hence, minimise disability 
in the long -term. A prospective clinical study of recombinant factor IX (BeneFIX (R); rFIX), 
designed to allow investigator prescribed prophylaxis according to customary practices, was 
conducted in children <6 years old with severe haemophilia B. Routine prophylaxis with 1 or 
2 rFIX infusions per week over an average of greater than 6 months of therapy resulted in near 
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children (77%) having none, including seven patients (32%) who had no bleeding episodes 
at all. Haemorrhages in joints were less common than those outside joints (27% vs. 73%) of 
haemorrhages. Factor IX Grifols (R) is a new high-purity plasma derived FIX concentrate 
with two specific pathogen elimination steps. Efficacy and safety study of a plasma-derived 
factor IX concentrate Mononine has shown that infusion therapy is safe and effective in the 
treatment of haemophilia B patients undergoing surgery, exposed to trauma, or experiencing 
severe spontaneous haemorrhage.
FACTOR V11a. Octaplex is presented as a powder and solvent for solution for injection 
containing human prothrombin complex. It nominally contains; human factor 11, V11, IX X, 
Protein S and C. It is indicated for the treatment of bleeding and perioperative prophylaxis 
of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as 
deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin 
K antagonists, when rapid correction of the deficiency is required. There are an increasing 
number of anecdotal reports and trials of recombinant activated factor VII (rFVIIa) for bleed-
ing during surgery. Factor V11a use for the management of bleeding following complex car-
diac surgery has shown that use of rFVIIa in cardiac surgery may be effective, but definitive 
clinical trials are needed to clarify its role in clinical practice and safety. Following immediate 
measures to control bleeding, the broad principles for managing massive blood loss have 
been summarized as follows: restore volume (administer colloids or crystalloids), perform 
laboratory investigations (full blood count, blood group and cross-match, coagulation screen-
ing and biochemistry), administer blood component therapy (red blood cells, platelets, fresh 
frozen plasma [FFP] or cryoprecipitate), and administer appropriate pharmacological agents 
(for instance, antifibrinolytic drugs or recombinant activated factor VII. Major blood loss can 
often be life-threatening and is most commonly encountered in the settings of surgery and 
trauma. Patients receiving anticoagulant therapy are also at increased risk of bleeding. There 
is a potential role for PCC in controlling bleeding in patients undergoing cardiac surgery 
and other surgical procedures. Major bleeding among patients receiving oral anticoagulant 
therapy (OAT) is common, affecting some 6.5% of patients per year.
Anti-Inhibitor Coagulation Complex (AICC). Strategies for the management of periopera-
tive bleeding in patients with haemophilia and inhibitors have evolved rapidly as a result 
of the development of the bypassing agents; Factor Eight Inhibitor Bypassing Activity, Anti-
inhibitor Coagulant Complex (FEIBA) and activated recombinant factor VII (rFVIIa). There 
are currently no established guidelines for perioperative use of bypassing agents, and few 
controlled clinical studies have been carried out. The experiences in a recent case review 
demonstrate that both major and minor surgical procedures can be safely performed in 
patients with haemophilia and high-titre inhibitors under the cover of bypassing agents, 
with a high expectation of success. Safety and efficacy study of combined rFVIIa and FEIBA 
therapy in patients with haemophilia A and inhibitors during bleeding episodes indicates 
that concomitant infusion of low-dose rFVIIa and low-dose FEIBA, seems to be safe, effica-
cious and economical in patients refractory to rFVIIa and probably other haemophilia A 
patients with an inhibitor.
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Albumin. The major protein in plasma is albumin. Albumin helps keep fluid from leaking 
out of blood vessels and into tissues, and albumin binds to and carries substances such as 
hormones and certain drugs. Evidence-based guidelines for severe traumatic brain injury 
(TBI) do not include strategies for fluid administration. A previous study investigated the 
use of albumin administration in traumatic brain injury to maintain normal colloid osmotic 
pressure and advocates a neutral to slightly negative fluid balance. Findings indicated that 
albumin administration in combination with a neutral to a slightly negative fluid balance was 
associated with low mortality in patients with severe TBI. In children with severe malaria, 
resuscitation with albumin infusion results in a lower mortality than resuscitation with sa-
line infusion. In patients with cirrhosis and spontaneous bacterial peritonitis, renal function 
frequently becomes impaired. This impairment is probably related to a reduction in effective 
arterial blood volume and is associated with a high mortality rate. In patients with cirrhosis 
and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an 
antibiotic reduces the incidence of renal impairment and death in comparison with treatment 
with an antibiotic alone. Albumin is a large molecule which plays an essential role in gener-
ating colloido-osmotic pressure which facilitates fluid retention in the intravascular space. 
Human Albumin is quiet useful in burnt patients. Licensed indications are the emergency 
treatment of shock and other conditions where restoration of blood volume is urgent, burns, 
and hypoproteinaemia.
Immune Globulins, including Rh Immune Globulin. The administration of Rh immune 
globulin (RhIG) to D–negative women after parturition is a remarkably successful therapy 
and has prevented many thousands of D+ infants worldwide suffering from hemolytic dis-
ease of the fetus and newborn (HDFN) since its introduction nearly 40 years ago. The mecha-
nism of action is due to the role for immunomodulatory cytokines and foetal red cell clear-
ance. Rh (D)-negative women with a large fetomaternal haemorrhage (FMH) from an Rh (D) 
positive fetus are at risk for anti-D alloimmunization if they do not receive adequate Rh im-
mune globulin (RhIG). Determination of the adequate RhIG dose for these women is a critical 
laboratory procedure for protecting their future Rh (D)+positive children. Laboratories per-
forming quantification of FMH should review their procedures and training for calculating 
RhIG dosage. Intravenous immunoglobulin and intravenous anti-D are common therapies 
in the management of patients with immune thrombocytopenia (ITP). Despite immediate 
increases in the platelet count, the duration of response is limited, with platelet increments 
lasting between 2 and 4 weeks. Infusion reactions are common but adverse events are rare.
Anti-Inhibitor Coagulant Complex (AICC). Anti-Inhibitor Coagulant Complex is a freeze-
dried sterile human plasma fraction with Factor VIII inhibitor bypassing activity. In vitro, it 
shortens the activated partial thromboplastin time (APTT) of plasma containing Factor VIII 
inhibitor. Factor VIII inhibitor bypassing activity is expressed in arbitrary units. It is indicated 
for the control of spontaneous bleeding episodes or to cover surgical interventions in hemo-
philia A and hemophilia B patients with inhibitors. Prophylactic infusion of factor concen-
trates is a safe, effective intervention for preventing arthropathy in patients with haemophilia; 
on demand treatment is insufficient to prevent the orthopaedic complications and subsequent 
haemophilic arthropathy that stem from recurrent joint haemorrhages. Patients with haemo-
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philia and inhibitors with bleeding episodes treated with bypassing agents showed that when 
APCC was administered regularly, most patients exhibited a reduction in the numbers of 
haemorrhages, an improvement in orthopaedic status, and an improvement in quality of life.
 Alpha-antitrypsin (AAT) is a serine protease 
inhibitor, which inhibits the proteolytic enzyme elastase. Alpha (1)-Antitrypsin (AAT) de
ficiency is a common but underrecognised condition. Since its first description by Laurell 
and Eriksson in 1963, significant advances have been made in understanding the genetics, 
physiology and pathophysiology of this condition. The intravenous administration of puri
fied AAT to AAT-deficient individuals has been shown to confer biochemical efficacy by rais
ing the serum AAT level above an epidemiologically established ‘protective threshold’ while 
preserving the biochemical properties and functional capacity of the protease inhibitor. Indi
viduals with a deficiency of AAT may develop clinical manifestations that include a decline 
in lung function. Deficiency of AAT can lead to many clinical manifestations, most commonly 
chronic obstructive pulmonary disease in the form of emphysema. Severe forms of alpha 
(1)-antitrypsin (AAT) deficiency require augmentation therapy by intravenous administra
tion of purified preparations of AAT concentrate. Aralast is one of three approved human 
plasma-derived treatment options used to prevent the progression of emphysema associated 
with AAT deficiency disorder.
Haemorrage is a leading cause of early death following traumatic injury, intra and post surgi
cal and ante and post partum. In most severely injured patient with injury severity score > 25 
the mortality rate is between 60-70%. Patient who suffer from uncontrolled haemorrage do so 
within the first 6 hours following injury. Haemorrhage accounts for 40% of deaths from trau
ma and is the most common cause of preventatable mortality in developing countries due to:
1. Chronic blood shortages, high prevalence of transfusion-transmissible 
infection
2. Reliance on whole blood transfusion and lack of other component re
quired to manage coagulopathy
3. Absence of national blood transfusion service and reliance on family re
placement and commercial blood donation
4. Inadequate use of pharmacologic and non pharmacologic alternatives to 
allogenic blood.
 Major haemorrhage is the replace of patient’s blood volume 
or transfusion of > 10 units of packed red cells with a 24 hours period. It can also be defined 
as the loss of 50% of blood volume within a 3 hours period or a loss of 150ml per minute. The 
144
 The major protein in plasma is albumin. Albumin helps keep fluid from leaking 
out of blood vessels and into tissues, and albumin binds to and carries substances such as 
hormones and certain drugs. Evidence-based guidelines for severe traumatic brain injury 
(TBI) do not include strategies for fluid administration. A previous study investigated the 
use of albumin administration in traumatic brain injury to maintain normal colloid osmotic 
pressure and advocates a neutral to slightly negative fluid balance. Findings indicated that 
albumin administration in combination with a neutral to a slightly negative fluid balance was 
associated with low mortality in patients with severe TBI. In children with severe malaria, 
resuscitation with albumin infusion results in a lower mortality than resuscitation with sa
line infusion. In patients with cirrhosis and spontaneous bacterial peritonitis, renal function 
frequently becomes impaired. This impairment is probably related to a reduction in effective 
arterial blood volume and is associated with a high mortality rate. In patients with cirrhosis 
and spontaneous bacterial peritonitis, treatment with intravenous albumin in addition to an 
antibiotic reduces the incidence of renal impairment and death in comparison with treatment 
with an antibiotic alone. Albumin is a large molecule which plays an essential role in gener
ating colloido-osmotic pressure which facilitates fluid retention in the intravascular space. 
Human Albumin is quiet useful in burnt patients. Licensed indications are the emergency 
treatment of shock and other conditions where restoration of blood volume is urgent, burns, 
and hypoproteinaemia.
Immune Globulins, including Rh Immune Globulin. The administration of Rh immune 
globulin (RhIG) to D–negative women after parturition is a remarkably successful therapy 
and has prevented many thousands of D+ infants worldwide suffering from hemolytic dis
ease of the fetus and newborn (HDFN) since its introduction nearly 40 years ago. The mecha
nism of action is due to the role for immunomodulatory cytokines and foetal red cell clear
ance. Rh (D)-negative women with a large fetomaternal haemorrhage (FMH) from an Rh (D) 
positive fetus are at risk for anti-D alloimmunization if they do not receive adequate Rh im
mune globulin (RhIG). Determination of the adequate RhIG dose for these women is a critical 
laboratory procedure for protecting their future Rh (D)+positive children. Laboratories per
forming quantification of FMH should review their procedures and training for calculating 
RhIG dosage. Intravenous immunoglobulin and intravenous anti-D are common therapies 
in the management of patients with immune thrombocytopenia (ITP). Despite immediate 
increases in the platelet count, the duration of response is limited, with platelet increments 
lasting between 2 and 4 weeks. Infusion reactions are common but adverse events are rare.
Anti-Inhibitor Coagulant Complex (AICC). Anti-Inhibitor Coagulant Complex is a freeze-
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philia and inhibitors with bleeding episodes treated with bypassing agents showed that when 
APCC was administered regularly, most patients exhibited a reduction in the numbers of 
haemorrhages, an improvement in orthopaedic status, and an improvement in quality of life.
Alpha 1-Proteinase Inhibitor Concentrate. Alpha-antitrypsin (AAT) is a serine protease 
inhibitor, which inhibits the proteolytic enzyme elastase. Alpha (1)-Antitrypsin (AAT) de-
ficiency is a common but underrecognised condition. Since its first description by Laurell 
and Eriksson in 1963, significant advances have been made in understanding the genetics, 
physiology and pathophysiology of this condition. The intravenous administration of puri-
fied AAT to AAT-deficient individuals has been shown to confer biochemical efficacy by rais-
ing the serum AAT level above an epidemiologically established ‘protective threshold’ while 
preserving the biochemical properties and functional capacity of the protease inhibitor. Indi-
viduals with a deficiency of AAT may develop clinical manifestations that include a decline 
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19. Management of major haemorrhage
Haemorrage is a leading cause of early death following traumatic injury, intra and post surgi-
cal and ante and post partum. In most severely injured patient with injury severity score > 25 
the mortality rate is between 60-70%. Patient who suffer from uncontrolled haemorrage do so 
within the first 6 hours following injury. Haemorrhage accounts for 40% of deaths from trau-
ma and is the most common cause of preventatable mortality in developing countries due to:
1. Chronic blood shortages, high prevalence of transfusion-transmissible 
infection
2. Reliance on whole blood transfusion and lack of other component re-
quired to manage coagulopathy
3. Absence of national blood transfusion service and reliance on family re-
placement and commercial blood donation
4. Inadequate use of pharmacologic and non pharmacologic alternatives to 
allogenic blood.
What is a major haemorrhage? Major haemorrhage is the replace of patient’s blood volume 
or transfusion of > 10 units of packed red cells with a 24 hours period. It can also be defined 
as the loss of 50% of blood volume within a 3 hours period or a loss of 150ml per minute. The 
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aim of blood volume replacement with concentrated red cells and other plasma products fol-
lowing massive haemorrhage are:
1. To rapidly and effectively restore adequate blood volume and prevent 
hypovolaemic shock and to allow for adequate haemostasis, oxygen car-
rying capacity and blood biochemistry.
2. To allow for an early and aggressive correction of coagulopathy
3. Allow for optimal resuscitation.
4. Reduce potentially preventable deaths.
Haemorrhage control measures
1. Direct pressure /tourniquet if appriopriate
2. Stabilization of fractures
3. Surgical interventions such as: Damage control surgery, Interventional 
radiology and use of endoscopic and obstetrics techniques
Use of haemostatic drugs such as:
1. Use of antifibrinolytic (aprotinin, tranexamic acid, epsilon-aminocaproic 
acid) to reduce blood loss. Aprotinin and tranexamic acid reduced signifi-
cantly the proportion of patients requiring allogeneic erythrocyte transfu-
sion according to a transfusion protocol. Tranexamic acid (1g bolus fol-
lowed by 1g over 8 hours).
2. Vitamin K and prothrombin complex concentrate (PCC) particularly for 
warfarinised patients. Prothrombin Complex Concentrate PCCs are a hu-
man blood product and both pasteurisation and nanofiltration are used 
for viral inactivation. Prothrombin Complex Concentrate PCCs contain 
the clotting factors II, VII, IX, X and Protein C. Warfarin and other cou-
marin derivatives exert their anticoagulant affect by preventing the pro-
duction of biologically active Vitamin K dependent co-factors (II, VII IX 
and X). These effects can be reversed by the administration of Vitamin K 
but the onset of action is delayed by 4-6 hours. Therefore, in situations 
where more rapid reversal of anticoagulation is required and where the 
thrombotic risks of complete reversal are less than the risks of continued 
bleeding, the use of a Prothrombin Complex Concentrate.
3. Novo 7: Nova 7 is a vitamin K-dependent recombinant human coagula-
tion Factor VIIa (rFVIIa), intended for promoting hemostasis by activat-
ing the extrinsic pathway of the coagulation cascade. It is a glycoprotein. 
It is an important factor in the clotting of blood that forms a complex with 
147Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
tissue thromboplastin and calcium to activate the prothrombinase, thus 
acting to accelerate the conversion of prothrombin to thrombin. 
 Intraoperative blood salvage, also known as autologous blood salvage, is a med
ical procedure involving recovering blood lost during surgery and trauma-related blood and 
re-infusing it into the patient. Several processes have been developed to assist in salvaging 
the patient’s own whole blood in the perioperative setting. These can be categorized into three 
general types of salvage procedures: Cell processors and salvage devices that wash and save 
red blood cells (cell washers or RBC-savers). Cell processors are red cell washing devices that 
collect anticoagulated shed or recovered blood, wash and separate the red blood cells (RBCs) 
by centrifugation, and reinfuse the RBCs. RBC washing devices can help remove byproducts 
in salvaged blood such as activated cytokines, anaphylatoxins, and other waste substances 
that may have been collected in the reservoir suctioned from the surgical field. Direct trans
fusion is a blood salvaging method that are used in surgery such as coronary artery bypass 
grafts (CABG), valve replacement, or surgical repair of the great vessels. Ultrafiltration de
vices filter the patient’s anticoagulated whole blood. The filter process removes unwanted 
excess non-cellular plasma water, low molecular weight solutes, platelet inhibitors and some 
particulate matter through hemoconcentration, including activated cytokines, anaphylatox
ins, and other waste substances making concentrated whole blood available for reinfusion.
1. Patient bleeding/collapses (loss of 150 mls/minute or in clinical shock)
2. Emergency group O (2 units) located in the nearest transfusion fridge 
can be used immediately in dare emergency. The managing clinical team 
must remember to inform the transfusion laboratory that emergency 
units have been taken to enable immediate replenishment.
3. Resuscitate (Ensure airway is clear, breathing and circulation)
4. Identify location of patient and call for help and allocate roles (team lead, 
communicator, samples, documenter and transporter).
5. Alert emergency response team as well as blood transfusion laboratory.
6. Take blood and send to laboratory for crossmatch, Full blood counts 
(FBC), Coagulation test (PT, APTT and Fibrinogen), Urea and creatinine, 
calcium and Blood gases).
7. Ask the managing clinician if major haemorrage pack 1 (MHP 1) required 
or tailored therapy. If major haemorrhage pack 1 required, prepare 8 
units of red cells, 8 units of FFP and 2 doses of platelet. If tailored therapy 
ask how many units of red cells, FFP and palatelets required.
8. Depending on urgency with which the product is required, emergency 
group O positive, group specific blood or fully crossmatched blood may 
be made available.
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tissue thromboplastin and calcium to activate the prothrombinase, thus 
acting to accelerate the conversion of prothrombin to thrombin. 
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the patient’s own whole blood in the perioperative setting. These can be categorized into three 
general types of salvage procedures: Cell processors and salvage devices that wash and save 
red blood cells (cell washers or RBC-savers). Cell processors are red cell washing devices that 
collect anticoagulated shed or recovered blood, wash and separate the red blood cells (RBCs) 
by centrifugation, and reinfuse the RBCs. RBC washing devices can help remove byproducts 
in salvaged blood such as activated cytokines, anaphylatoxins, and other waste substances 
that may have been collected in the reservoir suctioned from the surgical field. Direct trans-
fusion is a blood salvaging method that are used in surgery such as coronary artery bypass 
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vices filter the patient’s anticoagulated whole blood. The filter process removes unwanted 
excess non-cellular plasma water, low molecular weight solutes, platelet inhibitors and some 
particulate matter through hemoconcentration, including activated cytokines, anaphylatox-
ins, and other waste substances making concentrated whole blood available for reinfusion.
Management plan in case of massive haemorrhage
1. Patient bleeding/collapses (loss of 150 mls/minute or in clinical shock)
2. Emergency group O (2 units) located in the nearest transfusion fridge 
can be used immediately in dare emergency. The managing clinical team 
must remember to inform the transfusion laboratory that emergency 
units have been taken to enable immediate replenishment.
3. Resuscitate (Ensure airway is clear, breathing and circulation)
4. Identify location of patient and call for help and allocate roles (team lead, 
communicator, samples, documenter and transporter).
5. Alert emergency response team as well as blood transfusion laboratory.
6. Take blood and send to laboratory for crossmatch, Full blood counts 
(FBC), Coagulation test (PT, APTT and Fibrinogen), Urea and creatinine, 
calcium and Blood gases).
7. Ask the managing clinician if major haemorrage pack 1 (MHP 1) required 
or tailored therapy. If major haemorrhage pack 1 required, prepare 8 
units of red cells, 8 units of FFP and 2 doses of platelet. If tailored therapy 
ask how many units of red cells, FFP and palatelets required.
8. Depending on urgency with which the product is required, emergency 
group O positive, group specific blood or fully crossmatched blood may 
be made available.
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• Emergency O positive blood (male, women >60, not known to 
have allo anti-D). Unlimited issue until a suitably identified 
sample is received and a secure group is obtained.
• Group specific (ABO/D matched) – suitable sample/secure 
group obtained. Not fully crossmatched.
• Full crossmatch (ABO/D matched, antibody screen per-
formed, specifically ‘crossmatched’ patient’s plasma versus 
donor’s red cells). 
1. Give the ordered blood products and reassess patient for suspected con-
tinuing haemorrhage requiring further transfusion. Take and send post 
transfusion blood samples to the laboratory for repeat FBC, PT, APTT, 
Fibrinogen, Urea and creatinine, Calcium and Blood gas.
2. The aim of any further intervention is to maintain the following:
• Haemoglobin between 8-10g/dl
• Platelet count above 75 x 109/l
• International normalized ratio below 1.5
• APTT ratio below 1.5
• Fibrinogen above 1g/l. If not met; consider giving 2 units of 
cryoprecipitate.
• Calcium above 1mmol/l. If not met, consider giving 10 mls of 
calcium chloride (10%) over 10 minutes period.
• Temerature above 36°C. If not met, use warm fluid device or 
use forced air warming blanket.
• Ph above 7.35
3. If the above aim is not achieved and patient continue to bleed, order MHP 
2 (4 red cells, 4 FFP, 1 platelet and 2 units of cryoprecipitate if fibrinogen 
is <1g/l or <2g/l in case of obstetric haemorrhage. 
4. Give blood products in MHP 2/tailored therapy and reassess patient 
for suspected continuing haemorrhage. Take and send post transfusion 
blood samples to the laboratory for repeat FBC, PT, APTT, Fibrinogen, 
Urea and creatinine, Calcium and Blood gas.
5. If further blood product is required inform the transfusion laboratory. At 
this point if patient continue to bleed you can seek the advice of the Hae-
matologist to consider the use of Novo 7. If bleeding ceases send a stand 
down call to transfusion, return all unused blood component to the trans-
fusion laboratory, complete all transfusion-related documentation. Com-
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plete an audit of the management and identify any non-conformances, 
determine root causes, identify the preventive and corrective action as 
well as lessions learnt that can potentially improve subsequent manage
ment of massive haemorrhage in the hospital.
Most (25%) severe trauma patients seen in emergency depart
ment often present with a triad of; Hypotherma, Acidosis and Acute traumatic coagulapathy 
(ATC). Acute traumatic coagulapathy is assocaited with a four-fold increase in trauma-related 
mortality. Damage control suscitation is immediately required to effectively and urgently address 
this triad. This involves the silmutaneous replacement of plasma component and red blood cells. 
The FFP: RBC OF 1:1, 1:2 and 1:3 has been suggested. Evidenced based findings however show 
that ratio of > 1:1 does not seem to offer any additional advantage. There is growing advocacy for 
the application of thromboelastometry. Thromboelastometry (TEM) is an established viscoelastic 
method for haemostatis testing in whole blood. TEM investigates the interaction of coagulation 
factors, their inhibitors, anticoagulant drugs, blood cells, specifically platelets, during clotting and 
subsequent fibrinolysis. It can serve as a guide with regards to componet usage in traumatic mas
sive haemorrhage. There is also growing advocacy for the increased use of alternatives to conven
tional blood component particularly fibrinogen concentrate for fibrinogen replacement.
20. Storage conditions, shelf life indication and mode of transfusion
Red cell optimum storage temperature is 4°C ± 2°c. Time out of storage should not exceed 30 
minutes at any material time (or must be discarded). Transfuse over 2-3 hours per unit. Used 
to treat acute blood loss to maintain HB above 7g/dl in otherwise fit patients and above 8g/dl 
in elderly patient or in peri operative situation when HB is < 7g/dl or <8g/dl in patients with 
known cardiovascular disease (elderly patients, those with hypertension, diabetes mellitus 
and other vascular diseases), in critical care to maintain HB >7 g/dl, in post chemotherapy to 
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plete an audit of the management and identify any non-conformances, 
determine root causes, identify the preventive and corrective action as 
well as lessions learnt that can potentially improve subsequent manage-
ment of massive haemorrhage in the hospital.
Acute Traumatic coagulopathy. Most (25%) severe trauma patients seen in emergency depart-
ment often present with a triad of; Hypotherma, Acidosis and Acute traumatic coagulapathy 
(ATC). Acute traumatic coagulapathy is assocaited with a four-fold increase in trauma-related 
mortality. Damage control suscitation is immediately required to effectively and urgently address 
this triad. This involves the silmutaneous replacement of plasma component and red blood cells. 
The FFP: RBC OF 1:1, 1:2 and 1:3 has been suggested. Evidenced based findings however show 
that ratio of > 1:1 does not seem to offer any additional advantage. There is growing advocacy for 
the application of thromboelastometry. Thromboelastometry (TEM) is an established viscoelastic 
method for haemostatis testing in whole blood. TEM investigates the interaction of coagulation 
factors, their inhibitors, anticoagulant drugs, blood cells, specifically platelets, during clotting and 
subsequent fibrinolysis. It can serve as a guide with regards to componet usage in traumatic mas-
sive haemorrhage. There is also growing advocacy for the increased use of alternatives to conven-
tional blood component particularly fibrinogen concentrate for fibrinogen replacement.
20. Storage conditions, shelf life indication and mode of transfusion
Red blood cells
 
Red cell optimum storage temperature is 4°C ± 2°c. Time out of storage should not exceed 30 
minutes at any material time (or must be discarded). Transfuse over 2-3 hours per unit. Used 
to treat acute blood loss to maintain HB above 7g/dl in otherwise fit patients and above 8g/dl 
in elderly patient or in peri operative situation when HB is < 7g/dl or <8g/dl in patients with 
known cardiovascular disease (elderly patients, those with hypertension, diabetes mellitus 
and other vascular diseases), in critical care to maintain HB >7 g/dl, in post chemotherapy to 
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maintain HB > 8g/dl and in post radiotherapy to maintain HB > 10g/dl and in patients with 
chronic symptomatic anaemia with the hope of maintaining HB >8g/dl.
Fresh frozen plasma
 
The optimum storage temperature for FFP is < - 30°C. Takes about 20-30 minutes to thaw. 
Once thawed, it should be used within 4 hours for optimum benefit or for up to 24 hours if 
stored at 4°C. Adult therapeutic dose is 4 units. Transfuse at rate of 12-15 ml/kg body weight. 
Transfuse over 30 mins per unit. FFP is indicated in the following situations; for the replace-
ment of single coagulation factor deficiencies where the specific or combined factors is not 
available for example factor V with INR > 1.5, in liver disease patients with a pt >4 seconds of 
the control value (>1.5), in massive transfusion and surgery-related bleeding with INR > 1.5, 
in thrombotic thrombocytopenic purpura (TTP) in conjunction with plasma exchange with 
INR >1.5, in cases of Disseminated Intravascular Coagulation (DIC) in the presence of bleed-
ing and abnormal coagulation results and for the immediate reversal of warfarin effect in the 
presence of life threatening bleeding. However prothrombin complex concentrate (PCC) is 
the optimal preferred treatment since FFP only has a partial effect.
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The optimum storage temperature for cryoprecipitate is < - 30 0c. Takes about 20-30 minutes to 
thaw. Once thawed, it should be used immediately within 4 hours. Adult therapeutic dose is 2 
units. Transfuse at rate of 12-15 ml/kg body weight. Transfuse over 30 mins per unit. Cryopre
cipitate is indicated in the following conditions; in cases of Disseminated Intravascular Coagula
tion (DIC) in the presence of bleeding and a fibrinogen level of < 1g/L, in cases of renal failure 
with bleeding and fibrinogem level of <1 g/L, in cases of hypofibrinogenaemia secondary to 
massive blood transfusion with fibrinogem level of <1 g/L, in cases of bleeding associated with 
thrombolytic therapy and associated hypofibrinogenaemia and in advanced renal disease to 
correct bleeding or as a prophylaxis in surgery in patients with fibrinogem level of <1 g/L.
1
- - -
Table: Selection of FFP for transfusion
* = Group O FFP must be reserved only for O recipients
** = All FFP for use against ABO blood group barrier must be test for high titre haemolysins and found 
negative
***= AB FFP are often in short supply
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Cryoprecipitate
 t
The optimum storage temperature for cryoprecipitate is < - 30 0c. Takes about 20-30 minutes to 
thaw. Once thawed, it should be used immediately within 4 hours. Adult therapeutic dose is 2 
units. Transfuse at rate of 12-15 ml/kg body weight. Transfuse over 30 mins per unit. Cryopre-
cipitate is indicated in the following conditions; in cases of Disseminated Intravascular Coagula-
tion (DIC) in the presence of bleeding and a fibrinogen level of < 1g/L, in cases of renal failure 
with bleeding and fibrinogem level of <1 g/L, in cases of hypofibrinogenaemia secondary to 
massive blood transfusion with fibrinogem level of <1 g/L, in cases of bleeding associated with 
thrombolytic therapy and associated hypofibrinogenaemia and in advanced renal disease to 
correct bleeding or as a prophylaxis in surgery in patients with fibrinogem level of <1 g/L.
Receipient group O A B AB
1st choice O* A B AB***
2nd choice A AB*** AB*** A**
3rd choice B B** A** B**
4th choice AB*** - - -
Table: Selection of FFP for transfusion
Key 
* = Group O FFP must be reserved only for O recipients
** = All FFP for use against ABO blood group barrier must be test for high titre haemolysins and found 
negative
***= AB FFP are often in short supply
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Platelet
 
The optimum storage temperature in the platelet agitator is 22 0C. Maximum shelf life is 5 
days. Transfuse at rate of 15 ml/kg body weight. Transfuse over 30 mins per unit. Platelet 
concentrate is indicated in the following conditions; When thrombocytopenic patients do not 
achieve the expected post-transfusion platelet count increment they are said to be refractory. 
This usually occurs in patients receiving frequent platelet transfusions. There are clinical and 
immunological causes of platelet refractoriness. Clinical causes include; sepsis, DIC, bleeding, 
fever, some drugs, and enlarged spleen. Immunological causes include the development of 
antibodies to human leucocyte antigens (HLA) or human platelet antigens (HPA). Immu-
nological refractoriness can be managed by the provision of HLA or HPA matched platelets. 
Leucocyte reduction of blood products to levels less than 106/unit reduces the likelihood of 
alloimmunisation. This can be achieved through the use of pre storage or bedside leucocyte 
reduced blood products. Platelet concentrate is indicated; to prevent spontaneous bleeding 
in patients with a platelet count <10 x 109/l, in cases of autoimmune thrombocytopenia in 
the presence of major bleeding, in cases of acute Disseminated Intravascular Coagulation 
(DIC) in the presence of bleeding and thrombocytopenia, in cases of neonatal alloimmune 
thrombocytopenia to treat haemorrhage or as a prophylaxis prior to surgery, in cases of post 
transfusion purpura in the presence of life threatening haemorrhage and in patients with an 
inherited platelet dysfunction such as Glanzman, s thrombosthenia associated with haemor-
rhage or as a prophylaxis prior to surgery, in patients with haemorrhage that is not surgically 
corrected (post-cardiopulmonary bypass surgery) and associated with acquired platelet dys-
function and in patients on anti-platelet drugs like Clopidogriel, in a massively transfused 
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patient (1.5-2 times the blood volume replacement) who are bleeding with a platelet count 
< 50 x 109/l. The aim is to maintain platelet count above 50 x 109/l, to prevent spontaneous 
bleeding in patients with platelet count of <20 x 109/l in the presence of other bleeding risk 
factors such as sepsis and other coagulopathies, to prevent bleeding associated with invasive 
procedures (lumbar puncture, insertion of intravascular lines, epidural anaesthesia, trans
bronchial and liver biopsy and laparotomy) in thrombocytopenic subjects. The platelet count 
should be raised to 50 x 109/l. In cases of surgery of critical sites such as the brain and eyes, 
the aim is to maintain platelet count >100 x 109/l.
In a bid to protect the national blood inventory and optimally maximize the use of our blood 
stock, there is need to develop a conservative approach in deciding whether transfusion is 
required in the managements of patients. Transfusion of the right unit of blood to the right 
patient at the right time, and in the right condition and according to appropriate guidelines. 
A chain of integrated events that begins with a correct decision that the patient needs blood 
and ends with an assessment of the clinical outcome of the transfusion. Its goal is to achieve 
optimal use of blood. Optimal use of blood ensures:
• Transfusion are safe (No adverse reactions or infections)
• Clinically effective (Benefits the patient)
• Efficient use of donated human blood (No unnecessary transfusions 
and that transfusion should only be given at the time the patient 
needs it).
Apprioprite use of blood component has become very important in the last few years for the 
following reasons; The cost of providing blood components has increased as a result of new 
safety requirements and other technical developments, the safety of hospital treatment and 
the effectiveness of care have become major concerns in healthcare systems. Blood transfu
sion has been the subject of legal proceedings and investigations in most countries. Hospitals 
should are now expected to be in a position to show that their practice of blood transfusion 
is safe, clinically effective and efficient, blood is a human tissue and is a precious and scarce 
resource. Many countries have difficulties matching supplywith demand. There is increasing 
challenge with supply of blood components (recruitment and retention issues) in most coun
tries coupled with the fact that population in most countries are ageing. As well as the obliga
tion for hospitals and blood collection services to demonstrate to blood donors that each gift 
of human tissue is carefully, wisely and effectively used and that it can be fully accounted 
for, legal actions, public inquiries, investigations or adverse media attention stimulated by 
transfusion-related harm to patientsare gainimg serious management attention and are help
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patient (1.5-2 times the blood volume replacement) who are bleeding with a platelet count 
< 50 x 109/l. The aim is to maintain platelet count above 50 x 109/l, to prevent spontaneous 
bleeding in patients with platelet count of <20 x 109/l in the presence of other bleeding risk 
factors such as sepsis and other coagulopathies, to prevent bleeding associated with invasive 
procedures (lumbar puncture, insertion of intravascular lines, epidural anaesthesia, trans-
bronchial and liver biopsy and laparotomy) in thrombocytopenic subjects. The platelet count 
should be raised to 50 x 109/l. In cases of surgery of critical sites such as the brain and eyes, 
the aim is to maintain platelet count >100 x 109/l.
21. Use of indication coding system to ensure the appriopriate use 
of blood components
In a bid to protect the national blood inventory and optimally maximize the use of our blood 
stock, there is need to develop a conservative approach in deciding whether transfusion is 
required in the managements of patients. Transfusion of the right unit of blood to the right 
patient at the right time, and in the right condition and according to appropriate guidelines. 
A chain of integrated events that begins with a correct decision that the patient needs blood 
and ends with an assessment of the clinical outcome of the transfusion. Its goal is to achieve 
optimal use of blood. Optimal use of blood ensures:
• Transfusion are safe (No adverse reactions or infections)
• Clinically effective (Benefits the patient)
• Efficient use of donated human blood (No unnecessary transfusions 
and that transfusion should only be given at the time the patient 
needs it).
Apprioprite use of blood component has become very important in the last few years for the 
following reasons; The cost of providing blood components has increased as a result of new 
safety requirements and other technical developments, the safety of hospital treatment and 
the effectiveness of care have become major concerns in healthcare systems. Blood transfu-
sion has been the subject of legal proceedings and investigations in most countries. Hospitals 
should are now expected to be in a position to show that their practice of blood transfusion 
is safe, clinically effective and efficient, blood is a human tissue and is a precious and scarce 
resource. Many countries have difficulties matching supplywith demand. There is increasing 
challenge with supply of blood components (recruitment and retention issues) in most coun-
tries coupled with the fact that population in most countries are ageing. As well as the obliga-
tion for hospitals and blood collection services to demonstrate to blood donors that each gift 
of human tissue is carefully, wisely and effectively used and that it can be fully accounted 
for, legal actions, public inquiries, investigations or adverse media attention stimulated by 
transfusion-related harm to patientsare gainimg serious management attention and are help-
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ing to define the application of blood resource ensure effective use and to avoid future prob-
lems. The indications for transfusion provided below are taken from UK national guidelines 
for the use of blood components. Clinical judgement plays an essential part in the decision to 
transfuse or not to transfuse and help clinicians decide when blood transfusion is appropri-
ate, and to minimise unnecessary exposure to transfusion. Each indication has been assigned 
a number, which may be used by clinicians when requesting blood or for purposes of audit.
Red cell concentrates. Red cell concentrate are indicated to treat anaemia in the following 
clinical situations.
R1. Acute blood loss:-In acute blood loss the objective is to maintain circulating blood volume 
and haemoglobin (Hb) concentration > 7 g/dl in otherwise fit patients, and > 8g/dl in elderly 
patients and those with known cardiovascular disease. If there is 15-30% loss of blood volume 
(800-1500ml in an adult) you can transfuse crystalloids or synthetic colloids. Red cell transfu-
sion is unlikely to be necessary. 30-40% loss of blood volume (1500-2000ml in an adult): rapid 
volume replacement is required with crystalloids or synthetic colloids. Red cell transfusion 
will probably be required to maintain recommended Hb levels. >40% loss of blood volume 
(>2000ml in an adult): rapid volume replacement including red cell transfusion is required. 
For Peri-operative transfusion, many patients undergoing elective surgical operations should 
not require transfusion support if their Haemoglobin (Hb) concentration is normal before 
surgery. Assuming normovolaemia has been maintained, the Hb can be used to guide the use 
of red cell transfusion.
R2. Patient Hb concentration below 7g/dl. Anaemia with haemoglobin concentration of <70g/l 
in otherwise healthy/critical care patients may require red cell transfusion.
R3. Hb concentration below 8g/dl in a patient with known cardiovascular disease, or those 
with significant risk factors for cardiovascular disease (for example elderly patients, and 
those with hypertension, diabetes mellitus, peripheral vascular disease).
R4. Critical Care. Transfuse to maintain the Hb >7g/dl.
R5. Post-chemotherapy. There is no evidence-base to guide practice. Most hospitals use a 
transfusion threshold of a Hb of 8 or 9g/dl.
R6. Radiotherapy. Transfuse to maintain Hb above 10g/dl.
R7. Chronic anaemia. Transfuse to maintain the haemoglobin just above the lowest concentra-
tion which is not associated with symptoms of anaemia. Many patients with chronic anaemia 
may be asymptomatic with a haemoglobin concentration >8g/dl.
Fresh frozen plasma (FFP). The normal adult dose of FFP is 12-15 ml/kg body weight equiva-
lent to 4 units for an adult. FFP are indicated in the following clinical situations.
F1. Replacement of single coagulation factor deficiencies, where a specific or combined factor 
concentrate is unavailable for example factor V.
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Immediate reversal of warfarin effect, in the presence of life-threatening bleeding. FFP 
only has a partial effect and is not the optimal treatment; prothrombin complex concentrates 
are preferred.
Acute disseminated intravascular coagulation (DIC) in the presence of bleeding and ab
normal coagulation results.
 Thrombotic thrombocytopenic purpura (TTP), usually in conjunction with plasma exchange.
Massive transfusion and surgical bleeding; the use of FFP should be guided by timely tests 
of coagulation including near patient testing.
Liver disease; patients with a prothrombin time (PT) within 4 seconds of the control value 
are unlikely to benefit from the use of FFP.
The optimum dose for cryoprecipitate is 1 unit/5kg body weight equivalent 
to 10 units for an adult. Cryoprecipitate is indicated in the following clinical situations.
Acute disseminated intravascular coagulation (DIC), where there is bleeding and a fi
brinogen level < 1g/l.
Advanced liver disease, to correct bleeding or as prophylaxis before surgery, when the 
fibrinogen level <1g/l.
Bleeding associated with thrombolytic therapy causing hypofibrinogenaemia.
Hypofibrinogenaemia (fibrinogen level <1g/l) secondary to massive transfusion
Renal failure or liver failure associated with abnormal bleeding where DDAVP is con
traindicated or ineffective
The optimum dose of platelet concentrate is 15 ml/kg body weight for 
children <20kg; 1 adult therapeutic dose for adults and older children. Platelet concentrateare 
indicated in the following clinical situations.
Bone marrow failure: To prevent spontaneous bleeding when the platelet count <10 x 109/l.
 To prevent spontaneous bleeding when the platelet count <20 x 109/l in the presence of 
additional risk factors for bleeding such as sepsis or haemostatic abnormalities.
To prevent bleeding associated with invasive procedures. The platelet count should be 
raised to >50 x 109/l before lumbar puncture, epidural anaesthesia, insertion of intravascular 
lines, transbronchial and liver biopsy, and laparotomy, and to >100 x 109/L before surgery in 
critical sites such as the brain or the eyes.
 Critical care/surgery: Massive blood transfusion. The platelet count can be anticipated to 
be <50 x 109/l after 1.5-2 x blood volume replacement. The aim in massively transfused patient 
is to maintain platelet count >50 x 109/l.
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R1. Acute blood loss:-In acute blood loss the objective is to maintain circulating blood volume 
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patients and those with known cardiovascular disease. If there is 15-30% loss of blood volume 
(800-1500ml in an adult) you can transfuse crystalloids or synthetic colloids. Red cell transfu
sion is unlikely to be necessary. 30-40% loss of blood volume (1500-2000ml in an adult): rapid 
volume replacement is required with crystalloids or synthetic colloids. Red cell transfusion 
will probably be required to maintain recommended Hb levels. >40% loss of blood volume 
(>2000ml in an adult): rapid volume replacement including red cell transfusion is required. 
For Peri-operative transfusion, many patients undergoing elective surgical operations should 
not require transfusion support if their Haemoglobin (Hb) concentration is normal before 
surgery. Assuming normovolaemia has been maintained, the Hb can be used to guide the use 
of red cell transfusion.
Patient Hb concentration below 7g/dl. Anaemia with haemoglobin concentration of <70g/l 
in otherwise healthy/critical care patients may require red cell transfusion.
Hb concentration below 8g/dl in a patient with known cardiovascular disease, or those 
with significant risk factors for cardiovascular disease (for example elderly patients, and 
those with hypertension, diabetes mellitus, peripheral vascular disease).
 Critical Care. Transfuse to maintain the Hb >7g/dl.
Post-chemotherapy. There is no evidence-base to guide practice. Most hospitals use a 
transfusion threshold of a Hb of 8 or 9g/dl.
 Radiotherapy. Transfuse to maintain Hb above 10g/dl.
R7. Chronic anaemia. Transfuse to maintain the haemoglobin just above the lowest concentra
tion which is not associated with symptoms of anaemia. Many patients with chronic anaemia 
may be asymptomatic with a haemoglobin concentration >8g/dl.
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F2. Immediate reversal of warfarin effect, in the presence of life-threatening bleeding. FFP 
only has a partial effect and is not the optimal treatment; prothrombin complex concentrates 
are preferred.
F3. Acute disseminated intravascular coagulation (DIC) in the presence of bleeding and ab-
normal coagulation results.
F4. Thrombotic thrombocytopenic purpura (TTP), usually in conjunction with plasma exchange.
F5. Massive transfusion and surgical bleeding; the use of FFP should be guided by timely tests 
of coagulation including near patient testing.
F6. Liver disease; patients with a prothrombin time (PT) within 4 seconds of the control value 
are unlikely to benefit from the use of FFP.
Cryoprecipitate. The optimum dose for cryoprecipitate is 1 unit/5kg body weight equivalent 
to 10 units for an adult. Cryoprecipitate is indicated in the following clinical situations.
C1. Acute disseminated intravascular coagulation (DIC), where there is bleeding and a fi-
brinogen level < 1g/l.
C2. Advanced liver disease, to correct bleeding or as prophylaxis before surgery, when the 
fibrinogen level <1g/l.
C3. Bleeding associated with thrombolytic therapy causing hypofibrinogenaemia.
C4. Hypofibrinogenaemia (fibrinogen level <1g/l) secondary to massive transfusion
C5. Renal failure or liver failure associated with abnormal bleeding where DDAVP is con-
traindicated or ineffective
Platelet concentrates. The optimum dose of platelet concentrate is 15 ml/kg body weight for 
children <20kg; 1 adult therapeutic dose for adults and older children. Platelet concentrateare 
indicated in the following clinical situations.
P1. Bone marrow failure: To prevent spontaneous bleeding when the platelet count <10 x 109/l.
P2. To prevent spontaneous bleeding when the platelet count <20 x 109/l in the presence of 
additional risk factors for bleeding such as sepsis or haemostatic abnormalities.
P3. To prevent bleeding associated with invasive procedures. The platelet count should be 
raised to >50 x 109/l before lumbar puncture, epidural anaesthesia, insertion of intravascular 
lines, transbronchial and liver biopsy, and laparotomy, and to >100 x 109/L before surgery in 
critical sites such as the brain or the eyes.
P4. Critical care/surgery: Massive blood transfusion. The platelet count can be anticipated to 
be <50 x 109/l after 1.5-2 x blood volume replacement. The aim in massively transfused patient 
is to maintain platelet count >50 x 109/l.
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P5. In cases of bleeding, not surgically correctable and associated acquired platelet dysfunc-
tion e.g. postcardiopulmonary bypass, possibly combined with the use of potent anti-platelet 
agents such as clopidigrel.
P6. In acute disseminated intravascular coagulation (DIC) in the presence of bleeding and 
severe thrombocytopenia.
P7. In inherited platelet dysfunction for example Glanzmanns thrombasthenia with bleeding 
or as prophylaxis before surgery.
P8. Immune thrombocytopenia. Autoimmune thrombocytopenia, in the presence of major 
haemorrhage.
P9. Post-transfusion purpura, in the presence of major haemorrhage.
P10. Neonatal alloimmune thrombocytopenia, to treat bleeding or as prophylaxis to maintain 







Red cells 35 days in CPDA 4°C ± 2°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
Platelets 5 Days 22°C ± 2°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
Fresh frozen 
plasma
2 years < -30°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
Cryoprecipitate 2 years < -30°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
Table: Storage condition of blood components
Special transfusion requirements
Irradiated Blood Component. Graft versus host disease is a serious and often fatal disease that 
occurs as a result of histocompatibility differences between donor and recipients. It often results 
from recipient receiving immunocompetent donors’ cells or marrow. It often occurs in immuno-
compromised patients (congenital immunodeficiency, marrow transplant patient and patients 
on myeloablative therapy such as chemotherapy and radiotherapy) and seldom in immuno-
competent subjects. The viable lymphocytes contained in the blood components can cause fatal 
GVHD in susceptible subjects. GVHD is thought to occur when the donor is HLA homozygous 
and haploidentical with the recipient. In such a situation, even though the patient is immuno-
competent, it is unable to identify the donor’s cells as foreign thus allowing for its proliferation 
and eventual GVHD. To prevent transfusion-associated GVHD, blood components are sub-
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jected to radiation (gamma radiation or x-ray) which damages the DNA and interfere with the 
ability of the lymphocyte to proliferate by forming electrically charged particles or ions. Com
monly used isotopes for irradiation is Cs or Co at a minimum dose of 3,000 rads. It is essential 
to put a quality control measure in place for blood irradiators to ensure that, irradiation was 
performed as intended and daily check to ensure that timer is working optimally and periodic 
surveys to prevent leakages of isotope.
Acute leukaemia in the absence of bone marrow All HLA matched platelets and donations from 1st 
and 2nd degree relatives
Patients who has received autologous bone mar-
row and peripheral blood stem cell transplant
Irradiated product required from initiation of chemo-
therapy until 3-6 months post transplant. It may be 
safer to continue with lifelong irradiated products
Patients who have received allogeneic haemopoi-
From initiation of chemotherapy until 6 months 
post transplant and if patient continues to be on 
immunosuppressive drugs
Patients having allogeneic haemopoietic cell 
donation and peripheral stem cell donation for 
possible use in future autologous infusion
A week before, during and until harvest is com-
Hodgkin’s disease, T cell Lymphoma & Indefinitely from time of diagnosis &
In transplant patients treated with (ATG)/Alemtuzamab. 
Transplant patients and patients with CLL and 
lymphoma on purine analogues (Fludarabine, 
Irradiated products are indicated indefinitely from 
diagnosis/treatment
Patients with cellular immunodeficiency syn-
dromes (Di George syndrome, Wiskott –Aldrich 
Irradiated products are indicated indefinitely from 
diagnosis.
Exchange and intrauterine (IUT) transfusion
Red cells and platelets must be irradiated for IUT 
and for exchange and top up transfusion provided 
delay of irradiation does not put patient at risk.
Granulocytes transfusions and transfusions from 
1st or 2nd degree relatives.
Red cells and platelets must be irradiated
Indication for Gamma/X-irradiated red cells and platelets
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tion e.g. postcardiopulmonary bypass, possibly combined with the use of potent anti-platelet 
agents such as clopidigrel.
In acute disseminated intravascular coagulation (DIC) in the presence of bleeding and 
severe thrombocytopenia.
In inherited platelet dysfunction for example Glanzmanns thrombasthenia with bleeding 
or as prophylaxis before surgery.
 Immune thrombocytopenia. Autoimmune thrombocytopenia, in the presence of major 
haemorrhage.
 Post-transfusion purpura, in the presence of major haemorrhage.
Neonatal alloimmune thrombocytopenia, to treat bleeding or as prophylaxis to maintain 
the platelet count >50 x 109 /l.
4°C ± 2°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
22°C ± 2°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
Fresh frozen 
< -30°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
< -30°C
Temperture recorder and alarm system 
when temperature is sub-optimal.
Table: Storage condition of blood components
Graft versus host disease is a serious and often fatal disease that 
occurs as a result of histocompatibility differences between donor and recipients. It often results 
from recipient receiving immunocompetent donors’ cells or marrow. It often occurs in immuno
compromised patients (congenital immunodeficiency, marrow transplant patient and patients 
on myeloablative therapy such as chemotherapy and radiotherapy) and seldom in immuno
competent subjects. The viable lymphocytes contained in the blood components can cause fatal 
GVHD in susceptible subjects. GVHD is thought to occur when the donor is HLA homozygous 
and haploidentical with the recipient. In such a situation, even though the patient is immuno
competent, it is unable to identify the donor’s cells as foreign thus allowing for its proliferation 
and eventual GVHD. To prevent transfusion-associated GVHD, blood components are sub
157Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
jected to radiation (gamma radiation or x-ray) which damages the DNA and interfere with the 
ability of the lymphocyte to proliferate by forming electrically charged particles or ions. Com-
monly used isotopes for irradiation is Cs or Co at a minimum dose of 3,000 rads. It is essential 
to put a quality control measure in place for blood irradiators to ensure that, irradiation was 
performed as intended and daily check to ensure that timer is working optimally and periodic 
surveys to prevent leakages of isotope.
Disease conditions When to prescribe/provide
Acute leukaemia in the absence of bone marrow 
transplantation
All HLA matched platelets and donations from 1st 
and 2nd degree relatives
Patients who has received autologous bone mar-
row and peripheral blood stem cell transplant
Irradiated product required from initiation of chemo-
therapy until 3-6 months post transplant. It may be 
safer to continue with lifelong irradiated products
Patients who have received allogeneic haemopoi-
etic cell transplant
From initiation of chemotherapy until 6 months 
post transplant and if patient continues to be on 
immunosuppressive drugs
Patients having allogeneic haemopoietic cell 
donation and peripheral stem cell donation for 
possible use in future autologous infusion
A week before, during and until harvest is com-
pleted.
Hodgkin’s disease, T cell Lymphoma & Indefinitely from time of diagnosis &
Aplastic Anaemia In transplant patients treated with (ATG)/Alemtuzamab. 
Transplant patients and patients with CLL and 
lymphoma on purine analogues (Fludarabine, 
Cladribine, Eshap and others) 
Irradiated products are indicated indefinitely from 
diagnosis/treatment
Patients with cellular immunodeficiency syn-
dromes (Di George syndrome, Wiskott –Aldrich 
syndrome and others. 
Irradiated products are indicated indefinitely from 
diagnosis.
Exchange and intrauterine (IUT) transfusion
Red cells and platelets must be irradiated for IUT 
and for exchange and top up transfusion provided 
delay of irradiation does not put patient at risk.
Granulocytes transfusions and transfusions from 
1st or 2nd degree relatives.
Red cells and platelets must be irradiated
Indication for Gamma/X-irradiated red cells and platelets
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Indications for CMV negative blood components. Cytomegalovirus (CMV) can be transmit-
ted by blood transfusion and sometimes be fatal. Although most previously infected CMV 
donors may no longer be infectious despite being CMV antibody positive, providing suscep-
tible CMV negative patient with CMV negative blood is a viable way to prevent transfusion-
transmitted CMV disease. Providing CMV negative blood products is sometimes difficult 
because a significant number of blood donors are CMV positive. Since leucocytes are reser-
voirs of CMV in asymptomatic blood donors, leucodepletion can potentially reduce the risk 
of transfusion-transmitted CMV infection 
Condition When to prescribe
Pregnancy
All components must be CMV negative prior to 
delivery.
Intrauterine transfusion All components transfused in utero 
Infants and neonates < 1 year 
All blood for IUT, exchange and top up red cell for 
neonatal use must be CMV negative.
Patients who have received bone marrow/periph-
eral blood progenitor cell transplants
Continue until CMV status of patient is known 
and indefinitely if patient is CMV negative.
Patients who has received allogeneic bone mar-
row/ peripheral blood stem cell transplant/kidney 
transplant
Continue until CMV status of patient is known 
and indefinitely if patient is CMV negative. 
HIV/AIDS infected and
Congenital immune deficient
Patients as well as patients receiving extensive 
chemotherapy
If patients are CMV negative, they should receive 
CMV negative blood products.
Table: Indication for CMV negative blood products
Condition When to prescribe
Emergency O Negative red cells
Select rr, Kell Negative, High titre Negative and 
CMV negative units for emergency use
Rhesus Negative women < 60 years old
Select Rh (D) Negative and Kell negative except in 
life threatening haemorrhage when Rh (D) Nega-
tive and Kell negative is unavailable.
Patients with clinically significant alloantibodies
Select red cells that are antigen negative for anti-
body patient has.
Autoimmune haemolytic anaemia
Check for presence of any alloantibodies and give 
units that are negative for antibody patient has as 
well as ABO and Rh (D) matched, Kell negative. 
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Sickle cell patients with alloantibodies
Select units that are rr, Hb S negative and 
negative for antigen to which patient antibody is 
specific. Sometimes it may be more effective to do 
an exchange transfusion to reduce the burden of 
haemoglobin S.
Transfusion –dependent patients Provide ABO, Rh (D) matched Kell negative unit.
Recipients of allogeneic haematopoietic stem 
In these patient, if there will be ABO mismatch, trans-
fuse patient with own ABO group until their ABO 
blood group antibody disappear and DAT is negative 
and donor group takes over. If minor ABO mismatch, 
transfuse donor ABO group that is plasma depleted 
until patient original group are no longer detected. 
For Rh positive patient that receives an Rh negative 
graft, transfuse them with Rh(D) red cells.
Summary of indications for antigen/phenotyped Red cells
Platelet refractoriness
Patients that show a poor increment in platelet 
count after 2 or more platelet transfusion should 
be tested for refractoriness. Patient may have an-
tibodies to HLA class A and B antigens and should 
receive HLA-matched platelets. If patient is nega-
tive for HLA antibodies then test patients for HPA 
antibody. If positive give HPA matched platelets
Neonates and neonatal alloimmune thrombocy-
Patients should receive ABO/Rh (D) matched 
HPA-1A-5b that is compatible with maternal 
IgA Deficient Blood products
When to prescribe
Patients with IgA deficiency or with anti-IgA Patients should receive IgA deficient units that is 
saline washed.
Table: Indications for HLA or HPA matched platelets and IgA deficient blood products 
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All blood for IUT, exchange and top up red cell for 
neonatal use must be CMV negative.
Patients who have received bone marrow/periph-
eral blood progenitor cell transplants
Continue until CMV status of patient is known 
and indefinitely if patient is CMV negative.
Patients who has received allogeneic bone mar-
row/ peripheral blood stem cell transplant/kidney 
Continue until CMV status of patient is known 
and indefinitely if patient is CMV negative. 
HIV/AIDS infected and
Congenital immune deficient
Patients as well as patients receiving extensive 
If patients are CMV negative, they should receive 
CMV negative blood products.
Table: Indication for CMV negative blood products
Emergency O Negative red cells
Select rr, Kell Negative, High titre Negative and 
CMV negative units for emergency use
Rhesus Negative women < 60 years old
Select Rh (D) Negative and Kell negative except in 
life threatening haemorrhage when Rh (D) Nega-
tive and Kell negative is unavailable.
Patients with clinically significant alloantibodies
Select red cells that are antigen negative for anti-
Autoimmune haemolytic anaemia
Check for presence of any alloantibodies and give 
units that are negative for antibody patient has as 
well as ABO and Rh (D) matched, Kell negative. 
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Sickle cell patients with alloantibodies
Select units that are rr, Hb S negative and 
negative for antigen to which patient antibody is 
specific. Sometimes it may be more effective to do 
an exchange transfusion to reduce the burden of 
haemoglobin S.
Transfusion –dependent patients Provide ABO, Rh (D) matched Kell negative unit.
Recipients of allogeneic haematopoietic stem 
cells transplant
In these patient, if there will be ABO mismatch, trans-
fuse patient with own ABO group until their ABO 
blood group antibody disappear and DAT is negative 
and donor group takes over. If minor ABO mismatch, 
transfuse donor ABO group that is plasma depleted 
until patient original group are no longer detected. 
For Rh positive patient that receives an Rh negative 
graft, transfuse them with Rh(D) red cells.
Summary of indications for antigen/phenotyped Red cells
Condition When to prescribe
HLA or HPA matched platelets
Platelet refractoriness
Patients that show a poor increment in platelet 
count after 2 or more platelet transfusion should 
be tested for refractoriness. Patient may have an-
tibodies to HLA class A and B antigens and should 
receive HLA-matched platelets. If patient is nega-
tive for HLA antibodies then test patients for HPA 
antibody. If positive give HPA matched platelets
Neonates and neonatal alloimmune thrombocy-
topenia
Patients should receive ABO/Rh (D) matched 
HPA-1A-5b that is compatible with maternal 
alloantibody.
IgA Deficient Blood products
Condition When to prescribe
Patients with IgA deficiency or with anti-IgA 
antibody
Patients should receive IgA deficient units that is 
saline washed.
Table: Indications for HLA or HPA matched platelets and IgA deficient blood products 
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Methelene Blue treated plasma products. Methelene blue is an important nuclear stain com-
monly used in cytology. It is useful in the inactivation of pathogens. Methyelene blue inactiva-
tion property is bourne of its ability to attach to the base pairs in the nucleic acid double helix. 
Exposure of methylene blue treated plasma products to light (yellow spectrum at wavelength 
of 590nm) activates the methylene blue with attendant destruction of the genetic material of 
the infective agent including vCJD and prevention of replicaion and infectivity. Methelene 
blue treatment must only be done after leucodepletion of the product. Methylene blue plasma 
products are indicated in neonate and children below 16 years on the day of transfusion. 
Method of red cell and platelet inactivation are being developed. Red cells photo- inactiva-
tion agent using psolalens (amotosalen) and platelet inactivation agent (riboflavin) are in the 
validation phases of possible use. 
Requirements for Intrauterine/exchange transfusion
Unit must be tested and found CMV negative
Must be prepared from a donor who is a regular donor
Units must be gamma irradiated
Blood for exchange should have a PCV of 0.50- 0.55 and < 5 days old & HbS
O product must be negative for high tite A and B haemolysins
Unit must be leucodepleted
Free from any clinically significant alloantibody
22. Fractionated plasma products 
Plasma fractionation involves the use of selective precipitation and extraction of plasma pro-
teins using cold alcohol. A large volume of pooled and microbiologically tested plasma is 
often used. Use of different alcohol concentration, PH and temperature precipitates different 
plasma proteins. Fractionated products includes; albumin, immunoglobulins and coagula-
tions products. The fractionation process involves thawing the frozen plasma first to produce 
cryoprecipitate which is a raw material for production of coagulation factors. Secondly the 
reminant crosupernatant is treated at cold temperature with various concentration of ethanol 
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and buffers to precipitate fractions containing different plasma proteinsThe purified fractions 
are then either freeze dried or in stabilized ready to use solutions.
Human albumin solution (HAS) is prepared as 5% (50g/l) or 20% (200g/l) solu
tion. The final product is sterilized by filtration and heat treatment (60°C) for ten hours. The 
shelf life and optimum storage temperature are 3 years and 20°C respectively. Albumin is 
commonly used to restore plasma volume and plasma colloid osmotic pressure after trauma, 
surgery and shock. Albumin  be used as a supplemental source of protein calories in 
patients requiring nutritional intervention. Indications for albumin includes;
1. Albumin is quiet useful for the management of extensive burns. Large 
volumes of crystalloids can be infused following extensive burns within 
the first 24 hours to restore depleted extracellular fluid. However post 24 
hours albumin must be used to maintain plasma colloid osmotic pressure.
2. Albumin should not be administered in conjunction with phototherapy 
in exchange blood transfusion. 
3. Albumin may be a useful adjuvant to exchange transfusions when ad
ministered concurrently with blood transfusion but it should not be used 
before transfusion.
4. Using albumin alone to treat ascites without large-volume paracentesis 
or to treat patients with noncirrhotic postsinusoidal portal hypertension 
should be avoided. Albumin and nonprotein colloids may be useful for 
postoperative liver transplant patients to control ascites and severe pul
monary and peripheral edema. Albumin may be used if the following 
conditions are met; serum albumin less than 2.5 g/dL, pulmonary capil
lary wedge pressure less than 12 mm Hg and haematocrit greater than 
30 percent. 
5. The use of albumin in conjunction with large volume plasma exchange 
(greater than 20 mL/kg in one session, or greater than 20 mL/kg/week in 
repeated sessions) is appropriate.
6. If cerebral edema is a concern, albumin should be used in concentrated 
form (25 percent) as a colloid to maintain Cerebral Perfusion Pressure.
7. Using albumin to maintain effective circulation volume following major 
hepatic resection (greater than 40 percent) is appropriate. 
8. Albumin is indicated when clinically important edema develops second
ary to crystalloid administration.
Human immunoglobulin is derived from fractionation of pooled 
normal plasma. The immunoglobulin content of product is a reflection of the immune status 
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 Methelene blue is an important nuclear stain com
monly used in cytology. It is useful in the inactivation of pathogens. Methyelene blue inactiva
tion property is bourne of its ability to attach to the base pairs in the nucleic acid double helix. 
Exposure of methylene blue treated plasma products to light (yellow spectrum at wavelength 
of 590nm) activates the methylene blue with attendant destruction of the genetic material of 
the infective agent including vCJD and prevention of replicaion and infectivity. Methelene 
blue treatment must only be done after leucodepletion of the product. Methylene blue plasma 
products are 
Method of red cell and platelet inactivation are being developed. Red cells photo- inactiva
tion agent using psolalens (amotosalen) and platelet inactivation agent (riboflavin) are in the 
validation phases of possible use. 
Free from any clinically significant alloantibody
Plasma fractionation involves the use of selective precipitation and extraction of plasma pro
teins using cold alcohol. A large volume of pooled and microbiologically tested plasma is 
often used. Use of different alcohol concentration, PH and temperature precipitates different 
plasma proteins. Fractionated products includes; albumin, immunoglobulins and coagula
tions products. The fractionation process involves thawing the frozen plasma first to produce 
cryoprecipitate which is a raw material for production of coagulation factors. Secondly the 
reminant crosupernatant is treated at cold temperature with various concentration of ethanol 
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and buffers to precipitate fractions containing different plasma proteinsThe purified fractions 
are then either freeze dried or in stabilized ready to use solutions.
Examples of fractionated plasma products
Albumin. Human albumin solution (HAS) is prepared as 5% (50g/l) or 20% (200g/l) solu-
tion. The final product is sterilized by filtration and heat treatment (60°C) for ten hours. The 
shelf life and optimum storage temperature are 3 years and 20°C respectively. Albumin is 
commonly used to restore plasma volume and plasma colloid osmotic pressure after trauma, 
surgery and shock. Albumin must not be used as a supplemental source of protein calories in 
patients requiring nutritional intervention. Indications for albumin includes;
1. Albumin is quiet useful for the management of extensive burns. Large 
volumes of crystalloids can be infused following extensive burns within 
the first 24 hours to restore depleted extracellular fluid. However post 24 
hours albumin must be used to maintain plasma colloid osmotic pressure.
2. Albumin should not be administered in conjunction with phototherapy 
in exchange blood transfusion. 
3. Albumin may be a useful adjuvant to exchange transfusions when ad-
ministered concurrently with blood transfusion but it should not be used 
before transfusion.
4. Using albumin alone to treat ascites without large-volume paracentesis 
or to treat patients with noncirrhotic postsinusoidal portal hypertension 
should be avoided. Albumin and nonprotein colloids may be useful for 
postoperative liver transplant patients to control ascites and severe pul-
monary and peripheral edema. Albumin may be used if the following 
conditions are met; serum albumin less than 2.5 g/dL, pulmonary capil-
lary wedge pressure less than 12 mm Hg and haematocrit greater than 
30 percent. 
5. The use of albumin in conjunction with large volume plasma exchange 
(greater than 20 mL/kg in one session, or greater than 20 mL/kg/week in 
repeated sessions) is appropriate.
6. If cerebral edema is a concern, albumin should be used in concentrated 
form (25 percent) as a colloid to maintain Cerebral Perfusion Pressure.
7. Using albumin to maintain effective circulation volume following major 
hepatic resection (greater than 40 percent) is appropriate. 
8. Albumin is indicated when clinically important edema develops second-
ary to crystalloid administration.
Immunoglobulin products. Human immunoglobulin is derived from fractionation of pooled 
normal plasma. The immunoglobulin content of product is a reflection of the immune status 
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of the donor population. Human immunoglobulin are used in the treatment of several disor-
ders as well as usage prophylactically to prevent several diseases. It can also be used to treat a 
variety of autoimmune disorders and patient with immunodeficiency. Immunoglobulins can 
also be used to provide passive immunization against a number of infections such as rabies. Im-
munoglobulin D is prepared from pooled plasma donation that contains a high titre anti-D and 
is used to prevent haemolytic disease of the foetus and newborn. Nearly 70 percent of primary 
immune deficient patients use intravenous immune globulin (IVIG) to maintain their health. 
IVIG is a pooled plasma derivative administered intravenously every three or four weeks that 
replaces antibodies in patients who are unable to adequately produce these protective proteins 
themselves. Examples of immunoglobulin products includes; Anti-D immunoglobulin (250 
IU, 500 IU, 1500 IU and 2500 IU), anti-Tetanus (250 IU), Anti-Hepatitis B (200IU and 500IU), 
Anti-Varicella Zoster (250mg), Anti –Rabies (250IU) and Anti-Hepatitis A. These products are 
typically given as an intramuscular injection. Antibody replacement therapy, the use of IgG 
concentrates administered intravenously, is an important therapeutic option for patients who 
are unable to produce adequate amounts of antibodies. The IgG product, prepared from large 
pools of human plasma to assure a broad spectrum of antibodies, is known as immunoglobulin, 
gammaglobulin, or immune serum globulin. The intravenous preparations are known as IVIG 
(intravenous immunoglobulin) or immunoglobulin intravenous (IGIV).
Coagulation factors. Coagulation products (freeze dried concentrate) powders of known po-
tency and purity can be produced by fractionating pooled plasma. Typical products includes;
Factor V111. Factor VIII (FVIII) is an essential blood clotting factor also known as anti-hemo-
philic factor (AHF). Antibody formation to Factor VIII can also be a major concern for patients 
receiving therapy against bleeding; the incidence of these inhibitors is dependent of various 
factors, including the Factor VIII product itself Factor VIII participates in blood coagulation; 
it is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids forms a com-
plex that converts factor X to the activated form Xa. FVIII concentrated from donated blood 
plasma or alternatively recombinant FVIII can be given to hemophiliacs to restore hemostasis.
High purity factor V111. Commercial virus-inactivated high-purity factor VIII concentrate 
contains native von Willebrand factor. High-purity factor VIII concentrate is efficacious and 
safe product for use in cases of von Willebrand’s disease when pharmacological correction of 
the hemostatic defect is not possible. In the surgical patients, the bleeding time can be cor-
rected and clinical hemostasis can be achieved with use of high-purity factor VIII concentrate 
in patients in whom they are indicated.
High purity factor 1X. Patients with factor IX deficiency may be treated with a factor IX com-
plex to manage an acute hemorrhage. Factor IX high purity (Factor 9 high purity) is a fraction-
ated plasma product which is used in a number of thromboembolic diseases. Factor IX high 
purity (Factor 9 high purity) is used in haemophilia B and people who need additional factor 
IX for proper blood clotting. Factor IX high purity (Factor 9 high purity) is a medicine which is 
used in haemophilia, haemophilia B, haemophilia A, acquired haemophilia and haemophilia 
with inhibitors.
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Antithrombin III (ATIII) is a potent inhibitor of the coagulation cascade. 
It is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and 
factor Xa. Antithrombin III activity is markedly potentiated by heparin; potentiation of its 
activity is the principle mechanism by which both heparin and low molecular weight heparin 
result in anticoagulation. Congenital antithrombin III deficiency is an autosomal dominant 
disorder in which can individual inherits one copy of a defective gene. This condition leads 
to increased risk of venous and arterial thrombosis, with an onset of clinical manifestations 
typically appearing in young adulthood. Acquired antithrombin III deficiency is a deficiency 
of antithrombin primarily due to consumption. It is observed in situations in which activation 
of the coagulation system is inappropriate. Antithrombin (AT) concentrates can be therapeuti
cally useful in cases of primary and acquired AT deficiency. Common conditions that result 
in acquired antithrombin III deficiency include;reduced production, acute and chronic liver 
disorders, premature neonates, treatment with L-asparaginase, increased excretion/loss, pro
tein-losing enteropathy, nephrotic syndrome, burns, dilutional coagulopathy associated with; 
massive transfusion, plasma exchange, extracorporeal circulation, increased consumption as
sociated with disseminated intravascular coagulation (DIC), major surgery, heparin infusion, 
multiple trauma, severe sepsis/septic shock, severe thromboembolism, haemolytic-uraemic 
syndrome and pre-eclampsia.
Factor-VII-rich concentrate may be the treatment of choice in patients 
with liver disease who require temporary correction of their coagulation defect. Use of the 
concentrate was associated with uncomplicated delivery and minimal postpartum bleeding 
in pregnant patient with hereditary factor V11 deficiency. The aim of prophylactic administra
tion of factor VIII to patients with haemophilia A is to reduce their number of bleeds. Factor 
VIII concentrate can be used in children and adults with severe haemophilia A. Factor VII con
centrate appears to be effective in patients with refractory coagulopathy undergoing high-risk 
cardiovascular surgery. Prophylaxis results in a reduction in the frequency of haemarthroses 
which has been demonstrated to protect joints from the development and progression of ar
thropathy.
 Factor XI or plasma thromboplastin antecedent is the zymogen form of factor XIa, 
one of the enzymes of the coagulation cascade. Deficiency of factor XI causes the rare Hae
mophilia C; this mainly occurs in Ashkenazi Jews and is believed to affect approximately 8% 
of that population, of both sexes. Individuals with factor X1 deficiency are not likely to bleed 
spontaneously, and hemorrhage normally occurs after trauma or surgery. Certain procedures 
carry an increased risk of bleeding such as, dental extractions, tonsillectomies, surgery in the 
urinary and genital tracts and nasal surgery. Joint bleeds are uncommon. Patients are more 
prone to bruising, nosebleeds, or blood in the urine. Woman may experience menorrhagia 
and prolonged bleeding after childbirth. Factor XI (FXI) deficiency is an autosomal disorder 
that may be associated with bleeding. Currently there are two factor XI concentrates pro
duced in Europe for use in patient with factor X1 defieicency.
Octaplex is presented as a powder and solvent for solution for injection contain
ing human prothrombin complex. It nominally contains; human factor 11, V11, IX X, Protein S 
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of the donor population. Human immunoglobulin are used in the treatment of several disor
ders as well as usage prophylactically to prevent several diseases. It can also be used to treat a 
variety of autoimmune disorders and patient with immunodeficiency. Immunoglobulins can 
also be used to provide passive immunization against a number of infections such as rabies. Im
munoglobulin D is prepared from pooled plasma donation that contains a high titre anti-D and 
is used to prevent haemolytic disease of the foetus and newborn. Nearly 70 percent of primary 
immune deficient patients use intravenous immune globulin (IVIG) to maintain their health. 
IVIG is a pooled plasma derivative administered intravenously every three or four weeks that 
replaces antibodies in patients who are unable to adequately produce these protective proteins 
themselves. Examples of immunoglobulin products includes; Anti-D immunoglobulin (250 
IU, 500 IU, 1500 IU and 2500 IU), anti-Tetanus (250 IU), Anti-Hepatitis B (200IU and 500IU), 
Anti-Varicella Zoster (250mg), Anti –Rabies (250IU) and Anti-Hepatitis A. These products are 
typically given as an intramuscular injection. Antibody replacement therapy, the use of IgG 
concentrates administered intravenously, is an important therapeutic option for patients who 
are unable to produce adequate amounts of antibodies. The IgG product, prepared from large 
pools of human plasma to assure a broad spectrum of antibodies, is known as immunoglobulin, 
gammaglobulin, or immune serum globulin. The intravenous preparations are known as IVIG 
(intravenous immunoglobulin) or immunoglobulin intravenous (IGIV).
Coagulation products (freeze dried concentrate) powders of known po
tency and purity can be produced by fractionating pooled plasma. Typical products includes;
 Factor VIII (FVIII) is an essential blood clotting factor also known as anti-hemo
philic factor (AHF). Antibody formation to Factor VIII can also be a major concern for patients 
receiving therapy against bleeding; the incidence of these inhibitors is dependent of various 
factors, including the Factor VIII product itself Factor VIII participates in blood coagulation; 
it is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids forms a com
plex that converts factor X to the activated form Xa. FVIII concentrated from donated blood 
plasma or alternatively recombinant FVIII can be given to hemophiliacs to restore hemostasis.
Commercial virus-inactivated high-purity factor VIII concentrate 
contains native von Willebrand factor. High-purity factor VIII concentrate is efficacious and 
safe product for use in cases of von Willebrand’s disease when pharmacological correction of 
the hemostatic defect is not possible. In the surgical patients, the bleeding time can be cor
rected and clinical hemostasis can be achieved with use of high-purity factor VIII concentrate 
in patients in whom they are indicated.
Patients with factor IX deficiency may be treated with a factor IX com
plex to manage an acute hemorrhage. Factor IX high purity (Factor 9 high purity) is a fraction
ated plasma product which is used in a number of thromboembolic diseases. Factor IX high 
purity (Factor 9 high purity) is used in haemophilia B and people who need additional factor 
IX for proper blood clotting. Factor IX high purity (Factor 9 high purity) is a medicine which is 
used in haemophilia, haemophilia B, haemophilia A, acquired haemophilia and haemophilia 
with inhibitors.
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Anti-thrombin 111. Antithrombin III (ATIII) is a potent inhibitor of the coagulation cascade. 
It is a nonvitamin K-dependent protease that inhibits coagulation by lysing thrombin and 
factor Xa. Antithrombin III activity is markedly potentiated by heparin; potentiation of its 
activity is the principle mechanism by which both heparin and low molecular weight heparin 
result in anticoagulation. Congenital antithrombin III deficiency is an autosomal dominant 
disorder in which can individual inherits one copy of a defective gene. This condition leads 
to increased risk of venous and arterial thrombosis, with an onset of clinical manifestations 
typically appearing in young adulthood. Acquired antithrombin III deficiency is a deficiency 
of antithrombin primarily due to consumption. It is observed in situations in which activation 
of the coagulation system is inappropriate. Antithrombin (AT) concentrates can be therapeuti-
cally useful in cases of primary and acquired AT deficiency. Common conditions that result 
in acquired antithrombin III deficiency include;reduced production, acute and chronic liver 
disorders, premature neonates, treatment with L-asparaginase, increased excretion/loss, pro-
tein-losing enteropathy, nephrotic syndrome, burns, dilutional coagulopathy associated with; 
massive transfusion, plasma exchange, extracorporeal circulation, increased consumption as-
sociated with disseminated intravascular coagulation (DIC), major surgery, heparin infusion, 
multiple trauma, severe sepsis/septic shock, severe thromboembolism, haemolytic-uraemic 
syndrome and pre-eclampsia.
Factor V11 concentrate. Factor-VII-rich concentrate may be the treatment of choice in patients 
with liver disease who require temporary correction of their coagulation defect. Use of the 
concentrate was associated with uncomplicated delivery and minimal postpartum bleeding 
in pregnant patient with hereditary factor V11 deficiency. The aim of prophylactic administra-
tion of factor VIII to patients with haemophilia A is to reduce their number of bleeds. Factor 
VIII concentrate can be used in children and adults with severe haemophilia A. Factor VII con-
centrate appears to be effective in patients with refractory coagulopathy undergoing high-risk 
cardiovascular surgery. Prophylaxis results in a reduction in the frequency of haemarthroses 
which has been demonstrated to protect joints from the development and progression of ar-
thropathy.
Factor X1. Factor XI or plasma thromboplastin antecedent is the zymogen form of factor XIa, 
one of the enzymes of the coagulation cascade. Deficiency of factor XI causes the rare Hae-
mophilia C; this mainly occurs in Ashkenazi Jews and is believed to affect approximately 8% 
of that population, of both sexes. Individuals with factor X1 deficiency are not likely to bleed 
spontaneously, and hemorrhage normally occurs after trauma or surgery. Certain procedures 
carry an increased risk of bleeding such as, dental extractions, tonsillectomies, surgery in the 
urinary and genital tracts and nasal surgery. Joint bleeds are uncommon. Patients are more 
prone to bruising, nosebleeds, or blood in the urine. Woman may experience menorrhagia 
and prolonged bleeding after childbirth. Factor XI (FXI) deficiency is an autosomal disorder 
that may be associated with bleeding. Currently there are two factor XI concentrates pro-
duced in Europe for use in patient with factor X1 defieicency.
Factor V11a. Octaplex is presented as a powder and solvent for solution for injection contain-
ing human prothrombin complex. It nominally contains; human factor 11, V11, IX X, Protein S 
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and C. It is indicated for the treatment of bleeding and perioperative prophylaxis of bleeding in 
acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused 
by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when 
rapid correction of the deficiency is required. There are an increasing number of anecdotal re-
ports and trials of recombinant activated factor VII (rFVIIa) for bleeding during surgery. Major 
blood loss can often be life-threatening and is most commonly encountered in the settings of 
surgery and trauma. Patients receiving anticoagulant therapy are also at increased risk of bleed-
ing. PCC can potentially play a role in controlling bleeding in patients undergoing cardiac sur-
gery and other surgical procedures and reduce, and sometimes abolish, the need for allogenic 
blood in surgical and non surgical patients. Although some of these may remain unavailable 
to patients particularly in sub Saharan Africa because of financial constraints on the health care 
system. Nonetheless, physicians in sub Saharan Africa must always keep in mind that the first 
and foremost strategy to avoid transfusion of allogenic blood is:
1. Their thorough understanding of the pathophysiologic mechanisms in-
volved in anaemia and coagulopathy
2. Their thoughtful adherence to evidence based good practices in the de-
veloped world may potentially reduce the likelihood of allogenic blood 
transfusion in many patients groups.
23. Rhesus Blood Group System
The Rhesus (Rh) blood group system is one of the most clinically significant blood group systems 
after the ABO blood group system. The Rh blood group system currently consists of about 50 de-
fined blood-group antigens. The five most significant antigens includes; D, C, c, E, and e. Of these, 
the D antigen is very important in transfusion and is a most common cause of the hemolytic disease 
of the foetus and newborn (HDFN) or erythroblastosis fetalis. Based on the presence or absence of 
D antigen on the surface of an individual’s red cells, they are classed as Rh positive and Rh nega-
tive respectively. However other antigens of this Rh blood group system are also clinically relevant. 
In contrast to the ABO blood group, immunization against Rh can generally only occur through 
blood transfusion or placental exposure during pregnancy. The Rh blood group system was first 
described in 1939 by Dr Philip Levine and Dr Rufus Stetson when they observed that the serum of 
a woman who had had a still birth caused a severe haemolytic transfusion reaction to red cells of 
the same ABO blood group donated by her husband. This serum was also observed to agglutinate 
the red blood cells of about 80% of the general population despite being of the same ABO blood 
group. This antibody was faound to have been produced in response to the stimulus of an antigen 
on the surface of the foetus red cell which he inherited from the father and which the mother lacked. 
A year later in 1940, Dr Karl Landsteiner and Dr Alexander S. Wiener reported a serum sample 
obtained by immunizing rabbits with red blood cells from Rhesus macaque which reacted with 
about 85% of human red blood cells. The antigen responsible for this immunization was termed Rh 
factor. Based on the serologic similarities between the anibody described by Levine and colleages 
and those described Landsteiner and Wiener the Rh factor was maintained for antigens, and anti-Rh 
165Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
for antibodies, found in humans. However it was shown in 1942 and clearly demonstrated in 1963 
that the clinically described human antibodies were different from the ones related to the Rhesus 
monkey. This real factor found in Rhesus Macaque was named as Landsteiner-Wiener antigen sys
tem. Between 1943-45 the other common antigens of the Rh system were identified. For many years 
the exact inheritance pattern of the Rh factors were debated. While Weiner promoted the Rh and 
hr terminology, Fisher-Race utilizing DCcEe for the various Rh antigens. However in 1993 Tippett 
discovered true mode of Rh inheritance using molecular diagnostics. Although the exact role of the 
Rh polypeptides are unknown, they are are thought to play a role in cation transport across the red 
cell membrane. Absence of red cells antigens on the red cell membrane has been associated with sto
matocytes (red cells that have a characteristic slit or mouth shaped pallor rather than a central pallor) 
which have been associated with a mild type haemolytic anaemia. There is a considerable variation 
in the distribution of Rh (D) antigen in various population groups.





Distribution of the Dantigen in various population groups
Rh Genes and Antigens The Rh gene is located on chromosome 1. There are 2 Rh gene on the 
locus of chromosome 1 (D and CE). While the D gene control the production of the protein mol
ecule that carry the D antigen, the CE gene control the molecule that carry the other Rh antigen 
combinations (ce, Ce, cE, and CE). Individuals who are Rh (D) negative lack the D protein are are 
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and C. It is indicated for the treatment of bleeding and perioperative prophylaxis of bleeding in 
acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused 
by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when 
rapid correction of the deficiency is required. There are an increasing number of anecdotal re
ports and trials of recombinant activated factor VII (rFVIIa) for bleeding during surgery. Major 
blood loss can often be life-threatening and is most commonly encountered in the settings of 
surgery and trauma. Patients receiving anticoagulant therapy are also at increased risk of bleed
ing. PCC can potentially play a role in controlling bleeding in patients undergoing cardiac sur
gery and other surgical procedures and reduce, and sometimes abolish, the need for allogenic 
blood in surgical and non surgical patients. Although some of these may remain unavailable 
to patients particularly in sub Saharan Africa because of financial constraints on the health care 
system. Nonetheless, physicians in sub Saharan Africa must always keep in mind that the first 
and foremost strategy to avoid transfusion of allogenic blood is:
1. Their thorough understanding of the pathophysiologic mechanisms in
volved in anaemia and coagulopathy
2. Their thoughtful adherence to evidence based good practices in the de
veloped world may potentially reduce the likelihood of allogenic blood 
transfusion in many patients groups.
The Rhesus (Rh) blood group system is one of the most clinically significant blood group systems 
after the ABO blood group system. The Rh blood group system currently consists of about 50 de
fined blood-group antigens. The five most significant antigens includes; D, C, c, E, and e. Of these, 
the D antigen is very important in transfusion and is a most common cause of the hemolytic disease 
of the foetus and newborn (HDFN) or erythroblastosis fetalis. Based on the presence or absence of 
D antigen on the surface of an individual’s red cells, they are classed as Rh positive and Rh nega
tive respectively. However other antigens of this Rh blood group system are also clinically relevant. 
In contrast to the ABO blood group, immunization against Rh can generally only occur through 
blood transfusion or placental exposure during pregnancy. The Rh blood group system was first 
described in 1939 by Dr Philip Levine and Dr Rufus Stetson when they observed that the serum of 
a woman who had had a still birth caused a severe haemolytic transfusion reaction to red cells of 
the same ABO blood group donated by her husband. This serum was also observed to agglutinate 
the red blood cells of about 80% of the general population despite being of the same ABO blood 
group. This antibody was faound to have been produced in response to the stimulus of an antigen 
on the surface of the foetus red cell which he inherited from the father and which the mother lacked. 
A year later in 1940, Dr Karl Landsteiner and Dr Alexander S. Wiener reported a serum sample 
obtained by immunizing rabbits with red blood cells from Rhesus macaque which reacted with 
about 85% of human red blood cells. The antigen responsible for this immunization was termed Rh 
factor. Based on the serologic similarities between the anibody described by Levine and colleages 
and those described Landsteiner and Wiener the Rh factor was maintained for antigens, and anti-Rh 
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for antibodies, found in humans. However it was shown in 1942 and clearly demonstrated in 1963 
that the clinically described human antibodies were different from the ones related to the Rhesus 
monkey. This real factor found in Rhesus Macaque was named as Landsteiner-Wiener antigen sys-
tem. Between 1943-45 the other common antigens of the Rh system were identified. For many years 
the exact inheritance pattern of the Rh factors were debated. While Weiner promoted the Rh and 
hr terminology, Fisher-Race utilizing DCcEe for the various Rh antigens. However in 1993 Tippett 
discovered true mode of Rh inheritance using molecular diagnostics. Although the exact role of the 
Rh polypeptides are unknown, they are are thought to play a role in cation transport across the red 
cell membrane. Absence of red cells antigens on the red cell membrane has been associated with sto-
matocytes (red cells that have a characteristic slit or mouth shaped pallor rather than a central pallor) 
which have been associated with a mild type haemolytic anaemia. There is a considerable variation 
in the distribution of Rh (D) antigen in various population groups.
Figure: Stomatocytes in Peripheral blood
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Rhesus (D) Antigen
Rh (D) Positive (%) Rh (D) Negative (%)





Distribution of the Dantigen in various population groups
Rh Genes and Antigens The Rh gene is located on chromosome 1. There are 2 Rh gene on the 
locus of chromosome 1 (D and CE). While the D gene control the production of the protein mol-
ecule that carry the D antigen, the CE gene control the molecule that carry the other Rh antigen 
combinations (ce, Ce, cE, and CE). Individuals who are Rh (D) negative lack the D protein are are 
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susceptible to anti-D antibody when exposed to red cells containing the D protein. Although both 
the D and CE locus produces different protins, they are closely linked on the red cell membrane 
as a complex of antigens. The combination of the presence or absence of the D protein along with 
the 4 possible combination of the CE gene products produces 8 gene halotypes. Each of these 8 
halotypes have their own shorthand notations. An individual will produce various combinations 
of these antigens depending upon which halotype is inherited from both parents. The absence 
of the D antigen is often conventionally expressed as d even though it is not a gene product. The 
presence of the D antigen is identified with the shorthand nomenclature R while the absence of D 
is identified with r.
D Gene CE Gene
Halotype Gene Product
(Fisher and Race Nomenclature)
Shorthand nomenclature (Wie-
ner notation)
D Ce CDe R1
D cE cDE R
2
D Ce cDe R0
D CE DCE R
Z
D Ce Cde r’
D Ce cdE r”
D Ce Cde R
D CE CdE ry







Phenptype reaction with anti-sera
Rhesus
Group
Anti-D Anti –C Anti-c Anti-E Anti-e
CDe/CDe R1R1 4 4 0 0 4 RhD+
cDE/cDE R2R2 4 0 4 4 0 RhD+
CDe/cDE R1R2 4 4 4 4 4 RhD+
CDE/cde RZr 4 4 4 4 4 RhD+
CDe/cde R1r 4 4 4 0 4 RhD+ 
cDE/cde R2r 4 0 4 4 4 RhD+
cDe/cDe R0 4 0 4 0 4 RhD+
Dce/dCE R0rY 4 4 4 4 4 RhD+
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Dce/DCE R0RZ
cde/cde 0 0 0 RhD-
Cde/cde 0 0 RhD-
cdE/cde 0 0 RhD-
Cde/Cde 0 0 0 RhD-
cdE/cdE 0 0 0 RhD-
CdE/cde 0 RhD-
The Rh genotype of an individual is made up of a composition of two of the 8 halotypes 
inherited from both parents. The genotype of an individual can be expressed as either the ha
lotype combinations (cde/cde), (CDe/cde) and (cDE/cdE) or in shorthand notation (rr), (R1r) 
and (R2rʹʹ). There are at over 50 Rh antigens that have been identified including those that are 
either combinations of these antigens or weak expressions of the above antigens, but most 
transfusion and HDFN Rh-related problems are caused by; D, C, E, c or e antigens. There are 
5 principle antigens that may be found in most individuals. They are: 
1. D found in 85% of the population 
2. C found in 70% of the population 
3. E found in 30% of the population 
4. c found in 80% of the population 
5. e found in 98% of the population 
6. (d) which has never been identified but refers to the 15% of the popula
tion who lack the D antigen 
1. C and c are alleles with Cw occasionally seen as a weaker expression of C. 
2. E and e are alleles although E is seen only a third as often as e. The e 
antigen is referred to as a high incidence antigen since it is found in 98% 
of the population. 
3. D and the lack of D (or d) are alleles. 
 The Rh antigens are made up of a total of 417 amino acids. These 
proteins cross the red cell membrane 12 times. The Rh antigens are not as available to react with their 
specific antibodies and there are fewer antigen determinants than ABO. Unlike the ABO system the 
Rh antigens are not soluble and are not expressed on the tissues. They are well developed at birth 
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susceptible to anti-D antibody when exposed to red cells containing the D protein. Although both 
the D and CE locus produces different protins, they are closely linked on the red cell membrane 
as a complex of antigens. The combination of the presence or absence of the D protein along with 
the 4 possible combination of the CE gene products produces 8 gene halotypes. Each of these 8 
halotypes have their own shorthand notations. An individual will produce various combinations 
of these antigens depending upon which halotype is inherited from both parents. The absence 
of the D antigen is often conventionally expressed as d even though it is not a gene product. The 
presence of the D antigen is identified with the shorthand nomenclature R while the absence of D 
is identified with r.
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0
Fisher and Weiner model of the Rh gene halotypes






cDe/cDe R0 0 0
Dce/dCE R0rY
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Dce/DCE R0RZ 4 4 4 4 4 RhD+
cde/cde Rr 0 0 4 0 4 RhD-
Cde/cde r’r 0 4 4 0 4 RhD-
cdE/cde r’’r 0 0 4 4 4 RhD-
Cde/Cde r’r’ 0 4 0 0 4 RhD-
cdE/cdE r’’r’’ 0 0 4 4 0 RhD-
CdE/cde ryr 0 4 4 4 4 RhD-
Phenotype reaction with Rhesus anti-sera
The Rh genotype of an individual is made up of a composition of two of the 8 halotypes 
inherited from both parents. The genotype of an individual can be expressed as either the ha-
lotype combinations (cde/cde), (CDe/cde) and (cDE/cdE) or in shorthand notation (rr), (R1r) 
and (R2rʹʹ). There are at over 50 Rh antigens that have been identified including those that are 
either combinations of these antigens or weak expressions of the above antigens, but most 
transfusion and HDFN Rh-related problems are caused by; D, C, E, c or e antigens. There are 
5 principle antigens that may be found in most individuals. They are: 
1. D found in 85% of the population 
2. C found in 70% of the population 
3. E found in 30% of the population 
4. c found in 80% of the population 
5. e found in 98% of the population 
6. (d) which has never been identified but refers to the 15% of the popula-
tion who lack the D antigen 
The common alleles are Rh blood group system:
1. C and c are alleles with Cw occasionally seen as a weaker expression of C. 
2. E and e are alleles although E is seen only a third as often as e. The e 
antigen is referred to as a high incidence antigen since it is found in 98% 
of the population. 
3. D and the lack of D (or d) are alleles. 
Characteristics of Rh antigens. The Rh antigens are made up of a total of 417 amino acids. These 
proteins cross the red cell membrane 12 times. The Rh antigens are not as available to react with their 
specific antibodies and there are fewer antigen determinants than ABO. Unlike the ABO system the 
Rh antigens are not soluble and are not expressed on the tissues. They are well developed at birth 
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and have been identified in early foetal life (as early as 38 days) as well as immunogenic (ability to 
stimulate antibody production) and therefore can easily cause hemolytic disease of the foetus and 
newborn if the baby has a Rh antigen that the mother lacks. Molecular genetic foetal D genotyping 
can detect small quantity of D genomic DNA and thus allow for the D antigen status of the foetus 
from small quantity of foetal cells obtaind from a chorionic villus or amniocentesis sample. This is 
very vital particularly in Rh negative mother with high titre of anti-D (>15 iu) and whose partner is 
D positive (Dd). The test help to determine the D genotype of the foetus and its predisposition to 
HDFN. Approximately 60% of Rh negative transfused with Rh positive red cells will produce im-
mune anti-D. After the D antigen, Kell antigen is next most immunogenic. Approximately 10% of 
kell negative persons develop anti-K when transfused with Kell positice red cells. One third of non-
anti-D are anti-K. Unlike the ABO antibodies that are mainly IgM, the Rh antibodies are commonly 
IgG and formed by immune stimulus due to transfusions or baby’s red blood cells entering maternal 
circulation during pregnancy. Since Rh antibodies are IgG they react optimally at 37oC and their 
reactions will be observed with the indirect antiglobulin technique. Agglutination reactions are en-
hanced by high protein (albumin), low-ionic strength saline (LISS), proteolytic enzymes (ficin) and 
polytheylene glycol (PEG). Rh antibodies exhibit dosage effect and will always react more strongly 
with homozygous cells than with heterozygous cells. For example, an anti-E will react with strongly 
with E+E+ cells and more weakly with E+e+ cells. The number of D antigenic determinant on the red 
cell membrane varies depending of the Rh phenotype/genotype of the individual. These number of 
antigen sites can be determined by radio-labelled anti-D. T he strongest D reacting red cell an high-
est antigen sites are the –D-/-D- (CE deletion) followed by R2R2 (cDE /cDE).
Rh Genotype Shorthand notation Number of D antigenic sites
CDe/cde R1r 10,000- 15,000






-D-/-D- CE deletion 111,000 – 202,000
Table: Variation of number of D antigen sites on different Rh genotypes
Both Hemolytic Disease of the Foetus and Newborn and Hemolytic Transfusion Reactions 
can occur due the various Rh antibodies. To prevent sensitization of a patient the following 
step must be taken; transfuse Rh-negative individuals Rh-negative red blood cells and plate-
lets and administer prophylactic immunoglobulin –D to all Rh-negative mothers following 
any potentially sensitizing events during pregnancy to prevent them from producing im-
mune anti-D. The incidence of Rh antibodies
1. Anti-D most common antibody seen in Rh(D) negative people 
2. Anti-E most common antibody seen in Rh pos people since only 30% of 
the population have the antigen 
3. Anti-C or Anti-c less common - most people have the antigen 
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4. Anti-e often seen as autoantibody and will make it difficult to find com
patible blood since 98% of the population have the e antigen 
5. Anti-C, e or Anti-c, E often seen in combination. If a patient lacks both a 
C and e and has made an anti-C, then enhancement techniques should be 
done to make sure that an anti-e is not also present. 
From the 1940’s to the 1990’s the mechanism for inheritance of the Rh 
Blood Group System was in question. The terminology that is part of the Fisher-Race Theory 
is most commonly used even today.
The Fisher-Race theory involved the presence of 3 pairs of closely linked 
genes D, C, and E and their alleles c and e and the absence of D since an anti-d has never been 
found. These three genes are closely linked on the same chromosome and are inherited as a 
group of 3. The most common group of 3 genes inherited is CDe and ce (D negative) is the 
second most common.
 Weiner believed there was one gene complex with a number of alleles resulting in 
the presence of various Rh antigens. According to Weiner there were 8 alleles; R , R1, R2, Rz, r, r’, r”, 
y, which ended up with different antigens on the red cells that he called Rh , rh’, rh”, hr’, hr”. Weiner 
terminology is not use as often today, but you will often see Rh  (D) when a person considered to 
be Rh-positive. At times the gene terms are easier to use than Fisher-Race. If a person has the Fisher-
Race genotype of DCe/DCe, it is easier to refer to that type as R1 1.
Tippett Theory. In 1986, Tippett predicted that there are two closely-linked genes - RHD and 
RHCE. The RHD gene determines whether the D antigen that spans the membrane is present. 
Caucasians who are D negative have no gene at those gene loci. In the Japanese, Chinese, and 
Blacks of African descent have an inactive or partial gene at this site. The RHCE gene deter




  DcE  2  14% 
 
(more common in Blacks)
Dce    4% 
dCe 
r”  dcE  r”  1%
z  DCE  z  <1%
    <1%
Translating From Wiener to Fisher-Race
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and have been identified in early foetal life (as early as 38 days) as well as immunogenic (ability to 
stimulate antibody production) and therefore can easily cause hemolytic disease of the foetus and 
newborn if the baby has a Rh antigen that the mother lacks. Molecular genetic foetal D genotyping 
can detect small quantity of D genomic DNA and thus allow for the D antigen status of the foetus 
from small quantity of foetal cells obtaind from a chorionic villus or amniocentesis sample. This is 
very vital particularly in Rh negative mother with high titre of anti-D (>15 iu) and whose partner is 
D positive (Dd). The test help to determine the D genotype of the foetus and its predisposition to 
HDFN. Approximately 60% of Rh negative transfused with Rh positive red cells will produce im
mune anti-D. After the D antigen, Kell antigen is next most immunogenic. Approximately 10% of 
kell negative persons develop anti-K when transfused with Kell positice red cells. One third of non-
anti-D are anti-K. Unlike the ABO antibodies that are mainly IgM, the Rh antibodies are commonly 
IgG and formed by immune stimulus due to transfusions or baby’s red blood cells entering maternal 
circulation during pregnancy. Since Rh antibodies are IgG they react optimally at 37 C and their 
reactions will be observed with the indirect antiglobulin technique. Agglutination reactions are en
hanced by high protein (albumin), low-ionic strength saline (LISS), proteolytic enzymes (ficin) and 
polytheylene glycol (PEG). Rh antibodies exhibit dosage effect and will always react more strongly 
with homozygous cells than with heterozygous cells. For example, an anti-E will react with strongly 
with E+E+ cells and more weakly with E+e+ cells. The number of D antigenic determinant on the red 
cell membrane varies depending of the Rh phenotype/genotype of the individual. These number of 
antigen sites can be determined by radio-labelled anti-D. T he strongest D reacting red cell an high
est antigen sites are the –D-/-D- (CE deletion) followed by R2 2 (cDE /cDE).
CDe/cde 1 10,000- 15,000
CDe/CDe 1 1 15,000- 20,000
cDE/ cDE 16,000 – 33,000
-D-/-D- 111,000 – 202,000
Table: Variation of number of D antigen sites on different Rh genotypes
Both Hemolytic Disease of the Foetus and Newborn and Hemolytic Transfusion Reactions 
can occur due the various Rh antibodies. To prevent sensitization of a patient the following 
step must be taken; transfuse Rh-negative individuals Rh-negative red blood cells and plate
lets and administer prophylactic immunoglobulin –D to all Rh-negative mothers following 
any potentially sensitizing events during pregnancy to prevent them from producing im
mune anti-D. The incidence of Rh antibodies
1. Anti-D most common antibody seen in Rh(D) negative people 
2. Anti-E most common antibody seen in Rh pos people since only 30% of 
the population have the antigen 
3. Anti-C or Anti-c less common - most people have the antigen 
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4. Anti-e often seen as autoantibody and will make it difficult to find com-
patible blood since 98% of the population have the e antigen 
5. Anti-C, e or Anti-c, E often seen in combination. If a patient lacks both a 
C and e and has made an anti-C, then enhancement techniques should be 
done to make sure that an anti-e is not also present. 
Rh System Inheritance. From the 1940’s to the 1990’s the mechanism for inheritance of the Rh 
Blood Group System was in question. The terminology that is part of the Fisher-Race Theory 
is most commonly used even today.
Fisher-Race Theory. The Fisher-Race theory involved the presence of 3 pairs of closely linked 
genes D, C, and E and their alleles c and e and the absence of D since an anti-d has never been 
found. These three genes are closely linked on the same chromosome and are inherited as a 
group of 3. The most common group of 3 genes inherited is CDe and ce (D negative) is the 
second most common.
Weiner Theory. Weiner believed there was one gene complex with a number of alleles resulting in 
the presence of various Rh antigens. According to Weiner there were 8 alleles; Ro, R1, R2, Rz, r, r’, r”, 
ry, which ended up with different antigens on the red cells that he called Rh
o
, rh’, rh”, hr’, hr”. Weiner 
terminology is not use as often today, but you will often see Rh
o
 (D) when a person considered to 
be Rh-positive. At times the gene terms are easier to use than Fisher-Race. If a person has the Fisher-
Race genotype of DCe/DCe, it is easier to refer to that type as R1R1.
Tippett Theory. In 1986, Tippett predicted that there are two closely-linked genes - RHD and 
RHCE. The RHD gene determines whether the D antigen that spans the membrane is present. 
Caucasians who are D negative have no gene at those gene loci. In the Japanese, Chinese, and 
Blacks of African descent have an inactive or partial gene at this site. The RHCE gene deter-
mines C, c, E, e antigens produced from the alleles; RHCe, RHCE, RHcE and RHce. 
Rh Halotypes Gene present Antigen present Phenotype
Percentage among 
Caucasian
R1 RHD RHCe D,C,e R1 42% 
R RHce dce   R 37% 
R2  RHD RHcE DcE  R2  14% 
Ro 
RHD RHce  




r’ RHCe dCe  r’ 2%
r”  RHcE dcE  r”  1%
Rz  RHD RHCE DCE  Rz  <1%
ry  RHCE Dce ry  <1%
Translating From Wiener to Fisher-Race
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There are times when you will need to convert Weiner to Fisher-Race or vice versa. It will be 
easier to do these conversions if you remember the following:
1. R always refers to D whether it is Ro, R1, R2, or the very rare Rz. 
2. r always refers to the lack of D 
3. o refers to having no C or E 
4. 1 or ‘ always refers to C 
5. 2 or “ always refers to E 
6. The very rare haplotypes that have both a C and E are given letters from 
the end of the alphabet z and y. 
Determining genotypes from phenotypes. The following steps will be helpful in determining 
an individual’s phenotype. These rules are based on probability so the least likely genotypes will 
involve Rz or ry. Type patient for the five Rh antigens: D, C, c, E, e and start with D: is it positive 
or negative? If negative, the individual will be homozygous d. If positive for D, you can’t tell yet 
whether the individual is homozygous or heterozygous for D. Therefore, put D on just one chro-
mosome. Look at C: is it positive or negative. If negative, put c on each chromosome. If positive, 
look at c result to determine if the C is homozygous or heterozygous. If there is no c present, there 
would be two C and it would be homozygous. If a c is present as well as C, they are heterozygous. 
If homozygous, and then put C on each chromosome. If heterozygous, put C on same chromosome 
as D; put c on other. Look at E: is it positive or negative. If negative, put e on each chromosome. If 
positive, look at e result to determine if homozygous or heterozygous. If homozygous, put E on 
each chromosome. If heterozygous, put E on same chromosome as the D unless the D already has 
a C; put e on other chromosome. DCe is more common than DcE and DCE is extremely rare. Only 
put C and E together on the same chromosome if no other combinations are possible. 
Most Common Rh Genotypes. The following genotypes are listed as the most common (R1r) 
among caucasians and while (Ror) is the most common among blacks. Rz and ry are so rare 







1 D, C, c, e DCe/ce R1r 31.1 8.8
    DCe/Dce R1Ro 3.4 15
    Dce/Ce Ror 0.2 1.8
2 D, C, e DCe/DCe R1R1 17.6 2.9
    DCe/Ce R1r’ 1.7 0.7
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ce/ce 15
DCe/DcE R1R2 11.8
    DCe/cE R1r” 0.8 <0.1
    DcE/Ce 0.6 0.4
DcE/ce 10.4
    DcE/Dce 1.1
Dce/ce 3.0
    Dce/Dce 0.2 19.4
DcE/DcE 2.0 1.3
    DcE/cE 0.3  < 0.1
Incidence of the most common Rh genotypes
1. Paternity testing of the blood group antigens is based on a process of 
exclusion. Since the RHD and RHCE are closely linked and Ce, ce, cE 
are produced by a single gene, there are limited combinations that the 
father can provide.
2. It is helpful in HDN predictability by determining the father’s Rh geno
type. This helps predict likelihood of of the foetus being Rh positive and 
by extension the risk for HDFN due to Rh incompatibility between moth
er and baby particularly when the mother has a high titre of immune 
anti-D (>15iu). The Rh genotype of the father will indicate whether the 
baby has a O%, 50%, or 100% chance of being D positive.
3. If the father is also D negative (ce/ce), the baby will be D negative as well 
and there is a 0% probability of the baby suffering from Rh  HDFN. 
4. If the father’s Rh genotype appears to be either, R1r, R2 r, the baby 
has a 50% probability of being D positive and suffering from Rh  HDFN. 
On the other hand if a father’s Rh genotype appears to be any of the following, R1 1, R2 2, 
1 2, R , R1 , or R2 , the baby has a 100% probably of getting a D gene from his father and 
therefore being D positive and suffering from Rh .
Rhesus D Haemolytic Disease of the Foetus and Newborn (HDFN). The hemolytic condi
tion occurs when there is an Rh incompatibility between the the mother and the foetus. The 
disorder in the fetus due to Rh D incompatibility is known as erythroblastosis fetalis. Hemo
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There are times when you will need to convert Weiner to Fisher-Race or vice versa. It will be 
easier to do these conversions if you remember the following:
1. R always refers to D whether it is R , R1, R2, or the very rare Rz. 
2. r always refers to the lack of D 
3. o refers to having no C or E 
4. 1 or ‘ always refers to C 
5. 2 or “ always refers to E 
6. The very rare haplotypes that have both a C and E are given letters from 
the end of the alphabet z and y. 
The following steps will be helpful in determining 
an individual’s phenotype. These rules are based on probability so the least likely genotypes will 
involve Rz y. Type patient for the five Rh antigens: D, C, c, E, e and start with D: is it positive 
or negative? If negative, the individual will be homozygous d. If positive for D, you can’t tell yet 
whether the individual is homozygous or heterozygous for D. Therefore, put D on just one chro
mosome. Look at C: is it positive or negative. If negative, put c on each chromosome. If positive, 
look at c result to determine if the C is homozygous or heterozygous. If there is no c present, there 
would be two C and it would be homozygous. If a c is present as well as C, they are heterozygous. 
If homozygous, and then put C on each chromosome. If heterozygous, put C on same chromosome 
as D; put c on other. Look at E: is it positive or negative. If negative, put e on each chromosome. If 
positive, look at e result to determine if homozygous or heterozygous. If homozygous, put E on 
each chromosome. If heterozygous, put E on same chromosome as the D unless the D already has 
a C; put e on other chromosome. DCe is more common than DcE and DCE is extremely rare. Only 
put C and E together on the same chromosome if no other combinations are possible. 
The following genotypes are listed as the most common (R1r) 
among caucasians and while (R r) is the most common among blacks. Rz y are so rare 
they are not included in the following table.
1 DCe/ce R1r 31.1
    DCe/Dce R1Ro 15
    Dce/Ce 0.2 1.8
DCe/DCe R1R1 17.6
    DCe/Ce R1r’ 1.7 0.7
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3 Ce ce/ce Rr 15 7
4 DCcEe DCe/DcE R1R2 11.8 3.7
    DCe/cE R1r” 0.8 <0.1
    DcE/Ce R2r’ 0.6 0.4
5 DcEe DcE/ce R2r 10.4 5.7
    DcE/Dce R2Ro 1.1 9.7
6 Dce Dce/ce Ror 3.0 22.9
    Dce/Dce RoRo 0.2 19.4
7 DcE DcE/DcE R2R2 2.0 1.3
    DcE/cE R2r” 0.3  < 0.1
Incidence of the most common Rh genotypes
Applications of Rh genotyping
1. Paternity testing of the blood group antigens is based on a process of 
exclusion. Since the RHD and RHCE are closely linked and Ce, ce, cE 
are produced by a single gene, there are limited combinations that the 
father can provide.
2. It is helpful in HDN predictability by determining the father’s Rh geno-
type. This helps predict likelihood of of the foetus being Rh positive and 
by extension the risk for HDFN due to Rh incompatibility between moth-
er and baby particularly when the mother has a high titre of immune 
anti-D (>15iu). The Rh genotype of the father will indicate whether the 
baby has a O%, 50%, or 100% chance of being D positive.
3. If the father is also D negative (ce/ce), the baby will be D negative as well 
and there is a 0% probability of the baby suffering from Rh
o
 HDFN. 
4. If the father’s Rh genotype appears to be either, R1r, R2r or Ror, the baby 
has a 50% probability of being D positive and suffering from Rh
o
 HDFN. 
On the other hand if a father’s Rh genotype appears to be any of the following, R1R1, R2R2, 
R1R2, RoRo, R1Ro, or R2Ro, the baby has a 100% probably of getting a D gene from his father and 
therefore being D positive and suffering from Rh
o
.
Rhesus D Haemolytic Disease of the Foetus and Newborn (HDFN). The hemolytic condi-
tion occurs when there is an Rh incompatibility between the the mother and the foetus. The 
disorder in the fetus due to Rh D incompatibility is known as erythroblastosis fetalis. Hemo-
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lytic (blood lysis or destruction) or breaking down of red blood cells. Erythroblastosis refers 
to the release of immature red blood cells into the peripheral blood to compensate for HDFN 
assocaited anaemia. Foetalis refers to the foetus. When the condition is caused by the Rh D 
antigen-antibody incompatibility; it is called Rh D Hemolytic disease of the newborn (often 
called Rhesus disease). The sensitization to Rh D antigens usually result from feto-maternal 
transfusion during pregnancy or during delivery and often lead to the production of maternal 
immue (IgG) anti-D antibodies which have a low molecular weight and thus can pass through 
the placenta barrier. The first baby is usually unaffcted. This is of particular importance to D 
negative females at or below childbearing age, because any subsequent pregnancy may be 
affected by Rhesus D hemolytic disease of the newborn if subsequent babies are D positive. 
The sensitization is preventable in by injections of prophylactic IgG anti-D antibodies (Rho(D) 
Immune Globulin) given following any potentially sensitizing events during pregnancy and 
within 72 hours after delivery of a Rh positive baby. 
Symptoms and signs in the fetus
1. Hepatosplenomegaly (enlarged of liver and spleen).
2. Anaemia that results in newborn’s pallor.
3. Jaundice or yellow discoloration of the newborn’s skin, sclera or mucous 
membrane. This may be evident right after birth or after 24–48 hours after 
birth. This is caused by hyperbilirubinaemia (one of the end products of 
red blood cell destruction).
4. Enlargement of the newborn’s liver and spleen.
5. The newborn may have severe oedema of the entire body.
6. Dyspnea or difficulty breathing.
7. Anaemia may be severe enough to warrant a top up transfusion
8. Hyperbilirubinaemia may be severe enough to warrant an exchange 
blood transfusion to prevent kinecterus (an encephalopathy associated 
with degeneration and yellow pigmentation of basal ganglia and other 
nerve cells in the spinal cord and brain, caused by the severe unconju-
gated bilirubinemia occurring in newborn infants with HDFN).
D Variants
Weak D (Du). Du or weak D is a weakly expressed D antigen that can only be demonstrated after 
incubation at 37oC followed with antiglobulin testing (Coombs technique). Weak D often occur as a 
result of the presence of few D antigen sites per red cells compared to normal D positive individu-
als. Most monoclonal anti-D reagents give a normal strength reaction with weak D compared to 
polyclonal anti-D reagent. When there is discrepant results with 2 different anti-D typing reagents, 
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it is safer to treat such patient as Rh-negative and give them Rh-negative red cell until the Rh Ssta
tus is confirmed by the referene laboratory. If confirmed as a weak D, the person should be treated 
as Rh positive whether as a donor or receipient. Individuals who are weak D are not capable of 
producing anti-D if transfused with Rh-positvie red cells. An Rh control must always be run along 
with the weak D test. Always consult the product insert to determine if Rh control needs to be run 
when performing the immediate spin D testing. 
Anti-D Anti-D Anti-D
0
0 0 0 0 0 Weak
0 0 0 0 0 0 Negative
0 0 0 0
Indeterminate. Result 
Table: Results obtained when performing the D testing
 It is recommended that all donor blood that originally fails to react 
with anti-D at immediate spin must be tested for weak D. Units that test positive for weak D 
should be labeled D positive and should be transfused only to D positive individuals. When 
performing testing on prenatal and postnatal mothers, D-negative blood at immediate spin 
should be tested for weak D as well to determine if they are eligible for prophylactic D im
mune globulin. Why do weak D’s exist. There are three explanations for weak D’s.
1. Quantitative Weak D. There are individuals that quantitatively produce 
fewer D antigen sites. This is more common in Blacks and is often seen 
with the Dce haplotype. On rare occasions among Whites an unusual 
DCe or DcE may also produce a quantitatively decrease weak D. 
2. Position effect Weak D. In this case the D is weakened by the position of 
a C on the opposite haplotype which is called the trans position. The two 
Rh genotype combinations where this type of weak D is seen are: Dce/Ce 
and DcE/Ce. Today this type of weak D would type as a regular D due to 
the use of IAT cards. 
3.  Partial D antigen (Mosaic D). It has been found that some D-positive 
individuals make an alloanti-D that reacts with other D positive cells but 
not their own. Many of these will demonstrate a weak D type of reaction. 
In this type of weak D, the individuals lack some of the components of 
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lytic (blood lysis or destruction) or breaking down of red blood cells. Erythroblastosis refers 
to the release of immature red blood cells into the peripheral blood to compensate for HDFN 
ssocaited anaemia. Foetalis refers to the foetus. When the condition is caused by the Rh D 
antigen-antibody incompatibility; it is called Rh D Hemolytic disease of the newborn (often 
called Rhesus disease). The sensitization to Rh D antigens usually result from feto-maternal 
transfusion during pregnancy or during delivery and often lead to the production of maternal 
immue (IgG) anti-D antibodies which have a low molecular weight and thus can pass through 
the placenta barrier. The first baby is usually unaffcted. This is of particular importance to D 
negative females at or below childbearing age, because any subsequent pregnancy may be 
affected by Rhesus D hemolytic disease of the newborn if subsequent babies are D positive. 
The sensitization is preventable in by injections of prophylactic IgG anti-D antibodies (Rho(D) 
Immune Globulin) given following any potentially sensitizing events during pregnancy and 
within 72 hours after delivery of a Rh positive baby. 
1. Hepatosplenomegaly (enlarged of liver and spleen).
2. Anaemia that results in newborn’s pallor.
3. Jaundice or yellow discoloration of the newborn’s skin, sclera or mucous 
membrane. This may be evident right after birth or after 24–48 hours after 
birth. This is caused by hyperbilirubinaemia (one of the end products of 
red blood cell destruction).
4. Enlargement of the newborn’s liver and spleen.
5. The newborn may have severe oedema of the entire body.
6. Dyspnea or difficulty breathing.
7. Anaemia may be severe enough to warrant a top up transfusion
8. Hyperbilirubinaemia may be severe enough to warrant an exchange 
blood transfusion to prevent kinecterus (an encephalopathy associated 
with degeneration and yellow pigmentation of basal ganglia and other 
nerve cells in the spinal cord and brain, caused by the severe unconju
gated bilirubinemia occurring in newborn infants with HDFN).
W ).  or weak D is a weakly expressed D antigen that can only be demonstrated after 
incubation at 37 C followed with antiglobulin testing (Coombs technique). Weak D often occur as a 
result of the presence of few D antigen sites per red cells compared to normal D positive individu
als. Most monoclonal anti-D reagents give a normal strength reaction with weak D compared to 
polyclonal anti-D reagent. When there is discrepant results with 2 different anti-D typing reagents, 
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it is safer to treat such patient as Rh-negative and give them Rh-negative red cell until the Rh Ssta-
tus is confirmed by the referene laboratory. If confirmed as a weak D, the person should be treated 
as Rh positive whether as a donor or receipient. Individuals who are weak D are not capable of 
producing anti-D if transfused with Rh-positvie red cells. An Rh control must always be run along 
with the weak D test. Always consult the product insert to determine if Rh control needs to be run 
when performing the immediate spin D testing. 




Anti-D Rh control Anti-D Rh control Anti-D Rh control
4+ 0 Positive
0 0 0 0 4+ 0 Weak
0 0 0 0 0 0 Negative
0 0 0 0 4+ 4+
Indeterminate. Result 
not interpretable. Repeat
Table: Results obtained when performing the D testing
Testing for Weak D. It is recommended that all donor blood that originally fails to react 
with anti-D at immediate spin must be tested for weak D. Units that test positive for weak D 
should be labeled D positive and should be transfused only to D positive individuals. When 
performing testing on prenatal and postnatal mothers, D-negative blood at immediate spin 
should be tested for weak D as well to determine if they are eligible for prophylactic D im-
mune globulin. Why do weak D’s exist. There are three explanations for weak D’s.
1. Quantitative Weak D. There are individuals that quantitatively produce 
fewer D antigen sites. This is more common in Blacks and is often seen 
with the Dce haplotype. On rare occasions among Whites an unusual 
DCe or DcE may also produce a quantitatively decrease weak D. 
2. Position effect Weak D. In this case the D is weakened by the position of 
a C on the opposite haplotype which is called the trans position. The two 
Rh genotype combinations where this type of weak D is seen are: Dce/Ce 
and DcE/Ce. Today this type of weak D would type as a regular D due to 
the use of IAT cards. 
3.  Partial D antigen (Mosaic D). It has been found that some D-positive 
individuals make an alloanti-D that reacts with other D positive cells but 
not their own. Many of these will demonstrate a weak D type of reaction. 
In this type of weak D, the individuals lack some of the components of 
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the D antigen and therefore are able to make allantibodies to those spe-
cific components if they are transfused with D positive blood containing 
the specific components that they lack. 
D Variants. Some individuals have a variant D protein as a result of changes in their in-
herited D gene. These changes are often as a result of a change in the amino acid sequence 
of the D carrier molecule. This changes results in variable reaction with the anti-D reagent. 
Based on reactictivity these variant are categorised into ; II, IIIb,IIIc, Iva, IVb, Va, Vb, VI 
and VII. Other additional minor variations continue to be described. Anti-D reagents used 
for typing must be capable of detecting these variants D antigens except category VI and 
above. Individuals in category VI and above have the least amount of D antigen and capa-
ble of producing immune anti-D if transfused with red cells containing the portion of the D 
antigen which they lack. These individuals should be treated as Rh negative and transfused 
only with Rh D negative red cells.
Other Rh System Variants
Anti- Cw. Originally thought to be produced by an allele of C and c genes. Cw is a relatively 
low frequency antigen found in approximately 2% of Whites and 1% of Blacks. It is not an 
allele of C and c. Its allele is MAR, which is found in 99.9% of the population. CW positive 
red cells are often C+. However the antigen associated with CW is weaker than normal C. 
Anti- CW is not an uncommon antibody often thought to be naturally occurring may be clini-
cally significant in causing a mild type HDFN.
V and VS. V and VS are low frequency alleles found in 1% or less of caucasians but are more 
common in Blacks. V is found in 30% of the Blacks and VS in 32%. 
G and anti-G. G is present when D or C present due to the presence of the amino acid ser-
ine at the 103 position of the Rh polypeptide. Anti-G will recongnizes the the serine amino 
acid at position 103 and react with both D+ and C+ cells. Red cells that are weak C and D 
also react weakly with anti-G. Anti –G has been separated by adsorption-elution techniques 
from sera containing anti-C+D. Cases have been described of Rh negative (rr) patients who 
have produced anti-C+D when her partner was D+ AND C- (cDE or cDe) or D- or C= (Cde 
or CdE) or when they have been delivered of C+ and D- babies (Cde/cde). Those antibodies 
have actually been found to be either anti-G or Anti-C+G. G antigen is highly immunogenic 
particularly in Rh negative (cde/cde) individuals.  
Rh deletions and suppressions. A number of variants resulting from deletions or sup-
pressions involving various part of the Rh complex have been described. Examples in-
clude; (-D-/-D-, Rh
null
, cD-/cD- and CWD-). In some of these cases some or all of the Rh 
antigens are missing on the red cell membrane. The –D- phenotype is heterozygous is 
occurs either as a result of the deletion or suppression of the CE gene. The red cell of –D- 
phenotype expresses both D and G antigens. These red cells express more D antigens than 
normal D+ individuals and are readily immunized by common Rh phenotype red cells 
via pregnancy and or transfusion to produce anti-Hr0 or anti-RH17. These antibodies are 
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clinically significant, capable of reacting with all Rh positive excluding Rh deletion and 
Rh  and are capable of causing HDFN. Patient with these antibodies must only receve 
red cells that are –D- or Rh
Rh deficiency syndrome (Rhnull phenotype). Rh has no Rh antigens on their red cells 
but these individual can transmit normal Rh antigens to their offspring. In the most com
mon type the core Rh polypeptide is missing. A less common type has the regulator gene 
that turns off the expression of Rh. There have been at least 43 individuals in 14 families 
that are Rh .  In these individuals the red blood cell membrane is abnormal has a short
ened red cell survival and some of these have been identified when it was observed that 
they had hemolytic anemia and abnormal red cell morphology (Rh  disease). If these 
individuals develop an Rh antibody following a transfusion or pregnancy, it is consid
ered a anti-total Rh antibody. The amorphic type of Rh is caused by the absence of 
silent alleles at the Rh locus (---/---). The parents and children with amorphic Rh are 
heterozygous for the silent gene. Pregnancy and transfusion can stimulate Rh people to 
produce an antibody (anti-Rh29) or anti-total Rh which reacts with (Rh29 antigen which 
is a high frequency antigen present in all red cells except Rh ) all red cell phenotypes 
except Rhnull.
. The Rh genome is made up of a mosaic of D, C, E, d, c, e alleles. You can pro
duce antibodies to any one of D, C, E, c and e (anti-D is usually the most clinically significant 
and common also known as Rh disease). Rh antibodies are produced through exposure to 
and of these mosaic antigens during previous blood transfusion or pregnancy. It is important 
to determine a baby father’s Rh group and genotype. If positive for the antigen for which 
mother has developed antibodies; the child runs the risk of being positive for the antigen and 
being affected by HDFN. If he doesn’t have the antigen, the baby won’t have it and won’t be 
affected by HDFN. Testing dad is often the first and important step. If baby is positive for the 
offending antigen, it may be important to closely monitor mother’s antibody titers for the 
mother to be under the care of an obstetrician. Rising titres is a way of assessing the likely 
severity of disease. Antibody- D titres of 4-15 iu are often associated with moderate HDN risk. 
However titres of > 15 iu are often associated with hish risk of HDN. It may be important in 
cases where the father is positive for the offending antigen to determine the feotal genotype 
at 16 weeks gestation. If baby is positive for the offending antigen and titre continues to rise, 
it may be important to access for that suggest hydrophic changes and foetal anaemia by car
rying out amniocentesis and analysing the amniotic fluid for product of haemoglobin brake
down. Severely affected babies may need intrauterine blood transfusion and may need to be 
delivered earlier. Rh immunoglobulin prevents Rh sensitization to “D” the major Rh protein, 
but may not prevent sensitization to the other Rh antigens antigen (C, E, c and e). Character
istics of Rh antibodies include:
1. They are generally IgG although some particularly anti-C may have an 
IgM component.
2. React optimally at 37°C
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clinically significant, capable of reacting with all Rh positive excluding Rh deletion and 
Rh
null
 and are capable of causing HDFN. Patient with these antibodies must only receve 
red cells that are –D- or Rh
null
Rh deficiency syndrome (Rhnull phenotype). Rh
null 
has no Rh antigens on their red cells 
but these individual can transmit normal Rh antigens to their offspring. In the most com-
mon type the core Rh polypeptide is missing. A less common type has the regulator gene 
that turns off the expression of Rh. There have been at least 43 individuals in 14 families 
that are Rh
null
.  In these individuals the red blood cell membrane is abnormal has a short-
ened red cell survival and some of these have been identified when it was observed that 
they had hemolytic anemia and abnormal red cell morphology (Rh
null
 disease). If these 
individuals develop an Rh antibody following a transfusion or pregnancy, it is consid-
ered a anti-total Rh antibody. The amorphic type of Rh
null 
is caused by the absence of 
silent alleles at the Rh locus (---/---). The parents and children with amorphic Rh
null 
are 
heterozygous for the silent gene. Pregnancy and transfusion can stimulate Rh
null 
people to 
produce an antibody (anti-Rh29) or anti-total Rh which reacts with (Rh29 antigen which 
is a high frequency antigen present in all red cells except Rh
null
) all red cell phenotypes 
except Rhnull.
Rh antibodies. The Rh genome is made up of a mosaic of D, C, E, d, c, e alleles. You can pro-
duce antibodies to any one of D, C, E, c and e (anti-D is usually the most clinically significant 
and common also known as Rh disease). Rh antibodies are produced through exposure to 
and of these mosaic antigens during previous blood transfusion or pregnancy. It is important 
to determine a baby father’s Rh group and genotype. If positive for the antigen for which 
mother has developed antibodies; the child runs the risk of being positive for the antigen and 
being affected by HDFN. If he doesn’t have the antigen, the baby won’t have it and won’t be 
affected by HDFN. Testing dad is often the first and important step. If baby is positive for the 
offending antigen, it may be important to closely monitor mother’s antibody titers for the 
mother to be under the care of an obstetrician. Rising titres is a way of assessing the likely 
severity of disease. Antibody- D titres of 4-15 iu are often associated with moderate HDN risk. 
However titres of > 15 iu are often associated with hish risk of HDN. It may be important in 
cases where the father is positive for the offending antigen to determine the feotal genotype 
at 16 weeks gestation. If baby is positive for the offending antigen and titre continues to rise, 
it may be important to access for that suggest hydrophic changes and foetal anaemia by car-
rying out amniocentesis and analysing the amniotic fluid for product of haemoglobin brake-
down. Severely affected babies may need intrauterine blood transfusion and may need to be 
delivered earlier. Rh immunoglobulin prevents Rh sensitization to “D” the major Rh protein, 
but may not prevent sensitization to the other Rh antigens antigen (C, E, c and e). Character-
istics of Rh antibodies include:
1. They are generally IgG although some particularly anti-C may have an 
IgM component.
2. React optimally at 37°C
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3. They are generally immune although some so called naturally occurring 
anti-E, CW and anti-c have been described.
4. They are enhanced by enzyme treatment and react optimally by anti-hu-
man globulin (AHG) technique.
5. They are clinically significant antibodies and are often incriminated in 
HDFN and transfusion reactions.
6. They do not activate complement but can destroy incompatible red cells 
invivo. Rh antibody coated red cells are detected by macrophages and 
removed from circulation by the spleen.
7. Some Rh antibodies occur as antibody mixtures (anti C+D, anti-c+E, anti-
D+K, anti D+Fya).
Anti-D. Produced when Rh negative patients are transfused with Rh positive red cell in emer-
gency as a result of lack of Rh negative red cells or by D negative mothers exposed to Rh posi-
tive foetal red cells during pregnancy or delivery. Anti D show dosage effect and may occur 
with other antibody specificity such as anti-D+ Fya or anti-D+ K. Is a clinically significant 
antibody and can cause transfusion reaction and HDFN.
Anti-c. Usually produced by R1R1 (CDe/CDe) and other phenotypes such as R1rʹ (CDe/Cde) 
and rʹ rʹ (Cde/Cde). Occur either singly or in combination with E (anti-c+E). Is the most clini-
cally significant antibody after anti-D and can cause transfusion reaction and HDFN. Anti-c 
titers of > 7.5 iu are associated with moderate and high risk HDFN.
Anti-C. It is a rare antidoby and commonly produced in combination with anti-D by (cde/cde preg-
nant women). It can also be produced in combination with anti-e by R2R2 (cDE/ cDE) individuals. 
It is usually a combination of IgG and IgM antibodies. Anti-C seldom causes HDFN and when it 
does, the disease is usally mild.
Anti-E. Anti-E is a more common antibody compared to anti-C. Immune antibody but may 
sometimes be so called naturally occurring. Some reacts only in enzyme technique. Common-
ly produced in R1R1 individuals exposed to R2R2 or R2r red cells and exist mostly in compona-
tion with anti-c. Individuals positive for anti-E are obviously e/e genetically. Reacts variable 
in LISS-IAT in sensitive IAT and enzyme technique. Seldon causes HDFN and when it does 
the disease is usually mild.
Anti –e. Anti-e is a rare antibody and the antigen that stimulates its production is a weak 
immunogen. Antibody reacts optimally in enzyme techniques. Seldon causes HDFN and 
when it does the disease is usually mild. Your red blood cells must be little e negative or you 
wouldn’t be able to make anti-e antibodies. Patients with anti-e may have been exposed to e 
antigens in a prior pregnancy or during a blood transfusion. Itis important to determine if 
baby’s father is e positive. If positive, it is likely he may have passed that characteristic to your 
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baby. If he doesn’t have the e antigen, the baby won’t have it and won’t be affected at all by 
the e antibodies. Testing dad is often the first and important step. If baby may have e antigen, 
it may be important to closely monitor mother’s antibody titers.
Anti Rh (D) 
A,B
D (1) D(2)
1 0 0 0 0 0 0 0 A Negative
0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0 B Negative
0 0 0 0 0 0 0 AB Negative
0 0 0 0 ? Acquired B 
0 0 0 0 0 ? Acquired B 
4 mf 0 4 mf 0 0 0 0
1
10 0 0
ABO and Rh (D) Grouping result
Key: 4 = Positive, 0 = Negative and MF= Mixed field reaction
 An individual may or may not have the 
the surface of their red blood cells. This term strictly refers only to the most immunogenic D 
antigen of the Rh blood group system. Rh grouping is performed by reacting the red cells of 
an individual with 2 potent and highly specific monoclonal anti-Rh D reagents. The status is 
usually indicated by  (Rh+) to indicate the presence or  (Rh-) to indicate 
the absence of the D antigen. Rh phenotyping is performed by reacting the red cell sample 
against 2 specific anti- Rh reagents (anti-D, C, E, c and e). The detected Rh antigen combina
tion determine the Rh phenotype of the individual. It is impossiblle to determine the geno
type of an individual from the phenotype result. The phenotype cannot indicate if the red cell 
is homozygous (DD) or heterozygous (Dd) since there is no d gene antigenic product.
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baby. If he doesn’t have the e antigen, the baby won’t have it and won’t be affected at all by 
the e antibodies. Testing dad is often the first and important step. If baby may have e antigen, 
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1 4 0 4 0 0 0 0 0 4 0 A Negative
2 0 4 4 4 4 0 4 4 0 0 B Positive
3 4 4 4 4 4 0 0 0 0 0 AB Positive
4 4 0 4 4 4 0 0 0 4 0 A Positive
5 0 4 4 0 0 0 4 4 0 0 B Negative
6 4 4 4 0 0 0 0 0 0 0 AB Negative
7 4 4 4 4 4 0 0 0 4 0 ? Acquired B 
8 0 4 4 4 4 0 0 0 4 0 ? Acquired B 
9 4 mf 0 4 mf 4 4 0 0 0 4 0
Indeterminate 
(? A1+A2). 
10 4 4 4 4 4 4 0 0 4 4
Indeterminate. 
? positive DAT
ABO and Rh (D) Grouping result
Key: 4 = Positive, 0 = Negative and MF= Mixed field reaction
Rh grouping and Phenotyping. An individual may or may not have the “Rhesus factor” on 
the surface of their red blood cells. This term strictly refers only to the most immunogenic D 
antigen of the Rh blood group system. Rh grouping is performed by reacting the red cells of 
an individual with 2 potent and highly specific monoclonal anti-Rh D reagents. The status is 
usually indicated by Rh positive (Rh+) to indicate the presence or Rh negative (Rh-) to indicate 
the absence of the D antigen. Rh phenotyping is performed by reacting the red cell sample 
against 2 specific anti- Rh reagents (anti-D, C, E, c and e). The detected Rh antigen combina-
tion determine the Rh phenotype of the individual. It is impossiblle to determine the geno-
type of an individual from the phenotype result. The phenotype cannot indicate if the red cell 
is homozygous (DD) or heterozygous (Dd) since there is no d gene antigenic product.
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Reaction with antisera
Antigen present/Rh phenotype
Anti-C Anti-D Anti-E Anti-c Anti-e
4 4 0 4 4 CcDe
0 4 4 4 4 CDEe
4 4 0 0 4 CDe
0 4 4 4 0 Cde
0 0 0 4 4 Cde
Rh Phenotyping Result
Key: 4 = Positive and 0 = Negative
Applications of Rhesus D grouping result
1. All new blood donors and transfusion receipient should be tested rou-
tinely for their Rh (D) group using two examples of monoclonal anti D 
reagent obtained from same or different clones. Donors and transfusion 
receipient’s red cells (particularly those that have Rh-alloantibodies) may 
be further tested to identify their Rh phenotypes to allow for selection of 
appriopriate red cells antigen for patients with alloantibodies to ensure 
that thet receive red cells negative for the alloantibody they have devel-
oped. It is very important that the reagent used for grouping are control-
led by reacting them against known D + and D – samples.
2. Patients found negative should be transfused with Rh D negative red 
cells only while those found positive should be transfused with Rh D 
positive red cells. Certain D negative males and women who have no 
child bearing potential may be transfused in certain situation with Rh 
D positive red cells (when stock level are low, in emergency situation 
such as massive haemorrhages and liver transplant when a large volume 
of red cells are required and the blood bank is unable to meet the Rh D 
negative red cell requirements). All effort must be made to ensure that 
Transfusion-dependent patients receive preferable bloods that are Rh 
and Kell compatible with the receipient to prevent them fro developing 
antibodies to these antigens. Rh antibodies are capable of causing severe 
transfusion reactions and HDFN. The aim of Rh (D) grouping and phe-
notyping of donors and reciepients includes; To prevent the stimulation 
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of anti-D antibbodies as a result of transfusion by ensuring that D nega
tive individuals are transfused with D negative red cells and to detect the 
presence of Rh alloantibodies in the recipients’s plasma and to ensure 
that such patient receive red antigen negative and crossmatch compatible 
red cell transfusion.
 When following through to AGT for weak D a positive reaction is observed 
in the Rh control. This is commonly seen in patients/donors whose DAT are strongly positive. 
These red cells are coated with antibody (not necessarily Rh antibody) in vivo. Albumin is 
potentiating medium that enables reagent Anti-D to overcome the zeta potential allowing 
cells coated with IgG Anti-D to get close enough together to agglutinate. Cells coated in vivo 
with any IgG antibody will also agglutinate in the presence of albumin. These false positives 
are corrected by using form of Anti-D that does not require albumin. False positive can also be 
caused by rouleaux formation, which will look like agglutination macroscopically. Rouleaux 
would be identified microscopically due to the “coin-stacking” appearance of the red cells. 
This false positive reaction can be obviated by washing cells 3 to 4 times in saline and then 
retesting. There are two types of alternative types of anti-D: 
1. Monoclonal (IgM) anti-D which is capable of agglutinating D positive 
cells without the presence of albumin at room temperature. A number of 
facilities normally use this type of anti-D and therefore do not routinely 
use Rh control. 
2. Use of chemically modified anti-D reagents (modified with albumin) to 
break the disulfide bonds closest to the hinge region so antibody can 
reach cells that are farther apart. 
False negatives are not readily identifiable, but can occur in the following 
circumstances. Antigen and antibody reaction occur in optimum proportion. The most com
mon cause of a false negative reaction is the use of too heavy a cell suspension. In such cases 
there are to too many cells for the amount of antibody in the antisera. They may also rarely 
be caused by extremely strong positive DAT. In this case a patient’s D antigen sites are coated 
in vivo and there are no sites left for commercial anti-D to attach to. This can be corrected by 
heating cells gently to elute off antibody off the red cell surface without damaging cells and 
then re-testing.
 The Lewis antigen system first discovered in 1946 (ISBT 007) is a human blood group system based 
upon genes expressed on chromosome 19 q13.3, (FUT2) and 19p13.3 (FUT3). Both genes have fuco
syltransferase activity. Two main types of Lewis antigens exist (Lewis a and Lewis b). Lewis red cell 
antigens which are not produced by the erythrocyte itself. Instead, they are a component of exo
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negative red cell requirements). All effort must be made to ensure that 
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of anti-D antibbodies as a result of transfusion by ensuring that D nega-
tive individuals are transfused with D negative red cells and to detect the 
presence of Rh alloantibodies in the recipients’s plasma and to ensure 
that such patient receive red antigen negative and crossmatch compatible 
red cell transfusion.
False Positives. When following through to AGT for weak D a positive reaction is observed 
in the Rh control. This is commonly seen in patients/donors whose DAT are strongly positive. 
These red cells are coated with antibody (not necessarily Rh antibody) in vivo. Albumin is 
potentiating medium that enables reagent Anti-D to overcome the zeta potential allowing 
cells coated with IgG Anti-D to get close enough together to agglutinate. Cells coated in vivo 
with any IgG antibody will also agglutinate in the presence of albumin. These false positives 
are corrected by using form of Anti-D that does not require albumin. False positive can also be 
caused by rouleaux formation, which will look like agglutination macroscopically. Rouleaux 
would be identified microscopically due to the “coin-stacking” appearance of the red cells. 
This false positive reaction can be obviated by washing cells 3 to 4 times in saline and then 
retesting. There are two types of alternative types of anti-D: 
1. Monoclonal (IgM) anti-D which is capable of agglutinating D positive 
cells without the presence of albumin at room temperature. A number of 
facilities normally use this type of anti-D and therefore do not routinely 
use Rh control. 
2. Use of chemically modified anti-D reagents (modified with albumin) to 
break the disulfide bonds closest to the hinge region so antibody can 
reach cells that are farther apart. 
False Negatives. False negatives are not readily identifiable, but can occur in the following 
circumstances. Antigen and antibody reaction occur in optimum proportion. The most com-
mon cause of a false negative reaction is the use of too heavy a cell suspension. In such cases 
there are to too many cells for the amount of antibody in the antisera. They may also rarely 
be caused by extremely strong positive DAT. In this case a patient’s D antigen sites are coated 
in vivo and there are no sites left for commercial anti-D to attach to. This can be corrected by 
heating cells gently to elute off antibody off the red cell surface without damaging cells and 
then re-testing.
24. Lewis Blood Group System
 The Lewis antigen system first discovered in 1946 (ISBT 007) is a human blood group system based 
upon genes expressed on chromosome 19 q13.3, (FUT2) and 19p13.3 (FUT3). Both genes have fuco-
syltransferase activity. Two main types of Lewis antigens exist (Lewis a and Lewis b). Lewis red cell 
antigens which are not produced by the erythrocyte itself. Instead, they are a component of exo-
crine epithelial secretions (glycolipid plasma secretion), and are subsequently adsorbed onto the 
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surface of the erythrocyte. Absorption can only take place if the Se (secreter) gene is also present in 
the individual. It is often possible to have any combination of Lewis a, Lewis b, both or neither anti-
gens. The most common are Lewis a negative and Lewis b positive Le (a-b+). Having both antigens 
present on red cells Le (a+b+) is extremely rare and is thought to be caused by a weak expression 
of the secretor gene. Unlike ABO blood group antigen, the Lewis antigens are not present at birth. 
They develop during the first 15 months of life. Lewis antibody seems to be naturally occurring 
IGM antibodies and react optimally in saline normally up to 20°C. It may also react at 37°C by AHG 
technique. They do not cause HDFN and are rarely implicated to cause transfusion reactions. They 
may activate complement and cause haemolysis of test red cells. Patients with Lewis alloantibody 
do not require antigen negative red cell transfusion. The link between the Lewis blood group and 
secretion of the ABO blood group antigens was possibly the first example of multiple effects of a 
human gene. The presence of fucosyltransferase converts the Lewis a antigen to Lewis b. This is 
the same fucosyltransferase which can convert membrane bound A, B or H antigens into soluble 
A, B and H, allowing the person to secrete them into body fluids. Therefore, people with Lewis a 
antigens will not secrete the A, B or H antigens (and are called ABH non-secretors), and the pres-
ence of the Lewis b antigen is only found in people who are ABH secretors. Lewis negative (Le a-, 
Le b-) can be either secretors or non-secretors. People who are heterozygous are either Le(a+b+) or 
Le(a-b-). The latter is more common. Le(a-b-) individuals are capable of producing anti Lea +Leb. 
Due to the fact that these antigen are adsorbed onto red cells from the plasma, it is posible for the 
Lewis antigen of an individual to be weak or even temorary disappear. It is also possible for 
a person Lewis phenotype to change from Le(a-b+) to Le(a-b-) particularly during pregnancy 
or in patients on steroid treatment.
Basic chemical structural relationship between H and Lewis blood group antigens
Precursor Substance (PS): Glycoprotein + Gal +GlcNAc +Gal
H Substance: Glycoprotein + Gal +GlcNAc +Gal----Fuc
Lea Substance: Glycoprotein + Gal +GlcNAc-----Fuc +Gal






Distinct characteristics of antigens of the Lewis Blood Group System
1. Manufactured by the tissues 
2. Lewis antigens are secreted into body fluids 
3. Absorbed onto red cells from the plasma 
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The development of the Lewis antigens is controlled by two alleles of the Lewis blood group 
system; Le is dominant and results in the presence of Lewis Antigen and the recessive le (ab
sence of Lewis gene) is recessive and therefore 2 le/le needs to be inherited. 
. Both Le/Le and Le/le result Lewis positive antigen. Lewis antigen exists as either 
Lewis a (Le ) or Lewis b (Leb). 
What Lewis antigens are formed depends on interaction between Lewis (Le/le), Secretor (Se) 
and H genes in the tissues to produce Lewis antigens in the secretions. Lewis antigens have 
a similar structure to ABO antigens. They are formed at terminal sugars of Type I precursor 
substance made by tissue cell in plasma. If person has the Lewis gene, it adds fucose to second 
sugar from the end = Lea. If a person is also a secretor, H gene adds fucose to terminal sugar 
of precursor substance = Leb antigen. If person NOT a secretor, no H added to precursor sub
stance made by tissue cell, so it remains as Lea. 
Not part of red cell membrane but are synthesized by tissue cells, carried by plasma, adsorb 
onto red cell surface. Not present on newborn red cells and it can disappear during pregnancy 
and in patients on steroid therapy. 
b)
Lewis Antibodies can either be Anti-Le  or Anti-Leb. Almost always produced by Lewis a neg
ative; Lewis b negative people. Naturally occurring but not regularly occurring (unexpected 
antibodies). Frequently seen in pregnancy (due to loss of Lewis antigen during pregnancy). 
IgM, therefore usually not clinically significant. Does not cross placenta. Reacts optimally 
at room temperature, but some may react at 37°C. If anti-Lea present at 37°C, may cause 
hemolytic transfusion reaction. Anti-Leb is usually clinically insignificant. There is variation 
in the trequency of Lewis antigen in black and white population with Le (b+) more common 




Variation of Lewis antigen in various population groups
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surface of the erythrocyte. Absorption can only take place if the Se (secreter) gene is also present in 
the individual. It is often possible to have any combination of Lewis a, Lewis b, both or neither anti
gens. The most common are Lewis a negative and Lewis b positive Le (a-b+). Having both antigens 
present on red cells Le (a+b+) is extremely rare and is thought to be caused by a weak expression 
of the secretor gene. Unlike ABO blood group antigen, the Lewis antigens are not present at birth. 
They develop during the first 15 months of life. Lewis antibody seems to be naturally occurring 
IGM antibodies and react optimally in saline normally up to 20°C. It may also react at 37°C by AHG 
technique. They do not cause HDFN and are rarely implicated to cause transfusion reactions. They 
may activate complement and cause haemolysis of test red cells. Patients with Lewis alloantibody 
do not require antigen negative red cell transfusion. The link between the Lewis blood group and 
secretion of the ABO blood group antigens was possibly the first example of multiple effects of a 
human gene. The presence of fucosyltransferase converts the Lewis a antigen to Lewis b. This is 
the same fucosyltransferase which can convert membrane bound A, B or H antigens into soluble 
A, B and H, allowing the person to secrete them into body fluids. Therefore, people with Lewis a 
antigens will not secrete the A, B or H antigens (and are called ABH non-secretors), and the pres
ence of the Lewis b antigen is only found in people who are ABH secretors. Lewis negative (Le a-, 
Le b-) can be either secretors or non-secretors. People who are heterozygous are either Le(a+b+) or 
Le(a-b-). The latter is more common. Le(a-b-) individuals are capable of producing anti Lea +Leb. 
Due to the fact that these antigen are adsorbed onto red cells from the plasma, it is posible for the 
Lewis antigen of an individual to be weak or even temorary disappear. It is also possible for 
a person Lewis phenotype to change from Le(a-b+) to Le(a-b-) particularly during pregnancy 
or in patients on steroid treatment.
Precursor Substance (PS): Glycoprotein + Gal +GlcNAc +Gal
H Substance: Glycoprotein + Gal +GlcNAc +Gal----Fuc
Le  Substance: Glycoprotein + Gal +GlcNAc-----Fuc +Gal
Leb Substance: Glycoprotein + Gal +GlcNAc-----Fuc +Gal---Fuc
1. Manufactured by the tissues 
2. Lewis antigens are secreted into body fluids 
3. Absorbed onto red cells from the plasma 
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Lewis Antigens 
The development of the Lewis antigens is controlled by two alleles of the Lewis blood group 
system; Le is dominant and results in the presence of Lewis Antigen and the recessive le (ab-
sence of Lewis gene) is recessive and therefore 2 le/le needs to be inherited. 
Genotypes. Both Le/Le and Le/le result Lewis positive antigen. Lewis antigen exists as either 
Lewis a (Lea) or Lewis b (Leb). 
Lewis negative results from le/le.
Formation of Lewis Antigens
What Lewis antigens are formed depends on interaction between Lewis (Le/le), Secretor (Se) 
and H genes in the tissues to produce Lewis antigens in the secretions. Lewis antigens have 
a similar structure to ABO antigens. They are formed at terminal sugars of Type I precursor 
substance made by tissue cell in plasma. If person has the Lewis gene, it adds fucose to second 
sugar from the end = Lea. If a person is also a secretor, H gene adds fucose to terminal sugar 
of precursor substance = Leb antigen. If person NOT a secretor, no H added to precursor sub-
stance made by tissue cell, so it remains as Lea. 
Not part of red cell membrane but are synthesized by tissue cells, carried by plasma, adsorb 
onto red cell surface. Not present on newborn red cells and it can disappear during pregnancy 
and in patients on steroid therapy. 
Characteristics of Lewis antibodies (Anti-Lea and Leb)
Lewis Antibodies can either be Anti-Lea or Anti-Leb. Almost always produced by Lewis a neg-
ative; Lewis b negative people. Naturally occurring but not regularly occurring (unexpected 
antibodies). Frequently seen in pregnancy (due to loss of Lewis antigen during pregnancy). 
IgM, therefore usually not clinically significant. Does not cross placenta. Reacts optimally 
at room temperature, but some may react at 37°C. If anti-Lea present at 37°C, may cause 
hemolytic transfusion reaction. Anti-Leb is usually clinically insignificant. There is variation 
in the trequency of Lewis antigen in black and white population with Le (b+) more common 
in whites than blacks and Le (a+) more common in blacks than whites.
Lewis group antigen





Variation of Lewis antigen in various population groups




4 0 Le(a+b-) H Le sese
0 4 Le(a-b+) H Le Se
0 0 Le(a-b-) H lele
Reaction of Lewis antibodies
Features Anti-Lea Anti-Leb
Immune/Naturally occurring
Naturally occurring in Le(a-b-) 
individuals
Naturally occurring in Le(a-b-) 
individuals but rarely in Le(a+b-)
Immunoglobulin class IgM IgM
Complement binding capacity
Bind complement and cause the 
haemolysis of Le(a+) red cells
Some examples bind comple-
ment
Haemolytic transfusion reaction May cause HTR Do not cause HTR
Ability to cause HDFN Does not cause HDFN Donot cause HDFN
Agglutination pattern
Show stingy agglutination 
reaction
Show stingy agglutination 
reaction
Detection method
Readily detected in enzyme 
technique, usually a cold agglu-
tinin and may react at 37°C
Readily detected in enzyme 
technique, usually a cold agglu-
tinin and may react at 37°C
Differences between Anti-Lea and Leb antibodies
Secretor Status
1. Secretor status controlled by Secretor (Se) gene
2. Secretor = Se/Se or Se/se (80%)
3. Non-secretor = se/se (20%)
4. Secretors have soluble A, B and H antigens in body fluids ( plasma, tears 
and saliva)
5. Can test saliva for presence of ABH antigens
Practical application of saliva testing
1. Determine ABO type in patients with ABO discrepancies
2. Determine ABO type in patients massively transfused with another 
blood type
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3. Can also use Lewis types to determine secretor status:
4. Lewis a positive, Lewis b negative = non-secretor
5. Lewis a negative, Lewis b positive = secretor
6. Lewis a negative, Lewis b negative = can’t tell secretor status from Lewis types
7. Can only use this method if patient has not been heavily transfused recently 
 Secretor status investigation is based on the principle of aggluti
nation inhibition. The procedure include;
1. Patient’s saliva boiled and cleared.
2. Cooled saliva mixed with reagent anti-A, anti-B and anti-H.
3. If soluble A, B, or H antigens present in saliva, these will react with anti
bodies in reagent antiserum, and neutralize it, so no antibody available 
to agglutinate test cells.
4. If no soluble A, B or H antigens in saliva, antibodies in reagent antiserum 
will not be neutralized, and will be free to react with test cells.
Have A antigens in saliva. Addition of reagent anti-A: antibodies tied up 
by soluble A antigens. Addition of known A cells results in no agglutination (no free A an
tibody to cause agglutination). No agglutination indicates = Positive test for secretor status
No ABO antigens in saliva. Addition of reagent Anti-A leaves free 
antibody in serum. Addition of known A cells causes agglutination. Agglutination reaction 
indicates a negative reaction for secretor status
The genes that control the expression of antigens of the MNS system is located on chromo
some 4. The antigens M and N are co-dominant alleles that are closely linked to the S and 
s antigens, which are also co-dominant. These antigens are inherited by a complex pattern 
similar to the Rh system. 
The Ms and Ns linkage is more common than the MS and NS linkages. M+ and N+ RBCs are 
common (75% of population) and M+N+ cells are the most common genotype (50% of popula
tion). These antigens were an early discovery and are some of the oldest blood antigens known 
after the ABO system. 
They were first described by Karl Landsteiner and Philip Levine in 1927. Anti-M and anti-N 
antibodies are usually IgM and are rarely associated with transfusion reactions. Anti-N is 
sometimes seen in dialysis patients due to cross-reactions with the residual formaldehyde 
from sterilizing the dialysis equipment. This is usually irrelevant for transfusion since this 
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0 Le(a+b-) H Le sese
0 Le(a-b+) H Le Se
0 0 Le(a-b-)
Reaction of Lewis antibodies
Immune/Naturally occurring
Naturally occurring in Le(a-b-) 
individuals
Naturally occurring in Le(a-b-) 
individuals but rarely in Le(a+b-)
Immunoglobulin class IgM IgM
Complement binding capacity
Bind complement and cause the 
haemolysis of Le(a+) red cells
Some examples bind comple-
Haemolytic transfusion reaction May cause HTR Do not cause HTR
Ability to cause HDFN Does not cause HDFN Donot cause HDFN
Agglutination pattern
Show stingy agglutination Show stingy agglutination 
Readily detected in enzyme 
technique, usually a cold agglu-
°
Readily detected in enzyme 
technique, usually a cold agglu-
°
Differences between Anti-Le  and Le
1. Secretor status controlled by Secretor (Se) gene
2. Secretor = Se/Se or Se/se (80%)
3. Non-secretor = se/se (20%)
4. Secretors have soluble A, B and H antigens in body fluids ( plasma, tears 
and saliva)
5. Can test saliva for presence of ABH antigens
1. Determine ABO type in patients with ABO discrepancies
2. Determine ABO type in patients massively transfused with another 
blood type
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3. Can also use Lewis types to determine secretor status:
4. Lewis a positive, Lewis b negative = non-secretor
5. Lewis a negative, Lewis b positive = secretor
6. Lewis a negative, Lewis b negative = can’t tell secretor status from Lewis types
7. Can only use this method if patient has not been heavily transfused recently 
Testing for Secretor Status. Secretor status investigation is based on the principle of aggluti-
nation inhibition. The procedure include;
1. Patient’s saliva boiled and cleared.
2. Cooled saliva mixed with reagent anti-A, anti-B and anti-H.
3. If soluble A, B, or H antigens present in saliva, these will react with anti-
bodies in reagent antiserum, and neutralize it, so no antibody available 
to agglutinate test cells.
4. If no soluble A, B or H antigens in saliva, antibodies in reagent antiserum 
will not be neutralized, and will be free to react with test cells.
Group A Secretor. Have A antigens in saliva. Addition of reagent anti-A: antibodies tied up 
by soluble A antigens. Addition of known A cells results in no agglutination (no free A an-
tibody to cause agglutination). No agglutination indicates = Positive test for secretor status
Group A Non-Secretor. No ABO antigens in saliva. Addition of reagent Anti-A leaves free 
antibody in serum. Addition of known A cells causes agglutination. Agglutination reaction 
indicates a negative reaction for secretor status
25. MNS blood group system 
The genes that control the expression of antigens of the MNS system is located on chromo-
some 4. The antigens M and N are co-dominant alleles that are closely linked to the S and 
s antigens, which are also co-dominant. These antigens are inherited by a complex pattern 
similar to the Rh system. 
The Ms and Ns linkage is more common than the MS and NS linkages. M+ and N+ RBCs are 
common (75% of population) and M+N+ cells are the most common genotype (50% of popula-
tion). These antigens were an early discovery and are some of the oldest blood antigens known 
after the ABO system. 
They were first described by Karl Landsteiner and Philip Levine in 1927. Anti-M and anti-N 
antibodies are usually IgM and are rarely associated with transfusion reactions. Anti-N is 
sometimes seen in dialysis patients due to cross-reactions with the residual formaldehyde 
from sterilizing the dialysis equipment. This is usually irrelevant for transfusion since this 
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variant of the antibody does not react at body temperature. The S antigen is relatively com-
mon (55% of the population) and the s antigen is very common (89% of the population). 
Anti-S and anti-s can cause hemolytic transfusion reactions and HDFN. The U antigen is a 
high incidence antigen, occurring in more than 99.9% of the population. The U was origi-
nally referred to as “Universal”, though this is not the case. U negative RBCs can be found 
in people of African descent. This mutation in red cell surface structure also makes the 
RBCs S- and s-. Anti-U has been associated with both hemolytic transfusion reactions and 
hemolytic disease of the newborn. The other 41 identified antigens in the MNS group are 
low incidence.
They include the He (0.8% of the population) or high incidence, such as ENa (>99.9% of the 
population). All the antigens of the MNS blood group system are fairly frequent in the popu-
lation with the following overall frequencies:
• M = 78% 
• N = 72% 
• S = 55% 
• s = 89% 
• U = Greater than 99% 
U antigen is a high incident antigen NOT seen in individuals who lack both S and s antigens. 
Individuals who lack this antigen (<1%) have a high likelihood of forming anti-U as well as 
anti-S and anti-s. 
Biochemistry of the MNS antigens. The M and N antigens are glycoproteins containing sial-
ic acid that cross the cell membrane. Carboxyl terminus extends into the red cells interior, a 
hydrophobic segment as part cell membrane and an amino terminal segment on the external 
environment of the red cell. The external components of the antigens are destroyed by the 
enzymes like fiacin, typsin and papain. The antigens of the MNSU blood group system are 
well developed in newborns. Therefore a mother who is negative for one of these antigens 
could be stimulated to make antibodies that may cause HDN. The antibody would have to be 
an IgG immunoglobulin that reacts at 37°C).
MNS System Antibodies. Anti-M is frequently seen as a saline agglutinin if testing is done 
at room temperature. It is predominantly IgM and can be naturally occurring. It will show 
dosage and therefore M homozygous cells will react with antibody more strongly than 
heterozygous cells. Therefore the predominant form of the antibody is not clinically signifi-
cant. There are instances where some or the entire antibody is IgG in nature. If you have an 
anti-M that strongly at 37°C and/or AHG, it should be considered to be potentially clinically 
significant. Mild to severe cases of hemolytic disease of the new born have been reported. 
Since the M antigen can be removed by enzyme, the reactivity of anti-M can be destroyed 
by enzyme.






S-s-U- 0 Less than 1
Ethnic distribution of antigens of the MNS blood group system
When performing a crossmatch on a recipient’s specimen that contains anti-M, a pre-warmed 
crossmatch should be preformed. Anti-N is very rare and has similar reactivity as anti-M. 
Most often seen in kidney dialysis patients as cross-reacting antibody to formaldehyde. For
maldehyde is used to sterilize Dialysis equipment. Anti-S anti-s and anti-U usually form fol
lowing red cell immunization due to transfusions and pregnancies. 
They are usually IgG and react best after 37°C with AGT (Coombs) technique. All are capable 
of causing haemolytic transfusion reactions (HTR) (delayed) and Hemolytic Disease of the 
Newborn (HDN). S is usually destroyed by enzyme but s is variable and U is not destroyed 
by enzyme treatment. Anti-U is rare but should be considered if a previously transfused or 
pregnant Black patient has an antibody to a high-incident antigen
Immune/naturally occurring Naturally occurring Naturally occurring
Immunoglobulin class IgM and IgG IgM and IgG
Frequency of detection
Cold agglutinin but may react 
in IAT at 37°C. Not detectable 
with enzymes. Rxn enhanced at 
Cold agglutinin but may react in 
IAT at 37°C. Not detectable with 
enzymes
Unlikely to bind complement Unlikely to bind complement
Haemolytic transfusion reaction 
May cause HTR at 37°C May cause HTR at 37°C
Haemolytic disease of foetus 
and newborn
May cause HDFN May cause HDFN
Diferences between anti-M and N Properties of the MNS blood group system
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variant of the antibody does not react at body temperature. The S antigen is relatively com
mon (55% of the population) and the s antigen is very common (89% of the population). 
Anti-S and anti-s can cause hemolytic transfusion reactions and HDFN. The U antigen is a 
high incidence antigen, occurring in more than 99.9% of the population. The U was origi
nally referred to as “Universal”, though this is not the case. U negative RBCs can be found 
in people of African descent. This mutation in red cell surface structure also makes the 
RBCs S- and s-. Anti-U has been associated with both hemolytic transfusion reactions and 
hemolytic disease of the newborn. The other 41 identified antigens in the MNS group are 
low incidence.
They include the He (0.8% of the population) or high incidence, such as EN  (>99.9% of the 
population). All the antigens of the MNS blood group system are fairly frequent in the popu
lation with the following overall frequencies:
• M = 78% 
• N = 72% 
• S = 55% 
• s = 89% 
• U = Greater than 99% 
U antigen is a high incident antigen NOT seen in individuals who lack both S and s antigens. 
Individuals who lack this antigen (<1%) have a high likelihood of forming anti-U as well as 
anti-S and anti-s. 
 The M and N antigens are glycoproteins containing sial
ic acid that cross the cell membrane. Carboxyl terminus extends into the red cells interior, a 
hydrophobic segment as part cell membrane and an amino terminal segment on the external 
environment of the red cell. The external components of the antigens are destroyed by the 
enzymes like fiacin, typsin and papain. The antigens of the MNSU blood group system are 
well developed in newborns. Therefore a mother who is negative for one of these antigens 
could be stimulated to make antibodies that may cause HDN. The antibody would have to be 
an IgG immunoglobulin that reacts at 37°C).
. Anti-M is frequently seen as a saline agglutinin if testing is done 
at room temperature. It is predominantly IgM and can be naturally occurring. It will show 
dosage and therefore M homozygous cells will react with antibody more strongly than 
heterozygous cells. Therefore the predominant form of the antibody is not clinically signifi
cant. There are instances where some or the entire antibody is IgG in nature. If you have an 
anti-M that strongly at 37°C and/or AHG, it should be considered to be potentially clinically 
significant. Mild to severe cases of hemolytic disease of the new born have been reported. 
Since the M antigen can be removed by enzyme, the reactivity of anti-M can be destroyed 
by enzyme.










S-s-U- 0 Less than 1
Ethnic distribution of antigens of the MNS blood group system
When performing a crossmatch on a recipient’s specimen that contains anti-M, a pre-warmed 
crossmatch should be preformed. Anti-N is very rare and has similar reactivity as anti-M. 
Most often seen in kidney dialysis patients as cross-reacting antibody to formaldehyde. For-
maldehyde is used to sterilize Dialysis equipment. Anti-S anti-s and anti-U usually form fol-
lowing red cell immunization due to transfusions and pregnancies. 
They are usually IgG and react best after 37°C with AGT (Coombs) technique. All are capable 
of causing haemolytic transfusion reactions (HTR) (delayed) and Hemolytic Disease of the 
Newborn (HDN). S is usually destroyed by enzyme but s is variable and U is not destroyed 
by enzyme treatment. Anti-U is rare but should be considered if a previously transfused or 
pregnant Black patient has an antibody to a high-incident antigen
Characteristics Anti-M Anti-M
Immune/naturally occurring Naturally occurring Naturally occurring
Immunoglobulin class IgM and IgG IgM and IgG
Frequency of detection Fairly common Rare
Detection
Cold agglutinin but may react 
in IAT at 37°C. Not detectable 
with enzymes. Rxn enhanced at 
Ph <6.5
Cold agglutinin but may react in 
IAT at 37°C. Not detectable with 
enzymes
Ability to bind complement Unlikely to bind complement Unlikely to bind complement
Haemolytic transfusion reaction 
(HTR)
May cause HTR at 37°C May cause HTR at 37°C
Haemolytic disease of foetus 
and newborn
May cause HDFN May cause HDFN
Diferences between anti-M and N Properties of the MNS blood group system
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Characteristics Anti-S Anti-s
Immune/naturally occurring Immune Immune
Immunoglobulin class IgG and IgM IgG and IgM
Frequency of detection Rare Rare
Detection
May act as a cold agglutinin. Re-
act optimally in IAT at 37°C. Show 
variable reaction with enzymes
React optimally in IAT at 37°C.
Show variable reaction with 
enzymes
Ability to bind complement May bind complement May bind complement
Haemolytic transfusion reaction 
(HTR)
May cause HTR May cause HTR
Haemolytic disease of foetus 
and newborn
May cause mild to severe HDFN May cause mild to severe HDFN
Diferences between anti-M and N Properties of the MNS blood group system
26. Kell blood group system 
The Kell blood group system was first discovered in the serum of a number of mothers; Mrs Ka-
llacher in 1945 (K1), and Mrs Cellano(K2) who were believed to have babies with hemolytic disease 
of the newborn. One of the reactions was not due to Anti-D. “The non-Rh antigen involved in this 
case was that subsequently known as Kell. Thus at the very outset the test had detected a previously 
unknown blood group system which has since proved to be of some clinical importance. The K0 
phenotype was first described in 1957 and the McLeod phenotype was found in Hugh McLeod, a 
Harvard dental student, in 1961. The Kell antigen system (Kell-Cellano system) is a group of anti-
gens on the human red blood cell surface which are important determinants of blood type and are 
targets for autoimmune or alloimmune diseases which destroy red blood cells. Kell can be noted as 
K, k, or Kp. 
The Kell antigens are peptides found within the kell protein, a 93 kilodalton transmembrane zinc-
dependent endopeptidase which is responsible for cleaving endothelin-3. The KEL gene encodes a 
type II transmembrane glycoprotein that is the highly polymorphic Kell blood group antigen. The 
Kell glycoprotein links via a single disulfide bond to the XK membrane protein that carries the Kx 
antigen. There are several alleles of the gene which creates Kell protein. Two such alleles, K1 (Kell) 
and K2 (Cellano), are the most common. The kell protein is tightly bound to a second protein, XK, 
by a disulfide bond. Absence of the XK protein leads to marked reduction of the Kell antigens on 
the red blood cell surface. Absence of the Kell protein (K0), however, does not affect the XK protein. 
Kell antigens are important in transfusion medicine, autoimmune and hemolytic disease of the 
newborn (anti-Kell). Individuals lacking a specific Kell antigen may develop antibodies against 
Kell antigens when transfused with blood containing that antigen. Subsequent blood transfusions 
may be marked by destruction of the new cells by these antibodies (haemolysis). People without 
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Kell antigens (K0), must be transfused with blood from donors who are also K0 to prevent trans
fusion-related hemolysis of Kell positive red cells. Autoimmune hemolytic anemia (AIHA) occurs 
when the body produces an antibody against a blood group antigen on its own red blood cells. The 
antibodies lead to destruction of the red blood cells with resulting anemia. Similarly, a pregnant 
woman may develop antibodies against fetal red blood cells, resulting in destruction, anemia, and 
hydrops fetalis in a process known as HDN. 
Both AIHA and HDFN may be severe when caused by anti-Kell antibodies, as they are the most 
immunogenic antigens after thoseof the ABO and Rhesus blood group systems. McLeod pheno
type (or McLeod syndrome) is an X-linked anomaly of the Kell blood group system in which Kell 
antigens are poorly detected by laboratory tests. The McLeod gene encodes the XK protein, a pro
tein with structural characteristics of a membrane transport protein but an unknown function. The 
XK appears to be required for proper synthesis or presentation of the Kell antigens on the red blood 
ell surface. There are three pairs of alleles within the Kell system. Each pair has a high frequency 
and low frequency gene that is co-dominated if present. 
The three pairs are;
1. K (Kell), or K1, and k (Cellano), K2 
2. Kp  (K3) and Kpb (K4)(Penney) 
3. Js (K6)and Jsb (K7)(Sutter) 
K, Kp  and Js  are low frequency antigens and k, Kpb and Jsb are high frequency antigens. 
There is a Kell phenotype, K null (K  or K5), is very rare and K, k, Kp , Kpb, Js , Jsb antigens 
are not expressed. The Kell Systems antigens are found in only small amounts on the red cell 
carried on a single protein. K has approximately 3500 sites and k has between 2000-5000. The 









Ko [K-,k-,Kp(a-b-),Js(a-b-)] Extremely rare
Variation in the distribution of Kell phenotypes in different population groups
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Immune/naturally occurring Immune Immune
Immunoglobulin class IgG and IgM IgG and IgM
Frequency of detection
May act as a cold agglutinin. Re-
act optimally in IAT at 37°C. Show 
variable reaction with enzymes
React optimally in IAT at 37°C.
Show variable reaction with 
enzymes
Haemolytic transfusion reaction 
May cause HTR May cause HTR
Haemolytic disease of foetus 
and newborn
May cause mild to severe HDFN May cause mild to severe HDFN
Diferences between anti-M and N Properties of the MNS blood group system
The Kell blood group system was first discovered in the serum of a number of mothers; Mrs Ka
llacher in 1945 (K1), and Mrs Cellano(K2) who were believed to have babies with hemolytic disease 
of the newborn. One of the reactions was not due to Anti-D. “The non-Rh antigen involved in this 
case was that subsequently known as Kell. Thus at the very outset the test had detected a previously 
unknown blood group system which has since proved to be of some clinical importance. The K0
phenotype was first described in 1957 and the McLeod phenotype was found in Hugh McLeod, a 
Harvard dental student, in 1961. The Kell antigen system (Kell-Cellano system) is a group of anti
gens on the human red blood cell surface which are important determinants of blood type and are 
targets for autoimmune or alloimmune diseases which destroy red blood cells. Kell can be noted as 
K, k, or Kp.
The Kell antigens are peptides found within the kell protein, a 93 kilodalton transmembrane zinc-
dependent endopeptidase which is responsible for cleaving endothelin-3. The KEL gene encodes a 
type II transmembrane glycoprotein that is the highly polymorphic Kell blood group antigen. The 
Kell glycoprotein links via a single disulfide bond to the XK membrane protein that carries the Kx 
antigen. There are several alleles of the gene which creates Kell protein. Two such alleles, K1 (Kell) 
and K2 (Cellano), are the most common. The kell protein is tightly bound to a second protein, XK, 
by a disulfide bond. Absence of the XK protein leads to marked reduction of the Kell antigens on 
the red blood cell surface. Absence of the Kell protein (K0), however, does not affect the XK protein. 
Kell antigens are important in transfusion medicine, autoimmune and hemolytic disease of the 
newborn (anti-Kell). Individuals lacking a specific Kell antigen may develop antibodies against 
Kell antigens when transfused with blood containing that antigen. Subsequent blood transfusions 
may be marked by destruction of the new cells by these antibodies (haemolysis). People without 
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Kell antigens (K0), must be transfused with blood from donors who are also K0 to prevent trans-
fusion-related hemolysis of Kell positive red cells. Autoimmune hemolytic anemia (AIHA) occurs 
when the body produces an antibody against a blood group antigen on its own red blood cells. The 
antibodies lead to destruction of the red blood cells with resulting anemia. Similarly, a pregnant 
woman may develop antibodies against fetal red blood cells, resulting in destruction, anemia, and 
hydrops fetalis in a process known as HDN. 
Both AIHA and HDFN may be severe when caused by anti-Kell antibodies, as they are the most 
immunogenic antigens after thoseof the ABO and Rhesus blood group systems. McLeod pheno-
type (or McLeod syndrome) is an X-linked anomaly of the Kell blood group system in which Kell 
antigens are poorly detected by laboratory tests. The McLeod gene encodes the XK protein, a pro-
tein with structural characteristics of a membrane transport protein but an unknown function. The 
XK appears to be required for proper synthesis or presentation of the Kell antigens on the red blood 
ell surface. There are three pairs of alleles within the Kell system. Each pair has a high frequency 
and low frequency gene that is co-dominated if present. 
The three pairs are;
1. K (Kell), or K1, and k (Cellano), K2 
2. Kpa (K3) and Kpb (K4)(Penney) 
3. Jsa (K6)and Jsb (K7)(Sutter) 
K, Kpa and Jsa are low frequency antigens and k, Kpb and Jsb are high frequency antigens. 
There is a Kell phenotype, K null (K
o
 or K5), is very rare and K, k, Kpa, Kpb, Jsa, Jsb antigens 
are not expressed. The Kell Systems antigens are found in only small amounts on the red cell 
carried on a single protein. K has approximately 3500 sites and k has between 2000-5000. The 













Ko [K-,k-,Kp(a-b-),Js(a-b-)] Extremely rare
Variation in the distribution of Kell phenotypes in different population groups
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Kell System Antibodies. Anti-Kell is the most clinically significant antibody within this system. 
The Kell antigen is considered the next most antigenic after the D antigen of the Rh system. Indi-
viduals lacking the K antigen can make anti-Kell after only two exposures to Kell-positive blood. 
Because over 90% of the population are Kell negative it is not difficult to find donor blood that is 
compatible with the recipient. Antibodies to other antigens in Kell system are very rare. 
Antibody Characteristics of the antibodies to the Kell System 
1. IgG 
2. Cause HDN and HTR (delayed) 
3. React best in Coombs after 37oC incubation. Enzyme has no effect 
4. Does not show dosage (homozygous KK and heterozygous Kk cells react 













< RT* 37 AHG Enzymes
K Some Some Most No Some No Yes
Mild-
Severe
K Few Few Most No (Some) No Yes Mild
Kpa Some Some Most No (Some) No Yes Mild
Kpb Few Few Most No (Some) No Yes Mild
Jsa Few Few Most No (Some) No Yes Moderate
Jsb (No) (No) Most No (Some) No Yes Moderate
Properties of antibodies of the Kell blood group system
HT = Room Temperature
HTR = Haemolytic Transfusion Reaction
HDFN = Hemolytic Disease of the Foetus and Newborn
27. Duffy Blood Group System 
The Duffy antigen is located on the surface of red blood cells and is named after the patient 
in which it was discovered. The protein encoded by this gene is a glycosylated membrane 
protein and a non-specific receptor for several chemokines. The protein is also the receptor for 
the human malarial parasites Plasmodium vivax and Plasmodium knowlesi. Polymorphisms 
in this gene are the basis of the Duffy blood group system. It was noted in the 1920s that black 
Africans had some intrinsic resistance to infection with malaria but the basis for this remained 
unknown. The Duffy antigen gene was the fourth gene associated with the resistance after the 
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genes responsible for sickle cell anaemia, thalassemia and glucose-6-phosphate dehydroge
nase. In 1950 the Duffy antigen was discovered in a multiply transfused hemophiliac whose 
serum contained the first example of anti-Fya antibody. In 1951 the antibody to a second an
tigen, Fyb, was discovered in serum. Using these two antibodies three common phenotypes 
were defined: Fy(a+b+), Fy(a+b-), and Fy (a-b+). Several other types were later discovered 
bringing the current total up to six: Fya, Fyb, Fy3, Fy4, Fy5 and Fy6. Only Fya, Fyb and Fy3 are 
considered clinically important. Reactions to Fy5 have also rarely been reported. The Duffy 
antigen /chemokine receptor gene (gp-Fy; CD234) is located on the long arm of chromosome 
1 (1.q22-1.q23) and was cloned in 1993. The gene was first localised to chromosome 1 in 1968 
and was the first blood system antigen to be localised. It is a single copy gene spanning over 
1500 bases and is in two exons. It encodes a 336 amino acid acidic glycoprotein. 
The gene carries the antigenic determinants of the Duffy blood group system which consist of 
four codominant alleles—FY*A and FY*B—coding for the Fya and Fyb antigens respectively, 
FY*X and FY*Fy, five phenotypes (Fy-a, Fy-b, Fy-o, Fy-x and Fy-y) and five antigens. Fyx is a 
form of Fyb where the Fyb gene is poorly expressed. Fya and Fyb differ by in a single amino 
acid at position 42: glycine in Fya and aspartic acid in Fyb (G in Fya and A in Fyb at position 
125). A second mutation causing a Duffy negative phenotype is known: the responsible mu
tation is G -> A at position 298. The genetic basis for the Fy(a-b-) phenotype is a point muta
tion in the erythroid specific promoter (a T -> C mutation at position -33 in the GATA box). 
This mutation occurs in the Fyb allelle and has been designated Fyb  (erythroid silent). Two 
isotypes have been identified. The Fy-x allelle is characterized by a weak anti-Fyb reaction 
and appears to be the result of two separate transitions: Cytosine265Threonine (Arginine
89Cysteine) and Guanine298Adenosine (Alanine100Threonine). Another rare genotype is the 
FybWk. Most Duffy negative blacks carry a silent Fy-b allele with a single T to C substitution 
at nucleotide -46, impairing the promoter activity in erythroid cells by disrupting a binding 
site for the GATA1 erythroid transcription factor. The gene is still transcribed in non erythroid 
cells in the presence of this mutation. The Duffy negative phenotype occurs at low frequency 
among whites (3.5%) and is due to a third mutation that results in an unstable protein (Ar
g89Cys: C -> T at position 265). Differences in the racial distribution of the Duffy antigens 
were discovered in 1954, when it was found that the overwhelming majority of blacks had the 
erythrocyte phenotype Fy(a-b-): 68% in African Americans and 88-100% in African blacks (in
cluding more than 90% of West African blacks). This phenotype is exceedingly rare in whites. 
Because the Duffy antigenis uncommon in those of Black African descent, the presence of this 
antigen has been used to detect genetic admixture. Overall the frequencies of Fya and Fyb an
tigens in Caucasians are 66% and 83% respectively, in Asians 99% and 18.5% respectively and 
in blacks 10% and 23% respectively. The frequency of Fy3 is 100% Caucasians, 99.9% Asians 
and 32% Blacks. Phenotype fequencies are: Fy(a+b+): 49% Caucasians, 1% Blacks, 9% Chi
nese Fy(a-b+): 34% Caucasians, 22% Blacks, <1% Chinese Fy(a+b-): 17% Caucasians, 9% Blacks, 
91% Chinese. A Duffy negative blood recipient may have a transfusion reaction if the donor 
is Duffy positive. Since most Duffy-negative people are of African descent, blood donations 
from people of black African origin are important to transfusion banks. The Duffy antigens 
Fya and Fyb are a pair of co-dominant alleles found on chromosome 1. The phenotypes Fy 
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 Anti-Kell is the most clinically significant antibody within this system. 
The Kell antigen is considered the next most antigenic after the D antigen of the Rh system. Indi
viduals lacking the K antigen can make anti-Kell after only two exposures to Kell-positive blood. 
Because over 90% of the population are Kell negative it is not difficult to find donor blood that is 
compatible with the recipient. Antibodies to other antigens in Kell system are very rare. 
1. IgG 
2. Cause HDN and HTR (delayed) 
3. React best in Coombs after 37 C incubation. Enzyme has no effect 
4. Does not show dosage (homozygous KK and heterozygous Kk cells react 






Properties of antibodies of the Kell blood group system
HT = Room Temperature
HTR = Haemolytic Transfusion Reaction
HDFN = Hemolytic Disease of the Foetus and Newborn
27. Duffy Blood Group System 
The Duffy antigen is located on the surface of red blood cells and is named after the patient 
in which it was discovered. The protein encoded by this gene is a glycosylated membrane 
protein and a non-specific receptor for several chemokines. The protein is also the receptor for 
the human malarial parasites Plasmodium vivax and Plasmodium knowlesi. Polymorphisms 
in this gene are the basis of the Duffy blood group system. It was noted in the 1920s that black 
Africans had some intrinsic resistance to infection with malaria but the basis for this remained 
unknown. The Duffy antigen gene was the fourth gene associated with the resistance after the 
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genes responsible for sickle cell anaemia, thalassemia and glucose-6-phosphate dehydroge-
nase. In 1950 the Duffy antigen was discovered in a multiply transfused hemophiliac whose 
serum contained the first example of anti-Fya antibody. In 1951 the antibody to a second an-
tigen, Fyb, was discovered in serum. Using these two antibodies three common phenotypes 
were defined: Fy(a+b+), Fy(a+b-), and Fy (a-b+). Several other types were later discovered 
bringing the current total up to six: Fya, Fyb, Fy3, Fy4, Fy5 and Fy6. Only Fya, Fyb and Fy3 are 
considered clinically important. Reactions to Fy5 have also rarely been reported. The Duffy 
antigen /chemokine receptor gene (gp-Fy; CD234) is located on the long arm of chromosome 
1 (1.q22-1.q23) and was cloned in 1993. The gene was first localised to chromosome 1 in 1968 
and was the first blood system antigen to be localised. It is a single copy gene spanning over 
1500 bases and is in two exons. It encodes a 336 amino acid acidic glycoprotein. 
The gene carries the antigenic determinants of the Duffy blood group system which consist of 
four codominant alleles—FY*A and FY*B—coding for the Fya and Fyb antigens respectively, 
FY*X and FY*Fy, five phenotypes (Fy-a, Fy-b, Fy-o, Fy-x and Fy-y) and five antigens. Fyx is a 
form of Fyb where the Fyb gene is poorly expressed. Fya and Fyb differ by in a single amino 
acid at position 42: glycine in Fya and aspartic acid in Fyb (G in Fya and A in Fyb at position 
125). A second mutation causing a Duffy negative phenotype is known: the responsible mu-
tation is G -> A at position 298. The genetic basis for the Fy(a-b-) phenotype is a point muta-
tion in the erythroid specific promoter (a T -> C mutation at position -33 in the GATA box). 
This mutation occurs in the Fyb allelle and has been designated FybEs (erythroid silent). Two 
isotypes have been identified. The Fy-x allelle is characterized by a weak anti-Fyb reaction 
and appears to be the result of two separate transitions: Cytosine265Threonine (Arginine-
89Cysteine) and Guanine298Adenosine (Alanine100Threonine). Another rare genotype is the 
FybWk. Most Duffy negative blacks carry a silent Fy-b allele with a single T to C substitution 
at nucleotide -46, impairing the promoter activity in erythroid cells by disrupting a binding 
site for the GATA1 erythroid transcription factor. The gene is still transcribed in non erythroid 
cells in the presence of this mutation. The Duffy negative phenotype occurs at low frequency 
among whites (3.5%) and is due to a third mutation that results in an unstable protein (Ar-
g89Cys: C -> T at position 265). Differences in the racial distribution of the Duffy antigens 
were discovered in 1954, when it was found that the overwhelming majority of blacks had the 
erythrocyte phenotype Fy(a-b-): 68% in African Americans and 88-100% in African blacks (in-
cluding more than 90% of West African blacks). This phenotype is exceedingly rare in whites. 
Because the Duffy antigenis uncommon in those of Black African descent, the presence of this 
antigen has been used to detect genetic admixture. Overall the frequencies of Fya and Fyb an-
tigens in Caucasians are 66% and 83% respectively, in Asians 99% and 18.5% respectively and 
in blacks 10% and 23% respectively. The frequency of Fy3 is 100% Caucasians, 99.9% Asians 
and 32% Blacks. Phenotype fequencies are: Fy(a+b+): 49% Caucasians, 1% Blacks, 9% Chi-
nese Fy(a-b+): 34% Caucasians, 22% Blacks, <1% Chinese Fy(a+b-): 17% Caucasians, 9% Blacks, 
91% Chinese. A Duffy negative blood recipient may have a transfusion reaction if the donor 
is Duffy positive. Since most Duffy-negative people are of African descent, blood donations 
from people of black African origin are important to transfusion banks. The Duffy antigens 
Fya and Fyb are a pair of co-dominant alleles found on chromosome 1. The phenotypes Fy 
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(a-b+), Fy (a+b+), Fy(a-b+) are very common among the US white population. Fy (a-b-) is very 
rare in the white population but makes up 68% of the black population of the United States. 
Biochemically the Duffy antigens are glycoproteins that have an external loop. This external 
loop can be destroyed by enzymes such as ficin, papain, and trypsin. The Fya and Fyb anti-
gens are receptors for the malarial parasite, Plasmodium vivax. Therefore individuals that are 
phenotypically Fy(a-b-) have a resistance to malaria. This particular phenotype is found up to 







Fy(a-b-) Very rare 68
Phenotype and frequency of the Duffy blood group system
Properties of Duffy System Antibodies 
1. Duffy antibodies frequently seen in multiply-transfused Blacks. 
2. Anti-Fya much more common than anti-Fyb and is more likely to cause 
HTR and HDN. 
3. They are of the IgG immunoglobulin class 
4. Anti-Fya can cause HDN and HTR (delayed) and anti-Fyb is milder and no 
HDN cases have been reported but could possibly be a cause. 
5. React best in Coombs after 37oC incubation 




Bind Complement Hemolysis HTR HDN
< RT 37 AHG Enzymes
Fya Rare Rare Most Destroy Some No Yes Mild- Severe
Fyb Rare Rare Most Destroy Some No Yes (Yes)
Properties of antibodies of the Duffy blood group system
RT = Room Temperature
HTR = Hemolytic Transfusion Reaction
HDFN = HAemolytic Disease of the Foetus and Newborn
191Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
 (also known as ) is present on the membranes of red blood 
cells and the kidney and helps determine a person’s blood type. The Jk antigen is found on a pro
tein responsible for urea transport in the red blood cells and the kidney. The gene encoding this 
protein is found on chromosome 18. Two common Jk alleles are Jk(a) and Jk(b). Jk (a) was discov
ered by Allen et al in the year 1951. Whereas Jk (b) was discovered by Plant et al in 1953. Individuals 
who lack the Jk antigen (Jk null) are unable to maximally concentrate their urine. The Jk antigen is 
important in transfusion medicine. People with two Jk(a) antigens, for instance, may form antibod
ies against donated blood containing two Jk(b) antigens (and thus no Jk(a) antigens). This can lead 
to hemolytic anemia, in which the body destroys the transfused blood, leading to low red blood cell 
counts. Another disease associated with the Jk antigen is hemolytic disease of the newborn (HDN), 
in which a pregnant woman’s body creates antibodies against the blood of her fetus, leading to 
destruction of the fetal blood cells. HDN associated with Jk antibodies is typically mild, though 
fatal cases have been reported. Jk  and Jkb antigens are inherited on chromosome 18 where urea 
transport mechanisms are located. Cells that are Jk(a-b-) are less likely to to lyse in the presence of 
high concentration of urea. These antigens are inherited by the co-dominant alleles Jk  and Jkb that 
are high frequency antigens. The Kidd antigens are thought to be grouped very close together in 
clusters on the red cell membrane. Due to the close proximity of the antigens when the antibodies 
are attached complement can be activated. The activation of complement can cause intravascular 
transfusion reactions. Approximate frequencies among the white US population are the following; 
Jka = 75%, Jkb = 75% and approximately 50% of the white population is Jk  and Jkb positive. The 





Phenotype and frequency of the Kidd Blood Group System 
Both anti-JK  and anti-Jkb are hard to detect and identify since they are very weak and are detected 
primarily at the antiglobulin phase of testing. These antibodies are usually low titer as well as be
ing weak reactions. The antibodies disappear rapidly from circulation and also in stored serum 
since their recognition is enhanced if complement is present. These antibodies will often show 
dosage. Enzyme can enhance the reaction as well as PEG enhancement solution. Characteristics of 
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(a-b+), Fy (a+b+), Fy(a-b+) are very common among the US white population. Fy (a-b-) is very 
rare in the white population but makes up 68% of the black population of the United States. 
Biochemically the Duffy antigens are glycoproteins that have an external loop. This external 
loop can be destroyed by enzymes such as ficin, papain, and trypsin. The Fya and Fyb anti
gens are receptors for the malarial parasite,  Therefore individuals that are 
phenotypically Fy(a-b-) have a resistance to malaria. This particular phenotype is found up to 





Phenotype and frequency of the Duffy blood group system
Properties of Duffy System Antibodies 
1. Duffy antibodies frequently seen in multiply-transfused Blacks. 
2. Anti-Fy  much more common than anti-Fyb and is more likely to cause 
HTR and HDN. 
3. They are of the IgG immunoglobulin class 
4. Anti-Fy  can cause HDN and HTR (delayed) and anti-Fyb is milder and no 
HDN cases have been reported but could possibly be a cause. 
5. React best in Coombs after 37 C incubation 
6. Reactions destroyed by enzyme of the red cells 
Mild- Severe
Properties of antibodies of the Duffy blood group system
RT = Room Temperature
HTR = Hemolytic Transfusion Reaction
HDFN = HAemolytic Disease of the Foetus and Newborn
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28. Kidd Blood Group System
The Kidd antigen system (also known as Jk antigen) is present on the membranes of red blood 
cells and the kidney and helps determine a person’s blood type. The Jk antigen is found on a pro-
tein responsible for urea transport in the red blood cells and the kidney. The gene encoding this 
protein is found on chromosome 18. Two common Jk alleles are Jk(a) and Jk(b). Jk (a) was discov-
ered by Allen et al in the year 1951. Whereas Jk (b) was discovered by Plant et al in 1953. Individuals 
who lack the Jk antigen (Jk null) are unable to maximally concentrate their urine. The Jk antigen is 
important in transfusion medicine. People with two Jk(a) antigens, for instance, may form antibod-
ies against donated blood containing two Jk(b) antigens (and thus no Jk(a) antigens). This can lead 
to hemolytic anemia, in which the body destroys the transfused blood, leading to low red blood cell 
counts. Another disease associated with the Jk antigen is hemolytic disease of the newborn (HDN), 
in which a pregnant woman’s body creates antibodies against the blood of her fetus, leading to 
destruction of the fetal blood cells. HDN associated with Jk antibodies is typically mild, though 
fatal cases have been reported. Jka and Jkb antigens are inherited on chromosome 18 where urea 
transport mechanisms are located. Cells that are Jk(a-b-) are less likely to to lyse in the presence of 
high concentration of urea. These antigens are inherited by the co-dominant alleles Jka and Jkb that 
are high frequency antigens. The Kidd antigens are thought to be grouped very close together in 
clusters on the red cell membrane. Due to the close proximity of the antigens when the antibodies 
are attached complement can be activated. The activation of complement can cause intravascular 
transfusion reactions. Approximate frequencies among the white US population are the following; 
Jka = 75%, Jkb = 75% and approximately 50% of the white population is Jka and Jkb positive. The 








Phenotype and frequency of the Kidd Blood Group System 
Kidd System Antibodies 
Both anti-JKa and anti-Jkb are hard to detect and identify since they are very weak and are detected 
primarily at the antiglobulin phase of testing. These antibodies are usually low titer as well as be-
ing weak reactions. The antibodies disappear rapidly from circulation and also in stored serum 
since their recognition is enhanced if complement is present. These antibodies will often show 
dosage. Enzyme can enhance the reaction as well as PEG enhancement solution. Characteristics of 
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anti-Jka and anti-Jkb are as follows; They are of the immunoglobulin class IgG. React best after 37°C 
with Coombs technique. Can cause HDFN. Can cause Hemolytic Transfusion reactions that are 
acute intravascular reactions, or they may be delayed transfusion reactions that show up after the 
patient’s immune system is re-exposed and the memory cells quickly produce antibodies to the an-
tigens. While most of the antibodies discussed in newsletter are more likely to cause extravascular 
hemolytic transfusion reactions, the Kidd antibodies can activate complement and therefore cause 




Bind Complement Hemolysis HTR HDFN
< RT 37 AHG Enzymes
Jka Few Few Most Enhance All Some Yes Mild
Jkb Few Few Most Enhance All Some Yes Mild
Characteristics of the Kidd Blood Group antibody
RT = Room Temperature
HTR = Hemolytic Transfusion Reaction
HDFN = HAemolytic Disease of the Foetus and Newborn
29. Bg Antibodies 
The Bg antibodies were first described by Bennett and Goodspeed. They are not considered 
clinically significant, but may mask clinically significant antibodies. They are antibodies to 
white cell antigen remnants on red cells. Anti-Bga reacts with Human Leukocyte Antigen 
(HLA)-B7. Anti-Bgb reacts with Human Leukocyte Antigen (HLA)-B17. Anti-Bgc reacts with 
Human Leukocyte Antigen (HLA)-A28. Reactions relating to these antibodies are weak, react 
possibly at room temperature or more commonly in the antiglobulin (Coombs) phase. They 
react with only a few cells in a cell panel.
They do not cause hemolytic disease of the newborn or hemolytic transfusion reactions. 
They are seen frequently seen in multiply transfused patients or in multiparous women 
(multiple pregnancies). 
HTLA Antibodies (High Titer Low Avidity antibodies)
High Titer Low Avidity antibodies are not clinically significant, but serological reactions make 
them look like they are High Titer if the antibodies are titered. The titers are usually at least 
1:64 and often will be over 1:1000. Reactions are very weak and will break apart very readily 
due to the weak attraction between the antigens and antibodies (low avidity). These antibod-
ies basically have a high titer but a very weak reaction. Some institutions actually score the 
strength of the antigen reaction in points which will allow them to differentiate some of the 
differences seen in various reactions. 
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Score = strength of reaction given points or score ; 4+ (12 points), 3+(10 points), 2+ ( 8 points), 
1+(5 points) and negative ( 0 points). Specific serologic characteristics of the HTLA antibodies 
are; IgG, react best in Coombs after 37°C incubation, react with most cells (antibodies to high-
frequency antigens), not clinically significant since they are not known to cause hemolytic 
disease of the newborn or haemolytic transfusion reactions. Since they are antibodies to high-
frequency antigens they may mask clinically significant antibodies that are also in the serum. 
 The I antigen is found on almost all adults and is part of the precursor 
component of the oligosaccharide that forms the A, B, and H antigens. There are two types of 
oligosaccharides: type 1 and type 2. These chains that are part of the ABH antigens form the 
I antigen found in infants. All cord bloods form i antigen from straight-line sugar chains on 
precursor substance of the A, B, and H antigens. As indicated: in most children i is converted 
to I by the age of 2 years. 
Anti-I, Anti-IH, and Anti-i Antibodies. Anti-I antibodies are the most common antibodies found 
if antibody screenings are done at immediate spin, room temperature. Their are IgM immu
noglobulins and therefore are saline agglutinins with their optimal temperature at 4°C. Since they 
are IgM they also do not cross the placenta. Anti-I is naturally occurring often due to a Myco
plasma pneumoniae infection or some lymphomas and leukemias. These antibodies are usually 
not clinically significant Anti-I reacts with all adult cells (including patient’s own, all reagent cells, 
all donor cells). Anti-I does not react with cord cells. Auto-anti-I is a common cold agglutinin. 
In ABO typing, the forward grouping may have patient cells coated with IgM autoantibody, 
so all cells agglutinate. When this happens all results are positive and the group looks like 
AB+. On the reverse grouping anti-I in serum reacts with all adult cells, so A1 and B cells al
ways agglutinate. All results are positive and the group looks like an O.
Unknown ABO Group
1. Correct forward typing by washing cells in warm saline and re-testing.
2. Correct reverse by warming the serum before testing, or adsorbing the 
cold autoantibody out of the serum. 
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anti-Jk  and anti-Jkb are as follows; They are of the immunoglobulin class IgG. React best after 37°C 
with Coombs technique. Can cause HDFN. Can cause Hemolytic Transfusion reactions that are 
acute intravascular reactions, or they may be delayed transfusion reactions that show up after the 
patient’s immune system is re-exposed and the memory cells quickly produce antibodies to the an
tigens. While most of the antibodies discussed in newsletter are more likely to cause extravascular 
hemolytic transfusion reactions, the Kidd antibodies can activate complement and therefore cause 
intravascular hemolytic transfusion reactions. 
Jka Few Few
Jkb Few Few
Characteristics of the Kidd Blood Group antibody
RT = Room Temperature
HTR = Hemolytic Transfusion Reaction
HDFN = HAemolytic Disease of the Foetus and Newborn
The Bg antibodies were first described by Bennett and Goodspeed. They are not considered 
clinically significant, but may mask clinically significant antibodies. They are antibodies to 
white cell antigen remnants on red cells. Anti-Bg  reacts with Human Leukocyte Antigen 
(HLA)-B7. Anti-Bgb reacts with Human Leukocyte Antigen (HLA)-B17. Anti-Bgc reacts with 
Human Leukocyte Antigen (HLA)-A28. Reactions relating to these antibodies are weak, react 
possibly at room temperature or more commonly in the antiglobulin (Coombs) phase. They 
react with only a few cells in a cell panel.
They do not cause hemolytic disease of the newborn or hemolytic transfusion reactions. 
They are seen frequently seen in multiply transfused patients or in multiparous women 
(multiple pregnancies). 
HTLA Antibodies (High Titer Low Avidity antibodies)
High Titer Low Avidity antibodies are not clinically significant, but serological reactions make 
them look like they are High Titer if the antibodies are titered. The titers are usually at least 
1:64 and often will be over 1:1000. Reactions are very weak and will break apart very readily 
due to the weak attraction between the antigens and antibodies (low avidity). These antibod
ies basically have a high titer but a very weak reaction. Some institutions actually score the 
strength of the antigen reaction in points which will allow them to differentiate some of the 
differences seen in various reactions. 
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Score = strength of reaction given points or score ; 4+ (12 points), 3+(10 points), 2+ ( 8 points), 
1+(5 points) and negative ( 0 points). Specific serologic characteristics of the HTLA antibodies 
are; IgG, react best in Coombs after 37°C incubation, react with most cells (antibodies to high-
frequency antigens), not clinically significant since they are not known to cause hemolytic 
disease of the newborn or haemolytic transfusion reactions. Since they are antibodies to high-
frequency antigens they may mask clinically significant antibodies that are also in the serum. 
30. I Blood Group Systems
I Blood Group System. The I antigen is found on almost all adults and is part of the precursor 
component of the oligosaccharide that forms the A, B, and H antigens. There are two types of 
oligosaccharides: type 1 and type 2. These chains that are part of the ABH antigens form the 
I antigen found in infants. All cord bloods form i antigen from straight-line sugar chains on 
precursor substance of the A, B, and H antigens. As indicated: in most children i is converted 
to I by the age of 2 years. 
Anti-I, Anti-IH, and Anti-i Antibodies. Anti-I antibodies are the most common antibodies found 
if antibody screenings are done at immediate spin, room temperature. Their are IgM immu-
noglobulins and therefore are saline agglutinins with their optimal temperature at 4°C. Since they 
are IgM they also do not cross the placenta. Anti-I is naturally occurring often due to a Myco-
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not clinically significant Anti-I reacts with all adult cells (including patient’s own, all reagent cells, 
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4+ 4+ 4+ 4+ 4+ 4+ 4+ Unknown ABO Group
Method to resolve these Problems
1. Correct forward typing by washing cells in warm saline and re-testing.
2. Correct reverse by warming the serum before testing, or adsorbing the 
cold autoantibody out of the serum. 
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3. Crossmatch results will indicate that all donors are incompatible. This 
anomaly can be correct by:
4. Warming the donor cells and patient’s serum before crossmatching, 
5. Omitting potentiators like LISS 
6. Using monospecific anti-IgG. Anti-IH antibodies directed against both I 
antigens and H antigens.
7. Therefore they react most strongly with group O adult cells, least with 
cord cells or A1 cells. 
Antibody Adult A Cells Adult O Cells Cord A Cells Cord O Cells
Anti-I 2+ 2+ 0 0
Anti-IH 2+ 4+ 0 2+
Anti-H 0 2+ 0 2+
Anti-i 0 0 2+ 2+
Table : Comparison of Anti-I, Anti-IH, and Anti-H Reactions
Anti-IH is seen most often in A1 adults and is not clinically significant but may cause problems with 
the ABO grouping and crossmatch results just as anti-I does. Follow the same steps for resolving the 
problem as indicated for anti-I.
Disease predisposition
Anti-I and anti-IH are only clinically significant when they cause Cold Hemagglutinin Disease 
(CHD). In this disease a strong autoanti-I is present. The blood in patient toes, fingertips, ear-
lobes is cooler than than 37°C and the antibody coats cooled cells, binds complement, and caus-
es hemolysis. This disease is treated by keeping the patient’s extremities warm so the blood is 
not allowed to cool. High-titer anti-I also commonly associated with Mycoplasma. Pneumoniae 
infections. Treatment would be giving the patient appropriate antibiotics. Anti-i, which is fairly 
uncommon and transient, is associated with infectious mononucleosis. 
31. P Blood Group System
Antigens of the P system include; Pk, P and P1. Basic structure is the precursor substance, 
but is called globoside (P) or paragloboside (p) in the P system. P antigens are poorly devel-
oped at birth and therefore do not usually cause Hemolytic Disease of the newborn. They 
are present in variable amounts on different red cells and seem to diminish in storage. Like 
ABO and Ii antigens; they are composed of sugar chains. Like A and B antigens, they are 
present on tissue cells as well as red cells. Similar antigens found in nature (bird droppings, 
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pigeon eggs, hydatid cyst fluid) and these substances can be used to neutralize anti-P in a 
patient’s serum. These similar antigen solutions can be useful when the antibody is inter
fering with ABO and crossmatch testing. The Pk antigen occurs when the Pk antigen does 
not convert to P. 80% of people with P antigen are P1 phenotype (have P and P1 antigens) 
and 20% of people with P antigen are P2 (P antigen only - no P1). The P2 phenotype merely 
signifies absence of P1 antigen in people with P antigen (globoside). Individuals who are Pk 
consistantly have an alloanti-P that is an IgM antibody. The absence of the P antigen is very 
rare and is designated as p. 
Alloanti-P1 is the most common of the antibodies in the P system. This antibody is commonly seen 
in P2 people. Alloanti-P1’s characteristics includes; IgM class and therefore is saline reactive, en
hanced by cold incubation, may bind complement. Not clinically significant naturally occurring 
but not regularly occurring. It is formed with no known red blood cell stimulus - either pregnancy 
or transfusion.  If individuals are P1 negative, they do not automatically have anti-P1 i, but it is 
fairly common. Antigen-antibody reactions in P system enhanced by adding albumin to system, 
or by treating red cells with enzymes. Auto anti-P is an IgG antibody seen in P1 or P2 persons and 
causes clinically significant Paroxysmal Cold Hemoglobinuria (PCH). The Donath-Landsteiner 
Test helps diagnose PCH. It is designed to detect biphasic anti-P. A biphasic antibody reacts with 
the antigen on the red blood cell at colder temperature, binding complement. When antigen-an
tibody-complement complex warms up, the red blood cells are hemolyzed. Donath-Lansteiner 
test is performed by incubating patient’s serum with his own cells first at 4°C, then at 37°C, and 
then looking for hemolysis. A positive Donath-Landsteiner = no hemolysis at 4°C, no hemolysis 
at 37°C, hemolysis only in the tube that was incubated at both temperatures. A negative Donath-
Landsteiner = Negative at both temperatures or hemolysis at 4°C as well as 37°C 
4°C incubation: 
No hemolysis = Negative
37°C incubation:
No hemolysis = Negative
4°C + 37°C incubation:
hemolysis: = POSITIVE
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not allowed to cool. High-titer anti-I also commonly associated with Mycoplasma. Pneumoniae 
infections. Treatment would be giving the patient appropriate antibiotics. Anti-i, which is fairly 
uncommon and transient, is associated with infectious mononucleosis. 
Antigens of the P system include; Pk, P and P1. Basic structure is the precursor substance, 
but is called globoside (P) or paragloboside (p) in the P system. P antigens are poorly devel
oped at birth and therefore do not usually cause Hemolytic Disease of the newborn. They 
are present in variable amounts on different red cells and seem to diminish in storage. Like 
ABO and Ii antigens; they are composed of sugar chains. Like A and B antigens, they are 
present on tissue cells as well as red cells. Similar antigens found in nature (bird droppings, 
195Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
pigeon eggs, hydatid cyst fluid) and these substances can be used to neutralize anti-P in a 
patient’s serum. These similar antigen solutions can be useful when the antibody is inter-
fering with ABO and crossmatch testing. The Pk antigen occurs when the Pk antigen does 
not convert to P. 80% of people with P antigen are P1 phenotype (have P and P1 antigens) 
and 20% of people with P antigen are P2 (P antigen only - no P1). The P2 phenotype merely 
signifies absence of P1 antigen in people with P antigen (globoside). Individuals who are Pk 
consistantly have an alloanti-P that is an IgM antibody. The absence of the P antigen is very 
rare and is designated as p. 
P- antibodies 
Alloanti-P1 is the most common of the antibodies in the P system. This antibody is commonly seen 
in P2 people. Alloanti-P1’s characteristics includes; IgM class and therefore is saline reactive, en-
hanced by cold incubation, may bind complement. Not clinically significant naturally occurring 
but not regularly occurring. It is formed with no known red blood cell stimulus - either pregnancy 
or transfusion.  If individuals are P1 negative, they do not automatically have anti-P1 i, but it is 
fairly common. Antigen-antibody reactions in P system enhanced by adding albumin to system, 
or by treating red cells with enzymes. Auto anti-P is an IgG antibody seen in P1 or P2 persons and 
causes clinically significant Paroxysmal Cold Hemoglobinuria (PCH). The Donath-Landsteiner 
Test helps diagnose PCH. It is designed to detect biphasic anti-P. A biphasic antibody reacts with 
the antigen on the red blood cell at colder temperature, binding complement. When antigen-an-
tibody-complement complex warms up, the red blood cells are hemolyzed. Donath-Lansteiner 
test is performed by incubating patient’s serum with his own cells first at 4°C, then at 37°C, and 
then looking for hemolysis. A positive Donath-Landsteiner = no hemolysis at 4°C, no hemolysis 
at 37°C, hemolysis only in the tube that was incubated at both temperatures. A negative Donath-
Landsteiner = Negative at both temperatures or hemolysis at 4°C as well as 37°C 
Donath-Landsteiner Test 
4°C incubation:  
No hemolysis = Negative
37°C incubation: 
No hemolysis = Negative
4°C + 37°C incubation: 
hemolysis: = POSITIVE
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32. Lutheran Blood Group System
Lutheran antigen system is a human blood group system based upon genes on chromosome 19. 
This system is a single locus system, with antigens Lua and Lub. The Lu (b) negative phenotype is 
very rare. Antibodies to Lutheran antigens are IgG. The genes of the Lutheran group are linked to 
the genes responsible for the secretion of ABH substances. Lutheran blood group system, classifica-
tion of human blood based on the presence of substances called Lutheran antigens on the surfaces of 
red blood cells. There are 19 known Lutheran antigens, all of which arise from variations in a gene 
called BCAM (basal cell adhesion molecule). The system is based on the expression of two codomi-
nant alleles, designated Lua and Lub. The antigens Aua and Aub, known as the Auberger antigens, 
were once thought to make up a separate blood group but were later shown to be Lutheran antigens 
arising from variations in the BCAM gene. The phenotypes Lu(a+b−) and Lu(a+b+) are found at 
various frequencies within populations. The Lu(a−b+) phenotype is the most common in all popula-
tions, whereas the Lu(a−b−) phenotype is extremely uncommon. Though present in the fetus, Lua is 
seldom the cause of erythroblastosis fetalis or of transfusion reactions. Lutheran antigens are weakly 
expressed on cord red cells. They are destroyed by enzyme treatment (papain and trypsin). They 
are thought to play a role in red cell adhesion. The Luthran null phenotype Lu(a-b-) which occur 
from either recessive or dorminant genetic background. The incidence of The Luthran null (Lunull) 
phenotype is rare (0.02% in the UK). Lutheran antibody Anti-Lua and Anti-Lub are rarely found 
in serum. They are often found in the serum of patients who have developed other alloantibodies. 
Anti-Lua is not a clinically significant antibody. It is an IgM antibody and react optimally in saline 
at 4-20°C and seldom react at warm temperature of 37°C. Anti-Lub is an IgG antibody and reacts 
optimally at a warm temperature of 37°C and show variable clinical significance.
33. Minor Blood Group systems
There are other minor less clinically significant but important blood group system. Their fre-
quency varies from one ethnic group to the other. Their occurrence is low in certain popula-
tion and is virtually restricted to specific ethnic groups. Information on patient ethnic group 
often plays a role in identification. These minor antigens are often not Included in antibody 
screening and identification panels. Samples in which antibody to these system is suspected 
should be referred to the reference laboratory. Antibodies to these systems are often seen in 
patients that have developed other clinically significant antibodies.
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Antibody reaction pattern of the clinically significant blood group systems.
 Some individuals produce antibodies to a low incidence (1% of population 
and not part of an established blood group system) antigen (private antigens). These antigens 
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System Antibody Origin Ig class
Medium of reactivity
Sal 200C Sal 370C AHG 370C Enz 370C
ABO
Anti-A NO/I IgM Y Y Y Y
Anti-B NO/I IgM Y Y Y Y
Anti-A,B NO/I IgM(G) Y Y Y Y
Anti-A1 NI/I IgM(G) Y R R R
Rh 
Anti-D I IgG/M Rare Some Y Y
Anti-C I IgG/M Rare Some Y Y
Anti-c I IgG Rare Rare Y Y
Anti-E NO/I IgG/M Some Some Y Y
Anti-e I IgG Rare Rare Y Y
MNS
Anti-M NO/I IgM Y Rare Some N
Anti-N NO/I IgM Y Rare Rare N
Anti-S I IgG Rare Rare Y N
Anti –s I IgG Rare Rare Y N
P Anti-P1 NO/I IgM Y Rare Rare Some
Kell
Anti-K I IgG Rare Some Y Some
Anti-k I IgG Rare Rare Y Some
Duffy
Anti-Fya I IgG Rare Rare Y N
Anti-Fyb I IgG Rare Rare Y N
Kidd
Anti-Jka I IgG Rare Rare Y Some
Anti-Jkb I IgG Rare Rare Y Some
Lewis
Anti-Lea NO/I IgM/G Y Y Y Y
Anti-Leb NO/I IgM/G Y Y Y Y
Lutheran
Anti-Lua NO/I IgM/G Y Rare Some Some
Anti-Lub NO/I IgM/G Rare Rare Y Some
Antibody reaction pattern of the clinically significant blood group systems.
Private antigens. Some individuals produce antibodies to a low incidence (1% of population 
and not part of an established blood group system) antigen (private antigens). These antigens 
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are not clinically significant, rare, not included in antibody screening cells as well as antigen 
panels for antibody identification. They are often detected by chance during a crossmatch and 
in HDFN investigation and are often referred to the reference laboratory for identification. 
Examples of private antigens includes; Swa, Wu and Pta.
Public antigen. Private antigens are antigens that are found which are present in red cells of a 
vast majority of the population (>99%) and do not form part of any blood group system. Indi-
viduals with antibodies to these antigens are likely to react with all red cells included in anti-
body detection and identification panels. DAT and auto control in these individuals are often 
negative-an indication that the reaction is caused by an alloantibody rather than an autoanti-
body. Some antibodies to high frequency antigens are clinically significant and can cause HDFN 
and HTR. Examples of public antigens are; Vel, Lan, Jra, Oka. It is often difficult to get antigen 
negative red cells for these individuals. Some countries may hold blood of these rare pheno-
type in their frozen bank. Anti-Fy3, anti-U and anti-Jsb are common in Africans due to a large 
number of Africans having the rare Fy(a-b-), U and Js (a+b-) phenotypes while the anti-Jra and 
anti-Inb are frequent among Asian population due to Asian people having the rare Jr(a-) and 
In(a+b-) phenotype.
High titre low affinity antibodies (HTLA). High titre low affinity antibodies although not 
clinically significant and cause no red cell destruction, their identification can be quiet chal-
lenging. Examples are Kna (Knops). Antibodies to high frequency antigens (Chido/Rodgers) 
are directed to complement protein C4 which is commonly seen in varying amount on some 
red cells. These antibodies reacts with some red cells and not at all with others.
34. Complement 
Complement helps fight off bacterial and viral infections, eliminates protein complexes, and 
helps in the immune response complex. The three major roles of complement are; promot-
ing acute inflammation process that allow white cells and macrophages to migrate to the 
source of the problem, altering the cell surfaces to encourage phagocytosis (opsonization) 
and modifying the cell surface that will eventually lead to cell lysis. Complement is a series 
of proteins found in fresh, normal serum. It is in the beta region on protein electrophoresis 
and is categorized as a beta globulin. The complement component that is found in the highest 
concentration is C3. Terminology commonly used for the various complement components: 
1. Complement components are identified by C and their number: C1, C2, 
C3 etc 
2. Complement products resulting from the splitting of these proteins during 
the activation process are followed by a lower case letter: C3a, C3b, C1q 
Characteristics of Complement: Complement cause cell destruction through lysis, can cause 
cell destruction through opsonization (enhanced phagocytosis) especially with C3b as well as 
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chemotaxis via certain split products acting as chemical signals to the phagocytic cells. Ana
phylaxis can also occur through the split products (C5a and C3a), which promote inflamma
tion. C5a and C3a can bind with mast cells and basophils leading to the release of histamine. 
This is turn results in; increases vascular permeability, smooth muscle contraction to preserve 
blood for vital organs and increases cellular membrane adhersion. Complement is normally 
inactive in serum or if activated the activation pathways are inhibited by control mechanisms 
of other complement proteins. It becomes activated by; antigen-antibody reactions - most 
often IgM (classical pathway) and bacterial polysaccharides, virus particles, enzymes, endo
toxins (alternate and lectin pathway). 
Complement Cascade - (Classical Pathway). The complement cascade is made up of 9 pro
tein molecules (C1-C9). These proteins act sequentially. Each protein once activated is able 
to activate others. The classic complement cascade is activated once one IgM (IgM molecule 
since it has 5 immunoglobulin subunits) or 2 IgG (certain IgG molecues are capable of binding 
with complement includes; IgG 1, 2, or 3) molecule attaches to the red cell membrane. Com
plement needs 2 IgG molecules bound to antigen sites that are within 30-40 nm of each other. 
The sequence of reaction is (C1- C4- C2- C3- C5- C6- C7- C8- C9). If the complement activation 
proceeds to completion, channels are formed through the red cell membrane at the site of the 
complement activation resulting in the flow of fluid (water) into the red cells and results in 
lysis (rupture) of the red cells.
The steps of the classical pathway 
1. Antigen-Antibody reaction occurs 
2. Complement senses adjacent Fc receptors 
3. Complement is activated and forms C1qrs complex 
4. C1qrs activates C4 
5. Activated C4 breaks down to C4a and C4b 
6. C4b activates C2 to form C4b2a complex 
7. C4b2a complex is also known as C3 convertase 
8. In presence of Ca+, C4b2a activates C3 
9. Activated C3 breaks down to C3a and C3b 
10. C3b attaches to RBC membrane and is sensed by Reticulo Endothelial 
(RE) system and removed from circulation. 
11. Activated C3a activates many C5 molecules that lead to the development 
of the Membrane Attack Complex. 
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of other complement proteins. It becomes activated by; antigen-antibody reactions - most 
often IgM (classical pathway) and bacterial polysaccharides, virus particles, enzymes, endo-
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Complement Cascade - (Classical Pathway). The complement cascade is made up of 9 pro-
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to activate others. The classic complement cascade is activated once one IgM (IgM molecule 
since it has 5 immunoglobulin subunits) or 2 IgG (certain IgG molecues are capable of binding 
with complement includes; IgG 1, 2, or 3) molecule attaches to the red cell membrane. Com-
plement needs 2 IgG molecules bound to antigen sites that are within 30-40 nm of each other. 
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lysis (rupture) of the red cells.
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5. Activated C4 breaks down to C4a and C4b 
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7. C4b2a complex is also known as C3 convertase 
8. In presence of Ca+, C4b2a activates C3 
9. Activated C3 breaks down to C3a and C3b 
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12. Each activated C5 activates many more C6 and C7 molecules 
13. C6 and C7 conversion proceed rapidly to C8 and C9 activation 
14. Activated C8 activates many more C9 molecules 
15. Activated C9 attacks red cell membrane, boring holes in it.
16. Contents of red cell leak out into plasma leading to intravascular hemo-
lysis. As the complement cascade results in biologic side-effects such as 
chemotaxis, opsonization, and anaphylaxis.
Phases of the classical complement pathway 
Activation phase: This phase involves the activity of complement component C1 following the for-
mation of an antigen-antibody complex and the subsequent activation of component C2 and C4. 
Complement component C1 is made up of 3 subunits (C1q, C1r and C1s). C1 is activated following 
an antigen-antibody reaction in the presence of free calcium ions. The use of EDTA and citrated 
plasma disrupt the activity of C1 and inhibit complement activation. The C1q portion of the C1 
molecule is made up of 6 immunoglobulin-binding sites. This facilitate the interaction between the 
C1 molecule and the CH2 domain of the Fc portion of the IgG (1 ansd 3 ) as well as the IgM-antigen 
bound immunoglobulin. Binding of two Fc portion of the IgG (within <40nm of each other) or a 
single IgM molecule (have 5 Fc binding sites) to the red cell membrane activates C1q. The binding of 
C1q with the Fc portion of two IgG or one IgM bound to the red cell membrane activated C1. Actic-
vated C1 acts on C4 and C2 molecules. This results in the cleavage of C4 into two component (C4a 
and C4b). While the C4a is release into the fluid phase, the C4b covalently bind to the Fc region of 
the red cell bound immunoglobulin. The activation of C1 also result in the cleavage of C2 molecule 
into C2a and C2b. While C2a is released into the fluid state, the C2b in the presence of calcium ions 
bind to C4b to form the C4b2b complex (C3 convertase). The activity of C4 and C2 can be inhibited 
by either the C1 inhibitor (C1 INH) or by the short half life of C2b molecule.
Amplification phase: The amplication phase involves the activation of C3 by the C1 activated 
C4B2b complex (convertase). This results in the cleavage of C3 into C3a and C3b. The C3a is 
released into the fluid state acting as anaphylatoxin and causes increased vascular permeability. 
The C3b binds unto the C4b2b to form C4b2b3b complex. The binding of C3b on the red cell 
membrane facilitates immune adherence and promotes the binding of such C3b bound red cells 
to C3b receptor site of macrophages. This results in the sequesteration of such C3b bound red 
cells by macrophages in the spleen or liver. A positive reaction with and C3d AHG reagent in a 
positive DAT test is a sign that complement activation has taken place in the patient circulation. 
The amplification phase of complement activation can be inactivated bythe activity of C3b and /
or C4b inactivator proteins (C3Bina AND C4bINA). The complement cascade frequently stops at 
the C3B stage.
Membrane attack phase: This involves the activation of C5 by C4b2b3b complex and subsequent 
activation of C6, C7, C8 and C9. This activation results in the cleavage of C5 into C5a and C5b. The 
C5a is released into the fluid state where it acts as an analphylatoxin and increases red cell perme-
ability. The C5b binds to C6 and C7 to form a tri-molecular complex which is firmly inserted into 
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the red cell membrane. C8 and C9 are the bound to the C5b67 complex in a circular fashion and 
produces a membrane lesion or hole of about 10nm diameter. This facilitates the flow of ions and 
water across the red cell membrane resulting in the loss of the osmotic gradient and red cell lysis
Facors affecting the clinical significance of an antibody. Not all red cell alloantibodies are 
capable of activating complements and causing red cell destruction invivo. The red cell de
struction potential of an antibody depends on a number of factors:
 IgM antibodies are the best because they have more 
antigen-binding sites. They can achieve binding of two adjacent antigens by single IgM mol
ecule. Only certain IgG subclasses are capable of activating complement: IgG subclasses 1, 2, 
and 3 of these IgG subsets, IgG 3 are the best. IgG subclass 4 does not activate complement. 
The more antigen sites found on the red blood cell, the 
more likely two adjacent ones are bound by antibody. The A and B antigens are in very high 
concentration on the red blood cells. The natural-occurring, expected antibodies (anti-A, anti-
B, and anti-A, B) are IgM. ABO incompatibilities are the most likely to result in intravascular 
transfusion reactions from the activation of the classical pathway. Other factors include; abil
ity of the antibody to activate complement, the blood group specificity and the temperature 
of optimum reactivity of the antibody. Generally antibodies that react optimally at 37°C are 
mostly clinically significant. They are capable of causing haemolytic transfusion reaction (re
sulting from incompatible red cell transfusion) and or HDFN.
 The signs and symptoms 
of complement activated –related invivo red cells destruction similar to that seen in haemolytic 
transfusion reaction include; intravascular hemolysis (complement cascade goes to completion) 
and the cells are lysed, extravascular hemolysis where the complement cascade stops at C3b step. 
Cells coated with C3b are removed from circulation via macrophages and neutrophils, “Damaged 
cells” (spherocytes and stroma fragments) lead to decreased cell survival and possible activation 
of Hageman factor that in turn leads to coagulation activation, unexplained Disseminated In
travascular Coagulation (DIC)-related bleeding may also occur due to small clumps of agglu
tinated cells in the blood stream, fibrinogen consumption, activation of fibrinogen system and 
fibrin destruction, when leukocytes are exposed to various antigen-antibody complexes they will 
also respond by secreting various cytokines that will lead to: fever, a drop in blood pressure and 
additional release of white blood cells from the bone marrow as well as a number of other activi
ties; renal failure (anuria and renal damage) is the most common complication of an untreated 
hemolytic transfusion reaction, hypotension, contraction of the blood vessels in the kidney since 
it is one of the smooth muscles that respond in anaphylaxis, intravascular clots, fever (>10c rise in 
temperature), toxic effects of free haemoglobin, flushing of the face, chest and lumbar pain, nau
sea and haemoglobinuria.
 Physical factors that can cause haemolysis include; temperature 
extremes (outside body), hypotonic solutions (IV solutions), mechanical (pumps, intravas
cular clots) and chemical- toxins. Causes of immune-mediated cell destruction (Hemolysis) 
include; antibodies that bind complements, antibodies that do not bind complement and 
Complement activation only. 
200
12. Each activated C5 activates many more C6 and C7 molecules 
13. C6 and C7 conversion proceed rapidly to C8 and C9 activation 
14. Activated C8 activates many more C9 molecules 
15. Activated C9 attacks red cell membrane, boring holes in it.
16. Contents of red cell leak out into plasma leading to intravascular hemo
lysis. As the complement cascade results in biologic side-effects such as 
chemotaxis, opsonization, and anaphylaxis.
 This phase involves the activity of complement component C1 following the for
mation of an antigen-antibody complex and the subsequent activation of component C2 and C4. 
Complement component C1 is made up of 3 subunits (C1q, C1r and C1s). C1 is activated following 
an antigen-antibody reaction in the presence of free calcium ions. The use of EDTA and citrated 
plasma disrupt the activity of C1 and inhibit complement activation. The C1q portion of the C1 
molecule is made up of 6 immunoglobulin-binding sites. This facilitate the interaction between the 
C1 molecule and the CH2 domain of the Fc portion of the IgG (1 ansd 3 ) as well as the IgM-antigen 
bound immunoglobulin. Binding of two Fc portion of the IgG (within <40nm of each other) or a 
single IgM molecule (have 5 Fc binding sites) to the red cell membrane activates C1q. The binding of 
C1q with the Fc portion of two IgG or one IgM bound to the red cell membrane activated C1. Actic
vated C1 acts on C4 and C2 molecules. This results in the cleavage of C4 into two component (C4a 
and C4b). While the C4a is release into the fluid phase, the C4b covalently bind to the Fc region of 
the red cell bound immunoglobulin. The activation of C1 also result in the cleavage of C2 molecule 
into C2a and C2b. While C2a is released into the fluid state, the C2b in the presence of calcium ions 
bind to C4b to form the C4b2b complex (C3 convertase). The activity of C4 and C2 can be inhibited 
by either the C1 inhibitor (C1 INH) or by the short half life of C2b molecule.
Amplification phase: The amplication phase involves the activation of C3 by the C1 activated 
C4B2b complex (convertase). This results in the cleavage of C3 into C3a and C3b. The C3a is 
released into the fluid state acting as anaphylatoxin and causes increased vascular permeability. 
The C3b binds unto the C4b2b to form C4b2b3b complex. The binding of C3b on the red cell 
membrane facilitates immune adherence and promotes the binding of such C3b bound red cells 
to C3b receptor site of macrophages. This results in the sequesteration of such C3b bound red 
cells by macrophages in the spleen or liver. A positive reaction with and C3d AHG reagent in a 
positive DAT test is a sign that complement activation has taken place in the patient circulation. 
The amplification phase of complement activation can be inactivated bythe activity of C3b and /
or C4b inactivator proteins (C3Bina AND C4bINA). The complement cascade frequently stops at 
the C3B stage.
Membrane attack phase: This involves the activation of C5 by C4b2b3b complex and subsequent 
activation of C6, C7, C8 and C9. This activation results in the cleavage of C5 into C5a and C5b. The 
C5a is released into the fluid state where it acts as an analphylatoxin and increases red cell perme
ability. The C5b binds to C6 and C7 to form a tri-molecular complex which is firmly inserted into 
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the red cell membrane. C8 and C9 are the bound to the C5b67 complex in a circular fashion and 
produces a membrane lesion or hole of about 10nm diameter. This facilitates the flow of ions and 
water across the red cell membrane resulting in the loss of the osmotic gradient and red cell lysis
Facors affecting the clinical significance of an antibody. Not all red cell alloantibodies are 
capable of activating complements and causing red cell destruction invivo. The red cell de-
struction potential of an antibody depends on a number of factors:
Nature of antibody coating the cell. IgM antibodies are the best because they have more 
antigen-binding sites. They can achieve binding of two adjacent antigens by single IgM mol-
ecule. Only certain IgG subclasses are capable of activating complement: IgG subclasses 1, 2, 
and 3 of these IgG subsets, IgG 3 are the best. IgG subclass 4 does not activate complement. 
Number of antigen sites on red cell. The more antigen sites found on the red blood cell, the 
more likely two adjacent ones are bound by antibody. The A and B antigens are in very high 
concentration on the red blood cells. The natural-occurring, expected antibodies (anti-A, anti-
B, and anti-A, B) are IgM. ABO incompatibilities are the most likely to result in intravascular 
transfusion reactions from the activation of the classical pathway. Other factors include; abil-
ity of the antibody to activate complement, the blood group specificity and the temperature 
of optimum reactivity of the antibody. Generally antibodies that react optimally at 37°C are 
mostly clinically significant. They are capable of causing haemolytic transfusion reaction (re-
sulting from incompatible red cell transfusion) and or HDFN.
Possible Outcomes of Complement Activation in Blood Banking. The signs and symptoms 
of complement activated –related invivo red cells destruction similar to that seen in haemolytic 
transfusion reaction include; intravascular hemolysis (complement cascade goes to completion) 
and the cells are lysed, extravascular hemolysis where the complement cascade stops at C3b step. 
Cells coated with C3b are removed from circulation via macrophages and neutrophils, “Damaged 
cells” (spherocytes and stroma fragments) lead to decreased cell survival and possible activation 
of Hageman factor that in turn leads to coagulation activation, unexplained Disseminated In-
travascular Coagulation (DIC)-related bleeding may also occur due to small clumps of agglu-
tinated cells in the blood stream, fibrinogen consumption, activation of fibrinogen system and 
fibrin destruction, when leukocytes are exposed to various antigen-antibody complexes they will 
also respond by secreting various cytokines that will lead to: fever, a drop in blood pressure and 
additional release of white blood cells from the bone marrow as well as a number of other activi-
ties; renal failure (anuria and renal damage) is the most common complication of an untreated 
hemolytic transfusion reaction, hypotension, contraction of the blood vessels in the kidney since 
it is one of the smooth muscles that respond in anaphylaxis, intravascular clots, fever (>10c rise in 
temperature), toxic effects of free haemoglobin, flushing of the face, chest and lumbar pain, nau-
sea and haemoglobinuria.
Non-Immune Hemolysis. Physical factors that can cause haemolysis include; temperature 
extremes (outside body), hypotonic solutions (IV solutions), mechanical (pumps, intravas-
cular clots) and chemical- toxins. Causes of immune-mediated cell destruction (Hemolysis) 
include; antibodies that bind complements, antibodies that do not bind complement and 
Complement activation only. 
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Types of Immune-Mediated Hemolysis 
Intravascular Hemolysis. Antigen–antibody reaction often results in complement actication. 
When such activation proceeds to completion, the red cell membrane are damaged and lyses 
within the circulation. Intravascular hemolysis is complement mediated since the hemolysis is 
due to activation of the complement pathway by the classical pathway. Intravascular indicates the 
cell destruction takes place within the blood vessels. This type of hemolysis can be life-threatening 
due to both the possibility of anaphylaxis and renal failure. The lyses of the red cells releases hae-
moglobin into the circulation resulting in haemoglobinaemia and haemoglobinuria. Examples of 
antibodies that can cause haemolysis invivo includes anti-A, anti-B and most particularly anti A,B. 
These antibodies are often incriminated in haemolytic transfusion reactions resulting from the 
transfusion of ABO incompatible red cells (Acells to a group B patient, Bcell to a group A patient 
or A or B cells to a blood group O individual).
Figure: Steps of a macrophage ingesting an antibody coated red cells 
a. Ingestion of the antibody caoted red cells through phagocytosis (a phagosome is formed) 
b. The fusion of lysosomes with the phagosome creates a phagolysosome. The antibody caoted red cell 
is broken down by enzymes. 
c. Waste material is expelled
Extravascular Hemolysis. Anti- A, anti- B, anti-AB and most other antibodies can cause the 
destruction of red cells by macrophages outside the circulation. Not all IgG and IgM antibodies 
activates complement. Rhesus antibodies for example does not activate complement. The bind-
ing of such antibody to red cells can however be recongnised by macrophage IgG receptors. 
This binding often occurs in the spleen. The IgG coated red cells are not fit for circulation and 
are thus either engulfed or digested by the macrophage. This results in the digestion of the red 
cell membrane resulting in fluid loss leading to formation of a spherocyte. These sherocytes 
loses that permeability and are trapped as they go through the microcirculation of the spleen. 
Extravascular hemolysis may be antibody mediated or complement mediated. The cell destruc-
tion takes place within RE system (sinusoidal lining cells of the spleen) and is generally not 
life-threatening. The survival rate of the transfused cells will be decreased. Red cells coated with 
C3b are recongnized and selectively removed by macrophages in the liver (kupffer cell). Red 
cells coated with IgG and C3b aere removed in either the spleen and /or the liver. The rate of 
extravascular haemolysis however depends on the number of antibody bound red cells present 
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as well as the volume of incompatible red cell transfused. The haemolysis may sometimes be 
rapid enough to result in haemoglobinuria. A condition in which the oxygen transport protein 
haemoglobin is found in abnormally high concentrations in the urine. The condition is often 
associated with haemolytic anaemia, in which red blood cells are destroyed, thereby increasing 
levels of free plasma haemoglobin. The excess hemoglobin is filtered by the kidneys, which re
lease it into the urine, giving urine a red color. Management of haemolytic transfusion reaction 
include; maintaining a good fluid balance by infusing saline to support the kidney fuction and 
replacing coagulation factors and platelet in cases of DIC-related consumption coagulopathy by 
transfusing fresh frozen plasma (FFP), cryoprecipitate and platelet concentrate.
Immune Response Following a Blood Transfusion Leading to Alloimmunization. 
red cells carrying foreign antigens die normally and are phagocytized by RE system. Foreign 
antigens are processed and stimulate immune response. IgM antibody produced after several 
weeks, probably produce no cell destruction. Gradual decline of red cells results in continu
ous re-exposure of the antigen to the immune system. Primary and secondary responses can 
overlap each other. IgG antibodies can be produced while IgM antibody productions is going 
on, from the same blood transfusion (same “stimulating event”). Low-titer IgM antibodies may 
not cause cell destruction, but higher-titer IgG antibodies will eventually lead to extravascular 
hemolysis. 
Intravascular Hemolysis (complement mediated) 
Complement is activated when two adjacent antigen 
sites are bound by antibody. The activated complement rapidly proceeds through several chem
ical changes to membrane attack complex. The membrane attack complex bores a hole through 
red cell membrane, causing hemolysis. The rate of complement activation and amount of com
plement activated determines whether complement cascade goes to completion. 
 Sudden drop in blood pressure due to the anaphylactox
ins: C5a and C3a. Hemoglobinuria due to the lysis of of the red blood cells. If more hemo
globulin is released that can be carried by albumin. Hemoglobinemia (plasma hemoglobulin 
levels) occurs again due to the lysis of red blood cells in the blood vessels. Decreased hap
toglobin since haptoglobin can also carry hemoglobin. There are limited amounts of hap
toglobulin produced so once it is used, it will be removed by the liver and the haptoglobulin 
levels decreased. No rise in hematocrit following blood transfusion since the donor blood is 
destroyed. Anaphylactic shock, death may result if large amounts of complement activated. 
Antibodies that bind complement (classical pathway) includes IgM antibodies ( anti-A, anti-B, 
anti-I, anti-Lewisa) as well as IgG antibodies (anti-A, B, auto anti-P, anti-D, anti-Kidd, anti-
Kell and others). 
 Antibodies attach to antigens on red cell 
membrane and are sensed by phagocytes in RE system. The the antibody-coated red cells are 
ingested by the phagocytic cells and destroyed at a rate faster than normal cell destruction. 
RE system plucks antibody off cells, leaving damaged membrane. Cell becomes a spherocyte 
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 Antigen–antibody reaction often results in complement actication. 
When such activation proceeds to completion, the red cell membrane are damaged and lyses 
within the circulation. Intravascular hemolysis is complement mediated since the hemolysis is 
due to activation of the complement pathway by the classical pathway. Intravascular indicates the 
cell destruction takes place within the blood vessels. This type of hemolysis can be life-threatening 
due to both the possibility of anaphylaxis and renal failure. The lyses of the red cells releases hae
moglobin into the circulation resulting in haemoglobinaemia and haemoglobinuria. Examples of 
antibodies that can cause haemolysis invivo includes anti-A, anti-B and most particularly anti A,B. 
These antibodies are often incriminated in haemolytic transfusion reactions resulting from the 
transfusion of ABO incompatible red cells (Acells to a group B patient, Bcell to a group A patient 
or A or B cells to a blood group O individual).
Figure: Steps of a macrophage ingesting an antibody coated red cells
a. Ingestion of the antibody caoted red cells through phagocytosis (a phagosome is formed)
b. The fusion of lysosomes with the phagosome creates a phagolysosome. The antibody caoted red cell 
is broken down by enzymes.
c. Waste material is expelled
 Anti- A, anti- B, anti-AB and most other antibodies can cause the 
destruction of red cells by macrophages outside the circulation. Not all IgG and IgM antibodies 
activates complement. Rhesus antibodies for example does not activate complement. The bind
ing of such antibody to red cells can however be recongnised by macrophage IgG receptors. 
This binding often occurs in the spleen. The IgG coated red cells are not fit for circulation and 
are thus either engulfed or digested by the macrophage. This results in the digestion of the red 
cell membrane resulting in fluid loss leading to formation of a spherocyte. These sherocytes 
loses that permeability and are trapped as they go through the microcirculation of the spleen. 
Extravascular hemolysis may be antibody mediated or complement mediated. The cell destruc
tion takes place within RE system (sinusoidal lining cells of the spleen) and is generally not 
life-threatening. The survival rate of the transfused cells will be decreased. Red cells coated with 
C3b are recongnized and selectively removed by macrophages in the liver (kupffer cell). Red 
cells coated with IgG and C3b aere removed in either the spleen and /or the liver. The rate of 
extravascular haemolysis however depends on the number of antibody bound red cells present 
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as well as the volume of incompatible red cell transfused. The haemolysis may sometimes be 
rapid enough to result in haemoglobinuria. A condition in which the oxygen transport protein 
haemoglobin is found in abnormally high concentrations in the urine. The condition is often 
associated with haemolytic anaemia, in which red blood cells are destroyed, thereby increasing 
levels of free plasma haemoglobin. The excess hemoglobin is filtered by the kidneys, which re-
lease it into the urine, giving urine a red color. Management of haemolytic transfusion reaction 
include; maintaining a good fluid balance by infusing saline to support the kidney fuction and 
replacing coagulation factors and platelet in cases of DIC-related consumption coagulopathy by 
transfusing fresh frozen plasma (FFP), cryoprecipitate and platelet concentrate.
Immune Response Following a Blood Transfusion Leading to Alloimmunization. Donor 
red cells carrying foreign antigens die normally and are phagocytized by RE system. Foreign 
antigens are processed and stimulate immune response. IgM antibody produced after several 
weeks, probably produce no cell destruction. Gradual decline of red cells results in continu-
ous re-exposure of the antigen to the immune system. Primary and secondary responses can 
overlap each other. IgG antibodies can be produced while IgM antibody productions is going 
on, from the same blood transfusion (same “stimulating event”). Low-titer IgM antibodies may 
not cause cell destruction, but higher-titer IgG antibodies will eventually lead to extravascular 
hemolysis. 
Intravascular Hemolysis (complement mediated) 
Mechanism of intravascular hemolysis. Complement is activated when two adjacent antigen 
sites are bound by antibody. The activated complement rapidly proceeds through several chem-
ical changes to membrane attack complex. The membrane attack complex bores a hole through 
red cell membrane, causing hemolysis. The rate of complement activation and amount of com-
plement activated determines whether complement cascade goes to completion. 
Signs of intravascular hemolysis. Sudden drop in blood pressure due to the anaphylactox-
ins: C5a and C3a. Hemoglobinuria due to the lysis of of the red blood cells. If more hemo-
globulin is released that can be carried by albumin. Hemoglobinemia (plasma hemoglobulin 
levels) occurs again due to the lysis of red blood cells in the blood vessels. Decreased hap-
toglobin since haptoglobin can also carry hemoglobin. There are limited amounts of hap-
toglobulin produced so once it is used, it will be removed by the liver and the haptoglobulin 
levels decreased. No rise in hematocrit following blood transfusion since the donor blood is 
destroyed. Anaphylactic shock, death may result if large amounts of complement activated. 
Antibodies that bind complement (classical pathway) includes IgM antibodies ( anti-A, anti-B, 
anti-I, anti-Lewisa) as well as IgG antibodies (anti-A, B, auto anti-P, anti-D, anti-Kidd, anti-
Kell and others). 
Mechanism of antibody-mediated hemolysis. Antibodies attach to antigens on red cell 
membrane and are sensed by phagocytes in RE system. The the antibody-coated red cells are 
ingested by the phagocytic cells and destroyed at a rate faster than normal cell destruction. 
RE system plucks antibody off cells, leaving damaged membrane. Cell becomes a spherocyte 
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with shorter lifespan. Antibodies that do not bind complement but promote extravascular cell 
destruction. Extravascular hemolysis processes are caused by IgG antibodies: 
1. Rh antibodies (anti-D, anti-C, anti-c, anti-E, and anti-e) 
2. Anti-Kell (anti-K, anti-k, anti-Kpa, anti-Jsa etc.) 
3. Anti-Kidd (anit-Jka  and anti-Jkb) 
4. Anti-Duffy (anit-Fya  and anti-Fyb) 
5. Anti-S 
Signs of extravascular hemolysis include;
1. A falling hematocrit
2. Increased bilirubin (unconjugated)
3. Increased LD
4. Abnormal peripheral smear (polychromasia, spherocytes and fragments). 
Extravascular Hemolysis - Complement Mediated. In extravascular hemolysis that is com-
plement mediated the breakdown products of activated complement attach to red cell mem-
brane (primarily C4b and C3b and C3d). Presence of C3b coated cells are sensed by phago-
cytes in RE system. Complement-coated cells are ingested and destroyed at a rate faster than 
normal cell destruction. 
Causes of Complement-Mediated Extravascular Hemolysis. Any of the IgM or IgG anti-
bodies that are capable of activating complement can cause this type of hemolysis. Besides 
the classical pathway the alternate pathway of complement activation can also occur due to 
the presence of various components like cell walls of bacteria and yeast, dialysis membranes, 
dextran, and some tumor cells. Certain drugs can also activate complement and can lead to a 
complement-mediated extravascular hemolysis. 
Complement reaction invitro. Sometimes a serum sample used in an antigen-antibody reac-
tion in the transfusion laboratory may activate complement and result in the binding of C3 
onto the red cells. The anti-human globulin test will often detect such binding. In such cases 
the C3 coated red cell may be lysed if the complement activation goes to completion. In such 
cases lysis is often noted as a positive reaction. Complements can be inactivated in the fol-
lowing ways; heating the plasma at 56°C for 30 minutes (complement components C1 and C2 
are heat labile) and use of calcium binding anticoagulants (EDTA and citrate). The activity 
of complement component C1 is dependent on the presence of free calcium ions. Antibodies 
present in EDTA and citrate plasma unlike serum will not produce the binding of C3 onto red 
cell neither will they cause lysis of red cells. Broad spectrum AHG reagent contains anti-C3 
and anti-IgG and can detect the presence of C3 and IgG coating on red cells.
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The antiglobulin test, which is also referred to as the anti-human globulin test (AHG) or the 
Coombs test, is the cornerstone of detecting clinically significant unexpected antibodies that 
have coated cells either in vivo or in vitro. Red cells coated with complement or IgG antibod
ies do not agglutinate directly when centrifuged. These cells are said to be sensitized with 
IgG or complement. Antiglobulin test is one of the most important serological tests done in 
a routine blood transfusion laboratory. It utilizes the anti-human globulin (AHG) reagent 
to bring about agglutination of red cells coated with immunoglobulin or complement com
ponent, which do not show any agglutination in saline. Red cells which are coated with in
complete (IgG) antibodies show agglutination on addition of anti-human globulin (AHG or 
Coombs reagent). The coating can occur either in vivo or in vitro following incubation with 
serum containing the antibody. The majority of incomplete antibodies are IgG which attach to 
the red cell membrane by the Fab portion. The two arm of IgG molecule are unable to bridge 
the gap between red cells which are separated from each other because of the negative charge 
on their surface. While this results in sensitization of the cells, agglutination is not seen as 
the RBCs do not form lattice. Addition of AHG reagent results in the Fab portion of the AHG 
molecule combining with the Fc portion of two adjacent IgG molecules, thereby bridging the 
gap between the red cells and causing agglutination.
Types of Antiglobulin Tests
There are two types of antiglobulin tests:
• Direct Antiglobulin Test (DAT). Detects antibodies or complement 
coating patient’s cells in vivo. 
• Indirect Antiglobulin Test (IAT). Uses a 37oC incubation step so an
tibodies in serum can react with antigens on cells in vitro after wash
ing the cells antiglobulin reagent is used to detect antibody coating 
of cells. 
Anti-Human Globulin (AHG) Reagent.
Anti-human globulin reagent is produced by immunizing rabbits, goats or sheep with human 
serum or purified add type antigen. Animals are bled after a specified period and the reagent 
is purified by absorbing unwanted antibodies. Anti-human globulin reagent can be polyspe
cific and monospecific. Polyspecific antiglobulin reagent contains antibodies to human IgG, 
C3 and C4 components of the complement. Monospecific antiglobulin reagent may be against 
any one of the human IgM, IgG, and IgA or complement component C3 or C4. Monoclonal 
AHG is now available against IgG or complement components. Monoclonal technology may 
be used to make monoclonal antiglobulin reagent. Specificity types include; polyspecific An
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with shorter lifespan. Antibodies that do not bind complement but promote extravascular cell 
destruction. Extravascular hemolysis processes are caused by IgG antibodies: 
1. Rh antibodies (anti-D, anti-C, anti-c, anti-E, and anti-e) 
2. Anti-Kell (anti-K, anti-k, anti-Kpa, anti-Jsa etc.) 
3. Anti-Kidd (anit-Jka  and anti-Jkb) 
4. Anti-Duffy (anit-Fya  and anti-Fyb) 
5. Anti-S 
Signs of extravascular hemolysis include;
1. A falling hematocrit
2. Increased bilirubin (unconjugated)
3. Increased LD
4. Abnormal peripheral smear (polychromasia, spherocytes and fragments). 
 In extravascular hemolysis that is com
plement mediated the breakdown products of activated complement attach to red cell mem
brane (primarily C4b and C3b and C3d). Presence of C3b coated cells are sensed by phago
cytes in RE system. Complement-coated cells are ingested and destroyed at a rate faster than 
normal cell destruction. 
Any of the IgM or IgG anti
bodies that are capable of activating complement can cause this type of hemolysis. Besides 
the classical pathway the alternate pathway of complement activation can also occur due to 
the presence of various components like cell walls of bacteria and yeast, dialysis membranes, 
dextran, and some tumor cells. Certain drugs can also activate complement and can lead to a 
complement-mediated extravascular hemolysis. 
Sometimes a serum sample used in an antigen-antibody reac
tion in the transfusion laboratory may activate complement and result in the binding of C3 
onto the red cells. The anti-human globulin test will often detect such binding. In such cases 
the C3 coated red cell may be lysed if the complement activation goes to completion. In such 
cases lysis is often noted as a positive reaction. Complements can be inactivated in the fol
lowing ways; heating the plasma at 56°C for 30 minutes (complement components C1 and C2 
are heat labile) and use of calcium binding anticoagulants (EDTA and citrate). The activity 
of complement component C1 is dependent on the presence of free calcium ions. Antibodies 
present in EDTA and citrate plasma unlike serum will not produce the binding of C3 onto red 
cell neither will they cause lysis of red cells. Broad spectrum AHG reagent contains anti-C3 
and anti-IgG and can detect the presence of C3 and IgG coating on red cells.
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35. The antiglobulin test
The antiglobulin test, which is also referred to as the anti-human globulin test (AHG) or the 
Coombs test, is the cornerstone of detecting clinically significant unexpected antibodies that 
have coated cells either in vivo or in vitro. Red cells coated with complement or IgG antibod-
ies do not agglutinate directly when centrifuged. These cells are said to be sensitized with 
IgG or complement. Antiglobulin test is one of the most important serological tests done in 
a routine blood transfusion laboratory. It utilizes the anti-human globulin (AHG) reagent 
to bring about agglutination of red cells coated with immunoglobulin or complement com-
ponent, which do not show any agglutination in saline. Red cells which are coated with in-
complete (IgG) antibodies show agglutination on addition of anti-human globulin (AHG or 
Coombs reagent). The coating can occur either in vivo or in vitro following incubation with 
serum containing the antibody. The majority of incomplete antibodies are IgG which attach to 
the red cell membrane by the Fab portion. The two arm of IgG molecule are unable to bridge 
the gap between red cells which are separated from each other because of the negative charge 
on their surface. While this results in sensitization of the cells, agglutination is not seen as 
the RBCs do not form lattice. Addition of AHG reagent results in the Fab portion of the AHG 
molecule combining with the Fc portion of two adjacent IgG molecules, thereby bridging the 
gap between the red cells and causing agglutination.
Types of Antiglobulin Tests
There are two types of antiglobulin tests:
• Direct Antiglobulin Test (DAT). Detects antibodies or complement 
coating patient’s cells in vivo. 
• Indirect Antiglobulin Test (IAT). Uses a 37oC incubation step so an-
tibodies in serum can react with antigens on cells in vitro after wash-
ing the cells antiglobulin reagent is used to detect antibody coating 
of cells. 
Anti-Human Globulin (AHG) Reagent.
Anti-human globulin reagent is produced by immunizing rabbits, goats or sheep with human 
serum or purified add type antigen. Animals are bled after a specified period and the reagent 
is purified by absorbing unwanted antibodies. Anti-human globulin reagent can be polyspe-
cific and monospecific. Polyspecific antiglobulin reagent contains antibodies to human IgG, 
C3 and C4 components of the complement. Monospecific antiglobulin reagent may be against 
any one of the human IgM, IgG, and IgA or complement component C3 or C4. Monoclonal 
AHG is now available against IgG or complement components. Monoclonal technology may 
be used to make monoclonal antiglobulin reagent. Specificity types include; polyspecific An-
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ti-human Globulin: blend of Anti-IgG & Anti-C3b, -C3d and monospecific reagents: Anti-IgG 
alone or Anti-C3b,-C3d alone.
Direct antiglobulin test (DAT/DCT) 
Direct antiglobulin test is used to detect in-vivo sensitization (coating) of red cells with immune 
antibody (IgG) or the complement component (C3d or C3c). It is a useful test in the diagnosis 
of haemolytic disease of the newborn (HDFN), diagnosis of autoimmune haemolytic anemia 
(AIHA), investigation of haemolytic transfusion reaction and in the investigation of drug in-
duced red cell sensitization.  If antigen-antibody reaction has taken place in vivo, cells becomes 
coated with IgG antibody and/or complement. If the cells are washed 3-4 times to remove un-
bound or free antibody or complement, the only antibody or complement left attached to red 
cells will be those thar are bound to the red cells. Addition of AHG (Coombs serum) causes the 
anti- human globulin in Coombs serum reacts with anti human globulin (antibodies or comple-
ment) coating on red cells resulting in agglutination. If no visible agglutination occurs, the test is 
negative. Coombs Control Check Cells must be added to all negative samples to ensure that the 
reagent is performing optimally. The Direct Antiglobulin Test uses a polyspecific reagent (anti-
IgG or anti C3) and detects in vivo coating of patient cells by either IgG antibodies, complement, 
or both. Within the patient’s blood stream antibodies attach to their specific antigens on the red 
blood cells. This happens in Hemolytic Disease of the Foeus and Newborn (HDFN), in transfu-
sion reactions, and in autoimmune hemolytic anemia. Certain drugs are also known to acti-
vate complement and it can also coat the cells in vivo. DAT is one of the investigations carried 
out to effectively diagnose immune red cells and sometimes platelet destruction. To confirm a 
suspected autoimmune haemolytic anaemia in which the DAT is positive with a polyspecific 
reagents, it may be necessary to use monospecific reagents (anti-IgG, anti-C3b, anti-IgM and 
anti-IgA) to identify the class of antibody responsible. Evidence of red cell destruction includes; 
falling haemoglobin without any other cause, haemolytic anaemia –associated reticulocytosis, 
reduced haptoglobins, elevated serum bilirubin (unconjugated), excess urinary urobilinogen, 
raised serum lactic dehydrogenase (LDH), haemosiderinuria, methemalbuminemia, polychro-
masia, erythroid hyperplasia of the bone marrow and positive DAT. 
Sample collection 
Blood sample for DAT should be collected in EDTA (Na2 or K2) to prevent in-vitro uptake of 
complement.
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Anti-human globulin reagent (AHG) 
Positive Control: Sensitized 0 Rh (D) positive cells 
Negative Control: Unsensitized 0 Rh (D) positive cells 
Preparation of 0 Rh (D) positive sensitized red cells 
1. Take 0.5 ml of 5-6 times washed and packed 0 Rh (D) +ve red cells in a 
test tube. 
2. Add 2-3 drops of IgG anti-D (select a dilution (titre 1:4) of anti-D which 
coats the red cells but does not agglutinate them at 37°C). 
3. Mix and incubate at 37°C for 30 minutes. If there is agglutination, repeat 
the procedure using more diluted anti-D. 
4. Wash 3-4 times and make 5% suspension in saline for use. 
5. Perform a Direct antiglobulin test which should give a 2+ reaction. If no 
agglutination occurs, repeat the test by using less diluted anti-D serum. 
6. 0 Rh (D) negative sensitized red cells are also prepared by treating 0 Rh 
(D) negative cells in the same manner. The preparation should give a neg
ative direct antiglobulin test (DAT). 
Procedure (DAT) 
1. Place 1 drop of 2-5% suspension of red cells in a clean labeled test tube. 
2. Wash the red cells 3-4 times with saline and decant the final wash com
pletely. 
3. Add 1-2 drops of Al-IG reagent. 
4. Mix and centrifuge at 1000 rpm for 1 minute. 
5. Shake the tube gently to dislodge the cell button and read the results us
ing a concave mirror. 
6. If result is negative, incubate the test for further 5 minutes at room tem
perature, centrifuge and look for agglutination and record the results. 
7. Add 1 drop of 5% IgG-sensitized red cells to the negative test. Look for 
agglutination, if a negative result is obtained the test result is invalid and 
the test should be repeated. 
8. Appropriate controls are run with the test. 
 Agglutination of red cells indicates a positive result. DAT Controls tubes 
should be read before final interpretation. A positive reaction after immediate spin indicates 
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Reagents 
Anti-human globulin reagent (AHG) 
Positive Control: Sensitized 0 Rh (D) positive cells 
Negative Control: Unsensitized 0 Rh (D) positive cells 
Preparation of 0 Rh (D) positive sensitized red cells 
1. Take 0.5 ml of 5-6 times washed and packed 0 Rh (D) +ve red cells in a 
test tube. 
2. Add 2-3 drops of IgG anti-D (select a dilution (titre 1:4) of anti-D which 
coats the red cells but does not agglutinate them at 37°C). 
3. Mix and incubate at 37°C for 30 minutes. If there is agglutination, repeat 
the procedure using more diluted anti-D. 
4. Wash 3-4 times and make 5% suspension in saline for use. 
5. Perform a Direct antiglobulin test which should give a 2+ reaction. If no 
agglutination occurs, repeat the test by using less diluted anti-D serum. 
6. 0 Rh (D) negative sensitized red cells are also prepared by treating 0 Rh 
(D) negative cells in the same manner. The preparation should give a neg-
ative direct antiglobulin test (DAT). 
Procedure (DAT) 
1. Place 1 drop of 2-5% suspension of red cells in a clean labeled test tube. 
2. Wash the red cells 3-4 times with saline and decant the final wash com-
pletely. 
3. Add 1-2 drops of Al-IG reagent. 
4. Mix and centrifuge at 1000 rpm for 1 minute. 
5. Shake the tube gently to dislodge the cell button and read the results us-
ing a concave mirror. 
6. If result is negative, incubate the test for further 5 minutes at room tem-
perature, centrifuge and look for agglutination and record the results. 
7. Add 1 drop of 5% IgG-sensitized red cells to the negative test. Look for 
agglutination, if a negative result is obtained the test result is invalid and 
the test should be repeated. 
8. Appropriate controls are run with the test. 
Interpretation: Agglutination of red cells indicates a positive result. DAT Controls tubes 
should be read before final interpretation. A positive reaction after immediate spin indicates 
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presence of IgG coating antibodies. Reactions due to IgG become weaker after incubation. A 
positive reaction after 5 minute incubation indicates coating by complement component. 
Indirect antiglobulin test (IAT/ICT) 
This test is used to detect the presence of incomplete antibodies and complement-binding an-
tibodies in the serum after coating on to the red cell in-vitro in. It is useful in the screening and 
identification of unexpected (irregular) antibodies in serum, compatibility testing and detec-
tion of red cell antigens using specific antibodies reacting only in antiglobulin test (K, Fya, Fyb, 
Jkb, e.t.c.) and in the investigation of haemolytic disease of the newborn. Add equal volume 
of serum to 3-5% red cell suspension. If no antigen-antibody reaction occurred, no attachment 
of antibody or complement to red cells occurs. Cells washed three to four times. This causes 
all plasma or serum antibodies not attached to the red cells are washed away. Anti-human 
globulin (Coombs serum) is added, which would react with antibody-coated cells if present 
to give agglutination. No agglutination will occur if no antibodies or complement has been at-
tached to the red cells for the anti-human globulin (Coombs serum) to react with. To confirm a 
negative reaction, Coombs Control Check Cells must be added. Coombs Control Check Cells 
will react with antibodies in Coombs serum still “floating around” in the tube to give a posi-
tive reaction. Agglutination following addition of CCC verifies negative result. Blood sample 
for IAT should be collected in plain labeled test tube (serum). EDTA anticoagulated plasma 
sample can also be used.
Reagents. Anti-human globulin reagent. In order for agglutination to occur an additional 
antibody, which reacts with the Fc portion of the IgG antibody, or with the C3b or C3d com-
ponent of complement, must be added to the system. This will form a “bridge” between the 
antibodies or complement coating the red cells, causing agglutination. The light-colored 
antibody molecule represents the anti-globulin reagent that binds with the Fc portion of 
the IgG antibody attached to the red blood cells. The light-colored antibody molecule rep-
resents the anti-globulin reagent that binds with the complement attached to the red blood 
cells. Traditionally rabbits were immunized with human gamma globulin to make this an-
tibody to IgG or C3d.
 Preparation of reagent 0 cells. Obtain pooled 0 Rh (D) positive cells (reagent O cells) in 2 
test tubes X and Y. Each tube should contain at least 2 donor’s samples. Reagent cells should 
preferably be homozygous (double dose) for antigens and must contain the main clinically 
significant antigens (Rh, Kell, Kidd, Duffy, MNS and Lewis). Wash 3 times with normal sa-
line. Prepare a 5% suspension for use. Reagent 0 cells, commercially available or prepared 
in the laboratory.
Controls 
• Positive Control: Sensitized 0 Rh (D) positive cells.
• Negative Control: Unsensitized 0 Rh (D) positive cells
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Procedure (IAT) 
1. Centrifuge the tubes at 3000 rpm for 5 minutes to separate the serum. 
2. Add 2 drops of serum in each of the tubes labeled C and D (sample should 
be fresh for detecting complement - binding antibodies).
3. Add 1 drop of 5% suspension of X cells to tube labeled 1 and I drop of Y 
cells to tube labeled 2.
4. Mix and incubate both tubes at 37°C for 30-60 minutes.
5. Spin at 1000 rpm for 1 minute and examine for agglutination. Record the 
results. Agglutination will not occur if incomplete antibodies are present.
6. Wash the cells in each of the tube 3-4 times with warm saline. Decant the 
saline completely after the last wash over a filter paper.
7. Add 1-2 drops of AHG reagent to each tube. Centrifuge immediately and 
look for centrifugation.
8. If negative, incubate at room temperature (22°-24°C) for further 5 minutes.
9. Re-centrifuge and look for agglutination.
10. Confirm negative test by adding a drop of IgG sensitized 0 Rh (D) positive 
cells. Agglutination should be seen. Autocontrol must be kept with IAT. 
 Agglutination in one or both the tubes indicates presence of unexpected an
tibody in the test serum. If no agglutination occurs, use enhancing techniques. Results of 
control tubes should be considered before final interpretation.
Factors Affecting the Sensitivity of IAT 
The optimal temperature of reactivity of IgG antibodies is 37°C. Incubation at 
higher or lower temperature may give false results. 
Increasing the ratio of serum to cells increases the antibody coating. 
Commonly used ratio for for IAT 2:1 but for cells suspended in LISS use equal volume of 
serum and 2% cell suspension. 
Optimum incubation time for saline, albumin or enzyme technique is 30-60 
minutes. For red cells suspended in saline incubation time is routinely 15 minutes while in 
emergency cases the incubation time is about 5 minutes 
The sensitivity of IAT can be increased with addition of 22% bovine 
albumin, enzyme or by using red cells suspended in LISS.
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Procedure (IAT) 
1. Centrifuge the tubes at 3000 rpm for 5 minutes to separate the serum. 
2. Add 2 drops of serum in each of the tubes labeled C and D (sample should 
be fresh for detecting complement - binding antibodies).
3. Add 1 drop of 5% suspension of X cells to tube labeled 1 and I drop of Y 
cells to tube labeled 2.
4. Mix and incubate both tubes at 37°C for 30-60 minutes.
5. Spin at 1000 rpm for 1 minute and examine for agglutination. Record the 
results. Agglutination will not occur if incomplete antibodies are present.
6. Wash the cells in each of the tube 3-4 times with warm saline. Decant the 
saline completely after the last wash over a filter paper.
7. Add 1-2 drops of AHG reagent to each tube. Centrifuge immediately and 
look for centrifugation.
8. If negative, incubate at room temperature (22°-24°C) for further 5 minutes.
9. Re-centrifuge and look for agglutination.
10. Confirm negative test by adding a drop of IgG sensitized 0 Rh (D) positive 
cells. Agglutination should be seen. Autocontrol must be kept with IAT. 
Interpretation. Agglutination in one or both the tubes indicates presence of unexpected an-
tibody in the test serum. If no agglutination occurs, use enhancing techniques. Results of 
control tubes should be considered before final interpretation.
Factors Affecting the Sensitivity of IAT 
Temperature. The optimal temperature of reactivity of IgG antibodies is 37°C. Incubation at 
higher or lower temperature may give false results. 
Serum: red cell ratio. Increasing the ratio of serum to cells increases the antibody coating. 
Commonly used ratio for for IAT 2:1 but for cells suspended in LISS use equal volume of 
serum and 2% cell suspension. 
Incubation time. Optimum incubation time for saline, albumin or enzyme technique is 30-60 
minutes. For red cells suspended in saline incubation time is routinely 15 minutes while in 
emergency cases the incubation time is about 5 minutes 
Suspension medium. The sensitivity of IAT can be increased with addition of 22% bovine 
albumin, enzyme or by using red cells suspended in LISS.
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Reasons for false negative results include: 
1. Inadequate washing of the cells in the Coombs phase. Residual serum 
neutralizes  AHG. 
2. A small fibrin clot has formed in the tube, neutralizing AHG. Be sure sam-
ple has thoroughly clotted. 
3. Coombs reagent was omitted or is inactive. 
4. Weak or questionable reactions may be enhanced by: 
5. Increasing the amount of serum used to 3-4 drops. PEG must be omitted, 
and the incubation time extended to 30 minutes. 
6. Omitting PEG and adding albumin to the test mixture. Extend the incu-
bation time to at least 20 minutes. 
7. Using enzyme treated cells. See manufacturer’s directions. 
8. Repeat testing using PEG to the test mixture. See manufacturer’s directions. 
9. Occasionally you may get a moderately strong reaction at room tempera-
ture that persists weakly in Coombs. This may not be clinically significant 
if it is due to complement binding at room temperature from a cold-reac-
tive antibody. To determine if the reaction is due to complement binding, 
do a pre-warmed screen 
Examples of alloimmune hemolysis
1. Hemolytic disease of the foetus and newborn (HDFN or erythroblastosis fetalis).
2. Rh D haemolytic disease of the newborn (Rh disease).
3. ABO hemolytic disease of the newborn (may only be weakly positive)
4. Anti-Kell hemolytic disease of the newborn
5. Rh c hemolytic disease of the newborn
6. Rh E hemolytic disease of the newborn
7. Other blood group incompatibility (RhC, Rhe, Kidd, Duffy, MN, P and others)
8. Alloimmune hemolytic transfusion reactions
Examples of autoimmune hemolysis
1. Warm antibody autoimmune hemolytic anemia
2. Idiopathic
3. Systemic lupus erythematosus
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4. Evans’ syndrome (antiplatelet antibodies and hemolytic antibodies)
5. Cold antibody autoimmune hemolytic anemia
6. Idiopathic cold hemagglutinin syndrome
7. Infectious mononucleosis
8. Paroxysmal cold hemoglobinuria 
1. Methyldopa (IgG mediated type II hypersensitivity)
2. Penicillin (high dose)
3. Quinidine 
Anti-A Anti-B Anti-A+B Auto control A1 cell
Polyagglutinable effect of positive DAT on RBC typing
Anti-A Anti-B Anti-A+B A1 cell
0 0 0
Effect of positive DAT obviated by washing of red cells prior to testing
 IgG-coated red blood cells
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4. Evans’ syndrome (antiplatelet antibodies and hemolytic antibodies)
5. Cold antibody autoimmune hemolytic anemia
6. Idiopathic cold hemagglutinin syndrome
7. Infectious mononucleosis
8. Paroxysmal cold hemoglobinuria 
Drug-induced immune-mediated hemolysis
1. Methyldopa (IgG mediated type II hypersensitivity)
2. Penicillin (high dose)
3. Quinidine 
Forward (Cell group) Back (Serum group)
Anti-A Anti-B Anti-A+B Auto control A1 cell B cell
2+ 2+ 2+ 2+ 4+ 4+
Polyagglutinable effect of positive DAT on RBC typing
Forward (Cell group) Back (Serum group)
Anti-A Anti-B Anti-A+B A1 cell B cell
0 0 0 4+ 4+
Effect of positive DAT obviated by washing of red cells prior to testing
 
 IgG-coated red blood cells
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Complement-coated red blood cells
False-Negative Reactions. False-negative reactions can occur when antigen-antibody reac-
tions have occurred but washing is inadequate and free antibody remains when the anti-
human globulin is added. Anti-human globulin (Coombs) antibody prefers to react first with 
free antibody and then with antibody-coated cells. If the free antibody has already reacted 
with the anti-human globulin, no free Coombs serum to react with Coombs Control Check 
Cells (CCC). False negatives that are detected by negative Coombs control cells include; inad-
equate cell washing will lead to unbound antibody remaining in the red cell suspension that 
are available to neutralize the AHG (Coombs serum) so it will not react with red cells bound 
with antibody, delay in adding Coombs serum after washing step will lead to antibody elut-
ing off, detaching from the cells while cells are sitting in saline. Now free antibody present in 
the saline neutralizes the Coombs, serum so it will not be able to react with the cells bound 
with antibody, small fibrin clot among the cells that were not washed away will have im-
munoglobulins and complement present. The antibodies and complement in the fibrin clot 
neutralizes AHG, Coombs, serum leading to a negative test, inactive AHG (Coombs serum) 
or the failure to add AHG (Coombs serum) will also be detected by a negative reaction when 
adding Coombs Control Check Cells. There are also false negatives NOT detected by negative 
Coombs Control Cells that include; too heavy cell suspension, delay during cell washing pro-
cedure, which can lead to antibody eluting off cells while they are sitting in saline and then 
the antibody is washed away during the remaining washes, improper centrifugation can ei-
ther lead to lost of cells during the washing or the need to shake too hard during resuspension. 
False positives. False positive reactions can also occur when performing this test. These 
would not be detected by the use of Coombs Control Check Cells. Reasons for a false positive 
reaction could be the following; using improper sample (clotted cells instead of EDTA for 
Direct Antiglobulin Test, DAT), spontaneous agglutination (cells heavily coated with IgM), 
non-specific agglutination (sticky cells). All of these reactions would be the result of cells ap-
pearing to agglutinate, or actually agglutinating. Using a clotted tube for the DAT may allow 
complement to become activated in the test tube since calcium ions are free to be part of the 
complement cascade.
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Autoimmune Haemolytic Anaemia (AIHA). Autoimmune hemolytic anemia (AIHA) refers 
to a collection of disorders characterized by the presence of autoantibodies that bind to the 
patient’s own erythrocytes, leading to premature red cell destruction. Specific characteristics 
of the autoantibodies, especially the type of antibody; its optimal binding temperature; and 
whether it binds complement can play a role in its diagnosis. In all cases of AIHA, however, 
the autoantibody leads to a shortened red blood cell survival (haemolysis) and when the 
rate of haemolysis exceeds the ability of the bone marrow to replace the destroyed red cells 
anaemia with its attendant signs and symptoms reuslts. AIHA affect an estimated annual 
incidence of 1 in 80,000 persons in the general population. Positive DAT has been reported 
(IgG and /or C3) have been reported in patient with Plasmodium falciparum malaria. AIHA 
can be subdivided into 
1. Warm AIHA
2. Cold AIHA
3. Cold Paroxysmal Cold Haemoglobinuria (PNH)
4. Drug associated AIHA
Warm Type Autoimmune Haemolytic Anaemia (WAIHA). Warm AIHA is the most common 
of the autoimmune hemolytic diseases. About half of the cases are idiopathic the second half 
are attributable to other predisposing factors such as medications. The most common anti
body involved in warm antibody AIHA is IgG. Sometimes the C3 component of complement 
and IgA is also incriminated. Diagnosis is often by the use of monospecfic anti-IgG reagents. 
These IgG antibodies attach to a red blood cell, leaving their FC portion exposed. The FC re
gion is recognized and grabbed onto by FC receptors found on monocytes and macrophages 
in the spleen. These cells will bite off portions of the red cell membrane. The loss of membrane 
causes the red blood cells to become spherocytes. Spherocytes are not as flexible in micro 
circulation as normal biconcave RBCs, and will be singled-out for destruction by the reticu
loendothelial system including the spleen. The red blood cells trapped in the spleen cause the 
spleen to enlarge (splenomegaly). Two models have been postulated to explain this immune-
related red cell destruction: the hapten model and the autoantibody model. 
1. The hapten model proposes that certain drugs (penicillin, cephalosporins, 
tetracyclines, antihistamines, sulphonamides, ibuproten, levodopa and 
methyldopa) bind to certain proteins on the red cell membrane and act 
as haptens. A hapten (in this case the drug) is a small molecule that can 
elicit an immune response leading to the production of an antibody only 
when attached to a large carrier such as a protein (red cell membrane pro
tein). Antibodies are created against the protein-drug complex, leading to 
haemolysis of the patient’s RBCS. 
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Coombs Control Cells that include; too heavy cell suspension, delay during cell washing pro
cedure, which can lead to antibody eluting off cells while they are sitting in saline and then 
the antibody is washed away during the remaining washes, improper centrifugation can ei
ther lead to lost of cells during the washing or the need to shake too hard during resuspension. 
 False positive reactions can also occur when performing this test. These 
would not be detected by the use of Coombs Control Check Cells. Reasons for a false positive 
reaction could be the following; using improper sample (clotted cells instead of EDTA for 
Direct Antiglobulin Test, DAT), spontaneous agglutination (cells heavily coated with IgM), 
non-specific agglutination (sticky cells). All of these reactions would be the result of cells ap
pearing to agglutinate, or actually agglutinating. Using a clotted tube for the DAT may allow 
complement to become activated in the test tube since calcium ions are free to be part of the 
complement cascade.
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Causes of positive DAT
Autoimmune Haemolytic Anaemia (AIHA). Autoimmune hemolytic anemia (AIHA) refers 
to a collection of disorders characterized by the presence of autoantibodies that bind to the 
patient’s own erythrocytes, leading to premature red cell destruction. Specific characteristics 
of the autoantibodies, especially the type of antibody; its optimal binding temperature; and 
whether it binds complement can play a role in its diagnosis. In all cases of AIHA, however, 
the autoantibody leads to a shortened red blood cell survival (haemolysis) and when the 
rate of haemolysis exceeds the ability of the bone marrow to replace the destroyed red cells 
anaemia with its attendant signs and symptoms reuslts. AIHA affect an estimated annual 
incidence of 1 in 80,000 persons in the general population. Positive DAT has been reported 
(IgG and /or C3) have been reported in patient with Plasmodium falciparum malaria. AIHA 
can be subdivided into 
1. Warm AIHA
2. Cold AIHA
3. Cold Paroxysmal Cold Haemoglobinuria (PNH)
4. Drug associated AIHA
Warm Type Autoimmune Haemolytic Anaemia (WAIHA). Warm AIHA is the most common 
of the autoimmune hemolytic diseases. About half of the cases are idiopathic the second half 
are attributable to other predisposing factors such as medications. The most common anti-
body involved in warm antibody AIHA is IgG. Sometimes the C3 component of complement 
and IgA is also incriminated. Diagnosis is often by the use of monospecfic anti-IgG reagents. 
These IgG antibodies attach to a red blood cell, leaving their FC portion exposed. The FC re-
gion is recognized and grabbed onto by FC receptors found on monocytes and macrophages 
in the spleen. These cells will bite off portions of the red cell membrane. The loss of membrane 
causes the red blood cells to become spherocytes. Spherocytes are not as flexible in micro 
circulation as normal biconcave RBCs, and will be singled-out for destruction by the reticu-
loendothelial system including the spleen. The red blood cells trapped in the spleen cause the 
spleen to enlarge (splenomegaly). Two models have been postulated to explain this immune-
related red cell destruction: the hapten model and the autoantibody model. 
1. The hapten model proposes that certain drugs (penicillin, cephalosporins, 
tetracyclines, antihistamines, sulphonamides, ibuproten, levodopa and 
methyldopa) bind to certain proteins on the red cell membrane and act 
as haptens. A hapten (in this case the drug) is a small molecule that can 
elicit an immune response leading to the production of an antibody only 
when attached to a large carrier such as a protein (red cell membrane pro-
tein). Antibodies are created against the protein-drug complex, leading to 
haemolysis of the patient’s RBCS. 
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2. The autoantibody model proposes that, through a mechanism not yet un-
derstood including certain drugs can cause antibodies to be made against 
red blood cells and leads to red cell destruction. It is possible for it to oc-
cur in an immunocompromised patient
WAIHA may be idiopathic (without any known cause), secondary to another disease such as 
systemic lupus erythematosus or  rheumatoid arthritis or a haematological malignancy such 
as chronic lymphocytic leukemia (CLL) and Myelo Dysplastic Syndrome (MDS). It may also 
be associated with receiving a drug. Laboratory findings in WAIHA include
1. Severe anemia
2. Increased mean corpuscular volume (MCV) due to the presence of a large 
number of young erythrocytes
3. Hyperbilirubinemia (from increased red cell destruction) conjugated or 
unconjugated type. 
4. Diagnosis is made by a positive direct Coombs test
5. Clinical examination and history. 
Treatment. Commonly used treatments for warm antibody AIHA includes; initial medical 
treatment consists of prednisone, corticosteroids, immunoglobulins, splenectomy should be 
considered if other treatments are ineffective. If refractory to both these therapies other op-
tions include rituximab, danazol, cyclosphosphamide, azathioprine and cyclosporine. High 
dose intravenous immune globulin may be effective in controlling hemolysis but the benefit 
is short lived (1–4 weeks).
Cold Type Autoimmune Haemolytic Anaemia. Cold AIHA or cold agglutinin disease, caused by 
IgM antibodies most active at <30oC, is a hemolytic anemia characterized by RBC agglutination 
and hemolysis in acral cold exposed areas of the body. An IgM complement fixing antibody binds 
to RBCs at 28-31oC. In cold type AIHA, IgM antibodies which react optimally at low temperatures 
below that of the core temperature of the body. They are therefore called “cold agglutinins. Usu-
ally C3 is often present. At lower body temperature these cold antibodies bind to red cells and 
initiate the complement cascade. As RBCs are warmed in the central organs the bound IgM is lost 
leaving only bound C3. The complement cascade already triggered can go to completion with 
resultant intravascular haemolysis and associate haemoglobinuria. Cold agglutinin disease is as-
sociated with; Iymphoma (antibodies against anti-i), mycoplasma pneumonia (antibodies against 
anti-I), rarely infectious mononucleosis (antibodies against anti-i), people with cold agglutinin 
disease have a chronic hemolytic anemia with periods of jaundice, and hemoglobinuria. Cold ag-
glutinin disease with RBC agglutination may be associated with Raynaud’s phenomenon.
Paroxysmal cold haemoglobinuria. Paroxysmal cold hemoglobinuria (PCH) (Donath-Land-
steiner syndrome) is a cold type AIHA characterized by the sudden presence of hemoglobin in 
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the urine (hemoglobinuria) typically after exposure to cold temperatures. In people with PCH, 
a polyclonal IgG usually with anti-P autoantibody binds to red blood cell surface antigens in 
the cold. This can occur in a susceptible individual as blood passes through cold extremities 
in cold weather. When the blood returns to the warmer central circulation, the red blood cells 
are lysed with complement causing intravascular hemolysis. PNH is often associated with he
moglobinuria and anemia. The anaemia may be mild or severe. PCH is a rare autoimmune 
haemolytic anaemia that can occur following an infection, when a microorganism triggers the 
formation of antibodies that cross-react with the P antigen on the red blood cell membrane. 
Treatment with prednisone may be used in individuals with PCH and severe anemia. Viral 
infections that can cause PCH include:measles, mumps, influenza, adenovirus, chickenpox, cy
tomegalovirus, and Epstein-Barr virus. Bacterial infections that can cause PCH include syphilis, 
Haemophilus influenzae and Mycoplasma pneumoniae. Chronic PCH associated with syphilis 
resolves after the syphilis is treated with appropriate antibiotics. PCH can also be a side effect 
of some vaccinations. People with PCH are advised to avoid exposure to cold temperatures. If 
anemia is severe, blood transfusion may be needed. Careful compatibility testing by the blood 
bank is necessary because autoantibodies may interfere with blood typing. P positive red cells 
is normally tolerated by a number of patient and in other it may be necessary to transfuse rare P 
negative if P positive red cell transfusion results in haemolysis and non-increment of the patient 
haemoglobin after transfusion of P positive red cells. The Donath-Landsteiner test is used to 
confirm PCH. In the test you incubate group O cells with serum at 00C and the 37°C. The contrl 
is incubated only at 37°C. In a positive test haemolysis is observed in the tube incubated at 00C 
and then 37°C but not in the tube incubated at 37°C alone.
A number of drugs are capable of binding to 
red cells and initiating an immune response leading to the stimulation of antibodies to the 
drug. These antibodies can react with the drug or the drugs, the drug and red cell mem
brane component or the red cell membrane component. The DAT in most cases are positive 
with IgG and sometimes with C3. The antibodies can either be; drug –dependent antibodies 
which react with the drug coated red cells and may cause haemolysis of the drug coated red 
cells. Drug –related immune complexes that attach to surface of RBCS causing haemolysis, 
haemoglobinuria and renal failure. Re-adminstration of the culprit drug can cause severe 
haemolysis, positive C3-related DAT. Drug can independently stimulate an antibody that re
acts with the red cell membrane without the drug. Drugs such as methyldopa causes this type 
of DAT positive. Eluates react with the RBCS without the drug. Some drugs (cephalosporins) 
can alter the red cell membrane and cause a non-immunological uptake of IgG or IgM pro
teins. Autoimmune and drug associated immune destruction is not confined to red cells alone. 
Destruction of platelet can also occur and result in auto immune thrombocytopenia. Drugs 
commonly incriminated in drug-related positive DAT include; penicillin, cephalosporins, 
tetracyclines, antihistamines, sulphonamides, ibuproten, levodopa and methyldopa. When 
the blood is drawn the antibodies and/or complement have already attached to the red cells. 
Those red cells from the EDTA tube will be washed 3 or more times and a 3% cell suspension 
is made. A drop of cell suspension and the anti-human globulin are mixed in a tube and then 
centrifuged. If agglutination occurs, it indicates the patient has a positive Direct Antiglobulin 
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a polyclonal IgG usually with anti-P autoantibody binds to red blood cell surface antigens in 
the cold. This can occur in a susceptible individual as blood passes through cold extremities 
in cold weather. When the blood returns to the warmer central circulation, the red blood cells 
are lysed with complement causing intravascular hemolysis. PNH is often associated with he-
moglobinuria and anemia. The anaemia may be mild or severe. PCH is a rare autoimmune 
haemolytic anaemia that can occur following an infection, when a microorganism triggers the 
formation of antibodies that cross-react with the P antigen on the red blood cell membrane. 
Treatment with prednisone may be used in individuals with PCH and severe anemia. Viral 
infections that can cause PCH include:measles, mumps, influenza, adenovirus, chickenpox, cy-
tomegalovirus, and Epstein-Barr virus. Bacterial infections that can cause PCH include syphilis, 
Haemophilus influenzae and Mycoplasma pneumoniae. Chronic PCH associated with syphilis 
resolves after the syphilis is treated with appropriate antibiotics. PCH can also be a side effect 
of some vaccinations. People with PCH are advised to avoid exposure to cold temperatures. If 
anemia is severe, blood transfusion may be needed. Careful compatibility testing by the blood 
bank is necessary because autoantibodies may interfere with blood typing. P positive red cells 
is normally tolerated by a number of patient and in other it may be necessary to transfuse rare P 
negative if P positive red cell transfusion results in haemolysis and non-increment of the patient 
haemoglobin after transfusion of P positive red cells. The Donath-Landsteiner test is used to 
confirm PCH. In the test you incubate group O cells with serum at 00C and the 37°C. The contrl 
is incubated only at 37°C. In a positive test haemolysis is observed in the tube incubated at 00C 
and then 37°C but not in the tube incubated at 37°C alone.
Drugs that can cause a positive DAT test. A number of drugs are capable of binding to 
red cells and initiating an immune response leading to the stimulation of antibodies to the 
drug. These antibodies can react with the drug or the drugs, the drug and red cell mem-
brane component or the red cell membrane component. The DAT in most cases are positive 
with IgG and sometimes with C3. The antibodies can either be; drug –dependent antibodies 
which react with the drug coated red cells and may cause haemolysis of the drug coated red 
cells. Drug –related immune complexes that attach to surface of RBCS causing haemolysis, 
haemoglobinuria and renal failure. Re-adminstration of the culprit drug can cause severe 
haemolysis, positive C3-related DAT. Drug can independently stimulate an antibody that re-
acts with the red cell membrane without the drug. Drugs such as methyldopa causes this type 
of DAT positive. Eluates react with the RBCS without the drug. Some drugs (cephalosporins) 
can alter the red cell membrane and cause a non-immunological uptake of IgG or IgM pro-
teins. Autoimmune and drug associated immune destruction is not confined to red cells alone. 
Destruction of platelet can also occur and result in auto immune thrombocytopenia. Drugs 
commonly incriminated in drug-related positive DAT include; penicillin, cephalosporins, 
tetracyclines, antihistamines, sulphonamides, ibuproten, levodopa and methyldopa. When 
the blood is drawn the antibodies and/or complement have already attached to the red cells. 
Those red cells from the EDTA tube will be washed 3 or more times and a 3% cell suspension 
is made. A drop of cell suspension and the anti-human globulin are mixed in a tube and then 
centrifuged. If agglutination occurs, it indicates the patient has a positive Direct Antiglobulin 
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Test due to antibody coating the cells in vivo.  If IgM antibodies involved, DAT will be iden-
tified by complement binding since the polyspecific antisera has both anti-IgG and anti-C3. 
Technique for DAT Test
1. Add 1 drop of patient cells from EDTA tube to tube 
2. Wash these drops of blood 3-4 times to remove plasma antibodies (hu-
man globulin) and make a 3% cell suspension. 
3. Add a drop of 3% cell suspension to a clean, labeled tube. 
4. Add drop of Polyspecific AHG (Coombs serum) to the tube. 
5. If test is positive with polyspecific reagent, set up again using monospecific 
reagents to see if it is antibody or complement or both coating the cells. 
6. We want to make the test as sensitive as possible, so allow all negatives to 
incubate 5 minutes to enhance complement coating. 
7. Read all negatives microscopically to detect weak coating. 
8. False positives may occur if sample is collected in EDTA tube. 
9. In-vitro complement coating frequently happens when sample clots or 
cools down due to weak cold-acting auto-antibodies like anti-I 
10. Complement coating is prevented by using a lavender. 
11. Whenever positive DAT is obtained, obtain the following information on 
the patient: 
12. Diagnostic in cases of autoimmune hemolytic anemia, hemolytic disease 
of the foetus and newborn and transfusion reactions. 
13. Medications 
14. Recent transfusion history of both red cell and plasma components 
15. Other lab values that may indicate red cell destruction (hematocrit, bi-
lirubin, LDH) 
Clinical challenges of a positive DAT
1. Normal patient with unexplainable reasons for a positive DAT
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2. Transfusion reaction work-ups require that a DAT be performed on the 
post-transfusion specimen since the patient’s antibodies and/or comple
ment may coat the transfused donor cells. These reactions are usually 
weak positive or mixed field agglutination since you are testing a mixed 
population of patient and donor cells. 
3. Warm-acting autoimmune disease can lead to patient antibodies coating 
their own cells. This results in a strong positive result. A cold-acting au
toimmune haemolytic anemia would be due to IgM antibodies that in 
turn activate complement. The complement-coated cells would then be 
detected by the antiglobulin reagent. 
4. Haemolytic disease of the foetus and newborn is due to the mother’s IgG 
antibodies crossing the placenta and coating the antigens on the fetal red 
blood cells. Cord blood collected at the time of birth would be tested, but 
may need to follow up by a heel stick of EDTA blood. The reaction is usu
ally a strong positive.
5. Complement on the red cells may be the result of antigen-antibody reac
tions which may involve the lysis of red cells. Complement can also be 
activated if immune complexes are present in the plasma and the acti
vated complement attaches to the red cells. Complement can also become 
activated by the C3 by-pass mechanism and the lectin activation process. 
6. Passive transfer of antibody from donor units of plasma or platelets may 
attach to the patient’s red cells since recipients are given ABO compat
ible blood but other unexpected red cell antibodies may not have been 
detected. These antibodies in donor plasma can coat antigens on patient 
cells when group AB, A, or B receive group O plasma products (platelets)
7. ABO mismatched transplants of particularly bone marrow can occur if 
a universal “O” donor bone marrow is given to an A, B, or AB recipi
ent. Passenger lymphocytes from group O donor organ make antibody 
to group AB, A, or B recipient cells and these in turn can activate comple
ment. It is also more common for “O” individuals to make an IgG anti-
A,B, which would also contribute to a positive DAT.
8. Sensitization of red cells due to medications like penicillin and cepha
losporins that usually involves non-specific coating of red cells. Other 
drugs like tetracyclines, antihistamines and sulphonamides cause the 
development of immune complexes that are capable of activating com
plement. Some drugs, like ibuproten, levodopa and methyldopa, are also 
known to cause autoimmunity. If a patient has a positive DAT, drug-in
duced problems should be considered. 
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Indirect Antiglobulin Testing
The indirect antiglobulin test is one of the most important and commonly used techniques in 
immunohematology. It is used commonly for the detection of; weak D’s in donor bloods and 
pregnant females of individuals who type D (-) at room temperature when doing ABO and Rh 
typing, the presence or absence of antigens on a person cells from particularly the Kell, Kidd, 
and Duffy Blood Group systems and the presence of unexpected, clinically significant antibod-
ies in the patient’s serum during the antibody screening procedure and the antibody identifica-
tion procedure. The purpose of the indirect antiglobulin test is to detect In vitro sensitization 
of red cells. This is done when sensitization does not lead to direct agglutination. This occurs 
when there are too few antigens on the red cell, too few antibodies in the serum and those anti-
bodies are in the IgG class. In summary, we incubate cells containing most clinically significant 
antigens with test serum at 37oC for 15 to 30 minutes. After incubation wash the cells three to 
four times in saline. Add AHG (Coombs reagent), centrifuge and read for agglutination.  If the 
test is negative, add Coombs Control Check Cells to check for false negatives. 
Uses. Screening serum for unexpected antibodies usually Involves patient serum plus rea-
gent red cells (screening cells) I and II or I, II and III depending on manufacturer. The patient’s 
serum potentially has unknown antibodies. Screening cells contain known and common clini-
cally significant antigens. If there is agglutination after Coombs step with the screening cells, 
it means that the patient has an unexpected antibody. If antibody screen positive, the serum 
is further reacted against a panel of cells containing known antigens (IAT and Enzyme panel) 
to allow for the antibody to be specifically identified. 
The importance of antibody screen. Testing donor plasma to make sure no unexpected anti-
bodies will be transfused to the recipient. Testing recipient serum before transfusion to make 
sure patient has no unexpected antibodies to react with donor cells and to enable those with 
alloantibody to receive antigen negative red cell transfusion. Testing maternal serum to make 
sure pregnant mother has no antibodies to react with fetal cells causing hemolytic disease of 
the foetus and newborn. 
Red Cell Antigen Typing. Red cell antigen typing involves patient cells plus reagent antiserum. 
The patient’s cells are the unknown antigen and the reagent antiserum is the known antibody. 
The antiglobulin technique is used for antigen typing for a weak D and a number of other clini-
cally significant antibodies like the Kell, Kidd, and Duffy antibodies. If there is agglutination 
after the addition of anti-human globulin, or Coombs step, patient cells had that corresponding 
group specific antigen. The specific procedure varies depending on what antigen is being tested 
for, and what brand of antiserum is being used. Remember you must always read and follow 
manufacturer’s standard operating procedure in the product insert carefully.
Uses for red cell antigen typing. Typing donors for antigen if patient has antibody. You 
would want units that are negative for that antigen. Verifying that patient is negative for an 
antigen. For example the husband of a pregnant woman with a clinically significant alloanti-
body (anti- D and K) will need to have his red cells typed to determine the likelihood of the 
developing foetus being positive for the antigen for which the mum has the corresponding 
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group specific antibody. Typing patient to see what antigens he/she lacks can help predict 
what antibodies he/she is capable of producing if they seem to be particularly likely to make 
additional antibodies. An individual as a rule only make antibody when exposed to red cell 
antigen which they lack.
 When performing red cell antigen testing always run known positive and negative 
controls. This will verify that antiserum is acting properly and helps you interpret your test 
results. The positive control should be heterozygous for the antigen to ensure antiserum is 
capable of detecting weaker antigens. For example, when performing antigen typing for K, you 
would want a cell that is K+ and k+. 
Heterozygous cells Cells with no antigen
0  0 4, 0 or MF
Reagent Antiserum Reagent Antiserum Antiserum.
 Positive = 4, Negative = 0 and MF = Mixed Field Reaction
36. Good Manufacturing Practice (GMP) 
 Good Manufacturing Practice (GMP) is that part of the quality system that 
ensures that blood products are consistently produced and controlled to the quality stand
ards appriopriate to their intended use. It is used to describe a group of practical activities 
and controls put in place to facilitate the production of blood products that meet the required 
specification and is fit and safe for use. GMP covers all aspect of manufacturing;collection, 
transportation processing, storage, quality control and delivery of the finished product. The 
basic principle of GMP is that the responsibility for quality control should be held by an 
independent person from the people who are responsible for the production of the product.
 Quality is defined as the totality of the features and characteristics of a product or 
service which shows that it meet the stated or required specification. Quality Programs in
cludes; quality control, quality assurance and quality improvement. For Blood Banking Qual
ity Programs are essential requirements of agencies such as the Food and Drug Administra
tion (US), MHRA (UK), CPA (UK) and MLSCN (Nigeria). These agencies has the following 
responsibilities: Responsibilities of the blood product requirements (anticoagulants and pre
servatives, shelf life of blood products and clinical indication for use). Specific requirements 
related to independent quality control and quality assurance for overall quality of blood 
products and the processes related to storage, testing and transport of blood products. 
The sum total of organised arrangement put in place by an organisation 
to ensure that medicinal products meet the quality required for their intended use. Quality 
218
The indirect antiglobulin test is one of the most important and commonly used techniques in 
immunohematology. It is used commonly for the detection of; weak D’s in donor bloods and 
pregnant females of individuals who type D (-) at room temperature when doing ABO and Rh 
typing, the presence or absence of antigens on a person cells from particularly the Kell, Kidd, 
and Duffy Blood Group systems and the presence of unexpected, clinically significant antibod
ies in the patient’s serum during the antibody screening procedure and the antibody identifica
tion procedure. The purpose of the indirect antiglobulin test is to detect In vitro sensitization 
of red cells. This is done when sensitization does not lead to direct agglutination. This occurs 
when there are too few antigens on the red cell, too few antibodies in the serum and those anti
bodies are in the IgG class. In summary, we incubate cells containing most clinically significant 
antigens with test serum at 37oC for 15 to 30 minutes. After incubation wash the cells three to 
four times in saline. Add AHG (Coombs reagent), centrifuge and read for agglutination.  If the 
test is negative, add Coombs Control Check Cells to check for false negatives. 
 Screening serum for unexpected antibodies usually Involves patient serum plus rea
gent red cells (screening cells) I and II or I, II and III depending on manufacturer. The patient’s 
serum potentially has unknown antibodies. Screening cells contain known and common clini
cally significant antigens. If there is agglutination after Coombs step with the screening cells, 
it means that the patient has an unexpected antibody. If antibody screen positive, the serum 
is further reacted against a panel of cells containing known antigens (IAT and Enzyme panel) 
to allow for the antibody to be specifically identified. 
Testing donor plasma to make sure no unexpected anti
bodies will be transfused to the recipient. Testing recipient serum before transfusion to make 
sure patient has no unexpected antibodies to react with donor cells and to enable those with 
alloantibody to receive antigen negative red cell transfusion. Testing maternal serum to make 
sure pregnant mother has no antibodies to react with fetal cells causing hemolytic disease of 
the foetus and newborn. 
 Red cell antigen typing involves patient cells plus reagent antiserum. 
The patient’s cells are the unknown antigen and the reagent antiserum is the known antibody. 
The antiglobulin technique is used for antigen typing for a weak D and a number of other clini
cally significant antibodies like the Kell, Kidd, and Duffy antibodies. If there is agglutination 
after the addition of anti-human globulin, or Coombs step, patient cells had that corresponding 
group specific antigen. The specific procedure varies depending on what antigen is being tested 
for, and what brand of antiserum is being used. Remember you must always read and follow 
manufacturer’s standard operating procedure in the product insert carefully.
 Typing donors for antigen if patient has antibody. You 
would want units that are negative for that antigen. Verifying that patient is negative for an 
antigen. For example the husband of a pregnant woman with a clinically significant alloanti
body (anti- D and K) will need to have his red cells typed to determine the likelihood of the 
developing foetus being positive for the antigen for which the mum has the corresponding 
219Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
group specific antibody. Typing patient to see what antigens he/she lacks can help predict 
what antibodies he/she is capable of producing if they seem to be particularly likely to make 
additional antibodies. An individual as a rule only make antibody when exposed to red cell 
antigen which they lack.
Controls. When performing red cell antigen testing always run known positive and negative 
controls. This will verify that antiserum is acting properly and helps you interpret your test 
results. The positive control should be heterozygous for the antigen to ensure antiserum is 
capable of detecting weaker antigens. For example, when performing antigen typing for K, you 
would want a cell that is K+ and k+. 
PositiveControl Negative Control Patient Control Patient Test
Heterozygous cells Cells with no antigen  Patient Cells Patient cells
4 0  0 4, 0 or MF
Reagent Antiserum Reagent Antiserum  Rh control Antiserum.
  Key 
 Positive = 4, Negative = 0 and MF = Mixed Field Reaction
36. Good Manufacturing Practice (GMP) 
What is GMP. Good Manufacturing Practice (GMP) is that part of the quality system that 
ensures that blood products are consistently produced and controlled to the quality stand-
ards appriopriate to their intended use. It is used to describe a group of practical activities 
and controls put in place to facilitate the production of blood products that meet the required 
specification and is fit and safe for use. GMP covers all aspect of manufacturing;collection, 
transportation processing, storage, quality control and delivery of the finished product. The 
basic principle of GMP is that the responsibility for quality control should be held by an 
independent person from the people who are responsible for the production of the product.
Quality. Quality is defined as the totality of the features and characteristics of a product or 
service which shows that it meet the stated or required specification. Quality Programs in-
cludes; quality control, quality assurance and quality improvement. For Blood Banking Qual-
ity Programs are essential requirements of agencies such as the Food and Drug Administra-
tion (US), MHRA (UK), CPA (UK) and MLSCN (Nigeria). These agencies has the following 
responsibilities: Responsibilities of the blood product requirements (anticoagulants and pre-
servatives, shelf life of blood products and clinical indication for use). Specific requirements 
related to independent quality control and quality assurance for overall quality of blood 
products and the processes related to storage, testing and transport of blood products. 
Quality Assurance. The sum total of organised arrangement put in place by an organisation 
to ensure that medicinal products meet the quality required for their intended use. Quality 
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)220
control is a process of measuring actual quality performance and comparing it with a stand-
ard and taking action whenever there is a deviation from the standard. This comparism must 
take place during the production stages and before the product is released for use to ensure 
that the specification required is met.
Why GMP. GMP is important because it ensures that a quality system is built into an or-
ganisation and the processes involved in the manufacturing of blood and blood products. The 
control of quality begins even before the blood product is collected (designing of laboratory, 
equipment specification and defining of procedures). The principle of GMP recommends that 
there are clear written specification for the product, the packaging of the products, testing and 
processing, handling and storage, receipt and despatch, suitable premises, equipment and 
trained workforce. Every blood transfusion laboratory is required by law and on the bais of 
the principle of Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) to 
actively support the quality systems in place for the following procedures.
1. Standard Operating Procedures (SOP’s)
2. Training plans, competencies and development of procedures 
3. Approval of lot release of reagents, quality control of reagents and main-
tenance of equipment. 
4. Review and approval of practices relating to personnel, equipment, selec-
tion of suppliers, process control, final inspection and handling of non-
conforming components, methods in place for handling incidents, errors, 
and accidents. 
GMP requirements. The principle of GMP requires that the following factors that play a role 
in ensuring that the quality of a product are consistently met and that the product meet the 
quality required for it’s intended use.
1. Quality management
2. Personnel




7. Contract manufacture and analysis
8. Complaints and product recall
9. Self inspection
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. Manufacturer must ensure that product is fit for intended use and will 
not put the recipient of blood product at risk. Ensure that senior management staff of the organi
zation takes responsiblility for ensuring product quality and safety as well commitment of staff 
responsible for production and supply of product. A blood transfusion organisation must have 
in place and implement an effective and comprehensive Quality Assurance system based on the 
principles of good manufacturing and good laboratory practices as well as quality control. The 
quality assurance system must be supported by adequate material endowment (premises, equip
ment and facilities) as well as supported by adequate staffing by trained and competent personnel.
 Any successful quality assurance system will depend on person
nel. Robust method must be in place for hiring of qualified personnel. Job descriptions and 
responsibilities for all positions need to exist and be available. Every staff must engage in 
Continuing Professional Development (CPD) activities and must have a Personal Develop
ment Plan (PDP) that is reviewed annually. Training program and full documentation of that 
training for new and continuous employees. Whenever a new procedure or instrument is im
plemented a training program needs to be in place. Regular competency evaluations includ
ing direct observation and documentation of such must occur as well as appraisal should be 
carried out at least anually. All staff must be aware and work on the principles of GMP. Ensure 
that all staffs exposed to infective agents (viral infective agents such as HBV) are up-to-date 
with their vaccination.
 Premises and equipment must be built and 
proactively maintained to suit the task being carried out. The premises must be adequate, 
health and safety considerations must be made. Layout and design must be optimum to mini
mize errors and facillitae maintenance and effective cleaning and disinfection. Work must 
be done accurately and precisely, keeping the work area clean and uncluttered. Validation of 
new equipment must be carried out before its certification for use. Calibration and preventa
tive maintenance must be carried out on all equipment including standard equipment like re
frigerators, complex equipment and computer systems. Continual monitoring of blood bank 
refrigerators extremely important in both blood centers and transfusion services. Equipment 
must be kept cleaned and proactively maintained, should have an equipment operating pro
cedure (EOP) for every equipment, maintenance log and evidence of quality control report 
run daily on equipment. There should be no entry for unauthorized persons. Production and 
storage areas must not be used as right of way. Defective equipment should be removed or 
appriopriate labelled as defective with a do not use sign. Although both transfusion services 
and blood centers are primarily concerned with safe transfusions and related issues, there 
also needs to have processes in place related to employee safety. The following needs should 
be met; Compliance with (control of substances hazardous to health) COSHH requirements: 
chemical and biologic, disaster preparedness, adequate space and ventilation, adequate sani
tation and water systems as well as evaluations of limitations of physical structure prior to 
implementation of new equipment or processes. 
. Clearly written documentation pre
vents errors from spoken communication. Therefore the following must be standard operat
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Quality Management. Manufacturer must ensure that product is fit for intended use and will 
not put the recipient of blood product at risk. Ensure that senior management staff of the organi-
zation takes responsiblility for ensuring product quality and safety as well commitment of staff 
responsible for production and supply of product. A blood transfusion organisation must have 
in place and implement an effective and comprehensive Quality Assurance system based on the 
principles of good manufacturing and good laboratory practices as well as quality control. The 
quality assurance system must be supported by adequate material endowment (premises, equip-
ment and facilities) as well as supported by adequate staffing by trained and competent personnel.
Personnel Requirements. Any successful quality assurance system will depend on person-
nel. Robust method must be in place for hiring of qualified personnel. Job descriptions and 
responsibilities for all positions need to exist and be available. Every staff must engage in 
Continuing Professional Development (CPD) activities and must have a Personal Develop-
ment Plan (PDP) that is reviewed annually. Training program and full documentation of that 
training for new and continuous employees. Whenever a new procedure or instrument is im-
plemented a training program needs to be in place. Regular competency evaluations includ-
ing direct observation and documentation of such must occur as well as appraisal should be 
carried out at least anually. All staff must be aware and work on the principles of GMP. Ensure 
that all staffs exposed to infective agents (viral infective agents such as HBV) are up-to-date 
with their vaccination.
Premises and Equipment- related requirements. Premises and equipment must be built and 
proactively maintained to suit the task being carried out. The premises must be adequate, 
health and safety considerations must be made. Layout and design must be optimum to mini-
mize errors and facillitae maintenance and effective cleaning and disinfection. Work must 
be done accurately and precisely, keeping the work area clean and uncluttered. Validation of 
new equipment must be carried out before its certification for use. Calibration and preventa-
tive maintenance must be carried out on all equipment including standard equipment like re-
frigerators, complex equipment and computer systems. Continual monitoring of blood bank 
refrigerators extremely important in both blood centers and transfusion services. Equipment 
must be kept cleaned and proactively maintained, should have an equipment operating pro-
cedure (EOP) for every equipment, maintenance log and evidence of quality control report 
run daily on equipment. There should be no entry for unauthorized persons. Production and 
storage areas must not be used as right of way. Defective equipment should be removed or 
appriopriate labelled as defective with a do not use sign. Although both transfusion services 
and blood centers are primarily concerned with safe transfusions and related issues, there 
also needs to have processes in place related to employee safety. The following needs should 
be met; Compliance with (control of substances hazardous to health) COSHH requirements: 
chemical and biologic, disaster preparedness, adequate space and ventilation, adequate sani-
tation and water systems as well as evaluations of limitations of physical structure prior to 
implementation of new equipment or processes. 
Documentation and document control requirements. Clearly written documentation pre-
vents errors from spoken communication. Therefore the following must be standard operat-
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ing procedures for carrying out test. These documents should be written in ink, be unam-
biguous and must have a clear and concise content, title and purpose and must be reviewed 
regularly. Each document must have a unique identifier. Every laboratory organization must 
have a document control policy defining how documents (SOPs, forms, worksheet and oth-
ers) in use in the laboratory must be uniquely identified (including document number and 
version), written, validated, approved and issued for use, reviewed and what should insti-
gate a document change or review. Documents used in the transfusion laboratory fall into 
5 levels/categories; policies (relates to “What to do” in response to various situations), proc-
esses (relates to “how it happens”), procedures (relates to “How to do it”), forms/records, 
supporting documents that need to be completed when you are performing the procedures 
and following the processes and policies and documentation of incidents, errors, near misses 
and accidents. In order to build a continually improving system, methods need to be in place 
to detect incidents, errors, near misses and accidents. Therefore the following should be in 
place; A process to capture incidents and errors. If incident occurs, the severity of the incident 
must be determined by the facility. If it is a one-time incident or multiple similar incidents. 
There should be a system in place to carry out a root cause analysis (What might be the root 
cause?) to determine the likelihood is that it will re-occur again and determine what process 
(corrective action) is be put in place to ensure that it does not happen again. Develop proc-
esses for continuous improvement to help eliminate both one-time incidents and multiple 
similar incidents. Audit the process from time to time. Develop a robust process to get things 
right first time and all the time avoid defects and repeats. Documentation requirements vary 
from hospital to hospital but there is requisite information that must be documented by the 
transfusion laboratory and on the patient’s medical record. This is important in order to allow 
for tracability of transfusion of blood components should an adverse event occur in future, 
or a new threat to the blood supply is identified or becomes required for litigation purposes. 
Documentation must include information on component type (RBC, pooled platelet, FFP or 
cryoprecipitate). Other information required include;
1. Donation (unit) number, including centre code. 
2. ABO/Rh of the component, if applicable;
3. Time transfusion of each unit was started and completed including a note 
of any adverse events observed.
4. Signatures of the individuals (requester, nursing staff that did the bed 
side check and set up the transfusion).
5. Time the transfusion was started, discontinued, and completed.
6. Volume of blood product administered and whether a reaction to the 
transfusion occurred.
7. Clear and accurate records of daily temperature monitoring of blood 
bank and reagent fridges, proficiency testing of staff, equipment main-
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tenance, validation, reagent records, quality control checks, crossmatch 
documentation must be stored for a set period of time (30 years in the 
UK). These records must show what was done and by whom.
8. Clear and accurate record keeping provides a complete audit trail which fa
cillitates the investigations of complaints, defects, problems and incidents 
and help the laboratory take necessary corrective and preventive action. 
9. As a rule the compatibility label must remain on blood component until 
the transfusion is discontinued.
. Production activities must follow clearly defined standard procedures and must 
only be performed by designated, qualified, trained and competent staff. All materials used 
for the production process must be stored optimally and in an expiry date order to allow 
for materials closest to expiry to be use first in preference with longer expiration date. Effort 
must be made to prevent microbial contamination of the product. Production process must 
strictly follow the standard operating procedures. Changes can be made to the document but 
this must be approved by a competent person in charge of quality. All equipment used for the 
production process must be validated, regularly maintained to ensure that activity produces 
expected results. Process control include;development of SOP, control of changes in policies, 
processes or procedures, acceptance testing to new/revised software involved in blood bank 
procedures, validation of new policies, processes or procedures, monitoring and control of 
production processes, participation in proficiency testing appropriate for each testing system 
in place, established QC procedures for supplies and equipment, supplier qualifications and 
product specification need to be in place and control processes for non-conforming blood and 
blood components and products. 
 Quality control is associated with independent sampling and 
testing to ensure that a process meets the stated specification. A Quality control program in
cludes both internal quality control (IQC) and External Qaulity Assessment (EQA). Internal 
assessment includes daily QC checks of reagents used in the laboratory and must be managed 
by the department quality team. IQC is a measure of precision. External Quality Assessments 
includes inspections, surveys, and proficiency surveys performed by Quality Assessment agen
cies like the MLSCN, CPA, MHRA, NEQAS and AABB. EQA ensures that diagnostic laboratory 
results are accurate reliable and comparable. The principles of quality control requires that: All 
reagents in use in the transfusion laboratory are adequately controlled (IQC) before use. Inter
nal QC testing is a measure of precision. It is a quality control requirement that every transfu
sion laboratory registers and partakes in external quality assurance (EQA) scheme (NEQAS 
and WEQAS in the UK). Participation in EQA facilitates optimal patient care ensuring that the 
results of investigations are reliable and comparable wherever they are produced. Enrolment 
in an EQA scheme can help the laboratory to; improve their process and increase profitability, 
improve customer satisfaction, comply with current legislation (MLSCN, CPA, MHRA) and im
prove the laboratory’s credibility with potential customers. When a new shipment of reagents 
is received, the product insert needs to be reviewed and any changes in the standard operating 
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tenance, validation, reagent records, quality control checks, crossmatch 
documentation must be stored for a set period of time (30 years in the 
UK). These records must show what was done and by whom.
8. Clear and accurate record keeping provides a complete audit trail which fa-
cillitates the investigations of complaints, defects, problems and incidents 
and help the laboratory take necessary corrective and preventive action. 
9. As a rule the compatibility label must remain on blood component until 
the transfusion is discontinued.
Production. Production activities must follow clearly defined standard procedures and must 
only be performed by designated, qualified, trained and competent staff. All materials used 
for the production process must be stored optimally and in an expiry date order to allow 
for materials closest to expiry to be use first in preference with longer expiration date. Effort 
must be made to prevent microbial contamination of the product. Production process must 
strictly follow the standard operating procedures. Changes can be made to the document but 
this must be approved by a competent person in charge of quality. All equipment used for the 
production process must be validated, regularly maintained to ensure that activity produces 
expected results. Process control include;development of SOP, control of changes in policies, 
processes or procedures, acceptance testing to new/revised software involved in blood bank 
procedures, validation of new policies, processes or procedures, monitoring and control of 
production processes, participation in proficiency testing appropriate for each testing system 
in place, established QC procedures for supplies and equipment, supplier qualifications and 
product specification need to be in place and control processes for non-conforming blood and 
blood components and products. 
Quality control requirements. Quality control is associated with independent sampling and 
testing to ensure that a process meets the stated specification. A Quality control program in-
cludes both internal quality control (IQC) and External Qaulity Assessment (EQA). Internal 
assessment includes daily QC checks of reagents used in the laboratory and must be managed 
by the department quality team. IQC is a measure of precision. External Quality Assessments 
includes inspections, surveys, and proficiency surveys performed by Quality Assessment agen-
cies like the MLSCN, CPA, MHRA, NEQAS and AABB. EQA ensures that diagnostic laboratory 
results are accurate reliable and comparable. The principles of quality control requires that: All 
reagents in use in the transfusion laboratory are adequately controlled (IQC) before use. Inter-
nal QC testing is a measure of precision. It is a quality control requirement that every transfu-
sion laboratory registers and partakes in external quality assurance (EQA) scheme (NEQAS 
and WEQAS in the UK). Participation in EQA facilitates optimal patient care ensuring that the 
results of investigations are reliable and comparable wherever they are produced. Enrolment 
in an EQA scheme can help the laboratory to; improve their process and increase profitability, 
improve customer satisfaction, comply with current legislation (MLSCN, CPA, MHRA) and im-
prove the laboratory’s credibility with potential customers. When a new shipment of reagents 
is received, the product insert needs to be reviewed and any changes in the standard operating 
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procedure needs to incorporated into the laboratory procedure before the reagents are used by 
the laboratory. Total compliance with the manufacturer’s directions must be followed. Blood 
bank reagents must never be used after the expiration date. Daily quality control testing needs 
to be done for ABO, Rh, and Antibody Screening. Typing antisera for other red cell antigens will 
be tested when performing the antigen testing on the patient and donors since this test is not 
done each day. Prior to use of incoming supplies they need to be tested. Each manufacturer is 
required to provide a product insert for each reagent. The product inserts needs to include the 
following; reagent’s description, proper use procedures, what to expect in regards to perform-
ance and limitations of reagents. Determination needs to be made relating to whether they are 
satisfactory for intended use. Documentation of package, storage and transportation. Docu-
mentation of testing that needs to done by facility before being put into use. 
Contract, Manufacture and analysis. Contract manufacture and analysis must be correctly 
defined, agreed and controlled in order to avoid misunderstandings which could result in 
a product or work of unsatisfactory quality. There must be a written contract between the 
Contract Giver and the Contract Acceptor which clearly establishes the duties of each party. 
The Contract Giver (transfusion laboratory) is responsible for assessing the competence of 
the Contract Acceptor (contractor) to carry out successfully the work required and for ensur-
ing by means of the contract that the principles and guidelines of GMP as interpreted in this 
Guide are followed. The Contract Giver should provide the Contract Acceptor with all the 
information necessary to carry out the contracted operations correctly in accordance with the 
marketing authorisation and any other legal requirements. The Contract Giver should ensure 
that the Contract Acceptor is fully aware of any problems associated with the product or the 
work which might pose a hazard to his premises, equipment, personnel, other materials or 
other products. The contract giver should ensure that all processed products and materials 
delivered to him by the Contract Acceptor comply with their specifications or that the prod-
ucts have been released by a qualified person. The contract acceptor must have adequate 
premises and equipment, knowledge and experience and competent personnel to carry out 
satisfactorily the work ordered by the contract giver. The contract acceptor should ensure 
that all products or materials delivered to him are suitable for their intended purpose. The 
contract acceptor should not pass to a third party any of the work entrusted to him under the 
contract without the contract giver’s prior evaluation and approval of the arrangements. Ar-
rangements made between the contract acceptor and any third party should ensure that the 
manufacturing and analytical information is made available in the same way as between the 
original contract giver and contract acceptor.
The Contract. A contract should be drawn up between the Contract Giver and the Contract 
Acceptor which specifies their respective responsibilities relating to the manufacture and con-
trol of the product. Technical aspects of the contract should be drawn up by competent per-
sons suitably knowledgeable in transfusion technology, analysis and Good Manufacturing 
Practice. The contract should describe clearly who is responsible for purchasing materials, 
testing and releasing materials, undertaking production and quality controls, including in-
process controls, and who has responsibility for sampling and analysis. Any records relevant 
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to assessing the quality of a product in the event of complaints or a suspected defect must be 
accessible and specified in the defect/recall procedures of the Contract Giver. 
 GMP principle stipulates that all complaints and other in
formation concerning adverse events and potentially defective product must be investigated. 
There should a procedure in place for recall of defective blood and blood products. Recall 
process should be free from any ambiguity and could be initiated promptly by all qualified 
staff and should be regularly reviewed. A process should be in place to carry out a root cause 
analysis in cases of complaints and any adverse events to enable a corrective and preventive 
action to be taken to prevent a re-occurrence of the root cause. The quality control officer 
should be involved in all cases of complaints, defects and near –misses. 
Self inspection (Internal Audits). An audit is defined as a systematic, independent & docu
mented process for obtaining evidence and evaluating objectively the extent to which audit 
(GMP principles) criteria are fulfilled. Audits can either be horizontal, vertical or examination. 
Horizontal audit involves the assessment of one element of the quality system. Examination 
audit involves a process whereby the assessor watches a test being performed, to ascertain if 
SOP is being followed. It is a method used to confirm competence of the staff and level of train
ing. Vertical audit: involves a process whereby a sample is tracked from sample receipt to the 
issue of result. Regular audits are essential to sustain or improve a quality system. Non -com
pliance notes raised against identified short falls are being addressed and will be reviewed in 
subsequent audits. All identified non-compliances must be resolved. Root cause analysis must 
be carried out and all appropriate corrective actions must be implemented. Internal audits verti
cal and horizontal as well as examination audits should be conducted regularly to monitor the 
implementation and compliance with GMP principles. All internal audits must be carried out 
by an independent and designated persons. It must be as objective as possible
37. Principle of Good Laboratory Practice (GLP) and its application in 
Good Laboratory Practice (GLP) embodies a set of principles that provides a framework 
within which studies are planned, performed, monitored, recorded, reported and archived. 
Laboratory testing carried out by Biomedical Scientist are generally recognized as affecting 
decisions literally concerned with life and death issues. There is therefore the need to adopt 
sound laboratory practices directed at assuring the quality of service delivered. The primary 
product of a transfusion laboratory is laboratory results of analysis carried out on a blood 
specimen. Quality assurance (QA) of such a laboratory must include all of the activities as
sociated with ensuring that biologic testing is done properly, interpreted correctly, reported 
with appropriate estimates of error and confidence levels and communicated effectively and 
timely to the requesting clinician to facilitate the offering of best possible care to custom
ers. QA activities also include those maintaining appropriate records of sample origins and 
history (sample-tracking), as well as procedures, raw data, and results associated with each 
procedure needs to incorporated into the laboratory procedure before the reagents are used by 
the laboratory. Total compliance with the manufacturer’s directions must be followed. Blood 
bank reagents must never be used after the expiration date. Daily quality control testing needs 
to be done for ABO, Rh, and Antibody Screening. Typing antisera for other red cell antigens will 
be tested when performing the antigen testing on the patient and donors since this test is not 
done each day. Prior to use of incoming supplies they need to be tested. Each manufacturer is 
required to provide a product insert for each reagent. The product inserts needs to include the 
following; reagent’s description, proper use procedures, what to expect in regards to perform
ance and limitations of reagents. Determination needs to be made relating to whether they are 
satisfactory for intended use. Documentation of package, storage and transportation. Docu
mentation of testing that needs to done by facility before being put into use. 
Contract, Manufacture and analysis. Contract manufacture and analysis must be correctly 
defined, agreed and controlled in order to avoid misunderstandings which could result in 
a product or work of unsatisfactory quality. There must be a written contract between the 
Contract Giver and the Contract Acceptor which clearly establishes the duties of each party. 
The Contract Giver (transfusion laboratory) is responsible for assessing the competence of 
the Contract Acceptor (contractor) to carry out successfully the work required and for ensur
ing by means of the contract that the principles and guidelines of GMP as interpreted in this 
Guide are followed. The Contract Giver should provide the Contract Acceptor with all the 
information necessary to carry out the contracted operations correctly in accordance with the 
marketing authorisation and any other legal requirements. The Contract Giver should ensure 
that the Contract Acceptor is fully aware of any problems associated with the product or the 
work which might pose a hazard to his premises, equipment, personnel, other materials or 
other products. The contract giver should ensure that all processed products and materials 
delivered to him by the Contract Acceptor comply with their specifications or that the prod
ucts have been released by a qualified person. The contract acceptor must have adequate 
premises and equipment, knowledge and experience and competent personnel to carry out 
satisfactorily the work ordered by the contract giver. The contract acceptor should ensure 
that all products or materials delivered to him are suitable for their intended purpose. The 
contract acceptor should not pass to a third party any of the work entrusted to him under the 
contract without the contract giver’s prior evaluation and approval of the arrangements. Ar
rangements made between the contract acceptor and any third party should ensure that the 
manufacturing and analytical information is made available in the same way as between the 
original contract giver and contract acceptor.
A contract should be drawn up between the Contract Giver and the Contract 
Acceptor which specifies their respective responsibilities relating to the manufacture and con
trol of the product. Technical aspects of the contract should be drawn up by competent per
sons suitably knowledgeable in transfusion technology, analysis and Good Manufacturing 
Practice. The contract should describe clearly who is responsible for purchasing materials, 
testing and releasing materials, undertaking production and quality controls, including in-
process controls, and who has responsibility for sampling and analysis. Any records relevant 
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to assessing the quality of a product in the event of complaints or a suspected defect must be 
accessible and specified in the defect/recall procedures of the Contract Giver. 
Complaints and product recall. GMP principle stipulates that all complaints and other in-
formation concerning adverse events and potentially defective product must be investigated. 
There should a procedure in place for recall of defective blood and blood products. Recall 
process should be free from any ambiguity and could be initiated promptly by all qualified 
staff and should be regularly reviewed. A process should be in place to carry out a root cause 
analysis in cases of complaints and any adverse events to enable a corrective and preventive 
action to be taken to prevent a re-occurrence of the root cause. The quality control officer 
should be involved in all cases of complaints, defects and near –misses. 
Self inspection (Internal Audits). An audit is defined as a systematic, independent & docu-
mented process for obtaining evidence and evaluating objectively the extent to which audit 
(GMP principles) criteria are fulfilled. Audits can either be horizontal, vertical or examination. 
Horizontal audit involves the assessment of one element of the quality system. Examination 
audit involves a process whereby the assessor watches a test being performed, to ascertain if 
SOP is being followed. It is a method used to confirm competence of the staff and level of train-
ing. Vertical audit: involves a process whereby a sample is tracked from sample receipt to the 
issue of result. Regular audits are essential to sustain or improve a quality system. Non -com-
pliance notes raised against identified short falls are being addressed and will be reviewed in 
subsequent audits. All identified non-compliances must be resolved. Root cause analysis must 
be carried out and all appropriate corrective actions must be implemented. Internal audits verti-
cal and horizontal as well as examination audits should be conducted regularly to monitor the 
implementation and compliance with GMP principles. All internal audits must be carried out 
by an independent and designated persons. It must be as objective as possible
37. Principle of Good Laboratory Practice (GLP) and its application in 
transfusion 
Good Laboratory Practice (GLP) embodies a set of principles that provides a framework 
within which studies are planned, performed, monitored, recorded, reported and archived. 
Laboratory testing carried out by Biomedical Scientist are generally recognized as affecting 
decisions literally concerned with life and death issues. There is therefore the need to adopt 
sound laboratory practices directed at assuring the quality of service delivered. The primary 
product of a transfusion laboratory is laboratory results of analysis carried out on a blood 
specimen. Quality assurance (QA) of such a laboratory must include all of the activities as-
sociated with ensuring that biologic testing is done properly, interpreted correctly, reported 
with appropriate estimates of error and confidence levels and communicated effectively and 
timely to the requesting clinician to facilitate the offering of best possible care to custom-
ers. QA activities also include those maintaining appropriate records of sample origins and 
history (sample-tracking), as well as procedures, raw data, and results associated with each 
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sample. The various elements of good laboratory practice includes; use of standard oper-
ating procedures (SOP’s), statistical procedures for data evaluation, availability and use of 
personal protective equipment, availability and use of infection control equipment, effective 
management of waste including sharps, availability of post exposure prophylaxis, provision 
protective vaccination, instrumentation validation, reagent/materials certification, analyst 
certification, laboratory facilities certification, specimen/sample tracking and availability of 
audit process and investigation of incidents.
Standard Operating Procedures (SOP’s)
SOPs are a written document or instruction detailing all steps and activities of a process or 
procedure. ISO 9001 principles essentially require the documentation of all procedures used 
in any manufacturing process that could affect the quality of the product. Standard Operat-
ing Procedure (SOP) is a set of written instructions that document how a routine or repetitive 
activity should be a laboratory. The development and use of SOPs are an integral part of a 
successful quality system as it provides individuals with the information to perform a job 
properly, and facilitates consistency in the quality and integrity of a product or end-result. 
SOP Preparation. Those SOPs should be written by individuals knowledgeable with the activity 
and the organization’s internal structure. These individuals are essentially subject-matter experts 
who actually perform the work or use the process. A team approach can be followed, especially 
for multi-tasked processes where the experiences of a number of individuals are critical. Char-
acteristic of a good SOP includes; should be written with sufficient detail so that someone with 
limited experience with or knowledge of the procedure, but with a basic understanding, can suc-
cessfully reproduce the procedure when unsupervised, should be reviewed (validated) by one 
or more individuals with appropriate training and experience with the process. It is especially 
helpful if draft SOPs are actually tested by individuals other than the original writer before the 
SOPs are finalized. The finalized SOPs should be approved as described in the organization’s 
Quality Management Plan. Signature approval indicates that an SOP has been both reviewed and 
approved by management, need to remain current to be useful. Therefore, whenever procedures 
are changed, SOPs should be updated and re-approved. If desired, modify only the pertinent 
section of an SOP and indicate the change date/revision number for that section in the Table of 
Contents and the document control notation and SOPs should also be systematically reviewed on 
a periodic basis (every 1-2 years) to ensure that the policies and procedures remain current and ap-
propriate, or to determine whether the SOPs are even needed. The review date should be added to 
each SOP that has been reviewed. If an SOP describes a process that is no longer needed, it should 
be withdrawn from the current file and archived. 
General format for standard operating procedures (SOP)
Title Page and table of content. The first page or cover page of each SOP should contain the 
following information: a title that clearly identifies the activity or procedure, an SOP identi-
fication (ID) number, date of issue and/or revision, the name of the laboratory to which this 
SOP applies, and the signatures and signature dates of those individuals who prepared and 
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approved the SOP as well as signature of those who have read, been trained and are commit
ted to following the SOP in carrying out the process/task. Electronic signatures are acceptable 
for SOPs maintained on a computerized database. A Table of Contents may be needed for 
quick reference, especially if the SOP is long, for locating information and to denote changes 
or revisions made only to certain sections of an SOP. 
Well-written SOPs should first briefly describe the following; the purpose of the work or 
process and the scope to indicate what is covered, denote what sequential procedures should be 
followed, divided into significant sections; possible interferences, equipment needed responsi
ble person, personnel qualifications, limitation, calculations, reporting, manual handling issues, 
risk assessment and health and safety considerations and describe all appropriate QA and qual
ity control (QC) activities for that procedure, and list any cited or significant references. 
. Data generated by a laboratory will need to be evaluated for the purpose of; 
showing a trend in workload, justification for employment of more staff, justification of need for a 
higher throughput equipment procurement, scientific research, quality and process improvement, 
maintenance of optimum stocking of reagents, consumables and blood products. Laboratories 
may adopt certain standards which are deemed acceptable within that field (for example using 
95% or 99% confidence levels for particular tests) or they may adopt specific statistical analysis 
procedures for defining detection limits, confidence intervals, analyte measurement units. 
GLP principle stipulates that labora
tory staff wear appriopriate personal protective equipment (PPE) when working with bio
logical agents and all potentially infectious materials. Personal protective equipment (PPE) 
is specialized clothing or equipment worn by a worker for protection against a hazard. The 
hazard in a health care setting is exposure to blood, saliva, or other bodily fluids or aerosols 
that may carry infectious materials such as Hepatitis C, HIV, or other blood borne or bod
ily fluid pathogen. PPE prevents contact with a potentially infectious material by creating a 
physical barrier between the potential infectious material and the healthcare worker. Personal 
protective equipments includes:
 Anyone working in a containment laboratory should wear a laboratory 
coat. The lab coat must be fastened at one side, to the neck with close fitting cuffs. Coats 
should be flame retardant and sufficiently impermeable to protect clothing underneath. Labo
ratory coats must be removed before leaving the laboratory and hung on appropriate hooks. 
Contaminated laboratory coats should be autoclaved before being sent for washing. Personal 
clothing must not be hung on the same hooks used for hanging lab coats.
 Gloves should be worn if indicated in the risk assessment for the task being per
formed. Gloves should be worn for all work with biological agents or potentially infectious 
material (cell cultures, HIV, HBV, HCV, and TB). Gloves must be worn when working in a 
category 3 laboratory. A range of sizes and materials (latex and nitrite) should be available 
for users to use. Latex gloves must not be used unless justified in a written risk assessment. 
Gloves should be removed before leaving the laboratory, and before using items that may be 
sample. The various elements of good laboratory practice includes; use of standard oper
ating procedures (SOP’s), statistical procedures for data evaluation, availability and use of 
personal protective equipment, availability and use of infection control equipment, effective 
management of waste including sharps, availability of post exposure prophylaxis, provision 
protective vaccination, instrumentation validation, reagent/materials certification, analyst 
certification, laboratory facilities certification, specimen/sample tracking and availability of 
audit process and investigation of incidents.
Standard Operating Procedures (SOP’s)
SOPs are a written document or instruction detailing all steps and activities of a process or 
procedure. ISO 9001 principles essentially require the documentation of all procedures used 
in any manufacturing process that could affect the quality of the product. Standard Operat
ing Procedure (SOP) is a set of written instructions that document how a routine or repetitive 
activity should be a laboratory. The development and use of SOPs are an integral part of a 
successful quality system as it provides individuals with the information to perform a job 
properly, and facilitates consistency in the quality and integrity of a product or end-result. 
Those SOPs should be written by individuals knowledgeable with the activity 
and the organization’s internal structure. These individuals are essentially subject-matter experts 
who actually perform the work or use the process. A team approach can be followed, especially 
for multi-tasked processes where the experiences of a number of individuals are critical. Char
acteristic of a good SOP includes; should be written with sufficient detail so that someone with 
limited experience with or knowledge of the procedure, but with a basic understanding, can suc
cessfully reproduce the procedure when unsupervised, should be reviewed (validated) by one 
or more individuals with appropriate training and experience with the process. It is especially 
helpful if draft SOPs are actually tested by individuals other than the original writer before the 
SOPs are finalized. The finalized SOPs should be approved as described in the organization’s 
Quality Management Plan. Signature approval indicates that an SOP has been both reviewed and 
approved by management, need to remain current to be useful. Therefore, whenever procedures 
are changed, SOPs should be updated and re-approved. If desired, modify only the pertinent 
section of an SOP and indicate the change date/revision number for that section in the Table of 
Contents and the document control notation and SOPs should also be systematically reviewed on 
a periodic basis (every 1-2 years) to ensure that the policies and procedures remain current and ap
propriate, or to determine whether the SOPs are even needed. The review date should be added to 
each SOP that has been reviewed. If an SOP describes a process that is no longer needed, it should 
be withdrawn from the current file and archived. 
General format for standard operating procedures (SOP)
The first page or cover page of each SOP should contain the 
following information: a title that clearly identifies the activity or procedure, an SOP identi
fication (ID) number, date of issue and/or revision, the name of the laboratory to which this 
SOP applies, and the signatures and signature dates of those individuals who prepared and 
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approved the SOP as well as signature of those who have read, been trained and are commit-
ted to following the SOP in carrying out the process/task. Electronic signatures are acceptable 
for SOPs maintained on a computerized database. A Table of Contents may be needed for 
quick reference, especially if the SOP is long, for locating information and to denote changes 
or revisions made only to certain sections of an SOP. 
Text. Well-written SOPs should first briefly describe the following; the purpose of the work or 
process and the scope to indicate what is covered, denote what sequential procedures should be 
followed, divided into significant sections; possible interferences, equipment needed responsi-
ble person, personnel qualifications, limitation, calculations, reporting, manual handling issues, 
risk assessment and health and safety considerations and describe all appropriate QA and qual-
ity control (QC) activities for that procedure, and list any cited or significant references. 
Statistical procedures. Data generated by a laboratory will need to be evaluated for the purpose of; 
showing a trend in workload, justification for employment of more staff, justification of need for a 
higher throughput equipment procurement, scientific research, quality and process improvement, 
maintenance of optimum stocking of reagents, consumables and blood products. Laboratories 
may adopt certain standards which are deemed acceptable within that field (for example using 
95% or 99% confidence levels for particular tests) or they may adopt specific statistical analysis 
procedures for defining detection limits, confidence intervals, analyte measurement units. 
Availability and use of personal protective equipment. GLP principle stipulates that labora-
tory staff wear appriopriate personal protective equipment (PPE) when working with bio-
logical agents and all potentially infectious materials. Personal protective equipment (PPE) 
is specialized clothing or equipment worn by a worker for protection against a hazard. The 
hazard in a health care setting is exposure to blood, saliva, or other bodily fluids or aerosols 
that may carry infectious materials such as Hepatitis C, HIV, or other blood borne or bod-
ily fluid pathogen. PPE prevents contact with a potentially infectious material by creating a 
physical barrier between the potential infectious material and the healthcare worker. Personal 
protective equipments includes:
Laboratory coats. Anyone working in a containment laboratory should wear a laboratory 
coat. The lab coat must be fastened at one side, to the neck with close fitting cuffs. Coats 
should be flame retardant and sufficiently impermeable to protect clothing underneath. Labo-
ratory coats must be removed before leaving the laboratory and hung on appropriate hooks. 
Contaminated laboratory coats should be autoclaved before being sent for washing. Personal 
clothing must not be hung on the same hooks used for hanging lab coats.
Gloves. Gloves should be worn if indicated in the risk assessment for the task being per-
formed. Gloves should be worn for all work with biological agents or potentially infectious 
material (cell cultures, HIV, HBV, HCV, and TB). Gloves must be worn when working in a 
category 3 laboratory. A range of sizes and materials (latex and nitrite) should be available 
for users to use. Latex gloves must not be used unless justified in a written risk assessment. 
Gloves should be removed before leaving the laboratory, and before using items that may be 
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used by others not wearing gloves such as telephones and computers. Heat resistant gloves 
must be worn when using the autoclave or handling a hot material.
Eye goggles. If the risk assessment indicates that splashes of blood or body fluids are likely, 
and work is not carried out in a microbiological safety cabinet, then suitable eye and/or face 
protection (goggles) or a visor should be worn to protect mucous membranes. Eye protection 
may also be required for work with chemicals that can harm the eyes.
Respiratory protective equipment (RPE). Suitable RPE, that has been fit-tested, must be worn 
when working with airborne hazardous substances. Exposures to airborne hazardous sub-
stances can be reduced by either: substituting with less toxic material, enclosing the process 
and ventilating the laboratory where the task takes place to ensure an acceptable concentration. 
Important point to note with use of RPE equipment include;must be used if other means of 
controlling substances hazardous to health are inadequate, should be used in addition to using 
other means of control. RPE equipment is only effective if used and maintained properly. The 
following must be in place; training should be given to all persons performing task on its use 
and maintenance, the type of protection used should have an appropriate protection factor in 
relation to the anticipated concentration of hazardous substance(s), the PPE should be comfort-
able for users to wear and a good seal to the face and all RPE equipments (except single use 
disposable types) should be tested regularly and must be in optimum stock levels at all times. 
Disposable aprons. Aprons must be worn over laboratory coats when carrying out a task that 
is associated with risk of spillages.
Availability and use of infection control equipment. Infection control addresses factors related 
to the spread of infections within the health-care setting (whether patient-to-patient, from pa-
tients to staff and from staff to patients, or among-staff) including prevention (via good hand 
hygiene/ hand washing, cleaning/disinfection/sterilization, vaccination, surveillance), monitor-
ing/investigation of demonstrated or suspected spread of infection within a particular health-
care setting (surveillance and outbreak investigation) and management. It is well documented 
that the most important measure for preventing the spread of pathogens is effective handwash-
ing. Hand washing is mandatory in most health care settings. Employers must provide readily 
accessible hand washing facilities, and must ensure that employees wash hands and any other 
skin with soap and water or flush mucous membranes with water as soon as feasible after 
contact with blood or other potentially infectious materials (OPIM). Drying of hand is also an 
essential part of the hand hygiene process. Warm air hand dryers and modern jet-air hand dry-
ers are required. 
There is effective management of waste including sharps. Infectious waste (Clinical waste) 
and is mainly produced by hospitals, health clinics, doctors’ surgeries and veterinary prac-
tices, but can come from residential homes, nursing homes and collection of blood for trans-
fusion, which may cause infection to any person coming into contact with it. Laboratory or 
clinical waste is made up completely or partly of, human or animal tissue, blood or other 
bodily fluids, excretions, drugs or other pharmaceutical products, swabs or dressings, sy-
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ringes, needles or other sharp instruments and also includes drugs or other pharmaceutical 
products. All sharps must be appriopriately disposed into sharps bin. Sharps bins should 
not be overfilled must have information on source, the signatute of staff that put the sharps 
bin together and the staff that closed it for final incineration and must be kept in a safe place, 
disposal should be through a registered waste carrier. Sharps are items that can cause cuts or 
puncture injuries and include; needles, syringes, lancets, scalpels, stitch cutters, razor blades, 
glass ampoules and sharp instruments. All producers of waste, their employees and service 
carriers, have a duty of care to ensure all waste is being disposed of legally. A duty of care is 
imposed on all those who produce, carry, keep, treat and dispose of controlled waste or have 
control of such waste. 
 Post-exposure prophylaxis (PEP) is any prophylactic treatment 
started immediately after exposure to a pathogen (such as a disease-causing virus) in order 
to prevent infection by the pathogen and the development of disease. In some cases where 
vaccines do not exist, Post Exposure prophylaxis is another method of protecting the health 
care worker exposed to a life threatening infectious disease. In case of exposure to blood 
and body fluid of an HIV –infected patient through needle stick injury, HIV infection can be 
prevented by giving the exposed heathcare worker post-exposure prophylaxis made up of a 
course of antiretroviral drugs. This reduces the risk of seroconversion after events with high 
risk of exposure to HIV. The antiretroviral regimen used in PEP is the same as the standard 
highly active antiretroviral therapy used to treat AIDS. It requires close compliance and can 
have unpleasant side effects including malaise, fatigue, diarrhea, headache, nausea and vom
iting. Human Normal Immunoglobulin (HNIG) or hepatitis A vaccine may be used as PEP 
for staff exposed to blood and body fluid of an hepatitis A positive source patient depending 
on the clinical situation. If a health care worker who is not previously vaccinated or a non- 
responder is exposed to an HBsAg  positive source patient blood or body fluid, HBV vaccine 
and hepatitis B imune globulin (HBIG) can be administered. But for those already vacinated 
and are responders, a booster dose should be given. Persons exposed to Hepatitis C should 
get monthly PCR test. If seroconversion occurs, then interferon +/- ribavirin must be started.
Staff must up-to-date for the protective vaccination. Health care workers may be exposed 
to certain infections in the course of their work. Vaccines are available to provide some pro
tection to workers in a healthcare setting. Depending on regulation, recommendation, the 
specific work function, or personal preference, healthcare workers may receive vaccinations 
for hepatitis B; Influenza, Measles, Mumps, Rubella, Tetanus, Diphtheria, Tetanus, Pertussis, 
Nieseria meningitidis and varicella. In general, vaccines do not guarantee complete protec
tion from disease, and there is potential for adverse effects from receiving the vaccine. Staff 
must be up-to-date for their protective vaccination.
. Instrument validation is a process that is very important for any 
analytical laboratory. Instrument validation ensures that an instrument is fit for its intended 
use (fit for purpose). Data produced by faulty instruments may give the appearance of valid 
data. These events are particularly difficult to detect with modern computer-controlled sys
used by others not wearing gloves such as telephones and computers. Heat resistant gloves 
must be worn when using the autoclave or handling a hot material.
. If the risk assessment indicates that splashes of blood or body fluids are likely, 
and work is not carried out in a microbiological safety cabinet, then suitable eye and/or face 
protection (goggles) or a visor should be worn to protect mucous membranes. Eye protection 
may also be required for work with chemicals that can harm the eyes.
Respiratory protective equipment (RPE). Suitable RPE, that has been fit-tested, must be worn 
when working with airborne hazardous substances. Exposures to airborne hazardous sub
stances can be reduced by either: substituting with less toxic material, enclosing the process 
and ventilating the laboratory where the task takes place to ensure an acceptable concentration. 
Important point to note with use of RPE equipment include;must be used if other means of 
controlling substances hazardous to health are inadequate, should be used in addition to using 
other means of control. RPE equipment is only effective if used and maintained properly. The 
following must be in place; training should be given to all persons performing task on its use 
and maintenance, the type of protection used should have an appropriate protection factor in 
relation to the anticipated concentration of hazardous substance(s), the PPE should be comfort
able for users to wear and a good seal to the face and all RPE equipments (except single use 
disposable types) should be tested regularly and must be in optimum stock levels at all times. 
 Aprons must be worn over laboratory coats when carrying out a task that 
is associated with risk of spillages.
. Infection control addresses factors related 
to the spread of infections within the health-care setting (whether patient-to-patient, from pa
tients to staff and from staff to patients, or among-staff) including prevention (via good hand 
hygiene/ hand washing, cleaning/disinfection/sterilization, vaccination, surveillance), monitor
ing/investigation of demonstrated or suspected spread of infection within a particular health-
care setting (surveillance and outbreak investigation) and management. It is well documented 
that the most important measure for preventing the spread of pathogens is effective handwash
ing. Hand washing is mandatory in most health care settings. Employers must provide readily 
accessible hand washing facilities, and must ensure that employees wash hands and any other 
skin with soap and water or flush mucous membranes with water as soon as feasible after 
contact with blood or other potentially infectious materials (OPIM). Drying of hand is also an 
essential part of the hand hygiene process. Warm air hand dryers and modern jet-air hand dry
ers are required. 
There is effective management of waste including sharps. Infectious waste (Clinical waste) 
and is mainly produced by hospitals, health clinics, doctors’ surgeries and veterinary prac
tices, but can come from residential homes, nursing homes and collection of blood for trans
fusion, which may cause infection to any person coming into contact with it. Laboratory or 
clinical waste is made up completely or partly of, human or animal tissue, blood or other 
bodily fluids, excretions, drugs or other pharmaceutical products, swabs or dressings, sy
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ringes, needles or other sharp instruments and also includes drugs or other pharmaceutical 
products. All sharps must be appriopriately disposed into sharps bin. Sharps bins should 
not be overfilled must have information on source, the signatute of staff that put the sharps 
bin together and the staff that closed it for final incineration and must be kept in a safe place, 
disposal should be through a registered waste carrier. Sharps are items that can cause cuts or 
puncture injuries and include; needles, syringes, lancets, scalpels, stitch cutters, razor blades, 
glass ampoules and sharp instruments. All producers of waste, their employees and service 
carriers, have a duty of care to ensure all waste is being disposed of legally. A duty of care is 
imposed on all those who produce, carry, keep, treat and dispose of controlled waste or have 
control of such waste. 
Post exposure prophylaxis. Post-exposure prophylaxis (PEP) is any prophylactic treatment 
started immediately after exposure to a pathogen (such as a disease-causing virus) in order 
to prevent infection by the pathogen and the development of disease. In some cases where 
vaccines do not exist, Post Exposure prophylaxis is another method of protecting the health 
care worker exposed to a life threatening infectious disease. In case of exposure to blood 
and body fluid of an HIV –infected patient through needle stick injury, HIV infection can be 
prevented by giving the exposed heathcare worker post-exposure prophylaxis made up of a 
course of antiretroviral drugs. This reduces the risk of seroconversion after events with high 
risk of exposure to HIV. The antiretroviral regimen used in PEP is the same as the standard 
highly active antiretroviral therapy used to treat AIDS. It requires close compliance and can 
have unpleasant side effects including malaise, fatigue, diarrhea, headache, nausea and vom-
iting. Human Normal Immunoglobulin (HNIG) or hepatitis A vaccine may be used as PEP 
for staff exposed to blood and body fluid of an hepatitis A positive source patient depending 
on the clinical situation. If a health care worker who is not previously vaccinated or a non- 
responder is exposed to an HBsAg  positive source patient blood or body fluid, HBV vaccine 
and hepatitis B imune globulin (HBIG) can be administered. But for those already vacinated 
and are responders, a booster dose should be given. Persons exposed to Hepatitis C should 
get monthly PCR test. If seroconversion occurs, then interferon +/- ribavirin must be started.
Staff must up-to-date for the protective vaccination. Health care workers may be exposed 
to certain infections in the course of their work. Vaccines are available to provide some pro-
tection to workers in a healthcare setting. Depending on regulation, recommendation, the 
specific work function, or personal preference, healthcare workers may receive vaccinations 
for hepatitis B; Influenza, Measles, Mumps, Rubella, Tetanus, Diphtheria, Tetanus, Pertussis, 
Nieseria meningitidis and varicella. In general, vaccines do not guarantee complete protec-
tion from disease, and there is potential for adverse effects from receiving the vaccine. Staff 
must be up-to-date for their protective vaccination.
Instrumentation validation. Instrument validation is a process that is very important for any 
analytical laboratory. Instrument validation ensures that an instrument is fit for its intended 
use (fit for purpose). Data produced by faulty instruments may give the appearance of valid 
data. These events are particularly difficult to detect with modern computer-controlled sys-
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tems which remove the analyst from the data collection and instrument control functions. 
Important points on instrument validation includes:
1. It is essential that some objective procedures are implemented for con-
tinuously assessing the validity of laboratory instrument and the data 
they provide. 
2. These procedures must be executed on a regular basis to establish the 
continuing acceptable operation of laboratory instruments within manu-
facturers prescribed specifications. 
3. Time-related graphical records of the results of these instrument valida-
tion procedures (control charts) must be documented either electronically 
or as a soft copy. 
Reagent/materials certification. GLP guidelines emphasize that all reagents intended for use 
in the analysis of patient sample must be tested and quality controlled and certified fit for it 
intended use. Certification must follow accepted procedures, and must be adequately docu-
mented. Each container of laboratory reagent must be labeled with information related to its 
certification value, date, and expiration time. Time expired reagents must never be used for 
diagnostic purposes on patients samples. Reagents must by quality controlled daily before use. 
Equipment must be quality controlled with reagents after every major maintenance work is 
done on it. Reagents including temperature dependent reagents must be appriopriately stored. 
Most temperature dependent reagents are stored optimally between 2-8°C. Evidence of tem-
perature monitoring of fridges used for storage of reagents must be kept to show remedial 
action to be taken when temperature is not maintained within the optimum temperature range. 
Certification of analysts. Certification of analyst is a required part of QA. Some acceptable 
proof of satisfactory training and/or competence with specific laboratory procedures must be 
established for each analyst. Because the American Chemical Society does not currently have 
a policy regarding “certification” of chemists or analysts, the requirements for “certification” 
vary, and are usually prescribed by the laboratory in question. These standards would have to 
be accepted by any agency or client obtaining results from that laboratory. For our biomedical 
scientist in the laboratory, the requirement is the completion of a degree course in Biomedical 
Science, certification by the Health Professions Council (UK), the Medical Laboratory Science 
Council of Nigeria (MLSCN) and other related regulatory authorities as well as training and 
competency on the task being performed.
Certification of laboratory facilities. Laboratory certification is normally done by some external 
agency. For example, an analytical laboratory might be audited by representatives of a federal 
agency with which they have a contract. An independent laboratory might file documentation 
with a responsible state or federal agency. The evaluation is concerned with such issues as space 
(amount, quality and relevance), ventilation, equipment, storage, hygiene, etc. Student chemis-
try laboratories are generally evaluated by the American Chemical Society, as part of the process 
of granting approval for the overall chemistry program presented by the college or university. 
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This latter approval process is not as detailed regarding analytical facilities as the certification 
processes pursued by agencies concerned specifically with quality assurance. 
Specimen tracking is an aspect of quality assurance which has received 
a great deal of attention particularly with the advent of computer-based Laboratory Information 
Management Systems (LIMS). GLP principle stipulates that; procedures should be in place for as
suring adequate specimen/sample-tracking may vary among laboratories; the procedures must 
however maintain the unmistakable connection between a set of analytical results and the specimen 
from which they were obtained. In addition, the original source of the specimen must be recorded 
and likewise unmistakably connected with the set of analytical data. Finally, in many cases there 
must be information or an audit trail of a sample (to include when sample was receive, booked on 
the LIMS, when sample was loaded on analyzer, when results was technically validated on the ana
lyzer, when result was clinically validated and available to the requesting clinician. At every stage of 
this trails all responsible laboratory staff must make comments on what was done and why.
 A central feature of GLP guidelines is the 
maintenance of records in a clear, accurate and auditable form. Documentation is important 
for several reasons:
1.  Specimen origins, chain-of-custody, raw analytical data, processed ana
lytical data, SOP’s, instrument validation results, reagent certification re
sults, analyst certification documents and other relevant records must be 
available and kept safe for a specified period of time.
2.  Maintenance of instrument and reagent certification records provides for 
post-evaluation of results, even after the passage of several years.
3.  Maintenance of all records specified provide documentation which may 
be required in the event of legal challenges due to repercussions of deci
sions based on the original analytical results.
4. Many vendors are now providing many of these capabilities as part 
of computer packages for operating modern instruments. For exam
ple most modern computer-based instruments will provide for the 
indefinite storage of raw analytical data for specific samples in a pro
tected (tamper-proof) environment as well as maintenance of histori
cal records of control chart data establishing the operational quality of 
instruments during any period during which analytical data have been 
acquired by that instrument.
5. The length of time over which laboratory records should be maintained 
will vary with the situation. The general guidelines followed in regulated 
laboratories are to maintain records for at least five years. In some coun
tries these records are being maintained much longer. The development 
of higher density storage devices for digitized data is making this kind of 
record-keeping possible.
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tems which remove the analyst from the data collection and instrument control functions. 
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competency on the task being performed.
Certification of laboratory facilities. Laboratory certification is normally done by some external 
agency. For example, an analytical laboratory might be audited by representatives of a federal 
agency with which they have a contract. An independent laboratory might file documentation 
with a responsible state or federal agency. The evaluation is concerned with such issues as space 
(amount, quality and relevance), ventilation, equipment, storage, hygiene, etc. Student chemis
try laboratories are generally evaluated by the American Chemical Society, as part of the process 
of granting approval for the overall chemistry program presented by the college or university. 
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and likewise unmistakably connected with the set of analytical data. Finally, in many cases there 
must be information or an audit trail of a sample (to include when sample was receive, booked on 
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lyzer, when result was clinically validated and available to the requesting clinician. At every stage of 
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for several reasons:
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lytical data, SOP’s, instrument validation results, reagent certification re-
sults, analyst certification documents and other relevant records must be 
available and kept safe for a specified period of time.
2.  Maintenance of instrument and reagent certification records provides for 
post-evaluation of results, even after the passage of several years.
3.  Maintenance of all records specified provide documentation which may 
be required in the event of legal challenges due to repercussions of deci-
sions based on the original analytical results.
4. Many vendors are now providing many of these capabilities as part 
of computer packages for operating modern instruments. For exam-
ple most modern computer-based instruments will provide for the 
indefinite storage of raw analytical data for specific samples in a pro-
tected (tamper-proof) environment as well as maintenance of histori-
cal records of control chart data establishing the operational quality of 
instruments during any period during which analytical data have been 
acquired by that instrument.
5. The length of time over which laboratory records should be maintained 
will vary with the situation. The general guidelines followed in regulated 
laboratories are to maintain records for at least five years. In some coun-
tries these records are being maintained much longer. The development 
of higher density storage devices for digitized data is making this kind of 
record-keeping possible.
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Accountability. GLP procedures inherently establish accountability for laboratory results. A 
laboratory organization, the analysts and manufacturers of instruments and reagents are re-
sponsible to a larger extent for laboratory results generated by the laboratory. Responsibil-
ity for all aspects of the laboratory processes leading to technical results and conclusions 
must be clearly defined and documented. Laboratory organization have the responsibility 
to ensure that a robust process is in place to assure the quality of results emanating from the 
laboratory. This situation should place appropriate pressure on analysts to conduct studies 
with adequate care and concern, laboaratory organization to put a process in place to assure 
quality and instrument manaufacturers to ensure that their instruments and reagents are fit 
for purpose. Moreover justify that a process should be in place in the laboratory that ensures 
the possibility of identifying more quickly and succinctly the source(s) of error(s), identifying 
the root causes and taking corrective and preventive action to maintain acceptable quality of 
laboratory data.
Other GLP general rules
1.  Develop SOP for all task, ensure that all staff performing the task are 
tranied to the SOP, sign to the SOP and infact are following the SOP strictly.
2.  Ensure that correct equipment and reagents are being used. Outdated 
reagents, malfunctioning equipment and equipment that have not been 
adequately cleaned, calibrated, maintined and quality controlled must 
not be used for diagnosis on patient sample.
3.  Put a robust method in place to avoid mix up of samples as well as label-
ling errors.
4. Report and root cause every mistakes, near misses, errors and bad prac-
tices and come up with corrective and preventive action to prevent such 
errors (Never cover up. Cover up is dangerous and can cause loss of lives).
5.  Put in place a mechanism for implementing corrective and preventive action 
(re-training of staff with deficiencies, modification of process. Records must 
be clear, accurate and securely kept for several years depending on regulation. 
Records must identify person responsible, confirm what was done.
38. Quality Issues in Transfusion Medicine
Quality assurance is a vital topic in transfusion medicine. Quality management system (QMS) is 
the sum total of all the processes that allow for the effective control of the whole operation. It is 
not just an added-on to the process but it is a very vital part of the process control in the transfu-
sion laboratory. It includes the use of a documented set of policies and procedures which define 
how you achieve a defined quality of product or service. In the laboratory, a quality product or 
service is a service that meets the customer requirements. It is providing the right result on the 
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right specimen from the right patient that is cost effective (value for money), reliable, accurate, 
reproducible (best possible care), timely (improving health), effectively and appropriately com
municated by a highly motivate laboratory professional (joy and pride at work) to the users of 
the service, enhances the quality of care offered to customer. To achieve our goal of making the 
availability of safe blood at all times without shortage, a uniform and updated national blood 
policy should be introduced all over Nigera. This will definitely give confidence in introducing 
good quality control, quality assurance and accreditation at all levels of transfusion practices. 
Standard Operating Procedures (SOP) are needed for the blood banks. 
Quality management system (QMS) is the sum total of all the processes that allow for the effective 
control of the whole operation. It includes the use of a documented set of policies and procedures 
which define how you achieve a defined quality of product   or service. In the lab, a quality prod
uct or service is a service that meets the customer requirements. It is providing the right result on 
the right specimen from the right patient that is cost effective (value for money), reliable, accurate, 
reproducible (best possible care), timely (improving health), effectively and appropriately com
municated by a highly motivate laboratory professional (joy and pride at work) to the users of the 
service, enhances the quality of care offered customer. A simple definition of quality is ‘fitness for 
a purpose’. In blood transfusion service, the primary goal of quality is ‘transfusion of safe unit of 
blood.’ The objective is to ensure availability of a sufficient supply of blood, blood components of 
high quality with maximum efficacy and minimum risk to both donors and patients. To achieve 
quality in a defined procedure, a laboratory may encounter constraints such as; organizational 
constraints in terms of staffing patterns, finances available, training of staff and technical con
straints for example the ability of laboratory to perform a specific test. 
A failure in the quality of blood collected or screening of donated blood unit can be very 
serious and may result in fatal consequences. If appropriate quality systems are designed, 
mplemented and monitored, the issue of an improperly tested unit can be avoided. Besides 
laboratory testing, a failure in the quality system can lead to numerous situations which may 
be potentially dangerous to the patient, i.e. 
1.  failure to identify the patient correctly 
2. wrong sample labelling 
3. mix-up of results amongst different patients 
4. Failure to detect presence of an abnormality in the patient’s sample. 
5. issue of unscreened blood due to faulty laboratory procedures 
Therefore, it is very important to recognise the need for quality and implementation of 
quality assurance scheme in all laboratory procedures. The difference between these two 
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the sum total of all the processes that allow for the effective control of the whole operation. It is 
not just an added-on to the process but it is a very vital part of the process control in the transfu
sion laboratory. It includes the use of a documented set of policies and procedures which define 
how you achieve a defined quality of product or service. In the laboratory, a quality product or 
service is a service that meets the customer requirements. It is providing the right result on the 
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right specimen from the right patient that is cost effective (value for money), reliable, accurate, 
reproducible (best possible care), timely (improving health), effectively and appropriately com-
municated by a highly motivate laboratory professional (joy and pride at work) to the users of 
the service, enhances the quality of care offered to customer. To achieve our goal of making the 
availability of safe blood at all times without shortage, a uniform and updated national blood 
policy should be introduced all over Nigera. This will definitely give confidence in introducing 
good quality control, quality assurance and accreditation at all levels of transfusion practices. 
Standard Operating Procedures (SOP) are needed for the blood banks. 
Quality management system 
Quality management system (QMS) is the sum total of all the processes that allow for the effective 
control of the whole operation. It includes the use of a documented set of policies and procedures 
which define how you achieve a defined quality of product   or service. In the lab, a quality prod-
uct or service is a service that meets the customer requirements. It is providing the right result on 
the right specimen from the right patient that is cost effective (value for money), reliable, accurate, 
reproducible (best possible care), timely (improving health), effectively and appropriately com-
municated by a highly motivate laboratory professional (joy and pride at work) to the users of the 
service, enhances the quality of care offered customer. A simple definition of quality is ‘fitness for 
a purpose’. In blood transfusion service, the primary goal of quality is ‘transfusion of safe unit of 
blood.’ The objective is to ensure availability of a sufficient supply of blood, blood components of 
high quality with maximum efficacy and minimum risk to both donors and patients. To achieve 
quality in a defined procedure, a laboratory may encounter constraints such as; organizational 
constraints in terms of staffing patterns, finances available, training of staff and technical con-
straints for example the ability of laboratory to perform a specific test. 
Need for Quality 
A failure in the quality of blood collected or screening of donated blood unit can be very 
serious and may result in fatal consequences. If appropriate quality systems are designed, 
implemented and monitored, the issue of an improperly tested unit can be avoided. Besides 
laboratory testing, a failure in the quality system can lead to numerous situations which may 
be potentially dangerous to the patient, i.e. 
1.  failure to identify the patient correctly 
2. wrong sample labelling 
3. mix-up of results amongst different patients 
4. Failure to detect presence of an abnormality in the patient’s sample. 
5. issue of unscreened blood due to faulty laboratory procedures 
Therefore, it is very important to recognise the need for quality and implementation of 
quality assurance scheme in all laboratory procedures. The difference between these two 
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terms may be unclear to many people and the terms cannot be used interchangeably. Qual-
ity assurance deals with the maintenance of a system to ensure that the performance in a 
laboratory is of the required quality. In a blood transfusion centre, it means that a manage-
ment system should exist to look into provision of a safe unit of blood and, if any errors 
are identified, these should be corrected. Quality control is the inspection system which 
involves specific actions performed to monitor the effectiveness of the system and checks 
that the mistakes have not occurred.
Indicators to monitor the quality of your laboratory’s performance 
1. Turnaround times. 
2. Internal quality assessment. 
3. External quality assessment. 
4. It is not sufficient to sit back and assume that we are doing fine quality 
wise. 
5. In fact, since no system is perfect, there is every tendency that we do 
make mistakes. If we do, then;
6. How many do we make and why? Are there trends.
7. How often do we exceed our turnaround times? 
8. How often does our LIMS go down?
9. How often do we produce an incorrect result, or send the correct result 
but for the wrong patient? 
10. We need to measure our performance.
11. Measuring our performance is the only was to monitor and measure im-
provements. 
What constitutes quality from a customer’s perspective?
1. Customer see the response time for lab test as critical to the quality of 
care. 
2. Want to be informed about the turnaround times.
3. Expect that laboratory results are reliable.
4. Expect a simple and easy to follow instructions on sample collection and 
handling.
5. Require a prompt, customer focused and friendly phlebotomy service.
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6. Want a continually improving service.
7. Require a cost effective quality service 
8. Want a safety, environment and infection control conscious lab service. 
9. Customers like a process oriented service with a feedback system.
 All arrangements in place to ensure that products and services 
meet the quality required. It includes; staff training, equipment maintenance, use of inter
nal quality, enrolment in external quality programmes, use of STD operating procedures, 
objective performance of audits, submission to accreditation and carrying out user satisfac
tion survey.
Benefits of a quality system includes
1. Achieving accreditation. 
2. Achieving better control of processes. 
3. Drives improvement (documented quality system is mechanism for im
provement).
4. Proof those adequate procedures are in place in the event of legal pro
ceedings.
5. Improved service for the customer.
6. Increased efficiency through reduction of mistakes and waste. 
 Internal quality control (IQC) is the 
analysis of material of known content. Confirms that the procedures are performing within 
predetermined specifications. Day-to-day monitoring of reproducibility or precision but not 
accuracy. Detect errors in any one analytical run. Qualitative assays include internal controls 
to validate run. Use of QC run on analyzers requires control charts (or Shewhart plots) using 
Westgard rules. Control material for use in control charts must: 
1. Behave like real samples 
2. Be sufficient for a period of time.
3. Be stable over time period of use. 
4. Be appropriately apportioned for convenient use.
5. Vary little in concentration between aliquots. 
terms may be unclear to many people and the terms cannot be used interchangeably. Qual
ity assurance deals with the maintenance of a system to ensure that the performance in a 
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2. Want to be informed about the turnaround times.
3. Expect that laboratory results are reliable.
4. Expect a simple and easy to follow instructions on sample collection and 
handling.
5. Require a prompt, customer focused and friendly phlebotomy service.
235Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
6. Want a continually improving service.
7. Require a cost effective quality service 
8. Want a safety, environment and infection control conscious lab service. 
9. Customers like a process oriented service with a feedback system.
What is quality assurance?. All arrangements in place to ensure that products and services 
meet the quality required. It includes; staff training, equipment maintenance, use of inter-
nal quality, enrolment in external quality programmes, use of STD operating procedures, 
objective performance of audits, submission to accreditation and carrying out user satisfac-
tion survey.
Benefits of a quality system includes
1. Achieving accreditation. 
2. Achieving better control of processes. 
3. Drives improvement (documented quality system is mechanism for im-
provement).
4. Proof those adequate procedures are in place in the event of legal pro-
ceedings.
5. Improved service for the customer.
6. Increased efficiency through reduction of mistakes and waste. 
Internal quality control and external quality assurance. Internal quality control (IQC) is the 
analysis of material of known content. Confirms that the procedures are performing within 
predetermined specifications. Day-to-day monitoring of reproducibility or precision but not 
accuracy. Detect errors in any one analytical run. Qualitative assays include internal controls 
to validate run. Use of QC run on analyzers requires control charts (or Shewhart plots) using 
Westgard rules. Control material for use in control charts must: 
1. Behave like real samples 
2. Be sufficient for a period of time.
3. Be stable over time period of use. 
4. Be appropriately apportioned for convenient use.
5. Vary little in concentration between aliquots. 
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Internal Quality Assessment (IQA) and External Quality Assessment (EQA). Quality assur-
ance in clinical laboratories is for the provision of precise and accurate analyses to support 
optimal healthcare. The importance and value of internal quality control and external quality 
assessment have gained a higher professional profile particularly with the introduction of 
the new Clinical Pathology Accreditation standards. Quality assurance improves test reliabil-
ity through helping to minimise the variability arising from biological or analytical sources 
inherent in all qualitative and quantitative measurements. An important contribution to the 
reliability of laboratory results however lies in ensuring correct specimen collection, handling 
and identification. Although most modern analytical systems are apparently simple to use, 
the quality of results does not come automatically  with the equipment. Appropriate quality 
assurance measures that include; analytical quality control measures (IQA and EQA) need to 
be taken, including of course staff motivation, training and assessment. Internal and external 
quality assessments are vital components of a quality system that offers valuable insights into 
the effectiveness of the quality system.
Internal quality assessment (IQA): Internal quality assessment assesses in real time whether the 
performance of an individual laboratory or testing site is sufficiently similar to their previous per-
formance for results to be used. It controls reproducibility or precision and facilitates continuity of 
patient care overtime. Most IQA procedures employ analysis of a control material and compare 
the results with pre-determined limits of acceptability. Discrepancies in results are investigated, 
with major discrepancies requiring repeat testing, possibly with request for another specimen. 
Larger numbers of samples can be handled in IQA than in EQA schemes. There is also flexibility 
of sample types to be assessed. External quality assessment (EQA) by contrast looks at differences 
between sites testing the same analyte, so there can be continuity of testing over geography. This 
usually involves the analysis of identical specimens at many laboratories and the comparison of 
results with those of other sites. While IQA controls the precision of investigations, EQA should 
be providing an assessment of their accuracy since it lack bias with respect to other test sites. EQA 
is done periodically and retrospectively. EQA also provides assessment of the overall standard of 
performance, the relative performance of the analytical procedures (method principle, reagents 
and instruments) as well as the specimen distributed. EQA is likely to help stimulate needed 
quality improvement. EQA may also indicate analytical procedures showing excellent perform-
ance characteristics and which can be recommended and also identify unsatisfactory procedures 
which should be discouraged. Internal quality assurance is meant to allow laboratory scientist to 
check their performance by themselves and help them to monitor the reliability of their technique. 
In other words, it deals with the measures taken by a local laboratory to maintain laboratory 
standards. IQA includes procedures designed for continuous evaluation of the work of the labora-
tory concerned and it aims at achieving high level of safety and efficiency. 
External quality assessment (EQA). This is the challenge of the efficacy of laboratory quality as-
surance procedures by specimens of known but undisclosed content. A central body periodically 
distributes EQA specimens to different testing sites, and compare individual laboratory results 
with that of other participating laboratories, and with the correct answer. It gives participants an 
insight into their routine performance so that they take appropriate corrective action where neces-
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sary. External quality assessment facilitates optimal patient care by providing a comprehensive 
external quality assessment service in laboratory medicine. Through education and the promo
tion of best services, it helps ensure that the results of investigations are reliable and comparable 
wherever they are produced. Assessment of IQA results can be more sensitive to local clinical 
and technical styles than it is possible with EQA schemes and scoring made more stringent than 
in EQA. External quality assurance involves a central reference laboratory which monitors the 
standards of local laboratories. EQA is a system whereby a set of reagents and techniques are as
sessed by an external source and the results of testing laboratory being compared with those of an 
approved reference laboratory. External quality assessment has the following merits:
1. Comparability: Participating laboratories are able to assess whether their 
results are comparable with those of other laboratories. This provides a 
means of detecting and checking whether such differences are affecting 
results of investigations of clinical specimens, hence patient care.
2. Educational stimulus: Participation in EQA can serve as an educational 
tool for laboratory staff, especially in the area of quality management.
3. Credibility: Participation in EQA scheme is a demonstration that the labo
ratory has a responsible attitude to quality issues.
4. Insight into National Performance levels: EQA results provide laboratory 
professionals, funding organisations, and health service administrators 
with an insight into national performance levels for informed decision 
making on the use of and support for laboratory services.
5. Improvement in national performance levels: Identification of problem 
areas enables laboratory professionals to take action to remedy deficien
cies, which results in performance improvements over time.
6. External quality assessment schemes are standardised and has expert di
rection.
The EQA process is essentially retrospective and provides an assessment of performance 
rather than control for each test performed. Participating laboratories may give EQA samples 
special treatment to improve their chances of getting a high performance score. This practice 
oes not give a fair reflection of the performance of the laboratory and may not give true 
insight into where there may be genuine problems in the process, therefore hinder improve
ments in the system. In contrast however, IQA results can be more sensitive to local clinical 
and technical styles than it is possible with EQA schemes and scoring made more stringent 
than in EQA. Internal quality assessment can be used to monitor the whole laboratory, from 
specimen registration to issue of reports. Performance standards can be derived from the 
process. Used together IQA and EQA provide a method of ensuring accuracy and consistency 
of results and are vital tools in the quality assurance of the clinical laboratory. IQA and EQA 
results should be reviewed at laboratory meetings and should be readily available informa
tion that could stimulate quality improvement in the laboratory.
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performance, the relative performance of the analytical procedures (method principle, reagents 
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ance characteristics and which can be recommended and also identify unsatisfactory procedures 
which should be discouraged. Internal quality assurance is meant to allow laboratory scientist to 
check their performance by themselves and help them to monitor the reliability of their technique. 
In other words, it deals with the measures taken by a local laboratory to maintain laboratory 
standards. IQA includes procedures designed for continuous evaluation of the work of the labora
tory concerned and it aims at achieving high level of safety and efficiency. 
External quality assessment (EQA). This is the challenge of the efficacy of laboratory quality as
surance procedures by specimens of known but undisclosed content. A central body periodically 
distributes EQA specimens to different testing sites, and compare individual laboratory results 
with that of other participating laboratories, and with the correct answer. It gives participants an 
insight into their routine performance so that they take appropriate corrective action where neces
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sary. External quality assessment facilitates optimal patient care by providing a comprehensive 
external quality assessment service in laboratory medicine. Through education and the promo-
tion of best services, it helps ensure that the results of investigations are reliable and comparable 
wherever they are produced. Assessment of IQA results can be more sensitive to local clinical 
and technical styles than it is possible with EQA schemes and scoring made more stringent than 
in EQA. External quality assurance involves a central reference laboratory which monitors the 
standards of local laboratories. EQA is a system whereby a set of reagents and techniques are as-
sessed by an external source and the results of testing laboratory being compared with those of an 
approved reference laboratory. External quality assessment has the following merits:
1. Comparability: Participating laboratories are able to assess whether their 
results are comparable with those of other laboratories. This provides a 
means of detecting and checking whether such differences are affecting 
results of investigations of clinical specimens, hence patient care.
2. Educational stimulus: Participation in EQA can serve as an educational 
tool for laboratory staff, especially in the area of quality management.
3. Credibility: Participation in EQA scheme is a demonstration that the labo-
ratory has a responsible attitude to quality issues.
4. Insight into National Performance levels: EQA results provide laboratory 
professionals, funding organisations, and health service administrators 
with an insight into national performance levels for informed decision 
making on the use of and support for laboratory services.
5. Improvement in national performance levels: Identification of problem 
areas enables laboratory professionals to take action to remedy deficien-
cies, which results in performance improvements over time.
6. External quality assessment schemes are standardised and has expert di-
rection.
The EQA process is essentially retrospective and provides an assessment of performance 
rather than control for each test performed. Participating laboratories may give EQA samples 
special treatment to improve their chances of getting a high performance score. This practice 
does not give a fair reflection of the performance of the laboratory and may not give true 
insight into where there may be genuine problems in the process, therefore hinder improve-
ments in the system. In contrast however, IQA results can be more sensitive to local clinical 
and technical styles than it is possible with EQA schemes and scoring made more stringent 
than in EQA. Internal quality assessment can be used to monitor the whole laboratory, from 
specimen registration to issue of reports. Performance standards can be derived from the 
process. Used together IQA and EQA provide a method of ensuring accuracy and consistency 
of results and are vital tools in the quality assurance of the clinical laboratory. IQA and EQA 
results should be reviewed at laboratory meetings and should be readily available informa-
tion that could stimulate quality improvement in the laboratory.
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Risk assessment. Think about all the steps involved from specimen collection to result avail-
ability to clinician. Think about all the critical control points. This is a form of risk assessment. 
At each step, there is a possibility that something could go wrong. Also at each step it is im-
portant to consider if specific conditions need to be met, e.g., incubation at 37°C. Identify the 
risks in all the steps and document what control measures in place in your lab to manage risks. 
Consider measures not being taken or inadequate in your own laboratory to manage a risk 
that you have identified. Risk analysis can play a role in continuous improvement. 
Continuous quality improvement (CQI) in transfusion
Quality system can provide a mechanism for improvements by generating evidence based 
data to monitor quality improvements. By carrying out regular and objective audits and im-
plementing corrective and preventive action. By building a culture of continual improvement. 
Only thing that adds value is transformation of raw material into something the customer 
wants. A continuous improvement process is an ongoing effort to improve products, services, 
or processes. These efforts can seek “incremental” improvement over time or “breakthrough” 
improvement all at once. Delivery (customer valued) processes are constantly evaluated and 
improved in the light of their efficiency, effectiveness and flexibility. Some successful imple-
mentations use the approach known as Kaizen (the translation of Kai (change) zen (good or 
improvement). This method became famous by the book of Masaaki Imai “Kaizen: The Key 
to Japan’s Competitive Success.”The core principle of CIP is the (self) reflection of processes. 
(Feedback). The purpose of continuous improving process (CIP) is the identification, reduc-
tion, and elimination of suboptimal processes (Efficiency). The emphasis of CIP is on incre-
mental, continuous steps rather than giant leaps (Evolution). Key features of Kaizen include:
• Quality system can provide a mechanism for improvements by gen-
erating evidence based data to monitor quality improvements.
• By carrying out regular and objective audits and implementing cor-
rective and preventive action.
• By building a culture of continual improvement.
• Only thing that adds value is transformation of raw material into 
something the customer wants. 
• Improvements are based on many, small changes rather than the rad-
ical changes that might arise from research and development.
• As the ideas come from the workers themselves, they are less likely to 
be radically different, and therefore easier to implement.
• Small improvements are less likely to require major capital invest-
ment than major process changes.
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• The ideas come from the talents of the existing workforce, as op
posed to using R&D, consultants or equipment – any of which could 
be very expensive.
• All employees should continually be seeking ways to improve their 
own performance.
• It helps encourage workers to take ownership for their work, and can 
help reinforce team working, thereby improving worker motivation.
The elements above are the more tactical elements of CIP. The more strategic elements in
clude deciding how to increase the value of the delivery process output to the customer (Ef
fectiveness) and how much flexibility is valuable in the process to meet changing needs. The 
involvement of all workers require training, it is necessary to be able to distinguish between 
symptom and ailment so that efforts are spent solving the root causes of the problem.
 Quality is a cycle of continuous improvement. Proper CQI 
starts with planning and data collection. Statistical analysis on the wrong or incorrect data is 
not useful, the analysis must be appropriate for the data collected. Be sure to PLAN, and then 
constantly re-evaluate your situation to make sure the plan is correct. The key to any process 
improvement program is the PDSA cycle described by Walter Shewart.
 Collect data and establish a baseline – what is the current process doing now? Identify 
the problem and the possible causes. The QC tools described in this manual can help organi
zations identify problems and possible causes, and to prioritize corrective actions.
 Make changes designed to correct or improve the situation. These changes often come 
form quality improvement suggestions made by staff or from feed back from service user’s 
satisfaction surveys and findings from root cause analysis carried out following an incident 
or complaint from service users.
 Study the effect of these changes on the situation. Collect data on the new process 
and compare to the baseline. This is where control charts are used – they show the effects of 
changes on a process over time. Evaluate the results and then replicate the change or abandon 
it and try something different.
 If the result is successful, standardize the changes and then work on further improve
ments or the next prioritized problem. If the outcome is not yet successful, look for other ways 
to change the process or identify different causes for the problem. Control charting is one of a 
number of steps involved in CQI. The steps include discovery, analysis, prioritization, clarifi
cation, and then charting. Before using the Statit software, appropriate data must be collected 
for analysis. Then, you need to begin again and do it over and and over. 
 Think about all the steps involved from specimen collection to result avail
ability to clinician. Think about all the critical control points. This is a form of risk assessment. 
At each step, there is a possibility that something could go wrong. Also at each step it is im
portant to consider if specific conditions need to be met, e.g., incubation at 37°C. Identify the 
risks in all the steps and document what control measures in place in your lab to manage risks. 
Consider measures not being taken or inadequate in your own laboratory to manage a risk 
that you have identified. Risk analysis can play a role in continuous improvement. 
Continuous quality improvement (CQI) in transfusion
Quality system can provide a mechanism for improvements by generating evidence based 
data to monitor quality improvements. By carrying out regular and objective audits and im
plementing corrective and preventive action. By building a culture of continual improvement. 
Only thing that adds value is transformation of raw material into something the customer 
wants. A continuous improvement process is an ongoing effort to improve products, services, 
or processes. These efforts can seek “incremental” improvement over time or “breakthrough” 
improvement all at once. Delivery (customer valued) processes are constantly evaluated and 
improved in the light of their efficiency, effectiveness and flexibility. Some successful imple
mentations use the approach known as Kaizen (the translation of Kai (change) zen (good or 
improvement). This method became famous by the book of Masaaki Imai “Kaizen: The Key 
to Japan’s Competitive Success.”The core principle of CIP is the (self) reflection of processes. 
(Feedback). The purpose of continuous improving process (CIP) is the identification, reduc
tion, and elimination of suboptimal processes (Efficiency). The emphasis of CIP is on incre
mental, continuous steps rather than giant leaps (Evolution). Key features of Kaizen include:
• Quality system can provide a mechanism for improvements by gen
erating evidence based data to monitor quality improvements.
• By carrying out regular and objective audits and implementing cor
rective and preventive action.
• By building a culture of continual improvement.
• Only thing that adds value is transformation of raw material into 
something the customer wants. 
• Improvements are based on many, small changes rather than the rad
ical changes that might arise from research and development.
• As the ideas come from the workers themselves, they are less likely to 
be radically different, and therefore easier to implement.
• Small improvements are less likely to require major capital invest
ment than major process changes.
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• The ideas come from the talents of the existing workforce, as op-
posed to using R&D, consultants or equipment – any of which could 
be very expensive.
• All employees should continually be seeking ways to improve their 
own performance.
• It helps encourage workers to take ownership for their work, and can 
help reinforce team working, thereby improving worker motivation.
The elements above are the more tactical elements of CIP. The more strategic elements in-
clude deciding how to increase the value of the delivery process output to the customer (Ef-
fectiveness) and how much flexibility is valuable in the process to meet changing needs. The 
involvement of all workers require training, it is necessary to be able to distinguish between 
symptom and ailment so that efforts are spent solving the root causes of the problem.
Steps Involved In Using CQI. Quality is a cycle of continuous improvement. Proper CQI 
starts with planning and data collection. Statistical analysis on the wrong or incorrect data is 
not useful, the analysis must be appropriate for the data collected. Be sure to PLAN, and then 
constantly re-evaluate your situation to make sure the plan is correct. The key to any process 
improvement program is the PDSA cycle described by Walter Shewart.
Plan. Collect data and establish a baseline – what is the current process doing now? Identify 
the problem and the possible causes. The QC tools described in this manual can help organi-
zations identify problems and possible causes, and to prioritize corrective actions.
Do. Make changes designed to correct or improve the situation. These changes often come 
form quality improvement suggestions made by staff or from feed back from service user’s 
satisfaction surveys and findings from root cause analysis carried out following an incident 
or complaint from service users.
Study. Study the effect of these changes on the situation. Collect data on the new process 
and compare to the baseline. This is where control charts are used – they show the effects of 
changes on a process over time. Evaluate the results and then replicate the change or abandon 
it and try something different.
Act. If the result is successful, standardize the changes and then work on further improve-
ments or the next prioritized problem. If the outcome is not yet successful, look for other ways 
to change the process or identify different causes for the problem. Control charting is one of a 
number of steps involved in CQI. The steps include discovery, analysis, prioritization, clarifi-
cation, and then charting. Before using the Statit software, appropriate data must be collected 
for analysis. Then, you need to begin again and do it over and and over. 
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)240
Figure: Plan, do, study and act (PDSA cycle)
 
Quality Audits in transfusion
A quality audit is a systematic, independent and documented process of evaluating selected 
elements of a quality system. Ensure that system being implemented is effective and is being 
complied with. There are 3 types of audits;
• Horizontal audit: Involves the assessment of one element of the qual-
ity system 
• Examination audit: Involves a process whereby the assessor watches 
a test being performed, to ascertain if SOP is being followed. It is 
used to confirm competence of the staff and level of training. 
• Vertical audit: Involves a process whereby a sample is tracked from 
sample receipt to the issue of result. 
Quality audits re-emphasize the following:
1. The importance of proper record keeping and documentation. 
2. The need to work to defined standards and procedures. 
3. The importance for effective and appropriate storage and monitoring of 
temperature –dependent reagents.
4. The need for proactive maintenance of equipments.
5. The need to develop a culture of continuous improvement. 
Examples of vertical and horizontal audits
Horizontal audits include an element of the quality process; equipment, staff training, docu-
ment control, housekeeping, internal audit, evaluations. Important aspects to look at includes; 
associated records, SOPs, EOPs, visual appearance, suitability for use, staff interactions with 
the system & whether the system is achieving its intended result. Vertical audit cuts across 
the entire process from sample reception to result availability. It includes variables such as 
; storage of reagents, health and safety issues, staff training, infection control, competences, 
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equipment maintenance, internal and external quality assessments, premises, corrective ac
tions, pre, examination and post examination.
1. Preparation of a checklist. 
2. The better the checklist is, the easier and more standardised audits become. 
3. A checklist prepared for one audit may be updated and used for repeat 
audits of the same topic.
4. Organise a pre-audit meeting.
5. Consult relevant SOPs since you will need to ensure staff members are 
compliant to the SOP.
6. Draw up quality improvement notes arising from the audit to facilitate a 
continually improving process.
7. Organize a post audit meeting to discuss non-compliances & quality im
provement issues arising.
8. Implement suggested change. 
1.
Identify test, processes, proce-
dure being audited.
Are there SOP available for 
sample examination processes?
Have procedures been validated 
for use prior to introduction. List 
document examined
Are SOP current, signed and 
Are SOP being followed by staff 
performing task
Is there evidence of document 
-
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a test being performed, to ascertain if SOP is being followed. It is 
used to confirm competence of the staff and level of training. 
• Vertical audit: Involves a process whereby a sample is tracked from 
sample receipt to the issue of result. 
Quality audits re-emphasize the following:
1. The importance of proper record keeping and documentation. 
2. The need to work to defined standards and procedures. 
3. The importance for effective and appropriate storage and monitoring of 
temperature –dependent reagents.
4. The need for proactive maintenance of equipments.
5. The need to develop a culture of continuous improvement. 
Examples of vertical and horizontal audits
Horizontal audits include an element of the quality process; equipment, staff training, docu
ment control, housekeeping, internal audit, evaluations. Important aspects to look at includes; 
associated records, SOPs, EOPs, visual appearance, suitability for use, staff interactions with 
the system & whether the system is achieving its intended result. Vertical audit cuts across 
the entire process from sample reception to result availability. It includes variables such as 
; storage of reagents, health and safety issues, staff training, infection control, competences, 
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equipment maintenance, internal and external quality assessments, premises, corrective ac-
tions, pre, examination and post examination.
Performing a quality audit
1. Preparation of a checklist. 
2. The better the checklist is, the easier and more standardised audits become. 
3. A checklist prepared for one audit may be updated and used for repeat 
audits of the same topic.
4. Organise a pre-audit meeting.
5. Consult relevant SOPs since you will need to ensure staff members are 
compliant to the SOP.
6. Draw up quality improvement notes arising from the audit to facilitate a 
continually improving process.
7. Organize a post audit meeting to discuss non-compliances & quality im-
provement issues arising.
8. Implement suggested change. 
Example of an audit check list
Audit type/number and details ( Verical audit/ AUD 100: General duties in transfusion)/Com-
pleted by/completion date: Dr Osaro/3/11/2011
Number Audit question Response
1.
Identify test, processes, proce-
dure being audited.
2.
Are there SOP available for 
sample examination processes?
3.
Have procedures been validated 
for use prior to introduction. List 
document examined
4.
Are SOP current, signed and 
dated
5.
Are SOP being followed by staff 
performing task
6.
Is there evidence of document 
control in place. State last revi-
sion date
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)242
7.
Are there COSHH (control of 
substances hazardous to health)
risk and general assessment s 
available for all task.
8.
Are there procedure in place 
for reporting and monitoring of 
accidents and incidents
9.
Are staff responsible clearly 
identified and are there evi-
dence of training and education.
10.
Are there procedures for sample 
receipt, transport and booking 
in?
11.
What is the specimen number 
of the sample being audited. 
Is there sufficient information 
to uniquely identify patient. 
Is there evidence of date and 
time of sample collection. Does 
request form contain required 
clinical information.
12.
Is there process in place for 
handling urgent sample. Is there 
criteria for rejection of sample
13. 
Is there record available for each 
stage of the process such that 
there is complete audit trail of 
staff, equipment reagents and 
quality control procedures in-
volved. List document examined?
14.
Is there evidence that equip-
ment used is routinely main-
tained, daily checks done and 
quality controlled. List equip-
ment checked
15.
Is the lab enrolled into and 
EQA. Are EQA report reviewed.
indicate scheme
16.
Does lab report contain time 
and date of report, results and 
reason if no examination done.
Are there interpretive com-
ments and are abnormal results 
highlighted
17.
Does lab has turnaround time 
for test/process being audited.
Is set turnaround time feasible 
and are target being met
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1. The internal quality control used for a test run was out of limits and there 
is no evidence that any action was taken.
2. Purpose is to convey findings in a clear and accurate manner to the au
ditee (what was wrong and what to do next)
3. Fridges used for storage of temperature dependent reagents have gone 
outside ambient temperature several times and there is no remedial ac
tion taken.
4. Incidents, near misses and complaint are not investigated
5. Staff satisfaction surveys are not being done
6. Staff performing task have not been trained or competency tested
7. There are no standard work for task being performed
8. The transfusion lab is not registered for any EQA scheme
9. Thre are no policy in place for infection control, manual handling and 
there are no personal protective equipment for staff
10. Staff occupational health-related vaccination is not up to date.
11. Someone is doing a routine test for which there is no SOP. 
12. There is a bottle of clear liquid on the bench with no label on. A member 
of staff says it is only water. 
1. To advise the next auditor what you have found so that they can follow it up. 
2. To present a record that can be re-assessed at a later date during manage
ment review.
3. To enable auditee to determine root cause, determine remedial, corrective 
and prevention action to eliminate root causes. 
4. Non-compliance notes (NCNs) are used to report any deficiencies found 
during an audit. 
1. What remedial action (Quick fix) you would take. 
2. Consider the further corrective action to eliminate root causes. 
3. Implement corrective action.
4. Audit the process to ensure that root cause have been eliminated. 
Are there COSHH (control of 
substances hazardous to health)
risk and general assessment s 
available for all task.
Are there procedure in place 
for reporting and monitoring of 
Are staff responsible clearly 
identified and are there evi-
dence of training and education.
10.
Are there procedures for sample 
receipt, transport and booking 
11.
What is the specimen number 
of the sample being audited. 
Is there sufficient information 
to uniquely identify patient. 
Is there evidence of date and 
time of sample collection. Does 
request form contain required 
clinical information.
12.
Is there process in place for 
handling urgent sample. Is there 
criteria for rejection of sample
13. 
Is there record available for each 
stage of the process such that 
there is complete audit trail of 
staff, equipment reagents and 
quality control procedures in-
volved. List document examined?
14.
Is there evidence that equip-
ment used is routinely main-
tained, daily checks done and 
quality controlled. List equip-
ment checked
15. EQA. Are EQA report reviewed.
16.
and date of report, results and 
reason if no examination done.
-
ments and are abnormal results 
highlighted
17.
Does lab has turnaround time 
for test/process being audited.
Is set turnaround time feasible 
and are target being met
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Examples of non-conformance notes
1. The internal quality control used for a test run was out of limits and there 
is no evidence that any action was taken.
2. Purpose is to convey findings in a clear and accurate manner to the au-
ditee (what was wrong and what to do next)
3. Fridges used for storage of temperature dependent reagents have gone 
outside ambient temperature several times and there is no remedial ac-
tion taken.
4. Incidents, near misses and complaint are not investigated
5. Staff satisfaction surveys are not being done
6. Staff performing task have not been trained or competency tested
7. There are no standard work for task being performed
8. The transfusion lab is not registered for any EQA scheme
9. Thre are no policy in place for infection control, manual handling and 
there are no personal protective equipment for staff
10. Staff occupational health-related vaccination is not up to date.
11. Someone is doing a routine test for which there is no SOP. 
12. There is a bottle of clear liquid on the bench with no label on. A member 
of staff says it is only water. 
Aim of non-conformance notes
1. To advise the next auditor what you have found so that they can follow it up. 
2. To present a record that can be re-assessed at a later date during manage-
ment review.
3. To enable auditee to determine root cause, determine remedial, corrective 
and prevention action to eliminate root causes. 
4. Non-compliance notes (NCNs) are used to report any deficiencies found 
during an audit. 
Dealing with non conformances
1. What remedial action (Quick fix) you would take. 
2. Consider the further corrective action to eliminate root causes. 
3. Implement corrective action.
4. Audit the process to ensure that root cause have been eliminated. 
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5. Continuously solving root problems drives organizational learning and 
improvement.
6. Sophisticated technique for solving problems is to: ask “why?” objec-
tively five times. 
Responding to audit findings – non-compliance
Audit criterion 1. 
Guidelines require that patient records contain a record of the clinician’s reason for prescrib-
ing each red cell transfusion.
Audit findings
A doctor’s record of the reason for transfusing is found in only 20% of patients’ files.
Root Causes
Failure in the oversight function by supervising clinical staff and consultants.
Corrective action
Obtain the agreement of clinical staff to achieve a target of 90% documentation of the reason 
to transfuse and to participate in education on the importance of clinical accountability for 
transfusion and to a repeat audit.
Audit Criterion 2
Guidelines require that all patients undergoing transfusion have observations of pulse, 
blood pressure, respiration and temperature recorded before and at specified time intervals 
during the transfusion.
Audit Findings
These routine observations are performed incompletely or not at all in a substantial propor-
tion of transfusion episodes.
Root Causes
Failure in the supervisory function of clinical lead or consultants.
Corrective action
Obtain the agreement of clinical staff to achieve a target of 90% documentation of patient 
observations according to the guidelines and to a repeat audit. To overcome the problem that 
nursing staff believe that they do not have time to perform the task, consider action such as; 
review the priorities among nursing duties to make more nursing resource available and the 
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clinical responsibility for the decision should be clearly defined, and the Hospital Transfusion 
Committee should decide if notification to other authority (ies) is required.
Directive requires that the final fate of all blood components issued for recipients is recorded 
by the hospital blood bank.
Audit finding
Hospital blood bank does not have data on the final fate of all components.
Failure in the oversight function by senior nursing managers.
Obtain the agreement of clinical staff to achieve an initial target of 98%. Inform staff that 
monthly reports will be provided to senior nursing managers, identifying the clinical areas 
not meeting the agreed target. These mangers will be required to identify how non-conform
ance will be addressed.
Every transfusion laboratory must have a quality policy. The document should set out the 
laboratory stand on quality. A quality system provides service users the confidence that a 
laboratory has a system and procedure in place to allow for a continually improving quality 
service. It should include the following;
1. A statement on the type of quality service the lab intend to provide and 
over what hours of the day the service will be available
2. State the focal person or group responsible for quality issues in the lab.
3. The human and material resource required to run the quality service
4. Have a defined management structure
5. Should contain statement on quality elements; document control, compli
ant handling, incident handling, audits, staff training, health and safety.
6. Should include information on document control. Documents must be 
uniquely identified to include the number and version. It should be typed, 
validated, approved by authorized personnel, issued and reviewed regularly.
The laboratory management of the Nelson Laboratories shall establish a quality policy that 
includes the following:
5. Continuously solving root problems drives organizational learning and 
improvement.
6. Sophisticated technique for solving problems is to: ask “why?” objec
tively five times. 
Responding to audit findings – non-compliance
Guidelines require that patient records contain a record of the clinician’s reason for prescrib
ing each red cell transfusion.
Audit findings
A doctor’s record of the reason for transfusing is found in only 20% of patients’ files.
Failure in the oversight function by supervising clinical staff and consultants.
Obtain the agreement of clinical staff to achieve a target of 90% documentation of the reason 
to transfuse and to participate in education on the importance of clinical accountability for 
transfusion and to a repeat audit.
Guidelines require that all patients undergoing transfusion have observations of pulse, 
blood pressure, respiration and temperature recorded before and at specified time intervals 
during the transfusion.
These routine observations are performed incompletely or not at all in a substantial propor
tion of transfusion episodes.
Failure in the supervisory function of clinical lead or consultants.
Obtain the agreement of clinical staff to achieve a target of 90% documentation of patient 
observations according to the guidelines and to a repeat audit. To overcome the problem that 
nursing staff believe that they do not have time to perform the task, consider action such as; 
review the priorities among nursing duties to make more nursing resource available and the 
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clinical responsibility for the decision should be clearly defined, and the Hospital Transfusion 
Committee should decide if notification to other authority (ies) is required.
Audit Criterion 3
Directive requires that the final fate of all blood components issued for recipients is recorded 
by the hospital blood bank.
Audit finding
Hospital blood bank does not have data on the final fate of all components.
Root Causes
Failure in the oversight function by senior nursing managers.
Corrective action
Obtain the agreement of clinical staff to achieve an initial target of 98%. Inform staff that 
monthly reports will be provided to senior nursing managers, identifying the clinical areas 
not meeting the agreed target. These mangers will be required to identify how non-conform-
ance will be addressed.
Quality Policy
Every transfusion laboratory must have a quality policy. The document should set out the 
laboratory stand on quality. A quality system provides service users the confidence that a 
laboratory has a system and procedure in place to allow for a continually improving quality 
service. It should include the following;
1. A statement on the type of quality service the lab intend to provide and 
over what hours of the day the service will be available
2. State the focal person or group responsible for quality issues in the lab.
3. The human and material resource required to run the quality service
4. Have a defined management structure
5. Should contain statement on quality elements; document control, compli-
ant handling, incident handling, audits, staff training, health and safety.
6. Should include information on document control. Documents must be 
uniquely identified to include the number and version. It should be typed, 
validated, approved by authorized personnel, issued and reviewed regularly.
Example of a Quality policy
The laboratory management of the Nelson Laboratories shall establish a quality policy that 
includes the following:
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1. The Blood transfusion Laboratory shall provide all the elements of routine 
blood transfusion service. This shall include shall provide blood transfu-
sion services including; blood grouping, antenatal testing, compatibility 
testing, provision of routine antenatal anti-D prophylaxis, processing of 
blood components and plasma fractions for administration to patients and 
determination of Feto Maternal Haemorrhage and management. Blood 
transfusion services shall be provided on 24 hours a day by shift –working. 
2. The transfusion laboratory is committed to providing the highest qual-
ity and timely diagnostic service. We shall strive to provide service that 
is continually improving and takes into consideration the needs and re-
quirements of its users.
3. The laboratory shall operate a quality management system to integrate the 
organisation, procedures, processes and resources. Quality management 
shall be exercised using the lean principles in all her processes. It focuses on 
4 elements of quality; no avoidable deaths, no defects, no waste and highest 
staff morale). We shall use continuous improvement and lean tools in deliv-
ering services that meets the needs of our patients and other service users. 
4. The Department’s management team shall provide a framework for set-
ting quality objectives, ensuring that these objectives are reviewed regu-
larly to ensure that quality policy commitment and customer require-
ments are being met. 
5. Annual reviews of the quality management system by the laboratory 
management team will allow for a critical evaluation of current quality 
status to be compared with previous years. The responsibility for quality 
improvement shall reside with the department Board.
6. The department shall ensure that all personnel are familiar with the con-
tents and work within the context of the quality manuals and all pro-
cedures relevant to their work. We shall ensure that our personnel are 
adequately trained, certified and maintain a Continuous Professional De-
velopment (CPD) profile.
7. The department shall ensure that all personnel uphold professional and 
ethical values and continues to show commitment to good professional 
practice and conduct.
8. The department is committed to the health, safety and welfare of its entire staff. 
9. Visitors to the department will be treated with courtesy with due consid-
eration given to their safety while on site. 
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10. Our personnel shall remain our greatest resource. The department is 
committed to supporting and appreciating our staff ensuring that staff 
morale is continually enhanced.
11. The department is committed to complying with all relevant environ
mental legislation. As required by environmental regulators, we shall 
implement the following best practices by training employees on proper 
procedures to reduce our facility’s impact on the environment. 
12. Employee training may include the following; spill response training for per
sonnel who handle hazardous material and hazardous materials management. 
13. We shall ensure that all staff has a legal obligation to take reasonable care 
of your own health and safety and that of others who may be affected by 
your acts or omissions. 
14. All work will be carried out within current Health, Safety and environ
mental legislation. We will ensure that our employees understand the 
health, safety and environmental commitment of the department.
15. The department will comply with standards set by the Medical Labora
tory Science Council and other regulatory authorities and is committed 
to the following;
16. Staff recruitment, training and development and retention of qualified 
staff at all levels to provide a full and effective service to our users.
17. Proper procurement and maintenance of equipments as are needed for 
the provision of the service.
18. The collection, transport and handling of all specimens in such a way as 
to ensure the correct performance of laboratory examinations.
19. The use of examination procedures that will ensure the highest achiev
able quality of all laboratory tests performed.
20. Reporting results of examinations in a ways that are accurate, timely, con
fidential and clinically useful.
21. The assessment of user satisfaction in addition to internal audits and exter
nal quality assessment, in order to produce continual quality improvement. 
22. The quality policy shall be signed dated and issued by the Laboratory 
Medicine Department manager
23. The department is committed to ensuring that the quality policy is com
municated in an understandable language and that it is readily available 
and being implemented throughout the laboratory.
24. The department is committed to ensuring that the quality objectives set
for the department are reviewed regularly at annual laboratory depart
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staff morale). We shall use continuous improvement and lean tools in deliv
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larly to ensure that quality policy commitment and customer require
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improvement shall reside with the department Board.
6. The department shall ensure that all personnel are familiar with the con
tents and work within the context of the quality manuals and all pro
cedures relevant to their work. We shall ensure that our personnel are 
adequately trained, certified and maintain a Continuous Professional De
velopment (CPD) profile.
7. The department shall ensure that all personnel uphold professional and 
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practice and conduct.
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9. Visitors to the department will be treated with courtesy with due consid
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247Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
10. Our personnel shall remain our greatest resource. The department is 
committed to supporting and appreciating our staff ensuring that staff 
morale is continually enhanced.
11. The department is committed to complying with all relevant environ-
mental legislation. As required by environmental regulators, we shall 
implement the following best practices by training employees on proper 
procedures to reduce our facility’s impact on the environment. 
12. Employee training may include the following; spill response training for per-
sonnel who handle hazardous material and hazardous materials management. 
13. We shall ensure that all staff has a legal obligation to take reasonable care 
of your own health and safety and that of others who may be affected by 
your acts or omissions. 
14. All work will be carried out within current Health, Safety and environ-
mental legislation. We will ensure that our employees understand the 
health, safety and environmental commitment of the department.
15. The department will comply with standards set by the Medical Labora-
tory Science Council and other regulatory authorities and is committed 
to the following;
16. Staff recruitment, training and development and retention of qualified 
staff at all levels to provide a full and effective service to our users.
17. Proper procurement and maintenance of equipments as are needed for 
the provision of the service.
18. The collection, transport and handling of all specimens in such a way as 
to ensure the correct performance of laboratory examinations.
19. The use of examination procedures that will ensure the highest achiev-
able quality of all laboratory tests performed.
20. Reporting results of examinations in a ways that are accurate, timely, con-
fidential and clinically useful.
21. The assessment of user satisfaction in addition to internal audits and exter-
nal quality assessment, in order to produce continual quality improvement. 
22. The quality policy shall be signed dated and issued by the Laboratory 
Medicine Department manager
23. The department is committed to ensuring that the quality policy is com-
municated in an understandable language and that it is readily available 
and being implemented throughout the laboratory.
24. The department is committed to ensuring that the quality objectives set 
for the department are reviewed regularly at annual laboratory depart-
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ment management meetings to ensure that policy commitment and cus-
tomer requirements are being meant.
25. The department is committed to ensuring that confidentiality shall be our 
watch word in the handling of patient personal information of patients 
held by the laboratory. 
26. Document must be signed and dated by the Laboratory Medicine Depart-
ment Manager
Quality System & Total Quality Management (TQM) 
In a blood transfusion service, the quality system deals with all aspects to ensure that the 
product or the tested and ‘safe unit of blood’ is as safe as possible. Quality system must be 
applied to all laboratories, whether small or more advance. It should include the implemen-
tation, maintenance and monitoring of the quality assurance system. The introduction of a 
quality system in blood transfusion centre starts with: 
• In-depth vision and knowledge of all the aspects of blood transfu-
sion. 
• Planning required for effective donor selection, donor screening, and lab-
oratory work, issue of safe blood and transfusion of blood to the recipient. 
• Formulating the mechanism for monitoring to ensure that quality is 
maintained. 
Total quality management includes; Quality in procurement (donor, material, reagent), qual-
ity in preparation (efficient and effective blood component preparation), quality in design and 
development (improved techniques and procedures) and quality in supply (transportation 
and service). Laboratory quality assurance scheme include: 
1. Proper identification of all samples. 
2. Validation of the sensitivity, specificity and reproducibility of new batch 
of test kits and reagents. 
3. Strict adherence to the recommended procedure. 
4. Use of the appropriate test and internal controls. 
5. Regular proficiency testing exercise. 
6. Adherence to safety guidelines and safe disposal. 
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Besides assessment of function immediately after installation and repair of equipment, day to 
day checks in routine use of equipment are necessary. 
1. All the equipment in blood transfusion laboratory should meet manda
tory specifications. 
2. A written record of periodic function checks and maintenance on each 
piece of equipment should be mandatory. 
3. A preventive maintenance should be planned for trouble free operation. 
4. Uninterrupted power supply should be maintained for all the equipment 
with efficient back-up system. 
5. Annual maintenance contract with manufacturers and suppliers should 
be obtained.
Refrigerator for storage of blood 
Read recording temp chart frequent at least once 
a day (correct temp. range 2-6oC). Test alarm sys-
tem weekly. Test accuracy of alarm cut-in temp., 
once in 4 months. Check counter temp inside the 
cabinet with precision thermometer periodically. 
Deep Freeze 
Similar to blood storage refrigerator. Check 
accurate temp by thermometer kept inside the 
cabinet, twice a day. 
Bench centrifuge 
Check accuracy of speed and time with precision 
rpm meter (incho meter & stop watch every three 
months. Check motor brushes at regular intervals 
Refrigerated Centrifuge 
Check accuracy of speed & time with tachometer 
and stop watch every three months. Check temp in-
side the centrifuge bowl by a temp. tester with the 
lid closed & head stationary. Check motor brushes 
ment management meetings to ensure that policy commitment and cus
tomer requirements are being meant.
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applied to all laboratories, whether small or more advance. It should include the implemen
tation, maintenance and monitoring of the quality assurance system. The introduction of a 
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• In-depth vision and knowledge of all the aspects of blood transfu
sion. 
• Planning required for effective donor selection, donor screening, and lab
oratory work, issue of safe blood and transfusion of blood to the recipient. 
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maintained. 
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development (improved techniques and procedures) and quality in supply (transportation 
and service). Laboratory quality assurance scheme include: 
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Quality Control of Equipments 
Besides assessment of function immediately after installation and repair of equipment, day to 
day checks in routine use of equipment are necessary. 
Equipment requirements: 
1. All the equipment in blood transfusion laboratory should meet manda-
tory specifications. 
2. A written record of periodic function checks and maintenance on each 
piece of equipment should be mandatory. 
3. A preventive maintenance should be planned for trouble free operation. 
4. Uninterrupted power supply should be maintained for all the equipment 
with efficient back-up system. 
5. Annual maintenance contract with manufacturers and suppliers should 
be obtained.
Equipment Maintenance Required 
Refrigerator for storage of blood 
Read recording temp chart frequent at least once 
a day (correct temp. range 2-6oC). Test alarm sys-
tem weekly. Test accuracy of alarm cut-in temp., 
once in 4 months. Check counter temp inside the 
cabinet with precision thermometer periodically. 
Deep Freeze 
Similar to blood storage refrigerator. Check 
accurate temp by thermometer kept inside the 
cabinet, twice a day. 
Bench centrifuge 
Check accuracy of speed and time with precision 
rpm meter (incho meter & stop watch every three 
months. Check motor brushes at regular intervals 
Refrigerated Centrifuge 
Check accuracy of speed & time with tachometer 
and stop watch every three months. Check temp in-
side the centrifuge bowl by a temp. tester with the 
lid closed & head stationary. Check motor brushes 
every three months. 
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)250
Water bath 
Check temp 2-3 times a day. Check thermometer 
accuracy periodically. Change the water every week 
using only distilled water. Send the discarded water 
for culture to rule out any fungus/microbe contami-
nating the water bath. Use the stirrer for uniform 
maintenance of the temperature. If no stirrer is at-
tached check temp. at diagonal end of bath periodi-
cally to ensure reasonable degree of uniformity. 
Cell Washer 
Check shortly before use. Check speed & time month-
ly. Check function 6 monthly. Check temp. monthly. 
Check volume dispensed by cell washer monthly 
Incubator 
Check the temp. 2-3 times in a day. Check accu-
racy of temp. periodically 
pH meter 
Two point calibration (check control solution pH 
4-7 : 7-10) before each time of use. Full mainte-
nance every six months 
Weighing balance 
Check the sensitivity of electronic balances using 
known weights once a week. Full maintenance 
every six months 
ELISA reader 
Check the reproducibility of results every 3 
months Calibration graph six monthly. Full main-
tenance every six months. Check the filters for any 
fungal growth every 3 months. Keep the filters in 
the dessicator 
Auto pipettes Calibrate the pipettes regularly using mercury or water. 
Whole blood collection equipment (Vacuum 
agitator, non-vacuum agitator, balance and scales 
for weight) 
Check with known weights daily/day of use 
Micro haematocrit 
Check minimum packing time once every 3 
month 
Platelet incubator 
Check temp and agitator. Check speed agitator 
daily 
Thawing device 
Check temp daily or day of use. Checks for cleanli-
ness and replace water when contaminated 
Table: Guidelines for quality control of equipment in blood transfusion service
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Management review meeting is an extremely important part of the success of a quality man
agement system and it is an organization’s most significant source for improvements. Man
agement review can be used to tie together all the elements of an organization’s program and 
bring cohesiveness to the quality management system. Management review meetings should 
ideally be focused on “trends, objective evidence, and data-based decisions,” not on daily 
operations. The following topics should be included in the agenda of a typical management 
review meeting: 
1. Follow-up actions: Discuss matters arising from previous management 
review meetings.
2. Update reports from managerial and supervisory personnel. 
3. Quality Assurance Report: Discuss changes to the quality assurance 
standard, external quality assessment reports including non-conform
ance to standard procedures and regulatory issues.
4. Reports of assessment by outside regulatory authorities like the CPA and 
MHRA
5. Equipment/Maintenance: Discuss calibration information, repair & main
tenance trending data, trend on equipment maintenance cost and equip
ment downtime as well as effect of equipment downtime on the labora
tory set turnaround time.
6. Quality of Subcontractors: Subcontractor/suppliers performance, quality 
related subcontractor problems and actions, subcontractor trends.
7. Customer Complaints: Review results of audits, customer feedback serv
ice, summary of user satisfaction surveys, complaints for trending of 
feedback, issues and resulting actions.
8. Corrective and Preventive Actions: Status of previous preventive, correc
tive and improvement actions. Current type & source of corrective issues, 
areas most commonly having issues, trends of root causes, reoccurring 
problems and corrective improvement actions.
9. Internal Auditing of Quality management system: Discussion of internal 
audit results, audit schedule and non-conformances by units.
10. Quality Planning: Discussion on upcoming projects, status of ongoing 
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Check shortly before use. Check speed & time month-
ly. Check function 6 monthly. Check temp. monthly. 
Check volume dispensed by cell washer monthly 
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Check the temp. 2-3 times in a day. Check accu-
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Two point calibration (check control solution pH 
4-7 : 7-10) before each time of use. Full mainte-
nance every six months 
Weighing balance 
Check the sensitivity of electronic balances using 
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Check the reproducibility of results every 3 
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39. Management Review Meetings in the transfusion laboratory
Management review meeting is an extremely important part of the success of a quality man-
agement system and it is an organization’s most significant source for improvements. Man-
agement review can be used to tie together all the elements of an organization’s program and 
bring cohesiveness to the quality management system. Management review meetings should 
ideally be focused on “trends, objective evidence, and data-based decisions,” not on daily 
operations. The following topics should be included in the agenda of a typical management 
review meeting: 
1. Follow-up actions: Discuss matters arising from previous management 
review meetings.
2. Update reports from managerial and supervisory personnel. 
3. Quality Assurance Report: Discuss changes to the quality assurance 
standard, external quality assessment reports including non-conform-
ance to standard procedures and regulatory issues.
4. Reports of assessment by outside regulatory authorities like the CPA and 
MHRA
5. Equipment/Maintenance: Discuss calibration information, repair & main-
tenance trending data, trend on equipment maintenance cost and equip-
ment downtime as well as effect of equipment downtime on the labora-
tory set turnaround time.
6. Quality of Subcontractors: Subcontractor/suppliers performance, quality 
related subcontractor problems and actions, subcontractor trends.
7. Customer Complaints: Review results of audits, customer feedback serv-
ice, summary of user satisfaction surveys, complaints for trending of 
feedback, issues and resulting actions.
8. Corrective and Preventive Actions: Status of previous preventive, correc-
tive and improvement actions. Current type & source of corrective issues, 
areas most commonly having issues, trends of root causes, reoccurring 
problems and corrective improvement actions.
9. Internal Auditing of Quality management system: Discussion of internal 
audit results, audit schedule and non-conformances by units.
10. Quality Planning: Discussion on upcoming projects, status of ongoing 
projects, significant changes including staffing and staff morale boosting 
implementations. 
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11. Resources: Review major changes in organization, management, resource 
(staff, facility, and equipment) or process. 
12. Improvement: Review of quality policy, quality objectives and overall 
quality system effectiveness and improvement of system and product. 
13. Contribution to patient care: Discuss indicators that monitor the labora-
tory’s contributions to patient care.
14. Date and Time of Next Meeting. The date and time for the next meet-
ing should be fixed before the end of every management review meeting. 
The Quality Assurance Manager will produce documentation (including 
analyses, reviews, proposals, etc.) for circulation to participants before 
the next meeting. The content of the meetings will be formally document-
ed and recorded by the Quality Assurance Manager. These records will 
be made available to External Assessors.
Other topics may be added as appropriate depending on the nature and scope of the labora-
tory. There may be some slight variations between laboratories (equipments or subcontracting 
used). Although there is no specific requirement for frequency of management review meet-
ings, quarterly meetings are however most often recommended. This allows an organization 
to stay on top of upcoming issues and yet collect data between meetings that are meaningful. 
The disadvantage of annual meetings is that management may not be able to prevent issues or 
resolves issues in a timely manner. It is extremely important for management to try and keep 
good, detailed records of what was discussed, what conclusions were reached and what ac-
tions are needed. If meetings are set around an organization quality objectives, then for each 
topic at the meeting the following questions should be asked objectively:
1. What is our measurement? 
2. What are our objectives? 
3. How are we doing? 
4. Are there any trends? 
5. Is there any action needed? (e.g. people, process, materials, equipment) 
6. Is there anything else we should consider? 
These objective actions arrived at during management review meeting can help prompt lab-
oratory management to ensure that actions are discharged within appropriate and agreed 
timescale. Management Review Meetings are designed to ensure that all quality -related 
functions are reviewed at the highest possible level so that all levels of management affect-
ing quality are made aware of changes, updates revisions, verification activities and policies. 
Management review meetings allow for the coordination and Planning of changes in order 
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to provide a continuously improving user requirement focused service and to maximize the 
productivity of persons involved in the planning, coordinating and implementation of “qual
ity” changes.
An SOP is a written document or instruction detailing all steps and activities of a process or 
procedure. ISO 9001 essentially requires the documentation of all procedures used in any 
manufacturing process that could affect the quality of the product. The aim is to ensure that 
a trained staff can perform task to achieve consistently the desire outcome. It should have a 
named author and must be validated by a second party, approved by the responsible manage 
and have information on date issued and statement that photocopied version is not control
led. It should be uniquely identified (document control number) and reviewed regularly. It is 
a useful tool in the training of new staff. All staff performing the task spelt in the SOP must 
sign the SOP as an attestation that they have read, have been trained on the SOP and are 
committed to work consistently following the SOP. The development and use of SOPs are an 
integral part of a successful quality system as it provides individuals with the information to 
perform a job properly, and facilitates consistency in the quality and integrity of a product 
or end-result. In addition, the best written SOPs will fail if they are not followed. Therefore, 
the use of SOPs needs to be reviewed and re-enforced by management, preferably the direct 
supervisor. Current copies of the SOPs also need to be readily accessible for reference in the 
work areas of those individuals actually performing the task, either in hard copy or electronic 
format, otherwise SOPs serve little purpose. The development and use of SOPs minimizes 
variation and promotes quality through consistent implementation of a process or procedure 
within the organization, even if there are temporary or permanent personnel changes. SOPs 
should be written in a concise, step-by-step, easy-to-read format. The information presented 
should be unambiguous and not overly complicated. SOPs need to remain current to be use
ful. Therefore, whenever procedures are changed, SOPs should be updated and re-approved. 
If desired, modify only the pertinent section of an SOP and indicate the change date/revision 
number for that section in the Table of Contents and the document control notation. SOPs 
should be also systematically reviewed on a periodic basis, e.g. every 1-2 years, to ensure that 
the policies and procedures remain current and appropriate, or to determine whether the 
SOPs are even needed. Each organization should develop a numbering system to systemati
cally identify and label their SOPs, and the document control should be described in its Qual
ity Management Plan. An SOP should include the following sections:
1. The first page or cover page of each SOP should contain the following in
formation: a title that clearly identifies the activity or procedure, an SOP 
identification (ID) number, date of issue and/or revision, the name of the 
applicable agency, division, and/or branch to which this SOP applies, and 
the signatures and signature dates of those individuals who prepared 
and approved the SOP.
11. Resources: Review major changes in organization, management, resource 
(staff, facility, and equipment) or process. 
12. Improvement: Review of quality policy, quality objectives and overall 
quality system effectiveness and improvement of system and product. 
13. Contribution to patient care: Discuss indicators that monitor the labora
tory’s contributions to patient care.
14. Date and Time of Next Meeting. The date and time for the next meet
ing should be fixed before the end of every management review meeting. 
The Quality Assurance Manager will produce documentation (including 
analyses, reviews, proposals, etc.) for circulation to participants before 
the next meeting. The content of the meetings will be formally document
ed and recorded by the Quality Assurance Manager. These records will 
be made available to External Assessors.
Other topics may be added as appropriate depending on the nature and scope of the labora
tory. There may be some slight variations between laboratories (equipments or subcontracting 
used). Although there is no specific requirement for frequency of management review meet
ings, quarterly meetings are however most often recommended. This allows an organization 
to stay on top of upcoming issues and yet collect data between meetings that are meaningful. 
The disadvantage of annual meetings is that management may not be able to prevent issues or 
resolves issues in a timely manner. It is extremely important for management to try and keep 
good, detailed records of what was discussed, what conclusions were reached and what ac
tions are needed. If meetings are set around an organization quality objectives, then for each 
topic at the meeting the following questions should be asked objectively:
1. What is our measurement? 
2. What are our objectives? 
3. How are we doing? 
4. Are there any trends? 
5. Is there any action needed? (e.g. people, process, materials, equipment) 
6. Is there anything else we should consider? 
These objective actions arrived at during management review meeting can help prompt lab
oratory management to ensure that actions are discharged within appropriate and agreed 
timescale. Management Review Meetings are designed to ensure that all quality -related 
functions are reviewed at the highest possible level so that all levels of management affect
ing quality are made aware of changes, updates revisions, verification activities and policies. 
Management review meetings allow for the coordination and Planning of changes in order 
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to provide a continuously improving user requirement focused service and to maximize the 
productivity of persons involved in the planning, coordinating and implementation of “qual-
ity” changes.
40. Standard Operating Procedure
An SOP is a written document or instruction detailing all steps and activities of a process or 
procedure. ISO 9001 essentially requires the documentation of all procedures used in any 
manufacturing process that could affect the quality of the product. The aim is to ensure that 
a trained staff can perform task to achieve consistently the desire outcome. It should have a 
named author and must be validated by a second party, approved by the responsible manage 
and have information on date issued and statement that photocopied version is not control-
led. It should be uniquely identified (document control number) and reviewed regularly. It is 
a useful tool in the training of new staff. All staff performing the task spelt in the SOP must 
sign the SOP as an attestation that they have read, have been trained on the SOP and are 
committed to work consistently following the SOP. The development and use of SOPs are an 
integral part of a successful quality system as it provides individuals with the information to 
perform a job properly, and facilitates consistency in the quality and integrity of a product 
or end-result. In addition, the best written SOPs will fail if they are not followed. Therefore, 
the use of SOPs needs to be reviewed and re-enforced by management, preferably the direct 
supervisor. Current copies of the SOPs also need to be readily accessible for reference in the 
work areas of those individuals actually performing the task, either in hard copy or electronic 
format, otherwise SOPs serve little purpose. The development and use of SOPs minimizes 
variation and promotes quality through consistent implementation of a process or procedure 
within the organization, even if there are temporary or permanent personnel changes. SOPs 
should be written in a concise, step-by-step, easy-to-read format. The information presented 
should be unambiguous and not overly complicated. SOPs need to remain current to be use-
ful. Therefore, whenever procedures are changed, SOPs should be updated and re-approved. 
If desired, modify only the pertinent section of an SOP and indicate the change date/revision 
number for that section in the Table of Contents and the document control notation. SOPs 
should be also systematically reviewed on a periodic basis, e.g. every 1-2 years, to ensure that 
the policies and procedures remain current and appropriate, or to determine whether the 
SOPs are even needed. Each organization should develop a numbering system to systemati-
cally identify and label their SOPs, and the document control should be described in its Qual-
ity Management Plan. An SOP should include the following sections:
1. The first page or cover page of each SOP should contain the following in-
formation: a title that clearly identifies the activity or procedure, an SOP 
identification (ID) number, date of issue and/or revision, the name of the 
applicable agency, division, and/or branch to which this SOP applies, and 
the signatures and signature dates of those individuals who prepared 
and approved the SOP.
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2. A table of Contents may be needed for quick reference, especially if the 
SOP is long, for locating information and to denote changes or revisions 
made only to certain sections of an SOP. 
3. Well-written SOPs should first briefly describe the purpose of the process, 
including any regulatory information or standards that are appropriate 
to the SOP process, and the scope to indicate what is covered. Define any 
specialized or unusual terms. 
4. Denote what sequential procedures should be followed, divided into 
significant sections; possible interferences, equipment needed as well as 
state cautions (indicating activities that could result in equipment dam-
age, degradation of sample, or possible invalidation of results; listed here 
and at the critical steps in the procedure).
5. Procedure (identifying all pertinent steps, in order, and the materials need-
ed to accomplish the procedure such as; Instrument or method calibra-
tion and standardization, Sample Collection, Sample handling and pres-
ervation, Sample preparation and analysis (such as extraction, digestion, 
analysis, identification, and counting procedures), troubleshooting, data 
acquisition, calculations and data entering requirements, data and records 
management, identifying any calculations to be performed, forms to be 
used, reports to be written and data and record storage information).
6. State the personnel qualifications/responsibilities (denoting the minimal 
experience the user should have to complete the task satisfactorily, and 
citing any applicable requirements (certification).
7. Health & Safety Warnings (indicating operations that could result in per-
sonal injury or loss of life and explaining what will happen if the pro-
cedure is not followed or is followed incorrectly; listed here and at the 
critical steps in the procedure). Safety considerations (Risk assessments 
and hazard identification (Control of Substances Hazardous to Health 
(COSHH) and Material Safety Data Sheet (MSDS) and manual handling-
related risk) must be taken into consideration.
8. Result reporting, reference ranges, calculations, clinical interpretations 
and interferences (describing any component of the process that may in-
terfere with the accuracy of the result or outcome).
9. Information on risk assessment associated with the procedure, identifica-
tion of hazards associated and manual handling –related issues.
10. Describe next all appropriate QA and quality control (QC) activities for 
that procedure.
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11. List any cited or significant references and a signature section
Equipment validation, calibration and new reagent testing. All newly procured equip
ment and instruments as well as new reagents being introduced and new reagent batches are 
subjected to a documented validation and testing (acceptance process) to demonstrate they 
perform as specified by the manufacturers and that they are suitable for intended use. It is 
important that a laboratory has a process to regularly monitor the performance of automated 
equipment and reagents. There should also be a process of how to manage equipment and 
reagent failure and what needs to be done before such reagents is put back in use.
All the cold chain equipment should be regularly inspected recorded of the performance in
cluding the alarms. Calibrate, if required and temperature to be recorded at periodic intervals. 
The important equipment is:
1. Blood Bank Refrigerators. 
2. Deep Freezers. -40 & -80 deg C. 
3. Refrigerated Centrifuge 
4. Weighing Balance. 
5. Electronic Sealers 
6. Thawing Bath 
7. Desk Centrifuges & Cell Washers. 
8. Cell Separators. 
 Keeping clear and accurate records 
is vital in transfusion. Remember the slogan in laboratory documentation is: If it is not docu
mented then it was not done. The Following Registers should be maintained; ABO grouping and 
Rh typing register, blood collection register, preparation of stock of various components register, 
issue register for various components supplied, screening tests of blood donors for TTI’S register, 
compatibility register, stock register for all materials purchased, stocked and issued, transfusion 
requests received from clinicians, register for disposal of infected and contaminated materials, in
spection record register for all Instruments, register for cold chain management of blood products 
and register for error detection and rectification. Clear and accurate records keeping will contrib
ute to the success of diagnostic service delivery in the following ways:
1. Saves a lot of time and effort when in carrying out quality audit.
2. Keeps a good track of the costs of staff and their performance.
3. Allow for evidenced based decision when tendering for new equipment.
2. A table of Contents may be needed for quick reference, especially if the 
SOP is long, for locating information and to denote changes or revisions 
made only to certain sections of an SOP. 
3. Well-written SOPs should first briefly describe the purpose of the process, 
including any regulatory information or standards that are appropriate 
to the SOP process, and the scope to indicate what is covered. Define any 
specialized or unusual terms. 
4. Denote what sequential procedures should be followed, divided into 
significant sections; possible interferences, equipment needed as well as 
state cautions (indicating activities that could result in equipment dam
age, degradation of sample, or possible invalidation of results; listed here 
and at the critical steps in the procedure).
5. Procedure (identifying all pertinent steps, in order, and the materials need
ed to accomplish the procedure such as; Instrument or method calibra
tion and standardization, Sample Collection, Sample handling and pres
ervation, Sample preparation and analysis (such as extraction, digestion, 
analysis, identification, and counting procedures), troubleshooting, data 
acquisition, calculations and data entering requirements, data and records 
management, identifying any calculations to be performed, forms to be 
used, reports to be written and data and record storage information).
6. State the personnel qualifications/responsibilities (denoting the minimal 
experience the user should have to complete the task satisfactorily, and 
citing any applicable requirements (certification).
7. Health & Safety Warnings (indicating operations that could result in per
sonal injury or loss of life and explaining what will happen if the pro
cedure is not followed or is followed incorrectly; listed here and at the 
critical steps in the procedure). Safety considerations (Risk assessments 
and hazard identification (Control of Substances Hazardous to Health 
(COSHH) and Material Safety Data Sheet (MSDS) and manual handling-
related risk) must be taken into consideration.
8. Result reporting, reference ranges, calculations, clinical interpretations 
and interferences (describing any component of the process that may in
terfere with the accuracy of the result or outcome).
9. Information on risk assessment associated with the procedure, identifica
tion of hazards associated and manual handling –related issues.
10. Describe next all appropriate QA and quality control (QC) activities for 
that procedure.
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11. List any cited or significant references and a signature section
Equipment validation, calibration and new reagent testing. All newly procured equip-
ment and instruments as well as new reagents being introduced and new reagent batches are 
subjected to a documented validation and testing (acceptance process) to demonstrate they 
perform as specified by the manufacturers and that they are suitable for intended use. It is 
important that a laboratory has a process to regularly monitor the performance of automated 
equipment and reagents. There should also be a process of how to manage equipment and 
reagent failure and what needs to be done before such reagents is put back in use.
Maintenance of all cold chain and mechanical equipments 
All the cold chain equipment should be regularly inspected recorded of the performance in-
cluding the alarms. Calibrate, if required and temperature to be recorded at periodic intervals. 
The important equipment is:
1. Blood Bank Refrigerators. 
2. Deep Freezers. -40 & -80 deg C. 
3. Refrigerated Centrifuge 
4. Weighing Balance. 
5. Electronic Sealers 
6. Thawing Bath 
7. Desk Centrifuges & Cell Washers. 
8. Cell Separators. 
Requirement and maintenance of records - record keeping. Keeping clear and accurate records 
is vital in transfusion. Remember the slogan in laboratory documentation is: If it is not docu-
mented then it was not done. The Following Registers should be maintained; ABO grouping and 
Rh typing register, blood collection register, preparation of stock of various components register, 
issue register for various components supplied, screening tests of blood donors for TTI’S register, 
compatibility register, stock register for all materials purchased, stocked and issued, transfusion 
requests received from clinicians, register for disposal of infected and contaminated materials, in-
spection record register for all Instruments, register for cold chain management of blood products 
and register for error detection and rectification. Clear and accurate records keeping will contrib-
ute to the success of diagnostic service delivery in the following ways:
1. Saves a lot of time and effort when in carrying out quality audit.
2. Keeps a good track of the costs of staff and their performance.
3. Allow for evidenced based decision when tendering for new equipment.
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4. Highlights quickly areas where problems could arise and enable rem-
edies to be put in place.
5. Fulfils statutory obligations and compliance.
6. Assists in effective investigation of incidents, adverse events and near misses.
7. Assists in providing information required by your bankers.
8. Helps in detecting non compliance to process.
9. Provides valuable information and details for the future decision of staff-
ing levels.
10. May be required in case of litigation to prove a legal point.
Document Control. All blood transfusion records including compatibility slips, equipment 
monitoring records, quality control records and other associated are expected to be stored by 
law in a secured location un-tampered. In most developed countries these records are stored 
for up to 30 years. The aim is that if a ligation case arises as a result of the product transfused 
in the past, the records can be called for and analyzed to rule out liability. Blood transfu-
sion service should develop and maintain documents that demonstrate the achievement of 
specified quality standards. Documentation provides’ ability to trace prospectively and ret-
rospectively all the steps in a procedure which are necessary for monitoring the techniques, 
component preparation and laboratory testing. 
Quality Monitoring. A regular quality monitoring is essential to ensure that a full quality as-
surance system has been implemented and is effective. The purpose of a quality monitoring 
is to check the integrity of the QA programme. If during quality monitoring, problems are 
identified they must be resolved as soon as possible. A follow-up audit is required later to 
ensure that changes have actually been incorporated. A sequence of events can be followed 
from collection of a unit, passing through all the processes till it is issued, by checking all the 
necessary documentation. For example, during donor screening for HIV, data other than just 
the final screening results must be recorded: 
1. Temperature monitoring record for the laboratory equipments (incubator, 
refrigerators used for storing kits, reagents, water baths and others). 
2. Records of maintenance of equipment e.g. centrifuges, incubators, refrig-
erators, ELISA reader and others). 
3. The results obtained should be reviewed in light of the test run validity 
and the control values. 
4. Records of disposal of any positive donation.
Quality monitoring. The following quality monitoring should be carried out; monitoring of 
the results obtained, monitoring of the control values, monitoring of operation of the equip-
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ment, routine monitoring and calibrations of equipment (incubator, pipettes, centrifuges, 
platelet storage chamber, plasma thawer and others). Quality Control of Reagents. All rea
gents must be quality controlled before use in the analysis of a patient sample. The primary 
objective of a reagent quality control is to ensure that reagent is functioning as expected. The 
following principles apply to storage of reagents; The oldest reagents should be used first 
(first-in-first-out), there should be a system for indicating when supplies run low (effective 
stock control management), every new lot of reagents should be evaluated for potency and 
specificity. All the results should be recorded and a low potency, contaminated or defective 
reagent should never be used. 
1. All reagents should be clearly labelled with batch number, expiry date 
and storage temp; instructions for use should be enclosed with each rea
gent packing. 
2. All reagents and kit should be used according to the manufacturer’s in
structions. 
3. Use of positive and negative controls should be done with each batch to 
show that reagents are potent and specific. 
4. All reagents must be carefully stored at recommended temperature. Rea
gents to be kept at 4-8oC should never be frozen and are stored according 
to manufacturer’s instructions only. 
5. All reagents must be of high quality and have a shelf-life of at least one year. 
6. Supply, storage and transportation of kits and reagents should be strictly 
standardized and manufacturer’s instructions should be followed with 
ensured continuous power supply and periodic temperature monitoring. 
7. All the reconstituted reagents should be stored and reused according to 
manufacturer’s instructions. 
8. If a reagent produces results outside the limits set by the manufacturer, 
the deficiency should be reported to the manufacturer. 
9. Reagent records should include: The name of each reagent with lot 
number, batch number, expiry date and name of manufacturer and grade 
and strength of reactions.
10. Reagents that are out of date must never be used for patient testing.
Identification of Errors & Remedial Action. Each error must be analysed to assess the cause 
of error and should be properly documented. The major sources of errors are: 
4. Highlights quickly areas where problems could arise and enable rem
edies to be put in place.
5. Fulfils statutory obligations and compliance.
6. Assists in effective investigation of incidents, adverse events and near misses.
7. Assists in providing information required by your bankers.
8. Helps in detecting non compliance to process.
9. Provides valuable information and details for the future decision of staff
ing levels.
10. May be required in case of litigation to prove a legal point.
All blood transfusion records including compatibility slips, equipment 
monitoring records, quality control records and other associated are expected to be stored by 
law in a secured location un-tampered. In most developed countries these records are stored 
for up to 30 years. The aim is that if a ligation case arises as a result of the product transfused 
in the past, the records can be called for and analyzed to rule out liability. Blood transfu
sion service should develop and maintain documents that demonstrate the achievement of 
specified quality standards. Documentation provides’ ability to trace prospectively and ret
rospectively all the steps in a procedure which are necessary for monitoring the techniques, 
component preparation and laboratory testing. 
. A regular quality monitoring is essential to ensure that a full quality as
surance system has been implemented and is effective. The purpose of a quality monitoring 
is to check the integrity of the QA programme. If during quality monitoring, problems are 
identified they must be resolved as soon as possible. A follow-up audit is required later to 
ensure that changes have actually been incorporated. A sequence of events can be followed 
from collection of a unit, passing through all the processes till it is issued, by checking all the 
necessary documentation. For example, during donor screening for HIV, data other than just 
the final screening results must be recorded: 
1. Temperature monitoring record for the laboratory equipments (incubator, 
refrigerators used for storing kits, reagents, water baths and others). 
2. Records of maintenance of equipment e.g. centrifuges, incubators, refrig
erators, ELISA reader and others). 
3. The results obtained should be reviewed in light of the test run validity 
and the control values. 
4. Records of disposal of any positive donation.
 The following quality monitoring should be carried out; monitoring of 
the results obtained, monitoring of the control values, monitoring of operation of the equip
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ment, routine monitoring and calibrations of equipment (incubator, pipettes, centrifuges, 
platelet storage chamber, plasma thawer and others). Quality Control of Reagents. All rea-
gents must be quality controlled before use in the analysis of a patient sample. The primary 
objective of a reagent quality control is to ensure that reagent is functioning as expected. The 
following principles apply to storage of reagents; The oldest reagents should be used first 
(first-in-first-out), there should be a system for indicating when supplies run low (effective 
stock control management), every new lot of reagents should be evaluated for potency and 
specificity. All the results should be recorded and a low potency, contaminated or defective 
reagent should never be used. 
Reagent requirements 
1. All reagents should be clearly labelled with batch number, expiry date 
and storage temp; instructions for use should be enclosed with each rea-
gent packing. 
2. All reagents and kit should be used according to the manufacturer’s in-
structions. 
3. Use of positive and negative controls should be done with each batch to 
show that reagents are potent and specific. 
4. All reagents must be carefully stored at recommended temperature. Rea-
gents to be kept at 4-8oC should never be frozen and are stored according 
to manufacturer’s instructions only. 
5. All reagents must be of high quality and have a shelf-life of at least one year. 
6. Supply, storage and transportation of kits and reagents should be strictly 
standardized and manufacturer’s instructions should be followed with 
ensured continuous power supply and periodic temperature monitoring. 
7. All the reconstituted reagents should be stored and reused according to 
manufacturer’s instructions. 
8. If a reagent produces results outside the limits set by the manufacturer, 
the deficiency should be reported to the manufacturer. 
9. Reagent records should include: The name of each reagent with lot 
number, batch number, expiry date and name of manufacturer and grade 
and strength of reactions.
10. Reagents that are out of date must never be used for patient testing.
Identification of Errors & Remedial Action. Each error must be analysed to assess the cause 
of error and should be properly documented. The major sources of errors are: 
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1. Clerical errors usually occur due to carelessness or during transcription 
of records. 
2. Organizational errors may occur due to heavy workload or personal dif-
ficulties of staff members. 
3. Technical errors may be caused due to human factors or by poorly stand-
ardized techniques, reagents or equipment.
4. Error can also occur if staff performing task has not been adequately 
trained. 
5. Investigations would often reveal a breakdown in quality assurance sys-
tem and remedial action should be taken for each error detected. Reme-
dial action requires: 
6. Investigation of the error 
7. Reassessment of procedure, quality control, reagents and consumables 
and full documentation. 
8. Conclusion and recommendation 
9. Reporting and action to be taken 
Role of Training and Personnel Proficiency Testing. Adequate and competent staffs are the 
backbone of a quality laboratory. Most of the failures in quality are caused by human error, 
carelessness or ignorance and not by defective technology. Usually the techniques are vali-
dated and well documented but staff validation is often ignored. As human factors are the 
most important variables in any procedure, training of staff and evaluation of training is of 
particular importance. Training must be well-planned, relevant and on-going. The training 
protocol should be constantly assessed and updated when required. All new staff members 
should be oriented to the workplace and adequately trained based on the SOP. All the staff 
members should be encouraged to enrol in a Continuous Professional Development (CPD) 
scheme and have regular in service update training and must be encouraged to attend for-
mal courses, seminars, conferences to update their knowledge. All the personnel carrying 
out the test should follow the standard operating procedures. Periodic checking and review 
of results is another important step in a well-implemented quality assurance programme. 
The technical staff should be trained to carry out the test with prescribed quality control 
measures. The accuracy and precision of the work done by each Biomedical Scientist should 
be validated periodically. The external quality assurance samples will also help in perform-
ance evaluation. 
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Reducing mishaps from medical management is central to efforts to improve quality and 
lower costs in health care. Effective feedback from incident reporting systems in healthcare is 
essential if organizations are to learn from failures in the delivery of care. Risk rating of trans
fusion incidents (Severity) can either be; None, Minor, Moderate, Major or Catastrophic. The 
likelihood of a transfusion incident occurring can either be; rarely, unlikely, possible, likely 
or almost certain. All transfusion incidents, near misses and complaints must be investigat
ed. Clinical Pathology Accreditation (CPA) standards, Blood Quality and Safety Regulations 
(2005) both of the UK and the MLSCN of Nigeria requires that all incidents in transfusion be 
investigated and reported in a timely fashion to obtain accurate data, ensure optimum learn
ing outcome and to avoid subsequent occurrence of the incident. The aim and objectives of 
incident reporting includes:
1. To ensure that all incidents relating to quality and safety of blood transfu
sion are recorded promptly and appropriately in accordance with statu
tory regulation, principles of Good Laboratory Practice (GLP) and Good 
Manufacturing Practice (GMP). 
2. To instill the culture of corrective and preventive action to prevent the 
re-occurrence of incident.
3. It ensures that accurate recored of incident is available in case of audit 
and investigation.
4. To facilitate the reporting of incidents to statutory authority like the MLSCN.
1. Clerical errors usually occur due to carelessness or during transcription 
of records. 
2. Organizational errors may occur due to heavy workload or personal dif
ficulties of staff members. 
3. Technical errors may be caused due to human factors or by poorly stand
ardized techniques, reagents or equipment.
4. Error can also occur if staff performing task has not been adequately 
trained. 
5. Investigations would often reveal a breakdown in quality assurance sys
tem and remedial action should be taken for each error detected. Reme
dial action requires: 
6. Investigation of the error 
7. Reassessment of procedure, quality control, reagents and consumables 
and full documentation. 
8. Conclusion and recommendation 
9. Reporting and action to be taken 
Role of Training and Personnel Proficiency Testing. Adequate and competent staffs are the 
backbone of a quality laboratory. Most of the failures in quality are caused by human error, 
carelessness or ignorance and not by defective technology. Usually the techniques are vali
dated and well documented but staff validation is often ignored. As human factors are the 
most important variables in any procedure, training of staff and evaluation of training is of 
particular importance. Training must be well-planned, relevant and on-going. The training 
protocol should be constantly assessed and updated when required. All new staff members 
should be oriented to the workplace and adequately trained based on the SOP. All the staff 
members should be encouraged to enrol in a Continuous Professional Development (CPD) 
scheme and have regular in service update training and must be encouraged to attend for
mal courses, seminars, conferences to update their knowledge. All the personnel carrying 
out the test should follow the standard operating procedures. Periodic checking and review 
of results is another important step in a well-implemented quality assurance programme. 
The technical staff should be trained to carry out the test with prescribed quality control 
measures. The accuracy and precision of the work done by each Biomedical Scientist should 
be validated periodically. The external quality assurance samples will also help in perform
ance evaluation. 
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41. Incident Reporting Procedure in Transfusion 
Reducing mishaps from medical management is central to efforts to improve quality and 
lower costs in health care. Effective feedback from incident reporting systems in healthcare is 
essential if organizations are to learn from failures in the delivery of care. Risk rating of trans-
fusion incidents (Severity) can either be; None, Minor, Moderate, Major or Catastrophic. The 
likelihood of a transfusion incident occurring can either be; rarely, unlikely, possible, likely 
or almost certain. All transfusion incidents, near misses and complaints must be investigat-
ed. Clinical Pathology Accreditation (CPA) standards, Blood Quality and Safety Regulations 
(2005) both of the UK and the MLSCN of Nigeria requires that all incidents in transfusion be 
investigated and reported in a timely fashion to obtain accurate data, ensure optimum learn-
ing outcome and to avoid subsequent occurrence of the incident. The aim and objectives of 
incident reporting includes:
1. To ensure that all incidents relating to quality and safety of blood transfu-
sion are recorded promptly and appropriately in accordance with statu-
tory regulation, principles of Good Laboratory Practice (GLP) and Good 
Manufacturing Practice (GMP). 
2. To instill the culture of corrective and preventive action to prevent the 
re-occurrence of incident.
3. It ensures that accurate recored of incident is available in case of audit 
and investigation.
4. To facilitate the reporting of incidents to statutory authority like the MLSCN.
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Investigating a transfusion incident
Incident occurs
Immediately manage and report incident
Investigate and review incident
Identify root causes & agree corrective action
Change policy/ procedure if applicaable
Change process control & remove bottlenecks
Communicate change and train staff
Update documentation (SOP)
Review process & confim elimination of root cause
Close incident
Method of investigating a transfusion incident
1. Gather all relevant document related to the incident. This may include 
documents like patient name, hospital number, date of birth, gender, re-
quest forms, compatibility slips, witness statements, root cause analysis 
information, telephone request documentation, computer records, trans-
port records and temperature records of blood fridges.
2. Open an incident/non conformance file with relevant information of the 
date file opened, date of incident, nature of clinical incident (safety, qual-
ity or non conformance).
3. Collect information on immediate root cause analysis carried out after 
the incident, note the remedial action taken, the preventive active and 
corrective action taken to resolve the incident and prevent a re-occur-
rence of the incidents. 
4. Investigate the incident based on information available determine the 
risk of incident to patient, likelihood of it re-occurring, non- conform-
ances, root causes, the preventive and corrective action the laboratory 
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should put in place to prevent a re-occurrence of incident and a set a date 
to re-audit the process to ensure that the root causes has been dealt with.
1. Equipment and calibration failure
2. Quality control failure
3. Manufacturers-associated reagent failure
4. Sub-optimal cold chain-related issues
5. Equipment downtime reated issues
6. Deviation from Standard Operating Procedure (SOP) with adverse outcome
7. Deviation from Standard Operating Procedure (SOP) with no adverse 
outcome
8. Customer complain about quality and safety of blood and blood products
9. External Quality Assessment failure or error
10. Any non-conformances identified in routine audits carried out in the 
laboratory.
11. Presence in the laboratory inventory of time expired reagents.
1. Laboratory testing error.
2. Transfusion sample identification error.
3. Relevant blood transfusion documentation not signed.
4. Traceability –related issues related to non-returns of relevant transfusion 
documentation.
5. Inappriopriate transfusion or non-indicated transfusion.
6. Incorrect blood component transfused
7. Blood component wastage. Blood component (fresh frozen plasma, cryo
precipitate or platelet) ordered but not used and eventually wasted.
8. Blood component wastage due to negligent non observance of cold chain 
management requirement.
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Communicate change and train staff
Review process & confim elimination of root cause
1. Gather all relevant document related to the incident. This may include 
documents like patient name, hospital number, date of birth, gender, re
quest forms, compatibility slips, witness statements, root cause analysis 
information, telephone request documentation, computer records, trans
port records and temperature records of blood fridges.
2. Open an incident/non conformance file with relevant information of the 
date file opened, date of incident, nature of clinical incident (safety, qual
ity or non conformance).
3. Collect information on immediate root cause analysis carried out after 
the incident, note the remedial action taken, the preventive active and 
corrective action taken to resolve the incident and prevent a re-occur
rence of the incidents. 
4. Investigate the incident based on information available determine the 
risk of incident to patient, likelihood of it re-occurring, non- conform
ances, root causes, the preventive and corrective action the laboratory 
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should put in place to prevent a re-occurrence of incident and a set a date 
to re-audit the process to ensure that the root causes has been dealt with.
Examples of Laboratory non-conformances
1. Equipment and calibration failure
2. Quality control failure
3. Manufacturers-associated reagent failure
4. Sub-optimal cold chain-related issues
5. Equipment downtime reated issues
6. Deviation from Standard Operating Procedure (SOP) with adverse outcome
7. Deviation from Standard Operating Procedure (SOP) with no adverse 
outcome
8. Customer complain about quality and safety of blood and blood products
9. External Quality Assessment failure or error
10. Any non-conformances identified in routine audits carried out in the 
laboratory.
11. Presence in the laboratory inventory of time expired reagents.
Examples of clinical incidents in Transfusion
1. Laboratory testing error.
2. Transfusion sample identification error.
3. Relevant blood transfusion documentation not signed.
4. Traceability –related issues related to non-returns of relevant transfusion 
documentation.
5. Inappriopriate transfusion or non-indicated transfusion.
6. Incorrect blood component transfused
7. Blood component wastage. Blood component (fresh frozen plasma, cryo-
precipitate or platelet) ordered but not used and eventually wasted.
8. Blood component wastage due to negligent non observance of cold chain 
management requirement.
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9. Blood transfusion reaction and other transfusion-related adverse events.
10. Blood administration errors
11. Issue of wrong component/specification (for example Kell positive unit 
given to woman of child bearing age, CMV positive unit transfused to 
HIV or immunocompromised patient and transfusion of non-irradiated 
blood and blood product for patient in whom it is indicated (patient on 
purine analogue chemotherapy and patient who are potential candidates 
for transplant).
12. Poor/inappriopriate component storage issues such as storage of platelet 
in the fridge and transfusion of units that has been out of cold storage for 
greater than 30 minutes.
13. Blood component quality problems such as bacterial contamination of 
blood products.
Example of an incident Investigation                    Incident: Issue of time expired product 
(Novo 7) to patient (X)
Investigator’s name: Erhabor Osaro                       Date of Incident: 3rd April 2010
Give brief information of incident. On the 3rd day of April 2010 a time expired unit of batch 
product (NOVO 7) was mistakenly issued on a patient in HDU who had post partum haem-
orrhage and had continued to bleed even after the issue of several units of red cells, adult 
dose of fresh frozen plasma (FFP) and two units of platelet. The Novo 7 had been requested 
by the consultant to facilitate the immediate arrest of the life threatening haemorrhage. The 
discovery that the said batch product expired 4 months ago had been noted by the doctors 
and nursing staff during the pre- product administration checks by the patient bed side. The 
reconstitution fluid was however in date.
State the reasons for identifying this learning. I had identified this learning (incident) with 
the aim of carrying out a full investigation of the incident with the hope of determining the 
root causes, suggesting corrective and preventive measures to prevent the root causes, insti-
gating policy and procedural changes and to enhance our drive as a department for continu-
ous quality improvement.
Describe the root causes of this incident.
1. Poor inventory/stock control management of batch product (Novo 7).
2. Inadequate pre and post product allocation checks before issue of batch 
product.
3. Absence of SOP on inventory control management of batch products 
stipulating minimum, maximum and re-order level as well as lead time 
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between order and product availability for use. An SOP is a written docu
ment / instruction detailing all steps and activities of a process or proce
dure. These should be carried out without any deviation or modification 
to guarantee the expected outcome. Any modification or deviation from 
a given SOP should be thoroughly investigated and outcomes of the in
vestigation documented according the internal deviation procedure. All 
quality impacting processes and procedures should be laid out in Stand
ard Operating Procedures (SOPs). These SOPs should be the basis for 
the routine training program of each employee. SOPs should be available, 
followed strictly in laboratory analysis and regularly updated to assure 
compliance to CPA Standard F (Examination process) and sub standard 
F2 (Examination procedures) requirements. Changes of SOPs are in gen
eral triggered by process or procedural changes / adjustments.
1. Removed all remaining time expired Novo 7 out from stock to prevent 
re-occurrence of incident.
2. Rang the transfusion manager on call for advice.
3. Conveyed advice of consultant Haematologist to consultant managing 
the said patient in the high dependency unit.
4. On advise of the consultant Haematologist, requested an in date unit of 
the batch product from the nearest sister Hospital.
Non-compliances identified:
1. Issue of time expired batch product. This observation constitutes a non- 
compliance to CPA Standard D (Equipment, information system and ma
terials) and sub standard D3 (Management of reagents, calibration and 
quality control).
2. Absence of SOP on inventory control management of batch products. 
This observation constitutes a non- compliance to CPA Standard F (Ex
amination process) and sub standard F2 (Examination procedures).
3. Inadequate pre and post product allocation checks before issue of batch 
product. This observation constitutes a non- compliance to CPA Standard 
F (Examination process) and sub standard F2 (Examination procedure). 
1. Devise a more effective inventory /stock control system for batch products.
9. Blood transfusion reaction and other transfusion-related adverse events.
10. Blood administration errors
11. Issue of wrong component/specification (for example Kell positive unit 
given to woman of child bearing age, CMV positive unit transfused to 
HIV or immunocompromised patient and transfusion of non-irradiated 
blood and blood product for patient in whom it is indicated (patient on 
purine analogue chemotherapy and patient who are potential candidates 
for transplant).
12. Poor/inappriopriate component storage issues such as storage of platelet 
in the fridge and transfusion of units that has been out of cold storage for 
greater than 30 minutes.
13. Blood component quality problems such as bacterial contamination of 
blood products.
(Novo 7) to patient (X)
 On the 3  day of April 2010 a time expired unit of batch 
product (NOVO 7) was mistakenly issued on a patient in HDU who had post partum haem
orrhage and had continued to bleed even after the issue of several units of red cells, adult 
dose of fresh frozen plasma (FFP) and two units of platelet. The Novo 7 had been requested 
by the consultant to facilitate the immediate arrest of the life threatening haemorrhage. The 
discovery that the said batch product expired 4 months ago had been noted by the doctors 
and nursing staff during the pre- product administration checks by the patient bed side. The 
reconstitution fluid was however in date.
I had identified this learning (incident) with 
the aim of carrying out a full investigation of the incident with the hope of determining the 
root causes, suggesting corrective and preventive measures to prevent the root causes, insti
gating policy and procedural changes and to enhance our drive as a department for continu
ous quality improvement.
1. Poor inventory/stock control management of batch product (Novo 7).
2. Inadequate pre and post product allocation checks before issue of batch 
product.
3. Absence of SOP on inventory control management of batch products 
stipulating minimum, maximum and re-order level as well as lead time 
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between order and product availability for use. An SOP is a written docu-
ment / instruction detailing all steps and activities of a process or proce-
dure. These should be carried out without any deviation or modification 
to guarantee the expected outcome. Any modification or deviation from 
a given SOP should be thoroughly investigated and outcomes of the in-
vestigation documented according the internal deviation procedure. All 
quality impacting processes and procedures should be laid out in Stand-
ard Operating Procedures (SOPs). These SOPs should be the basis for 
the routine training program of each employee. SOPs should be available, 
followed strictly in laboratory analysis and regularly updated to assure 
compliance to CPA Standard F (Examination process) and sub standard 
F2 (Examination procedures) requirements. Changes of SOPs are in gen-
eral triggered by process or procedural changes / adjustments.
Describe the immediate remedial action taken to prevent harm to patient:
1. Removed all remaining time expired Novo 7 out from stock to prevent 
re-occurrence of incident.
2. Rang the transfusion manager on call for advice.
3. Conveyed advice of consultant Haematologist to consultant managing 
the said patient in the high dependency unit.
4. On advise of the consultant Haematologist, requested an in date unit of 
the batch product from the nearest sister Hospital.
Non-compliances identified:
1. Issue of time expired batch product. This observation constitutes a non- 
compliance to CPA Standard D (Equipment, information system and ma-
terials) and sub standard D3 (Management of reagents, calibration and 
quality control).
2. Absence of SOP on inventory control management of batch products. 
This observation constitutes a non- compliance to CPA Standard F (Ex-
amination process) and sub standard F2 (Examination procedures).
3. Inadequate pre and post product allocation checks before issue of batch 
product. This observation constitutes a non- compliance to CPA Standard 
F (Examination process) and sub standard F2 (Examination procedure). 
Describe the corrective and preventive action that could be taken to eliminate root cause.
1. Devise a more effective inventory /stock control system for batch products.
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2. Draw up a standard operating procedure inventory /stock control system 
for batch products.
3. Train all employees carrying out the specific activity on the SOP and get 
them to sign the SOP as an attestation that they are aware of the presence 
of a standard procedure for the task and that they will continue to carry 
out the task based on the Standard operating procedure.
4. Re-iterate in the continuous improvement meetings held every morning 
the need to do a pre and post batch product allocation checks before des-
patching products to the wards or satellite fridges.
5. State the steps that should be taken to implement the corrective actions 
arising from this investigation and how lessons learnt from this incident 
enhanced the department quest for continuous improvement?
6. Amend SOP on issue of batch products (Novo 7) to reflect suggested 
change with regards to separating the batch product (Novo 7) from the 
diluents.
7. Communicate change to all staff performing task by way of training on 
new SOP.
8. Devise a more effective inventory control measure for batch products 
(Novo 7).
9. Draw up an SOP on inventory control management of batch products.
10. Review process in the next 3 months to ensure that the root causes has 
been eliminated.
42. Laboratory techniques and transfusion sample requirements 
Blood banking reagents. The techniques used in blood bank involve mixing/reacting anti-
gens, usually on red blood cells with antibodies. The environment where this reaction occurs 
can range in temperature from 4°C to 37°C. With the most common being room tempera-
ture for ABO and the initial Rh(D) testing and 37°C when screening and identifying other 
clinically significant antigen-antibody reactions. Situations for testing in the blood bank range 
from determination of antigens on the red cell (A or B antigens to determine a patient’s ABO 
type and to determine the Rhesus group) to looking for particular antibodies that may cause 
transfusion reactions or hemolytic disease of the newborn. Depending on whether we are 
looking for a particular antigen or antibody will determine what reagents we are going to use. 
If we are looking for an antigen on a patient’s red cells, we will use known antibody contain-
ing the group specific antibody that will cause agglutination of the antigens on the red cells. 
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If our aim is to detect the presence of antibody in the plasma or serum, we react the plasma/
serum against red cell panel containing known antigen to facillitae the identification of the 
corresponding antibody in the plasma. This reaction is based on the principle that antigen 
and antibody reaction are specific.
 In almost all blood bank techniques we have red cells with an
tigens present. These red cells may either be reagent red cells with known antigens, patient 
red cells, or donor red cells. The reagent red cells are commercially prepared and have all 
the red cell antigens identified. When we use red cells where the antigens have already been 
determined, we can identify the possible antibodies present. A1 and B cells for confirmation 
of the ABO type in all patients and donors other than newborn babies. Antibody screening 
cells are O cells that have been studied to determine the presence of a number of antigens for 
specific antibodies that are known to cause transfusion reactions and hemolytic disease of 
the newborn. The antibody screening technique is part of all compatibility tests done before 
blood is transfused. Some of the more common antibodies detected are anti-D, anti-E and 
anti-K. Antibody identification cell panel are again O cells with the specific antigens known. 
Usually there are between 8 and 12 different cells in a cell panel. The pattern of positive and 
negative reactions helps identify the antibody. 
Antibody is found in serum. If it is the patient’s serum that 
is being tested, we do not know what antibody may be present so we are using one of the 3 
types of reagent cells listed above. If the serum is commercial reagent, the specific antibody 
present is already known. The commercial serum reagent is referred to as antisera. Therefore, 
we use Anti-A antisera to determine if a patient or donor has antigen A on his red cells. If we 
are trying to determine if the patient is Rh + or Rh -, we will use anti-Rho (D) antisera. Table 1 
is a summary of known and unknown sources of both antigens and antibodies.
Antigen Reagent Red Blood Cells 
Patient or donors plasma/serum
Table: Sources of known and unknown antigen red cells and antibody plasma/ serum reagents
In a transfusion service there are a 
number of procedures routinely done. They include; ABO/Rh(D) typing, antigen typing from 
other blood group systems such as Rh antigens other than D, Kell, Kidd, and Duffy, allontibody 
screening for antibodies formed to blood group antigens other than A and B, alloantibody iden
tification to determine the specificity of the antibodies detected in the antibody screening to 
allow for the selection of antigen negative red cells for transfusion, crossmatch, or compatibility 
testing, which determines whether donor blood can probably be safely transfused to the re
cipient. Other procedures include determination of Direct and indirect antihuman globulin test, 
2. Draw up a standard operating procedure inventory /stock control system 
for batch products.
3. Train all employees carrying out the specific activity on the SOP and get 
them to sign the SOP as an attestation that they are aware of the presence 
of a standard procedure for the task and that they will continue to carry 
out the task based on the Standard operating procedure.
4. Re-iterate in the continuous improvement meetings held every morning 
the need to do a pre and post batch product allocation checks before des
patching products to the wards or satellite fridges.
5. State the steps that should be taken to implement the corrective actions 
arising from this investigation and how lessons learnt from this incident 
enhanced the department quest for continuous improvement?
6. Amend SOP on issue of batch products (Novo 7) to reflect suggested 
change with regards to separating the batch product (Novo 7) from the 
diluents.
7. Communicate change to all staff performing task by way of training on 
new SOP.
8. Devise a more effective inventory control measure for batch products 
(Novo 7).
9. Draw up an SOP on inventory control management of batch products.
10. Review process in the next 3 months to ensure that the root causes has 
been eliminated.
 The techniques used in blood bank involve mixing/reacting anti
gens, usually on red blood cells with antibodies. The environment where this reaction occurs 
can range in temperature from 4°C to 37°C. With the most common being room tempera
ture for ABO and the initial Rh(D) testing and 37°C when screening and identifying other 
clinically significant antigen-antibody reactions. Situations for testing in the blood bank range 
from determination of antigens on the red cell (A or B antigens to determine a patient’s ABO 
type and to determine the Rhesus group) to looking for particular antibodies that may cause 
transfusion reactions or hemolytic disease of the newborn. Depending on whether we are 
looking for a particular antigen or antibody will determine what reagents we are going to use. 
If we are looking for an antigen on a patient’s red cells, we will use known antibody contain
ing the group specific antibody that will cause agglutination of the antigens on the red cells. 
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If our aim is to detect the presence of antibody in the plasma or serum, we react the plasma/
serum against red cell panel containing known antigen to facillitae the identification of the 
corresponding antibody in the plasma. This reaction is based on the principle that antigen 
and antibody reaction are specific.
Sources of Antigen Testing. In almost all blood bank techniques we have red cells with an-
tigens present. These red cells may either be reagent red cells with known antigens, patient 
red cells, or donor red cells. The reagent red cells are commercially prepared and have all 
the red cell antigens identified. When we use red cells where the antigens have already been 
determined, we can identify the possible antibodies present. A1 and B cells for confirmation 
of the ABO type in all patients and donors other than newborn babies. Antibody screening 
cells are O cells that have been studied to determine the presence of a number of antigens for 
specific antibodies that are known to cause transfusion reactions and hemolytic disease of 
the newborn. The antibody screening technique is part of all compatibility tests done before 
blood is transfused. Some of the more common antibodies detected are anti-D, anti-E and 
anti-K. Antibody identification cell panel are again O cells with the specific antigens known. 
Usually there are between 8 and 12 different cells in a cell panel. The pattern of positive and 
negative reactions helps identify the antibody. 
Sources of Antibody for Testing. Antibody is found in serum. If it is the patient’s serum that 
is being tested, we do not know what antibody may be present so we are using one of the 3 
types of reagent cells listed above. If the serum is commercial reagent, the specific antibody 
present is already known. The commercial serum reagent is referred to as antisera. Therefore, 
we use Anti-A antisera to determine if a patient or donor has antigen A on his red cells. If we 
are trying to determine if the patient is Rh + or Rh -, we will use anti-Rho (D) antisera. Table 1 
is a summary of known and unknown sources of both antigens and antibodies.
Source of anti-
gen or antibody
Source with known component Source with unknown component
Antigen Reagent Red Blood Cells Patient or Donor red blood cells
Antibody Commercial Antisera Patient or donors plasma/serum
Table: Sources of known and unknown antigen red cells and antibody plasma/ serum reagents
Testing procedures routinely done in blood banking. In a transfusion service there are a 
number of procedures routinely done. They include; ABO/Rh(D) typing, antigen typing from 
other blood group systems such as Rh antigens other than D, Kell, Kidd, and Duffy, allontibody 
screening for antibodies formed to blood group antigens other than A and B, alloantibody iden-
tification to determine the specificity of the antibodies detected in the antibody screening to 
allow for the selection of antigen negative red cells for transfusion, crossmatch, or compatibility 
testing, which determines whether donor blood can probably be safely transfused to the re-
cipient. Other procedures include determination of Direct and indirect antihuman globulin test, 
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dtermination of feto maternal haemorrhage (FMH), issue of prophylactic anti-D to pregnant 
rhesus negative women or following potentially sensitising event in pregnancy.
Procedure Purpose Source of antigen Source of antibody 




Detects antigens of 
other blood group 
systems (examples: K, E, 
C, Fya, Jka)
Patient’s RBC’s or Donor 
RBC’s
Commercial antisera 
to the specific antigens 
(examples: anti-K, anti-










Identifies the specificity 
of RBC antibodies
Commercial panel cells Patient’s serum




donor and patient 
before transfusion
Donor RBC’s Patient’s serum
Summary the sources of both the antigen and antibody 
Grading agglutination reactions in the blood transfusion laboratory 
Grading agglutination reactions gives an indication of the relative amount of antigen or antibody 
present. All tubes tests should be graded. The technique used in the resuspension of the cells will 
affect the grading of the reaction. The correct procedure for resuspending and grading reactions in-
cludes;
1. Use lighted agglutination viewer 
2. Read only one tube at a time 
3. Hold tube upright 
4. Position cell button so it is facing you in the mirror 
5. Very gently shake the tube and observe how the cells come off the cell button 
Figure : Example of lighted agglutination viewer
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Swirling off. A fine suspension indicates a negative reac
tion. Agglutination in chunks indicates a positive reaction. Continue shaking till all cells resus
pended. Tilt tube, read and grade reaction. Solid agglutination clump is graded as 4+, several 
large clumps as 3+, small to medium sized clumps on a clear background as 2+, small clumps 
with cloudy background as 1+ and tiny aggregates with cloudy background as 0.5+. Sometimes 
agglutination can be observed microscopically and can either be positive upon microscopic 
examination or negative. Observation of small clumps amidst many unagglutinated cells is 
called mixed field reaction (MF). Haemolyzed reaction is indicative of a positive reaction. If no 
agglutination, the test is said to be negative. It is not advisable to use ( ) to represent a negative 
reaction as it may be mis-understood. Rather it is more appriopriate to use either . 
 Between 2-5% cell suspension provides optimum anti
gen concentration for the tube method for red blood cells typing. To make sure your suspen
sion is within this range use reagent red cells for comparison. 
. The purpose of washing 
the red blood cells is to remove plasma, which contains substance that may interfere with 
antigen-antibody reaction. The following may be in the plasma and may interfere with test
ing. Such substances include; soluble antigens such as A and B may be present and neutralize 
your reagent, interfering proteins such as Wharton’s jelly that is seen in newborn cord blood, 
cold-acting autoimmune antibodies and increased levels of immunoglobulins that may cause 
either agglutination or rouleaux, haemolyzed red blood cells due to a difficult draw will in
terfere in your grading interpretation and fibrinogen can result in fibrin strands forming that 
makes grading reactions difficult. 
1. Place 1 to 3 drops of blood in the tube 
dtermination of feto maternal haemorrhage (FMH), issue of prophylactic anti-D to pregnant 





Detects antigens of 
other blood group 
systems (examples: K, E, 
C, Fya, Jka)
to the specific antigens 
(examples: anti-K, anti-
E, anti-C, anti-Fya and 
anti-Jka).





Identifies the specificity 
of RBC antibodies
Patient’s serum





Summary the sources of both the antigen and antibody 
Grading agglutination reactions gives an indication of the relative amount of antigen or antibody 
present. All tubes tests should be graded. The technique used in the resuspension of the cells will 
affect the grading of the reaction. The correct procedure for resuspending and grading reactions in
cludes;
1. Use lighted agglutination viewer 
2. Read only one tube at a time 
3. Hold tube upright 
4. Position cell button so it is facing you in the mirror 
5. Very gently shake the tube and observe how the cells come off the cell button 
Figure : Example of lighted agglutination viewer
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Grading Agglutination Reactions. Swirling off. A fine suspension indicates a negative reac-
tion. Agglutination in chunks indicates a positive reaction. Continue shaking till all cells resus-
pended. Tilt tube, read and grade reaction. Solid agglutination clump is graded as 4+, several 
large clumps as 3+, small to medium sized clumps on a clear background as 2+, small clumps 
with cloudy background as 1+ and tiny aggregates with cloudy background as 0.5+. Sometimes 
agglutination can be observed microscopically and can either be positive upon microscopic 
examination or negative. Observation of small clumps amidst many unagglutinated cells is 
called mixed field reaction (MF). Haemolyzed reaction is indicative of a positive reaction. If no 
agglutination, the test is said to be negative. It is not advisable to use (-) to represent a negative 
reaction as it may be mis-understood. Rather it is more appriopriate to use either Neg or 0. 
Preparation of red cells suspension. Between 2-5% cell suspension provides optimum anti-
gen concentration for the tube method for red blood cells typing. To make sure your suspen-
sion is within this range use reagent red cells for comparison. 
Washing red blood cells prior to preparing the 3% suspension. The purpose of washing 
the red blood cells is to remove plasma, which contains substance that may interfere with 
antigen-antibody reaction. The following may be in the plasma and may interfere with test-
ing. Such substances include; soluble antigens such as A and B may be present and neutralize 
your reagent, interfering proteins such as Wharton’s jelly that is seen in newborn cord blood, 
cold-acting autoimmune antibodies and increased levels of immunoglobulins that may cause 
either agglutination or rouleaux, haemolyzed red blood cells due to a difficult draw will in-
terfere in your grading interpretation and fibrinogen can result in fibrin strands forming that 
makes grading reactions difficult. 
Good technique in preparation of a 3% cell suspension involves the following
1. Place 1 to 3 drops of blood in the tube 
Dr Osaro Erhabor (Ph.D, CSci, FIBMS) and Dr Teddy Charles Adias (Ph.D, FIBMS)268
2. Aim the tip of the saline bottle towards the center of the tube and forcibly 
squirt saline into the tube. 
3. Fill the tube 3/4 full of saline (there will be less splattering in the centrifuge) 
4. Centrifuge long enough spin to pull most of cells into a button in the bot-
tom of the tube. 
5. Decant the saline completely. 
6. Shake the tube to resuspend cell button before washing the cells again. It 
will depend on the procedure being done as to how many types of wash-
ing are going to be done. 
Sample Requirement in Blood Transfusion. Most samples for blood banking are drawn into 
an Ethylene Diamine Tetra Acetic Acid (red top tube). A few tests require an EDTA sample if 
complement is not to be activated. Serum must be tested while fresh to ensure good comple-
ment activity. Antigens on cells are stable longer (months) in a clot tube.
Patient Identification. The patient MUST be positively identified and preferably wrist band-
ed. Some institutions use specific blood bank arm bands. Ask patient to state his/her name 
and date of birth. Responsible party should identify patient if he/she cannot. Verify informa-
tion by comparing it to ID wrist band and ensuring that it matches what is on the request 
form. Resolve any differences before proceeding with the blood draw.
Labeling of Sample. The information on sample must match information on ID band, which 
would also need to be consistent with the order. Information on samples must be hand writ-
ten (addressograph label is not allowed on a transfusion sample) must include the following; 
sample drawn should be 7.5 ml EDTA sample, name (last, first, middle initial) and no nick-
names, unique identification number such as hospital number or medical record number or 
possibly social security number, ward, date and time sample drawn along with the signature 
or unique identifier of phlebotomist (on sample and on orders), gender and birthdate desir-
able but not mandatory. The date of birth provides another unique identifier along with the 
medical record number and full name of the patient. All unknown or unconscious patients 
admitted into Accident and Emergency (A&E) must be given a unique A&E identification 
number and an estimated date of birth until patient can be properly identified, sample label-
ling must be done at the patient bed side as one continuous uninterrupted process, mislabeled 
samples must not be accepted and all samples must be properly labeled. The following are 
what would warrant an improperly labeled specimen; missing information (Date of birth, 
hospital number, name), incorrect information (incorrectly spelt name, incorrect date of birth 
and incorrect hospital number), information on sample not matching information on orders, 
sample not signed by requesting clinician, unlabelled/ improperly labeled samples must be 
discarded if the problem cannot be resolved. In the case of an emergency blood drawn on a 
patient who is unidentified at that time can be tested but must have a unique identifier (A&E 
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number, estimated date of birth and name (for example Unknown Male) and blood specimen 
must also be discarded when both name and medical record number have changed (example: 
Erhabor Osaro and Hospital number 1365200 becomes Adias Teddy Charles 1423562). 
 All patients to be transfused must 
have a wrist band. Details on the unit intended for transfusion must be checked by 2 nursing 
staff against the prescription and the patient medical notes. The following must be checked; 
surname, first name, hospital number, date of birth, blood group on the unit and patients 
blood group, donor number and expiry and suitability date. Finally check the wrist band to 
ensure that the unit is being transfused to the intended patient.
. Registered doctors, midwives, nurses and ODP’s can ad
minister blood. All transfusion must be prescribed on a transfusion record transcription. Drugs 
and other fluids be added to blood component or infused through the same cannula si
multaneously. A blood giving set with a filter must be used to transfuse blood component. A drip 
giving set  be used to transfuse blood component. The right sized cannula appriopriate 
for the size of the vein and the rate of transfusion must be used. The cannula must be flushed with 
2-5ml of 0.9% saline pre and post transfusion. Red cell can be warmed prior to ensure that it attain 
ambient temperature to prevent hypotherma. Patient should be kept warm during the transfusion. 
Vital signs ( temperature, blood pressure and pulse must be recorded before commencing trans
fusion and after the first 15 minutes of commencing transfusion, following any adverse events 
during transfusion and after each unit is transfused. There is no need to prime with saline before 
connecting the blood and there is no need to flush with saline after the residual volume is minimal. 
The blood giving set must be replaced after every 12 hours (after every 2-3 red cells, after a dose 
of FFP is given (4 units) and after 1-2 units of platelets) and when a different blood component 
type or fluid is being commenced. A unit of red cell must be transfused over 2-3 hours. Unit must 
be discarded after 4 hours. A unit of FFP or platelet is transfused over 30 minutes. If transfusion 
reaction is observed (mild febrile reaction with temperature < 38°C) review and give paracetamol 
and recommence transfusion but at a slow rate and observe. If symptom resolve, there is no need 
to report to transfusion laboratory. However one must be cautious if patient is neutropenic. If 
symptom do not resolve, stop the transfusion, report to transfusion laboratory for investigation of 
transfusion reaction. If urticaria, itching, wheals confirmed to the skin is observed, review patient 
and give piriton or hydrocortisone, slow down the transfusion and observe more frequently. If 
symptom do not resolve, stop the transfusion, report to transfusion laboratory for investigation of 
transfusion reaction. If there is severe transfusin reaction; fever >38°C with other symptoms such 
as rigors, flushing, restlessness, dyspnoea, headache, pain at infusion site, respiratory distress, 
loin and back pain, hypotension, tachycardia, haemoglobinuria, unexpected bleeding (DIC), ana
phylaxis/haemolytic incompatible wrong blood incident, bacteremic shock and TRALI, the blood 
must be stopped, check the patient and unit ID, infuse normal saline to maintain systolic blood 
pressure, inform the transfusion laboratory and send reminant of unit and giving set, samples for 
blood culture on the patient and from sample taken from the blood bag, post transfusion blood 
and urine sample to enable the investigation of the transfusion reaction. 
2. Aim the tip of the saline bottle towards the center of the tube and forcibly 
squirt saline into the tube. 
3. Fill the tube 3/4 full of saline (there will be less splattering in the centrifuge) 
4. Centrifuge long enough spin to pull most of cells into a button in the bot
tom of the tube. 
5. Decant the saline completely. 
6. Shake the tube to resuspend cell button before washing the cells again. It 
will depend on the procedure being done as to how many types of wash
ing are going to be done. 
 Most samples for blood banking are drawn into 
an Ethylene Diamine Tetra Acetic Acid (red top tube). A few tests require an EDTA sample if 
complement is not to be activated. Serum must be tested while fresh to ensure good comple
ment activity. Antigens on cells are stable longer (months) in a clot tube.
Patient Identification. The patient MUST be positively identified and preferably wrist band
ed. Some institutions use specific blood bank arm bands. Ask patient to state his/her name 
and date of birth. Responsible party should identify patient if he/she cannot. Verify informa
tion by comparing it to ID wrist band and ensuring that it matches what is on the request 
form. Resolve any differences before proceeding with the blood draw.
 The information on sample must match information on ID band, which 
would also need to be consistent with the order. Information on samples must be hand writ
ten (addressograph label is not allowed on a transfusion sample) must include the following; 
sample drawn should be 7.5 ml EDTA sample, name (last, first, middle initial) and no nick
names, unique identification number such as hospital number or medical record number or 
possibly social security number, ward, date and time sample drawn along with the signature 
or unique identifier of phlebotomist (on sample and on orders), gender and birthdate desir
able but not mandatory. The date of birth provides another unique identifier along with the 
medical record number and full name of the patient. All unknown or unconscious patients 
admitted into Accident and Emergency (A&E) must be given a unique A&E identification 
number and an estimated date of birth until patient can be properly identified, sample label
ling must be done at the patient bed side as one continuous uninterrupted process, mislabeled 
samples must not be accepted and all samples must be properly labeled. The following are 
what would warrant an improperly labeled specimen; missing information (Date of birth, 
hospital number, name), incorrect information (incorrectly spelt name, incorrect date of birth 
and incorrect hospital number), information on sample not matching information on orders, 
sample not signed by requesting clinician, unlabelled/ improperly labeled samples must be 
discarded if the problem cannot be resolved. In the case of an emergency blood drawn on a 
patient who is unidentified at that time can be tested but must have a unique identifier (A&
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number, estimated date of birth and name (for example Unknown Male) and blood specimen 
must also be discarded when both name and medical record number have changed (example: 
Erhabor Osaro and Hospital number 1365200 becomes Adias Teddy Charles 1423562). 
Double bedside Check Procedure before transfusion. All patients to be transfused must 
have a wrist band. Details on the unit intended for transfusion must be checked by 2 nursing 
staff against the prescription and the patient medical notes. The following must be checked; 
surname, first name, hospital number, date of birth, blood group on the unit and patients 
blood group, donor number and expiry and suitability date. Finally check the wrist band to 
ensure that the unit is being transfused to the intended patient.
Administration of Blood component. Registered doctors, midwives, nurses and ODP’s can ad-
minister blood. All transfusion must be prescribed on a transfusion record transcription. Drugs 
and other fluids must not be added to blood component or infused through the same cannula si-
multaneously. A blood giving set with a filter must be used to transfuse blood component. A drip 
giving set must never be used to transfuse blood component. The right sized cannula appriopriate 
for the size of the vein and the rate of transfusion must be used. The cannula must be flushed with 
2-5ml of 0.9% saline pre and post transfusion. Red cell can be warmed prior to ensure that it attain 
ambient temperature to prevent hypotherma. Patient should be kept warm during the transfusion. 
Vital signs ( temperature, blood pressure and pulse must be recorded before commencing trans-
fusion and after the first 15 minutes of commencing transfusion, following any adverse events 
during transfusion and after each unit is transfused. There is no need to prime with saline before 
connecting the blood and there is no need to flush with saline after the residual volume is minimal. 
The blood giving set must be replaced after every 12 hours (after every 2-3 red cells, after a dose 
of FFP is given (4 units) and after 1-2 units of platelets) and when a different blood component 
type or fluid is being commenced. A unit of red cell must be transfused over 2-3 hours. Unit must 
be discarded after 4 hours. A unit of FFP or platelet is transfused over 30 minutes. If transfusion 
reaction is observed (mild febrile reaction with temperature < 38°C) review and give paracetamol 
and recommence transfusion but at a slow rate and observe. If symptom resolve, there is no need 
to report to transfusion laboratory. However one must be cautious if patient is neutropenic. If 
symptom do not resolve, stop the transfusion, report to transfusion laboratory for investigation of 
transfusion reaction. If urticaria, itching, wheals confirmed to the skin is observed, review patient 
and give piriton or hydrocortisone, slow down the transfusion and observe more frequently. If 
symptom do not resolve, stop the transfusion, report to transfusion laboratory for investigation of 
transfusion reaction. If there is severe transfusin reaction; fever >38°C with other symptoms such 
as rigors, flushing, restlessness, dyspnoea, headache, pain at infusion site, respiratory distress, 
loin and back pain, hypotension, tachycardia, haemoglobinuria, unexpected bleeding (DIC), ana-
phylaxis/haemolytic incompatible wrong blood incident, bacteremic shock and TRALI, the blood 
must be stopped, check the patient and unit ID, infuse normal saline to maintain systolic blood 
pressure, inform the transfusion laboratory and send reminant of unit and giving set, samples for 
blood culture on the patient and from sample taken from the blood bag, post transfusion blood 
and urine sample to enable the investigation of the transfusion reaction. 
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Pre-transfusion investigation of a patient’s blood sample
Resolution of discrepancy in ABO grouping
Check samples (name, hospital number & DOB)Check samples (name, hospital number & DOB)
Repeat test with fresh sample
Repeat test on primary sample with contols
Check sample integrity and reagents (expiration) haemolysis)
Check for possible effect of diagnosis and race
Clinical blood transfusion process
Monitor patient
Blood component is delivered
Pre-transfusion checks done and component transfused
Monitor patient for adverse transfusion-related event
Carry out pre-transfusion test and checks
Order clinically indicated blood component/s
Decide based on clinical and lab evidence whether to transfuse
Issues to consider in deciding to transfuse a patient
Assess clinical condition
Record the decision and rationale
Obtain consent from patient
Inform patient about transfusion and why it is required
Use clinical guidelines & ensure it is indicated
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Detect clinically significant red cell antibodies
Check labelling & ensure it match patient identifiers
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Check for possible effect of diagnosis and race
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Cirical issues to remember when ordering blood component
Identify the patient correctly
Take blood sample and correctly label at patient bed side 
Complete the request/electronic order form correctly
Take note of special transfusion requirements
Send the sample and request form to the Blood Bank
Communicate with Blood Bank if blood is required urgently
Process to consider during pretransfusion testing
Determine patient’s ABO and RhD type
Apply compatibility label
Detect clinically significant red cell antibodies
Carry out antibody screen on patient sample
Select and crossmatch appriopriate red cell units
Things to consider delivering blood component ward
Check labelling & ensure it match patient identifiers
Maintain correct storage conditions until transfusion
Deliver to appropriate person in clinical area
Record removal of unit from storage location
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Essentials of administering blood components
Identify the patient correctly
Ensure there is a written instruction to transfuse
Record pretransfusion vital signs
Check patients group & ensure it is compatible with component
Repeat check of patient identification against component
Inspect components for signs of contamination and leakages
Check unit for expiry date
Get a 2nd nursing staff to cross check patient & component details






















Essentials of patient monitoring transfused patient
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Wrong clinical Transfusion 
circulatory overload
Lack of transfusion
knowledge or failure 
to follow guidelines











Inadequate clinical Ensure that 
guidiance are strictly 
complied with 
regularly audited.
Discuss with patient Failure to give a 
necessary transfusion
Risk of myocardial Unaware of 
of information and
Ensure that 
has a thorough 
knowledge of the 
indications for blood 







provided, at right 
time and is legible 
and understandable.
for transfusion and 
the discussion with 
 Wrong component 





Consent must be 
Wrong dose given Patient couldn’t 









learned from root 
cause analysis of 
Repeat check of patient identification against component
Get a 2nd nursing staff to cross check patient & component details
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Steps in the proc-
ess

















knowledge or failure 
to follow guidelines

















guidiance are strictly 
complied with 
and that they are 
regularly audited.










has a thorough 
knowledge of the 
indications for blood 
components and 
the knowledge to 
answer Patient’s 
questions.









provided, at right 
time and is legible 
and understandable.
Record indication 
for transfusion and 
the discussion with 
patient
 Wrong component 
given
No record 





Consent must be 
recorded.
Wrong dose given Patient couldn’t 





Patient not informed Errors, events 
and reactions are 
investigated




improved by lessons 
learned from root 
cause analysis of 
errors and near 
misses.
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Clinical Decision toTransfuse









Correctly identify the 
patient
Pretransfusion 
sample taken from 
the wrong patient.
Immunosuppressed 





policy must be in 




















Manimum data set 
for patient ID must 









of child bearing 
age sensitized to 
produce immune 
anti-D by transfusing 
Rh positive unit. 
Incorrect details on 
sample.
Prescriber must 















instead of FFP) or 
quantity (TACO).
Correct patient but 
sample tube wrongly 
labelled.
Prescriber must be 





units) and order 
component correctly.
Send blood sample 
and request to blood 
bank
Patient receives unit 





Sample taken from 
wrong patient.
Laboratory staff 
and transport staff 
9porters) must be 
trained on major 
haemorrhage 
procedure.
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If a major 
haemorrhage, 
initiate a major 
haemorrhage 
procedure (MHP).
Failure to recongnise 
major haemorrhage.
Death or serious 




procedure must be 
Failure to activate 
major haemorrhage 
procedure.
Ignorance of major 
haemorrhage 
procedure (MHP) 
Procedures must be 




must be investigated 
actions put in place.
Procedures must 
be improved from 
lesion learnt from 
Table: Analysis and prevention of errors in ordering blood components (Patient Sample and Request for Blood)
Note urgency of 













urgent request are 
communicated.
procedure for level of 
urgency.
procedure selected.





transfusion lab to 
issue uncrossmatched 
Blood bank must 
identification and 
a fresh sample if 
Check that patient 
what is on form and 
minmum data set.
and request form 
not checked. For 
Delayed transfusion. Reluctance of clinical 
unit to transfuse 
uncrossmatched red 
Staff performing task 
must be trained and 
Clinical Decision toTransfuse
Correctly identify the Pretransfusion 
sample taken from 
the wrong patient.
Immunosuppressed 





policy must be in 











Request form Manimum data set 
for patient ID must 
being followed.
request form. group in the patient 
Young Rhesus 
negative female 
of child bearing 
age sensitized to 
produce immune 
anti-D by transfusing 
Rh positive unit. 
Prescriber must 






or volume requested. transfused with 
wrong component 
instead of FFP) or 
quantity (TACO).
Correct patient but 
sample tube wrongly 
Prescriber must be 




units) and order 
and request to blood 
bank
Patient receives unit 
meant for another 
Sample taken from 
wrong patient.
Laboratory staff 
and transport staff 
9porters) must be 
trained on major 
haemorrhage 
procedure.
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If a major 
haemorrhage, 
initiate a major 
haemorrhage 
procedure (MHP).
Failure to recongnise 
major haemorrhage.
Death or serious 






procedure must be 
practised periodically 
(drill).
Failure to activate 
major haemorrhage 
procedure.
Ignorance of major 
haemorrhage 
procedure (MHP) 
and no MHP 
available. 
Procedures must be 




All error, events, near 
misses and reactions 
must be investigated 
and corrective 
actions put in place.
Procedures must 
be improved from 
lesion learnt from 
error, events, near 
misses and reactions.
Table: Analysis and prevention of errors in ordering blood components (Patient Sample and Request for Blood)
Steps in process What can go wrong Consequences on 
patient




Note urgency of 













urgent request are 
communicated.
Select appriopriate 









transfusion lab to 
issue uncrossmatched 
red cells.
Blood bank must 
insist on correct 
identification and 
a fresh sample if 
necessary.
Check that patient 
ID on sample match 
what is on form and 
that both contains the 
minmum data set.
Patient sample 
and request form 
not checked. For 
consistency and 
completeness
Delayed transfusion. Reluctance of clinical 
unit to transfuse 
uncrossmatched red 
cells.
Staff performing task 
must be trained and 
competency tested.
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Steps in process What can go wrong Consequences on 
patient













due to missed 
alloantibody.
Staff failure to comply 
with SOP.
Blood bank must carry 
out internal qualiy 
control and participate 
in EQA programme.
Determine patient 
ABO, Rh group as well 
as antibody screen 
to detect presence 
of alloantibodies to 
enable the selection of 
antigen negative units.
Blood bank staff 
does not register the 
requirement.
Risk of GVHD. Poor training of staff Install effective 
computerised record 
system and train staff.
There should be in 
place a paper back-up 
should the computer 
system fail.
Confirm that result 
of ABO and Rh group 
matches previous 
laboratory records.
Error in testing and 
recording of results
No SOP, failure by 
reqesting clinical 








unit and carry out 
compatibility testing.
Failure to check 
previous report or 
record.
Failure to select 
appriopriate 
component and 
despatch of unit to 




system in blood bank 
and suitable units not 
available.
Label, record and 
dispatch selected units.
No SOP, failure by 
reqesting clinical 




system in blood bank 
and suitable units not 
available.
Table: Analysis and prevention of errors in pretransfusion testing
Steps in the process What can go wrong Consequences for 
the patient




Pick up blood 
component from 
storage site.
Wrong unit selected Fatal and serious 
haemolytic transfusion 
reaction.
Patient details not 
used to select blood 
unit from storage.
Staff collecting unit 





One or more patient 




Delivery of blood to 
wrong location.
Staff collecting 
blood from fridge 
must be trained and 
competency tested.
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Delay in supplying Clinical staff not aware 
that units have been 
All procedures (SOP) 
must be documented
stored correctly until 
transfused.
wrong location.
Increased risk of 
transfusion of blood 
to wrong patient.
due to inappriopriate 
storage.
procedures must be 
audited regularly.
Blood discarded due 
to incorrect storage 
Blood unit wasted
misses must be 
investigated. Lessons 
learnt must be used as 
a learning process to 
improve procedures
Wrong storage for 
example red cell 
placed in fridge or left 
in platelet storage area.
Transfusion reaction 
due to contaminated 
or thermally damaged 
Analysis and prevention of errors in delivering blood to the clinical area
Check patient identity Delay of transfusion Transfusion-related Pack not inspected. Patient identification 
policy must be in place 
and bedside check 
must be observed.




change in colour 
of component not 
Minumum data set for 
patient ID must be in 
Ensure IV line is in Outdated pack not Morbidity due 
to transfusion of 
outdated component.
Expired pack not 
identified.
Staff responsible for 
administering blood 
must be trained and 
Take baseline Death due to ABO Check of patient 
and unit details not 
checked.
All Standard operating 
procedures must be 
documented and 
followed strictly.
Inspect contidion of 
unit transfused too quickly.
Transfusion associated Instruction on rate of 
transfusion not clear 
and not followed.
standard procedure 
must be audited 
regularly for 





does not specify 
special requirement.
transfusion reaction 
due to missed 
Staff failure to comply 
with SOP.
Blood bank must carry 
out internal qualiy 
in EQA programme.
ABO, Rh group as well 
of alloantibodies to 
enable the selection of 
antigen negative units.
Blood bank staff 
does not register the 
requirement.
Risk of GVHD. Poor training of staff Install effective 
computerised record 
system and train staff.
There should be in 
place a paper back-up 
should the computer 
system fail.
Confirm that result 
of ABO and Rh group 
matches previous 
Error in testing and 
recording of results
No SOP, failure by 
reqesting clinical 
staff, use of defective 
reagents and 
equipment.
stock levels of blood 
component, reagents 
and consumables.
unit and carry out 
compatibility testing.
Failure to check 
previous report or 
Failure to select 
despatch of unit to 
wrong destination or 
using inappriopriate 
Inadequate records 
system in blood bank 
and suitable units not 
Label, record and 
dispatch selected units.
No SOP, failure by 
reqesting clinical 




system in blood bank 
and suitable units not 
Table: Analysis and prevention of errors in pretransfusion testing
Pick up blood 
component from 
storage site.
Wrong unit selected Fatal and serious 
haemolytic transfusion used to select blood 
unit from storage.
Staff collecting unit 
from fridge must go 
with patient ID.
transfusion.
Delivery of blood to 
wrong location.
Staff collecting 
blood from fridge 
must be trained and 
277Transfusion Medicine Made Easy for Students of Allied Medical Sciences and Medicine
Steps in the process What can go wrong Consequences for 
the patient





received in clinical 
araea




Clinical staff not aware 
that units have been 
delivered.
All procedures (SOP) 
must be documented
Blood component 
stored correctly until 
transfused.
Blood delivered to the 
wrong location.
Increased risk of 
transfusion of blood 
to wrong patient.
Component discarded 
due to inappriopriate 
storage.
Compliance to 
procedures must be 
audited regularly.
Blood discarded due 
to incorrect storage 
condition.
Blood unit wasted Errors, events, near 
misses must be 
investigated. Lessons 
learnt must be used as 
a learning process to 
improve procedures
Wrong storage for 
example red cell 
placed in fridge or left 
in platelet storage area.
Transfusion reaction 
due to contaminated 
or thermally damaged 
blood
Analysis and prevention of errors in delivering blood to the clinical area
Steps in the process What can go wrong Consequences for 
the patient




Check patient identity 
details.
Delay of transfusion Transfusion-related 
sepsis
Pack not inspected. Patient identification 
policy must be in place 










change in colour 
of component not 
noticed.
Minumum data set for 
patient ID must be in 
place and observed.
Ensure IV line is in 
order.
Outdated pack not 
detected
Morbidity due 
to transfusion of 
haemolysed and 
outdated component.
Expired pack not 
identified.
Staff responsible for 
administering blood 






Death due to ABO 
incompatibility.
Check of patient 
and unit details not 
checked.
All Standard operating 
procedures must be 
documented and 
followed strictly.







Instruction on rate of 




must be audited 
regularly for 
compliance.
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Steps in the process What can go wrong Consequences for 
the patient




Check expiry date. Transfusion details not 
documented.
Unit not tracable. Failure to adhere to 
SOP.
Errors, events, near 
misses must be 
investigated. Outcome 
of investigation must 
be used as a learning 
process to improve 
procedures.
Check and ensure that 
patient ID details on 
blood match that on 
the wrist band.
Computerized support 
system must be 
available.
Check and ensure 
that ABO and Rh D 
group on patient ID 
and component label 
match.
Start transfusion at 
flow rate instructed.
Table: Analysis and prevention of errors in administering blood
Steps in process What can go wrong Consequences on 
patient





vital signs and general 
condition
Adverse reaction not 
detected
Avoidable harm to 
patient.
Patient not monitored Doctors and nurses 
responsible for trans-
fusion must be trained 
on blood adminstra-
tion and management 






Adverse reaction not 
managed correctly.
Delayed response to 
transfusion reaction.
Adverse reaction not 
recongnised.
Clinical guidelines 
must be available and 
being observed for 
the management of 
transfusion-related 
adverse events.
Record outcome of 
transfusion.
Delay in obtaining 
medical assistance.
Major morbidity or 
death due to transfu-
sion event.
Adverse reaction not 
responded to apprio-
priately and urgently.
Adverse reactions are 
investigated.
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Assess need for further 
transfusion.
Delayed in assessing 
continued transfusion 
requirement.
Incomplete follow up 
of investigation. for.
Procedures must be 
learnt from the inves-
tigation of transfusion 
Incomplete transfu-
non-compliance to 
legal and statutory 
requirement.
Clinician called fails to 
Analysis and prevention of errors in monitoring the transfused patient 
This topic will help transfusion practitioners understand the principles of patient confidenti
ality and the need for informed consent, understand the policies regarding informed consent 
for service users, know how to follow standard operational procedures to take and obtain 
informed consent, understand that it is part of their duty of care as health professional and 
that they are accountable for the release of information on a client or patient, understand that 
if patients or client´s record need to be used to help student gain the knowledge and skills 
which they require or for research purposes, the same principle of informed consent applies. 
Transfusion practitioners must be able to:
1. Practice within local policy and procedures regarding patient confidenti
ality and informed consent.
2. Practice within national and local policies regarding informed consent.
3. Demonstrate the policies as they apply to diagnostic service users.
4. Carry out your professional duties and responsibilities appreciating the 
need to obtain explicit consent from a patient or client before disclosing spe
cific information as well as understand that the client or patient can make an 
informed consent as to whether the information should be disclosed.
5. Carry out your professional duties and responsibilities appreciating the 
fact that it is the right and responsibility of every competent individual to 
advance his or her own welfare. This right and responsibility is exercised 
by freely and voluntarily consenting or refusing consent to recommend
ed medical procedures, based on a sufficient knowledge of the benefits, 
burdens, and risks involved.
6. Treat with discretion the confidential information about patient or client 
and ensure that they are used for the purposes for which it was intended 
Check expiry date. Transfusion details not 
documented.
Failure to adhere to 
misses must be 
investigated. Outcome 
of investigation must 
be used as a learning 
procedures.
Check and ensure that 
the wrist band.
Computerized support 
system must be 
Check and ensure 
group on patient ID 
Start transfusion at 
flow rate instructed.
Table: Analysis and prevention of errors in administering blood
vital signs and general 
Doctors and nurses 
responsible for trans-
fusion must be trained 
-
tion and management 
of associated adverse 
-
Recongnise and re-
managed correctly. transfusion reaction. recongnised.
Clinical guidelines 
must be available and 
being observed for 
the management of 
transfusion-related 
Record outcome of 
transfusion.
Delay in obtaining Major morbidity or 
death due to transfu- -
priately and urgently.
investigated.
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Steps in process What can go wrong Consequences on 
patient




Assess need for further 
transfusion.
Delayed in assessing 
continued transfusion 
requirement.
Incomplete follow up 
of investigation.
Clinical help not called 
for.
Procedures must be 
improved by lessons 
learnt from the inves-
tigation of transfusion 
events.
Incomplete transfu-
sion records and 
non-compliance to 
legal and statutory 
requirement.
Clinician called fails to 
respond.
Clinician does not 
treat patient’s reaction 
correctly.
Analysis and prevention of errors in monitoring the transfused patient 
43. Principle of informed consent in transfusion medicine
This topic will help transfusion practitioners understand the principles of patient confidenti-
ality and the need for informed consent, understand the policies regarding informed consent 
for service users, know how to follow standard operational procedures to take and obtain 
informed consent, understand that it is part of their duty of care as health professional and 
that they are accountable for the release of information on a client or patient, understand that 
if patients or client´s record need to be used to help student gain the knowledge and skills 
which they require or for research purposes, the same principle of informed consent applies. 
Transfusion practitioners must be able to:
1. Practice within local policy and procedures regarding patient confidenti-
ality and informed consent.
2. Practice within national and local policies regarding informed consent.
3. Demonstrate the policies as they apply to diagnostic service users.
4. Carry out your professional duties and responsibilities appreciating the 
need to obtain explicit consent from a patient or client before disclosing spe-
cific information as well as understand that the client or patient can make an 
informed consent as to whether the information should be disclosed.
5. Carry out your professional duties and responsibilities appreciating the 
fact that it is the right and responsibility of every competent individual to 
advance his or her own welfare. This right and responsibility is exercised 
by freely and voluntarily consenting or refusing consent to recommend-
ed medical procedures, based on a sufficient knowledge of the benefits, 
burdens, and risks involved.
6. Treat with discretion the confidential information about patient or client 
and ensure that they are used for the purposes for which it was intended 
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and will not be released to unauthorised persons without their permis-
sion (consent).
7. Appreciate the fact that informed consent has legal, ethical, and clinical 
dimensions.
What is informed consent? A process of obtaining a patient’s permission before disclosing 
specific information on the patient. A process of obtaining a patient’s permission for a pro-
cedure after the patient and doctor have discussed the risks, benefits, and alternatives of the 
procedure and the patient understands them. A process by which a patient/client confirms his 
or her willingness to participate in a particular trial, after having been informed of all aspects 
of the trial that are relevant to the subject’s decision to participate voluntarily in an experi-
ment after understanding the risks involved. 
What are the principles of informed consent? To trust another person with private and per-
sonal information about oneself is a significant matter. The patient or client has a right to 
believe that this information given in confidence will only be used for the purposes for which 
it was intended and will not be released to others without their permission (consent). It is 
impractical to obtain the consent of a patient every time you need to share information with 
other health professionals or staff involved in the health care of the patient or client. What is 
important is that the patient understands that some information may be made available to 
others involved in the delivery of their care. We need to obtain the explicit consent of a patient 
or client before we disclose specific information and it is important that the client or patient 
can make an informed consent as to whether the information should be disclosed.
 How can disclosure of patient information occur?
1. With the consent (written or verbal) of a client or patient.
2. Without the consent of the patient or client when disclosure is required by 
the law or by the order of a court.
3. Without the consent of the patient when the disclosure is in the interest of 
public interest.
4. The public interest means the interest of an individual, or groups of indi-
viduals or of society as a whole and would cover issues such as; serious 
crime, child abuse, drug trafficking or other activities which places others 
at serious risk.
5. It is our responsibility as health professional (part of our duty of care) and 
we are accountable for the release of information on a client or patient. The 
deliberate release of patient information without their consent even in the 
interest of the public must be justified.
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6. The organization that employs the health professions who make records 
are the legal owners of the records, but this does not give anyone in the 
organization the legal right to access or release this information to a third 
party without the consent of the client.
7. If patients or clients record need to be used to help student gain the knowl
edge and skills which they require, the same principle of informed consent 
applies. The person providing the training will be responsible for making 
sure the student understand the need for confidentiality and informed con
sent and the need to follow local procedures for handling and storing of 
records.
8. Informed consent includes being informed and giving consent. These two 
are closely related elements. Being informed requires offering information 
to potential human subjects. In any research on human beings, each poten
tial subject must be adequately informed of the aims, methods, sources of 
funding, any possible conflicts of interest, institutional affiliations of the 
researcher, the anticipated benefits and potential risks of the study and the 
discomfort it may entail. Information provided by researcher should be 
simple and clear enough for the potential subject to understand and it is 
the duty of researcher to answer their questions. The subject should also 
be informed of the right to abstain from participation in the study or with
draw consent to participate at any time without reprisal. The principle of 
informed consent, aimed at the lawfulness of health assistance, tends to 
reflect the concept of autonomy and of decisional auto determination of 
the person requiring and requesting medical and/or surgical interventions. 
It is the right and responsibility of every competent individual to advance 
his or her own welfare. This right and responsibility is exercised by freely 
and voluntarily consenting or refusing consent to recommended medical 
procedures, based on a sufficient knowledge of the benefits, burdens, and 
risks involved. The ability to give informed consent depends on;adequate 
disclosure of information, patient freedom of choice, patient comprehen
of information given and patient capacity for decision-making.
9. Three necessary conditions that must be satisfied in obtaining informed 
consent are;that the individual’s decision is voluntary, that this decision 
is made with an appropriate understanding of the circumstances, that 
the patient’s choice is deliberate insofar as the patient has carefully con
sidered all of the expected benefits, burdens, risk and reasonable alterna
tives, legally, adequate disclosure includes information concerning the 
following;diagnosis, nature and purpose of treatment, risks of treatment 
and treatment alternatives.
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and will not be released to unauthorised persons without their permis
sion (consent).
7. Appreciate the fact that informed consent has legal, ethical, and clinical 
dimensions.
A process of obtaining a patient’s permission before disclosing 
specific information on the patient. A process of obtaining a patient’s permission for a pro
cedure after the patient and doctor have discussed the risks, benefits, and alternatives of the 
procedure and the patient understands them. A process by which a patient/client confirms his 
or her willingness to participate in a particular trial, after having been informed of all aspects 
of the trial that are relevant to the subject’s decision to participate voluntarily in an experi
ment after understanding the risks involved. 
To trust another person with private and per
sonal information about oneself is a significant matter. The patient or client has a right to 
believe that this information given in confidence will only be used for the purposes for which 
it was intended and will not be released to others without their permission (consent). It is 
impractical to obtain the consent of a patient every time you need to share information with 
other health professionals or staff involved in the health care of the patient or client. What is 
important is that the patient understands that some information may be made available to 
others involved in the delivery of their care. We need to obtain the explicit consent of a patient 
or client before we disclose specific information and it is important that the client or patient 
can make an informed consent as to whether the information should be disclosed.
1. With the consent (written or verbal) of a client or patient.
2. Without the consent of the patient or client when disclosure is required by 
the law or by the order of a court.
3. Without the consent of the patient when the disclosure is in the interest of 
public interest.
4. The public interest means the interest of an individual, or groups of indi
viduals or of society as a whole and would cover issues such as; serious 
crime, child abuse, drug trafficking or other activities which places others 
at serious risk.
5. It is our responsibility as health professional (part of our duty of care) and 
we are accountable for the release of information on a client or patient. The 
deliberate release of patient information without their consent even in the 
interest of the public must be justified.
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6. The organization that employs the health professions who make records 
are the legal owners of the records, but this does not give anyone in the 
organization the legal right to access or release this information to a third 
party without the consent of the client.
7. If patients or clients record need to be used to help student gain the knowl-
edge and skills which they require, the same principle of informed consent 
applies. The person providing the training will be responsible for making 
sure the student understand the need for confidentiality and informed con-
sent and the need to follow local procedures for handling and storing of 
records.
8. Informed consent includes being informed and giving consent. These two 
are closely related elements. Being informed requires offering information 
to potential human subjects. In any research on human beings, each poten-
tial subject must be adequately informed of the aims, methods, sources of 
funding, any possible conflicts of interest, institutional affiliations of the 
researcher, the anticipated benefits and potential risks of the study and the 
discomfort it may entail. Information provided by researcher should be 
simple and clear enough for the potential subject to understand and it is 
the duty of researcher to answer their questions. The subject should also 
be informed of the right to abstain from participation in the study or with-
draw consent to participate at any time without reprisal. The principle of 
informed consent, aimed at the lawfulness of health assistance, tends to 
reflect the concept of autonomy and of decisional auto determination of 
the person requiring and requesting medical and/or surgical interventions. 
It is the right and responsibility of every competent individual to advance 
his or her own welfare. This right and responsibility is exercised by freely 
and voluntarily consenting or refusing consent to recommended medical 
procedures, based on a sufficient knowledge of the benefits, burdens, and 
risks involved. The ability to give informed consent depends on;adequate 
disclosure of information, patient freedom of choice, patient comprehen-
sion of information given and patient capacity for decision-making.
9. Three necessary conditions that must be satisfied in obtaining informed 
consent are;that the individual’s decision is voluntary, that this decision 
is made with an appropriate understanding of the circumstances, that 
the patient’s choice is deliberate insofar as the patient has carefully con-
sidered all of the expected benefits, burdens, risk and reasonable alterna-
tives, legally, adequate disclosure includes information concerning the 
following;diagnosis, nature and purpose of treatment, risks of treatment 
and treatment alternatives.
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Questions and answers on the principle of informed consent
Question 1: Mrs Ford came to the laboratory to have her blood taken for HIV screening. Later 
that morning her husband Mr Ford who is on warfarin also attends the clinic to have his 
blood taken for INR investigation. He enquires about whether his wife had attended clinic 
that morning and what the report of her HIV test was. How will you Handel this situation?
Answer 1: We need to obtain the explicit consent from a patient or client before we disclose 
specific information and it is important that the client or patient can make an informed con-
sent as to whether the information should be disclosed.
Question 2: A staff nurse in Eye clinic that has no duty of care for a patient refereed from STD 
clinic has called the laboratory to enquire about the urine microscopy, culture and sensitivity 
result of her ex –partner who is suspected to have a sexually transmitted infection. How will 
you handle this enquiry?
Answer 2: The organization that employs the health professions who make records are the 
legal owners of the records, but this does not give anyone in the organization the legal right to 
access or release this information to a third party without the consent of the client particularly 
when the information accessed is not for the purpose of patient care.
Question 3: Mrs James goes to her family GP in Bolton to submit her early morning urine 
for pregnancy test. Later that afternoon a GP based in Wigan who has no duty of care to the 
patient but who introduces himself as a GP and partner of Mrs A rings to enquire about her 
pregnancy test result. How will you deal with such situation?
Answer 3: It is against the principles of patient confidentiality and informed consent to give 
confidential information on a patient to a relative clinician or healthcare worker who has no 
duty of care whatsoever to the patient and does not require the information for the manage-
ment of the patient.
Question 4: Your brother’s partner has just returned from holidays in the Caribbean. She pre-
sented to her GP with an episode of vomiting and abdominal pain. Her GP promptly referred 
her to the laboratory for pregnancy test. Your brother knowing you work in the laboratory in 
Port Harcourt Teaching Hospital rings you to enquire about his partner’s laboratory results. 
How will you deal with this situation?
Answer 4: As healthcare workers, we are ethical bound not to disclose confidential informa-
tion on patients or clients to third parties without their consent. 
Question 5: A man has just been told that his son’s blood group is O positive by his GP. The 
man however knows that his own blood group is AB positive and that his wife’s blood group 
is O positive. He has read from the internet that a blood group AB parent cannot give birth 
to an O child. He rings you in the Laboratory to confirm the wife’s blood group and enquire 
about the possibility of the child being his. How will you deal with this issue?
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Answer 5: It is against the principles of patient confidentiality and informed consent to give 
confidential information on a patient or client to a third party without the consent of the pa
tient. By giving such information without the consent of the wife, the husband will know that 





I give consent for myself / child to be a participant in this study. I have been fully informed 
what participation will involve and had all my questions answered. I understand that I can 
withdraw from this study at any time without giving reason and without penalty.
I also give consent for recordings to be made relating to my participation.
I also give consent for my personal data to be used by the research workers in any way they 
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Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hemat
opoietic stem cell or blood, usually derived from either the bone marrow (BMT) or peripheral 
blood stem cells. In the case of a bone marrow transplant, the HSC are removed from a large 
bone of the donor, typically the pelvis, through a large needle that reaches the center of the 
bone, the technique is referred to as a bone marrow harvest and is performed under general 
anesthesia and Stored heparinized and the mononuclear cell count of 2-4 x 106 nucleated 
cells/kg is indicated). In peripheral blood stem cells transplant, the stem cells are collected 
using cell separator equipment. Mononuclear cells are collected (aphaeresis) after centrifuga
tion before returning the red cells back into the patient. Stem cell content of PBSC is low and 
collection may be insufficient for transplantation. Prior chemotherapy (cyclophosphamide) 
and collection during the recovery phase. The peripheral stem cell yield is boosted a 100 times 
Question 1: Mrs Ford came to the laboratory to have her blood taken for HIV screening. Later 
that morning her husband Mr Ford who is on warfarin also attends the clinic to have his 
blood taken for INR investigation. He enquires about whether his wife had attended clinic 
that morning and what the report of her HIV test was. How will you Handel this situation?
Answer 1: We need to obtain the explicit consent from a patient or client before we disclose 
specific information and it is important that the client or patient can make an informed con
sent as to whether the information should be disclosed.
Question 2: A staff nurse in Eye clinic that has no duty of care for a patient refereed from STD 
clinic has called the laboratory to enquire about the urine microscopy, culture and sensitivity 
result of her ex –partner who is suspected to have a sexually transmitted infection. How will 
you handle this enquiry?
Answer 2: The organization that employs the health professions who make records are the 
legal owners of the records, but this does not give anyone in the organization the legal right to 
access or release this information to a third party without the consent of the client particularly 
when the information accessed is not for the purpose of patient care.
Question 3: Mrs James goes to her family GP in Bolton to submit her early morning urine 
for pregnancy test. Later that afternoon a GP based in Wigan who has no duty of care to the 
patient but who introduces himself as a GP and partner of Mrs A rings to enquire about her 
pregnancy test result. How will you deal with such situation?
Answer 3: It is against the principles of patient confidentiality and informed consent to give 
confidential information on a patient to a relative clinician or healthcare worker who has no 
duty of care whatsoever to the patient and does not require the information for the manage
ment of the patient.
Question 4: Your brother’s partner has just returned from holidays in the Caribbean. She pre
sented to her GP with an episode of vomiting and abdominal pain. Her GP promptly referred 
her to the laboratory for pregnancy test. Your brother knowing you work in the laboratory in 
Port Harcourt Teaching Hospital rings you to enquire about his partner’s laboratory results. 
How will you deal with this situation?
Answer 4: As healthcare workers, we are ethical bound not to disclose confidential informa
tion on patients or clients to third parties without their consent. 
Question 5: A man has just been told that his son’s blood group is O positive by his GP. The 
man however knows that his own blood group is AB positive and that his wife’s blood group 
is O positive. He has read from the internet that a blood group AB parent cannot give birth 
to an O child. He rings you in the Laboratory to confirm the wife’s blood group and enquire 
about the possibility of the child being his. How will you deal with this issue?
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Answer 5: It is against the principles of patient confidentiality and informed consent to give 
confidential information on a patient or client to a third party without the consent of the pa-
tient. By giving such information without the consent of the wife, the husband will know that 
he is most likely not the putative father of the child.





I give consent for myself / child to be a participant in this study. I have been fully informed 
what participation will involve and had all my questions answered. I understand that I can 
withdraw from this study at any time without giving reason and without penalty.
I also give consent for recordings to be made relating to my participation.
I also give consent for my personal data to be used by the research workers in any way they 




This study is approved by the hospital Research Ethics Committee
44. Stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hemat-
opoietic stem cell or blood, usually derived from either the bone marrow (BMT) or peripheral 
blood stem cells. In the case of a bone marrow transplant, the HSC are removed from a large 
bone of the donor, typically the pelvis, through a large needle that reaches the center of the 
bone, the technique is referred to as a bone marrow harvest and is performed under general 
anesthesia and Stored heparinized and the mononuclear cell count of 2-4 x 106 nucleated 
cells/kg is indicated). In peripheral blood stem cells transplant, the stem cells are collected 
using cell separator equipment. Mononuclear cells are collected (aphaeresis) after centrifuga-
tion before returning the red cells back into the patient. Stem cell content of PBSC is low and 
collection may be insufficient for transplantation. Prior chemotherapy (cyclophosphamide) 
and collection during the recovery phase. The peripheral stem cell yield is boosted a 100 times 
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with daily subcutaneous injections of Granulocyte-colony stimulating factor, as well as treat-
ment growth factor (at a dose of 10µg/kg/day for 4-6 days). GCFU help to mobilize stem cells 
from the donor’s bone marrow into the peripheral circulation. Optimum yield with CD34+ 
cells of >2.5 X 106/kg and granulocyte-macrophage colony forming unit (CFU-GM) of 1-5 x 
105/kg is considered optimal for transplantation. Other sources of stem cells include amniotic 
fluid and umblical cord blood. It is also possible to extract hematopoietic stem cells from 
amniotic fluid for both autologous and heterogonous use at the time of childbirth. Umbilical 
cord blood is obtained when a mother donates her infant’s umbilical cord and placenta after 
birth. Cord blood has a higher concentration of HSC than is normally found in adult blood. 
However, the small quantity of blood obtained from an umbilical cord (typically about 50 mL) 
makes it more suitable for transplantation into small children than into adults.
History of stem cell transplant
Georges Mathé, a French oncologist, performed the first bone marrow transplant in 1959 
on five Yugoslavian nuclear workers whose own marrow had been damaged by irradiation 
caused by a Criticality accident at the Vinča Nuclear Institute, but all of these transplants 
were rejected. Mathé later pioneered the use of bone marrow transplants in the treatment of 
leukemia. Stem cell transplantation was pioneered using bone-marrow-derived stem cells by 
a team at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s led 
by Donnall Thomas. Thomas’ work showed that bone marrow cells infused intravenously 
could repopulate the bone marrow and produce new blood cells. The first physician to per-
form a successful human bone marrow transplant on a disease other than cancer was Robert 
A. Good at the University of Minnesota in 1968. Hematopoietic stem cell transplantation re-
mains a risky procedure with many possible complications. It has traditionally been reserved 
for patients with life-threatening diseases. While it remains a procedure involving a high 
degree of risk, one must keep in mind that many disorders (mainly acute leukemias and neo-
plastic lymphoproliferative disorders) treated by this procedure. Stem cell transplantation is a 
medical procedure in the fields of hematology and oncology, most often performed for people 
with diseases of the blood, bone marrow, or certain cancers. It involves; elimination of a pa-
tient immune system using chemotherapy and or radiotherapy and replacement with patient 
stem cells previously harvested prior to chemotherapy or radiotherapy (autologous) or stem 
cells from another donor (allogeneic) or from an HLA -matched identical twin (syngeneic). 
Haemopoietic stem cells are indiated in the following disease conditions.
1. Non malignant disorders such as myelodysplastic syndrome, multiple 
myeloma and lymphoma.
2. Pediatric cases where the patient has an inborn defect such as severe com-
bined immunodeficiency or congenital neutropenia with defective stem 
cells.
3. Leukemia (ALL, AML, CML and CLL) patients who would not benefit 
from prolonged treatment with or are already resistant to chemotherapy.
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4. Children or adults with aplastic anemia who have lost their stem cells 
after birth including Fanconi’s anaemia. 
5. Inherited disorders such as sickle-cell disease, thalassaemia, immune de
ficiencies, inborn errors of metabolism.
6. Severe autoimmune disorders.
7. Neuroblastoma (Neuroblastoma is the most common extracranial solid 
cancer in childhood and the most common cancer in infancy. It is a neu
roendocrine tumor, arising from any neural crest element of the sympa
thetic nervous system or SNS. It most frequently originates in one of the 
adrenal glands, but can also develop in nerve tissues in the neck, chest, 
abdomen, or pelvis).
8. Ewing’s Sarcoma (A malignant round-cell tumour. It is a rare disease in 
which cancer cells are found in the bone or in soft tissue. The most com
mon areas in which it occurs are the pelvis, the femur, the humerus, the 
ribs and clavicle.
9. Amyloidosis (A conditions in which amyloid proteins are abnormally 
deposited in organs and/or tissues. There are numerous symptoms that 
are associated with this disease. The most common ones have to do with 
the heart, such as heart failure, arrhythmia, and an irregular heartbeat. 
Also the respiratory tract can be affected and cause hemoptysis. Usually 
the spleen enlarges and sometimes ruptures. The gastrointestinal tract is 
usually affected and causes vomiting, hemorrhaging and diarrhea. The 
amyloidosis can also affect the motor functions and cause polyneurop
athy. When the amyloid fibrils and oligomers get to the skin they can 
cause skin lesions and petechiae. One of the most famous symptoms is 
macroglossia. 
10. Acquired severe marrow diseases (paroxysmal nocturnal haemoglobinu
ria, red cell aplasia and myelofibrosis).
11. Desmoplastic small round cell tumor.
12. Chronic granulomatous disease. 
13. Hodgkin’s disease. 
Graft types
 In autologous HSCT patient is given a high dose of chemotherapy with or without 
radiotherapy with the intention of eradicating the patient’s malignant cell population at the cost 
of partial or complete bone marrow ablation (destruction of patient’s bone marrow function to 
with daily subcutaneous injections of Granulocyte-colony stimulating factor, as well as treat
ment growth factor (at a dose of 10µg/kg/day for 4-6 days). GCFU help to mobilize stem cells 
from the donor’s bone marrow into the peripheral circulation. Optimum yield with CD34+ 
cells of >2.5 X 106/kg and granulocyte-macrophage colony forming unit (CFU-GM) of 1-5 x 
105/kg is considered optimal for transplantation. Other sources of stem cells include amniotic 
fluid and umblical cord blood. It is also possible to extract hematopoietic stem cells from 
amniotic fluid for both autologous and heterogonous use at the time of childbirth. Umbilical 
cord blood is obtained when a mother donates her infant’s umbilical cord and placenta after 
birth. Cord blood has a higher concentration of HSC than is normally found in adult blood. 
However, the small quantity of blood obtained from an umbilical cord (typically about 50 mL) 
makes it more suitable for transplantation into small children than into adults.
Georges Mathé, a French oncologist, performed the first bone marrow transplant in 1959 
on five Yugoslavian nuclear workers whose own marrow had been damaged by irradiation 
caused by a Criticality accident at the Vinča Nuclear Institute, but all of these transplants 
were rejected. Mathé later pioneered the use of bone marrow transplants in the treatment of 
leukemia. Stem cell transplantation was pioneered using bone-marrow-derived stem cells by 
a team at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s led 
by Donnall Thomas. Thomas’ work showed that bone marrow cells infused intravenously 
could repopulate the bone marrow and produce new blood cells. The first physician to per
form a successful human bone marrow transplant on a disease other than cancer was Robert 
A. Good at the University of Minnesota in 1968. Hematopoietic stem cell transplantation re
mains a risky procedure with many possible complications. It has traditionally been reserved 
for patients with life-threatening diseases. While it remains a procedure involving a high 
degree of risk, one must keep in mind that many disorders (mainly acute leukemias and neo
plastic lymphoproliferative disorders) treated by this procedure. Stem cell transplantation is a 
medical procedure in the fields of hematology and oncology, most often performed for people 
with diseases of the blood, bone marrow, or certain cancers. It involves; elimination of a pa
tient immune system using chemotherapy and or radiotherapy and replacement with patient 
stem cells previously harvested prior to chemotherapy or radiotherapy (autologous) or stem 
cells from another donor (allogeneic) or from an HLA -matched identical twin (syngeneic). 
Haemopoietic stem cells are indiated in the following disease conditions.
1. Non malignant disorders such as myelodysplastic syndrome, multiple 
myeloma and lymphoma.
2. Pediatric cases where the patient has an inborn defect such as severe com
bined immunodeficiency or congenital neutropenia with defective stem 
cells.
3. Leukemia (ALL, AML, CML and CLL) patients who would not benefit 
from prolonged treatment with or are already resistant to chemotherapy.
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4. Children or adults with aplastic anemia who have lost their stem cells 
after birth including Fanconi’s anaemia. 
5. Inherited disorders such as sickle-cell disease, thalassaemia, immune de-
ficiencies, inborn errors of metabolism.
6. Severe autoimmune disorders.
7. Neuroblastoma (Neuroblastoma is the most common extracranial solid 
cancer in childhood and the most common cancer in infancy. It is a neu-
roendocrine tumor, arising from any neural crest element of the sympa-
thetic nervous system or SNS. It most frequently originates in one of the 
adrenal glands, but can also develop in nerve tissues in the neck, chest, 
abdomen, or pelvis).
8. Ewing’s Sarcoma (A malignant round-cell tumour. It is a rare disease in 
which cancer cells are found in the bone or in soft tissue. The most com-
mon areas in which it occurs are the pelvis, the femur, the humerus, the 
ribs and clavicle.
9. Amyloidosis (A conditions in which amyloid proteins are abnormally 
deposited in organs and/or tissues. There are numerous symptoms that 
are associated with this disease. The most common ones have to do with 
the heart, such as heart failure, arrhythmia, and an irregular heartbeat. 
Also the respiratory tract can be affected and cause hemoptysis. Usually 
the spleen enlarges and sometimes ruptures. The gastrointestinal tract is 
usually affected and causes vomiting, hemorrhaging and diarrhea. The 
amyloidosis can also affect the motor functions and cause polyneurop-
athy. When the amyloid fibrils and oligomers get to the skin they can 
cause skin lesions and petechiae. One of the most famous symptoms is 
macroglossia. 
10. Acquired severe marrow diseases (paroxysmal nocturnal haemoglobinu-
ria, red cell aplasia and myelofibrosis).
11. Desmoplastic small round cell tumor.
12. Chronic granulomatous disease. 
13. Hodgkin’s disease. 
Graft types
Autologous. In autologous HSCT patient is given a high dose of chemotherapy with or without 
radiotherapy with the intention of eradicating the patient’s malignant cell population at the cost 
of partial or complete bone marrow ablation (destruction of patient’s bone marrow function to 
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grow new blood cells). Stem cells are extracted (aphaeresis) from the patient and stored frozen. 
The patient’s own stored stem cells are then returned to his/her body, where they replace de-
stroyed tissue and resume the patient’s normal blood cell production. Autologous transplants 
have several advantages over alogenic transplant; lower risk of infection during the immune-
compromised portion of the treatment, the recovery of immune function is rapid, the incidence 
of patients experiencing rejection (graft-versus-host disease) is very rare due to the donor and 
recipient being the same individual, graft versus host disease (GVHD) is not a challenge and the 
procedure-related mortality is low (<5%). These advantages have established autologous HSCT 
as one of the standard second-line treatments for such diseases as lymphoma. A limitation of 
this procedure is the risk of tumour cells contaminating the stem cell harvest.
Allogeneic. Allogeneic HSCT involves two people: the (healthy) donor and the (patient) re-
cipient. Allogeneic HSC donors must have a tissue (HLA) type that matches the recipient. 
Matching is performed on the basis of variability at three or more loci of the HLA gene, and 
a perfect match at these loci is preferred. Even if there is a good match at these critical alle-
les, the recipient will require immunosuppressive medications to mitigate graft-versus-host 
disease. About 25 to 30 percent of allogeneic HSCT recipients have an HLA-identical sib-
ling. Even so-called “perfect matches” may have mismatched minor alleles that contribute 
to graft-versus-host disease. Allogeneic transplant donors may be related (usually a closely 
HLA matched sibling), syngeneic (a monozygotic or ‘identical’ twin of the patient - necessar-
ily extremely rare since few patients have an identical twin. Unrelated donors may be found 
through a registry of bone marrow donors such as the National Marrow Donor Program. Al-
logeneic transplants are also performed using umbilical cord blood as the source of stem cells. 
Transplanting healthy stem cells to the recipient’s immune system, allogeneic HSCTs appear 
to improve chances for cure or long-term remission once the immediate transplant-related 
complications are resolved. The short arm of chromosome 6 contains a cluster of genes known 
as the Major Histocompatibility Complex (MHC) or the HLA region. These genes encode the 
HLA antigens and molecules like complement components, tumuor necrosis factor (TNF) 
and antigens related to antigen processing. A compatible donor is found by doing additional 
HLA-testing from the blood of potential donors. The HLA genes fall in two categories (type 
I and type II). In general, mismatches of the type-I genes (i.e. HLA-A, HLA-B, or HLA-C) in-
crease the risk of graft rejection and are present in CD8+ cells. HLA-type 11 is present in CD4+ 
T-cells. A mismatch of an HLA type II gene (i.e. HLA-DR, or HLA-DQB1) increases the risk of 
graft-versus-host disease. In addition a genetic mismatch as small as a single DNA base pair 
is significant so perfect matches require knowledge of the exact DNA sequence of these genes 
for both donor and recipient. Leading transplant centers currently perform testing for all 
five of these HLA genes before declaring that a donor and recipient are HLA-identical. HLA 
typing is carried out either by serological technique using antibodies that are specific for indi-
vidual HLA alleles or by molecular testing using PCR sequence-specific primers. The advan-
tage of this procedure is associated graft versus leukemia (GVL). Mortality from allogeneic 
stem cell transplantation is higher for the following reasons; immunological incompatibility 
between donors and recipients despite HLA matching and immunological incompatibility - 
related immunodeficiency, GVHD and graft failure.
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Acute lymphoblastic and myeloid leukaemia
Chronic myeloid leukaemia Severe autoimmune disorders
Severe aplastic anaemia including Fanconi, s 
Acute and chronic leukaemia
Haemoglobinopathies (thalasaemia and sickle 
Multiple myeloma
Inborn errors of metabolism in the haemopoietic 
and mesenchymal system such as osteopetrosis.
Hodgkins and non-Hodgkins lymphoma
Acquired marrow syndrome (aplastic anaemia, my-
elofibrosis, paroxysmal nocturnal haemoglobinuria)
Malignant disorders (myelodysplasia, multiple myelo-
ma, chronic lymphocytic leukaemia and lymphoma)
 HSC because the cells must be harvested from the recipient months in ad
vance of the transplant treatment. Bone marrow cells can be frozen (cryopreserved) for pro
longed periods, without damaging too many cells. In the case of allogeneic transplants, fresh 
HSC are preferred, in order to avoid cell loss that might occur during the freezing and thaw
ing process. Allogeneic cord blood is stored frozen at a cord blood bank because it is only 
obtainable at the time of childbirth. To cryopreserve HSC, a preservative called Dimethyl sul
foxide (DMSO) (DMSO has been used as a cryoprotectant and is still an important constituent 
of cryoprotectant vitrification mixtures used to preserve organs, tissues, and cell suspensions. 
Without it, up to 90% of frozen cells will become inactive. In a controlled-rate freezer DMSO 
prevent osmotic cellular injury during ice crystal formation. HSC may be stored for years in a 
cryofreezer, which typically utilizes liquid nitrogen.
After harvesting of HSC, it is processed (red cells are removed, the 
mononuclear cells are concentrated, autologous collections are purged by chemotherapy 
or antibody treatment to remove residual malignant cells and T-cells to reduce incidence of 
GVHD).
Prior to infusing stem cells into a patient, conditioning (chemotherapy and total 
body irradiation (TBI) is carried out. The aim of this is to; eradicate patient’s haemopoietic and 
immune system, eradicate residual malignancy and to suppresses in case of allogeneic stem 
cell transplant the host immune system to prevent rejection of transplanted foreign stem cells.
The chemotherapy or irra
diation given immediately prior to a transplant is called the conditioning or preparative regi
men, the purpose of which is to help eradicate the patient’s disease prior to the infusion of 
grow new blood cells). Stem cells are extracted (aphaeresis) from the patient and stored frozen. 
The patient’s own stored stem cells are then returned to his/her body, where they replace de
stroyed tissue and resume the patient’s normal blood cell production. Autologous transplants 
have several advantages over alogenic transplant; lower risk of infection during the immune-
compromised portion of the treatment, the recovery of immune function is rapid, the incidence 
of patients experiencing rejection (graft-versus-host disease) is very rare due to the donor and 
recipient being the same individual, graft versus host disease (GVHD) is not a challenge and the 
procedure-related mortality is low (<5%). These advantages have established autologous HSCT 
as one of the standard second-line treatments for such diseases as lymphoma. A limitation of 
this procedure is the risk of tumour cells contaminating the stem cell harvest.
 Allogeneic HSCT involves two people: the (healthy) donor and the (patient) re
cipient. Allogeneic HSC donors must have a tissue (HLA) type that matches the recipient. 
Matching is performed on the basis of variability at three or more loci of the HLA gene, and 
a perfect match at these loci is preferred. Even if there is a good match at these critical alle
les, the recipient will require immunosuppressive medications to mitigate graft-versus-host 
disease. About 25 to 30 percent of allogeneic HSCT recipients have an HLA-identical sib
ling. Even so-called “perfect matches” may have mismatched minor alleles that contribute 
to graft-versus-host disease. Allogeneic transplant donors may be related (usually a closely 
HLA matched sibling), syngeneic (a monozygotic or ‘identical’ twin of the patient - necessar
ily extremely rare since few patients have an identical twin. Unrelated donors may be found 
through a registry of bone marrow donors such as the National Marrow Donor Program. Al
logeneic transplants are also performed using umbilical cord blood as the source of stem cells. 
Transplanting healthy stem cells to the recipient’s immune system, allogeneic HSCTs appear 
to improve chances for cure or long-term remission once the immediate transplant-related 
complications are resolved. The short arm of chromosome 6 contains a cluster of genes known 
as the Major Histocompatibility Complex (MHC) or the HLA region. These genes encode the 
HLA antigens and molecules like complement components, tumuor necrosis factor (TNF) 
and antigens related to antigen processing. A compatible donor is found by doing additional 
HLA-testing from the blood of potential donors. The HLA genes fall in two categories (type 
I and type II). In general, mismatches of the type-I genes (i.e. HLA-A, HLA-B, or HLA-C) in
crease the risk of graft rejection and are present in CD8+ cells. HLA-type 11 is present in CD4+ 
T-cells. A mismatch of an HLA type II gene (i.e. HLA-DR, or HLA-DQB1) increases the risk of 
graft-versus-host disease. In addition a genetic mismatch as small as a single DNA base pair 
is significant so perfect matches require knowledge of the exact DNA sequence of these genes 
for both donor and recipient. Leading transplant centers currently perform testing for all 
five of these HLA genes before declaring that a donor and recipient are HLA-identical. HLA 
typing is carried out either by serological technique using antibodies that are specific for indi
vidual HLA alleles or by molecular testing using PCR sequence-specific primers. The advan
tage of this procedure is associated graft versus leukemia (GVL). Mortality from allogeneic 
stem cell transplantation is higher for the following reasons; immunological incompatibility 
between donors and recipients despite HLA matching and immunological incompatibility - 
related immunodeficiency, GVHD and graft failure.
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Allogeneic or syngeneic Autologous
Acute lymphoblastic and myeloid leukaemia Amyloidosis
Chronic myeloid leukaemia Severe autoimmune disorders
Severe aplastic anaemia including Fanconi, s 
anaemia
Acute and chronic leukaemia
Haemoglobinopathies (thalasaemia and sickle 
cell disease)
Multiple myeloma
Inborn errors of metabolism in the haemopoietic 
and mesenchymal system such as osteopetrosis.
Hodgkins and non-Hodgkins lymphoma
Acquired marrow syndrome (aplastic anaemia, my-
elofibrosis, paroxysmal nocturnal haemoglobinuria)
Malignant disorders (myelodysplasia, multiple myelo-
ma, chronic lymphocytic leukaemia and lymphoma)
Stem cell transplant indications
Storage of HSC. HSC because the cells must be harvested from the recipient months in ad-
vance of the transplant treatment. Bone marrow cells can be frozen (cryopreserved) for pro-
longed periods, without damaging too many cells. In the case of allogeneic transplants, fresh 
HSC are preferred, in order to avoid cell loss that might occur during the freezing and thaw-
ing process. Allogeneic cord blood is stored frozen at a cord blood bank because it is only 
obtainable at the time of childbirth. To cryopreserve HSC, a preservative called Dimethyl sul-
foxide (DMSO) (DMSO has been used as a cryoprotectant and is still an important constituent 
of cryoprotectant vitrification mixtures used to preserve organs, tissues, and cell suspensions. 
Without it, up to 90% of frozen cells will become inactive. In a controlled-rate freezer DMSO 
prevent osmotic cellular injury during ice crystal formation. HSC may be stored for years in a 
cryofreezer, which typically utilizes liquid nitrogen.
Stem cell processing. After harvesting of HSC, it is processed (red cells are removed, the 
mononuclear cells are concentrated, autologous collections are purged by chemotherapy 
or antibody treatment to remove residual malignant cells and T-cells to reduce incidence of 
GVHD).
Conditioning. Prior to infusing stem cells into a patient, conditioning (chemotherapy and total 
body irradiation (TBI) is carried out. The aim of this is to; eradicate patient’s haemopoietic and 
immune system, eradicate residual malignancy and to suppresses in case of allogeneic stem 
cell transplant the host immune system to prevent rejection of transplanted foreign stem cells.
Myeloablative transplants and non-myeloablative transplants. The chemotherapy or irra-
diation given immediately prior to a transplant is called the conditioning or preparative regi-
men, the purpose of which is to help eradicate the patient’s disease prior to the infusion of 
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HSC and to suppress immune reactions. In recent years there has been a shift from the use of 
myeloablative to non-myeloablative conditioning regimens. Unlike myeloablative regimens, 
non –myeloablative agents do not completely ablate (destroy) the patient’s bone marrow. TBI 
is used in patient with malignant disease. Drugs used include; cyclophoaphamide, bulsul-
phan, cytosine, arabinoside and etoposide or nitrosoureas. Stem cells are not transplanted 
immediately after TBI. It is preferable to allow for a period of 36hours post TBI to allow for 
the removal of residual chemotherapeutic agent from the patients circulation.
Myeloablative transplants. The bone marrow can be ablated with dose-levels that cause mini-
mal injury to other tissues. In allogeneic transplants a combination of myeloablative options 
are available include cyclophosphamide with busulfan and total body irradiation is commonly 
employed. This treatment also has an immunosuppressive effect which prevents rejection of the 
HSC by the recipient’s immune system. The post-transplant prognosis often includes acute and 
chronic graft-versus-host disease which may be life-threatening; however in certain leukemias 
this can coincide with protection against cancer relapse owing to the graft versus tumor effect. 
Non-myeloablative allogeneic transplants. This is a newer treatment approach using lower 
doses of chemotherapy and radiation which are too low to eradicate all of the bone marrow 
cells of a recipient. Instead, non-myeloablative transplants run lower risks of serious infec-
tions and transplant-related mortality while relying upon the graft versus tumor effect to 
resist the inherent increased risk of cancer relapse. Also it requires high doses of immunosup-
pressive agents in the early stages of treatment; these doses are less than for conventional 
transplants. This leads to a state of mixed chimerism early after transplant where both recipi-
ent and donor HSC coexist in the bone marrow space. Decreasing doses of immunosuppres-
sive therapy then allows donor T-cells to eradicate the remaining recipient HSC and to induce 
the graft versus tumor effect. This effect is often accompanied by mild graft-versus-host dis-
ease. Because of their gentler conditioning regimens, these transplants are associated with a 
lower risk of transplant-related mortality and morbidity and therefore allow patients who are 
considered too high-risk for conventional allogeneic HSCT to undergo potentially curative 
therapy for their disease. Examples of non-myeloablative regimens include; fludarabine, low 
dose irradiation, anti-lymphocyte globulin, low dose Busulfan and cyclophosphamide.
Engraftment. Engraftment is usually quicker with PBSC compared to BMT. Cytopenia typically 
occur within the first 1-3 weeks post transplant. First signs of successful engraftment include; 
increase in the monocyte and neutrophils followed by platelet coun, there is reticulosis, appear-
ance of natural killer cells (NK) which are the earliest donor-derived lymphocytes to appear. 
G-CSF can be used to reduce the period of neutropenia, marrow cellularity gradually returns to 
normal but bone marrow reserve remains impaired for 1-2 years. Profound immunodeficiency 
persists for 3-12 months and is usually associated with low CD4 helper cells, high CD8 count 
and high CD8:CD4 for 6 months, after several weeks of growth in the bone marrow, expansion 
of HSC and their progeny is sufficient to normalize the blood cell counts and reinitiate the 
immune system, the offspring of donor-derived hematopoietic stem cells then populate many 
different organs of the recipient, including the heart, liver, and muscle and help in regenerat-
ing injured tissue in these organs and patient blood group changes to that of the donor and the 
antigen specific immunity becomes that of the donor in about 60 days.
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HSCT is associated with a high treatment-related mortality and morbidity in 
the recipient (10% or higher), which limits its use to conditions that are themselves life-threat
ening. Major complications are: graft-versus-host disease, infection, veno-occlusive disease, 
mucositis, infections (sepsis), graft failureand the development of new malignancies.
Graft-versus-host disease. Graft-versus-host disease (GVHD) is an inflammatory disease 
caused by donor –derived immune cells (T lymphocytes) that react against recipient cells. 
It is an attack of the “new” bone marrow’s immune cells against the recipient’s tissues. Inci
dence is higher with increasing age of donor and recipient and in cases where there is HLA 
mismatch between donor and recipient. This can occur even if the donor and recipient are 
HLA-identical because the immune system can still recognize other differences between their 
tissues. Prophylaxis against GVHD usually involves use of ciclosporin (oral or intravenous) 
and methotrexate given to remove T cells from donor stem cell infusion. There are two types 
of GVHD ( Acute and chronic). 
Acute graft-versus-host disease. Typically occurs in the first 3 months after transplantation 
and may involve the skin, intestine, or the liver, and is often fatal. Skin rash typically affects 
the face, palms, soles, ears and sometimes the whole body. Diagnosis is usually by skin biopsy 
(cell necrosis in the basal layer of epidermis and lymphocyte infiltration). Diarrhoea and as
sociated electrolyte depletion and imbalance may occur. Bilirubin and alkaline phosphatase 
are elevated although other hepatic enzymes may be normal. Treatment is usually by the use 
of high-dose corticosteroids such as prednisone. This immuno-suppressive treatment often 
leads to deadly infections.
Chronic graft-versus-host disease. Chronic graft-versus-host disease may also develop after 
100 days following allogeneic transplant and it is the major source of late treatment-related 
complications. Chronic graft-versus-host disease may involve the joints, oral mucose, lacrimal 
glands and other serosal surfaces and often lead to the development of fibrosis, or scar tissue, 
similar to scleroderma. Sjogen’s syndrome andlichen planus may develop. The immune sys
tem is impaired resulting in hyposlenism. Malabsorption and pulmonary abnormalities are 
common. Management often include use of drugs such as ciclosporin, azathioprine, myco
phenolate, mofetil, thalidomide and corticosteriods.
 Bone marrow transplantation usually requires that the recipient’s own bone mar
row be destroyed (myeloablation). Prior to engraftment patients may go for several weeks 
without appreciable numbers of white blood cells to help fight infection (Bacterial and fungal 
infection are frequent). This puts a patient at high risk of infections, sepsis and septic shock, 
despite prophylactic antibiotics. However, antiviral medications, such as acyclovir and va
lacyclovir, are quite effective in prevention of HSCT-related outbreak of herpetic infection 
in sero-positive patients. Use of oral antibiotics and sometimes intravenous broad-spectrum 
antibiotics may be commenced after blood cultures and other microbiological samples have 
been collected to prevent bacterial infection. Oral penicillin can be given prophylactically to 
reduce effects of gram negative encapsulated organisms affecting the respiratory tract. An
tifungal agents such as amphotericin B and caspofungin or voriconazole, fluconazole and 
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myeloablative to non-myeloablative conditioning regimens. Unlike myeloablative regimens, 
non –myeloablative agents do not completely ablate (destroy) the patient’s bone marrow. TBI 
is used in patient with malignant disease. Drugs used include; cyclophoaphamide, bulsul
phan, cytosine, arabinoside and etoposide or nitrosoureas. Stem cells are not transplanted 
immediately after TBI. It is preferable to allow for a period of 36hours post TBI to allow for 
the removal of residual chemotherapeutic agent from the patients circulation.
The bone marrow can be ablated with dose-levels that cause mini
mal injury to other tissues. In allogeneic transplants a combination of myeloablative options 
are available include cyclophosphamide with busulfan and total body irradiation is commonly 
employed. This treatment also has an immunosuppressive effect which prevents rejection of the 
HSC by the recipient’s immune system. The post-transplant prognosis often includes acute and 
chronic graft-versus-host disease which may be life-threatening; however in certain leukemias 
this can coincide with protection against cancer relapse owing to the graft versus tumor effect. 
 This is a newer treatment approach using lower 
doses of chemotherapy and radiation which are too low to eradicate all of the bone marrow 
cells of a recipient. Instead, non-myeloablative transplants run lower risks of serious infec
tions and transplant-related mortality while relying upon the graft versus tumor effect to 
resist the inherent increased risk of cancer relapse. Also it requires high doses of immunosup
pressive agents in the early stages of treatment; these doses are less than for conventional 
transplants. This leads to a state of mixed chimerism early after transplant where both recipi
ent and donor HSC coexist in the bone marrow space. Decreasing doses of immunosuppres
sive therapy then allows donor T-cells to eradicate the remaining recipient HSC and to induce 
the graft versus tumor effect. This effect is often accompanied by mild graft-versus-host dis
ease. Because of their gentler conditioning regimens, these transplants are associated with a 
lower risk of transplant-related mortality and morbidity and therefore allow patients who are 
considered too high-risk for conventional allogeneic HSCT to undergo potentially curative 
therapy for their disease. Examples of non-myeloablative regimens include; fludarabine, low 
dose irradiation, anti-lymphocyte globulin, low dose Busulfan and cyclophosphamide.
Engraftment. Engraftment is usually quicker with PBSC compared to BMT. Cytopenia typically 
occur within the first 1-3 weeks post transplant. First signs of successful engraftment include; 
increase in the monocyte and neutrophils followed by platelet coun, there is reticulosis, appear
ance of natural killer cells (NK) which are the earliest donor-derived lymphocytes to appear. 
G-CSF can be used to reduce the period of neutropenia, marrow cellularity gradually returns to 
normal but bone marrow reserve remains impaired for 1-2 years. Profound immunodeficiency 
persists for 3-12 months and is usually associated with low CD4 helper cells, high CD8 count 
and high CD8:CD4 for 6 months, after several weeks of growth in the bone marrow, expansion 
of HSC and their progeny is sufficient to normalize the blood cell counts and reinitiate the 
immune system, the offspring of donor-derived hematopoietic stem cells then populate many 
different organs of the recipient, including the heart, liver, and muscle and help in regenerat
ing injured tissue in these organs and patient blood group changes to that of the donor and the 
antigen specific immunity becomes that of the donor in about 60 days.
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Complications. HSCT is associated with a high treatment-related mortality and morbidity in 
the recipient (10% or higher), which limits its use to conditions that are themselves life-threat-
ening. Major complications are: graft-versus-host disease, infection, veno-occlusive disease, 
mucositis, infections (sepsis), graft failureand the development of new malignancies.
Graft-versus-host disease. Graft-versus-host disease (GVHD) is an inflammatory disease 
caused by donor –derived immune cells (T lymphocytes) that react against recipient cells. 
It is an attack of the “new” bone marrow’s immune cells against the recipient’s tissues. Inci-
dence is higher with increasing age of donor and recipient and in cases where there is HLA 
mismatch between donor and recipient. This can occur even if the donor and recipient are 
HLA-identical because the immune system can still recognize other differences between their 
tissues. Prophylaxis against GVHD usually involves use of ciclosporin (oral or intravenous) 
and methotrexate given to remove T cells from donor stem cell infusion. There are two types 
of GVHD ( Acute and chronic). 
Acute graft-versus-host disease. Typically occurs in the first 3 months after transplantation 
and may involve the skin, intestine, or the liver, and is often fatal. Skin rash typically affects 
the face, palms, soles, ears and sometimes the whole body. Diagnosis is usually by skin biopsy 
(cell necrosis in the basal layer of epidermis and lymphocyte infiltration). Diarrhoea and as-
sociated electrolyte depletion and imbalance may occur. Bilirubin and alkaline phosphatase 
are elevated although other hepatic enzymes may be normal. Treatment is usually by the use 
of high-dose corticosteroids such as prednisone. This immuno-suppressive treatment often 
leads to deadly infections.
Chronic graft-versus-host disease. Chronic graft-versus-host disease may also develop after 
100 days following allogeneic transplant and it is the major source of late treatment-related 
complications. Chronic graft-versus-host disease may involve the joints, oral mucose, lacrimal 
glands and other serosal surfaces and often lead to the development of fibrosis, or scar tissue, 
similar to scleroderma. Sjogen’s syndrome andlichen planus may develop. The immune sys-
tem is impaired resulting in hyposlenism. Malabsorption and pulmonary abnormalities are 
common. Management often include use of drugs such as ciclosporin, azathioprine, myco-
phenolate, mofetil, thalidomide and corticosteriods.
Infection. Bone marrow transplantation usually requires that the recipient’s own bone mar-
row be destroyed (myeloablation). Prior to engraftment patients may go for several weeks 
without appreciable numbers of white blood cells to help fight infection (Bacterial and fungal 
infection are frequent). This puts a patient at high risk of infections, sepsis and septic shock, 
despite prophylactic antibiotics. However, antiviral medications, such as acyclovir and va-
lacyclovir, are quite effective in prevention of HSCT-related outbreak of herpetic infection 
in sero-positive patients. Use of oral antibiotics and sometimes intravenous broad-spectrum 
antibiotics may be commenced after blood cultures and other microbiological samples have 
been collected to prevent bacterial infection. Oral penicillin can be given prophylactically to 
reduce effects of gram negative encapsulated organisms affecting the respiratory tract. An-
tifungal agents such as amphotericin B and caspofungin or voriconazole, fluconazole and 
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itraconazole may be used to prevent fungal infections such as Candida and Aspergillus spe-
cies. The immunosuppressive agents employed in allogeneic transplants for the prevention 
or treatment of graft-versus-host disease further increase the risk of viral infections particu-
larly herpes simplex, cytomegalovirus (CMV), varicella zoster virus (VZV). CMV is a major 
threat and is usually associated with potentially fatal pneumonitis, hepatitis, falling blood 
counts. Recipients who are CMV negative or whose CMV status is unknown must receive 
CMV negative donor stem cells and blood products. Immunosuppressive drugs are given for 
a minimum of 6-months after transplantation, or much longer if required for the treatment 
of graft-versus-host disease. Transplant patients lose their acquired immunity, for example 
immunity to childhood diseases such as measles or polio. For this reason transplant patients 
must be re-vaccinated with childhood vaccines once they are off immunosuppressive medi-
cations. Pneumocystis carinii pneumonitis may occur and can be prevented by prophylac-
tic co-trimoxazole. Aciclovir may be a useful prophylaxis for varicella zoster virus infection. 
Epstein-Barr virus (EBV) and associated lympho-proliferative disease are rare. Haemorrhagic 
cystitis caused by the cyclophosphamide metabolite acrolein or adenovirus or polyomavirus 
can cause this complication. Mensa can help prevent this complication.
Veno-occlusive disease. Severe liver injury can result from hepatic veno-occlusive disease 
(VOD). Elevated levels of bilirubin (jaundice), hepatomegaly and fluid retention (ascites), 
weight gain and cardiac failures are clinical hallmarks of this condition. There is now a great-
er appreciation of the generalized cellular injury and obstruction in hepatic vein sinuses, and 
hepatic VOD has lately been referred to as sinusoidal obstruction syndrome (SOS). Severe 
cases of SOS are associated with a high mortality rate. Anticoagulants or defibrotide may 
be effective in reducing the severity of VOD but may also increase bleeding complications. 
Ursodiol has been shown to help prevent VOD, presumably by facilitating the flow of bile.
Graft failure. The risk of graft failure can occur in the following circumstances; patients 
with aplastic anaemia and in patients in whom T-cell depleted donor stem cells is used for 
transplant or as a GVHD prophylaxis. T –cell depletion of donor stem cells prevent donor T-
cells form overcoming resistance from host.
Mucositis. The injury of the mucosal lining of the mouth and throat and is a common regi-
men-related toxicity following ablative HSCT regimens. It is usually not life-threatening but 
is very painful, and prevents eating and drinking. Treatment is usually with pain medications 
plus intravenous infusions to prevent dehydration and malnutrition.
Graft-versus-tumor effect. Graft-versus-tumor effect (GVT) or “graft versus leukemia” effect 
is the beneficial aspect of the Graft-versus-Host phenomenon. HSCT patients with either acute 
or in particular chronic graft-versus-host disease after an allogeneic transplant tend to have a 
lower risk of cancer relapse. This is due to a therapeutic immune reaction of the grafted donor 
T lymphocytes against the diseased bone marrow of the recipient. This lower rate of relapse 
accounts for the increased success rate of allogeneic transplants compared to transplants from 
identical twins, and indicates that allogeneic HSCT is a form of immunotherapy. GVT is the 
major benefit of transplants which do not employ the highest immuno-suppressive regimens.
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1. Oral carcinoma. Patients after HSCT are at a higher risk for oral carci
noma. Post-HSCT oral cancer may have more aggressive behavior with 
poorer prognosis, when compared to oral cancer in non-HSCT patients. 
2. Haemolysis and microangiopathic haemolytic anaemia because of ABO 
blood group incompatibility between donors and recipients.
3. Relapse of original or residual disease for example acute and chronic leu
kaemia.
4. Delayed pulmonary complications including restrictive pneomonitis, 
bronchiolitis obliterans.
5. Endocrine complications including hypothyroidism particularly associ
ated with TBI and eye problems (cataracts).
6. Autoimmune disorders including myasthenia, rheumatoid arthritis, ane
mia and thrombocytopenia.
7. Secondary malignancies such non-Hodgkin’s lymphoma as well as CNS 
complications (neuropathies). 
8. Growth failure associated with low growth hormone levels in children.
9. Impaired sexual development and infertility.
Severe pan-cytopenia is often associated with SCT 
in the first 1-3 weeks. Blood product support may be required in these critical moments. Red 
cells concentrates are given to treat anemia, platelet concentrate are given to maintain the 
platelet count above 10 x 109/L. All blood product giving post transplant  irradiated 
(to kill any lymphocytes) and prevent GVHD.
Prognosis in HSCT varies widely dependent upon a number of factors; 
disease type, stage, stems cell source, HLA-matched status (for allogeneic HCST), and condi
tioning regimen. A transplant offers a chance for cure or long-term remission if; the inherent 
complications of graft versus host disease does not manifest, an Immuno-suppressive treat
ment does not produce a negative life threatening effect and if the recipient survives the spec
trum of opportunistic infections. In recent years, survival rates have been gradually improv
ing across almost all populations and sub-populations receiving transplants. Mortality for 
allogeneic stem cell transplantation can be estimated using the prediction model created by 
Sorror and colleagues using the Hematopoietic Cell Transplantation-Specific Co-morbidity 
Index (HCT-CI). The Hematopoietic Cell Transplantation-Specific Co-morbidity Index (HCT-
CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplanta
tion population and to enable risk assessment before allogeneic transplant. Use this calculator 
to identify comorbidities in the allogeneic stem cell transplantation population and to enable 
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itraconazole may be used to prevent fungal infections such as Candida and Aspergillus spe
cies. The immunosuppressive agents employed in allogeneic transplants for the prevention 
or treatment of graft-versus-host disease further increase the risk of viral infections particu
larly herpes simplex, cytomegalovirus (CMV), varicella zoster virus (VZV). CMV is a major 
threat and is usually associated with potentially fatal pneumonitis, hepatitis, falling blood 
counts. Recipients who are CMV negative or whose CMV status is unknown must receive 
CMV negative donor stem cells and blood products. Immunosuppressive drugs are given for 
a minimum of 6-months after transplantation, or much longer if required for the treatment 
of graft-versus-host disease. Transplant patients lose their acquired immunity, for example 
immunity to childhood diseases such as measles or polio. For this reason transplant patients 
must be re-vaccinated with childhood vaccines once they are off immunosuppressive medi
cations. Pneumocystis carinii pneumonitis may occur and can be prevented by prophylac
tic co-trimoxazole. Aciclovir may be a useful prophylaxis for varicella zoster virus infection. 
Epstein-Barr virus (EBV) and associated lympho-proliferative disease are rare. Haemorrhagic 
cystitis caused by the cyclophosphamide metabolite acrolein or adenovirus or polyomavirus 
can cause this complication. Mensa can help prevent this complication.
Severe liver injury can result from hepatic veno-occlusive disease 
(VOD). Elevated levels of bilirubin (jaundice), hepatomegaly and fluid retention (ascites), 
weight gain and cardiac failures are clinical hallmarks of this condition. There is now a great
er appreciation of the generalized cellular injury and obstruction in hepatic vein sinuses, and 
hepatic VOD has lately been referred to as sinusoidal obstruction syndrome (SOS). Severe 
cases of SOS are associated with a high mortality rate. Anticoagulants or defibrotide may 
be effective in reducing the severity of VOD but may also increase bleeding complications. 
Ursodiol has been shown to help prevent VOD, presumably by facilitating the flow of bile.
Graft failure. The risk of graft failure can occur in the following circumstances; patients 
with aplastic anaemia and in patients in whom T-cell depleted donor stem cells is used for 
transplant or as a GVHD prophylaxis. T –cell depletion of donor stem cells prevent donor T-
cells form overcoming resistance from host.
 The injury of the mucosal lining of the mouth and throat and is a common regi
men-related toxicity following ablative HSCT regimens. It is usually not life-threatening but 
is very painful, and prevents eating and drinking. Treatment is usually with pain medications 
plus intravenous infusions to prevent dehydration and malnutrition.
Graft-versus-tumor effect. Graft-versus-tumor effect (GVT) or “graft versus leukemia” effect 
is the beneficial aspect of the Graft-versus-Host phenomenon. HSCT patients with either acute 
or in particular chronic graft-versus-host disease after an allogeneic transplant tend to have a 
lower risk of cancer relapse. This is due to a therapeutic immune reaction of the grafted donor 
T lymphocytes against the diseased bone marrow of the recipient. This lower rate of relapse 
accounts for the increased success rate of allogeneic transplants compared to transplants from 
identical twins, and indicates that allogeneic HSCT is a form of immunotherapy. GVT is the 
major benefit of transplants which do not employ the highest immuno-suppressive regimens.
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Other complications
1. Oral carcinoma. Patients after HSCT are at a higher risk for oral carci-
noma. Post-HSCT oral cancer may have more aggressive behavior with 
poorer prognosis, when compared to oral cancer in non-HSCT patients. 
2. Haemolysis and microangiopathic haemolytic anaemia because of ABO 
blood group incompatibility between donors and recipients.
3. Relapse of original or residual disease for example acute and chronic leu-
kaemia.
4. Delayed pulmonary complications including restrictive pneomonitis, 
bronchiolitis obliterans.
5. Endocrine complications including hypothyroidism particularly associ-
ated with TBI and eye problems (cataracts).
6. Autoimmune disorders including myasthenia, rheumatoid arthritis, ane-
mia and thrombocytopenia.
7. Secondary malignancies such non-Hodgkin’s lymphoma as well as CNS 
complications (neuropathies). 
8. Growth failure associated with low growth hormone levels in children.
9. Impaired sexual development and infertility.
Blood products support following SCT. Severe pan-cytopenia is often associated with SCT 
in the first 1-3 weeks. Blood product support may be required in these critical moments. Red 
cells concentrates are given to treat anemia, platelet concentrate are given to maintain the 
platelet count above 10 x 109/L. All blood product giving post transplant must be irradiated 
(to kill any lymphocytes) and prevent GVHD.
Prognosis of SCT. Prognosis in HSCT varies widely dependent upon a number of factors; 
disease type, stage, stems cell source, HLA-matched status (for allogeneic HCST), and condi-
tioning regimen. A transplant offers a chance for cure or long-term remission if; the inherent 
complications of graft versus host disease does not manifest, an Immuno-suppressive treat-
ment does not produce a negative life threatening effect and if the recipient survives the spec-
trum of opportunistic infections. In recent years, survival rates have been gradually improv-
ing across almost all populations and sub-populations receiving transplants. Mortality for 
allogeneic stem cell transplantation can be estimated using the prediction model created by 
Sorror and colleagues using the Hematopoietic Cell Transplantation-Specific Co-morbidity 
Index (HCT-CI). The Hematopoietic Cell Transplantation-Specific Co-morbidity Index (HCT-
CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplanta-
tion population and to enable risk assessment before allogeneic transplant. Use this calculator 
to identify comorbidities in the allogeneic stem cell transplantation population and to enable 
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risk assessment before allogeneic transplant using the Hematopoietic Cell Transplantation-
Specific Co-morbidity Index (HCT-CI). The following co-morbidities can to a larger extent 
determine the success of a transplant.
Hepatic disease 
• None
• Mild (chronic hepatitis, bilirubin > Upper Limit of Normal (ULN) to 
1.5 x ULN, or AST/ALT > ULN to 2.5 x ULN).
• Moderate or severe (cirrhosis, bilirubin > 1.5 x ULN, or AST/ALT > 
2.5 x ULN).
Pulmonary disease
• None or mild disease
• Moderate pulmonary (DLCO and/or FEV1 66% to 80% or dyspnea 
on slight activity).
• Severe pulmonary (DLCO and/or FEV1 = 65% or dyspnea at rest or 
requiring oxygen).
Other factors
• Arrhythmia (Atrial fibrillation or flutter, sick sinus syndrome, or ven-
tricular arrhythmias).
• Inflammatory bowel disease (Crohn’s or ulcerative colitis)
• Cardiac (CAD, CHD, myocardial infarction or ejection fraction = 50%).
• Inflammatory bowel disease (Crohn’s or ulcerative colitis).
• Inflammatory bowel disease (Crohn’s or ulcerative colitis).
• Diabetes (requiring insulin or oral hypoglycemic)
• Psychiatric disturbance (depression or anxiety requiring psychiatric 
consult or treatment).
• Obesity (body mass index > 35 kg/m2)
• Infection (requiring continuation of antimicrobial treatment after day 0.
• Cerebrovascular disease (TIA or cerebrovascular accident).
• Rheumatologic (SLE, RA, polymyositis, polymyalgia rheumatica).
• Peptic ulcer (requiring treatment)
• Moderate or severe renal failure (serum Cr > 2 mg/dL or 177 µmol/L, 
dialysis, or prior renal transplant).
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• Prior solid tumor (excluding non-melanoma skin cancer).
• Valvular Heart Disease (except mitral valve prolapse).
The alkaline denaturation test is a test used for differentiating between foetal and adult blood. 
It is sometimes necessary to establish the origin of a blood sample (foetal, maternal or adult).
The principle of the test is based on the resistance of foetal red cells containing haemoglobin F 
to alkaline denaturation. Examples of cases where it may be necessary to determine the origin 
of a blood sample include:
• In cases of PV bleed in a pregnant mother (particularly Rhesus nega
tive mother)
• Inadequate or mis-labelling of samples (cord and maternal samples)
• In cases of a blood tap from amniocentesis
• In cases of forensic investigation to determine if blood spot on a 
crime scene is foetal or adult blood.
Sample must contain macroscopic unaltered blood free from contami
nation by faeces and vomit. The sample must be less than 3 days old. Each test is controlled 
using a cord sample as positive control and an adult sample as a negative control.






1. Prepare 0.12N NaOH by diluting 0.3N NaOH by adding 200mls of 0.12N 
NaOH to 500mls of distilled water.
2. Label the 75x12mm tubes appriopriately and prepare a haemolysate of 
the test and control samples by adding 2 drops of blood into a tube and 
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• Prior solid tumor (excluding non-melanoma skin cancer).
• Valvular Heart Disease (except mitral valve prolapse).
45. Alkaline denaturation test
The alkaline denaturation test is a test used for differentiating between foetal and adult blood. 
It is sometimes necessary to establish the origin of a blood sample (foetal, maternal or adult). 
The principle of the test is based on the resistance of foetal red cells containing haemoglobin F 
to alkaline denaturation. Examples of cases where it may be necessary to determine the origin 
of a blood sample include:
• In cases of PV bleed in a pregnant mother (particularly Rhesus nega-
tive mother)
• Inadequate or mis-labelling of samples (cord and maternal samples)
• In cases of a blood tap from amniocentesis
• In cases of forensic investigation to determine if blood spot on a 
crime scene is foetal or adult blood. 
Sample requirement. Sample must contain macroscopic unaltered blood free from contami-
nation by faeces and vomit. The sample must be less than 3 days old. Each test is controlled 
using a cord sample as positive control and an adult sample as a negative control.
Instrumentation /reagents required







1. Prepare 0.12N NaOH by diluting 0.3N NaOH by adding 200mls of 0.12N 
NaOH to 500mls of distilled water.
2. Label the 75x12mm tubes appriopriately and prepare a haemolysate of 
the test and control samples by adding 2 drops of blood into a tube and 
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filling it with distilled water. Test haemolysate can be prepared from 
blood samples, blood stained sheets and sanitary pads.
3. Place the tubes with the haemolysate in a centrifuge for 60 seconds to 
remove the stroma
4. Transfer 8 volumes of the haemolysate into a second tube and add 2 vol-
umes of 0.12N NaOH, mix and observe immediately. Compare the colour 
against the original haemolysate. Include positive 9 known foetal sample) 
and negative controls (known adult maternal sample).
Result. Foetal red cells containing haemoglobin F remains pink (resist denaturation) while 
adult maternal sample containg adult haemoglobin turns brown.
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filling it with distilled water. Test haemolysate can be prepared from 
blood samples, blood stained sheets and sanitary pads.
3. Place the tubes with the haemolysate in a centrifuge for 60 seconds to 
remove the stroma
4. Transfer 8 volumes of the haemolysate into a second tube and add 2 vol
umes of 0.12N NaOH, mix and observe immediately. Compare the colour 
against the original haemolysate. Include positive 9 known foetal sample) 
and negative controls (known adult maternal sample).
Foetal red cells containing haemoglobin F remains pink (resist denaturation) while 
adult maternal sample containg adult haemoglobin turns brown.
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